


**CUMULATIVE  
SUPPLEMENT 11  
NOVEMBER 2021**



**APPROVED  
DRUG PRODUCTS**

**WITH  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**41st EDITION**

**Department of Health and Human Services**

**Food and Drug Administration  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Generic Drug Policy**

**2021**

Prepared By  
Food and Drug Administration  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**41<sup>th</sup> EDITION**

**Cumulative Supplement 11  
November 2021**

**CONTENTS**

*PAGE*

**Contents**

1.0	INTRODUCTION.....	v
1.1	HOW TO USE THE CUMULATIVE SUPPLEMENT.....	vi
1.2	CUMULATIVE SUPPLEMENT CONTENT.....	vi
1.3	APPLICANT NAME CHANGES.....	vii
1.4	LEVOTHYROXINE SODIUM.....	viii
1.5	AVAILABILITY OF THE EDITION.....	x
1.6	REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST.....	x
1.7	CUMULATIVE SUPPLEMENT LEGEND.....	xii
<b>DRUG PRODUCT LISTS</b>		
	Prescription Drug Product List .....	1-1
	OTC Drug Product List .....	2-1
	Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List .....	3-1
	Orphan Products Designations and Approvals List .....	4-1
	Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution .....	5-1
<b>PATENT AND EXCLUSIVITY INFORMATION ADDENDUM</b>		
A.	Patent and Exclusivity Lists .....	A-1
B.	Patent and Exclusivity Terms .....	B-1

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**41<sup>st</sup> EDITION**

**CUMULATIVE SUPPLEMENT 11  
NOVEMBER 2021**

**1.0 INTRODUCTION**

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

## 1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

## 1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.

- All product changes received and processed as of the date of publication.
  - Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes
- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Division of Orange Book Publication and Regulatory Assessment (DOB/PRA) of any changes or corrections. The DOB/PRA can be contacted by email at [orangebook@fda.hhs.gov](mailto:orangebook@fda.hhs.gov).

### 1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME  
(FORMER ABBREVIATED NAME)

AUROBINDO PHARMA LTD  
(AUROBINDO PHARMA LTD)

AKORN INC  
(AKORN)

AKORN INC  
(AKORN INC)

NEW APPLICANT NAME  
(NEW ABBREVIATED NAME)

EUGIA PHARMA SPECIALITIES LTD  
(EUGIA PHARMA)

AKORN OPERATING CO LLC  
(AKORN)

AKORN OPERATING CO LLC  
(AKORN)

JIANGSU HENGRUI MEDICINE CO LTD (JIANGSU HENGRUI MED)	JIANGSU HENGRUI PHARMACEUTICALS CO LTD (JIANGSU PHARMS)
ORCHID HEALTHCARE (ORCHID HLTHCARE)	ORBION PHARMACEUTICALS PRIVATE LTD (ORBION PHARMS)
PADDOCK LABORATORIES LLC (PADDOCK LABS LLC)	PADAGIS US LLC (PADAGIS US)
PADDOCK LABORATORIES LLC (PADDOCK LLC)	PADAGIS US LLC (PADAGIS US)
PAR PHARMACEUTICAL (PAR PHARM)	STRIDES PHARMA GLOBAL PTE LTD (STRIDES PHARMA)
PAR PHARMACEUTICAL INC (PAR PHARM)	STRIDES PHARMA GLOBAL PTE LTD (STRIDES PHARMA)
PAR PHARMACEUTICAL INC (PAR PHARM INC)	STRIDES PHARMA GLOBAL PTE LTD (STRIDES PHARMA)
PERRIGO CO OF TENNESSEE INC (PERRIGO CO)	PADAGIS US LLC (PADAGIS US)
PERRIGO CO TENNESSEE INC (PERRIGO CO TENNESSEE)	PADAGIS US LLC (PADAGIS US)
PERRIGO NEW YORK INC (PERRIGO NEW YORK)	PADAGIS US LLC (PADAGIS US)
PERRIGO PHARMA INTERNATIONAL DAC (PERRIGO PHARMA INTL)	PADAGIS US LLC (PADAGIS US)
PERRIGO UK FINCO LTD PARTNERSHIP (PERRIGO UK FINCO)	PADAGIS ISRAEL PHARMACEUTICALS LTD (PADAGIS ISRAEL)
PERRIGO ISRAEL PHARMACEUTICALS LTD (PERRIGO ISRAEL)	PADAGIS ISRAEL PHARMACEUTICALS LTD (PADAGIS ISRAEL)
WEST-WARD PHARMACEUTICALS INTERNATIONAL LTD (WEST-WARD PHARMS INT)	HIKMA PHARMACEUTICALS USA INC (HIKMA PHARMS)

#### 1.4 LEVOTHYROXINE SODIUM<sup>1</sup>

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted

---

<sup>1</sup> In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.<sup>2</sup>

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).
- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN GROUP HOLDINGS 4 LLC	0.3MG	N021116	RLD	-
AB4	LEVOTHYROXINE SODIUM <sup>3</sup>	MYLAN	0.3MG	A076187	-	RS

<sup>2</sup> Please consult the Active Section of the Orange Book for information on other strengths.

<sup>3</sup> Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levotheroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also



## 1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket \*95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket \*95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

## 1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

---

may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

## DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

## DEFINITIONS

### Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

### New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

## REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES</u> <u>COUNTED</u>	<u>DEC</u> <u>2020</u>	<u>MAR</u> <u>2021</u>	<u>JUN</u> <u>2021</u>	<u>SEP</u> <u>2021</u>	<u>DEC</u> <u>2021</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	20478 (13.0%)	20726 (12.9%)	20916 (12.8%)	20919 (12.7%)	2659 (12.7%)
MULTISOURCE	17819 (87.0%)	18055 (87.1%)	18241 (87.2%)	18260 (87.3%)	
THERAPEUTICALLY EQUIVALENT	17746 (86.7%)	17990 (86.8%)	18175 (86.9%)	18114 (86.6%)	
NOT THERAPEUTICALLY EQUIVALENT	73 (0.4%)	65 (0.3%)	66 (0.3%)	146 (0.7%)	
EXCEPTIONS <sup>4</sup>	54 (0.3%)	54 (0.3%)	54 (0.3%)	54 (0.3%)	

<sup>4</sup> Amino acid containing products of varying composition (see Introduction, page xx of the List).

NEW MOLECULAR ENTITIES APPROVED	22	29	33	18
NUMBER OF APPLICANTS	1185	1184	1182	1167

## 1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN <sup>5</sup>	Applicant holder firm name has changed
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration
CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMKT	Change. RX to OTC marketing status switch.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug

<sup>5</sup> The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

CHRS	Change. Reference Standard
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

ABIRATERONE ACETATE

TABLET; ORAL		ABIRATERONE ACETATE					
AB	AMNEAL PHARMS	500MG		A208327	002	Dec 23, 2020	Apr NEWA
AB	QILU	500MG		A212462	002	Jun 25, 2021	Jun NEWA

ACARBOSE

TABLET; ORAL		ACARBOSE					
AB	EMCURE PHARMS LTD	25MG		A202271	001	Feb 07, 2012	Apr CMFD
AB		50MG		A202271	002	Feb 07, 2012	Apr CMFD
AB		100MG		A202271	003	Feb 07, 2012	Apr CMFD
	@ HANGZHOU ZHONGMEI	25MG		A213821	001	Aug 18, 2020	Aug DISC
	@	50MG		A213821	002	Aug 18, 2020	Aug DISC
	@	100MG		A213821	003	Aug 18, 2020	Aug DISC

ACETAMINOPHEN

SOLUTION; INTRAVENOUS		ACETAMINOPHEN					
	+! B BRAUN MEDICAL INC	500MG/50ML (10MG/ML)		N204957	001	Feb 18, 2021	Feb NEWA
	+!	1GM/100ML (10MG/ML)		N204957	002	Feb 18, 2021	Feb NEWA
AP	BAXTER HLTHCARE CORP	1GM/100ML (10MG/ML)		A214331	001	Sep 17, 2021	Sep NEWA

ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE

CAPSULE; ORAL		CODEINE, ASPIRIN, APAP FORMULA NO. 2					
	+ @ SCHERER LABS	150MG;180MG;15MG		A085640	001		Aug CRLD
CAPSULE; ORAL		CODEINE, ASPIRIN, APAP FORMULA NO. 3					
	+ @ SCHERER LABS	150MG;180MG;30MG		A085639	001		Aug CRLD

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL		BUTALBITAL AND ACETAMINOPHEN					
AA	ALVOGEN	300MG;50MG		A207635	001	Jun 05, 2017	Jun CAHN
AA		325MG;50MG		A205120	001	Oct 30, 2015	Jun CAHN
	+ @ WATSON LABS	325MG;50MG		A087550	001	Oct 19, 1984	Aug CRLD
PHRENILIN							
	+ @ VALEANT	325MG;50MG		A087811	001	Jun 19, 1985	Aug CRLD

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL		BUTALBITAL, ACETAMINOPHEN AND CAFFEINE					
	+ @ GILBERT LABS	325MG;50MG;40MG		A088825	001	Dec 05, 1984	Aug CRLD
AA	HAVIX	300MG;50MG;40MG		A214087	001	Aug 13, 2021	Aug NEWA
AA		325MG;50MG;40MG		A214087	002	Aug 13, 2021	Aug NEWA
>A> AA	RICONPHARMA LLC	300MG;50MG;40MG		A215047	001	Nov 17, 2021	Nov NEWA
AA	SENORES PHARMS	300MG;50MG;40MG		A214087	001	Aug 13, 2021	Aug CAHN
AA		325MG;50MG;40MG		A214087	002	Aug 13, 2021	Aug CAHN
AA	XSPIRE PHARMA	300MG;50MG;40MG		A206615	001	Aug 04, 2017	Feb CAHN
TABLET; ORAL		BUTALBITAL, ACETAMINOPHEN AND CAFFEINE					
AA	+ ACTAVIS LABS UT INC	325MG;50MG;40MG		A088616	001	Nov 09, 1984	Aug CRLD
AA	ALVOGEN	325MG;50MG;40MG		A204984	001	Jan 10, 2017	Jun CAHN
	@ GRANULES	325MG;50MG;40MG		A040864	001	Dec 01, 2008	Apr CAHN
AA	! STRIDES PHARMA	325MG;50MG;40MG		A040511	001	Aug 27, 2003	Oct CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL		BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE					
AB	NOSTRUM LABS INC	325MG;50MG;40MG;30MG		A075929	001	Apr 22, 2002	Jan CAHN

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL		TREZIX					
	XSPIRE PHARMA	320.5MG;30MG;16MG		A204785	001	Nov 26, 2014	Jul CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE

	CAPSULE;ORAL					
	PHENAPHEN W/ CODEINE NO. 3					
>D>	@	ROBINS AH	325MG;30MG	A 084445	001	Nov CRLD
>A>	+	@	325MG;30MG	A 084445	001	Nov CRLD
	PHENAPHEN W/ CODEINE NO. 4					
>D>	@	ROBINS AH	325MG;60MG	A 084446	001	Nov CRLD
>A>	+	@	325MG;60MG	A 084446	001	Nov CRLD
	SOLUTION;ORAL					
	ACETAMINOPHEN AND CODEINE PHOSPHATE					
	+	@ ACTAVIS MID ATLANTIC	120MG/5ML;12MG/5ML	A 085861	001	Aug CRLD
	+	@ ORTHO MCNEIL PHARM	120MG/5ML;12MG/5ML	A 085057	001	Aug CRLD
	TYLENOL W/ CODEINE					
	TABLET;ORAL					
	ACETAMINOPHEN AND CODEINE PHOSPHATE					
AA		NOSTRUM LABS INC	300MG;15MG	A 088629	002	Mar 06, 1985 Aug CMS1
AA			300MG;30MG	A 088629	003	Mar 06, 1985 Aug CMS1
AA	+	!	300MG;60MG	A 088629	001	Mar 06, 1985 Aug CRLD
	+	@ PUREPAC PHARM	300MG;30MG	A 086681	001	Aug CRLD
	+	@ SANDOZ	300MG;15MG	A 087433	001	Aug CRLD
	+	@	300MG;30MG	A 085917	001	Aug CRLD
	@	STRIDES PHARMA	300MG;15MG	A 089990	001	Sep 30, 1988 Oct CAHN
	@		300MG;30MG	A 089805	001	Sep 30, 1988 Oct CAHN
	@		300MG;60MG	A 089828	001	Sep 30, 1988 Oct CAHN
	@	VINTAGE	300MG;15MG	A 089990	001	Sep 30, 1988 Apr DISC
	@		300MG;30MG	A 089805	001	Sep 30, 1988 Apr DISC
	@		300MG;60MG	A 089828	001	Sep 30, 1988 Apr DISC
AA			300MG;60MG	A 089828	001	Sep 30, 1988 Apr CAHN
	TYLENOL W/ CODEINE NO. 2					
	+	@ JANSSEN PHARMS	300MG;15MG	A 085055	002	Aug CRLD
	TYLENOL W/ CODEINE NO. 3					
	+	@ JANSSEN PHARMS	300MG;30MG	A 085055	003	Aug CRLD
	TYLENOL W/ CODEINE NO. 4					
	+	@ JANSSEN PHARMS	300MG;60MG	A 085055	004	Aug CRLD

ACETAMINOPHEN; HYDROCODONE BITARTRATE

	TABLET;ORAL					
	ANEXSIA 5/325					
AA	!	SPECGX LLC	325MG;5MG	A 040409	001	Oct 20, 2000 Apr CHRS
	ANEXSIA 7.5/325					
AA	!	SPECGX LLC	325MG;7.5MG	A 040405	001	Sep 08, 2000 Apr CHRS
	HYDROCODONE BITARTRATE AND ACETAMINOPHEN					
	@	ALVOGEN	300MG;5MG	A 208540	001	Nov 08, 2018 Aug CAHN
	@		300MG;7.5MG	A 208540	002	Nov 08, 2018 Aug CAHN
	@		300MG;10MG	A 208540	003	Nov 08, 2018 Aug CAHN
	@		325MG;2.5MG	A 209958	001	Oct 24, 2018 Aug CAHN
	@		325MG;5MG	A 209958	002	Oct 24, 2018 Aug CAHN
	@		325MG;7.5MG	A 209958	003	Oct 24, 2018 Aug CAHN
	@		325MG;10MG	A 209958	004	Oct 24, 2018 Aug CAHN
AA	!	SPECGX LLC	325MG;10MG	A 040400	001	Jul 26, 2000 Apr CHRS
AA		STRIDES PHARMA	325MG;5MG	A 040655	001	Jan 19, 2006 Oct CAHN
AA			325MG;7.5MG	A 040656	001	Jan 19, 2006 Oct CAHN
>A>	AA		325MG;10MG	A 040355	001	May 31, 2000 Nov CAHN
>D>	AA	VINTAGE PHARMS	325MG;10MG	A 040355	001	May 31, 2000 Nov CAHN
	NORCO					
	@	APIL	325MG;2.5MG	A 040148	004	Jul 07, 2014 Apr DISC
	@		325MG;5MG	A 040099	001	Jun 25, 1997 Apr DISC
	@		325MG;5MG	A 040148	005	Jul 07, 2014 Apr DISC
	@		325MG;7.5MG	A 040148	003	Sep 12, 2000 Apr DISC
	@		325MG;10MG	A 040148	001	Feb 14, 1997 Apr DISC

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

	SOLUTION;ORAL					
	OXYCODONE AND ACETAMINOPHEN					
AA	!	ABHAI LLC	325MG/5ML;5MG/5ML	A 211499	001	Dec 31, 2018 Aug CTEC
AA		NOSTRUM LABS INC	325MG/5ML;5MG/5ML	A 201448	001	Aug 26, 2021 Aug NEWA
	TABLET;ORAL					
	OXYCODONE 5/APAP 500					
	+	@ BRISTOL MYERS SQUIBB	500MG;5MG	A 085911	001	Aug CRLD
	OXYCODONE AND ACETAMINOPHEN					
AA		CHARTWELL	325MG;5MG	A 207834	001	Aug 15, 2019 Jan CAHN

TABLET;ORAL

OXYCODONE AND ACETAMINOPHEN

AA		325MG;7.5MG	A207834	002	Aug 15, 2019	Jan	CAHN
AA		325MG;10MG	A207834	003	Aug 15, 2019	Jan	CAHN
>D>	AA	VINTAGE PHARMS	325MG;2.5MG	A090733	001	Jul 11, 2013	Nov DISC
>A>	@		325MG;2.5MG	A090733	001	Jul 11, 2013	Nov DISC
>D>	AA		325MG;5MG	A040105	001	Jul 30, 1996	Nov DISC
>A>	@		325MG;5MG	A040105	001	Jul 30, 1996	Nov DISC
>D>	AA		325MG;7.5MG	A090734	001	Jul 11, 2013	Nov DISC
>A>	@		325MG;7.5MG	A090734	001	Jul 11, 2013	Nov DISC
>D>	AA		325MG;10MG	A090734	002	Jul 11, 2013	Nov DISC
>A>	@		325MG;10MG	A090734	002	Jul 11, 2013	Nov DISC
		PERCOCET					
	+	@ VINTAGE PHARMS LLC	325MG;5MG	A085106	002		Aug CRLD
		ROXICET					
	+	@ HIKMA	325MG;5MG	A087003	001		Aug CRLD
	@	HIKMA PHARMS	325MG;5MG	A087003	001		Jan DISC

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE;ORAL

ACETAZOLAMIDE

AB		ACCORD HLTHCARE	500MG	A207659	001	Oct 18, 2018	Apr CMFD
AB	!	INDICUS PHARMA	500MG	A090779	001	Jul 14, 2011	Jun CAHN

TABLET;ORAL

ACETAZOLAMIDE

AB		APPCO	125MG	A211372	001	Feb 22, 2021	Feb NEWA
AB			250MG	A211372	002	Feb 22, 2021	Feb NEWA
AB		RUBICON	125MG	A215101	001	Aug 19, 2021	Aug NEWA
AB			250MG	A215101	002	Aug 19, 2021	Aug NEWA

ACETAZOLAMIDE SODIUM

INJECTABLE;INJECTION

ACETAZOLAMIDE SODIUM

>D>	@	EMCURE PHARMS LTD	EQ 500MG BASE/VIAL	A202693	001	Dec 19, 2014	Nov CMFD
>A>	AP		EQ 500MG BASE/VIAL	A202693	001	Dec 19, 2014	Nov CMFD
>A>	AP	HIKMA	EQ 500MG BASE/VIAL	A040089	001	Feb 28, 1995	Nov CAHN
>D>	AP	WEST-WARD PHARMS INT	EQ 500MG BASE/VIAL	A040089	001	Feb 28, 1995	Nov CAHN

ACETIC ACID, GLACIAL; ALUMINUM ACETATE

SOLUTION/DROPS;OTIC

DOMEBORO

	+	@ BAYER PHARMS	2%;0.79%	A084476	001		Aug CRLD
--	---	----------------	----------	---------	-----	--	----------

ACETYLCYSTEINE

INJECTABLE;INTRAVENOUS

ACETYLCYSTEINE

AP		EXELA PHARMA	6GM/30ML (200MG/ML)	A204797	001	Apr 15, 2021	Apr NEWA
>D>	@	MYLAN INSTITUTIONAL	6GM/30ML (200MG/ML)	A203624	001	Jun 19, 2015	Nov CAHN
>A>	@	RISING	6GM/30ML (200MG/ML)	A203624	001	Jun 19, 2015	Nov CAHN

ACITRETIN

CAPSULE;ORAL

ACITRETIN

AB	!	SIGMAPHARM LABS LLC	25MG	A204633	004	May 22, 2015	Sep CHRS
		SORIATANE					
	+	@ STIEFEL LABS INC	10MG	N019821	001	Oct 28, 1996	Sep DISC
	+	@	25MG	N019821	002	Oct 28, 1996	Sep DISC

ACLIDINIUM BROMIDE

POWDER, METERED;INHALATION

TUDORZA PRESSAIR

	+	!	ASTRAZENECA	0.4MG/INH	N202450	001	Jul 23, 2012	Feb CAHN
--	---	---	-------------	-----------	---------	-----	--------------	----------

ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE

POWDER, METERED;INHALATION

DUAKLIR PRESSAIR

	+	!	ASTRAZENECA	0.4MG/INH;0.012MG/INH	N210595	001	Mar 29, 2019	Jun CHRS
	+			0.4MG/INH;0.012MG/INH	N210595	001	Mar 29, 2019	Jun CRLD
				0.4MG/INH;0.012MG/INH	N210595	001	Mar 29, 2019	Feb CAHN

ACYCLOVIR

	CAPSULE; ORAL						
	ACYCLOVIR						
>D>	@ DAVA PHARMS INC	200MG	A 074833	001	Apr 22, 1997	Nov	CAHN
>A>	@ STRIDES PHARMA	200MG	A 074833	001	Apr 22, 1997	Nov	CAHN
	OINTMENT; TOPICAL						
	ACYCLOVIR						
	@ ANDA REPOSITORY	5%	A 206437	001	Jul 31, 2017	Jun	DISC
AB	MACLEODS PHARMS LTD	5%	A 212444	001	May 19, 2021	May	NEWA
>A> AB	PRINSTON INC	5%	A 212202	001	Nov 15, 2021	Nov	NEWA
	SUSPENSION; ORAL						
	ACYCLOVIR						
AB	VISTAPHARM	200MG/5ML	A 213951	001	Jan 11, 2021	Oct	CMFD
	@	200MG/5ML	A 213951	001	Jan 11, 2021	Jul	DISC
AB		200MG/5ML	A 213951	001	Jan 11, 2021	Jan	NEWA
	TABLET; ORAL						
	ACYCLOVIR						
>D> AB	DAVA PHARMS INC	400MG	A 074946	001	Nov 19, 1997	Nov	CAHN
>D> AB		800MG	A 074946	002	Nov 19, 1997	Nov	CAHN
>A> AB	STRIDES PHARMA	400MG	A 074946	001	Nov 19, 1997	Nov	CAHN
>A> AB		800MG	A 074946	002	Nov 19, 1997	Nov	CAHN

ACYCLOVIR SODIUM

	INJECTABLE; INJECTION						
	ACYCLOVIR SODIUM						
AP	NAMIGEN LLC	EQ 50MG BASE/ML	A 207919	001	Jun 17, 2020	Jun	CAHN
AP	ZYDUS PHARMS	EQ 50MG BASE/ML	A 206535	001	Aug 31, 2018	Jan	CHRS
AP	!	EQ 50MG BASE/ML	A 206535	001	Aug 31, 2018	Jan	CPOT

ADAPALENE

	GEL; TOPICAL						
	ADAPALENE						
	@ TOLMAR	0.3%	A 200298	001	Jun 14, 2012	Sep	DISC

ADAPALENE; BENZOYL PEROXIDE

	GEL; TOPICAL						
	ADAPALENE AND BENZOYL PEROXIDE						
AB	TARO	0.3%; 2.5%	A 209148	001	Oct 17, 2018	Oct	CMFD
	@ TOLMAR	0.1%; 2.5%	A 206164	001	May 23, 2018	Sep	DISC
	EPIDUO FORTE						
AB	+! GALDERMA LABS	0.3%; 2.5%	N 207917	001	Jul 15, 2015	Oct	CTEC
	+!	0.3%; 2.5%	N 207917	001	Jul 15, 2015	Feb	CTEC

ADENOSINE

	SOLUTION; INTRAVENOUS						
	ADENOSINE						
AP	EMCURE PHARMS LTD	60MG/20ML (3MG/ML)	A 202313	001	Sep 15, 2014	Feb	CMFD
AP		90MG/30ML (3MG/ML)	A 202313	002	Sep 15, 2014	Feb	CMFD

AIR POLYMER-TYPE A

	FOAM; INTRAUTERINE						
	EXEM FOAM KIT						
+!	GISKIT	10ML	N 212279	001	Nov 07, 2019	Aug	CAHN

ALBENDAZOLE

	TABLET; ORAL						
	ALBENDAZOLE						
AB	DR REDDYS	200MG	A 211034	001	Jan 26, 2021	Jan	NEWA
	@ LUPIN LTD	200MG	A 211636	001	Jun 10, 2020	Jan	DISC
AB	MSN	200MG	A 213435	001	Jan 21, 2021	Jan	NEWA

ALBUTEROL SULFATE

	AEROSOL, METERED; INHALATION						
	ALBUTEROL SULFATE						
	@ PADAGIS US	EQ 0.09MG BASE/INH	A 203760	001	Feb 24, 2020	Jul	CAHN
AB1	SANDOZ INC	EQ 0.09MG BASE/INH	A 207085	001	Jun 01, 2021	May	NEWA
	SOLUTION; INHALATION						
	ALBUTEROL SULFATE						
	@ LUOXIN AUROVITAS	EQ 0.021% BASE	A 211888	001	Apr 20, 2020	Aug	CAHN
	@	EQ 0.042% BASE	A 211888	002	Apr 20, 2020	Aug	CAHN
AN		EQ 0.083% BASE	A 206224	001	Oct 17, 2017	Aug	CAHN



TABLET;ORAL

ALBUTEROL SULFATE

AB	AIZANT	EQ 2MG BASE	A210948	001	Mar 15, 2019	Feb	CMFD
AB		EQ 4MG BASE	A210948	002	Mar 15, 2019	Feb	CMFD
AB	APPCO	EQ 2MG BASE	A210948	001	Mar 15, 2019	Sep	CAHN
AB		EQ 4MG BASE	A210948	002	Mar 15, 2019	Sep	CAHN
>A>	@ CHARTWELL RX	EQ 2MG BASE	A072151	001	Dec 05, 1989	Nov	CAHN
>A>	@	EQ 4MG BASE	A072152	001	Dec 05, 1989	Nov	CAHN
>D>	@ DAVA PHARMS INC	EQ 2MG BASE	A072860	002	Dec 20, 1989	Nov	CAHN
>D>	@	EQ 4MG BASE	A072860	001	Dec 20, 1989	Nov	CAHN
	@ EYWA	EQ 2MG BASE	A213524	001	Oct 08, 2020	Apr	DISC
	@	EQ 4MG BASE	A213524	002	Oct 08, 2020	Apr	DISC
>A>	@ STRIDES PHARMA	EQ 2MG BASE	A072860	002	Dec 20, 1989	Nov	CAHN
>A>	@	EQ 4MG BASE	A072860	001	Dec 20, 1989	Nov	CAHN
>D>	@ YAOPHARMA CO LTD	EQ 2MG BASE	A072151	001	Dec 05, 1989	Nov	CAHN
>D>	@	EQ 4MG BASE	A072152	001	Dec 05, 1989	Nov	CAHN

TABLET, EXTENDED RELEASE;ORAL

VOSPIRE ER

>D>	DAVA PHARMS INC	EQ 4MG BASE	A076130	002	Sep 26, 2002	Nov	CAHN
		EQ 4MG BASE	A076130	002	Sep 26, 2002	Sep	CTEC
>D>	@	EQ 8MG BASE	A076130	003	Sep 26, 2002	Nov	CAHN
>A>	STRIDES PHARMA	EQ 4MG BASE	A076130	002	Sep 26, 2002	Nov	CAHN
>A>	@	EQ 8MG BASE	A076130	003	Sep 26, 2002	Nov	CAHN

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION;INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

	@ AUROBINDO PHARMA LTD	EQ 0.083% BASE;0.017%	A206532	001	Jul 08, 2020	Jan	DISC
	@ LUOXIN AUROVITAS	EQ 0.083% BASE;0.017%	A206532	001	Jul 08, 2020	Aug	CAHN
AN	! NEPHRON	EQ 0.083% BASE;0.017%	A076749	001	Dec 31, 2007	Sep	CHRS

ALENDRONATE SODIUM

TABLET;ORAL

ALENDRONATE SODIUM

>A>	@ CHARTWELL RX	EQ 5MG BASE	A075871	001	Apr 22, 2009	Nov	CAHN
>A>	@	EQ 10MG BASE	A075871	002	Apr 22, 2009	Nov	CAHN
>A>	@	EQ 35MG BASE	A075871	004	Apr 22, 2009	Nov	CAHN
>A>	@	EQ 40MG BASE	A075871	003	Apr 22, 2009	Nov	CAHN
>A>	@	EQ 70MG BASE	A075871	005	Apr 22, 2009	Nov	CAHN
	@ IMPAX LABS INC	EQ 5MG BASE	A075710	001	Feb 06, 2008	Oct	DISC
	@	EQ 10MG BASE	A075710	002	Feb 06, 2008	Oct	DISC
	@	EQ 35MG BASE	A075710	003	Feb 06, 2008	Oct	DISC
	@	EQ 40MG BASE	A075710	004	Feb 06, 2008	Oct	DISC
	@	EQ 70MG BASE	A075710	005	Feb 06, 2008	Oct	DISC
	@ JUBILANT CADISTA	EQ 5MG BASE	A090557	001	Feb 18, 2010	Jun	DISC
	@	EQ 10MG BASE	A090557	002	Feb 18, 2010	Jun	DISC
	@	EQ 35MG BASE	A090557	003	Feb 18, 2010	Jun	DISC
	@	EQ 70MG BASE	A090557	004	Feb 18, 2010	Jun	DISC
	@ PICKET PHARMS	EQ 5MG BASE	A079049	003	Aug 04, 2008	Oct	CAHN
	@	EQ 10MG BASE	A079049	004	Aug 04, 2008	Oct	CAHN
	@	EQ 35MG BASE	A079049	001	Aug 04, 2008	Oct	CAHN
	@	EQ 70MG BASE	A079049	002	Aug 04, 2008	Oct	CAHN
>D>	@ UPSHER SMITH LABS	EQ 5MG BASE	A075871	001	Apr 22, 2009	Nov	CAHN
>D>	@	EQ 10MG BASE	A075871	002	Apr 22, 2009	Nov	CAHN
>D>	@	EQ 35MG BASE	A075871	004	Apr 22, 2009	Nov	CAHN
>D>	@	EQ 40MG BASE	A075871	003	Apr 22, 2009	Nov	CAHN
>D>	@	EQ 70MG BASE	A075871	005	Apr 22, 2009	Nov	CAHN
	@ US ANTIBIOTICS	EQ 5MG BASE	A079049	003	Aug 04, 2008	May	CAHN
	@	EQ 10MG BASE	A079049	004	Aug 04, 2008	May	CAHN
	@	EQ 35MG BASE	A079049	001	Aug 04, 2008	May	CAHN
	@	EQ 70MG BASE	A079049	002	Aug 04, 2008	May	CAHN

ALENDRONATE SODIUM; CHOLECALCIFEROL

TABLET;ORAL

FOSAMAX PLUS D

+	ORGANON	EQ 70MG BASE;2,800 IU	N021762	001	Apr 07, 2005	Jun	CAHN
+!		EQ 70MG BASE;5,600 IU	N021762	002	Apr 26, 2007	Jun	CAHN

ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

TEKTRUNA HCT

+ @	NODEN PHARMA	EQ 150MG BASE;12.5MG	N022107	001	Jan 18, 2008	May	DISC
+ @		EQ 150MG BASE;25MG	N022107	002	Jan 18, 2008	May	DISC

ALLOPURINOL

TABLET;ORAL

ALLOPURINOL

AB	CHARTWELL	100MG	A077353	001	Sep 08, 2005	Jun	CAHN
AB		300MG	A077353	002	Sep 08, 2005	Jun	CAHN

ALPRAZOLAM

TABLET;ORAL

ALPRAZOLAM

	@ MYLAN	0.25MG	A074215	001	Jan 27, 1994	Jun	DISC
	@	0.5MG	A074215	002	Jan 27, 1994	Jun	DISC
	@	1MG	A074215	003	Jan 27, 1994	Jun	DISC
	@	2MG	A074215	004	Jan 27, 1994	Jun	DISC
AB	NOVITIUM PHARMA	0.25MG	A074174	001	Oct 19, 1993	Apr	CMFD
AB		0.5MG	A074174	002	Oct 19, 1993	Apr	CMFD
AB		1MG	A074174	003	Oct 19, 1993	Apr	CMFD
AB		2MG	A074174	004	Oct 19, 1993	Apr	CMFD
AB	STRIDES PHARMA	0.25MG	A090248	001	Sep 17, 2010	Oct	CAHN
AB		0.5MG	A090248	002	Sep 17, 2010	Oct	CAHN
AB		1MG	A090248	003	Sep 17, 2010	Oct	CAHN
AB		2MG	A090248	004	Sep 17, 2010	Oct	CAHN

ALPROSTADIL

INJECTABLE; INJECTION

CAVERJECT

	+ @	PFIZER	0.005MG/VIAL	N020379	003	Jun 27, 1996	Jan	CAHN
AP	+		0.01MG/VIAL	N020379	001	Jul 06, 1995	Jan	CAHN
AP	+	!	0.02MG/VIAL	N020379	002	Jul 06, 1995	Jan	CAHN
AP	+	!	0.04MG/VIAL	N020379	004	May 19, 1997	Jan	CAHN

CAVERJECT IMPULSE

PFIZER

			0.01MG/VIAL	N021212	001	Jun 11, 2002	Jan	CAHN
			0.02MG/VIAL	N021212	002	Jun 11, 2002	Jan	CAHN

PROSTIN VR PEDIATRIC

AP	+	!	PFIZER	0.5MG/ML	N018484	001		Jan	CAHN
----	---	---	--------	----------	---------	-----	--	-----	------

AMANTADINE HYDROCHLORIDE

CAPSULE;ORAL

AMANTADINE HYDROCHLORIDE

BX		STRIDES PHARMA	100MG	A209047	001	Jun 07, 2017	Sep	CTEC
----	--	----------------	-------	---------	-----	--------------	-----	------

SYRUP;ORAL

AMANTADINE HYDROCHLORIDE

>A>	@	GENUS	50MG/5ML	A076352	001	Sep 10, 2004	Nov	CAHN
AA		INVATECH	50MG/5ML	A214178	001	Aug 20, 2021	Aug	NEWA
>D>	@	LANNETT CO INC	50MG/5ML	A076352	001	Sep 10, 2004	Nov	CAHN
AA		NOVELGENIX THERAPS	50MG/5ML	A214178	001	Aug 20, 2021	Sep	CAHN
	@	WOCKHARDT BIO AG	50MG/5ML	A075060	001	Dec 24, 1998	Jan	DISC

TABLET;ORAL

AMANTADINE HYDROCHLORIDE

	@	INVAGEN PHARMS	100MG	A207571	001	Jan 31, 2017	Jan	DISC
BX		STRIDES PHARMA	100MG	A209035	001	Jun 09, 2017	Sep	CTEC

TABLET, EXTENDED RELEASE;ORAL

OSMOLEX ER

+	ADAMAS PHARMA	EQ 129MG BASE	N209410	001	Feb 16, 2018	Jan	CAHN	
+	@		EQ 161MG BASE	N209410	004	Apr 22, 2020	Jan	CAHN
+		EQ 193MG BASE	N209410	002	Feb 16, 2018	Jan	CAHN	
+	@		EQ 258MG BASE	N209410	003	Feb 16, 2018	May	DISC
+	!		EQ 258MG BASE	N209410	003	Feb 16, 2018	Jan	CAHN
+	ADAMAS PHARMS	EQ 129MG BASE	N209410	001	Feb 16, 2018	Jan	CAHN	
+	@		EQ 161MG BASE	N209410	004	Apr 22, 2020	Jan	CAHN
+		EQ 193MG BASE	N209410	002	Feb 16, 2018	Jan	CAHN	
+	!		EQ 258MG BASE	N209410	003	Feb 16, 2018	Jan	CAHN

AMILORIDE HYDROCHLORIDE

TABLET;ORAL  
 AMILORIDE HYDROCHLORIDE  
 AB USPHARMA WINDLAS 5MG A204180 001 Aug 07, 2015 Sep CAHN

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL  
 AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE  
 @ CHARTWELL RX EQ 5MG ANHYDROUS;50MG A073357 001 Nov 27, 1991 Aug CAHN

AMINOCAPROIC ACID

SOLUTION;ORAL  
 AMICAR  
 AA +! AKORN 0.25GM/ML N015230 002 Feb CPOT  
 AA +! 1.25GM/5ML N015230 002 Feb CDFR  
 AMINOCAPROIC ACID  
 AA AIRIS PHARMA PVT LTD 0.25GM/ML A213825 001 Apr 08, 2021 Apr NEWA  
 AA AMNEAL 0.25GM/ML A212780 001 Aug 23, 2019 Feb CPOT  
 AA 1.25GM/5ML A212780 001 Aug 23, 2019 Feb CDFR  
 AA BELCHER 0.25GM/ML A213825 001 Apr 08, 2021 Jul CAHN  
 AA LEADING PHARMA LLC 0.25GM/ML A214140 001 Jan 26, 2021 Feb CPOT  
 AA 1.25GM/5ML A214140 001 Jan 26, 2021 Feb CDFR  
 AA TULEX PHARMS INC 0.25GM/ML A212494 001 Aug 11, 2020 Feb CPOT  
 AA 1.25GM/5ML A212494 001 Aug 11, 2020 Feb CDFR  
 AA VISTAPHARM 0.25GM/ML A212814 001 Feb 26, 2020 Feb CPOT  
 AA 1.25GM/5ML A212814 001 Feb 26, 2020 Feb CDFR

SYRUP;ORAL

AMINOCAPROIC ACID  
 AA LEADING PHARMA LLC 1.25GM/5ML A214140 001 Jan 26, 2021 Jan NEWA  
 TABLET;ORAL  
 AMINOCAPROIC ACID  
 AB EDENBRIDGE PHARMS 500MG A212110 001 Jun 14, 2021 Jun NEWA  
 AB LEADING PHARMA LLC 500MG A213928 001 Feb 12, 2021 Feb NEWA  
 AB 1GM A213928 002 Feb 12, 2021 Feb NEWA

AMINOPHYLLINE

INJECTABLE;INJECTION  
 AMINOPHYLLIN  
 + @ GD SEARLE LLC 25MG/ML A087243 001 May 24, 1982 Aug CRLD  
 + @ 25MG/ML A087621 001 May 24, 1982 Aug CRLD

AMIODARONE HYDROCHLORIDE

INJECTABLE;INJECTION  
 AMIODARONE HYDROCHLORIDE  
 AP ACELLA 50MG/ML A077610 001 Oct 30, 2008 Aug CAHN  
 AP 50MG/ML A077834 001 Oct 30, 2008 Aug CAHN  
 TABLET;ORAL  
 AMIODARONE HYDROCHLORIDE  
 AB RUBICON 100MG A078578 002 Feb 26, 2021 Feb NEWA  
 AB 400MG A078578 003 Feb 26, 2021 Feb NEWA

AMITRIPTYLINE HYDROCHLORIDE

CONCENTRATE;ORAL  
 ENDEP  
 + @ ROCHE 40MG/ML A085749 001 Oct CRLD

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE  
 AB MANKIND PHARMA 10MG A213999 001 Feb 19, 2021 Feb NEWA  
 AB 25MG A213999 002 Feb 19, 2021 Feb NEWA  
 AB 50MG A213999 003 Feb 19, 2021 Feb NEWA  
 AB 75MG A213999 004 Feb 19, 2021 Feb NEWA  
 AB 100MG A213999 005 Feb 19, 2021 Feb NEWA  
 AB 150MG A213999 006 Feb 19, 2021 Feb NEWA  
 @ MYLAN 10MG A086009 002 Jun DISC  
 @ 25MG A086009 003 Jun DISC  
 @ 50MG A086009 001 Jun DISC  
 @ 75MG A086009 004 Jun DISC  
 @ 100MG A086009 005 Jun DISC  
 @ 150MG A086009 006 Jun DISC  
 AB + SANDOZ 10MG A085968 004 Aug CRLD  
 >D> AB ! 25MG A085968 002 Nov CRLD

## TABLET;ORAL

## AMITRIPTYLINE HYDROCHLORIDE

>A>	AB	+	!	25MG	A 085968	002			Nov	CRLD
	AB	+		50MG	A 085968	001			Aug	CRLD
	AB	+		75MG	A 085968	006			Aug	CRLD
	AB	+		100MG	A 085968	003			Aug	CRLD
	AB	+		150MG	A 085968	005			Aug	CRLD
	AB		UNICHEM	10MG	A 214548	001	May 19, 2021		May	NEWA
	AB			25MG	A 214548	002	May 19, 2021		May	NEWA
	AB			50MG	A 214548	003	May 19, 2021		May	NEWA
	AB			75MG	A 214548	004	May 19, 2021		May	NEWA
	AB			100MG	A 214548	005	May 19, 2021		May	NEWA
	AB			150MG	A 214548	006	May 19, 2021		May	NEWA
>A>	AB		UPSHER SMITH LABS	10MG	A 212654	002	Sep 29, 2021		Nov	NEWA
>D>		@		25MG	A 212654	001	Apr 07, 2020		Nov	CMFD
>A>	AB			25MG	A 212654	001	Apr 07, 2020		Nov	CMFD
>A>	AB			50MG	A 212654	003	Sep 29, 2021		Nov	NEWA
>A>	AB			75MG	A 212654	004	Sep 29, 2021		Nov	NEWA
>A>	AB			100MG	A 212654	005	Sep 29, 2021		Nov	NEWA
>A>	AB			150MG	A 212654	006	Sep 29, 2021		Nov	NEWA

AMLODIPINE BESYLATE

## TABLET;ORAL

## AMLODIPINE BESYLATE

	AB		CHARTWELL RX	EQ 2.5MG BASE	A 076692	001	Jul 20, 2007		Oct	CAHN
	AB			EQ 5MG BASE	A 076692	002	Jul 20, 2007		Oct	CAHN
	AB			EQ 10MG BASE	A 076692	003	Jul 20, 2007		Oct	CAHN
>D>	AB		UPSHER SMITH LABS	EQ 2.5MG BASE	A 077759	001	Jul 09, 2007		Nov	DISC
>A>		@		EQ 2.5MG BASE	A 077759	001	Jul 09, 2007		Nov	DISC
>D>	AB			EQ 5MG BASE	A 077759	002	Jul 09, 2007		Nov	DISC
>A>		@		EQ 5MG BASE	A 077759	002	Jul 09, 2007		Nov	DISC
>D>	AB			EQ 10MG BASE	A 077759	003	Jul 09, 2007		Nov	DISC
>A>		@		EQ 10MG BASE	A 077759	003	Jul 09, 2007		Nov	DISC
		@	WOCKHARDT	EQ 2.5MG BASE	A 078500	001	Sep 06, 2007		Jan	DISC
		@		EQ 5MG BASE	A 078500	002	Sep 06, 2007		Jan	DISC
		@		EQ 10MG BASE	A 078500	003	Sep 06, 2007		Jan	DISC

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

## TABLET;ORAL

## AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

		@	MYLAN	EQ 2.5MG BASE;EQ 10MG BASE	A 200465	001	Nov 29, 2013		Oct	DISC
AB		@		EQ 2.5MG BASE;EQ 10MG BASE	A 200465	001	Nov 29, 2013		Oct	CAHN
		@		EQ 2.5MG BASE;EQ 20MG BASE	A 200465	002	Nov 29, 2013		Oct	DISC
AB		@		EQ 2.5MG BASE;EQ 20MG BASE	A 200465	002	Nov 29, 2013		Oct	CAHN
		@		EQ 2.5MG BASE;EQ 40MG BASE	A 200465	003	Nov 29, 2013		Oct	DISC
AB		@		EQ 2.5MG BASE;EQ 40MG BASE	A 200465	003	Nov 29, 2013		Oct	CAHN
AB				EQ 5MG BASE;EQ 10MG BASE	A 200465	004	Nov 29, 2013		Oct	CAHN
AB				EQ 5MG BASE;EQ 20MG BASE	A 200465	005	Nov 29, 2013		Oct	CAHN
AB				EQ 5MG BASE;EQ 40MG BASE	A 200465	006	Nov 29, 2013		Oct	CAHN
AB				EQ 5MG BASE;EQ 80MG BASE	A 200465	007	Nov 29, 2013		Oct	CAHN
AB				EQ 10MG BASE;EQ 10MG BASE	A 200465	008	Nov 29, 2013		Oct	CAHN
AB				EQ 10MG BASE;EQ 20MG BASE	A 200465	009	Nov 29, 2013		Oct	CAHN
AB				EQ 10MG BASE;EQ 40MG BASE	A 200465	010	Nov 29, 2013		Oct	CAHN
AB				EQ 10MG BASE;EQ 80MG BASE	A 200465	011	Nov 29, 2013		Oct	CAHN

AMLODIPINE BESYLATE; CELECOXIB

## TABLET;ORAL

## CONSENSI

	+	@	COEPTIS	EQ 2.5MG BASE;200MG	N 210045	001	May 31, 2018		Sep	DISC
	+	@		EQ 5MG BASE;200MG	N 210045	002	May 31, 2018		Sep	DISC
	+	@		EQ 10MG BASE;200MG	N 210045	003	May 31, 2018		Sep	DISC
	+	@	PURPLE BIOTECH	EQ 2.5MG BASE;200MG	N 210045	001	May 31, 2018		Oct	CAHN
	+	@		EQ 5MG BASE;200MG	N 210045	002	May 31, 2018		Oct	CAHN
	+	@		EQ 10MG BASE;200MG	N 210045	003	May 31, 2018		Oct	CAHN

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

## TABLET;ORAL

## AMLODIPINE AND OLMESARTAN MEDOXOMIL

	@	JUBILANT GENERICS	EQ 5MG BASE;20MG	A 207450	001	May 15, 2017		Jun	DISC
	@		EQ 5MG BASE;40MG	A 207450	002	May 15, 2017		Jun	DISC
	@		EQ 10MG BASE;20MG	A 207450	003	May 15, 2017		Jun	DISC
	@		EQ 10MG BASE;40MG	A 207450	004	May 15, 2017		Jun	DISC

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

AP	METHODIST	3.75mCi-260mCi/ML	A 215083	001	Jul 09, 2021	Jul	NEWA
AP	NUKEMED	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A 204455	001	Apr 23, 2015	Jan	CAHN

AMOXAPINE

TABLET; ORAL

AMOXAPINE

@ CHARTWELL RX

@

@

@

		25MG	A 072943	001	Jun 28, 1991	Oct	CAHN
		50MG	A 072944	001	Jun 28, 1991	Oct	CAHN
		100MG	A 072878	001	Jun 28, 1991	Oct	CAHN
		150MG	A 072879	001	Jun 28, 1991	Oct	CAHN

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

AB	CHARTWELL	250MG	A 062058	001		Jun	CAHN
AB		500MG	A 062058	002		Jun	CAHN
>D>	@ DAVA PHARMS INC	250MG	A 062884	001	Feb 25, 1988	Nov	CAHN
>D>	@	500MG	A 062881	001	Feb 25, 1988	Nov	CAHN
>A>	@ STRIDES PHARMA	250MG	A 062884	001	Feb 25, 1988	Nov	CAHN
>A>	@	500MG	A 062881	001	Feb 25, 1988	Nov	CAHN

AMOXIL

AB	US ANTIBIOTICS	250MG	A 062216	001		May	CAHN
AB		500MG	A 062216	004		May	CAHN

FOR SUSPENSION; ORAL

AMOXIL

AB	US ANTIBIOTICS	50MG/ML	A 062226	005		May	CAHN
AB		125MG/5ML	A 062226	001		May	CAHN
	+ @	200MG/5ML	N 050760	001	Apr 15, 1999	May	CAHN
AB		250MG/5ML	A 062226	002		May	CAHN
	+ @	400MG/5ML	N 050760	002	Apr 15, 1999	May	CAHN
	LAROTID						
AB	US ANTIBIOTICS	125MG/5ML	A 062226	003		May	CAHN
AB		250MG/5ML	A 062226	004		May	CAHN

TABLET; ORAL

AMOXICILLIN

>D>	@ DAVA PHARMS INC	875MG	A 065344	001	Jan 15, 2009	Nov	CAHN
>A>	@ STRIDES PHARMA	875MG	A 065344	001	Jan 15, 2009	Nov	CAHN

AMOXIL

+ @ US ANTIBIOTICS

+ @

		500MG	N 050754	002	Jul 10, 1998	May	CAHN
		875MG	N 050754	001	Jul 10, 1998	May	CAHN

TABLET, CHEWABLE; ORAL

AMOXICILLIN

>D>	@ DAVA PHARMS INC	125MG	A 064139	001	Jan 29, 1996	Nov	CAHN
>D>	@	250MG	A 064139	002	Jan 29, 1996	Nov	CAHN
BX	HIKMA	125MG	A 205274	001	Jun 25, 2020	Sep	CTEC
BX		250MG	A 205274	002	Jun 25, 2020	Sep	CTEC
>A>	@ STRIDES PHARMA	125MG	A 064139	001	Jan 29, 1996	Nov	CAHN
>A>	@	250MG	A 064139	002	Jan 29, 1996	Nov	CAHN

AMOXIL

+ @ US ANTIBIOTICS

@

+ @

@

		125MG	N 050542	002		May	CAHN
		200MG	N 050761	001	Apr 15, 1999	May	CAHN
		250MG	N 050542	001		May	CAHN
		400MG	N 050761	002	Apr 15, 1999	May	CAHN

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED REL PELLETS; ORAL

LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN (COPACKAGED)

@ ANI PHARMS

@

@

		500MG; 500MG; 30MG	A 200218	001	Aug 30, 2013	Jul	CTNA
		500MG; 500MG; 30MG	A 200218	001	Aug 30, 2013	Jul	CPOT
		500MG, N/A, N/A; N/A, 500MG, N/A; N/A, N/A, 30MG	A 200218	001	Aug 30, 2013	Jul	CDFR
AB	! RISING	500MG; 500MG; 30MG	A 206006	001	Oct 07, 2016	Jul	CTNA
AB	!	500MG; 500MG; 30MG	A 206006	001	Oct 07, 2016	Jul	CPOT
AB	!	500MG, N/A, N/A; N/A, 500MG, N/A; N/A, N/A, 30MG	A 206006	001	Oct 07, 2016	Jul	CDFR
AB	SANDOZ INC	500MG; 500MG; 30MG	A 202588	001	Mar 04, 2014	Jul	CTNA
AB		500MG; 500MG; 30MG	A 202588	001	Mar 04, 2014	Jul	CPOT
AB		500MG, N/A, N/A; N/A, 500MG, N/A; N/A, N/A, 30MG	A 202588	001	Mar 04, 2014	Jul	CDFR

CAPSULE, TABLET, CAPSULE, DELAYED REL PELLETS;ORAL  
PREVPAC (COPACKAGED)

+ @	TAKEDA PHARMS USA	500MG;500MG;30MG	N050757	001	Dec 02, 1997	Jul CTNA
+ @		500MG;500MG;30MG	N050757	001	Dec 02, 1997	Jul CPOT
+ @		500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30MG	N050757	001	Dec 02, 1997	Jul CDFR

AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED RELEASE;ORAL  
OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN

+ @	CUMBERLAND PHARMS	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,20MG	N050824	001	Feb 08, 2011	May DISC
-----	-------------------	--	---------	-----	--------------	----------

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL  
AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	MICRO LABS LTD INDIA	200MG/5ML;EQ 28.5MG BASE/5ML	A205187	001	May 21, 2021	May NEWA
AB		400MG/5ML;EQ 57MG BASE/5ML	A205187	002	May 21, 2021	May NEWA
	AUGMENTIN '125'					
AB	+ US ANTIBIOTICS	125MG/5ML;EQ 31.25MG BASE/5ML	N050575	001	Aug 06, 1984	May CAHN
	AUGMENTIN '200'					
	+ @ US ANTIBIOTICS	200MG/5ML;EQ 28.5MG BASE/5ML	N050725	001	May 31, 1996	May CAHN
	AUGMENTIN '250'					
AB	+! US ANTIBIOTICS	250MG/5ML;EQ 62.5MG BASE/5ML	N050575	002	Aug 06, 1984	May CAHN
	AUGMENTIN '400'					
	+ @ US ANTIBIOTICS	400MG/5ML;EQ 57MG BASE/5ML	N050725	002	May 31, 1996	May CAHN
	AUGMENTIN ES-600					
AB	+ US ANTIBIOTICS	600MG/5ML;EQ 42.9MG BASE/5ML	N050755	001	Jun 22, 2001	May CAHN
	TABLET;ORAL					
	AUGMENTIN '250'					
	+ @ US ANTIBIOTICS	250MG;EQ 125MG BASE	N050564	001	Aug 06, 1984	May CAHN
	AUGMENTIN '500'					
	+ @ US ANTIBIOTICS	500MG;EQ 125MG BASE	N050564	002	Aug 06, 1984	May CAHN
	AUGMENTIN '875'					
AB	+ US ANTIBIOTICS	875MG;EQ 125MG BASE	N050720	001	Feb 13, 1996	May CAHN
	TABLET, CHEWABLE;ORAL					
	AUGMENTIN '125'					
	+ @ US ANTIBIOTICS	125MG;EQ 31.25MG BASE	N050597	001	Jul 22, 1985	May CAHN
	AUGMENTIN '200'					
	+ @ US ANTIBIOTICS	200MG;EQ 28.5MG BASE	N050726	001	May 31, 1996	May CAHN
	AUGMENTIN '250'					
	+ @ US ANTIBIOTICS	250MG;EQ 62.5MG BASE	N050597	002	Jul 22, 1985	May CAHN
	AUGMENTIN '400'					
	+ @ US ANTIBIOTICS	400MG;EQ 57MG BASE	N050726	002	May 31, 1996	May CAHN
	TABLET, EXTENDED RELEASE;ORAL					
	AUGMENTIN XR					
	+ @ US ANTIBIOTICS	1GM;EQ 62.5MG BASE	N050785	001	Sep 25, 2002	May CAHN

AMPHETAMINE

SUSPENSION, EXTENDED RELEASE;ORAL  
ADZENYS ER

+ @	NEOS THERAPS INC	EQ 1.25MG BASE/ML	N204325	001	Sep 15, 2017	Sep DISC
-----	------------------	-------------------	---------	-----	--------------	----------

>A> TABLET, EXTENDED RELEASE;ORAL

>A> DYANAVAL XR

>A>	+ TRIS PHARMA INC	EQ 5MG BASE	N210526	001	Nov 04, 2021	Nov NEWA
>A>		EQ 10MG BASE	N210526	002	Nov 04, 2021	Nov NEWA
>A>		EQ 15MG BASE	N210526	003	Nov 04, 2021	Nov NEWA
>A>	+!	EQ 20MG BASE	N210526	004	Nov 04, 2021	Nov NEWA

AMPHETAMINE ASPARTATE ; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	RHODES PHARMS	2.5MG;2.5MG;2.5MG;2.5MG	A213111	003	Jan 13, 2021	Jan NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A213111	005	Jan 13, 2021	Jan NEWA
AB		5MG;5MG;5MG;5MG	A213111	006	Jan 13, 2021	Jan NEWA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DETROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	ASCENT PHARMS INC	1.25MG;1.25MG;1.25MG;1.25MG	A214959	001	Sep 29, 2021	Sep	NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A214959	002	Sep 29, 2021	Sep	NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A214959	003	Sep 29, 2021	Sep	NEWA
AB		5MG;5MG;5MG;5MG	A214959	004	Sep 29, 2021	Sep	NEWA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A214959	005	Sep 29, 2021	Sep	NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A214959	006	Sep 29, 2021	Sep	NEWA
>A>	LANNETT CO INC	1.25MG;1.25MG;1.25MG;1.25MG	A214403	001	Nov 26, 2021	Nov	NEWA
>A>		2.5MG;2.5MG;2.5MG;2.5MG	A214403	002	Nov 26, 2021	Nov	NEWA
>A>		3.75MG;3.75MG;3.75MG;3.75MG	A214403	003	Nov 26, 2021	Nov	NEWA
>A>		5MG;5MG;5MG;5MG	A214403	004	Nov 26, 2021	Nov	NEWA
>A>		6.25MG;6.25MG;6.25MG;6.25MG	A214403	005	Nov 26, 2021	Nov	NEWA
>A>		7.5MG;7.5MG;7.5MG;7.5MG	A214403	006	Nov 26, 2021	Nov	NEWA

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

>A>	@ AUROLIFE PHARMA LLC	1.25MG;1.25MG;1.25MG;1.25MG	A211876	001	Jun 24, 2020	Nov	CAHN
>A>	@	2.5MG;2.5MG;2.5MG;2.5MG	A211876	002	Jun 24, 2020	Nov	CAHN
>A>	@	3.75MG;3.75MG;3.75MG;3.75MG	A211876	003	Jun 24, 2020	Nov	CAHN
>A>	@	5MG;5MG;5MG;5MG	A211876	004	Jun 24, 2020	Nov	CAHN
>A>	@	6.25MG;6.25MG;6.25MG;6.25MG	A211876	005	Jun 24, 2020	Nov	CAHN
>A>	@	7.5MG;7.5MG;7.5MG;7.5MG	A211876	006	Jun 24, 2020	Nov	CAHN
>D>	@ MYLAN	1.25MG;1.25MG;1.25MG;1.25MG	A211876	001	Jun 24, 2020	Nov	CAHN
>D>	@	2.5MG;2.5MG;2.5MG;2.5MG	A211876	002	Jun 24, 2020	Nov	CAHN
>D>	@	3.75MG;3.75MG;3.75MG;3.75MG	A211876	003	Jun 24, 2020	Nov	CAHN
>D>	@	5MG;5MG;5MG;5MG	A211876	004	Jun 24, 2020	Nov	CAHN
>D>	@	6.25MG;6.25MG;6.25MG;6.25MG	A211876	005	Jun 24, 2020	Nov	CAHN
>D>	@	7.5MG;7.5MG;7.5MG;7.5MG	A211876	006	Jun 24, 2020	Nov	CAHN

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

>A>	AB	ACCORD HLTHCARE	1.25MG;1.25MG;1.25MG;1.25MG	A214347	001	Nov 22, 2021	Nov	NEWA
>A>	AB		1.875MG;1.875MG;1.875MG;1.875MG	A214347	002	Nov 22, 2021	Nov	NEWA
>A>	AB		2.5MG;2.5MG;2.5MG;2.5MG	A214347	003	Nov 22, 2021	Nov	NEWA
>A>	AB		3.125MG;3.125MG;3.125MG;3.125MG	A214347	004	Nov 22, 2021	Nov	NEWA
>A>	AB		3.75MG;3.75MG;3.75MG;3.75MG	A214347	005	Nov 22, 2021	Nov	NEWA
>A>	AB		5MG;5MG;5MG;5MG	A214347	006	Nov 22, 2021	Nov	NEWA
>A>	AB		7.5MG;7.5MG;7.5MG;7.5MG	A214347	007	Nov 22, 2021	Nov	NEWA
	AB	ASCENT PHARMS INC	1.25MG;1.25MG;1.25MG;1.25MG	A213709	001	Apr 22, 2021	Apr	NEWA
	AB		1.875MG;1.875MG;1.875MG;1.875MG	A213709	002	Apr 22, 2021	Apr	NEWA
	AB		2.5MG;2.5MG;2.5MG;2.5MG	A213709	003	Apr 22, 2021	Apr	NEWA
	AB		3.125MG;3.125MG;3.125MG;3.125MG	A213709	004	Apr 22, 2021	Apr	NEWA
	AB		3.75MG;3.75MG;3.75MG;3.75MG	A213709	005	Apr 22, 2021	Apr	NEWA
	AB		5MG;5MG;5MG;5MG	A213709	006	Apr 22, 2021	Apr	NEWA
	AB		7.5MG;7.5MG;7.5MG;7.5MG	A213709	007	Apr 22, 2021	Apr	NEWA
	AB	LIBERTY PHARMA INC	1.25MG;1.25MG;1.25MG;1.25MG	A210293	001	Apr 03, 2020	Aug	CAHN
	AB		1.875MG;1.875MG;1.875MG;1.875MG	A210293	002	Apr 03, 2020	Aug	CAHN
	AB		2.5MG;2.5MG;2.5MG;2.5MG	A210293	003	Apr 03, 2020	Aug	CAHN
	AB		3.75MG;3.75MG;3.75MG;3.75MG	A210293	004	Apr 03, 2020	Aug	CAHN
	AB		5MG;5MG;5MG;5MG	A210293	005	Apr 03, 2020	Aug	CAHN
	AB		7.5MG;7.5MG;7.5MG;7.5MG	A210293	006	Apr 03, 2020	Aug	CAHN
		@ MYLAN	1.25MG;1.25MG;1.25MG;1.25MG	A206721	001	Nov 10, 2015	Aug	CAHN
		@	1.25MG;1.25MG;1.25MG;1.25MG	A206721	001	Nov 10, 2015	Aug	DISC
		@	1.875MG;1.875MG;1.875MG;1.875MG	A206721	002	Nov 10, 2015	Aug	CAHN
		@	1.875MG;1.875MG;1.875MG;1.875MG	A206721	002	Nov 10, 2015	Aug	DISC
		@	2.5MG;2.5MG;2.5MG;2.5MG	A206721	003	Nov 10, 2015	Aug	CAHN
		@	2.5MG;2.5MG;2.5MG;2.5MG	A206721	003	Nov 10, 2015	Aug	DISC
		@	3.125MG;3.125MG;3.125MG;3.125MG	A206721	004	Nov 10, 2015	Aug	CAHN
		@	3.125MG;3.125MG;3.125MG;3.125MG	A206721	004	Nov 10, 2015	Aug	DISC
		@	3.75MG;3.75MG;3.75MG;3.75MG	A206721	005	Nov 10, 2015	Aug	CAHN
		@	3.75MG;3.75MG;3.75MG;3.75MG	A206721	005	Nov 10, 2015	Aug	DISC
		@	5MG;5MG;5MG;5MG	A206721	006	Nov 10, 2015	Aug	CAHN
		@	5MG;5MG;5MG;5MG	A206721	006	Nov 10, 2015	Aug	DISC
		@	7.5MG;7.5MG;7.5MG;7.5MG	A206721	007	Nov 10, 2015	Aug	CAHN
		@	7.5MG;7.5MG;7.5MG;7.5MG	A206721	007	Nov 10, 2015	Aug	DISC
	AB	RHODES PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A213111	001	Jan 13, 2021	Jan	NEWA
	AB		1.875MG;1.875MG;1.875MG;1.875MG	A213111	002	Jan 13, 2021	Jan	NEWA
	AB		3.125MG;3.125MG;3.125MG;3.125MG	A213111	004	Jan 13, 2021	Jan	NEWA
	AB		7.5MG;7.5MG;7.5MG;7.5MG	A213111	007	Jan 13, 2021	Jan	NEWA
	AB	USPHARMA WINDLAS	1.25MG;1.25MG;1.25MG;1.25MG	A210293	001	Apr 03, 2020	Sep	CAHN
	AB		1.875MG;1.875MG;1.875MG;1.875MG	A210293	002	Apr 03, 2020	Sep	CAHN
	AB		2.5MG;2.5MG;2.5MG;2.5MG	A210293	003	Apr 03, 2020	Sep	CAHN
	AB		3.75MG;3.75MG;3.75MG;3.75MG	A210293	004	Apr 03, 2020	Sep	CAHN
	AB		5MG;5MG;5MG;5MG	A210293	005	Apr 03, 2020	Sep	CAHN

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE  
 AB 7.5MG;7.5MG;7.5MG;7.5MG A210293 006 Apr 03, 2020 Sep CAHN

AMPHETAMINE SULFATE

TABLET;ORAL

AMPHETAMINE SULFATE  
 @ GLENMARK PHARMS LTD 5MG A212186 001 Jan 27, 2021 Jun DISC  
 AA 5MG A212186 001 Jan 27, 2021 Jan NEWA  
 @ 10MG A212186 002 Jan 27, 2021 Jun DISC  
 AA 10MG A212186 002 Jan 27, 2021 Jan NEWA  
 + @ LANNETT 5MG A083901 001 Aug 31, 1984 Aug CRLD  
 + @ 10MG A083901 002 Aug 31, 1984 Aug CRLD  
 @ MAYNE PHARMA 5MG A213898 001 Jul 14, 2020 Jan DISC  
 @ 10MG A213898 002 Jul 14, 2020 Jan DISC  
 @ NOVAST LABS 5MG A213763 001 Aug 24, 2020 Mar DISC  
 @ 10MG A213763 002 Aug 24, 2020 Mar DISC  
 AA RHODES PHARMS 5MG A213852 001 Sep 07, 2021 Aug NEWA  
 AA 10MG A213852 002 Sep 07, 2021 Aug NEWA  
 AA SENORES PHARMS 5MG A212901 001 May 22, 2020 Aug CAHN  
 AA 10MG A212901 002 May 22, 2020 Aug CAHN  
 AA SPECGX LLC 5MG A213583 001 Jan 22, 2021 Jan NEWA  
 AA 10MG A213583 002 Jan 22, 2021 Jan NEWA  
 AA SUN PHARM INDS INC 5MG A214574 001 Jan 27, 2021 Jan NEWA  
 AA 10MG A214574 002 Jan 27, 2021 Jan NEWA  
 TABLET, ORALLY DISINTEGRATING;ORAL  
 EVEKEO ODT  
 + @ ARBOR PHARMS LLC 2.5MG N209905 005 Apr 16, 2021 Jul DISC  
 + 2.5MG N209905 005 Apr 16, 2021 Apr NEWA  
 +! 20MG N209905 004 Jan 30, 2019 Apr CHRS

AMPICILLIN SODIUM

INJECTABLE;INJECTION

AMPICILLIN SODIUM  
 @ HQ SPECLT PHARMA EQ 125MG BASE/VIAL A062772 005 Apr 15, 1993 Mar CAHN  
 AP EQ 250MG BASE/VIAL A062772 006 Apr 15, 1993 Mar CAHN  
 AP EQ 500MG BASE/VIAL A062772 007 Apr 15, 1993 Mar CAHN  
 @ EQ 500MG BASE/VIAL A062772 008 Apr 15, 1993 Mar CAHN  
 AP EQ 1GM BASE/VIAL A062772 001 Apr 15, 1993 Mar CAHN  
 @ EQ 1GM BASE/VIAL A062772 002 Apr 15, 1993 Mar CAHN  
 AP EQ 2GM BASE/VIAL A062772 003 Apr 15, 1993 Mar CAHN  
 @ EQ 2GM BASE/VIAL A062772 004 Apr 15, 1993 Mar CAHN  
 AP EQ 10GM BASE/VIAL A063142 001 Apr 15, 1993 Mar CAHN

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE;INJECTION

AMPICILLIN AND SULBACTAM  
 AP HIKMA EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL A065074 001 Mar 19, 2002 Oct CAHN  
 AP EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL A065074 002 Mar 19, 2002 Oct CAHN  
 AP HQ SPECLT PHARMA EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL A065176 001 Nov 30, 2005 Mar CAHN  
 AP EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL A065176 002 Nov 30, 2005 Mar CAHN  
 AP EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL A065188 001 Nov 25, 2005 Mar CAHN

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE;ORAL

AMPICILLIN TRIHYDRATE  
 >D> @ DAVA PHARMS INC EQ 250MG BASE A062883 001 Feb 25, 1988 Nov CAHN  
 >D> @ EQ 500MG BASE A062882 001 Feb 25, 1988 Nov CAHN  
 >A> @ STRIDES PHARMA EQ 250MG BASE A062883 001 Feb 25, 1988 Nov CAHN  
 >A> @ EQ 500MG BASE A062882 001 Feb 25, 1988 Nov CAHN

ANAGRELIDE HYDROCHLORIDE

CAPSULE;ORAL

ANAGRELIDE HYDROCHLORIDE  
 @ CHARTWELL RX EQ 0.5MG BASE A076683 001 Apr 18, 2005 Aug CAHN  
 @ EQ 1MG BASE A076683 002 Apr 18, 2005 Aug CAHN





ARIPIPIRAZOLE

TABLET; ORAL  
ARIPIPIRAZOLE

>A>	AB	UNICHEM	2MG	A203025	001	Dec 01, 2021	Nov	NEWA
>A>	AB		5MG	A203025	002	Dec 01, 2021	Nov	NEWA
>A>	AB		10MG	A203025	003	Dec 01, 2021	Nov	NEWA
>A>	AB		15MG	A203025	004	Dec 01, 2021	Nov	NEWA
>A>	AB		20MG	A203025	005	Dec 01, 2021	Nov	NEWA
>A>	AB		30MG	A203025	006	Dec 01, 2021	Nov	NEWA

ARSENIC TRIOXIDE

INJECTABLE; INJECTION  
ARSENIC TRIOXIDE

AP		AMNEAL	1MG/ML	A210739	001	Jan 25, 2021	Aug	CMFD
		@	1MG/ML	A210739	001	Jan 25, 2021	May	DISC
AP			1MG/ML	A210739	001	Jan 25, 2021	Jan	NEWA
AP			2MG/ML	A210739	002	Aug 19, 2021	Aug	NEWA
AP		EUGIA PHARMA	2MG/ML	A214011	001	Oct 15, 2021	Oct	NEWA
AP		GLAND PHARMA LTD	2MG/ML	A215059	001	Oct 07, 2021	Oct	NEWA
		@ INGENUS PHARMS LLC	2MG/ML	A209315	002	Jan 14, 2021	Feb	DISC
AP			2MG/ML	A209315	002	Jan 14, 2021	Jan	NEWA
>A>	AP	SANDOZ INC	2MG/ML	A215359	001	Dec 02, 2021	Nov	NEWA

ASCIMINIB HYDROCHLORIDE

TABLET; ORAL  
SCEMBLIX

+		NOVARTIS	EQ 20MG BASE	N215358	001	Oct 29, 2021	Oct	NEWA
+	!		EQ 40MG BASE	N215358	002	Oct 29, 2021	Oct	NEWA

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE; INTRAVENOUS  
INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)

+	!	SANDOZ CANADA INC	80MG/VIAL; 0.02MG/VIAL; 400 IU/VIAL; 0.001MG/VIAL; 5MG/VIAL; 0.14 MG/VIAL; 17MG/VIAL; 1MG/VIAL; 1.4MG/VIAL; 1.2MG/VIAL; 7 IU/VIAL; 2,300 IU/VIAL; 0.2MG/VIAL	N021265	002	Jan 29, 2004	Feb	CAIN
---	---	-------------------	--	---------	-----	--------------	-----	------

ASENAPINE MALEATE

TABLET; SUBLINGUAL  
ASENAPINE MALEATE

AB		ALEMBIC PHARMS LTD	EQ 2.5MG BASE	A206098	003	Jul 19, 2021	Jul	NEWA
AB		BRECKENRIDGE	EQ 5MG BASE	A205960	003	Mar 08, 2021	Feb	NEWA

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL  
BUTALBITAL, ASPIRIN AND CAFFEINE

		LGM PHARMA	500MG; 50MG; 40MG	A205230	001	Oct 18, 2021	Oct	NEWA
--	--	------------	-------------------	---------	-----	--------------	-----	------

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL  
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

>A>		@ STRIDES PHARMA	325MG; 50MG; 40MG; 30MG	A075351	001	Mar 05, 1999	Nov	CAHN
>D>		@ VINTAGE PHARMS LLC	325MG; 50MG; 40MG; 30MG	A075351	001	Mar 05, 1999	Nov	CAHN

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL  
NORGESIC

+	@	BAUSCH	385MG; 30MG; 25MG	N013416	003	Oct 27, 1982	May	CAHN
+	@	BAUSCH	770MG; 60MG; 50MG	N013416	004	Oct 27, 1982	May	CAHN

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL  
PROPOXYPHENE COMPOUND 65

+	@	SANDOZ	389MG; 32.4MG; 65MG	A080044	002	Sep 16, 1983	Aug	CRLD
---	---	--------	---------------------	---------	-----	--------------	-----	------

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET;ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

!	INGENUS PHARMS NJ	325MG;200MG;16MG	A 040860	001	Jan 07, 2010	Jul	CHRS
		325MG;200MG;16MG	A 040860	001	Jan 07, 2010	Jul	CTEC
@	SANDOZ	325MG;200MG;16MG	A 040118	001	Apr 16, 1996	Jul	DISC

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE;ORAL

ASPIRIN AND DIPYRIDAMOLE

	@ LANNETT CO INC	25MG;200MG	A 204552	001	Mar 20, 2019	Apr	DISC
AB	MICRO LABS	25MG;200MG	A 209929	001	Aug 11, 2021	Jul	NEWA
	@ SUN PHARM	25MG;200MG	A 208572	001	Aug 21, 2018	Aug	DISC

ASPIRIN; HYDROCODONE BITARTRATE

TABLET;ORAL

HYDROCODONE BITARTRATE AND ASPIRIN

@	LGM PHARMA	500MG;5MG	A 205479	001	May 28, 2021	Oct	DISC
		500MG;5MG	A 205479	001	May 28, 2021	May	NEWA

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE AND ASPIRIN

@	MAYNE PHARMA INC	325MG;4.8355MG	A 091670	001	Mar 16, 2011	Jul	DISC
---	------------------	----------------	----------	-----	--------------	-----	------

ATAZANAVIR SULFATE

CAPSULE;ORAL

ATAZANAVIR SULFATE

AB	LAURUS	EQ 150MG BASE	A 212579	001	Apr 30, 2021	Apr	NEWA
AB		EQ 200MG BASE	A 212579	002	Apr 30, 2021	Apr	NEWA
AB		EQ 300MG BASE	A 212579	003	Apr 30, 2021	Apr	NEWA

ATENOLOL

TABLET;ORAL

ATENOLOL

@	STRIDES PHARMA	25MG	A 074099	001	Apr 28, 1992	Oct	CAHN
@		50MG	A 073542	001	Dec 19, 1991	Oct	CAHN
@		100MG	A 073543	001	Dec 19, 1991	Oct	CAHN

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL

ATENOLOL AND CHLORTHALIDONE

AB	NOVITIUM PHARMA	50MG;25MG	A 215560	001	Oct 25, 2021	Oct	NEWA
AB		100MG;25MG	A 215560	002	Oct 25, 2021	Oct	NEWA

ATOGEPAANT

TABLET;ORAL

QULIPTA

+	ABBVIE INC	10MG	N 215206	001	Sep 28, 2021	Sep	NEWA
+		30MG	N 215206	002	Sep 28, 2021	Sep	NEWA
+	!	60MG	N 215206	003	Sep 28, 2021	Sep	NEWA

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

AB	HETERO LABS LTD V	10MG	A 202682	001	Mar 11, 2021	Mar	NEWA
AB		18MG	A 202682	002	Mar 11, 2021	Mar	NEWA
AB		25MG	A 202682	003	Mar 11, 2021	Mar	NEWA
AB		40MG	A 202682	004	Mar 11, 2021	Mar	NEWA
AB		60MG	A 202682	005	Mar 11, 2021	Mar	NEWA
AB		80MG	A 202682	006	Mar 11, 2021	Mar	NEWA
AB		100MG	A 202682	007	Mar 11, 2021	Mar	NEWA
	@ MYLAN	10MG	A 079021	001	Feb 18, 2021	Feb	DISC
AB		10MG	A 079021	001	Feb 18, 2021	Feb	NEWA
	@	18MG	A 079021	002	Feb 18, 2021	Feb	DISC
AB		18MG	A 079021	002	Feb 18, 2021	Feb	NEWA
	@	25MG	A 079021	003	Feb 18, 2021	Feb	DISC
AB		25MG	A 079021	003	Feb 18, 2021	Feb	NEWA
	@	40MG	A 079021	004	Feb 18, 2021	Feb	DISC
AB		40MG	A 079021	004	Feb 18, 2021	Feb	NEWA
	@	60MG	A 079021	005	Feb 18, 2021	Feb	DISC

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

AB		60MG	A079021	005	Feb 18, 2021	Feb	NEWA
	@	80MG	A079021	006	Feb 18, 2021	Feb	DISC
AB		80MG	A079021	006	Feb 18, 2021	Feb	NEWA
	@	100MG	A079021	007	Feb 18, 2021	Feb	DISC
AB		100MG	A079021	007	Feb 18, 2021	Feb	NEWA

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

AB		ALKEM LABS LTD	EQ 10MG BASE	A209288	001	Dec 21, 2018	Jan	CAHN
AB			EQ 20MG BASE	A209288	002	Dec 21, 2018	Jan	CAHN
AB			EQ 40MG BASE	A209288	003	Dec 21, 2018	Jan	CAHN
AB			EQ 80MG BASE	A209288	004	Dec 21, 2018	Jan	CAHN
AB		AUGUST	EQ 10MG BASE	A214969	001	Sep 02, 2021	Aug	NEWA
AB			EQ 20MG BASE	A214969	002	Sep 02, 2021	Aug	NEWA
AB			EQ 40MG BASE	A214969	003	Sep 02, 2021	Aug	NEWA
AB			EQ 80MG BASE	A214969	004	Sep 02, 2021	Aug	NEWA
	@	DR REDDYS LABS LTD	EQ 10MG BASE	A214659	001	Jul 14, 2021	Oct	DISC
AB			EQ 10MG BASE	A214659	001	Jul 14, 2021	Jul	NEWA
	@		EQ 20MG BASE	A214659	002	Jul 14, 2021	Oct	DISC
AB			EQ 20MG BASE	A214659	002	Jul 14, 2021	Jul	NEWA
	@		EQ 40MG BASE	A214659	003	Jul 14, 2021	Oct	DISC
AB			EQ 40MG BASE	A214659	003	Jul 14, 2021	Jul	NEWA
	@		EQ 80MG BASE	A214659	004	Jul 14, 2021	Oct	DISC
AB			EQ 80MG BASE	A214659	004	Jul 14, 2021	Jul	NEWA

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET;ORAL

EZETIMIBE AND ATORVASTATIN CALCIUM

	@	SCOV3	EQ 10MG BASE;10MG	A206084	001	Apr 26, 2017	Jul	CAHN
	@		EQ 20MG BASE;10MG	A206084	002	Apr 26, 2017	Jul	CAHN
	@		EQ 40MG BASE;10MG	A206084	003	Apr 26, 2017	Jul	CAHN
	@		EQ 80MG BASE;10MG	A206084	004	Apr 26, 2017	Jul	CAHN
		LIPTRUZET						
	+ @	ORGANON	EQ 10MG BASE;10MG	N200153	001	May 03, 2013	Feb	CAHN
	+ @		EQ 20MG BASE;10MG	N200153	002	May 03, 2013	Feb	CAHN
	+ @		EQ 40MG BASE;10MG	N200153	003	May 03, 2013	Feb	CAHN
	+ @		EQ 80MG BASE;10MG	N200153	004	May 03, 2013	Feb	CAHN

ATOVAQUONE

SUSPENSION;ORAL

ATOVAQUONE

AB		ABON PHARMS LLC	750MG/5ML	A214272	001	Oct 25, 2021	Oct	NEWA
AB		BIONPHARMA INC	750MG/5ML	A212918	001	Mar 30, 2021	Mar	NEWA

ATROPINE SULFATE

SOLUTION;INTRAVENOUS

ATROPINE SULFATE

AP		ACCORD HLTHCARE	0.25MG/5ML (0.05MG/ML)	A212868	001	Jul 26, 2021	Jul	NFTG
AP			0.5MG/5ML (0.1MG/ML)	A212868	002	Jul 26, 2021	Jul	NFTG
AP			1MG/10ML (0.1MG/ML)	A212868	003	Jul 26, 2021	Jul	NEWA
AP	+	HOSPIRA	0.25MG/5ML (0.05MG/ML)	N021146	002	Jul 09, 2001	Jul	CFTG
AP	+		0.5MG/5ML (0.1MG/ML)	N021146	004	Aug 17, 2017	Jul	CFTG
AP	+		1MG/10ML (0.1MG/ML)	N021146	003	Jul 09, 2001	Jul	CTEC
AP		INTL MEDICATION SYS	1MG/10ML (0.1MG/ML)	A212461	001	Oct 05, 2020	Mar	CTEC

SOLUTION;INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, INTRAOSSEOUS, ENDOTRACHEAL

ATROPINE SULFATE

AP		ACCORD HLTHCARE	8MG/20ML (0.4MG/ML)	A213424	001	Mar 19, 2021	Mar	NFTG
AP	+	FRESENIUS KABI USA	8MG/20ML (0.4MG/ML)	N209260	001	Jan 26, 2018	Mar	CFTG
>A>	AP	HIKMA	8MG/20ML (0.4MG/ML)	A213561	001	Dec 01, 2021	Nov	NEWA

SOLUTION/DROPS;OPHTHALMIC

ATROPINE SULFATE

>D>	+	AKORN	1%	N206289	001	Jul 18, 2014	Nov	CFTG
>A>	AT		1%	N206289	001	Jul 18, 2014	Nov	CFTG
>A>	AT	APOTEX INC	1%	A215624	001	Nov 26, 2021	Nov	NFTG

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL		DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE					
AA	PHARMA LIFE	0.025MG; 2.5MG		A207128	001	Oct 21, 2020	Sep CAHN
AA	WINDER LABS LLC	0.025MG; 2.5MG		A211362	001	Jan 27, 2021	Jan NEWA

ATROPINE SULFATE; EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION		ENLON-PLUS					
	+ @ MYLAN	0.14MG/ML; 10MG/ML		N019678	001	Nov 06, 1991	Jan CAHN

AVACOPAN

CAPSULE; ORAL		TAVNEOS					
	+! CHEMOCENTRYX	10MG		N214487	001	Oct 07, 2021	Oct NEWA

AVAPRITINIB

TABLET; ORAL		AYVAKIT					
	+ BLUEPRINT MEDICINES	25MG		N212608	004	Jun 16, 2021	Jun NEWA
	+	50MG		N212608	005	Jun 16, 2021	Jun NEWA

AVIBACTAM SODIUM; CEFTAZIDIME

POWDER; INTRAVENOUS		AVYCAZ					
	+! ALLERGAN	EQ 0.5GM BASE; 2GM/VIAL		N206494	001	Feb 25, 2015	Jan CDFR

AZATHIOPRINE

TABLET; ORAL		AZATHIOPRINE					
AB	AMNEAL	75MG		A074069	002	Nov 02, 2021	Oct NEWA
AB		100MG		A074069	003	Nov 02, 2021	Oct NEWA

AZELASTINE HYDROCHLORIDE

SPRAY, METERED; NASAL		ASTELIN					
	+ @ MYLAN SPCLT VIATRIS	0.137MG/SPRAY		N020114	001	Nov 01, 1996	Oct DISC
AB	+!	0.137MG/SPRAY		N020114	001	Nov 01, 1996	Sep CAHN
AB	+! MYLAN SPECIALITY LP	0.137MG/SPRAY		N020114	001	Nov 01, 1996	Aug CPOT
ASTEPRO							
>D>	@ MYLAN SPECIALITY LP	0.137MG/SPRAY		N022203	001	Oct 15, 2008	Nov CRLD
>A>	+ @	0.137MG/SPRAY		N022203	001	Oct 15, 2008	Nov CRLD
	@	0.137MG/SPRAY		N022203	001	Oct 15, 2008	Aug CPOT
>D>	+ @	0.2055MG/SPRAY		N022203	002	Aug 31, 2009	Nov CRLD
>A>	@	0.2055MG/SPRAY		N022203	002	Aug 31, 2009	Nov CRLD
	+ @	0.2055MG/SPRAY		N022203	002	Aug 31, 2009	Jul DISC
AB	+!	0.2055MG/SPRAY		N022203	002	Aug 31, 2009	Jul CPOT
AZELASTINE HYDROCHLORIDE							
AB	AKORN	0.137MG/SPRAY		A207610	001	May 17, 2019	Aug CPOT
AB		0.2055MG/SPRAY		A210032	001	Aug 23, 2019	Aug CPOT
AB	ALKEM LABS LTD	0.137MG/SPRAY		A208156	001	Aug 18, 2017	Aug CPOT
AB	AMNEAL	0.137MG/SPRAY		A204660	001	Aug 28, 2017	Aug CPOT
AB		0.2055MG/SPRAY		A208199	001	Dec 15, 2017	Aug CPOT
AB	! APOTEX INC	0.137MG/SPRAY		A077954	001	Apr 30, 2009	Oct CHRS
AB		0.137MG/SPRAY		A077954	001	Apr 30, 2009	Aug CPOT
AB		0.2055MG/SPRAY		A201846	001	Aug 31, 2012	Aug CPOT
AB	AUROBINDO PHARMA LTD	0.137MG/SPRAY		A212289	001	May 08, 2020	Aug CPOT
AB		0.2055MG/SPRAY		A212775	001	Nov 12, 2020	Aug CPOT
AB	BRECKENRIDGE	0.137MG/SPRAY		A090176	001	Jul 28, 2015	Aug CPOT
AB	HIKMA	0.137MG/SPRAY		A091444	001	Oct 24, 2014	Aug CPOT
AB		0.2055MG/SPRAY		A207243	001	Sep 22, 2017	Aug CPOT
AB	SUN PHARM	0.137MG/SPRAY		A090423	001	May 23, 2012	Aug CPOT
AB	UPSHER SMITH LABS	0.137MG/SPRAY		A202609	001	Mar 17, 2017	Aug CPOT
AB	ZYDUS PHARMS	0.137MG/SPRAY		A091409	001	Aug 14, 2017	Aug CPOT

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

SPRAY, METERED; NASAL		AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE					
AB	APOTEX	0.137MG/SPRAY; 0.05MG/SPRAY		A207712	001	Apr 28, 2017	Aug CPOT
AB	PADAGIS ISRAEL	0.137MG/SPRAY; 0.05MG/SPRAY		A208111	001	Feb 18, 2021	Aug CPOT
AB	PERRIGO UK FINCO	EQ 0.125MG BASE/SPRAY; 0.05MG/SPRAY		A208111	001	Feb 18, 2021	Feb NEWA

SPRAY, METERED;NASAL  
DYMISTA

AB +! MYLAN SPECIALITY LP 0.137MG/SPRAY;0.05MG/SPRAY N202236 001 May 01, 2012 Aug CPOT

AZITHROMYCIN

FOR SUSPENSION;ORAL  
AZITHROMYCIN

AB TARO EQ 200MG BASE/5ML A211521 001 Dec 11, 2019 Feb CMFD

INJECTABLE;INJECTION  
AZITHROMYCIN

@ MYLAN ASI EQ 500MG BASE/VIAL A065506 001 Mar 24, 2009 Feb DISC

TABLET;ORAL  
AZITHROMYCIN

AB ALEMBIC PHARMS LTD EQ 600MG BASE A211793 001 Jan 27, 2020 Jul CMFD

AB YUNG SHIN PHARM EQ 600MG BASE A211068 001 May 08, 2020 Feb CMFD

AZTREONAM

INJECTABLE;INJECTION  
AZTREONAM

AP HOSPIRA INC 1GM/VIAL A206517 001 Nov 08, 2021 Oct NEWA

AP 2GM/VIAL A206517 002 Nov 08, 2021 Oct NEWA

BACITRACIN

INJECTABLE;INJECTION  
BACITRACIN

@ XELLIA PHARMS APS 50,000 UNITS/VIAL A203177 001 Aug 25, 2014 Jun DISC

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;TOPICAL  
CORTISPORIN

+ @ MONARCH PHARMS 400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM N050168 002 May 04, 1984 Jul DISC

BACLOFEN

>A> GRANULES;ORAL  
>A> LYVISPAH

>A> + SAOL THERAPS RES LTD 5MG/PACKET N215422 001 Nov 22, 2021 Nov NEWA

>A> + 10MG/PACKET N215422 002 Nov 22, 2021 Nov NEWA

>A> +! 20MG/PACKET N215422 003 Nov 22, 2021 Nov NEWA

INJECTABLE;INTRATHECAL  
BACLOFEN

AP MAIA PHARMS INC 0.05MG/ML A210777 001 Jan 15, 2021 Jan NEWA

AP 0.5MG/ML A210048 001 Sep 11, 2019 Aug CMFD

AP 2MG/ML A210048 002 Sep 11, 2019 Aug CMFD

GABLOFEN

AP +! PIRAMAL CRITICAL 0.05MG/ML N022462 001 Nov 19, 2010 Mar CHRS

AP + 0.05MG/ML N022462 001 Nov 19, 2010 Mar CRLD

AP +! 0.5MG/ML N022462 002 Nov 19, 2010 Mar CHRS

AP + 0.5MG/ML N022462 002 Nov 19, 2010 Mar CRLD

AP +! 2MG/ML N022462 003 Nov 19, 2010 Mar CHRS

AP + 2MG/ML N022462 003 Nov 19, 2010 Mar CRLD

TABLET;ORAL  
BACLOFEN

AB AUROBINDO PHARMA LTD 10MG A214099 001 Jul 13, 2021 Jul NEWA

AB 20MG A214099 002 Jul 13, 2021 Jul NEWA

AB BEXIMCO PHARMS USA 10MG A214114 001 Jul 16, 2021 Jul NEWA

AB 20MG A214114 002 Jul 16, 2021 Jul NEWA

AB IMPAX 5MG A077971 003 Jul 07, 2021 Jun NEWA

AB 10MG A077971 001 Oct 26, 2007 Jun CAHN

AB 20MG A077971 002 Oct 26, 2007 Jun CAHN

AB INNOGENIX 5MG A212378 003 Apr 30, 2021 Apr NEWA

>D> @ KARTHA 5MG A214374 001 Mar 05, 2021 Nov CMFD

>A> AB 5MG A214374 001 Mar 05, 2021 Nov CMFD

@ 5MG A214374 001 Mar 05, 2021 Oct DISC

AB 5MG A214374 001 Mar 05, 2021 Feb NEWA

>D> @ 10MG A214374 002 Mar 05, 2021 Nov CMFD

>A> AB 10MG A214374 002 Mar 05, 2021 Nov CMFD

@ 10MG A214374 002 Mar 05, 2021 Sep DISC

AB 10MG A214374 002 Mar 05, 2021 Feb NEWA

>D> @ 20MG A214374 003 Mar 05, 2021 Nov CMFD

>A> AB 20MG A214374 003 Mar 05, 2021 Nov CMFD

@ 20MG A214374 003 Mar 05, 2021 Sep DISC

	TABLET;ORAL							
	BACLOFEN							
AB		20MG	A214374	003	Mar 05, 2021	Feb	NEWA	
AB	LANNETT CO INC	5MG	A077241	003	Sep 22, 2021	Sep	NEWA	
	TABLET, ORALLY DISINTEGRATING;ORAL							
	KEMSTRO							
	+ @ UCB INC	10MG	N021589	001	Oct 30, 2003	May	CRLD	
	+ @	20MG	N021589	002	Oct 30, 2003	May	CRLD	
	<u>BALOXAVIR MARBOXIL</u>							
	TABLET;ORAL							
	XOFLUZA							
	+ GENENTECH INC	80MG	N210854	003	Mar 18, 2021	Mar	NEWA	
	<u>BELUMOSUDIL MESYLATE</u>							
	TABLET;ORAL							
	REZUROCK							
	+! KADMON PHARMS LLC	EQ 200MG BASE	N214783	001	Jul 16, 2021	Jul	NEWA	
	<u>BELZUTIFAN</u>							
	TABLET;ORAL							
	WELIREG							
	+! MERCK SHARP DOHME	40MG	N215383	001	Aug 13, 2021	Aug	NEWA	
	<u>BENAZEPRIL HYDROCHLORIDE</u>							
	TABLET;ORAL							
	BENAZEPRIL HYDROCHLORIDE							
AB	CADILA	5MG	A078848	001	May 23, 2008	Aug	CAHN	
AB		10MG	A078848	002	May 23, 2008	Aug	CAHN	
AB		20MG	A078848	003	May 23, 2008	Aug	CAHN	
AB		40MG	A078848	004	May 23, 2008	Aug	CAHN	
	LOTENSIN							
AB	+ VALIDUS PHARMS	5MG	N019851	001	Jun 25, 1991	Feb	CAHN	
AB	+	10MG	N019851	002	Jun 25, 1991	Feb	CAHN	
AB	+	20MG	N019851	003	Jun 25, 1991	Feb	CAHN	
AB	+!	40MG	N019851	004	Jun 25, 1991	Feb	CAHN	
	<u>BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE</u>							
	TABLET;ORAL							
	BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE							
	@ MYLAN	5MG;6.25MG	A076688	001	Feb 11, 2004	Jul	DISC	
	@	10MG;12.5MG	A076688	002	Feb 11, 2004	Jul	DISC	
	@	20MG;12.5MG	A076688	003	Feb 11, 2004	Jul	DISC	
	@	20MG;25MG	A076688	004	Feb 11, 2004	Jul	DISC	
	SANDOZ	5MG;6.25MG	A076631	001	Feb 11, 2004	Jul	CTEC	
	LOTENSIN HCT							
	+ @ VALIDUS PHARMS	5MG;6.25MG	N020033	001	May 19, 1992	Feb	CAHN	
AB	+	10MG;12.5MG	N020033	002	May 19, 1992	Feb	CAHN	
AB	+	20MG;12.5MG	N020033	004	May 19, 1992	Feb	CAHN	
AB	+!	20MG;25MG	N020033	003	May 19, 1992	Feb	CAHN	
	<u>BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM</u>							
	SOLUTION/DROPS;OPHTHALMIC							
	FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE							
	+! BAUSCH LOMB IRELAND	0.4%;0.3%	N211039	001	Mar 09, 2020	May	CAHN	
	<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE</u>							
	GEL;TOPICAL							
	CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE							
AB	ENCUBE	5%;1.2%	A212433	001	Apr 28, 2021	Apr	NEWA	
	@ TOLMAR	5%;EQ 1% BASE	A204087	001	Jun 27, 2017	Sep	DISC	
	@	5%;1.2%	A203688	001	Aug 25, 2016	Sep	DISC	
	DUAC							
AB	+ STIEFEL	5%;1.2%	N050741	001	Aug 26, 2002	Jan	CHRS	
	<u>BENZOYL PEROXIDE; ERYTHROMYCIN</u>							
	GEL;TOPICAL							
	ERYTHROMYCIN AND BENZOYL PEROXIDE							
>D>	AB	TOLMAR	A065112	001	Mar 29, 2004	Nov	DISC	
>A>	@	5%;3%	A065112	001	Mar 29, 2004	Nov	DISC	

BENZOYL PEROXIDE; TRETINOIN

CREAM;TOPICAL  
TWYNEO

+! SOL-GEL TECHNOLOGIES 3%;0.1% N214902 001 Jul 26, 2021 Jul NEWA

BENZPHETAMINE HYDROCHLORIDE

TABLET;ORAL  
BENZPHETAMINE HYDROCHLORIDE

@ SCINOPHARM TAIWAN 50MG A040578 001 Apr 17, 2006 Sep CAHN

BENZTROPINE MESYLATE

INJECTABLE;INJECTION  
BENZTROPINE MESYLATE

AP HIKMA 1MG/ML A209442 001 Oct 14, 2021 Oct NEWA

TABLET;ORAL  
BENZTROPINE MESYLATE

>D> @ CHARTWELL RX 1MG A081265 002 Jan 23, 1992 Nov CMFD

>A> AA 1MG A081265 002 Jan 23, 1992 Nov CMFD

>D> @ 2MG A081265 001 Jan 23, 1992 Nov CMFD

>A> AA 2MG A081265 001 Jan 23, 1992 Nov CMFD

BEPOTASTINE BESILATE

SOLUTION/DROPS;OPHTHALMIC  
BEPOTASTINE BESILATE

AT APOTEX 1.5% A206066 001 Mar 05, 2019 May CMFD

AT MYLAN 1.5% A206220 001 Mar 18, 2019 May CMFD

BEPREVE

AT +! BAUSCH AND LOMB INC 1.5% N022288 001 Sep 08, 2009 May CTEC

BETAINE

FOR SOLUTION;ORAL  
BETAINE

>A> AB NOVITIUM PHARMA 1GM/SCOOPFUL A214864 001 Nov 23, 2021 Nov NFTG

CYSTADANE

>D> +! ORPHAN EUROPE 1GM/SCOOPFUL N020576 001 Oct 25, 1996 Nov CFTG

>A> AB +! 1GM/SCOOPFUL N020576 001 Oct 25, 1996 Nov CFTG

BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION  
CELESTONE SOLUSPAN

AB +! ORGANON 3MG/ML;EQ 3MG BASE/ML N014602 001 Aug CAHN

BETAMETHASONE DIPROPIONATE

SPRAY;TOPICAL  
SERNIVO

+! PRIMUS PHARMS EQ 0.05% BASE/SPRAY N208079 001 Feb 05, 2016 Mar CAHN

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

LOTION;TOPICAL  
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB ! TARO EQ 0.05% BASE;1% A076493 001 Jul 28, 2004 Feb CHRS

BETAMETHASONE VALERATE

AEROSOL, FOAM;TOPICAL  
BETAMETHASONE VALERATE

>D> AB RICONPHARMA LLC 0.12% A207144 001 May 24, 2017 Nov DISC

>A> @ 0.12% A207144 001 May 24, 2017 Nov DISC

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC  
BETAXOLOL HYDROCHLORIDE

AT ACELLA EQ 0.5% BASE A078694 001 Nov 16, 2009 Aug CAHN

BETHANECHOL CHLORIDE

TABLET;ORAL  
BETHANECHOL CHLORIDE

AA BIOPHARM 5MG A040728 002 Oct 26, 2007 Sep CAHN

AA 10MG A040728 003 Oct 26, 2007 Sep CAHN

AA 25MG A040728 004 Oct 26, 2007 Sep CAHN

AA 50MG A040728 001 Oct 26, 2007 Sep CAHN



<u>TABLET;ORAL</u>							
BETHANECHOL CHLORIDE							
	@	WOCKHARDT	5MG	A 040532	001	Sep 29, 2003	Jan DISC
	@		50MG	A 040518	001	Sep 29, 2003	Jan DISC
URECHOLINE							
	+	@ ODYSSEY PHARMS	10MG	A 088440	001	May 29, 1984	Aug CRLD
	+	@	25MG	A 088441	001	May 29, 1984	Aug CRLD
<u>BEXAROTENE</u>							
CAPSULE;ORAL							
BEXAROTENE							
AB		TEVA PHARMS USA	75MG	A 209931	001	Jan 14, 2021	Jan NEWA
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE</u>							
TABLET;ORAL							
BIKTARVY							
	+	GILEAD SCIENCES INC	EQ 30MG BASE;120MG;EQ 15MG BASE	N 210251	002	Oct 07, 2021	Oct NEWA
<u>BIMATOPROST</u>							
SOLUTION/DROPS;OPHTHALMIC							
BIMATOPROST							
	@	AKORN	0.03%	A 203299	001	Nov 08, 2018	Feb CAHN
AT	!	ALEMBIC PHARMS LTD	0.03%	A 210263	001	Apr 12, 2019	Jan CHRS
AT		LUPIN LTD	0.03%	A 203991	001	Feb 20, 2015	Jan CHRS
<u>BISOPROLOL FUMARATE</u>							
TABLET;ORAL							
BISOPROLOL FUMARATE							
AB		NOVITIUM PHARMA	5MG	A 215563	001	Oct 29, 2021	Oct NEWA
AB			10MG	A 215563	002	Oct 29, 2021	Oct NEWA
AB		UNICHEM	5MG	A 078635	001	Aug 18, 2009	Apr CAHN
AB	!		10MG	A 078635	002	Aug 18, 2009	Apr CAHN
<u>BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE</u>							
TABLET;ORAL							
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE							
AB		NOVITIUM PHARMA	2.5MG;6.25MG	A 215562	001	Nov 04, 2021	Oct NEWA
AB			5MG;6.25MG	A 215562	002	Nov 04, 2021	Oct NEWA
AB			10MG;6.25MG	A 215562	003	Nov 04, 2021	Oct NEWA
<u>BIVALIRUDIN</u>							
INJECTABLE;INTRAVENOUS							
BIVALIRUDIN							
AP		HAINAN POLY PHARM	250MG/VIAL	A 213078	001	May 28, 2021	May NEWA
<u>BLEOMYCIN SULFATE</u>							
INJECTABLE;INJECTION							
BLEOMYCIN SULFATE							
	@	CIPLA	EQ 15 UNITS BASE/VIAL	A 209439	001	Mar 11, 2019	Aug DISC
AP		HIKMA	EQ 15 UNITS BASE/VIAL	A 065042	002	Oct 17, 2001	Oct CAHN
AP			EQ 30 UNITS BASE/VIAL	A 065042	001	Oct 17, 2001	Oct CAHN
<u>BORTEZOMIB</u>							
INJECTABLE;INTRAVENOUS, SUBCUTANEOUS							
VELCADE							
	+	! TAKEDA PHARMS USA	3.5MG/VIAL	N 021602	001	May 13, 2003	May CAHN
<u>BOSENTAN</u>							
TABLET;ORAL							
BOSENTAN							
	@	ALEMBIC PHARMS LTD	62.5MG	A 211461	001	Jan 23, 2020	Aug DISC
AB			62.5MG	A 211461	001	Jan 23, 2020	May CMFD
	@		125MG	A 211461	002	Jan 23, 2020	Aug DISC
AB			125MG	A 211461	002	Jan 23, 2020	May CMFD
	@	NATCO PHARMA LTD	62.5MG	A 206987	001	Apr 26, 2019	Sep DISC
	@		125MG	A 206987	002	Apr 26, 2019	Sep DISC
TRACLEER							
AB	+	ACTELION	62.5MG	N 021290	001	Nov 20, 2001	Feb CAHN
AB	+	!	125MG	N 021290	002	Nov 20, 2001	Feb CAHN

TABLET, FOR SUSPENSION;ORAL  
TRACLEER

+! ACTELION 32MG N209279 001 Sep 05, 2017 Feb CAHN

BRIGATINIB

TABLET;ORAL  
ALUNBRIG

+ TAKEDA PHARMS USA 30MG N208772 001 Apr 28, 2017 May CAHN  
+ 90MG N208772 002 Apr 28, 2017 May CAHN  
+! 180MG N208772 003 Oct 02, 2017 May CAHN

BRIMONIDINE TARTRATE

GEL;TOPICAL  
BRIMONIDINE TARTRATE

AB PADAGIS ISRAEL EQ 0.33% BASE A209158 001 Sep 23, 2021 Sep NFTG  
MIRVASO  
AB +! GALDERMA LABS LP EQ 0.33% BASE N204708 001 Aug 23, 2013 Sep CFTG

BRIMONIDINE TARTRATE; BRINZOLAMIDE

SUSPENSION/DROPS;OPHTHALMIC  
SIMBRINZA

+! ALCON LABS INC 0.2%;1% N204251 001 Apr 19, 2013 Sep CAHN

BRINCIDOFIVIR

SUSPENSION;ORAL  
TEMBEXA

+! CHIMERIX 10MG/ML N214460 001 Jun 04, 2021 Jun NEWA

TABLET;ORAL  
TEMBEXA

+! CHIMERIX 100MG N214461 001 Jun 04, 2021 Jun NEWA

BRINZOLAMIDE

SUSPENSION/DROPS;OPHTHALMIC  
BRINZOLAMIDE

AB BAUSCH 1% A204884 001 Aug 18, 2021 Aug NEWA

BROMFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC  
BROMFENAC SODIUM

@ NOVITIUM PHARMA EQ 0.09% ACID A201941 001 Feb 10, 2015 Sep CAHN  
BROMSITE

>A> +! SUN PHARM EQ 0.075% ACID N206911 001 Apr 08, 2016 Nov CAHN

>D> +! SUN PHARMA GLOBAL EQ 0.075% ACID N206911 001 Apr 08, 2016 Nov CAHN

BROMOCRIPTINE MESYLATE

CAPSULE;ORAL  
PARLODEL

AB + VALIDUS PHARMS EQ 5MG BASE N017962 002 Mar 01, 1982 Feb CAHN

TABLET;ORAL  
PARLODEL

AB + VALIDUS PHARMS EQ 2.5MG BASE N017962 001 Feb CAHN

BUDESONIDE

CAPSULE, DELAYED RELEASE;ORAL  
BUDESONIDE

@ ALVOGEN 3MG A206724 001 Nov 23, 2016 Apr CDFR  
AB AMNEAL PHARMS 3MG A206200 001 Jul 31, 2017 Apr CDFR  
AB MAYNE PHARMA 3MG A206623 001 Apr 08, 2016 Apr CDFR  
AB RISING 3MG A207367 001 Apr 07, 2017 Apr CDFR  
AB SCIECURE PHARMA INC 3MG A209041 001 Sep 28, 2017 Apr CDFR  
AB ZYDUS PHARMS 3MG A206134 001 May 04, 2017 Apr CDFR

CAPSULE, EXTENDED RELEASE;ORAL  
ORTIKOS

>A> + SUN PHARM INDS INC 6MG N211929 001 Jun 13, 2019 Nov CAHN

>A> +! 9MG N211929 002 Jun 13, 2019 Nov CAHN

>D> + SUN PHARMA GLOBAL 6MG N211929 001 Jun 13, 2019 Nov CAHN

>D> +! 9MG N211929 002 Jun 13, 2019 Nov CAHN

SUSPENSION;INHALATION  
BUDESONIDE

AN SUN PHARM 0.25MG/2ML A211922 001 Apr 14, 2021 Apr NEWA

AN 0.5MG/2ML A211922 002 Apr 14, 2021 Apr NEWA

SUSPENSION; INHALATION						
BUDESONIDE						
AN		1MG/2ML	A211922	003	Apr 14, 2021	Apr NEWA
<u>BUMETANIDE</u>						
TABLET; ORAL						
BUMETANIDE						
BX	RISING	0.5MG	A212019	001	Dec 12, 2019	Sep CTEC
BX		1MG	A212019	002	Dec 12, 2019	Sep CTEC
BX		2MG	A212019	003	Dec 12, 2019	Sep CTEC
<u>BUPIVACAINE</u>						
SOLUTION, EXTENDED RELEASE; INFILTRATION						
POSIMIR						
	+ @ DURECT	660MG/5ML (132MG/ML)	N204803	001	Feb 01, 2021	Mar DISC
	+!	660MG/5ML (132MG/ML)	N204803	001	Feb 01, 2021	Feb NEWA
<u>BUPIVACAINE HYDROCHLORIDE</u>						
INJECTABLE; INJECTION						
BUPIVACAINE HYDROCHLORIDE						
AP	HIKMA PHARMS	0.25%	A205141	001	Feb 11, 2021	Feb NEWA
AP		0.5%	A205141	002	Feb 11, 2021	Feb NEWA
BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE						
AP	HIKMA PHARMS	0.25%	A204842	001	Feb 11, 2021	Feb NEWA
AP		0.5%	A204842	002	Feb 11, 2021	Feb NEWA
AP		0.75%	A204842	003	Feb 11, 2021	Feb NEWA
<u>BUPIVACAINE; MELOXICAM</u>						
SOLUTION, EXTENDED RELEASE; PERIARTICULAR						
ZYNRELEF KIT						
	+! HERON THERAPS INC	60MG/2.3ML (29.25MG/ML); 1.8MG/2.3ML	N211988	001	May 12, 2021	Jun NEWA
	+!	200MG/7ML (29.25MG/ML); 6MG/7ML (0.88MG/ML)	N211988	002	May 12, 2021	Jun NEWA
	+!	300MG/10.5ML (29.25MG/ML); 9MG/10.5ML	N211988	003	May 12, 2021	Jun NEWA
	+!	400MG/14ML (29.25MG/ML); 12MG/14ML (0.88MG/ML)	N211988	004	May 12, 2021	Jun NEWA
<u>BUPRENORPHINE</u>						
FILM, EXTENDED RELEASE; TRANSDERMAL						
BUPRENORPHINE						
AB	AVEVA	5MCG/HR	A210272	001	Sep 23, 2021	Sep NEWA
AB		7.5MCG/HR	A210272	002	Sep 23, 2021	Sep NEWA
AB		10MCG/HR	A210272	003	Sep 23, 2021	Sep NEWA
AB		15MCG/HR	A210272	004	Sep 23, 2021	Sep NEWA
AB		20MCG/HR	A210272	005	Sep 23, 2021	Sep NEWA
	@ MYLAN TECH VIATRIS	5MCG/HR	A210162	001	May 03, 2021	Aug DISC
	@	5MCG/HR	A210162	001	May 03, 2021	Aug DISC
	@	7.5MCG/HR	A210162	002	May 03, 2021	Aug DISC
	@	7.5MCG/HR	A210162	002	May 03, 2021	Aug DISC
	@	10MCG/HR	A210162	003	May 03, 2021	Aug DISC
	@	10MCG/HR	A210162	003	May 03, 2021	Aug DISC
	@	15MCG/HR	A210162	004	May 03, 2021	Aug DISC
	@	15MCG/HR	A210162	004	May 03, 2021	Aug DISC
	@	20MCG/HR	A210162	005	May 03, 2021	Aug DISC
	@	20MCG/HR	A210162	005	May 03, 2021	Aug DISC
AB	MYLAN TECHNOLOGIES	5MCG/HR	A210162	001	May 03, 2021	Apr NEWA
AB		7.5MCG/HR	A210162	002	May 03, 2021	Apr NEWA
AB		10MCG/HR	A210162	003	May 03, 2021	Apr NEWA
AB		15MCG/HR	A210162	004	May 03, 2021	Apr NEWA
AB		20MCG/HR	A210162	005	May 03, 2021	Apr NEWA
AB	WATSON LABS TEVA	7.5MCG/HR	A204937	005	Jun 29, 2021	Jun NEWA
<u>BUPRENORPHINE HYDROCHLORIDE</u>						
FILM; BUCCAL						
BELBUCA						
AB	+ BDSI	EQ 0.075MG BASE	N207932	001	Oct 23, 2015	Jul CFTG
AB	+	EQ 0.15MG BASE	N207932	002	Oct 23, 2015	Jul CFTG
AB	+	EQ 0.3MG BASE	N207932	003	Oct 23, 2015	Jul CFTG
AB	+	EQ 0.45MG BASE	N207932	004	Oct 23, 2015	Jul CFTG
AB	+	EQ 0.6MG BASE	N207932	005	Oct 23, 2015	Jul CFTG
AB	+	EQ 0.75MG BASE	N207932	006	Oct 23, 2015	Jul CFTG

FILM;BUCCAL  
BELBUCA

AB	+	EQ 0.9MG BASE	N207932	007	Oct 23, 2015	Jul	CFTG
BUPRENORPHINE HYDROCHLORIDE							
AB		ALVOGEN EQ 0.075MG BASE	A211594	001	Aug 03, 2021	Aug	CAHN
AB		EQ 0.075MG BASE	A211594	001	Aug 03, 2021	Jul	NFTG
AB		EQ 0.15MG BASE	A211594	002	Aug 03, 2021	Aug	CAHN
AB		EQ 0.15MG BASE	A211594	002	Aug 03, 2021	Jul	NFTG
AB		EQ 0.3MG BASE	A211594	003	Aug 03, 2021	Aug	CAHN
AB		EQ 0.3MG BASE	A211594	003	Aug 03, 2021	Jul	NFTG
AB		EQ 0.45MG BASE	A211594	004	Aug 03, 2021	Aug	CAHN
AB		EQ 0.45MG BASE	A211594	004	Aug 03, 2021	Jul	NFTG
AB		EQ 0.6MG BASE	A211594	005	Aug 03, 2021	Aug	CAHN
AB		EQ 0.6MG BASE	A211594	005	Aug 03, 2021	Jul	NFTG
AB		EQ 0.75MG BASE	A211594	006	Aug 03, 2021	Aug	CAHN
AB		EQ 0.75MG BASE	A211594	006	Aug 03, 2021	Jul	NFTG
AB		EQ 0.9MG BASE	A211594	007	Aug 03, 2021	Aug	CAHN
AB		EQ 0.9MG BASE	A211594	007	Aug 03, 2021	Jul	NFTG

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE							
AB		ALKEM LABS LTD EQ 2MG BASE;EQ 0.5MG BASE	A214930	001	Jun 15, 2021	Jun	NEWA
AB		EQ 8MG BASE;EQ 2MG BASE	A214930	002	Jun 15, 2021	Jun	NEWA
	@	MAYNE PHARMA INC EQ 2MG BASE;EQ 0.5MG BASE	A206953	001	Jul 17, 2020	Jan	DISC
	@	EQ 8MG BASE;EQ 2MG BASE	A206953	002	Jul 17, 2020	Jul	DISC
AB		EQ 8MG BASE;EQ 2MG BASE	A206953	002	Jul 17, 2020	May	CMFD
	@	EQ 8MG BASE;EQ 2MG BASE	A206953	002	Jul 17, 2020	Jan	DISC
AB		RHODES PHARMS EQ 2MG BASE;EQ 0.5MG BASE	A205601	001	Mar 30, 2020	Jul	CMFD
AB		EQ 8MG BASE;EQ 2MG BASE	A205601	002	Mar 30, 2020	Jul	CMFD

BUPROPION HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

APLENZIN

+	BAUSCH	174MG	N022108	001	Apr 23, 2008	Feb	CAHN
+		348MG	N022108	002	Apr 23, 2008	Feb	CAHN
+	!	522MG	N022108	003	Apr 23, 2008	Feb	CAHN

BUPROPION HYDROCHLORIDE

TABLET;ORAL

BUPROPION HYDROCHLORIDE

	@	MYLAN	75MG	A075491	001	Apr 17, 2000	Aug	DISC
	@		100MG	A075491	002	Apr 17, 2000	Aug	DISC

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

>A>	@	AUROBINDO PHARMA USA	100MG	A090325	001	Apr 08, 2010	Nov	CAHN
>A>	@		150MG	A090325	002	Apr 08, 2010	Nov	CAHN
>A>	@		150MG	A090942	001	Jul 14, 2010	Nov	CAHN
>A>	@		200MG	A090325	003	Apr 08, 2010	Nov	CAHN
>A>	@		300MG	A090942	002	Jul 14, 2010	Nov	CAHN
	@	IMPAX LABS	150MG	A077415	001	Nov 26, 2008	Aug	DISC
	@		200MG	A076711	001	Dec 03, 2004	Aug	DISC
>D>	@	MYLAN	100MG	A090325	001	Apr 08, 2010	Nov	CAHN
>D>	@		150MG	A090325	002	Apr 08, 2010	Nov	CAHN
>D>	@		150MG	A090942	001	Jul 14, 2010	Nov	CAHN
>D>	@		200MG	A090325	003	Apr 08, 2010	Nov	CAHN
>D>	@		300MG	A090942	002	Jul 14, 2010	Nov	CAHN
	@	TORRENT	100MG	A203969	001	Oct 31, 2014	Jan	DISC
	@		150MG	A203969	002	Oct 31, 2014	Jan	DISC
	@		200MG	A203969	003	Oct 31, 2014	Jan	DISC
		FORFIVO XL						
+	!	ALMATICA	450MG	N022497	001	Nov 10, 2011	Sep	CAHN
		WELLBUTRIN XL						
AB3	+	BAUSCH	150MG	N021515	001	Aug 28, 2003	Feb	CAHN
AB3	+	!	300MG	N021515	002	Aug 28, 2003	Feb	CAHN

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

AB		RUBICON	5MG	A075521	001	Apr 05, 2002	Feb	CMFD
AB			7.5MG	A075521	004	Mar 16, 2021	Mar	NEWA
AB			10MG	A075521	002	Apr 05, 2002	Feb	CMFD
AB			15MG	A075521	003	Apr 05, 2002	Feb	CMFD

	TABLET;ORAL						
	BUSPIRONE HYDROCHLORIDE						
AB		30MG	A075521	005	Mar 16, 2021	Mar	NEWA
	<u>BUSULFAN</u>						
	INJECTABLE; INJECTION						
	BUSULFAN						
AP	AM REGENT	6MG/ML	A202259	001	Dec 22, 2015	Feb	CAHN
>A>	AP	ARTHUR GRP	A205106	001	Sep 21, 2018	Nov	CAHN
>D>	AP	ATHENEX INC	A205106	001	Sep 21, 2018	Nov	CAHN
	<u>BUTABARBITAL SODIUM</u>						
	TABLET;ORAL						
	BUTABARBITAL SODIUM						
	+ @ SANDOZ	15MG	A085938	001		Aug	CRLD
	<u>CABERGOLINE</u>						
	TABLET;ORAL						
	DOSTINEX						
	+ @ PFIZER	0.5MG	N020664	001	Dec 23, 1996	Jan	CAHN
	<u>CABOTEGRAVIR SODIUM</u>						
	TABLET;ORAL						
	VOCABRIA						
	+! VIIV HLHCARE	EQ 30MG BASE	N212887	001	Jan 21, 2021	Jan	NEWA
	<u>CABOTEGRAVIR; RILPIVIRINE</u>						
	SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR						
	CABENUVA KIT						
	+! VIIV HLHCARE	400MG/2ML (200MG/ML); 600MG/2ML (300MG/ML)	N212888	001	Jan 21, 2021	Jan	NEWA
	+!	600MG/3ML (200MG/ML); 900MG/3ML (300MG/ML)	N212888	002	Jan 21, 2021	Jan	NEWA
	<u>CAFFEINE CITRATE</u>						
	SOLUTION; INTRAVENOUS						
	CAF CIT						
AP	+! HIKMA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793	001	Sep 21, 1999	Jul	CAHN
	SOLUTION; ORAL						
	CAF CIT						
AA	+! HIKMA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793	002	Apr 12, 2000	Jul	CAHN
	<u>CAFFEINE; ERGOTAMINE TARTRATE</u>						
	TABLET; ORAL						
	CAF ERGOT						
	+ @ SANDOZ	100MG; 1MG	A084294	001		Aug	CRLD
	@	100MG; 1MG	A084294	001		Jul	DISC
	ERGOTAMINE TARTRATE AND CAFFEINE						
	! MIKART	100MG; 1MG	A040590	001	Sep 16, 2005	Jul	CHRS
		100MG; 1MG	A040590	001	Sep 16, 2005	Jul	CTEC
	<u>CALCITONIN SALMON</u>						
	INJECTABLE; INJECTION						
	CALCITONIN-SALMON						
AP	CUSTOPHARM INC	200 IU/ML	A212416	001	May 14, 2021	May	NFTG
>A>	AP	PAR STERILE PRODUCTS	A209358	001	Nov 10, 2021	Nov	NEWA
	MIACALCIN						
AP	+! MYLAN IRELAND LTD	200 IU/ML	N017808	002	Mar 29, 1991	May	CFTG
	<u>CALCIUM ACETATE</u>						
	CAPSULE; ORAL						
	CALCIUM ACETATE						
	@ AMNEAL PHARMS	667MG	A201658	001	Oct 06, 2014	Oct	DISC
	TABLET; ORAL						
	CALCIUM ACETATE						
AB	! CHARTWELL MOLECULAR	667MG	A202420	001	Feb 05, 2013	Apr	CHRS

CALCIUM CARBONATE; RISEDRONATE SODIUM

TABLET;ORAL

ACTONEL WITH CALCIUM (COPACKAGED)

+ @	WARNER CHILCOTT	EQ 500MG BASE;35MG	N021823	001	Aug 12, 2005	Jul	CPOT
+ @		EQ 500MG BASE,N/A;N/A,35MG	N021823	001	Aug 12, 2005	Jul	CDFR

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	FRESENIUS KABI USA	20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML	A211428	001	Nov 09, 2021	Oct	NFTG
----	--------------------	--	---------	-----	--------------	-----	------

CALCIUM GLUCEPTATE

INJECTABLE;INJECTION

CALCIUM GLUCEPTATE

+ @	ABBOTT	EQ 90MG CALCIUM/5ML	A080001	001		Aug	CRLD
-----	--------	---------------------	---------	-----	--	-----	------

CALCIUM GLUCONATE

SOLUTION;INTRAVENOUS

CALCIUM GLUCONATE IN SODIUM CHLORIDE

+!	FRESENIUS KABI USA	1GM/50ML (20MG/ML)	N208418	004	Jun 17, 2021	Aug	NEWA
+!		2GM/100ML (20MG/ML)	N208418	005	Jun 17, 2021	Aug	NEWA
+!	HQ SPCLT PHARMA	1GM/100ML (10MG/ML)	N210906	003	Jun 04, 2021	Jun	NEWA

CAPREOMYCIN SULFATE

INJECTABLE;INJECTION

CAPASTAT SULFATE

+ @	AKORN	EQ 1GM BASE/VIAL	N050095	001		Jun	DISC
-----	-------	------------------	---------	-----	--	-----	------

CAPTOPRIL

TABLET;ORAL

CAPTOPRIL

AB	ANNORA PHARMA	12.5MG	A074737	001	Oct 28, 1998	Jul	CMFD
AB		25MG	A074737	002	Oct 28, 1998	Jul	CMFD
AB		50MG	A074737	003	Oct 28, 1998	Jul	CMFD
AB		100MG	A074737	004	Oct 28, 1998	Jul	CMFD
>A>	@ CHARTWELL RX	12.5MG	A074363	001	Nov 09, 1995	Nov	CAHN
>A>	@	12.5MG	A074519	001	Feb 13, 1996	Nov	CAHN
>A>	@	25MG	A074363	002	Nov 09, 1995	Nov	CAHN
>A>	@	25MG	A074519	002	Feb 13, 1996	Nov	CAHN
>A>	@	50MG	A074363	003	Nov 09, 1995	Nov	CAHN
>A>	@	50MG	A074519	003	Feb 13, 1996	Nov	CAHN
>A>	@	100MG	A074363	004	Nov 09, 1995	Nov	CAHN
>A>	@	100MG	A074519	004	Feb 13, 1996	Nov	CAHN
AB	! HIKMA INTL PHARMS	100MG	A074505	004	Feb 13, 1996	Sep	CHRS
	@ MYLAN	12.5MG	A074434	001	Feb 13, 1996	Sep	CAHN
	@	12.5MG	A074434	001	Feb 13, 1996	Sep	DISC
	@	25MG	A074434	002	Feb 13, 1996	Sep	CAHN
	@	25MG	A074434	002	Feb 13, 1996	Sep	DISC
	@	50MG	A074434	003	Feb 13, 1996	Sep	CAHN
	@	50MG	A074434	003	Feb 13, 1996	Sep	DISC
	@	100MG	A074434	004	Feb 13, 1996	Sep	CAHN
	@	100MG	A074434	004	Feb 13, 1996	Sep	DISC
>D>	@ YAOPHARMA CO LTD	12.5MG	A074363	001	Nov 09, 1995	Nov	CAHN
>D>	@	12.5MG	A074519	001	Feb 13, 1996	Nov	CAHN
>D>	@	25MG	A074363	002	Nov 09, 1995	Nov	CAHN
>D>	@	25MG	A074519	002	Feb 13, 1996	Nov	CAHN
>D>	@	50MG	A074363	003	Nov 09, 1995	Nov	CAHN
>D>	@	50MG	A074519	003	Feb 13, 1996	Nov	CAHN
>D>	@	100MG	A074363	004	Nov 09, 1995	Nov	CAHN
>D>	@	100MG	A074519	004	Feb 13, 1996	Nov	CAHN

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

>A>	@ STRIDES PHARMA	25MG;15MG	A074788	001	Dec 29, 1997	Nov	CAHN
>A>	@	25MG;25MG	A074788	002	Dec 29, 1997	Nov	CAHN
>A>	@	50MG;15MG	A074788	004	Dec 29, 1997	Nov	CAHN
>A>	@	50MG;25MG	A074788	003	Dec 29, 1997	Nov	CAHN
>D>	@ VINTAGE PHARMS LLC	25MG;15MG	A074788	001	Dec 29, 1997	Nov	CAHN
>D>	@	25MG;25MG	A074788	002	Dec 29, 1997	Nov	CAHN
>D>	@	50MG;15MG	A074788	004	Dec 29, 1997	Nov	CAHN

	TABLET;ORAL							
	CAPTOPRIL AND HYDROCHLOROTHIAZIDE							
>D>	@	50MG;25MG	A 074788	003	Dec 29, 1997	Nov	CAHN	
	<u>CARBAMAZEPINE</u>							
	TABLET;ORAL							
	CARBAMAZEPINE							
AB	VGYAAN	200MG	A 214328	001	Aug 16, 2021	Aug	NEWA	
	TABLET, EXTENDED RELEASE;ORAL							
	CARBAMAZEPINE							
AB	ANBISON LAB	100MG	A 212948	001	Sep 30, 2021	Sep	NEWA	
AB		200MG	A 212948	002	Sep 30, 2021	Sep	NEWA	
AB		400MG	A 212948	003	Sep 30, 2021	Sep	NEWA	
AB	CSPC OUYI	100MG	A 213311	001	Apr 13, 2021	Apr	NEWA	
AB		200MG	A 213311	002	Apr 13, 2021	Apr	NEWA	
AB		400MG	A 213311	003	Apr 13, 2021	Apr	NEWA	
	<u>CARBIDOPA; LEVODOPA</u>							
	TABLET;ORAL							
	CARBIDOPA AND LEVODOPA							
AB	SCIEGEN PHARMS INC	10MG;100MG	A 214092	001	May 07, 2021	Apr	NEWA	
AB		25MG;100MG	A 214092	002	May 07, 2021	Apr	NEWA	
AB		25MG;250MG	A 214092	003	May 07, 2021	Apr	NEWA	
	DHIVY							
>A>	+!	AVION PHARMS	N 214869	001	Nov 12, 2021	Nov	CAHN	
	SINEMET							
AB	+	ORGANON	N 017555	001		Aug	CAHN	
AB	+		N 017555	003		Aug	CAHN	
AB	+		N 017555	002		Aug	CAHN	
	TABLET, EXTENDED RELEASE;ORAL							
	CARBIDOPA AND LEVODOPA							
AB	SCIEGEN PHARMS INC	25MG;100MG	A 214091	001	Oct 05, 2021	Sep	NEWA	
AB		50MG;200MG	A 214091	002	Oct 05, 2021	Sep	NEWA	
	SINEMET CR							
	+ @	ORGANON	N 019856	002	Dec 24, 1992	Sep	CAHN	
	+ @		N 019856	001	May 30, 1991	Sep	CAHN	
	TABLET, ORALLY DISINTEGRATING;ORAL							
	CARBIDOPA AND LEVODOPA							
AB	!	SUN PHARM	A 078690	003	Jul 31, 2009	Aug	CTEC	
AB	!		A 078690	003	Jul 31, 2009	Aug	CHRS	
	<u>CARBINOXAMINE MALEATE</u>							
	TABLET;ORAL							
	CARBINOXAMINE MALEATE							
>A>	@	STRIDES PHARMA	A 040639	002	May 30, 2008	Nov	CAHN	
>D>	@	VINTAGE PHARMS	A 040639	002	May 30, 2008	Nov	CAHN	
	<u>CARBOPLATIN</u>							
>D>	INJECTABLE;INJECTION							
>D>	CARBOPLATIN							
>D>	AP	EUGIA PHARMA	A 205487	004	Aug 03, 2020	Nov	CDFR	
>A>	INJECTABLE;INTRAVENOUS							
>A>	CARBOPLATIN							
>A>	AP	EUGIA PHARMA	A 205487	004	Aug 03, 2020	Nov	CDFR	
>A>	AP	GLAND PHARMA LTD	A 207324	001	Feb 15, 2017	Nov	CDFR	
AP	!	HOSPIRA	A 076517	001	Oct 14, 2004	Mar	CHRS	
AP	!		A 076517	002	Oct 14, 2004	Mar	CHRS	
AP	!		A 076517	003	Oct 14, 2004	Mar	CHRS	
AP	!		A 077059	001	Nov 23, 2004	Mar	CHRS	
	@	MEITHEAL	A 077096	001	Jun 14, 2005	Aug	DISC	
	@		A 077096	002	Jun 14, 2005	Aug	DISC	
	@		A 077096	003	Jun 14, 2005	Aug	DISC	
	@		A 077096	004	Jun 03, 2013	Aug	DISC	
AP		PHARMACHEMIE BV	A 077269	001	Oct 14, 2004	Mar	CHRS	
AP			A 077269	002	Oct 14, 2004	Mar	CHRS	
AP			A 077269	003	Oct 14, 2004	Mar	CHRS	
AP			A 077269	004	Dec 28, 2007	Mar	CHRS	
>D>	INJECTABLE;IV (INFUSION)							
>D>	CARBOPLATIN							
>D>	AP	GLAND PHARMA LTD	A 207324	001	Feb 15, 2017	Nov	CDFR	

CARBOPROST TROMETHAMINE

INJECTABLE; INJECTION  
CARBOPROST TROMETHAMINE

AP	SUNNY	EQ 0.25MG BASE/ML	A213118	001	Mar 25, 2021	Mar	NEWA
----	-------	-------------------	---------	-----	--------------	-----	------

CARFILZOMIB

POWDER; INTRAVENOUS  
CARFILZOMIB

AP	@ BRECKENRIDGE	10MG/VIAL	A209330	001	Jun 11, 2021	Aug	DISC
		10MG/VIAL	A209330	001	Jun 11, 2021	Jun	NFTG
	@	60MG/VIAL	A209330	002	Jun 11, 2021	Aug	DISC
AP		60MG/VIAL	A209330	002	Jun 11, 2021	Jun	NEWA
	KYPROLIS						
	+ ONYX THERAP	10MG/VIAL	N202714	003	Jun 07, 2018	Aug	CTEC
AP	+	10MG/VIAL	N202714	003	Jun 07, 2018	Jun	CFTG

CARGLUMIC ACID

TABLET, FOR SUSPENSION; ORAL  
CARBAGLU

AB	+! RECORDATI RARE	200MG	N022562	001	Mar 18, 2010	Oct	CFTG
	CARGLUMIC ACID						
AB	NOVITIUM PHARMA	200MG	A213729	001	Oct 13, 2021	Oct	NFTG

CARISOPRODOL

TABLET; ORAL  
CARISOPRODOL

AA	MLV	350MG	A040245	001	Sep 08, 1997	Sep	CAHN
AA		350MG	A211789	001	Oct 20, 2021	Oct	NEWA
BX	STRIDES PHARMA	250MG	A205513	001	Nov 12, 2015	Sep	CTEC
BX		350MG	A205513	002	Nov 12, 2015	Sep	CTEC

CARMUSTINE

INJECTABLE; INJECTION  
BICNU

AP	+! AVET LIFESCIENCES	100MG/VIAL	N017422	001		Aug	CAHN
	CARMUSTINE						
AP	HONG KONG	100MG/VIAL	A213460	001	Aug 02, 2021	Jul	NEWA
AP	MEITHEAL	100MG/VIAL	A213460	001	Aug 02, 2021	Sep	CAHN

CARVEDILOL

TABLET; ORAL  
CARVEDILOL

	@ ACI	3.125MG	A078786	001	Dec 22, 2009	Sep	CAHN
	@	6.25MG	A078786	002	Dec 22, 2009	Sep	CAHN
	@	12.5MG	A078786	003	Dec 22, 2009	Sep	CAHN
	@	25MG	A078786	004	Dec 22, 2009	Sep	CAHN
	@ AXXELENT PHARMA	3.125MG	A078786	001	Dec 22, 2009	Aug	CAHN
	@	6.25MG	A078786	002	Dec 22, 2009	Aug	CAHN
	@	12.5MG	A078786	003	Dec 22, 2009	Aug	CAHN
	@	25MG	A078786	004	Dec 22, 2009	Aug	CAHN
	COREG						
AB	+ WOODWARD	3.125MG	N020297	004	May 29, 1997	Jul	CAHN
AB	+	6.25MG	N020297	003	Sep 14, 1995	Jul	CAHN
AB	+!	12.5MG	N020297	002	Sep 14, 1995	Jul	CAHN
AB	+	25MG	N020297	001	Sep 14, 1995	Jul	CAHN

CARVEDILOL PHOSPHATE

CAPSULE, EXTENDED RELEASE; ORAL  
COREG CR

AB	+ WOODWARD	10MG	N022012	001	Oct 20, 2006	Jul	CAHN
AB	+	20MG	N022012	002	Oct 20, 2006	Jul	CAHN
AB	+!	40MG	N022012	003	Oct 20, 2006	Jul	CAHN
AB	+	80MG	N022012	004	Oct 20, 2006	Jul	CAHN

CASIMERSEN

SOLUTION; INTRAVENOUS  
AMONDYS 45

	+! SAREPTA THERAPS INC	100MG/2ML (50MG/ML)	N213026	001	Feb 25, 2021	Feb	NEWA
--	------------------------	---------------------	---------	-----	--------------	-----	------



CASPOFUNGIN ACETATEPOWDER; INTRAVENOUS  
CASPOFUNGIN ACETATE

AP	UBI	50MG/VIAL	A211263	001	Oct 01, 2021	Sep	NEWA
AP		70MG/VIAL	A211263	002	Oct 01, 2021	Sep	NEWA

CEFAZOLIN SODIUMSOLUTION; INTRAVENOUS  
CEFAZOLIN IN PLASTIC CONTAINER

+	!	BAXTER HLTHCARE CORP	EQ 1GM BASE/50ML (EQ 20MG BASE/ML)	N207131	002	Feb 01, 2021	Mar	NEWA
+	!		EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N207131	001	Aug 07, 2015	Mar	CRLD
	!		EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N207131	001	Aug 07, 2015	Mar	CHRS

CEFDINIRCAPSULE; ORAL  
CEFDINIR

AB	ALKEM LABS LTD	300MG	A210220	001	Feb 19, 2021	Feb	NEWA
	FOR SUSPENSION; ORAL						
	CEFDINIR						
AB	ALKEM LABS LTD	125MG/5ML	A210534	001	Feb 19, 2021	Feb	NEWA
AB		250MG/5ML	A210534	002	Feb 19, 2021	Feb	NEWA

CEFIXIMEFOR SUSPENSION; ORAL  
CEFIXIME

AB	ALKEM LABS LTD	100MG/5ML	A211775	001	Feb 19, 2021	Feb	NEWA
AB		200MG/5ML	A211775	002	Feb 19, 2021	Feb	NEWA

CEFOTAXIME SODIUMINJECTABLE; INJECTION  
CLAFORAN

+	@	VALIDUS PHARMS	EQ 500MG BASE/VIAL	N050547	001		Feb	CAHN
+	@		EQ 1GM BASE/VIAL	N050547	002		Feb	CAHN
+	@		EQ 2GM BASE/VIAL	N050547	003		Feb	CAHN
+	@		EQ 10GM BASE/VIAL	N050547	004	Dec 29, 1983	Feb	CAHN
		CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER						
	@	VALIDUS PHARMS	EQ 20MG BASE/ML	N050596	002	May 20, 1985	Feb	CAHN
	@		EQ 40MG BASE/ML	N050596	004	May 20, 1985	Feb	CAHN
		CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
	@	VALIDUS PHARMS	EQ 20MG BASE/ML	N050596	001	May 20, 1985	Feb	CAHN
	@		EQ 40MG BASE/ML	N050596	003	May 20, 1985	Feb	CAHN

CEFOXITIN SODIUMINJECTABLE; INJECTION  
CEFOXITIN

AP	HIKMA	EQ 1GM BASE/VIAL	A065051	001	Sep 11, 2000	Oct	CAHN
AP		EQ 2GM BASE/VIAL	A065051	002	Sep 11, 2000	Oct	CAHN
AP		EQ 10GM BASE/VIAL	A065050	001	Sep 11, 2000	Oct	CAHN

CEFTAROLINE FOSAMILPOWDER; INTRAVENOUS  
CEFTAROLINE FOSAMIL

AP	APOTEX	400MG/VIAL	A208075	001	Sep 21, 2021	Sep	NFTG	
AP		600MG/VIAL	A208075	002	Sep 21, 2021	Sep	NFTG	
	TEFLARO							
AP	+	ALLERGAN	400MG/VIAL	N200327	001	Oct 29, 2010	Sep	CHRS
AP	+		400MG/VIAL	N200327	001	Oct 29, 2010	Sep	CFTG
AP	+		600MG/VIAL	N200327	002	Oct 29, 2010	Sep	CFTG

CEFTAZIDIME SODIUMINJECTABLE; INJECTION  
FORTAZ IN PLASTIC CONTAINER

	@	TELGENT	EQ 10MG BASE/ML	N050634	001	Apr 28, 1989	Feb	CAHN
	+	@	EQ 20MG BASE/ML	N050634	002	Apr 28, 1989	Feb	CAHN
	+	@	EQ 40MG BASE/ML	N050634	003	Apr 28, 1989	Feb	CAHN

CEFUROXIME SODIUMINJECTABLE; INJECTION  
ZINACEF

AP	+	TELIGENT	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Feb	CAHN
AP	+		EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Feb	CAHN

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS  
ZINACEF

AB	+	TELIGENT	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	Feb	CAHN
----	---	----------	--------------------	---------	-----	--------------	-----	------

CELECOXIBCAPSULE; ORAL  
CELEBREX

AB	+	UPJOHN	50MG	N020998	004	Dec 15, 2006	Apr	CAHN
AB	+		100MG	N020998	001	Dec 31, 1998	Apr	CAHN
AB	+		200MG	N020998	002	Dec 31, 1998	Apr	CAHN
AB	+		400MG	N020998	003	Aug 29, 2002	Apr	CAHN

CELECOXIB

	@	ACIC PHARMS	200MG	A212925	001	Dec 09, 2020	Jun	DISC
	@		400MG	A212925	002	Dec 09, 2020	Jun	DISC
BX		AMNEAL PHARMS	50MG	A208833	001	May 31, 2018	Sep	CTEC
BX			100MG	A208833	002	May 31, 2018	Sep	CTEC
BX			200MG	A208833	003	May 31, 2018	Sep	CTEC
BX			400MG	A208833	004	May 31, 2018	Sep	CTEC
	@	JUBILANT GENERICS	50MG	A207061	001	Apr 04, 2017	Jun	DISC
	@		100MG	A207061	002	Apr 04, 2017	Jun	DISC
	@		200MG	A207061	003	Apr 04, 2017	Jun	DISC
	@		400MG	A207061	004	Apr 04, 2017	Jun	DISC
AB		UNICHEM	50MG	A213301	001	Jan 12, 2021	Jan	NEWA
AB			100MG	A213301	002	Jan 12, 2021	Jan	NEWA
AB			200MG	A213301	003	Jan 12, 2021	Jan	NEWA
AB			400MG	A213301	004	Jan 12, 2021	Jan	NEWA
AB		YILING	50MG	A211412	001	Mar 06, 2020	Jun	CMFD
AB			100MG	A211412	002	Mar 06, 2020	Jun	CMFD
AB			200MG	A211412	003	Mar 06, 2020	Jun	CMFD
AB			400MG	A211412	004	Mar 06, 2020	Jun	CMFD

SOLUTION; ORAL

ELYXYB

	+	@ BDSI	25MG/ML	N212157	001	May 05, 2020	Sep	CAHN
--	---	--------	---------	---------	-----	--------------	-----	------

CELECOXIB; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

SEGLENTIS

>D>	+	ESTEVE	56MG; 44MG	N213426	001	Oct 15, 2021	Nov	CAHN
	+		56MG; 44MG	N213426	001	Oct 15, 2021	Oct	NEWA
>A>	+	KOWA PHARMS	56MG; 44MG	N213426	001	Oct 15, 2021	Nov	CAHN

CENOAMATE

TABLET; ORAL

XCOPRI

	+	SK LIFE	12.5MG	N212839	001	Mar 10, 2020	Jul	CHRS
	+		200MG	N212839	006	Mar 10, 2020	Jul	CHRS

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

	!	ALKEM LABS LTD	EQ 750MG BASE	A090836	004	Mar 29, 2013	Sep	CTEC
AB	!		EQ 750MG BASE	A090836	004	Mar 29, 2013	Sep	CHRS
AB		YUNG SHIN PHARM	EQ 250MG BASE	A065152	001	Feb 24, 2005	Aug	CMFD
	@		EQ 250MG BASE	A065152	001	Feb 24, 2005	Mar	DISC
AB			EQ 500MG BASE	A065152	002	Feb 24, 2005	Aug	CMFD
	@		EQ 500MG BASE	A065152	002	Feb 24, 2005	Mar	DISC
		KEFLEX						
	+	@ PRAGMA	EQ 250MG BASE	N050405	002		May	DISC
	+	@	EQ 500MG BASE	N050405	003		May	DISC
	+	@	EQ 750MG BASE	N050405	005	May 12, 2006	Sep	DISC

CETIRIZINE HYDROCHLORIDE

SYRUP;ORAL

CETIRIZINE HYDROCHLORIDE

AA	MICRO LABS	5MG/5ML	A 090191	001	Nov 12, 2009	Aug	CAHN
AA	! PADAGIS US	5MG/5ML	A 078398	001	Jun 17, 2008	Jul	CAHN

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE;ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE

	@ CHARTWELL RX	5MG	A 084678	001		Apr	CAHN
	@	10MG	A 084041	001		Apr	CAHN
	@	25MG	A 084679	002		Apr	CAHN
	+ @ UPSHER SMITH LABS	10MG	A 084920	001		Aug	CRLD
	LIBRIUM						
AB	+! VALEANT PHARM INTL	25MG	A 085475	001		Aug	CRLD

CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE

CAPSULE;ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE

AB	ALKEM LABS LTD	5MG;2.5MG	A 214065	001	Apr 26, 2021	Apr	NEWA
AB	AMNEAL	5MG;2.5MG	A 215555	001	Oct 25, 2021	Oct	NEWA
AB	DR REDDYS	5MG;2.5MG	A 214698	001	May 10, 2021	Apr	NEWA
AB	PHARMA LIFE	5MG;2.5MG	A 213530	001	Oct 20, 2020	Sep	CAHN
AB	TEVA PHARMS USA	5MG;2.5MG	A 211476	001	Nov 02, 2021	Oct	NEWA

CHLORHEXIDINE GLUCONATE

SOLUTION;DENTAL

CHLORHEXIDINE GLUCONATE

AT	BAJAJ	0.12%	A 075561	001	Nov 14, 2000	Feb	CMFD
----	-------	-------	----------	-----	--------------	-----	------

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

CHLOROPROCAINE HYDROCHLORIDE

>A>	AP	HIKMA	2%	A 040273	001	Sep 09, 1998	Nov	CAHN
>A>	AP		3%	A 040273	002	Sep 09, 1998	Nov	CAHN
>D>	AP	WEST-WARD PHARMS INT	2%	A 040273	001	Sep 09, 1998	Nov	CAHN
>D>	AP		3%	A 040273	002	Sep 09, 1998	Nov	CAHN

CHLOROQUINE PHOSPHATE

TABLET;ORAL

CHLOROQUINE PHOSPHATE

AA	SUVEN PHARMS	500MG	A 214756	001	Sep 03, 2021	Aug	NEWA
----	--------------	-------	----------	-----	--------------	-----	------

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE;ORAL

CHLORPROMAZINE HYDROCHLORIDE

>D>		GENUS	30MG/ML	A 214542	001	Jun 02, 2021	Nov	CHRS
>A>	!		30MG/ML	A 214542	001	Jun 02, 2021	Nov	CHRS
			30MG/ML	A 214542	001	Jun 02, 2021	May	NEWA
>D>			100MG/ML	A 214542	002	Jun 02, 2021	Nov	CHRS
>A>	!		100MG/ML	A 214542	002	Jun 02, 2021	Nov	CHRS
			100MG/ML	A 214542	002	Jun 02, 2021	May	NEWA

TABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE

BX	AMNEAL PHARMS CO	10MG	A 209755	001	Sep 10, 2018	Sep	CTEC	
BX		25MG	A 209755	002	Sep 10, 2018	Sep	CTEC	
BX		50MG	A 209755	003	Sep 10, 2018	Sep	CTEC	
BX		100MG	A 209755	004	Sep 10, 2018	Sep	CTEC	
BX		200MG	A 209755	005	Sep 10, 2018	Sep	CTEC	
>A>	AB	ENALTEC	10MG	A 212630	001	Nov 29, 2021	Nov	NEWA
>A>	AB		25MG	A 212630	002	Nov 29, 2021	Nov	NEWA
>A>	AB		50MG	A 212630	003	Nov 29, 2021	Nov	NEWA
>A>	AB		100MG	A 212630	004	Nov 29, 2021	Nov	NEWA
>A>	AB		200MG	A 212630	005	Nov 29, 2021	Nov	NEWA
AB	GLENMARK PHARMS LTD	10MG	A 212144	001	Mar 23, 2021	Mar	NEWA	
AB		25MG	A 212144	002	Mar 23, 2021	Mar	NEWA	
AB		50MG	A 212144	003	Mar 23, 2021	Mar	NEWA	
AB		100MG	A 212144	004	Mar 23, 2021	Mar	NEWA	
AB		200MG	A 212144	005	Mar 23, 2021	Mar	NEWA	
AB	LANNETT CO INC	10MG	A 212996	001	Jan 22, 2021	Jan	NEWA	
AB		25MG	A 212996	002	Jan 22, 2021	Jan	NEWA	

TABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE

AB		50MG	A212996	003	Jan 22, 2021	Jan	NEWA
AB		100MG	A212996	004	Jan 22, 2021	Jan	NEWA
AB		200MG	A212996	005	Jan 22, 2021	Jan	NEWA
	@ MAYNE PHARMA	10MG	A213590	001	Aug 31, 2020	Mar	DISC
	@	25MG	A213590	002	Aug 31, 2020	Mar	DISC
	@	50MG	A213590	003	Aug 31, 2020	Mar	DISC
	@	100MG	A213590	004	Aug 31, 2020	Mar	DISC
	@	200MG	A213590	005	Aug 31, 2020	Mar	DISC
AB	TEVA PHARMS	10MG	A215659	001	Oct 25, 2021	Oct	NEWA
AB		25MG	A215659	002	Oct 25, 2021	Oct	NEWA
AB		50MG	A215659	003	Oct 25, 2021	Oct	NEWA
AB		100MG	A215659	004	Oct 25, 2021	Oct	NEWA
AB		200MG	A215659	005	Oct 25, 2021	Oct	NEWA
AB	+ UPSHER SMITH LABS	10MG	A083386	001		Aug	CRLD
AB	+!	25MG	A084112	001		Aug	CRLD
AB	+	50MG	A084113	001		Aug	CRLD
AB	+!	100MG	A084114	001		Aug	CRLD
AB	+	200MG	A084115	001		Aug	CRLD

CHLORPROPAMIDE

TABLET;ORAL

CHLORPROPAMIDE

	@ RISING	100MG	A088725	001	Aug 31, 1984	Jan	CAHN
	@	250MG	A088726	001	Aug 31, 1984	Jan	CAHN

CHLORTHALIDONE

TABLET;ORAL

CHLORTHALIDONE

>A>	AB	APPCO	25MG	A210742	001	Oct 12, 2018	Nov	CAHN
>A>	AB		50MG	A210742	002	Oct 12, 2018	Nov	CAHN
>D>	AB	DR REDDYS	25MG	A210742	001	Oct 12, 2018	Nov	CAHN
>D>	AB		50MG	A210742	002	Oct 12, 2018	Nov	CAHN
	AB	+ MYLAN	25MG	A086831	002		Aug	CRLD
	AB	+!	50MG	A086831	001		Aug	CRLD
	AB	NOVAST LABS	25MG	A206904	001	Mar 30, 2017	Sep	CAHN
	AB		50MG	A206904	002	Mar 30, 2017	Sep	CAHN
	BX	UMEDICA LABS PVT LTD	25MG	A207222	001	May 24, 2018	Sep	CTEC
	BX		50MG	A207222	002	May 24, 2018	Sep	CTEC
		THALITONE						
	+	CASPER PHARMA LLC	15MG	N019574	001	Dec 20, 1988	May	CMFD
	BX	+!	25MG	N019574	002	Feb 12, 1992	May	CMFD

CHLORZOXAZONE

TABLET;ORAL

CHLORZOXAZONE

AA		HAVIX	250MG	A215158	001	Jul 29, 2021	Jul	NEWA
AA	!	MIKART	250MG	A207483	001	Jun 24, 2016	Jul	CTEC
AB		PAR PHARM INC	375MG	A212743	002	Apr 29, 2021	Apr	NEWA
AA		SENORES PHARMS	250MG	A215158	001	Jul 29, 2021	Aug	CAHN

CHOLESTYRAMINE

POWDER;ORAL

CHOLESTYRAMINE

AB		ALKEM LABS LTD	EQ 4GM RESIN/PACKET	A211856	001	Oct 19, 2021	Oct	NEWA
AB			EQ 4GM RESIN/SCOOPFUL	A211856	002	Oct 19, 2021	Oct	NEWA
AB		TAGI	EQ 4GM RESIN/PACKET	A209597	001	Mar 09, 2021	Feb	NEWA
AB			EQ 4GM RESIN/SCOOPFUL	A209597	002	Mar 09, 2021	Feb	NEWA
		CHOLESTYRAMINE LIGHT						
AB		ALKEM LABS LTD	EQ 4GM RESIN/PACKET	A211799	001	Oct 19, 2021	Oct	NEWA
AB			EQ 4GM RESIN/SCOOPFUL	A211799	002	Oct 19, 2021	Oct	NEWA
		LOCHOLEST LIGHT						
	@	CHARTWELL RX	EQ 4GM RESIN/PACKET	A074562	001	Aug 15, 1996	Apr	CAHN
	@		EQ 4GM RESIN/SCOOPFUL	A074562	002	Aug 15, 1996	Apr	CAHN

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE;ORAL

FENOFIBRIC ACID

AB		ADAPTIS	EQ 45MG FENOFIBRIC ACID	A211626	001	Jul 18, 2019	Aug	CAHN
AB			EQ 135MG FENOFIBRIC ACID	A211626	002	Jul 18, 2019	Aug	CAHN
>D>		@ YICHANG HUMANWELL	EQ 45MG FENOFIBRIC ACID	A212562	001	Dec 23, 2020	Nov	CMFD
>A>	AB		EQ 45MG FENOFIBRIC ACID	A212562	001	Dec 23, 2020	Nov	CMFD

CAPSULE, DELAYED RELEASE;ORAL  
FENOFIBRIC ACID

	@	EQ 45MG FENOFIBRIC ACID	A212562	001	Dec 23, 2020	Jun	DISC
>D>	@	EQ 135MG FENOFIBRIC ACID	A212562	002	Dec 23, 2020	Nov	CMFD
>A>	AB	EQ 135MG FENOFIBRIC ACID	A212562	002	Dec 23, 2020	Nov	CMFD
	@	EQ 135MG FENOFIBRIC ACID	A212562	002	Dec 23, 2020	Jun	DISC

CICLESONIDE

SPRAY, METERED;NASAL  
OMNARIS

+!	COVIS	0.05MG/SPRAY	N022004	001	Oct 20, 2006	May	CPOT
----	-------	--------------	---------	-----	--------------	-----	------

CICLOPIROX

GEL;TOPICAL  
CICLOPIROX

AB	+!	ALVOGEN	0.77%	N020519	001	Jul 21, 1997	Jun	CAHN
----	----	---------	-------	---------	-----	--------------	-----	------

SOLUTION;TOPICAL  
CICLOPIROX

	@	AKORN	8%	A078975	001	Feb 17, 2010	Apr	DISC
>D>	@	ANDA REPOSITORY	8%	A077687	001	Sep 18, 2007	Nov	CAHN
AT		RISING	8%	A078124	001	Sep 18, 2007	May	CAHN
>A>	@	TOLMAR	8%	A077687	001	Sep 18, 2007	Nov	CAHN

CILOSTAZOL

TABLET;ORAL  
CILOSTAZOL

	@	EPIC PHARMA LLC	50MG	A077022	002	Mar 11, 2005	Jan	CMS1
	@	NOSTRUM LABS INC	50MG	A077708	001	Sep 28, 2009	Mar	DISC
AB			50MG	A077708	001	Sep 28, 2009	Jan	CAHN
	@		100MG	A077708	002	Sep 28, 2009	Mar	DISC
AB			100MG	A077708	002	Sep 28, 2009	Jan	CAHN

CIMETIDINE

TABLET;ORAL  
CIMETIDINE

	@	NOVITIUM PHARMA	300MG	A074340	001	Jun 23, 1995	Feb	CAHN
	@		400MG	A074340	002	Jun 23, 1995	Feb	CAHN
	@		800MG	A074339	001	Jun 23, 1995	Feb	CAHN
		TAGAMET						
+ @		GLAXOSMITHKLINE	200MG	N017920	002		Oct	CRLD
+ @			300MG	N017920	003		Oct	CRLD
+ @			400MG	N017920	004	Dec 14, 1983	Oct	CRLD
+ @			800MG	N017920	005	Apr 30, 1986	Oct	CRLD

CINACALCET HYDROCHLORIDE

TABLET;ORAL  
CINACALCET HYDROCHLORIDE

>A>	AB	AMNEAL PHARMS	30MG	A204364	001	Dec 02, 2021	Nov	NEWA
>A>	AB		60MG	A204364	002	Dec 02, 2021	Nov	NEWA
>A>	AB		90MG	A204364	003	Dec 02, 2021	Nov	NEWA
	@	MYLAN	EQ 30MG BASE	A203422	001	Oct 16, 2018	Aug	CAHN
	@		EQ 30MG BASE	A203422	001	Oct 16, 2018	Aug	DISC
	@		EQ 60MG BASE	A203422	002	Oct 16, 2018	Aug	CAHN
	@		EQ 60MG BASE	A203422	002	Oct 16, 2018	Aug	DISC
	@		EQ 90MG BASE	A203422	003	Oct 16, 2018	Aug	CAHN
	@		EQ 90MG BASE	A203422	003	Oct 16, 2018	Aug	DISC

CIPROFLOXACIN

INJECTABLE, SUSPENSION;OTIC  
OTIPRIO

+!	ALK ABELLO	6% (60MG/ML)	N207986	001	Dec 10, 2015	Jun	CAHN
----	------------	--------------	---------	-----	--------------	-----	------

CIPROFLOXACIN HYDROCHLORIDE

TABLET;ORAL  
CIPROFLOXACIN HYDROCHLORIDE

	@	AMNEAL	EQ 100MG BASE	A075939	001	Mar 03, 2005	Oct	CAHN
	@		EQ 250MG BASE	A075939	002	Jun 09, 2004	Oct	CAHN
	@		EQ 500MG BASE	A075939	003	Jun 09, 2004	Oct	CAHN
	@		EQ 750MG BASE	A075939	004	Jun 09, 2004	Oct	CAHN

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION  
CISATRACURIUM BESYLATE

@ SAGENT PHARMS INC	EQ 2MG BASE/ML	A201851	001	Nov 06, 2020	Jul	DISC
@ ZYDUS PHARMS	EQ 2MG BASE/ML	A213527	001	Aug 31, 2020	Feb	DISC

CITRIC ACID; UREA C-13

FOR SOLUTION, TABLET, FOR SOLUTION; ORAL  
IDKIT:HP

+! EXALENZ BIOSCIENCE	4GM; 75MG	N021314	001	Dec 17, 2002	Jul	CPOT
-----------------------	-----------	---------	-----	--------------	-----	------

CLARITHROMYCIN

TABLET; ORAL  
CLARITHROMYCIN

@ WOCKHARDT	250MG	A065266	001	May 31, 2006	Jan	DISC
@	500MG	A065266	002	May 31, 2006	Jan	DISC

CLASCOTERONE

CREAM; TOPICAL  
WINLEVI

+ @ CASSIOPEA SPA	1%	N213433	001	Aug 26, 2020	Mar	DISC
+! SUN PHARM	1%	N213433	001	Aug 26, 2020	Sep	CMFD
+ @	1%	N213433	001	Aug 26, 2020	Sep	CAHN

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL  
CLEOCIN HYDROCHLORIDE

AB + PFIZER	EQ 75MG BASE	N050162	001		Feb	CAHN
AB +	EQ 150MG BASE	N050162	002		Feb	CAHN
AB +!	EQ 300MG BASE	N050162	003	Apr 14, 1988	Feb	CAHN

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL  
CLEOCIN

AA ! PFIZER	EQ 75MG BASE/5ML	A062644	001	Apr 07, 1986	Feb	CAHN
-------------	------------------	---------	-----	--------------	-----	------

CLINDAMYCIN PHOSPHATE

AEROSOL, FOAM; TOPICAL  
CLINDAMYCIN PHOSPHATE

AT GLENMARK PHARMS LTD	1%	A210778	001	Sep 20, 2021	Sep	NEWA
------------------------	----	---------	-----	--------------	-----	------

CREAM; VAGINAL  
CLEOCIN

@ PFIZER	EQ 2% BASE	N050680	001	Aug 11, 1992	Feb	CAHN
+!	EQ 2% BASE	N050680	002	Mar 02, 1998	Feb	CAHN

GEL; TOPICAL  
CLEOCIN T

AB1 +! PFIZER	EQ 1% BASE	N050615	001	Jan 07, 1987	Aug	CTEC
AB +!	EQ 1% BASE	N050615	001	Jan 07, 1987	Feb	CAHN

CLINDAGEL

AB2 +! BAUSCH	EQ 1% BASE	N050782	001	Nov 27, 2000	Aug	CFTG
---------------	------------	---------	-----	--------------	-----	------

CLINDAMYCIN PHOSPHATE  
ENCUBE

AB1 ENCUBE	EQ 1% BASE	A212438	001	Mar 11, 2021	Aug	CTEC
AB ENCUBE	EQ 1% BASE	A212438	001	Mar 11, 2021	Mar	NEWA

AB1 FOUGERA PHARMS	EQ 1% BASE	A064160	001	Jan 28, 2000	Aug	CTEC
--------------------	------------	---------	-----	--------------	-----	------

AB1 GLENMARK PHARMS LTD	EQ 1% BASE	A214251	001	Feb 10, 2021	Aug	CTEC
-------------------------	------------	---------	-----	--------------	-----	------

AB GLENMARK PHARMS LTD	EQ 1% BASE	A214251	001	Feb 10, 2021	Jan	NEWA
------------------------	------------	---------	-----	--------------	-----	------

AB1 PADAGIS ISRAEL	EQ 1% BASE	A212104	001	Dec 31, 2020	Aug	CTEC
--------------------	------------	---------	-----	--------------	-----	------

AB PERRIGO UK FINCO	EQ 1% BASE	A212104	001	Dec 31, 2020	Jan	CAHN
---------------------	------------	---------	-----	--------------	-----	------

AB1 SOLARIS PHARMA CORP	EQ 1% BASE	A211872	001	Jul 29, 2020	Aug	CTEC
-------------------------	------------	---------	-----	--------------	-----	------

AB2	EQ 1% BASE	A212842	001	Aug 13, 2021	Aug	NFTG
-----	------------	---------	-----	--------------	-----	------

AB1 TARO PHARMS	EQ 1% BASE	A214052	001	Nov 10, 2020	Aug	CTEC
-----------------	------------	---------	-----	--------------	-----	------

INJECTABLE; INJECTION  
CLEOCIN PHOSPHATE

AP PFIZER	EQ 150MG BASE/ML	A062803	001	Oct 16, 1987	Feb	CAHN
AP +!	EQ 150MG BASE/ML	N050441	001		Feb	CAHN

CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

+ @ PFIZER	EQ 6MG BASE/ML	N050639	001	Aug 30, 1989	Feb	CAHN
+ @	EQ 12MG BASE/ML	N050639	002	Aug 30, 1989	Feb	CAHN
+ @	EQ 18MG BASE/ML	N050639	003	Apr 10, 1991	Feb	CAHN

INJECTABLE; INJECTION

Code	Product Name	Strength	NDA	Approval Date	Expiration Date	Agency
CLINDAMYCIN PHOSPHATE						
AP	ALMAJECT	EQ 150MG BASE/ML	A062800 001	Jul 24, 1987		Jul CAHN
	@	EQ 150MG BASE/ML	A062801 001	Jul 24, 1987		Jul CAHN
AP		EQ 150MG BASE/ML	A062943 001	Sep 29, 1988		Jul CAHN
LOTION; TOPICAL						
CLEOCIN T						
AB	+! PFIZER	EQ 1% BASE	N050600 001	May 31, 1989		Feb CAHN
CLINDAMYCIN PHOSPHATE						
AB	TARO PHARMS	EQ 1% BASE	A214526 001	Jun 28, 2021		Jun NEWA
SOLUTION; TOPICAL						
CLEOCIN T						
	+ @ PFIZER	EQ 1% BASE	N050537 001			Feb CAHN
	+ @ PHARMACIA AND UPJOHN	EQ 1% BASE	N050537 001			Jan DISC
SUPPOSITORY; VAGINAL						
CLEOCIN						
	+! PFIZER	100MG	N050767 001	Aug 13, 1999		Feb CAHN
SWAB; TOPICAL						
CLEOCIN						
	+ @ PFIZER	EQ 1% BASE	N050537 002	Feb 22, 1994		Mar DISC
AT	+!	EQ 1% BASE	N050537 002	Feb 22, 1994		Feb CAHN

CLINDAMYCIN PHOSPHATE; TRETINOIN

Code	Product Name	Strength	NDA	Approval Date	Expiration Date	Agency
GEL; TOPICAL						
ZIANA						
AB	+! BAUSCH	1.2%; 0.025%	N050802 001	Nov 07, 2006		May CAHN

CLOBAZAM

Code	Product Name	Strength	NDA	Approval Date	Expiration Date	Agency
SUSPENSION; ORAL						
CLOBAZAM						
AB	ALKEM LABS LTD	2.5MG/ML	A213039 001	May 06, 2021		Apr NEWA
AB	TARO	2.5MG/ML	A210978 001	Apr 15, 2019		Jul CMFD
TABLET; ORAL						
CLOBAZAM						
	@ CELLTRION	10MG	A211959 001	Dec 09, 2020		Jun DISC
	@	20MG	A211959 002	Dec 09, 2020		Jun DISC
	@ LANNETT CO INC	10MG	A212092 001	Oct 30, 2019		Mar DISC
	@	20MG	A212092 002	Oct 30, 2019		Mar DISC
>D> AB	MSN	10MG	A213404 001	May 11, 2021		Nov DISC
>A>	@	10MG	A213404 001	May 11, 2021		Nov DISC
AB		10MG	A213404 001	May 11, 2021		Apr NEWA
>D> AB		20MG	A213404 002	May 11, 2021		Nov DISC
>A>	@	20MG	A213404 002	May 11, 2021		Nov DISC
AB		20MG	A213404 002	May 11, 2021		Apr NEWA

CLOBETASOL PROPIONATE

Code	Product Name	Strength	NDA	Approval Date	Expiration Date	Agency
AEROSOL, FOAM; TOPICAL						
CLOBETASOL PROPIONATE						
>D> AB1	INGENUS PHARMS LLC	0.05%	A206805 001	Jul 31, 2017		Nov DISC
>A>	@	0.05%	A206805 001	Jul 31, 2017		Nov DISC
CREAM; TOPICAL						
CLOBETASOL PROPIONATE						
AB1	GLASSHOUSE PHARMS	0.05%	A211207 001	Mar 26, 2021		Mar NEWA
	@ PAI HOLDINGS PHARM	0.05%	A211207 001	Mar 26, 2021		Oct DISC
AB1		0.05%	A211207 001	Mar 26, 2021		Sep CAHN
IMPOYZ						
	+! PRIMUS PHARMS	0.025%	N209483 001	Nov 28, 2017		Mar CAHN
OINTMENT; TOPICAL						
CLOBETASOL PROPIONATE						
	@ TORRENT	0.05%	A212926 001	Oct 25, 2019		Jan DISC
SHAMPOO; TOPICAL						
CLOBETASOL PROPIONATE						
AB	AMNEAL	0.05%	A214895 001	Jun 14, 2021		Jun NEWA
AB	TARO PHARMS	0.05%	A214867 001	Mar 25, 2021		Mar NEWA
SOLUTION; TOPICAL						
CLOBETASOL PROPIONATE						
AT	PRINSTON INC	0.05%	A213139 001	Feb 08, 2021		Jan NEWA
SPRAY; TOPICAL						
CLOBETASOL PROPIONATE						
	@ AKORN	0.05%	A207218 001	Apr 28, 2017		Apr DISC

CLOFARABINE

SOLUTION; INTRAVENOUS

CLOFARABINE

AP	MEITHEAL	20MG/20ML (1MG/ML)	A213461	001	Oct 23, 2020	Jan	CAHN
	@ NOVAST LABS	20MG/20ML (1MG/ML)	A210270	001	Sep 14, 2018	Mar	DISC

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

CLOMIPRAMINE HYDROCHLORIDE

AB	ALEMBIC PHARMS LTD	25MG	A211822	001	Aug 04, 2021	Jul	NEWA
AB		50MG	A211822	002	Aug 04, 2021	Jul	NEWA
AB		75MG	A211822	003	Aug 04, 2021	Jul	NEWA
AB	VGYAAN	25MG	A213221	001	Jun 22, 2020	May	CMFD
AB		50MG	A213221	002	Jun 22, 2020	May	CMFD
AB		75MG	A213221	003	Jun 22, 2020	May	CMFD

CLONIDINE

SYSTEM; TRANSDERMAL

CATAPRES-TTS-1

AB	+ LAVIPHARM	0.1MG/24HR	N018891	001	Oct 10, 1984	Jan	CAHN
AB	+ TECHNOMED	0.1MG/24HR	N018891	001	Oct 10, 1984	Jan	CAHN

CATAPRES-TTS-2

AB	+ LAVIPHARM	0.2MG/24HR	N018891	002	Oct 10, 1984	Jan	CAHN
AB	+ TECHNOMED	0.2MG/24HR	N018891	002	Oct 10, 1984	Jan	CAHN

CATAPRES-TTS-3

AB	+! LAVIPHARM	0.3MG/24HR	N018891	003	Oct 10, 1984	Jan	CAHN
AB	+! TECHNOMED	0.3MG/24HR	N018891	003	Oct 10, 1984	Jan	CAHN

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CLONIDINE HYDROCHLORIDE

AP	! HIKMA FARMACEUTICA	5MG/10ML (0.5MG/ML)	A200300	002	Jan 26, 2011	Mar	CHRS
	+ @ MYLAN INSTITUTIONAL	5MG/10ML (0.5MG/ML)	N020615	002	Apr 27, 1999	Mar	DISC
	TABLET; ORAL						
	CATAPRES						
	+ @ BOEHRINGER INGELHEIM	0.1MG	N017407	001		Oct	DISC
	+ @	0.2MG	N017407	002		Oct	DISC
	+ @	0.3MG	N017407	003		Oct	DISC
	CLONIDINE HYDROCHLORIDE						
AB	! UNICHEM	0.3MG	A078895	003	Aug 26, 2009	Oct	CHRS

CLOPIDOGREL BISULFATE

TABLET; ORAL

CLOPIDOGREL BISULFATE

AB	POLYGEN PHARMS	EQ 75MG BASE	A213351	001	Jul 17, 2020	Feb	CMFD
AB		EQ 300MG BASE	A213351	002	Jul 17, 2020	Feb	CMFD
AB	RISING PHARMA	EQ 75MG BASE	A204359	001	Feb 02, 2017	Sep	CAHN

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL

TRANXENE

	+ @ RECORDATI RARE	3.75MG	N017105	001		May	CRLD
	+ @	7.5MG	N017105	002		May	CRLD
	+ @	15MG	N017105	003		May	CRLD

TABLET; ORAL

CLORAZEPATE DIPOTASSIUM

AB	AUROLIFE PHARMA LLC	3.75MG	A071858	002	Jul 17, 1987	Jan	CAHN	
AB		7.5MG	A071858	003	Jul 17, 1987	Jan	CAHN	
AB	!	15MG	A071858	001	Jul 17, 1987	Jan	CAHN	
>D>	GEN-XENE							
>D>	AB	ALRA	3.75MG	A071787	001	Apr 26, 1988	Nov	DISC
>A>	@	3.75MG	A071787	001	Apr 26, 1988	Nov	DISC	
>D>	AB		7.5MG	A071788	001	Apr 26, 1988	Nov	DISC
>A>	@	7.5MG	A071788	001	Apr 26, 1988	Nov	DISC	
>D>	AB		15MG	A071789	001	Apr 26, 1988	Nov	DISC
>A>	@	15MG	A071789	001	Apr 26, 1988	Nov	DISC	
	TRANXENE							
	+ @ RECORDATI RARE	3.75MG	N017105	006		May	CRLD	



TABLET;ORAL  
TRANXENE SD

+ @	RECORDATI RARE	11.25MG	N017105	005			May	CRLD
+ @		22.5MG	N017105	004			May	CRLD

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETH HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE

>D>	AA	PHARM ASSOC	10MG/5ML;5MG/5ML;6.25MG/5ML	A040660	001	Dec 07, 2006	Nov	CHRS	
>A>	AA	!	10MG/5ML;5MG/5ML;6.25MG/5ML	A040660	001	Dec 07, 2006	Nov	CHRS	
>D>		PROMETH VC W/ CODEINE							
>D>	AA	!	NOSTRUM LABS INC	10MG/5ML;5MG/5ML;6.25MG/5ML	A088764	001	Oct 31, 1984	Nov	DISC
>A>		@		10MG/5ML;5MG/5ML;6.25MG/5ML	A088764	001	Oct 31, 1984	Nov	DISC
		PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE							
AA		AKORN	10MG/5ML;5MG/5ML;6.25MG/5ML	A040674	001	Dec 23, 2014	Feb	CAHN	

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

AA	+!	ACTAVIS MID ATLANTIC	10MG/5ML;6.25MG/5ML	A088763	001	Oct 31, 1984	Aug	CRLD
----	----	----------------------	---------------------	---------	-----	--------------	-----	------

COLCHICINE

TABLET;ORAL

COLCHICINE

AB		HETERO LABS LTD V	0.6MG	A208993	001	Aug 13, 2021	Aug	NEWA
AB		PAR PHARM INC	0.6MG	A203976	001	Aug 12, 2021	Aug	NEWA

COLCHICINE; PROBENECID

TABLET;ORAL

COL-PROBENECID

AB	+!	WATSON LABS	0.5MG;500MG	A084279	001		Aug	CRLD
----	----	-------------	-------------	---------	-----	--	-----	------

COLESEVELAM HYDROCHLORIDE

FOR SUSPENSION;ORAL

COLESEVELAM HYDROCHLORIDE

		GLENMARK PHARMS LTD	1.875GM/PACKET	A202190	001	Jul 16, 2018	Feb	CTEC
		@ WATSON LABS INC	1.875GM/PACKET	A202178	001	Sep 01, 2020	Feb	DISC
		@	3.75GM/PACKET	A202178	002	Sep 01, 2020	Feb	DISC

TABLET;ORAL

COLESEVELAM HYDROCHLORIDE

AB		BEIJING TIDE PHARM	625MG	A206036	001	Oct 14, 2021	Oct	NEWA
		@ WATSON LABS INC	625MG	A200830	001	Sep 02, 2020	Feb	DISC

COLESTIPOL HYDROCHLORIDE

GRANULE;ORAL

COLESTID

AB	+	PFIZER	5GM/SCOOPFUL	N017563	003	Sep 22, 1995	Feb	CAHN
AB	+!		5GM/PACKET	N017563	004	Sep 22, 1995	Feb	CAHN
		FLAVORED COLESTID						
	+	PFIZER	5GM/PACKET	N017563	001		Feb	CAHN
	+		5GM/SCOOPFUL	N017563	002		Feb	CAHN

TABLET;ORAL

COLESTID

AB	+!	PFIZER	1GM	N020222	001	Jul 19, 1994	Feb	CAHN
----	----	--------	-----	---------	-----	--------------	-----	------

COLISTIMETHATE SODIUM

INJECTABLE;INJECTION

COLISTIMETHATE SODIUM

AP		EMCURE PHARMS LTD	EQ 150MG BASE/VIAL	A202359	001	Sep 28, 2012	Sep	CMFD
----	--	-------------------	--------------------	---------	-----	--------------	-----	------

CORTICOTROPIN

INJECTABLE;INJECTION

ACTHAR GEL

	@	MALLINCKRODT ARD	40 UNITS/ML	N008372	006		Sep	CTNA
	+!		80 UNITS/ML	N008372	008		Sep	CTNA

PURIFIED CORTROPHIN GEL

>D>		@ ANI PHARMS	80 UNITS/ML	N008975	002		Nov	CMFD
>A>	+!		80 UNITS/ML	N008975	002		Nov	CMFD

CROTAMITON

	CREAM; TOPICAL						
	EURAX						
	+ @ JOURNEY	10%		N006927	001		Jan CAHN
	LOTION; TOPICAL						
	EURAX						
AT	+! JOURNEY	10%		N009112	003		Jan CAHN

CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE

SOLUTION; INTRAVENOUS  
MULTRYS

>D>	+! AM REGENT	(1ML) EQ 0.06MG COPPER/ML; EQ 3MCG BASE/ML; EQ 6MCG BASE/ML; EQ 1MG BASE/ML		N209376	003	Jun 30, 2021	Nov CPOT
>A>	+!	EQ 60MCG COPPER/ML; EQ 3MCG BASE/ML; EQ 6MCG SELENIUM/ML; EQ 1000MCG BASE/ML (1ML)		N209376	003	Jun 30, 2021	Nov CPOT
	+!	(1ML) EQ 0.06MG COPPER/ML; EQ 3MCG BASE/ML; EQ 6MCG BASE/ML; EQ 1MG BASE/ML		N209376	003	Jun 30, 2021	Aug CTNA
	+!	(1ML) EQ 0.06MG COPPER/ML; EQ 3MCG BASE/ML; EQ 6MCG BASE/ML; EQ 1MG BASE/ML		N209376	003	Jun 30, 2021	Jul NEWA

TRALEMENT

>D>	+! AM REGENT	(1ML) EQ 0.3MG COPPER/ML; EQ 55MCG BASE/ML; EQ 60MCG BASE/ML; EQ 3MG BASE/ML		N209376	001	Jul 02, 2020	Nov CPOT
>A>	+!	EQ 0.3MG COPPER/ML; EQ 55MCG BASE/ML; EQ 60MCG SELENIUM/ML; EQ 3MG BASE/ML (1ML)		N209376	001	Jul 02, 2020	Nov CPOT
	+!	(1ML) EQ 0.3MG COPPER/ML; EQ 55MCG BASE/ML; EQ 60MCG BASE/ML; EQ 3MG BASE/ML		N209376	001	Jul 02, 2020	Oct CTNA
	+!	(1ML) EQ 0.3MG COPPER/ML; EQ 55MCG BASE/ML; EQ 60MCG BASE/ML; EQ 3MG BASE/ML		N209376	001	Jul 02, 2020	Aug CTNA
	+!	(1ML) EQ 0.3MG COPPER/ML; EQ 55MCG BASE/ML; EQ 60MCG BASE/ML; EQ 3MG BASE/ML		N209376	001	Jul 02, 2020	Jan CPOT
>D>	+!	(5ML) EQ 0.3MG COPPER/ML; EQ 55MCG BASE/ML; EQ 60MCG BASE/ML; EQ 3MG BASE/ML		N209376	002	Dec 02, 2020	Nov CPOT
>A>	+!	EQ 0.3MG COPPER/ML; EQ 55MCG BASE/ML; EQ 60MCG SELENIUM/ML; EQ 3MG BASE/ML (5ML)		N209376	002	Dec 02, 2020	Nov CPOT
	+!	(5ML) EQ 0.3MG COPPER/ML; EQ 55MCG BASE/ML; EQ 60MCG BASE/ML; EQ 3MG BASE/ML		N209376	002	Dec 02, 2020	Oct CTNA
	+!	(5ML) EQ 0.3MG COPPER/ML; EQ 55MCG BASE/ML; EQ 60MCG BASE/ML; EQ 3MG BASE/ML		N209376	002	Dec 02, 2020	Aug CTNA
	+!	(5ML) EQ 0.3MG COPPER/ML; EQ 55MCG BASE/ML; EQ 60MCG BASE/ML; EQ 3MG BASE/ML		N209376	002	Dec 02, 2020	Jan NEWA

CYANOCOBALAMIN

INJECTABLE; INJECTION  
CYANOCOBALAMIN

	@ XIROMED	1MG/ML		A215046	001	Aug 20, 2021	Sep DISC
AP		1MG/ML		A215046	001	Aug 20, 2021	Aug NEWA
	VIBISONE						
AP	+! FRESENIUS KABI USA	1MG/ML		A080557	003		Aug CRLD

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL  
CYCLOBENZAPRINE HYDROCHLORIDE

>A>	@ CHARTWELL RX	5MG		A072854	002	Feb 03, 2006	Nov CAHN
>A>	@	10MG		A072854	001	Nov 19, 1991	Nov CAHN
	@ MYLAN PHARMS INC	5MG		A073144	002	Feb 03, 2006	Aug DISC
	@	7.5MG		A073144	003	Mar 25, 2013	Aug DISC
	@	10MG		A073144	001	May 30, 1991	Aug DISC
>D>	@ UPSHER SMITH LABS	5MG		A072854	002	Feb 03, 2006	Nov CAHN
>D>	@	10MG		A072854	001	Nov 19, 1991	Nov CAHN

CYCLOPENTOLATE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC  
AKPENTOLATE

AT		AKORN	2%	A040165	001	Jan 13, 1997	Aug	CMFD
		CYCLOGYL						
AT	+	ALCON LABS INC	0.5%	A084109	001		Aug	CRLD
AT	+		1%	A084110	001		Aug	CRLD
AT	+		2%	A084108	001		Aug	CRLD
AT	!		2%	A084108	001		Aug	CTEC

CYCLOPHOSPHAMIDESOLUTION;INTRAVENOUS  
CYCLOPHOSPHAMIDE

	+	AUROMEDICS PHARMA	500MG/2.5ML (200MG/ML)	N210735	001	Aug 25, 2021	Aug	NEWA
	+		1GM/5ML (200MG/ML)	N210735	002	Aug 25, 2021	Aug	NEWA
	+	EUGIA PHARMA SPECLTS	500MG/2.5ML (200MG/ML)	N210735	001	Aug 25, 2021	Oct	CAHN
	+		1GM/5ML (200MG/ML)	N210735	002	Aug 25, 2021	Oct	CAHN
>A>	+	INGENUS PHARMS LLC	2GM/10ML (200MG/ML)	N212501	003	Nov 19, 2021	Nov	NEWA

CYCLOSPORINEEMULSION;OPHTHALMIC  
VERKAZIA

	+	SANTEN	0.1%	N214965	001	Jun 23, 2021	Jun	NEWA
		INJECTABLE;INJECTION CYCLOSPORINE						
AP		HIKMA	50MG/ML	A065004	001	Oct 29, 1999	Oct	CAHN
		SOLUTION;OPHTHALMIC CEQUA						
	+	SUN PHARM	0.09%	N210913	001	Aug 14, 2018	Oct	CAHN

CYPROHEPTADINE HYDROCHLORIDESYRUP;ORAL  
CYPROHEPTADINE HYDROCHLORIDE

	+	@ ACTAVIS MID ATLANTIC	2MG/5ML	A086833	001		Aug	CRLD
		TABLET;ORAL CYPROHEPTADINE HYDROCHLORIDE						
AA	+	HERITAGE PHARMA	4MG	A087056	001		Aug	CRLD
AA		QUAGEN	4MG	A212491	001	Feb 24, 2021	Feb	NEWA

CYSTEAMINE BITARTRATECAPSULE, DELAYED RELEASE;ORAL  
PROCYSBI

	+	HORIZON	EQ 25MG BASE	N203389	001	Apr 30, 2013	May	CAHN
	+		EQ 75MG BASE	N203389	002	Apr 30, 2013	May	CAHN

CYTARABINEINJECTABLE;INJECTION  
CYTARABINE

	@	HONG KONG	20MG/ML	A206189	001	Jun 26, 2020	Sep	DISC
	@	MEITHEAL	20MG/ML	A206190	001	Nov 09, 2017	Aug	DISC
	@	MYLAN LABS LTD	20MG/ML	A200914	001	Dec 13, 2011	May	DISC

DABIGATRAN ETEXILATE MESYLATEPELLET;ORAL  
PRADAXA

	+	BOEHRINGER INGELHEIM	EQ 20MG BASE/PACKET	N214358	001	Jun 21, 2021	Jun	NEWA
	+		EQ 30MG BASE/PACKET	N214358	002	Jun 21, 2021	Jun	NEWA
	+		EQ 40MG BASE/PACKET	N214358	003	Jun 21, 2021	Jun	NEWA
	+		EQ 50MG BASE/PACKET	N214358	004	Jun 21, 2021	Jun	NEWA
	+		EQ 110MG BASE/PACKET	N214358	005	Jun 21, 2021	Jun	NEWA
	+		EQ 150MG BASE/PACKET	N214358	006	Jun 21, 2021	Jun	NEWA

PELLETS;ORAL  
PRADAXA

	+	BOEHRINGER INGELHEIM	EQ 20MG BASE/PACKET	N214358	001	Jun 21, 2021	Jul	CDFR
	+		EQ 30MG BASE/PACKET	N214358	002	Jun 21, 2021	Jul	CDFR
	+		EQ 40MG BASE/PACKET	N214358	003	Jun 21, 2021	Jul	CDFR
	+		EQ 50MG BASE/PACKET	N214358	004	Jun 21, 2021	Jul	CDFR
	+		EQ 110MG BASE/PACKET	N214358	005	Jun 21, 2021	Jul	CDFR
	+		EQ 150MG BASE/PACKET	N214358	006	Jun 21, 2021	Jul	CDFR

DACTINOMYCIN

INJECTABLE; INJECTION  
DACTINOMYCIN

AP	AUROMEDICS PHARMA	0.5MG/VIAL	A203385	001	Nov 09, 2017	Jan	CAHN
AP	EUGIA PHARMA	0.5MG/VIAL	A203385	001	Nov 09, 2017	Aug	CAHN
	@ HIKMA	0.5MG/VIAL	A090304	001	Mar 16, 2010	Jul	CAHN
AP	MEITHEAL	0.5MG/VIAL	A213463	001	Nov 13, 2020	Feb	CAHN

DANTROLENE SODIUM

INJECTABLE; INJECTION  
DANTROLENE SODIUM

>A>	@ AUROMEDICS PHARMA	20MG/VIAL	A205239	001	Feb 18, 2016	Nov	CAHN
>D>	@ MYLAN INSTITUTIONAL	20MG/VIAL	A205239	001	Feb 18, 2016	Nov	CAHN

DAPSONE

TABLET; ORAL  
DAPSONE

AB	ALVOGEN	25MG	A205429	001	Jan 07, 2016	Jun	CAHN
AB		100MG	A205429	002	Jan 07, 2016	Jun	CAHN
AB	+ JACOBUS	25MG	A086841	001		Aug	CRLD
AB	+!	100MG	A086842	001		Aug	CRLD

DAPTOMYCIN

>A> POWDER; INTRAVENOUS  
>A> DAPTOMYCIN

>A>	AP	ACCORD HLTHCARE	350MG/VIAL	A212667	001	Jul 12, 2019	Nov	CDFR
>A>	AP	BE PHARMS	350MG/VIAL	A213425	001	Aug 20, 2020	Nov	CDFR
>A>	AP	DR REDDYS	350MG/VIAL	A211403	001	Aug 31, 2020	Nov	CDFR
>A>	AP	HANGZHOU ZHONGMEI	500MG/VIAL	A215215	001	Nov 26, 2021	Nov	NEWA
		@ HISUN PHARM HANGZHOU	500MG/VIAL	A212250	001	Apr 21, 2021	Oct	DISC
	AP		500MG/VIAL	A212250	001	Apr 21, 2021	Apr	NEWA
	AP	HONG KONG	500MG/VIAL	A213623	001	Jun 29, 2021	Jun	NEWA
	+!	HOSPIRA INC	350MG/VIAL	N210282	001	Jun 21, 2021	Jun	NEWA
	+!		500MG/VIAL	N210282	002	Jun 21, 2021	Jun	NEWA
>A>	AP	MEITHEAL	350MG/VIAL	A213786	001	Jun 29, 2021	Nov	CDFR
	AP		500MG/VIAL	A213623	001	Jun 29, 2021	Aug	CAHN
>D>	AP	QILU	500MG/VIAL	A215316	001	Aug 24, 2021	Nov	CAHN
	AP		500MG/VIAL	A215316	001	Aug 24, 2021	Aug	NEWA
>A>	AP	QILU PHARM HAINAN	500MG/VIAL	A215316	001	Aug 24, 2021	Nov	CAHN
>A>	AP	+! SAGENT PHARMS INC	350MG/VIAL	N208385	001	Sep 12, 2017	Nov	CDFR
>A>	AP	+! XELLIA PHARMS APS	350MG/VIAL	N209949	001	Oct 20, 2017	Nov	CDFR
>D>		POWDER; IV (INFUSION)						
>D>		DAPTOMYCIN						
>D>	AP	ACCORD HLTHCARE	350MG/VIAL	A212667	001	Jul 12, 2019	Nov	CDFR
>D>	AP	BE PHARMS	350MG/VIAL	A213425	001	Aug 20, 2020	Nov	CDFR
>D>	AP	DR REDDYS	350MG/VIAL	A211403	001	Aug 31, 2020	Nov	CDFR
	AP		350MG/VIAL	A211403	001	Aug 31, 2020	Oct	CMFD
		@	350MG/VIAL	A211403	001	Aug 31, 2020	May	DISC
	AP	HONG KONG	350MG/VIAL	A213786	001	Jun 29, 2021	Jun	NEWA
>D>	AP	MEITHEAL	350MG/VIAL	A213786	001	Jun 29, 2021	Nov	CDFR
	AP		350MG/VIAL	A213786	001	Jun 29, 2021	Aug	CAHN
>D>	AP	+! SAGENT PHARMS INC	350MG/VIAL	N208385	001	Sep 12, 2017	Nov	CDFR
>D>	AP	+! XELLIA PHARMS APS	350MG/VIAL	N209949	001	Oct 20, 2017	Nov	CDFR

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL  
DARIFENACIN HYDROBROMIDE

	@ JUBILANT GENERICS	EQ 7.5MG BASE	A205550	001	Oct 12, 2016	Jun	DISC
	@	EQ 15MG BASE	A205550	002	Oct 12, 2016	Jun	DISC
BX	XIROMED	EQ 7.5MG BASE	A209571	002	Oct 22, 2019	Sep	CTEC
BX		EQ 15MG BASE	A209571	001	Oct 22, 2019	Sep	CTEC

DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR

TABLET; ORAL  
VIEKIRA PAK (COPACKAGED)

+ @	ABBVIE INC	EQ 250MG BASE; 12.5MG, 75MG, 50MG	N206619	001	Dec 19, 2014	Sep	DISC
+!		EQ 250MG BASE; 12.5MG, 75MG, 50MG	N206619	001	Dec 19, 2014	Aug	CPOT

DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR

TABLET; ORAL

VIEKIRA PAK (COPACKAGED)

+!	ABBVIE INC	250.0MG; 12.5MG; 75.0MG; EQ 250MG BASE, N/A, N/A, N/A; N/A, 12.5MG, 75MG, 50MG	N206619	001	Dec 19, 2014	Aug	CDFR
----	------------	--	---------	-----	--------------	-----	------

DASATINIB

TABLET; ORAL

DASATINIB

>A>	AB	APOTEX	80MG	A203180	001	Nov 23, 2021	Nov	NFTG
>A>	AB		140MG	A203180	002	Nov 23, 2021	Nov	NFTG
		SPRYCEL						
>D>	+	BRISTOL MYERS SQUIBB	80MG	N021986	005	Oct 28, 2010	Nov	CFTG
>A>	AB	+	80MG	N021986	005	Oct 28, 2010	Nov	CFTG
>D>	+		140MG	N021986	006	Oct 28, 2010	Nov	CFTG
>A>	AB	+	140MG	N021986	006	Oct 28, 2010	Nov	CFTG

DASIGLUCAGON HYDROCHLORIDE

SOLUTION; SUBCUTANEOUS

ZEGALOGUE

+!	ZEALAND PHARMA	EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	N214231	001	Mar 22, 2021	May	CAHN
+!		EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	N214231	001	Mar 22, 2021	Mar	NEWA
		ZEGALOGUE (AUTOINJECTOR)					
+!	ZEALAND PHARMA	EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	N214231	002	Mar 22, 2021	May	CAHN
+!		EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	N214231	002	Mar 22, 2021	Mar	NEWA

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

CERUBIDINE

AP	!	HIKMA	EQ 20MG BASE/VIAL	A064103	001	Feb 03, 1995	Oct	CAHN
		DAUNORUBICIN HYDROCHLORIDE						
AP	+!	HIKMA	EQ 5MG BASE/ML	N050731	001	Jan 30, 1998	Jul	CAHN

DECITABINE

INJECTABLE; INTRAVENOUS

DECITABINE

	@	APOTEX	50MG/VIAL	A205539	001	Nov 23, 2020	May	DISC
	@	CIPLA	50MG/VIAL	A208601	001	Nov 16, 2017	May	DISC
AP		EUGIA PHARMA	50MG/VIAL	A214569	001	Sep 20, 2021	Sep	NEWA
AP		GLAND	50MG/VIAL	A205539	001	Nov 23, 2020	Jul	CMFD
	@		50MG/VIAL	A205539	001	Nov 23, 2020	Jul	CAHN
AP		HONG KONG	50MG/VIAL	A212959	001	Jul 02, 2021	Jun	NEWA
AP		MEITHEAL	50MG/VIAL	A212959	001	Jul 02, 2021	Sep	CAHN
>D>	AP	QILU	50MG/VIAL	A212826	001	Apr 12, 2021	Nov	CAHN
	AP		50MG/VIAL	A212826	001	Apr 12, 2021	Apr	NEWA
>A>	AP	QILU PHARM HAINAN	50MG/VIAL	A212826	001	Apr 12, 2021	Nov	CAHN
>A>	AP	ZYDUS PHARMS	50MG/VIAL	A214486	001	Nov 19, 2021	Nov	NEWA
		POWDER; INTRAVENOUS						
		DECITABINE						
>A>	+!	SUN PHARM	50MG/VIAL	N205582	001	Jan 28, 2014	Nov	CAHN
>D>	+!	SUN PHARMA GLOBAL	50MG/VIAL	N205582	001	Jan 28, 2014	Nov	CAHN

DEFERASIROX

GRANULE; ORAL

DEFERASIROX

AB		AMNEAL	90MG	A214194	003	Aug 02, 2021	Jul	NEWA
AB			180MG	A214194	001	Feb 09, 2021	Jan	NEWA
AB			360MG	A214194	002	Feb 09, 2021	Jan	NEWA
AB		AUCTA	90MG	A214559	001	Mar 09, 2021	Feb	NEWA
AB			180MG	A214559	002	Mar 09, 2021	Feb	NEWA
AB			360MG	A214559	003	Mar 09, 2021	Feb	NEWA
AB		MSN	180MG	A214650	001	Mar 17, 2021	Mar	NEWA
AB			360MG	A214650	002	Mar 17, 2021	Mar	NEWA
>A>	AB	TEVA PHARMS USA	90MG	A214180	001	Nov 19, 2021	Nov	NEWA
>A>	AB		180MG	A214180	002	Nov 19, 2021	Nov	NEWA
>A>	AB		360MG	A214180	003	Nov 19, 2021	Nov	NEWA

<u>TABLET;ORAL</u>							
DEFERASIROX							
AB	ANNORA PHARMA	90MG	A214341	001	May 14, 2021	May	NEWA
AB		180MG	A214341	002	May 14, 2021	May	NEWA
AB		360MG	A214341	003	May 14, 2021	May	NEWA
AB	CELLTRION	90MG	A212669	001	May 27, 2021	May	NEWA
AB		180MG	A212669	002	May 27, 2021	May	NEWA
AB		360MG	A212669	003	May 27, 2021	May	NEWA
<u>DEFERIPRONE</u>							
SOLUTION;ORAL							
FERRIPROX							
	+ @ CHIESI	80MG/ML	N208030	002	Apr 20, 2018	Aug	DISC
TABLET;ORAL							
DEFERIPRONE							
AB	HIKMA	500MG	A213239	001	Mar 29, 2021	Mar	NEWA
FERRIPROX							
AB	+! CHIESI	500MG	N021825	001	Oct 14, 2011	Mar	CTEC
<u>DEOXYCHOLIC ACID</u>							
SOLUTION;SUBCUTANEOUS							
DEOXYCHOLIC ACID							
AP	SLAYBACK PHARMA LLC	20MG/2ML (10MG/ML)	A212296	001	Apr 02, 2021	Mar	NFTG
KYBELLA							
AP	+! KYTHERA BIOPHARMS	20MG/2ML (10MG/ML)	N206333	001	Apr 29, 2015	Mar	CFTG
<u>DESIPRAMINE HYDROCHLORIDE</u>							
TABLET;ORAL							
DESIPRAMINE HYDROCHLORIDE							
AB	ALEMBIC PHARMS LTD	10MG	A209785	001	Jul 07, 2021	Jun	NEWA
AB		25MG	A209785	002	Jul 07, 2021	Jun	NEWA
AB		50MG	A209785	003	Jul 07, 2021	Jun	NEWA
AB		75MG	A209785	004	Jul 07, 2021	Jun	NEWA
AB		100MG	A209785	005	Jul 07, 2021	Jun	NEWA
AB		150MG	A209785	006	Jul 07, 2021	Jun	NEWA
NORPRAMIN							
AB	+ VALIDUS PHARMS	10MG	N014399	007	Feb 11, 1982	Feb	CAHN
AB	+	25MG	N014399	001		Feb	CAHN
AB	+	50MG	N014399	003		Feb	CAHN
AB	+	75MG	N014399	004		Feb	CAHN
AB	+!	100MG	N014399	005		Feb	CAHN
AB	+	150MG	N014399	006		Feb	CAHN
<u>DESLORATADINE</u>							
TABLET;ORAL							
CLARINEX							
AB	+! ORGANON	5MG	N021165	001	Dec 21, 2001	Aug	CAHN
DESLORATADINE							
	@ SUN PHARM INDS	5MG	A078359	001	Nov 16, 2010	Aug	DISC
<u>DESLORATADINE; PSEUDOEPHEDRINE SULFATE</u>							
TABLET, EXTENDED RELEASE;ORAL							
CLARINEX-D 12 HOUR							
	+! ORGANON	2.5MG;120MG	N021313	001	Feb 01, 2006	Jun	CAHN
<u>DESMOPRESSIN ACETATE</u>							
SPRAY, METERED;NASAL							
NOCTIVA							
	+ @ ROIVANT	0.00083MG/SPRAY	N201656	001	Mar 03, 2017	Feb	CAHN
	+ @	0.00166MG/SPRAY	N201656	002	Mar 03, 2017	Feb	CAHN
	+ @ SERENITY PHARMS LLC	0.00083MG/SPRAY	N201656	001	Mar 03, 2017	Sep	CAHN
	+ @	0.00166MG/SPRAY	N201656	002	Mar 03, 2017	Sep	CAHN
<u>DESONIDE</u>							
GEL;TOPICAL							
DESONATE							
	+ @ LEO PHARMA AS	0.05%	N021844	001	Oct 20, 2006	Mar	DISC
DESONIDE							
	! CINTEX SVCS	0.05%	A202470	001	May 11, 2020	Mar	CHRS
		0.05%	A202470	001	May 11, 2020	Mar	CTEC

DESOXIMETASONE

		CREAM; TOPICAL							
		DESOXIMETASONE							
		@ AKORN	0.05%	A203787	001	Jan 06, 2017	Apr	DISC	
		@	0.25%	A203234	001	Jun 12, 2015	Apr	DISC	
		OINTMENT; TOPICAL							
		DESOXIMETASONE							
AB	!	GLENMARK GENERICS	0.25%	A202838	001	Sep 20, 2013	Apr	CHRS	
		TOPICORT							
		@ TARO PHARM INDS LTD	0.25%	A074286	001	Jun 07, 1996	Apr	DISC	

DEXAMETHASONE

		ELIXIR; ORAL							
		DEXAMETHASONE							
>D>	AA	+ WOCKHARDT BIO AG	0.5MG/5ML	A088254	001	Jul 27, 1983	Nov	DISC	
>A>		+ @	0.5MG/5ML	A088254	001	Jul 27, 1983	Nov	DISC	
	AA	+	0.5MG/5ML	A088254	001	Jul 27, 1983	Aug	CRLD	
		TABLET; ORAL							
		DEXAMETHASONE							
	BP	ALVOGEN	0.5MG	A088481	002	Apr 28, 1983	Jun	CAHN	
	BP		0.75MG	A088481	003	Apr 28, 1983	Jun	CAHN	
	BP		4MG	A088481	004	Apr 28, 1983	Jun	CAHN	
	BP		6MG	A088481	001	Nov 28, 1983	Jun	CAHN	
	AB	AMNEAL	4MG	A215106	001	Oct 14, 2021	Oct	CTEC	
			4MG	A215106	001	Oct 14, 2021	Oct	NEWA	
	AB		6MG	A215106	002	Oct 14, 2021	Oct	NEWA	
>D>		@ ANI PHARMS	0.75MG	A080399	001		Nov	CAHN	
>A>		@ BAUSCH	1.5MG	A040700	001	Aug 15, 2008	Nov	DISC	
>D>	AB	ECR	1.5MG	A040700	001	Aug 15, 2008	Nov	DISC	
	BP	! HIKMA	1MG	A088306	001	Sep 15, 1983	Apr	CHRS	
>A>	BP	+	2MG	A087916	001	Aug 26, 1982	Nov	CRLD	
	AB		4MG	A084612	001		Oct	CTEC	
	AB	!	6MG	A088316	001	Sep 15, 1983	Oct	CTEC	
>D>	BP	! HIKMA PHARMS	2MG	A087916	001	Aug 26, 1982	Nov	CRLD	
	BP	!	2MG	A087916	001	Aug 26, 1982	Apr	CHRS	
>A>		@ PRASCO	0.75MG	A080399	001		Nov	CAHN	

DEXAMETHASONE SODIUM PHOSPHATE

		INJECTABLE; INJECTION							
		DEXAMETHASONE SODIUM PHOSPHATE							
AP		GLAND PHARMA LTD	EQ 4MG PHOSPHATE/ML	A215654	001	Aug 04, 2021	Jul	NEWA	
		+ @ LUITPOLD	EQ 4MG PHOSPHATE/ML	A087440	001	Jul 21, 1982	Aug	CRLD	

DEXAMETHASONE; TOBRAMYCIN

		SUSPENSION/DROPS; OPHTHALMIC							
		TOBRAMYCIN AND DEXAMETHASONE							
AB		AMNEAL	0.1%; 0.3%	A212991	001	Jul 15, 2021	Jul	NEWA	

DEXCHLORPHENIRAMINE MALEATE

		SYRUP; ORAL							
		DEXCHLORPHENIRAMINE MALEATE							
AA	+	WOCKHARDT BIO AG	2MG/5ML	A088251	001	Mar 23, 1984	Aug	CRLD	
		TABLET; ORAL							
		POLARAMINE							
		+ @ SCHERING	2MG	A086835	001		Aug	CRLD	

DEXMEDETOMIDINE HYDROCHLORIDE

		INJECTABLE; INJECTION							
		DEXMEDETOMIDINE HYDROCHLORIDE							
AP		GLAND	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A202126	001	Aug 20, 2015	May	CAHN	
AP		HIKMA	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A205046	001	Apr 26, 2017	Jul	CAHN	
AP		HONG KONG	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A204843	001	Jan 18, 2019	Jun	CMFD	
AP		PIRAMAL CRITICAL	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A214794	001	Sep 03, 2021	Aug	NEWA	

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL  
DEXMETHYLPHENIDATE HYDROCHLORIDE

>A>	AB	ASCENT PHARMS INC	5MG	A215523	001	Dec 08, 2021	Nov	NEWA
>A>	AB		10MG	A215523	002	Dec 08, 2021	Nov	NEWA
>A>	AB		15MG	A215523	003	Dec 08, 2021	Nov	NEWA
>A>	AB		20MG	A215523	004	Dec 08, 2021	Nov	NEWA
>A>	AB		25MG	A215523	005	Dec 08, 2021	Nov	NEWA
>A>	AB		30MG	A215523	006	Dec 08, 2021	Nov	NEWA
>A>	AB		35MG	A215523	007	Dec 08, 2021	Nov	NEWA
>A>	AB		40MG	A215523	008	Dec 08, 2021	Nov	NEWA
>A>	@	AUROLIFE PHARMA LLC	5MG	A204266	001	Aug 25, 2015	Nov	CAHN
>A>	@		10MG	A204266	002	Aug 25, 2015	Nov	CAHN
>A>	@		15MG	A204266	003	Aug 25, 2015	Nov	CAHN
>A>	@		20MG	A204266	004	Dec 21, 2015	Nov	CAHN
>A>	@		25MG	A204266	005	May 04, 2021	Nov	CAHN
>A>	@		35MG	A204266	006	May 04, 2021	Nov	CAHN
>A>	@		40MG	A204266	007	Aug 25, 2015	Nov	CAHN
>A>	AB	INTELLIPHARMACEUTICS	5MG	A078992	001	Nov 23, 2021	Nov	NEWA
>A>	AB		10MG	A078992	002	Nov 23, 2021	Nov	NEWA
>A>	AB		20MG	A078992	005	Nov 23, 2021	Nov	NEWA
>A>	AB		40MG	A078992	006	Nov 23, 2021	Nov	NEWA
>D>	@	MYLAN	5MG	A204266	001	Aug 25, 2015	Nov	CAHN
	@		5MG	A204266	001	Aug 25, 2015	Jul	DISC
>D>	@		10MG	A204266	002	Aug 25, 2015	Nov	CAHN
	@		10MG	A204266	002	Aug 25, 2015	Jul	DISC
>D>	@		15MG	A204266	003	Aug 25, 2015	Nov	CAHN
	@		15MG	A204266	003	Aug 25, 2015	Jul	DISC
>D>	@		20MG	A204266	004	Dec 21, 2015	Nov	CAHN
	@		20MG	A204266	004	Dec 21, 2015	Jul	DISC
>D>	@		25MG	A204266	005	May 04, 2021	Nov	CAHN
	@		25MG	A204266	005	May 04, 2021	Jul	DISC
AB			25MG	A204266	005	May 04, 2021	Apr	NEWA
	@		30MG	A202580	001	Aug 28, 2013	Jul	CAHN
	@		30MG	A202580	001	Aug 28, 2013	Jul	DISC
>D>	@		35MG	A204266	006	May 04, 2021	Nov	CAHN
	@		35MG	A204266	006	May 04, 2021	Jul	DISC
AB			35MG	A204266	006	May 04, 2021	Apr	NEWA
>D>	@		40MG	A204266	007	Aug 25, 2015	Nov	CAHN
	@		40MG	A204266	007	Aug 25, 2015	Jul	DISC
AB		SUN PHARM INDS INC	5MG	A206734	001	Nov 05, 2021	Oct	NEWA
AB			10MG	A206734	002	Nov 05, 2021	Oct	NEWA
AB			15MG	A206734	003	Nov 05, 2021	Oct	NEWA
AB			20MG	A206734	004	Nov 05, 2021	Oct	NEWA
AB			25MG	A206734	005	Nov 05, 2021	Oct	NEWA
AB			30MG	A206734	006	Nov 05, 2021	Oct	NEWA
AB			35MG	A206734	007	Nov 05, 2021	Oct	NEWA
AB			40MG	A206734	008	Nov 05, 2021	Oct	NEWA

TABLET;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

@	BIONPHARMA INC	5MG	A209754	001	Mar 24, 2020	Sep	CAHN
@		10MG	A209754	002	Mar 24, 2020	Sep	CAHN

DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE

CAPSULE;ORAL

AZSTARYS

+	COMMAVE THERAP	EQ 5.2MG BASE;EQ 26.1MG BASE	N212994	001	May 07, 2021	May	NEWA
+		EQ 7.8MG BASE;EQ 39.2MG BASE	N212994	002	May 07, 2021	May	NEWA
+	!	EQ 10.4MG BASE;EQ 52.3MG BASE	N212994	003	May 07, 2021	May	NEWA

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE;INJECTION

DEXRAZOXANE HYDROCHLORIDE

AP		AUROMEDICS PHARMA	EQ 250MG BASE/VIAL	A200752	001	Oct 19, 2011	Jan	CAHN
AP			EQ 500MG BASE/VIAL	A200752	002	Oct 19, 2011	Jan	CAHN
AP	!	EUGIA PHARMA	EQ 250MG BASE/VIAL	A200752	001	Oct 19, 2011	Aug	CHRS
AP			EQ 250MG BASE/VIAL	A200752	001	Oct 19, 2011	Aug	CAHN
AP	!		EQ 500MG BASE/VIAL	A200752	002	Oct 19, 2011	Aug	CHRS
AP			EQ 500MG BASE/VIAL	A200752	002	Oct 19, 2011	Aug	CAHN
		TOTECT						
+	@	CLINIGEN	EQ 500MG BASE/VIAL	N022025	001	Sep 06, 2007	Aug	DISC



INJECTABLE; INJECTION  
ZINECARD

	+ @ PFIZER	EQ 250MG BASE/VIAL	N020212	001	May 26, 1995	Aug	DISC
AP	+	EQ 250MG BASE/VIAL	N020212	001	May 26, 1995	Mar	CAHN
	+ @	EQ 500MG BASE/VIAL	N020212	002	May 26, 1995	Aug	DISC
AP	+	EQ 500MG BASE/VIAL	N020212	002	May 26, 1995	Mar	CAHN

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL  
DEXTROAMPHETAMINE SULFATE

>A>	AB	STRIDES PHARMA	5MG	A205673	001	Oct 31, 2017	Nov	CAHN
>A>	AB		10MG	A205673	002	Oct 31, 2017	Nov	CAHN
>A>	AB		15MG	A205673	003	Oct 31, 2017	Nov	CAHN
>D>	AB	VINTAGE PHARMS	5MG	A205673	001	Oct 31, 2017	Nov	CAHN
>D>	AB		10MG	A205673	002	Oct 31, 2017	Nov	CAHN
>D>	AB		15MG	A205673	003	Oct 31, 2017	Nov	CAHN

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

AA		ARBOR PHARMS LLC	2.5MG	A090533	001	Oct 25, 2011	May	CTEC
AA			7.5MG	A090533	003	Oct 25, 2011	May	CTEC
AA			15MG	A090533	005	Oct 25, 2011	May	CTEC
AA			20MG	A090533	006	Oct 25, 2011	May	CTEC
AA			30MG	A090533	007	Oct 25, 2011	May	CTEC
>A>	@	STRIDES PHARMA	5MG	A040299	001	May 13, 1999	Nov	CAHN
>D>	@	VINTAGE PHARMS LLC	5MG	A040299	001	May 13, 1999	Nov	CAHN
AA		WINDER LABS LLC	2.5MG	A212160	001	Jun 07, 2021	May	NEWA
AA			5MG	A212160	002	Jun 07, 2021	May	NEWA
AA			7.5MG	A212160	003	Jun 07, 2021	May	NEWA
AA			10MG	A212160	004	Jun 07, 2021	May	NEWA
AA			15MG	A212160	005	Jun 07, 2021	May	NEWA
AA			20MG	A212160	006	Jun 07, 2021	May	NEWA
AA			30MG	A212160	007	Jun 07, 2021	May	NEWA

DEXTROSTAT

	+ @ SHIRE	5MG	A084051	001		Aug	CRLD
	+ @	10MG	A084051	002		Aug	CRLD

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

>D>	@	TRIS PHARMA INC	15MG/5ML; 6.25MG/5ML	A091687	001	Jun 28, 2012	Nov	CMFD
>A>	AA		15MG/5ML; 6.25MG/5ML	A091687	001	Jun 28, 2012	Nov	CMFD

DEXTROSE

INJECTABLE; INJECTION  
DEXTROSE 50%

AP	+	HOSPIRA	500MG/ML	N019445	001	Jun 03, 1986	Mar	CFTG
AP		INTL MEDICATION SYS	500MG/ML	A203451	001	Mar 26, 2021	Mar	CFTG

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075%

@ FRESENIUS KABI USA 5GM/100ML; 75MG/100ML

A212346	001	Sep 10, 2020	Mar	DISC
---------	-----	--------------	-----	------

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15%

@ FRESENIUS KABI USA 5GM/100ML; 150MG/100ML

A212346	002	Sep 10, 2020	Mar	DISC
---------	-----	--------------	-----	------

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	5GM/100ML; 224MG/100ML	N017634	003		Mar	CTEC
---	-----------------	------------------------	---------	-----	--	-----	------

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

@ FRESENIUS KABI USA 5GM/100ML; 149MG/100ML; 225MG/100ML

A212348	001	Jul 30, 2021	Sep	DISC
---------	-----	--------------	-----	------

5GM/100ML; 149MG/100ML; 225MG/100ML

A212348	001	Jul 30, 2021	Jul	NFTG
---------	-----	--------------	-----	------

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%

@ FRESENIUS KABI USA 5GM/100ML; 74.5MG/100ML; 450MG/100ML

A213523	001	Mar 09, 2021	Sep	DISC
---------	-----	--------------	-----	------

5GM/100ML; 74.5MG/100ML; 450MG/100ML

A213523	001	Mar 09, 2021	Feb	NEWA
---------	-----	--------------	-----	------

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

@ FRESENIUS KABI USA 5GM/100ML; 149MG/100ML; 225MG/100ML

A212348	002	Jul 30, 2021	Sep	DISC
---------	-----	--------------	-----	------

5GM/100ML; 149MG/100ML; 225MG/100ML

A212348	002	Jul 30, 2021	Jul	NFTG
---------	-----	--------------	-----	------

+	ICU MEDICAL INC	5GM/100ML; 149MG/100ML; 225MG/100ML	N018365	001		Sep	CTEC
---	-----------------	-------------------------------------	---------	-----	--	-----	------

+		5GM/100ML; 149MG/100ML; 225MG/100ML	N018365	001		Jul	CFTG
---	--	-------------------------------------	---------	-----	--	-----	------

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%

@ FRESENIUS KABI USA 5GM/100ML; 149MG/100ML; 450MG/100ML

A213523	002	Mar 09, 2021	Sep	DISC
---------	-----	--------------	-----	------

INJECTABLE; INJECTION

		POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%						
AP		5GM/100ML;149MG/100ML;450MG/100ML	A213523	002	Mar 09, 2021	Feb	NEWA	
		POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%						
AP	@ FRESSENIUS KABI USA	5GM/100ML;149MG/100ML;900MG/100ML	A213445	001	Mar 09, 2021	Sep	DISC	
		5GM/100ML;149MG/100ML;900MG/100ML	A213445	001	Mar 09, 2021	Feb	NFTG	
		POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%						
AP	@ FRESSENIUS KABI USA	5GM/100ML;224MG/100ML;450MG/100ML	A213523	003	Mar 09, 2021	Sep	DISC	
		5GM/100ML;224MG/100ML;450MG/100ML	A213523	003	Mar 09, 2021	Feb	NEWA	
		POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%						
AP	@ FRESSENIUS KABI USA	5GM/100ML;298MG/100ML;450MG/100ML	A213523	004	Mar 09, 2021	Sep	DISC	
		5GM/100ML;298MG/100ML;450MG/100ML	A213523	004	Mar 09, 2021	Feb	NEWA	
		POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%						
AP	@ FRESSENIUS KABI USA	5GM/100ML;298MG/100ML;900MG/100ML	A213445	002	Mar 09, 2021	Sep	DISC	
		5GM/100ML;298MG/100ML;900MG/100ML	A213445	002	Mar 09, 2021	Feb	NFTG	

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

		DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER						
AP	FRESSENIUS KABI USA	2.5GM/100ML;450MG/100ML	A211190	001	Dec 20, 2019	May	CMFD	
		DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER						
AP	FRESSENIUS KABI USA	5GM/100ML;300MG/100ML	A211194	001	Aug 26, 2020	May	CMFD	
	@	5GM/100ML;300MG/100ML	A211194	001	Aug 26, 2020	Feb	DISC	
AP	+! ICU MEDICAL INC	5GM/100ML;300MG/100ML	N017799	001		May	CTEC	
	+!	5GM/100ML;300MG/100ML	N017799	001		Feb	CTEC	
		DEXTROSE 5% AND SODIUM CHLORIDE 0.45%						
AP	FRESSENIUS KABI USA	5GM/100ML;450MG/100ML	A211276	001	Sep 15, 2020	May	CMFD	
	@	5GM/100ML;450MG/100ML	A211276	001	Sep 15, 2020	Mar	DISC	
		DEXTROSE 5% AND SODIUM CHLORIDE 0.9%						
AP	FRESSENIUS KABI USA	5GM/100ML;900MG/100ML	A211211	001	Sep 14, 2020	May	CMFD	
	@	5GM/100ML;900MG/100ML	A211211	001	Sep 14, 2020	Mar	DISC	

DIAZEPAM

INJECTABLE; INJECTION

		DIAZEPAM						
AP	! BELOTECA INC	10MG/2ML (5MG/ML)	A210363	001	Mar 18, 2019	Aug	CTEC	

TABLET; ORAL

DIAZEPAM

>A>	AB	STRIDES PHARMA	2MG	A077749	001	Mar 31, 2006	Nov	CAHN
>A>	AB		5MG	A077749	002	Mar 31, 2006	Nov	CAHN
>A>	AB		10MG	A077749	003	Mar 31, 2006	Nov	CAHN
>D>	AB	VINTAGE PHARMS	2MG	A077749	001	Mar 31, 2006	Nov	CAHN
>D>	AB		5MG	A077749	002	Mar 31, 2006	Nov	CAHN
>D>	AB		10MG	A077749	003	Mar 31, 2006	Nov	CAHN

DICLOFENAC POTASSIUM

CAPSULE; ORAL

DICLOFENAC POTASSIUM

AB	AUROBINDO PHARMA LTD	25MG	A213875	001	Oct 19, 2021	Oct	NEWA	
		TABLET; ORAL						
		CATAFLAM						
AB	AMICI	25MG	A076561	002	Jul 21, 2021	Sep	CTEC	
		25MG	A076561	002	Jul 21, 2021	Jul	NEWA	
AB		50MG	A076561	001	Mar 18, 2004	May	CTNA	
		DICLOFENAC POTASSIUM						
AB	RICONPHARMA LLC	50MG	A215585	001	Oct 08, 2021	Oct	NEWA	
AB	RUBICON	25MG	A075229	002	Sep 16, 2021	Sep	NEWA	

DICLOFENAC SODIUM

GEL; TOPICAL

DICLOFENAC SODIUM

AB	! TARO	3%	A206298	001	Apr 28, 2016	Mar	CHRS	
		SOLARAZE						
	+ @ FOUGERA PHARMS	3%	N021005	001	Oct 16, 2000	Mar	DISC	
		SOLUTION; TOPICAL						
		DICLOFENAC SODIUM						
AT	AKORN	1.5%	A206655	001	Jan 28, 2021	Jan	NEWA	
	@ RISING	1.5%	A206715	001	Aug 07, 2017	May	CAHN	
		SOLUTION/DROPS; OPHTHALMIC						
		DICLOFENAC SODIUM						
AT	! BAUSCH AND LOMB	0.1%	A078792	001	Dec 28, 2007	Aug	CHRS	

SOLUTION/DROPS;OPHTHALMIC  
VOLTAREN

	+ @ NOVARTIS	0.1%	N020037	001	Mar 28, 1991	Aug	DISC
	TABLET, DELAYED RELEASE;ORAL						
	DICLOFENAC SODIUM						
	@ MICRO LABS	50MG	A074986	001	Feb 26, 1999	Feb	CAHN
	@	75MG	A074986	002	Feb 26, 1999	Feb	CAHN

DICLOFENAC SODIUM; MISOPROSTOL

	TABLET, DELAYED RELEASE;ORAL						
	DICLOFENAC SODIUM AND MISOPROSTOL						
AB	MICRO LABS	50MG;0.2MG	A204355	001	Jul 15, 2021	Jul	NEWA
AB		75MG;0.2MG	A204355	002	Jul 15, 2021	Jul	NEWA

DICLOXACILLIN SODIUM

	CAPSULE;ORAL						
	DICLOXACILLIN SODIUM						
	@ SANDOZ	EQ 125MG BASE	A061454	002		Jan	DISC
	@	EQ 250MG BASE	A061454	001		Jan	DISC
	@	EQ 500MG BASE	A061454	003		Jan	DISC
	TEVA	EQ 250MG BASE	A062286	001	Jun 03, 1982	Jan	CTEC
	!	EQ 500MG BASE	A062286	002	Jun 03, 1982	Jan	CTEC
AB	!	EQ 500MG BASE	A062286	002	Jun 03, 1982	Jan	CHRS

DICYCLOMINE HYDROCHLORIDE

	INJECTABLE;INJECTION						
	DICYCLOMINE HYDROCHLORIDE						
AP	GENE YORK PHARMS	10MG/ML	A212058	001	Apr 26, 2019	Sep	CAHN
AP	PRAXGEN	10MG/ML	A212058	001	Apr 26, 2019	Jun	CAHN
	SYRUP;ORAL						
	DICYCLOMINE HYDROCHLORIDE						
AA	NOVITIUM PHARMA	10MG/5ML	A214721	001	Apr 23, 2021	Apr	NEWA

DIDANOSINE

	CAPSULE, DELAYED REL PELLETS;ORAL						
	DIDANOSINE						
	@ AUROBINDO PHARMA	125MG	A090094	001	Sep 24, 2008	Jan	DISC
	@	200MG	A090094	002	Sep 24, 2008	Jan	DISC
	@	250MG	A090094	003	Sep 24, 2008	Jan	DISC
	@	400MG	A090094	004	Sep 24, 2008	Jan	DISC

DIFELIKEFALIN ACETATE

	SOLUTION;INTRAVENOUS						
	KORSUVA						
	+! CARA THERAP	EQ 0.065MG BASE/1.3ML (EQ 0.05MG BASE/ML)	N214916	001	Aug 23, 2021	Aug	NEWA

DIFLORASONE DIACETATE

	CREAM;TOPICAL						
	DIFLORASONE DIACETATE						
BX	! ANI PHARMS	0.05%	A076263	001	Dec 20, 2002	Apr	CAHN
	OINTMENT;TOPICAL						
	DIFLORASONE DIACETATE						
	@ AKORN	0.05%	A206572	001	Jul 24, 2015	Apr	DISC

DIFLUNISAL

	TABLET;ORAL						
	DIFLUNISAL						
	@ DASTECH INTL	250MG	A073562	001	Nov 27, 1992	Sep	CAHN
	@	500MG	A073563	001	Nov 27, 1992	Sep	CAHN

DIFLUPREDNATE

	EMULSION;OPHTHALMIC							
	DIFLUPREDNATE							
>A>	AB	AMNEAL	0.05%	A211526	001	Nov 17, 2021	Nov	NEWA
	AB	CIPLA	0.05%	A211776	001	Aug 09, 2021	Jul	NFTG
	DUREZOL							
	AB	+! NOVARTIS	0.05%	N022212	001	Jun 23, 2008	Jul	CFTG

DIGOXIN

ELIXIR;ORAL		DIGOXIN					
AA	NOVITIUM PHARMA	0.05MG/ML	A213000	001	Oct 04, 2019	Sep	CAHN
TABLET;ORAL		DIGOXIN					
>A>	AB	NOVITIUM PHARMA	0.125MG	A215307	001	Nov 22, 2021	Nov NEWA
>A>	AB		0.25MG	A215307	002	Nov 22, 2021	Nov NEWA

DIHYDROERGOTAMINE MESYLATE

INJECTABLE;INJECTION		DIHYDROERGOTAMINE MESYLATE					
>A>	AP	HIKMA	1MG/ML	A040453	001	Jun 09, 2003	Nov CAHN
	AP	PROVEPHARM SAS	1MG/ML	A212046	001	Jan 07, 2020	Jan CAHN
>D>	AP	WEST-WARD PHARMS INT	1MG/ML	A040453	001	Jun 09, 2003	Nov CAHN
SPRAY, METERED;NASAL		TRUDHESA					
+	!	IMPEL NEUROPHARMA	0.725MG/SPRAY	N213436	001	Sep 02, 2021	Sep NEWA

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL		DILTIAZEM HYDROCHLORIDE					
AB1	GLENMARK PHARMS LTD	60MG	A212317	001	Mar 22, 2021	Mar	NEWA
AB1		90MG	A212317	002	Mar 22, 2021	Mar	NEWA
AB1		120MG	A212317	003	Mar 22, 2021	Mar	NEWA
AB1	MYLAN	60MG	A074910	001	May 02, 1997	Mar	CTEC
AB1		90MG	A074910	002	May 02, 1997	Mar	CTEC
AB1	!	120MG	A074910	003	May 02, 1997	Mar	CTEC
INJECTABLE;INJECTION		DILTIAZEM HYDROCHLORIDE					
	@	INTL MEDICATION	5MG/ML	A075749	001	Nov 21, 2001	Jan DISC
SOLUTION;INTRAVENOUS		DILTIAZEM HYDROCHLORIDE IN DEXTROSE 5%					
+	!	EXELA PHARMA	125MG/125ML (1MG/ML)	N215252	001	Oct 28, 2021	Oct NEWA
+	!		250MG/250ML (1MG/ML)	N215252	002	Oct 28, 2021	Oct NEWA

DIMENHYDRINATE

INJECTABLE;INJECTION		DIMENHYDRINATE					
+	@	WATSON LABS TEVA	50MG/ML	A080615	001		Aug CRLD
TABLET;ORAL		DIMENHYDRINATE					
+	@	WATSON LABS	50MG	A085166	001		Aug CRLD

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE;ORAL		DIMETHYL FUMARATE					
AB	LUPIN	120MG	A210226	001	Oct 05, 2020	Jul	CAHN
AB		240MG	A210226	002	Oct 05, 2020	Jul	CAHN
AB	PHARMATHEN	120MG	A210436	001	Mar 26, 2021	Mar	NEWA
AB		240MG	A210436	002	Mar 26, 2021	Mar	NEWA
	@	ZYDUS PHARMS	120MG	A210538	001	Sep 24, 2020	Feb DISC
	@		240MG	A210538	002	Sep 24, 2020	Feb DISC
TECFIDERA							
AB	+	BIOGEN INC	120MG	N204063	001	Mar 27, 2013	Apr CAHN
AB	+	!	240MG	N204063	002	Mar 27, 2013	Apr CAHN

DINOPROSTONE

GEL;ENDOCERVICAL		PREPIDIL					
+	!	PFIZER	0.5MG/3GM	N019617	001	Dec 09, 1992	Jan CAHN
SUPPOSITORY;VAGINAL		PROSTIN E2					
+	@	PFIZER	20MG	N017810	001		Oct DISC
+	!		20MG	N017810	001		Jan CAHN

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION  
DIPHENHYDRAMINE HYDROCHLORIDE

AP +! WEST-WARD PHARMS INT 50MG/ML A 080817 002 Aug CRLD

DIPYRIDAMOLE

TABLET; ORAL  
DIPYRIDAMOLE

>D> @ ANI PHARMS 25MG A 086944 002 Apr 16, 1991 Nov CMFD  
>A> AB 25MG A 086944 002 Apr 16, 1991 Nov CMFD  
>D> @ 50MG A 086944 001 Feb 25, 1992 Nov CMFD  
>A> AB 50MG A 086944 001 Feb 25, 1992 Nov CMFD  
>D> @ 75MG A 086944 003 Feb 25, 1992 Nov CMFD  
>A> AB 75MG A 086944 003 Feb 25, 1992 Nov CMFD  
>A> @ GENUS 25MG A 040898 001 Apr 23, 2008 Nov CAHN  
>A> @ 50MG A 040898 002 Apr 23, 2008 Nov CAHN  
>A> @ 75MG A 040898 003 Apr 23, 2008 Nov CAHN  
>D> @ LANNETT CO INC 25MG A 040898 001 Apr 23, 2008 Nov CAHN  
>D> @ 50MG A 040898 002 Apr 23, 2008 Nov CAHN  
>D> @ 75MG A 040898 003 Apr 23, 2008 Nov CAHN  
AB OXFORD PHARMS 25MG A 040542 001 Apr 21, 2006 Jan CMFD  
AB 50MG A 040542 002 Apr 21, 2006 Jan CMFD  
AB 75MG A 040542 003 Apr 21, 2006 Jan CMFD

DIROXIMEL FUMARATE

CAPSULE, DELAYED RELEASE; ORAL  
VUMERITY

+! BIOGEN INC 231MG N 211855 001 Oct 29, 2019 Apr CAHN

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL  
DISOPYRAMIDE PHOSPHATE

@ MAYNE PHARMA EQ 100MG BASE A 070173 001 May 31, 1985 Feb DISC  
@ EQ 150MG BASE A 070173 002 May 31, 1985 Feb DISC

DISULFIRAM

TABLET; ORAL  
ANTABUSE

+ @ ODYSSEY PHARMS 250MG A 088482 001 Dec 08, 1983 Sep DISC  
AB + 250MG A 088482 001 Dec 08, 1983 Aug CRLD  
+ @ 500MG A 088483 001 Dec 08, 1983 Sep DISC  
AB +! 500MG A 088483 001 Dec 08, 1983 Aug CRLD  
DISULFIRAM  
AB ! HIKMA 500MG A 202652 002 Feb 05, 2014 Sep CHRS  
>D> @ PAR PHARM 250MG A 088792 001 Aug 14, 1984 Nov CAHN  
>D> @ 500MG A 088793 001 Aug 14, 1984 Nov CAHN  
>A> @ STRIDES PHARMA 250MG A 088792 001 Aug 14, 1984 Nov CAHN  
>A> @ 500MG A 088793 001 Aug 14, 1984 Nov CAHN

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS; ORAL  
DIVALPROEX SODIUM

@ TEVA PHARMS USA EQ 125MG VALPROIC ACID A 211505 001 Nov 17, 2020 May DISC

TABLET, DELAYED RELEASE; ORAL  
DIVALPROEX SODIUM

@ ANCHEN PHARMS EQ 500MG VALPROIC ACID A 078411 001 Nov 03, 2008 May DISC

TABLET, EXTENDED RELEASE; ORAL  
DIVALPROEX SODIUM

@ AMTA EQ 250MG VALPROIC ACID A 214462 001 Mar 15, 2021 Sep DISC  
AB EQ 250MG VALPROIC ACID A 214462 001 Mar 15, 2021 Mar NEWA  
@ EQ 500MG VALPROIC ACID A 214462 002 Mar 15, 2021 Sep DISC  
AB EQ 500MG VALPROIC ACID A 214462 002 Mar 15, 2021 Mar NEWA

DOCETAXEL

INJECTABLE; INJECTION  
DOCETAXEL

AP EUGIA PHARMA 20MG/2ML (10MG/ML) A 214575 001 Jun 25, 2021 Jun NEWA  
AP 80MG/8ML (10MG/ML) A 214575 002 Jun 25, 2021 Jun NEWA  
AP 160MG/16ML (10MG/ML) A 214575 003 Jun 25, 2021 Jun NEWA  
AP GLAND PHARMA LTD 20MG/2ML (10MG/ML) A 213510 001 Jul 01, 2021 Jun NEWA  
AP 80MG/8ML (10MG/ML) A 213510 002 Jul 01, 2021 Jun NEWA

INJECTABLE; INJECTION  
DOCETAXEL

AP		160MG/16ML (10MG/ML)	A213510	003	Jul 01, 2021	Jun	NEWA
AP	HIKMA	20MG/ML (20MG/ML)	A204490	001	Jan 14, 2021	Jan	NEWA
AP		80MG/4ML (20MG/ML)	A204490	002	Jan 14, 2021	Jan	NEWA
AP	HONG KONG	20MG/2ML (10MG/ML)	A209634	001	Aug 24, 2018	Jun	CMFD
AP		80MG/8ML (10MG/ML)	A209634	002	Aug 24, 2018	Jun	CMFD
AP		160MG/16ML (10MG/ML)	A209634	003	Aug 24, 2018	Jun	CMFD
	@ INGENUS PHARMS LLC	20MG/2ML (10MG/ML)	A207563	001	Aug 31, 2017	Apr	DISC
>D>	! JIANGSU PHARMS	40MG/ML	A203170	001	Feb 15, 2017	Nov	DISC
>A>	@	40MG/ML	A203170	001	Feb 15, 2017	Nov	DISC
AP	+! SHILPA	20MG/ML (20MG/ML)	N205934	001	Dec 22, 2015	Apr	CHRS
AP	+	20MG/ML (20MG/ML)	N205934	001	Dec 22, 2015	Apr	CRLD
AP		20MG/ML (20MG/ML)	N205934	001	Dec 22, 2015	Jan	CAHN
AP	+!	80MG/4ML (20MG/ML)	N205934	002	Dec 22, 2015	Apr	CHRS
AP	+	80MG/4ML (20MG/ML)	N205934	002	Dec 22, 2015	Apr	CRLD
AP		80MG/4ML (20MG/ML)	N205934	002	Dec 22, 2015	Jan	CAHN
AP	+!	160MG/8ML (20MG/ML)	N205934	003	Dec 22, 2015	Apr	CHRS
AP	+	160MG/8ML (20MG/ML)	N205934	003	Dec 22, 2015	Apr	CRLD
AP		160MG/8ML (20MG/ML)	N205934	003	Dec 22, 2015	Jan	CAHN

DOFETILIDE

CAPSULE; ORAL  
DOFETILIDE

AB	GRANULES	0.125MG	A212750	001	Oct 14, 2021	Oct	NEWA
AB		0.25MG	A212750	002	Oct 14, 2021	Oct	NEWA
AB		0.5MG	A212750	003	Oct 14, 2021	Oct	NEWA
	@ NOVAST LABS	0.125MG	A212410	001	Dec 27, 2019	Sep	CAHN
	@	0.25MG	A212410	002	Dec 27, 2019	Sep	CAHN
	@	0.5MG	A212410	003	Dec 27, 2019	Sep	CAHN
>D>	AB PAR PHARM INC	0.125MG	A208519	001	Oct 09, 2018	Nov	CAHN
>D>	AB	0.25MG	A208519	002	Oct 09, 2018	Nov	CAHN
>D>	AB	0.5MG	A208519	003	Oct 09, 2018	Nov	CAHN
	@ RICONPHARMA LLC	0.125MG	A212410	001	Dec 27, 2019	Feb	DISC
	@	0.25MG	A212410	002	Dec 27, 2019	Feb	DISC
	@	0.5MG	A212410	003	Dec 27, 2019	Feb	DISC
>A>	AB STRIDES PHARMA	0.125MG	A208519	001	Oct 09, 2018	Nov	CAHN
>A>	AB	0.25MG	A208519	002	Oct 09, 2018	Nov	CAHN
>A>	AB	0.5MG	A208519	003	Oct 09, 2018	Nov	CAHN

DOLASETRON MESYLATE

INJECTABLE; INJECTION  
ANZEMET

+	@ VALIDUS PHARMS	12.5MG/0.625ML (20MG/ML)	N020624	002	Sep 11, 1997	Feb	CAHN
+	@	100MG/5ML (20MG/ML)	N020624	001	Sep 11, 1997	Feb	CAHN
	@	500MG/25ML (20MG/ML)	N020624	003	Dec 11, 2001	Feb	CAHN

TABLET; ORAL  
ANZEMET

+	@ VALIDUS PHARMS	100MG	N020623	002	Sep 11, 1997	Feb	CAHN
---	------------------	-------	---------	-----	--------------	-----	------

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

AT	ALEMBIC PHARMS LTD	EQ 2% BASE; EQ 0.5% BASE	A213099	001	May 04, 2021	Apr	NEWA
AT	FDC LTD	EQ 2% BASE; EQ 0.5% BASE	A205295	001	Jun 13, 2019	Feb	CMFD

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION  
DOPRAM

AP	+! HIKMA	20MG/ML	N014879	001		Jul	CAHN
----	----------	---------	---------	-----	--	-----	------

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

>D>	@ DAVA PHARMS INC	EQ 1MG BASE	A076161	001	Jun 10, 2004	Nov	CAHN
>D>	@	EQ 2MG BASE	A076161	002	Jun 10, 2004	Nov	CAHN
>D>	@	EQ 4MG BASE	A076161	003	Jun 10, 2004	Nov	CAHN
>D>	@	EQ 8MG BASE	A076161	004	Jun 10, 2004	Nov	CAHN
BX	HERITAGE PHARMA	EQ 1MG BASE	A205210	001	Feb 13, 2018	Sep	CTEC
BX		EQ 2MG BASE	A205210	002	Feb 13, 2018	Sep	CTEC
BX		EQ 4MG BASE	A205210	003	Feb 13, 2018	Sep	CTEC
BX		EQ 8MG BASE	A205210	004	Feb 13, 2018	Sep	CTEC
>A>	@ STRIDES PHARMA	EQ 1MG BASE	A076161	001	Jun 10, 2004	Nov	CAHN

## TABLET;ORAL

## DOXAZOSIN MESYLATE

>A>	@	EQ 2MG BASE	A076161	002	Jun 10, 2004	Nov	CAHN
>A>	@	EQ 4MG BASE	A076161	003	Jun 10, 2004	Nov	CAHN
>A>	@	EQ 8MG BASE	A076161	004	Jun 10, 2004	Nov	CAHN

DOXEPIN HYDROCHLORIDE

## CAPSULE;ORAL

## DOXEPIN HYDROCHLORIDE

AB	ALEMBIC PHARMS LTD	EQ 10MG BASE	A215076	001	Apr 21, 2021	Apr	NEWA
AB		EQ 25MG BASE	A215076	002	Apr 21, 2021	Apr	NEWA
AB		EQ 50MG BASE	A215076	003	Apr 21, 2021	Apr	NEWA
AB		EQ 75MG BASE	A215076	004	Apr 21, 2021	Apr	NEWA
AB		EQ 100MG BASE	A215076	005	Apr 21, 2021	Apr	NEWA
AB	APPCO	EQ 10MG BASE	A214908	001	Apr 01, 2021	Mar	NEWA
AB		EQ 25MG BASE	A214908	002	Apr 01, 2021	Mar	NEWA
AB		EQ 50MG BASE	A214908	003	Apr 01, 2021	Mar	NEWA
AB		EQ 75MG BASE	A214908	004	Apr 01, 2021	Mar	NEWA
AB		EQ 100MG BASE	A214908	005	Apr 01, 2021	Mar	NEWA
	@ CHARTWELL RX	EQ 10MG BASE	A210268	001	Sep 04, 2020	Aug	CAHN
	@	EQ 25MG BASE	A210268	002	Sep 04, 2020	Aug	CAHN
	@	EQ 50MG BASE	A210268	003	Sep 04, 2020	Aug	CAHN
	@	EQ 75MG BASE	A210268	004	Sep 04, 2020	Aug	CAHN
	@	EQ 100MG BASE	A210268	005	Sep 04, 2020	Aug	CAHN
AB	LEADING PHARMA LLC	EQ 10MG BASE	A211619	001	Mar 09, 2021	Feb	NEWA
AB		EQ 25MG BASE	A211619	002	Mar 09, 2021	Feb	NEWA
AB		EQ 50MG BASE	A211619	003	Mar 09, 2021	Feb	NEWA
AB		EQ 75MG BASE	A211619	004	Mar 09, 2021	Feb	NEWA
AB		EQ 100MG BASE	A211619	005	Mar 09, 2021	Feb	NEWA
AB		EQ 150MG BASE	A211618	001	Mar 01, 2021	Feb	NEWA
	@ UPSHER SMITH LABS	EQ 10MG BASE	A210268	001	Sep 04, 2020	May	CAHN
	@	EQ 10MG BASE	A210268	001	Sep 04, 2020	Feb	DISC
	@	EQ 25MG BASE	A210268	002	Sep 04, 2020	May	CAHN
	@	EQ 25MG BASE	A210268	002	Sep 04, 2020	Feb	DISC
	@	EQ 50MG BASE	A210268	003	Sep 04, 2020	May	CAHN
	@	EQ 50MG BASE	A210268	003	Sep 04, 2020	Feb	DISC
	@	EQ 75MG BASE	A210268	004	Sep 04, 2020	May	CAHN
	@	EQ 75MG BASE	A210268	004	Sep 04, 2020	Feb	DISC
	@	EQ 100MG BASE	A210268	005	Sep 04, 2020	May	CAHN
	@	EQ 100MG BASE	A210268	005	Sep 04, 2020	Feb	DISC

## TABLET;ORAL

## DOXEPIN HYDROCHLORIDE

AB	RK PHARMA	EQ 3MG BASE	A202337	001	Jan 20, 2016	Jan	CAHN
AB		EQ 6MG BASE	A202337	002	Jan 20, 2016	Jan	CAHN

DOXERCALCIFEROL

## INJECTABLE;INJECTION

## DOXERCALCIFEROL

	@ SUN PHARM	2MCG/ML (2MCG/ML)	A203875	001	Nov 14, 2019	Aug	DISC
	@	4MCG/2ML (2MCG/ML)	A203875	002	Nov 14, 2019	Aug	DISC

DOXORUBICIN HYDROCHLORIDE

## INJECTABLE;INJECTION

## DOXORUBICIN HYDROCHLORIDE

	@ ALMAJECT	2MG/ML	A065515	001	Nov 08, 2012	Jul	CAHN
AP	HIKMA PHARMS	200MG/100ML	A064097	001	Sep 13, 1994	Oct	CAHN

## INJECTABLE, LIPOSOMAL;INJECTION

## DOXORUBICIN HYDROCHLORIDE

AB	AYANA PHARMA LTD	20MG/10ML (2MG/ML)	A207228	001	Oct 12, 2021	Oct	NEWA
AB		50MG/25ML (2MG/ML)	A207228	002	Oct 12, 2021	Oct	NEWA

DOXYCYCLINE

## CAPSULE;ORAL

## MONODOX

AB	+ CHARTWELL RX	EQ 50MG BASE	N050641	002	Feb 10, 1992	Jun	CMFD
AB	+	EQ 75MG BASE	N050641	003	Oct 18, 2006	Jun	CMFD
AB	+	EQ 100MG BASE	N050641	001	Dec 29, 1989	Jun	CMFD

## FOR SUSPENSION;ORAL

## DOXYCYCLINE

AB	CHARTWELL	EQ 25MG BASE/5ML	A065454	001	Jul 16, 2008	Jun	CAHN
----	-----------	------------------	---------	-----	--------------	-----	------

DOXYCYCLINE HYCLATE

CAPSULE;ORAL

DOXYCYCLINE HYCLATE

AB	CHARTWELL	EQ 50MG BASE	A062500	001	Sep 11, 1984	Jun	CAHN
AB		EQ 100MG BASE	A062500	002	Sep 11, 1984	Jun	CAHN
>A>	NESHER PHARMS	EQ 50MG BASE	A208263	001	Nov 22, 2021	Nov	NEWA
>A>		EQ 100MG BASE	A208263	002	Nov 22, 2021	Nov	NEWA
	@ NOSTRUM LABS INC	EQ 50MG BASE	A209393	001	Dec 10, 2020	Jul	DISC
	@	EQ 100MG BASE	A209393	002	Dec 10, 2020	Jul	DISC

CAPSULE, DELAYED RELEASE;ORAL

DOXYCYCLINE HYCLATE

	@ BAUSCH	EQ 75MG BASE	A065281	001	Dec 21, 2005	May	CAHN
	@	EQ 100MG BASE	A065281	002	Dec 21, 2005	May	CAHN

INJECTABLE;INJECTION

DOXYCYCLINE HYCLATE

AP	WEST-WARD PHARMS INT	EQ 100MG BASE/VIAL	A062992	001	Feb 16, 1989	May	CMFD
AP		EQ 200MG BASE/VIAL	A062992	002	Feb 16, 1989	May	CMFD

SYSTEM, EXTENDED RELEASE;PERIODONTAL

ATRIDOX

+	@ DEN-MAT	50MG	N050751	001	Sep 03, 1998	Sep	DISC
---	-----------	------	---------	-----	--------------	-----	------

TABLET;ORAL

DOXYCYCLINE HYCLATE

AB	ALEMBIC PHARMS LTD	EQ 50MG BASE	A210536	002	Sep 14, 2021	Sep	NEWA
	@ AMICI	EQ 100MG BASE	A213475	001	Mar 10, 2021	Sep	CAHN
>D>	AMNEAL PHARMS CO	EQ 75MG BASE	A209372	001	Oct 06, 2017	Nov	DISC
>A>	@	EQ 75MG BASE	A209372	001	Oct 06, 2017	Nov	DISC
>D>		EQ 150MG BASE	A209372	002	Oct 06, 2017	Nov	DISC
>A>	@	EQ 150MG BASE	A209372	002	Oct 06, 2017	Nov	DISC
AB	CARIBE HOLDINGS	EQ 50MG BASE	A062269	003	Oct 05, 1983	Jul	CTEC
AB	CHARTWELL	EQ 50MG BASE	A062505	002	Jul 27, 2021	Jul	NEWA
AB		EQ 100MG BASE	A062505	001	Sep 11, 1984	Jun	CAHN
AB		EQ 100MG BASE	A062505	001	Sep 11, 1984	Jun	CAHN
	@ MYLAN	EQ 100MG BASE	A062432	001	Feb 15, 1983	Jul	DISC
	@ ORYZA	EQ 100MG BASE	A213475	001	Mar 10, 2021	Apr	DISC
AB		EQ 100MG BASE	A213475	001	Mar 10, 2021	Feb	NEWA
>A>	@ STRIDES PHARMA	EQ 100MG BASE	A062538	001	Apr 07, 1986	Nov	CAHN
>D>	@ VINTAGE PHARMS	EQ 100MG BASE	A062538	001	Apr 07, 1986	Nov	CAHN

DROSPIRENONE; ESTETROL

TABLET;ORAL

NEXTSTELLIS

+	! MAYNE PHARMA	3MG;14.2MG	N214154	001	Apr 15, 2021	Apr	NEWA
---	----------------	------------	---------	-----	--------------	-----	------

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL

DROSPIRENONE AND ETHINYL ESTRADIOL

AB	HLTHCARE	3MG;0.02MG	A203291	001	Jul 18, 2017	Jun	CAHN
	@ JUBILANT CADISTA	3MG;0.02MG	A209423	001	Dec 22, 2017	Jun	DISC
	KYRA						
	@ SUN PHARM	3MG;0.02MG	A202318	001	Jul 23, 2019	Aug	DISC

TABLET;ORAL-28

DROSPIRENONE AND ETHINYL ESTRADIOL

	@ JUBILANT CADISTA	3MG;0.03MG	A210017	001	Sep 10, 2018	Jun	DISC
	KEMEYA						
	@ SUN PHARM	3MG;0.03MG	A202138	001	Mar 13, 2019	Aug	DISC

DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM

TABLET;ORAL

BEYAZ

AB	+	! BAYER HLTHCARE	3MG,N/A;0.02MG,N/A;0.451MG,0.451MG	N022532	001	Sep 24, 2010	Sep	CHRS
AB	+		3MG,N/A;0.02MG,N/A;0.451MG,0.451MG	N022532	001	Sep 24, 2010	Sep	CRLD

DROXIDOPA

CAPSULE;ORAL

DROXIDOPA

AB	AJANTA PHARMA LTD	100MG	A214391	001	Feb 18, 2021	Feb	NFTG
AB		200MG	A214391	002	Feb 18, 2021	Feb	NFTG
AB		300MG	A214391	003	Feb 18, 2021	Feb	NFTG
AB	ALKEM LABS LTD	100MG	A213911	001	Feb 18, 2021	Feb	NFTG
AB		200MG	A213911	002	Feb 18, 2021	Feb	NFTG
AB		300MG	A213911	003	Feb 18, 2021	Feb	NFTG



CAPSULE;ORAL							
DROXIDOPA							
AB	ANNORA	100MG	A211726	002	Aug 09, 2021	Jul	NEWA
AB		200MG	A211726	003	Aug 09, 2021	Jul	NEWA
AB		300MG	A211726	001	Feb 18, 2021	Feb	NFTG
AB	AUROBINDO PHARMA LTD	100MG	A214387	001	Feb 18, 2021	Feb	NFTG
AB		200MG	A214387	002	Feb 18, 2021	Feb	NFTG
AB		300MG	A214387	003	Feb 18, 2021	Feb	NFTG
AB	BIONPHARMA INC	100MG	A213033	001	Apr 28, 2021	May	CAHN
AB		200MG	A213033	002	Apr 28, 2021	May	CAHN
AB		300MG	A213033	003	Apr 28, 2021	May	CAHN
AB	BLUEPHARMA	100MG	A214543	001	May 05, 2021	Apr	NEWA
AB		200MG	A214543	002	May 05, 2021	Apr	NEWA
AB		300MG	A214543	003	May 05, 2021	Apr	NEWA
AB	HIKMA	100MG	A212835	001	Feb 18, 2021	Feb	NFTG
AB		200MG	A212835	002	Feb 18, 2021	Feb	NFTG
AB		300MG	A212835	003	Feb 18, 2021	Feb	NFTG
AB	LUPIN PHARMS	100MG	A211652	001	Feb 18, 2021	Feb	NFTG
AB		200MG	A211652	002	Feb 18, 2021	Feb	NFTG
AB		300MG	A211652	003	Feb 18, 2021	Feb	NFTG
AB	MSN PHARMS INC	100MG	A211741	001	Feb 18, 2021	Feb	NFTG
AB		200MG	A211741	002	Feb 18, 2021	Feb	NFTG
AB		300MG	A211741	003	Feb 18, 2021	Feb	NFTG
AB	MYLAN API	100MG	A213033	001	Apr 28, 2021	Apr	NEWA
AB		200MG	A213033	002	Apr 28, 2021	Apr	NEWA
AB		300MG	A213033	003	Apr 28, 2021	Apr	NEWA
AB	SCIEGEN PHARMS INC	100MG	A214017	001	Feb 18, 2021	Feb	NFTG
AB		200MG	A214017	002	Feb 18, 2021	Feb	NFTG
AB		300MG	A214017	003	Feb 18, 2021	Feb	NFTG
AB	SLATE	100MG	A215265	001	Nov 01, 2021	Oct	NEWA
AB		200MG	A215265	002	Nov 01, 2021	Oct	NEWA
AB		300MG	A215265	003	Nov 01, 2021	Oct	NEWA
AB	SUN PHARM	100MG	A214384	001	Feb 18, 2021	Feb	NFTG
AB		200MG	A214384	002	Feb 18, 2021	Feb	NFTG
AB		300MG	A214384	003	Feb 18, 2021	Feb	NFTG
AB	TASMAN PHARMA	100MG	A213661	001	Feb 18, 2021	Feb	NFTG
AB		200MG	A213661	002	Feb 18, 2021	Feb	NFTG
AB		300MG	A213661	003	Feb 18, 2021	Feb	NFTG
AB	@ TEVA PHARMS USA INC	100MG	A213162	001	Feb 18, 2021	Aug	DISC
AB	@	100MG	A213162	001	Feb 18, 2021	Feb	NFTG
AB	@	200MG	A213162	002	Feb 18, 2021	Aug	DISC
AB	@	200MG	A213162	002	Feb 18, 2021	Feb	NFTG
AB	@	300MG	A213162	003	Feb 18, 2021	Aug	DISC
AB		300MG	A213162	003	Feb 18, 2021	Feb	NFTG
AB	TRIS PHARMA INC	100MG	A214543	001	May 05, 2021	Jun	CAHN
AB		200MG	A214543	002	May 05, 2021	Jun	CAHN
AB		300MG	A214543	003	May 05, 2021	Jun	CAHN
AB	ZYDUS PHARMS	100MG	A211818	001	Feb 18, 2021	Feb	NFTG
AB		200MG	A211818	002	Feb 18, 2021	Feb	NFTG
AB		300MG	A211818	003	Feb 18, 2021	Feb	NFTG
NORTHERA							
AB	+ LUNDBECK NA LTD	100MG	N203202	001	Feb 18, 2014	Feb	CFTG
AB	+	200MG	N203202	002	Feb 18, 2014	Feb	CFTG
AB	+!	300MG	N203202	003	Feb 18, 2014	Feb	CFTG

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL							
DRIZALMA SPRINKLE							
+	SUN PHARMA GLOBAL	EQ 20MG BASE	N212516	001	Jul 19, 2019	Apr	CDFR
+		EQ 30MG BASE	N212516	002	Jul 19, 2019	Apr	CDFR
+		EQ 40MG BASE	N212516	003	Jul 19, 2019	Apr	CDFR
+	!	EQ 60MG BASE	N212516	004	Jul 19, 2019	Apr	CDFR
DULOXETINE HYDROCHLORIDE							
AB	SUNSHINE	EQ 20MG BASE	A212328	001	Feb 11, 2021	Feb	NEWA
AB		EQ 30MG BASE	A212328	002	Feb 11, 2021	Feb	NEWA
AB		EQ 60MG BASE	A212328	003	Feb 11, 2021	Feb	NEWA

DUTASTERIDE

CAPSULE;ORAL							
AVODART							
AB	+! WOODWARD	0.5MG	N021319	001	Nov 20, 2001	Jul	CAHN
DUTASTERIDE							
	@ NOSTRUM LABS INC	0.5MG	A204705	001	Nov 20, 2015	Apr	CAHN

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL  
 JALYN  
 AB +! WOODWARD 0.5MG; 0.4MG N022460 001 Jun 14, 2010 Jul CAHN

DYDROGESTERONE

TABLET; ORAL  
 GYNOREST  
 + @ SOLVAY 5MG N017388 001 Sep CRLD  
 @ 5MG N017388 001 Jul CRLD  
 + @ 10MG N017388 002 Sep CRLD  
 @ 10MG N017388 002 Jul CRLD

ECHOTHIOPHATE IODIDE

FOR SOLUTION; OPHTHALMIC  
 PHOSPHOLINE IODIDE  
 @ FERA PHARMS LLC 0.03% N011963 002 Aug CAHN  
 @ 0.06% N011963 004 Aug CAHN  
 +! 0.125% N011963 001 Aug CAHN  
 @ 0.25% N011963 003 Aug CAHN

ECONAZOLE NITRATE

AEROSOL, FOAM; TOPICAL  
 ECOZA  
 +! RESILIA PHARMS 1% N205175 001 Oct 24, 2013 Feb CAHN

EDETATE CALCIUM DISODIUM

INJECTABLE; INJECTION  
 CALCIUM DISODIUM VERSENATE  
 +! BAUSCH 200MG/ML N008922 001 May CAHN  
 TABLET; ORAL  
 CALCIUM DISODIUM VERSENATE  
 @ BAUSCH 500MG N008922 002 May CAHN

EFAVIRENZ

TABLET; ORAL  
 EFAVIRENZ  
 >D> BX MYLAN 600MG A091471 001 Feb 17, 2016 Nov DISC  
 >A> @ 600MG A091471 001 Feb 17, 2016 Nov DISC  
 BX 600MG A091471 001 Feb 17, 2016 Sep CTEC  
 AB STRIDES PHARMA 600MG A078509 001 Jun 16, 2021 Jun NEWA

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL  
 EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE  
 AB MACLEODS PHARMS LTD 600MG; 200MG; 300MG A204287 001 Sep 13, 2021 Sep NEWA

EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL  
 EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE  
 + @ AUROBINDO PHARMA LTD 600MG; 300MG; 300MG N022343 001 Aug 15, 2018 Feb DISC

EFINACONAZOLE

SOLUTION; TOPICAL  
 EFINACONAZOLE  
 AB ACRUX DDS 10% A211969 001 Jun 21, 2021 Jun NEWA  
 @ AUROBINDO PHARMA LTD 10% A212066 001 Mar 29, 2021 Sep DISC  
 AB 10% A212066 001 Mar 29, 2021 Mar NEWA  
 AB TEVA PHARMS USA 10% A211827 001 Dec 16, 2020 Feb CTEC  
 JUBLIA  
 AB +! BAUSCH 10% N203567 001 Jun 06, 2014 Feb CTEC

ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR

TABLET; ORAL  
 TRIKAFTA (COPACKAGED)  
 + VERTEX PHARMS INC 50MG, 37.5MG, 25MG; 75MG N212273 002 Jun 08, 2021 Jun NEWA  
 +! 100MG, 75MG, 50MG; 150MG N212273 001 Oct 21, 2019 Jun CPOT

ELIGLUSTAT TARTRATECAPSULE;ORAL  
CERDELGA

AB	+!	GENZYME CORP	EQ 84MG BASE	N205494	001	Aug 19, 2014	Aug	CFTG
		ELIGLUSTAT TARTRATE						
AB		AIZANT	EQ 84MG BASE	A212463	001	Sep 08, 2021	Aug	NFTG
AB		APPCO	EQ 84MG BASE	A212463	001	Sep 08, 2021	Sep	CAHN

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

AB		HETERO LABS LTD III	200MG;300MG	A201806	001	Oct 07, 2021	Oct	NEWA
		EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE						
AB		APOTEX	200MG;300MG	A208740	001	Jun 16, 2021	Jun	NEWA
AB		CIPLA	200MG;300MG	A090958	001	Apr 02, 2021	Mar	NEWA
AB		LAURUS	200MG;300MG	A212114	001	Jul 26, 2019	Jan	CMFD
AB		LUPIN LTD	200MG;300MG	A204131	001	Jun 04, 2021	May	NEWA
AB		MACLEODS PHARMS LTD	200MG;300MG	A203442	001	May 15, 2020	Feb	CMFD
AB		MYLAN	200MG;300MG	A206436	001	Apr 09, 2018	Feb	CMFD
AB		STRIDES PHARMA	200MG;300MG	A091055	001	Jan 13, 2021	Jan	NEWA
AB		ZYDUS PHARMS	100MG;150MG	A212689	002	Jul 01, 2021	Jun	NEWA
AB			133MG;200MG	A212689	003	Jul 01, 2021	Jun	NEWA
AB			167MG;250MG	A212689	004	Jul 01, 2021	Jun	NEWA

ENALAPRIL MALEATE

SOLUTION;ORAL

ENALAPRIL MALEATE

AB		BIONPHARMA INC	1MG/ML	A212408	001	Aug 10, 2021	Jul	NFTG
		EPANED						
AB	+!	AZURITY	1MG/ML	N208686	001	Sep 20, 2016	Jul	CFTG

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

>A>	@	CHARTWELL RX	5MG;12.5MG	A076116	001	Sep 19, 2001	Nov	CAHN
>A>	@		10MG;25MG	A076116	002	Sep 19, 2001	Nov	CAHN
>D>	@	UPSHER SMITH LABS	5MG;12.5MG	A076116	001	Sep 19, 2001	Nov	CAHN
>D>	@		10MG;25MG	A076116	002	Sep 19, 2001	Nov	CAHN

ENTECAVIR

TABLET;ORAL

ENTECAVIR

>A>	AB	YUNG SHIN PHARM	0.5MG	A208195	001	Nov 10, 2021	Nov	NEWA
>A>	AB		1MG	A208195	002	Nov 10, 2021	Nov	NEWA

ENZALUTAMIDE

CAPSULE;ORAL

ENZALUTAMIDE

AB		ACTAVIS LABS FL INC	40MG	A209614	001	May 14, 2021	May	NFTG
		XTANDI						
AB	+!	ASTELLAS	40MG	N203415	001	Aug 31, 2012	May	CFTG

EPHEDRINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

REZIPRES

+!	ETON	23.5MG/5ML (4.7MG/ML)	N213536	001	Jun 14, 2021	Jun	CAHN
+	@	47MG/ML (47MG/ML)	N213536	002	Jun 14, 2021	Jun	DISC
+!		47MG/ML (47MG/ML)	N213536	002	Jun 14, 2021	Jun	CAHN
+	@	47MG/5ML (9.4MG/ML)	N213536	003	Jun 14, 2021	Jun	DISC
+!		47MG/5ML (9.4MG/ML)	N213536	003	Jun 14, 2021	Jun	CAHN
+!	SINETTICA SA	23.5MG/5ML (4.7MG/ML)	N213536	001	Jun 14, 2021	Jun	NEWA
+!		47MG/ML (47MG/ML)	N213536	002	Jun 14, 2021	Jun	NEWA
+!		47MG/5ML (9.4MG/ML)	N213536	003	Jun 14, 2021	Jun	NEWA

EPHEDRINE SULFATE

SOLUTION;INTRAVENOUS

AKOVAZ

+!	EXELA PHARMA	25MG/5ML (5MG/ML)	N208289	002	Aug 02, 2021	Aug	NEWA
----	--------------	-------------------	---------	-----	--------------	-----	------

EPINEPHRINE

SOLUTION;INTRAVENOUS

>A>	EPINEPHRINE							
>A>	+!	HOSPIRA INC	1MG/10ML (0.1MG/ML)	N209359	001	Nov 05, 2019	Nov	CTNA
>D>	EPINEPHRINE (COPACKAGED)							
>D>	+!	HOSPIRA INC	1MG/10ML (0.1MG/ML)	N209359	001	Nov 05, 2019	Nov	CTNA

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

AP	B BRAUN MEDICAL INC	0.005MG/ML;1.5%		A208475	001	Sep 08, 2021	Aug	NEWA
----	---------------------	-----------------	--	---------	-----	--------------	-----	------

EPLERENONE

TABLET;ORAL

EPLERENONE

AB	CHARTWELL RX	25MG		A078482	001	Jul 30, 2008	Apr	CAHN
AB		50MG		A078482	002	Jul 30, 2008	Apr	CAHN
	@ PIRAMAL HLTHCARE UK	25MG		A212765	001	Aug 10, 2020	Feb	DISC
	@	50MG		A212765	002	Aug 10, 2020	Feb	DISC
AB	REGCON SOLUTIONS	25MG		A207842	001	Oct 25, 2021	Oct	NEWA
AB		50MG		A207842	002	Oct 25, 2021	Oct	NEWA
AB	WESTMINSTER PHARMS	25MG		A207842	001	Oct 25, 2021	Oct	CAHN
AB		50MG		A207842	002	Oct 25, 2021	Oct	CAHN
	INSPIRA							
AB	+ UPJOHN	25MG		N021437	001	Sep 27, 2002	Apr	CAHN
AB	+!	50MG		N021437	002	Sep 27, 2002	Apr	CAHN
	@	100MG		N021437	003	Sep 27, 2002	Apr	CAHN

EPOPROSTENOL SODIUM

INJECTABLE;INJECTION

EPOPROSTENOL SODIUM

AP2	SUN PHARM	EQ 0.5MG BASE/VIAL		A210473	001	Jan 15, 2021	Feb	CTEC
AP		EQ 0.5MG BASE/VIAL		A210473	001	Jan 15, 2021	Jan	NFTG
AP2		EQ 1.5MG BASE/VIAL		A210473	002	Jan 15, 2021	Feb	CTEC
AP		EQ 1.5MG BASE/VIAL		A210473	002	Jan 15, 2021	Jan	NFTG
AP1	TEVA PHARMS USA	EQ 0.5MG BASE/VIAL		A078396	001	Apr 23, 2008	Feb	CTEC
AP1		EQ 1.5MG BASE/VIAL		A078396	002	Apr 23, 2008	Feb	CTEC
	FLOLAN							
AP1	+! GLAXOSMITHKLINE LLC	EQ 0.5MG BASE/VIAL		N020444	001	Sep 20, 1995	Feb	CTEC
AP1	+!	EQ 1.5MG BASE/VIAL		N020444	002	Sep 20, 1995	Feb	CTEC
	VELETRI							
AP2	+! ACTELION	EQ 0.5MG BASE/VIAL		N022260	002	Jun 28, 2012	Feb	CAHN
AP2	+!	EQ 1.5MG BASE/VIAL		N022260	001	Jun 27, 2008	Feb	CAHN
AP2	+! ACTELION PHARMS LTD	EQ 0.5MG BASE/VIAL		N022260	002	Jun 28, 2012	Feb	CHRS
AP2	+	EQ 0.5MG BASE/VIAL		N022260	002	Jun 28, 2012	Feb	CTEC
AP	+	EQ 0.5MG BASE/VIAL		N022260	002	Jun 28, 2012	Jan	CFTG
AP2	+!	EQ 1.5MG BASE/VIAL		N022260	001	Jun 27, 2008	Feb	CTEC
AP	+!	EQ 1.5MG BASE/VIAL		N022260	001	Jun 27, 2008	Jan	CFTG

EPTIFIBATIDE

INJECTABLE;INJECTION

EPTIFIBATIDE

AP	! MYLAN LABS LTD	2MG/ML		A203258	001	Jul 20, 2018	Apr	CHRS
AP	!	75MG/100ML		A203258	002	Jul 20, 2018	Apr	CHRS
AP	SHUANGCHENG	2MG/ML		A213081	001	Sep 07, 2021	Aug	NEWA
	INTEGRILIN							
	+ @ SCHERING	2MG/ML		N020718	001	May 18, 1998	Apr	DISC
	+ @	75MG/100ML		N020718	002	May 18, 1998	Apr	DISC

ERGOCALCIFEROL

CAPSULE;ORAL

DRISDOL

AA	+!	VALIDUS PHARMS	50,000 IU	N003444	001		Feb	CAHN
	ERGOCALCIFEROL							
>D>	AA	SIGMAPHARM LABS LLC	50,000 IU	A091004	001	Jul 14, 2010	Nov	DISC
>A>	@		50,000 IU	A091004	001	Jul 14, 2010	Nov	DISC

ERLOTINIB HYDROCHLORIDE

TABLET;ORAL

ERLOTINIB HYDROCHLORIDE

AB	ALEMBIC PHARMS LTD	EQ 25MG BASE	A214719	001	Jul 08, 2021	Jul	NEWA
AB		EQ 100MG BASE	A214719	002	Jul 08, 2021	Jul	NEWA
AB		EQ 150MG BASE	A214719	003	Jul 08, 2021	Jul	NEWA
AB	MSN	EQ 25MG BASE	A214366	001	May 10, 2021	Apr	NEWA
AB		EQ 100MG BASE	A214366	002	May 10, 2021	Apr	NEWA
AB		EQ 150MG BASE	A214366	003	May 10, 2021	Apr	NEWA

ERTAPENEM SODIUM

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

ERTAPENEM SODIUM

AP	EUGIA PHARMA	EQ 1GM BASE/VIAL	A209133	001	Jun 25, 2018	Aug	CAHN
AP	GLAND PHARMA LTD	EQ 1GM BASE/VIAL	A212040	001	Mar 26, 2021	Mar	NEWA

ERYTHROMYCIN

SOLUTION;TOPICAL

ERYTHRA-DERM

AT	SAPTALIS PHARMS	2%	A062687	001	Feb 05, 1988	Apr	CMFD
----	-----------------	----	---------	-----	--------------	-----	------

TABLET;ORAL

ERYTHROMYCIN

BX	AMNEAL PHARMS CO	250MG	A209720	001	Mar 09, 2018	Sep	CTEC
BX		500MG	A209720	002	Mar 09, 2018	Sep	CTEC
AB	CADILA PHARMS LTD	250MG	A213628	001	Jun 28, 2021	Sep	CAHN
AB		500MG	A213628	002	Jun 28, 2021	Sep	CAHN
AB	ORANGE	250MG	A213628	001	Jun 28, 2021	Jun	NEWA
AB		500MG	A213628	002	Jun 28, 2021	Jun	NEWA
AB	TEVA PHARMS USA INC	250MG	A214549	001	Feb 11, 2021	Feb	NEWA
AB		500MG	A214549	002	Feb 11, 2021	Feb	NEWA

TABLET, DELAYED RELEASE;ORAL

ERYTHROMYCIN

AB	TORRENT	250MG	A211975	001	Jul 26, 2021	Jul	NEWA
AB		500MG	A211975	002	Jul 26, 2021	Jul	NEWA

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE;ORAL

ERYTHROMYCIN ETHYLSUCCINATE

@ PAR PHARM INC

EQ 200MG BASE/5ML

A211991 001 Oct 23, 2019 May DISC

@

EQ 400MG BASE/5ML

A211991 002 Oct 23, 2019 May DISC

ESLICARBAZEPINE ACETATE

TABLET;ORAL

APTOM

AB	+ SUNOVION PHARMS INC	200MG	N022416	001	Nov 08, 2013	Jun	CFTG
AB	+	400MG	N022416	002	Nov 08, 2013	Jun	CFTG
AB	+	600MG	N022416	003	Nov 08, 2013	Jun	CFTG
AB	+!	800MG	N022416	004	Nov 08, 2013	Jun	CFTG

ESLICARBAZEPINE ACETATE

AB	DR REDDYS LABS LTD	200MG	A211238	001	Jun 29, 2021	Jun	NFTG
AB		400MG	A211238	002	Jun 29, 2021	Jun	NFTG
AB		600MG	A211238	003	Jun 29, 2021	Jun	NFTG
AB		800MG	A211238	004	Jun 29, 2021	Jun	NFTG

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL

ESOMEPRAZOLE MAGNESIUM

@ AMTA

EQ 20MG BASE

A213859 001 Nov 18, 2020 May DISC

@

EQ 40MG BASE

A213859 002 Nov 18, 2020 May DISC

AB	ETHYPHARM	EQ 20MG BASE	A090841	001	Mar 31, 2021	Mar	NEWA
AB		EQ 40MG BASE	A090841	002	Mar 31, 2021	Mar	NEWA
AB	GRAVITI PHARMS	EQ 20MG BASE	A213486	001	Mar 19, 2021	Mar	NEWA
AB		EQ 40MG BASE	A213486	002	Mar 19, 2021	Mar	NEWA
AB	INDCHEMIE HEALTH	EQ 40MG BASE	A210559	002	Feb 26, 2021	Feb	NEWA

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE;ORAL

NAPROXEN AND ESOMEPRAZOLE MAGNESIUM

AB	MYLAN	EQ 20MG BASE;375MG	A204920	001	Jul 20, 2021	Jul	NEWA
AB		EQ 20MG BASE;500MG	A204920	002	Jul 20, 2021	Jul	NEWA

<u>ESTRADIOL</u>									
CREAM;VAGINAL									
ESTRACE									
AB	+	ALLERGAN	0.01%	A086069	001	Jan 31, 1984	Aug	CRLD	
ESTRADIOL									
AB		ALVOGEN	0.01%	A209767	001	Mar 05, 2018	Aug	CAHN	
AB		PRASCO LABS LLC	0.01%	A212313	001	Jul 15, 2021	Jul	NEWA	
FILM, EXTENDED RELEASE;TRANSDERMAL									
ALORA									
	@	ALLERGAN	0.025MG/24HR	N020655	004	Apr 05, 2002	Jul	DISC	
	@		0.05MG/24HR	N020655	001	Dec 20, 1996	Jul	DISC	
	@		0.075MG/24HR	N020655	002	Dec 20, 1996	Jul	DISC	
	@		0.1MG/24HR	N020655	003	Dec 20, 1996	Jul	DISC	
INSERT, EXTENDED RELEASE;VAGINAL									
ESTRING									
	+	PFIZER	0.0075MG/24HR	N020472	001	Apr 26, 1996	Jan	CAHN	
SYSTEM;TRANSDERMAL									
ESTRADIOL									
BX		AMNEAL	0.025MG/24HR	A211293	001	Feb 04, 2019	Sep	CTEC	
BX			0.0375MG/24HR	A211293	002	Feb 04, 2019	Sep	CTEC	
BX			0.05MG/24HR	A211293	003	Feb 04, 2019	Sep	CTEC	
BX			0.075MG/24HR	A211293	004	Feb 04, 2019	Sep	CTEC	
BX			0.1MG/24HR	A211293	005	Feb 04, 2019	Sep	CTEC	
TABLET;ORAL									
ESTRACE									
	+	@	BRISTOL MYERS SQUIBB	1MG	A084499	001		Aug	CRLD
	+	@		2MG	A084500	001		Aug	CRLD
ESTRADIOL									
	@	MYLAN	0.5MG	A040326	001	Apr 21, 1999	Oct	DISC	
AB			0.5MG	A040326	001	Apr 21, 1999	Oct	CAHN	
	@		1MG	A040326	002	Apr 21, 1999	Oct	DISC	
AB			1MG	A040326	002	Apr 21, 1999	Oct	CAHN	
	@		2MG	A040326	003	Apr 21, 1999	Oct	DISC	
AB			2MG	A040326	003	Apr 21, 1999	Oct	CAHN	
<u>ESTRADIOL CYPIONATE</u>									
INJECTABLE;INJECTION									
DEPO-ESTRADIOL									
	@	PFIZER	1MG/ML	A085470	001		Mar	CAHN	
	@		3MG/ML	A085470	002		Mar	CAHN	
	!		5MG/ML	A085470	003		Mar	CAHN	
<u>ESTRADIOL; NORETHINDRONE ACETATE</u>									
TABLET;ORAL									
AMABELZ									
BX		LUPIN LTD	0.5MG;0.1MG	A203339	001	Jun 20, 2016	Sep	CTEC	
BX			1MG;0.5MG	A203339	002	Jun 20, 2016	Sep	CTEC	
<u>ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX</u>									
TABLET;ORAL									
MYFEMBREE									
	+	!	MYOVANT SCIENCES	1MG;0.5MG;40MG	N214846	001	May 26, 2021	May	NEWA
<u>ESTROPIPATE</u>									
TABLET;ORAL									
OGEN .625									
	+	@	PFIZER	0.75MG	A083220	001		Aug	CRLD
	@			0.75MG	A083220	001		Jan	CAHN
OGEN 1.25									
	+	@	PFIZER	1.5MG	A083220	002		Aug	CRLD
	@			1.5MG	A083220	002		Jan	CAHN
OGEN 2.5									
	+	@	PFIZER	3MG	A083220	003		Aug	CRLD
	@			3MG	A083220	003		Jan	CAHN
OGEN 5									
	+		PFIZER	6MG	A083220	004		Aug	CRLD
				6MG	A083220	004		Jan	CAHN

ESZOPICLONE

TABLET;ORAL

ESZOPICLONE

	@ NOSTRUM LABS INC	1MG	A203087	001	May 08, 2019	Jan	CAHN
	@	2MG	A203087	002	May 08, 2019	Jan	CAHN
	@	3MG	A203087	003	May 08, 2019	Jan	CAHN

ETHACRYNIC ACID

TABLET;ORAL

ETHACRYNIC ACID

AB	ALVOGEN	25MG	A205709	001	Jul 24, 2018	Jun	CAHN
----	---------	------	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; ETONOGESTREL

RING;VAGINAL

ETHINYL ESTRADIOL; ETONOGESTREL

AB	TEVA PHARMS USA INC	0.015MG/24HR;0.12MG/24HR	A204305	001	Jan 13, 2021	Jan	NEWA
----	---------------------	--------------------------	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL

SYLEVIA

	@ SUN PHARM	0.03MG;0.15MG	A202988	001	Feb 06, 2019	Aug	DISC
--	-------------	---------------	---------	-----	--------------	-----	------

TABLET;ORAL-28

CERINTA

	@ SUN PHARM	0.02MG;0.1MG	A202817	001	Jan 07, 2019	Aug	DISC
--	-------------	--------------	---------	-----	--------------	-----	------

LEVONORGESTREL AND ETHINYL ESTRADIOL

BX	LUPIN LTD	0.02MG;0.1MG	A091425	001	Jan 18, 2013	Sep	CTEC
----	-----------	--------------	---------	-----	--------------	-----	------

BX		0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A200248	001	Nov 19, 2015	Sep	CTEC
----	--	---	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE;TRANSDERMAL

ETHINYL ESTRADIOL AND NORELGESTROMIN

BX	AMNEAL	0.035MG/24HR;0.15MG/24HR	A213950	001	Feb 25, 2021	Sep	CTEC
----	--------	--------------------------	---------	-----	--------------	-----	------

AB		0.035MG/24HR;0.15MG/24HR	A213950	001	Feb 25, 2021	Feb	NEWA
----	--	--------------------------	---------	-----	--------------	-----	------

ONSURA

AB	TEVA PHARMS USA	0.035MG/24HR;0.15MG/24HR	A213977	001	Aug 25, 2021	Aug	NEWA
----	-----------------	--------------------------	---------	-----	--------------	-----	------

XULANE

AB	! MYLAN TECHNOLOGIES	0.035MG/24HR;0.15MG/24HR	A200910	001	Apr 16, 2014	Feb	CTEC
----	----------------------	--------------------------	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-21

NORINYL 1+35 21-DAY

	@ ALLERGAN	0.035MG;1MG	N017565	001		Jul	DISC
--	------------	-------------	---------	-----	--	-----	------

TABLET;ORAL-28

CYCLAFEM 1/35

	@ VINTAGE PHARMS LLC	0.035MG;1MG	A076337	001	Nov 12, 2010	Aug	DISC
--	----------------------	-------------	---------	-----	--------------	-----	------

CYCLAFEM 7/7/7

	@ VINTAGE PHARMS LLC	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A076338	001	Nov 16, 2010	Aug	DISC
--	----------------------	--	---------	-----	--------------	-----	------

NORINYL 1+35 28-DAY

	@ ALLERGAN	0.035MG;1MG	N017565	002		Jul	DISC
--	------------	-------------	---------	-----	--	-----	------

PIRMELLA 1/35

BX	LUPIN LTD	0.035MG;1MG	A201512	001	Apr 24, 2013	Sep	CTEC
----	-----------	-------------	---------	-----	--------------	-----	------

PIRMELLA 7/7/7

BX	LUPIN LTD	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A201510	001	Apr 24, 2013	Sep	CTEC
----	-----------	--	---------	-----	--------------	-----	------

TABLET, CHEWABLE;ORAL

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

BX	LUPIN LTD	0.035MG;0.4MG	A091332	001	Mar 23, 2016	Sep	CTEC
----	-----------	---------------	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

CAPSULE;ORAL

GEMMILY

AB	XIROMED	0.02MG;1MG	A213317	001	Nov 09, 2020	Mar	CAHN
----	---------	------------	---------	-----	--------------	-----	------

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB	AMNEAL PHARMS	0.02MG;1MG	A214292	001	Jul 20, 2021	Jul	NEWA
----	---------------	------------	---------	-----	--------------	-----	------

TABLET;ORAL

FEMHRT

+	@ APIL	0.0025MG;0.5MG	N021065	001	Jan 14, 2005	Sep	CRLD
---	--------	----------------	---------	-----	--------------	-----	------

	@	0.0025MG;0.5MG	N021065	001	Jan 14, 2005	Sep	DISC
--	---	----------------	---------	-----	--------------	-----	------

TABLET;ORAL

	LOESTRIN 24 FE							
	+ @ TEVA BRANDED PHARM	0.02MG;1MG	N021871	001	Feb 17, 2006	Sep	DISC	
	TABLET;ORAL-21							
	GILDESS 1/20							
	@ VINTAGE PHARMS LLC	0.02MG;1MG	A077077	002	Jul 24, 2012	Jul	DISC	
	TABLET;ORAL-28							
	BLISOVI FE 1.5/30							
BX	LUPIN LTD	0.03MG;1.5MG	A201585	001	Nov 18, 2015	Sep	CTEC	
	CHABELINA FE							
AB	! NOVAST LABS	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	A202962	001	Apr 15, 2020	Sep	CHRS	
	ESTROSTEP FE							
	+ @ APIL	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N020130	002	Oct 09, 1996	Sep	DISC	
	GILDESS FE 1/20							
	@ VINTAGE PHARMS LLC	0.02MG;1MG	A077077	001	May 20, 2005	Jul	DISC	

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-28

NORGESTIMATE AND ETHINYL ESTRADIOL

	@ MYLAN	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A201897	001	Jan 27, 2016	Oct	CAHN	
	@	0.035MG;0.25MG	A201896	001	Jan 27, 2016	Oct	CAHN	
	@ MYLAN LABS LTD	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A201897	001	Jan 27, 2016	Oct	DISC	
	@	0.035MG;0.25MG	A201896	001	Jan 27, 2016	Oct	DISC	

ETHOSUXIMIDE

CAPSULE;ORAL

ETHOSUXIMIDE

BX	HERITAGE PHARMS INC	250MG	A200892	001	Sep 25, 2012	Sep	CTEC	
BX	PURACAP PHARM LLC	250MG	A210654	001	Mar 16, 2020	Sep	CTEC	
	SYRUP;ORAL							
	ZARONTIN							
AA	+! PARKE-DAVIS	250MG/5ML	A080258	001		Aug	CRLD	

ETODOLAC

TABLET;ORAL

ETODOLAC

AB	BAYSHORE PHARMS LLC	400MG	A210704	001	Dec 16, 2020	Aug	CMFD	
	@	400MG	A210704	001	Dec 16, 2020	Jul	DISC	
AB		500MG	A210704	002	Dec 16, 2020	Aug	CMFD	
	@	500MG	A210704	002	Dec 16, 2020	Jul	DISC	

ETOMIDATE

INJECTABLE;INJECTION

ETOMIDATE

AP	CAPLIN	2MG/ML	A215028	001	Dec 18, 2020	Jul	CMFD	
	@	2MG/ML	A215028	001	Dec 18, 2020	Jun	DISC	

ETOPOSIDE

CAPSULE;ORAL

VEPESID

>D>	+ @ DAVA PHARMS INC	50MG	N019557	001	Dec 30, 1986	Nov	CAHN	
>D>	+ @	100MG	N019557	002	Dec 30, 1986	Nov	CAHN	
>A>	+ @ STRIDES PHARMA	50MG	N019557	001	Dec 30, 1986	Nov	CAHN	
>A>	+ @	100MG	N019557	002	Dec 30, 1986	Nov	CAHN	

ETRAVIRINE

TABLET;ORAL

ETRAVIRINE

	@ AMNEAL	25MG	A214196	001	Jun 14, 2021	Jul	DISC	
AB		25MG	A214196	001	Jun 14, 2021	Jun	NFTG	
AB		100MG	A214196	002	Jun 14, 2021	Jun	NFTG	
AB		200MG	A214196	003	Jun 14, 2021	Jun	NFTG	
	INTELENCE							
	+ JANSSEN R AND D	25MG	N022187	003	Mar 26, 2012	Jul	CTEC	
AB	+	25MG	N022187	003	Mar 26, 2012	Jun	CFTG	
AB	+	100MG	N022187	001	Jan 18, 2008	Jun	CFTG	
AB	+!	200MG	N022187	002	Dec 22, 2010	Jun	CFTG	



EVEROLIMUS

TABLET;ORAL

AFINITOR

AB	+	NOVARTIS	10MG	N022334	002	Mar 30, 2009	Feb CTEC
		EVEROLIMUS					
>A>	AB	ALKEM LABS LTD	0.25MG	A214138	001	Nov 26, 2021	Nov NEWA
>A>	AB		0.5MG	A214138	002	Nov 26, 2021	Nov NEWA
>A>	AB		0.75MG	A214138	003	Nov 26, 2021	Nov NEWA
>A>	AB		1MG	A214138	004	Nov 26, 2021	Nov NEWA
AB		BIOCON PHARMA	2.5MG	A214182	001	Feb 11, 2021	Aug CMFD
		@	2.5MG	A214182	001	Feb 11, 2021	Feb DISC
AB			2.5MG	A214182	001	Feb 11, 2021	Feb NEWA
AB			5MG	A214182	002	Feb 11, 2021	Aug CMFD
		@	5MG	A214182	002	Feb 11, 2021	Feb DISC
AB			5MG	A214182	002	Feb 11, 2021	Feb NEWA
AB			7.5MG	A214182	003	Feb 11, 2021	Aug CMFD
		@	7.5MG	A214182	003	Feb 11, 2021	Feb DISC
AB			7.5MG	A214182	003	Feb 11, 2021	Feb NEWA
AB			10MG	A214182	004	Feb 11, 2021	Aug CMFD
		@	10MG	A214182	004	Feb 11, 2021	Feb DISC
AB			10MG	A214182	004	Feb 11, 2021	Feb NEWA
AB		BRECKENRIDGE	0.25MG	A205432	001	May 20, 2021	May NEWA
AB			0.5MG	A205432	002	May 20, 2021	May NEWA
AB			0.75MG	A205432	003	May 20, 2021	May NEWA
AB			2.5MG	A205426	001	Mar 05, 2021	Feb NEWA
AB			5MG	A205426	002	Mar 05, 2021	Feb NEWA
AB			7.5MG	A205426	003	Mar 05, 2021	Feb NEWA
AB			10MG	A205426	004	Mar 05, 2021	Feb NEWA
>A>	AB	HIKMA	1MG	A206133	004	Nov 18, 2021	Nov NEWA
>A>	AB		10MG	A207486	004	Nov 23, 2021	Nov NEWA
AB		MYLAN	10MG	A212936	004	Jun 08, 2020	Aug CMFD
AB		PAR PHARM	0.25MG	A205775	001	Oct 18, 2021	Oct NEWA
AB			0.5MG	A205775	002	Oct 18, 2021	Oct NEWA
AB			0.75MG	A205775	003	Oct 18, 2021	Oct NEWA
AB			1MG	A205775	004	Oct 18, 2021	Oct NFTG
		ZORTRESS					
AB	+	NOVARTIS	1MG	N021560	004	Aug 10, 2018	Oct CFTG
		TABLET, FOR SUSPENSION;ORAL					
		AFINITOR DISPERZ					
AB	+	NOVARTIS PHARM	2MG	N203985	001	Aug 29, 2012	Aug CTEC
AB	+		3MG	N203985	002	Aug 29, 2012	Aug CTEC
AB	+		5MG	N203985	003	Aug 29, 2012	Aug CTEC
		EVEROLIMUS					
AB		MYLAN	2MG	A210130	001	Apr 19, 2019	Aug CMFD
AB			3MG	A210130	002	Apr 19, 2019	Aug CMFD
AB			5MG	A210130	003	Apr 19, 2019	Aug CMFD

EXEMESTANE

TABLET;ORAL

AROMASIN

AB	+	PFIZER	25MG	N020753	001	Oct 21, 1999	Mar CAHN
----	---	--------	------	---------	-----	--------------	----------

EXENATIDE SYNTHETIC

FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

BYDUREON

+	@	ASTRAZENECA AB	2MG/VIAL	N022200	001	Jan 27, 2012	Feb DISC
---	---	----------------	----------	---------	-----	--------------	----------

BYDUREON PEN

+	@	ASTRAZENECA AB	2MG	N022200	002	Feb 28, 2014	Feb DISC
---	---	----------------	-----	---------	-----	--------------	----------

SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

BYDUREON BCISE

+	!	ASTRAZENECA AB	2MG/0.85ML (2MG/0.85ML)	N209210	001	Oct 20, 2017	Aug CAIN
---	---	----------------	-------------------------	---------	-----	--------------	----------

EZETIMIBE

TABLET;ORAL

ZETIA

AB	+	ORGANON	10MG	N021445	001	Oct 25, 2002	Feb CAHN
----	---	---------	------	---------	-----	--------------	----------

EZETIMIBE; ROSUVASTATIN CALCIUM

TABLET; ORAL

ROSZET

+	ALThERA PHARMS	10MG;EQ 5MG BASE	N213072	001	Mar 23, 2021	Mar	NEWA
+		10MG;EQ 5MG BASE	N213072	001	Mar 23, 2021	Mar	NEWA
+		10MG;EQ 10MG BASE	N213072	002	Mar 23, 2021	Mar	NEWA
+		10MG;EQ 10MG BASE	N213072	002	Mar 23, 2021	Mar	NEWA
+		10MG;EQ 20MG BASE	N213072	003	Mar 23, 2021	Mar	NEWA
+		10MG;EQ 20MG BASE	N213072	003	Mar 23, 2021	Mar	NEWA
+		10MG;EQ 40MG BASE	N213072	004	Mar 23, 2021	Mar	NEWA
+		10MG;EQ 40MG BASE	N213072	004	Mar 23, 2021	Mar	NEWA

EZETIMIBE; SIMVASTATIN

TABLET; ORAL

EZETIMIBE AND SIMVASTATIN

	@ ANI PHARMS	10MG;10MG	A201890	001	Apr 26, 2017	Jul	DISC
	@	10MG;20MG	A201890	002	Apr 26, 2017	Jul	DISC
	@	10MG;40MG	A201890	003	Apr 26, 2017	Jul	DISC
	@	10MG;80MG	A201890	004	Apr 26, 2017	Jul	DISC
	VYTORIN						
AB	+ ORGANON	10MG;10MG	N021687	001	Jul 23, 2004	Feb	CAHN
AB	+	10MG;20MG	N021687	002	Jul 23, 2004	Feb	CAHN
AB	+	10MG;40MG	N021687	003	Jul 23, 2004	Feb	CAHN
AB	+	10MG;80MG	N021687	004	Jul 23, 2004	Feb	CAHN

FAMOTIDINE

FOR SUSPENSION; ORAL

FAMOTIDINE

AB	AKORN	40MG/5ML	A201995	001	May 30, 2014	Feb	CAHN
AB	NOVITIUM PHARMA	40MG/5ML	A215043	001	Apr 20, 2021	Apr	NEWA

TABLET; ORAL

FAMOTIDINE

AB	ANNORA PHARMA	20MG	A215767	001	Nov 04, 2021	Oct	NEWA
AB		40MG	A215767	002	Nov 04, 2021	Oct	NEWA
AB	ASCENT PHARMS INC	20MG	A215689	001	Oct 15, 2021	Oct	NEWA
AB		40MG	A215689	002	Oct 15, 2021	Oct	NEWA
>A>	@ MANKIND PHARMA	20MG	A075302	001	Apr 16, 2001	Nov	CAHN
>A>	@	40MG	A075302	002	Apr 16, 2001	Nov	CAHN
>D>	@ PLD ACQUISITIONS	20MG	A075302	001	Apr 16, 2001	Nov	CAHN
>D>	@	40MG	A075302	002	Apr 16, 2001	Nov	CAHN
	PEPCID						
+	@ BAUSCH	20MG	N019462	001	Oct 15, 1986	Oct	CAHN
+	@	40MG	N019462	002	Oct 15, 1986	Oct	CAHN

FAMOTIDINE; IBUPROFEN

TABLET; ORAL

DUEXIS

AB	+	HORIZON	26.6MG;800MG	N022519	001	Apr 23, 2011	Jul	CFTG
		IBUPROFEN AND FAMOTIDINE						
AB		ALKEM LABS LTD	26.6MG;800MG	A211890	001	Aug 03, 2021	Jul	NFTG
AB		TEVA PHARMS USA	26.6MG;800MG	A211278	001	Oct 29, 2021	Oct	NEWA

FEBUXOSTAT

TABLET; ORAL

FEBUXOSTAT

>A>	AB	ALKEM LABS LTD	40MG	A212924	001	Dec 07, 2021	Nov	NEWA
>A>	AB		80MG	A212924	002	Dec 07, 2021	Nov	NEWA

FELBAMATE

SUSPENSION; ORAL

FELBAMATE

AB		NOVITIUM PHARMA	600MG/5ML	A211333	001	May 31, 2019	Sep	CAHN
----	--	-----------------	-----------	---------	-----	--------------	-----	------

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

FELODIPINE

	@ JUBILANT GENERICS	2.5MG	A203983	001	Aug 19, 2016	Jun	DISC
	@	5MG	A203983	002	Aug 19, 2016	Jun	DISC
	@	10MG	A203983	003	Aug 19, 2016	Jun	DISC

FENOFIBRATE

CAPSULE;ORAL

FENOFIBRATE (MICRONIZED)

AB	AUROBINDO PHARMA LTD	67MG	A212232	001	Sep 20, 2021	Sep	NEWA
AB		134MG	A212232	002	Sep 20, 2021	Sep	NEWA
AB		200MG	A212232	003	Sep 20, 2021	Sep	NEWA
>D>	AUSTARPHARMA	67MG	A207805	001	Nov 16, 2017	Nov	CAHN
>D>		134MG	A207805	002	Nov 16, 2017	Nov	CAHN
>D>		200MG	A207805	003	Nov 16, 2017	Nov	CAHN
>A>	@ MYLAN	67MG	A202676	001	Oct 23, 2012	Nov	DISC
>A>	@	134MG	A202676	002	Oct 23, 2012	Nov	DISC
>A>	@	200MG	A202676	003	Oct 23, 2012	Nov	DISC
>D>	MYLAN PHARMS INC	67MG	A202676	001	Oct 23, 2012	Nov	DISC
>D>		134MG	A202676	002	Oct 23, 2012	Nov	DISC
>D>		200MG	A202676	003	Oct 23, 2012	Nov	DISC
>A>	REYOUNG	67MG	A207805	001	Nov 16, 2017	Nov	CAHN
>A>		134MG	A207805	002	Nov 16, 2017	Nov	CAHN
>A>		200MG	A207805	003	Nov 16, 2017	Nov	CAHN

TABLET;ORAL

FENOFIBRATE

AB	ADAPTIS	54MG	A210606	001	Aug 17, 2018	Aug	CAHN
AB		160MG	A210606	002	Aug 17, 2018	Aug	CAHN
AB	AUSTARPHARMA	48MG	A208476	001	Feb 10, 2021	Jan	NEWA
AB		145MG	A208476	002	Feb 10, 2021	Jan	NEWA

FENOPROFEN CALCIUM

CAPSULE;ORAL

FENOPROFEN CALCIUM

	@ RISING	EQ 200MG BASE	A072394	001	Oct 17, 1988	Jan	CAHN
	@	EQ 300MG BASE	A072395	001	Oct 17, 1988	Jan	CAHN

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL

DURAGESIC-100

+	@ JANSSEN PHARMS	100MCG/HR	N019813	001	Aug 07, 1990	Oct	DISC
	DURAGESIC-12						
+	@ JANSSEN PHARMS	12.5MCG/HR	N019813	005	Feb 04, 2005	Oct	DISC
	DURAGESIC-25						
+	@ JANSSEN PHARMS	25MCG/HR	N019813	004	Aug 07, 1990	Oct	DISC
	DURAGESIC-37						
+	@ JANSSEN PHARMS	37.5MCG/HR	N019813	006	Jan 24, 2018	Oct	DISC
	DURAGESIC-50						
+	@ JANSSEN PHARMS	50MCG/HR	N019813	003	Aug 07, 1990	Oct	DISC
	DURAGESIC-75						
+	@ JANSSEN PHARMS	75MCG/HR	N019813	002	Aug 07, 1990	Oct	DISC
	FENTANYL-25						
AB	! SPECGX LLC	25MCG/HR	A077154	001	Feb 09, 2011	Oct	CHRS

FENTANYL CITRATE

INJECTABLE;INJECTION

FENTANYL CITRATE

AP	FRESENIUS KABI USA	EQ 0.05MG BASE/ML	A212086	001	Sep 01, 2020	Jun	CMFD
	@	EQ 0.05MG BASE/ML	A212086	001	Sep 01, 2020	Mar	DISC

SPRAY, METERED;NASAL

LAZANDA

+	BTCP PHARMA	EQ 0.1MG BASE	N022569	001	Jun 30, 2011	Oct	CMFD
+	@	EQ 0.1MG BASE	N022569	001	Jun 30, 2011	Sep	DISC
+	!	EQ 0.4MG BASE	N022569	002	Jun 30, 2011	Oct	CMFD
+	@	EQ 0.4MG BASE	N022569	002	Jun 30, 2011	Sep	DISC

FERRIC CARBOXYMALTOS

SOLUTION;INTRAVENOUS

INJECTAFER

+	AM REGENT	1GM IRON/20ML (50MG IRON/ML)	N203565	003	Apr 28, 2021	May	NEWA
---	-----------	------------------------------	---------	-----	--------------	-----	------

FERRIC MALTOL

CAPSULE;ORAL

ACCRUFER

+	SHIELD TX	30MG IRON	N212320	001	Jul 25, 2019	Apr	CMFD
---	-----------	-----------	---------	-----	--------------	-----	------

FERRIC OXYHYDROXIDE

INJECTABLE; INJECTION									
DEXFERRUM									
	@ AM REGENT	EQ 50MG IRON/ML		N040024	001	Feb 23, 1996	May	CAIN	
FERRLECIT									
AB	+! SANOFI AVENTIS US	EQ 62.5MG IRON/5ML (EQ 12.5MG IRON/ML)		N020955	001	Feb 18, 1999	May	CPOT	
AB	+!	62.5MG/5ML		N020955	001	Feb 18, 1999	May	CAIN	
INFED									
BP	+! ALLERGAN	EQ 100MG IRON/2ML (EQ 50MG IRON/ML)		N017441	001		May	CAIN	
IRON DEXTRAN									
	@ SANOFI AVENTIS US	EQ 50MG IRON/ML		N010787	002		May	CAIN	
PROFERDEX									
	@ NEW RIVER	EQ 50MG IRON/ML		N017807	001		May	CAIN	
SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE									
AB	WEST-WARD PHARMS INT	EQ 62.5MG IRON/5ML (EQ 12.5MG IRON/ML)		A078215	001	Mar 31, 2011	May	CPOT	
AB		62.5MG/5ML		A078215	001	Mar 31, 2011	May	CAIN	
INJECTABLE; INTRAVENOUS									
VENOFER									
+	AM REGENT	EQ 50MG IRON/2.5ML (EQ 20MG IRON/ML)		N021135	002	Mar 20, 2005	May	CPOT	
+		EQ 50MG BASE/2.5ML (EQ 20MG BASE/ML)		N021135	002	Mar 20, 2005	May	CAIN	
	@	EQ 65MG IRON/3.25ML (EQ 20MG IRON/ML)		N021135	005	Mar 29, 2013	May	CPOT	
	@	EQ 65MG BASE/3.25ML (EQ 20MG BASE/ML)		N021135	005	Mar 29, 2013	May	CAIN	
	@	EQ 75MG IRON/3.75ML (EQ 20MG IRON/ML)		N021135	003	Mar 29, 2005	May	CPOT	
	@	EQ 75MG BASE/3.75ML (EQ 20MG BASE/ML)		N021135	003	Mar 29, 2005	May	CAIN	
+	+!	EQ 100MG IRON/5ML (EQ 20MG IRON/ML)		N021135	001	Nov 06, 2000	May	CPOT	
+	+!	EQ 100MG BASE/5ML (EQ 20MG BASE/ML)		N021135	001	Nov 06, 2000	May	CAIN	
+	+	EQ 200MG IRON/10ML (EQ 20MG IRON/ML)		N021135	004	Feb 09, 2007	May	CPOT	
+	+	EQ 200MG BASE/10ML (EQ 20MG BASE/ML)		N021135	004	Feb 09, 2007	May	CAIN	
TABLET, CHEWABLE; ORAL									
VELPHORO									
+	+! VIFOR FRESENIUS	EQ 500MG IRON		N205109	001	Nov 27, 2013	May	CPOT	
+	+!	500MG		N205109	001	Nov 27, 2013	May	CAIN	

FERUMOXYTOL

SOLUTION; INTRAVENOUS									
FERAHEME									
AB	+! AMAG PHARMS INC	EQ 510MG IRON/17ML (EQ 30MG IRON/ML)		N022180	001	Jun 30, 2009	Jan	CFTG	
AB	+! COVIS	EQ 510MG IRON/17ML (EQ 30MG IRON/ML)		N022180	001	Jun 30, 2009	Mar	CAHN	
FERUMOXYTOL									
AB	SANDOZ INC	EQ 510MG IRON/17ML (EQ 30MG IRON/ML)		A206604	001	Jan 15, 2021	Jan	NFTG	

FEXINIDAZOLE

TABLET; ORAL									
FEXINIDAZOLE									
+	+! DNDI	600MG		N214429	001	Jul 16, 2021	Jul	NEWA	
+	+! SANOFI	600MG		N214429	001	Jul 16, 2021	Jul	CAHN	

FINASTERIDE

TABLET; ORAL									
FINASTERIDE									
	@ ACTAVIS TOTOWA TEVA	5MG		A077914	001	Mar 28, 2007	May	DISC	

FINERENONE

TABLET; ORAL									
KERENDIA									
+	+	BAYER HLTHCARE	10MG	N215341	001	Jul 09, 2021	Jul	NEWA	
+	+!		20MG	N215341	002	Jul 09, 2021	Jul	NEWA	

FINGOLIMOD HYDROCHLORIDE

CAPSULE;ORAL

FINGOLIMOD HYDROCHLORIDE

	@ ALKEM LABS LTD	EQ 0.5MG BASE	A208004	001	Dec 30, 2020	Aug	DISC
	@ APOTEX	EQ 0.5MG BASE	A207993	001	Dec 18, 2020	Jun	DISC
>D>	AB DR REDDYS	EQ 0.5MG BASE	A208000	001	Mar 05, 2021	Nov	DISC
>A>	@	EQ 0.5MG BASE	A208000	001	Mar 05, 2021	Nov	DISC
	AB	EQ 0.5MG BASE	A208000	001	Mar 05, 2021	Feb	NEWA
	@ GLENMARK PHARMS LTD	EQ 0.5MG BASE	A207985	001	Jun 18, 2020	Aug	DISC
>A>	AB HEC PHARM CO LTD	EQ 0.5MG BASE	A207939	001	Nov 10, 2021	Nov	NEWA
>D>	AB HETERO LABS LTD V	EQ 0.5MG BASE	A207933	001	May 18, 2020	Nov	DISC
>A>	@	EQ 0.5MG BASE	A207933	001	May 18, 2020	Nov	DISC
	@ MYLAN	EQ 0.5MG BASE	A208005	001	Jan 19, 2021	Jan	DISC
	AB	EQ 0.5MG BASE	A208005	001	Jan 19, 2021	Jan	NEWA
	@ STRIDES PHARMA	EQ 0.5MG BASE	A207971	001	Jun 29, 2020	Aug	DISC
	@ SUN PHARM	EQ 0.5MG BASE	A208014	001	Dec 04, 2019	Aug	DISC
>A>	AB TEVA PHARMS USA	EQ 0.25MG BASE	A212152	001	Nov 12, 2021	Nov	NFTG
	@ ZYDUS PHARMS	EQ 0.5MG BASE	A207994	001	Oct 14, 2020	Mar	DISC
	GILENYA						
>D>	+ NOVARTIS	EQ 0.25MG BASE	N022527	002	May 11, 2018	Nov	CFTG
>A>	AB +	EQ 0.25MG BASE	N022527	002	May 11, 2018	Nov	CFTG

FLECAINIDE ACETATE

TABLET;ORAL

TAMBOCOR

	+ @ ALVOGEN	50MG	N018830	004	Aug 23, 1988	Jun	CAHN
	+ @	100MG	N018830	001	Oct 31, 1985	Jun	CAHN
	+ @	150MG	N018830	003	Jun 03, 1988	Jun	CAHN
	@	200MG	N018830	002	Oct 31, 1985	Jun	CAHN
	+ @ CNTY LINE PHARMS	50MG	N018830	004	Aug 23, 1988	Jan	DISC
	+ @	100MG	N018830	001	Oct 31, 1985	Jan	DISC
	+ @	150MG	N018830	003	Jun 03, 1988	Jan	DISC

FLORBETABEN F-18

SOLUTION;INTRAVENOUS

NEURACEQ

	+! LIFE MOLECULAR	30ML (1.4-135mCi/ML)	N204677	001	Mar 19, 2014	Oct	CAHN
--	-------------------	----------------------	---------	-----	--------------	-----	------

FLUDEOXYGLUCOSE F-18

INJECTABLE;INTRAVENOUS

FLUDEOXYGLUCOSE F18

AP	CARDINAL HEALTH 414	20-500mCi/ML	A203603	002	Sep 27, 2018	Mar	NEWA
AP	ISOLOGIC INNOVATIVE	20-300mCi/ML	A204525	001	Oct 29, 2014	Oct	CAHN
	NUKEMED	4-500mCi/ML	A203911	001	Apr 22, 2015	Jan	CAHN
AP	PHARMALOGIC HLDGS	20-200mCi/ML	A203664	001	Feb 04, 2014	Jan	CAHN
AP	PRECISION NUCLEAR	20-500mCi/ML	A204546	001	Apr 07, 2015	Mar	CTEC

FLUMAZENIL

INJECTABLE;INJECTION

FLUMAZENIL

AP	BAXTER HLTHCARE CORP	0.5MG/5ML (0.1MG/ML)	A076755	002	Oct 12, 2004	Mar	CMFD
AP		1MG/10ML (0.1MG/ML)	A076755	001	Oct 12, 2004	Mar	CMFD

FLUOCINOLONE ACETONIDE

CREAM;TOPICAL

FLUOCINOLONE ACETONIDE

	@ ALLIED	0.01%	A088047	001	Dec 16, 1982	Sep	CAHN
	@	0.025%	A088045	001	Dec 16, 1982	Sep	CAHN
	@	0.025%	A088045	001	Dec 16, 1982	Sep	CAHN

OIL;TOPICAL

FLUOCINOLONE ACETONIDE

	@ AKORN	0.01%	A091514	001	Jun 25, 2015	Jul	DISC
AT	QUAGEN	0.01%	A212760	001	Apr 02, 2021	Sep	CAHN
AT		0.01%	A212761	001	Apr 02, 2021	Sep	CAHN
AT	SOLARIS PHARMA CORP	0.01%	A212760	001	Apr 02, 2021	Mar	NEWA
AT		0.01%	A212761	001	Apr 02, 2021	Mar	NEWA

OIL/DROPS;OTIC

FLUOCINOLONE ACETONIDE

	@ AKORN	0.01%	A202705	001	Sep 09, 2016	Jul	DISC
AT	QUAGEN	0.01%	A212762	001	Apr 02, 2021	Sep	CAHN
AT	SOLARIS PHARMA CORP	0.01%	A212762	001	Apr 02, 2021	Mar	NEWA

	OIL/DROPS;OTIC							
	FLUOCINOLONE ACETONIDE							
AT	TASMAN PHARMA	0.01%	A213264	001	Feb 05, 2021	Jan	NEWA	
	SOLUTION;TOPICAL							
	FLUOCINOLONE ACETONIDE							
	@ ALLIED	0.01%	A088048	001	Dec 16, 1982	Sep	CAHN	
	<u>FLUOCINONIDE</u>							
	CREAM;TOPICAL							
	LIDEX							
	+ @ ALVOGEN	0.05%	N016908	002		Jun	CAHN	
	LIDEX-E							
AB2	+ ALVOGEN	0.05%	N016908	003		Jun	CAHN	
	VANOS							
AB	+! BAUSCH	0.1%	N021758	001	Feb 11, 2005	May	CAHN	
	GEL;TOPICAL							
	FLUOCINONIDE							
AB	+ ALVOGEN	0.05%	N017373	001		Jun	CAHN	
	OINTMENT;TOPICAL							
	LIDEX							
AB	+ ALVOGEN	0.05%	N016909	002		Jun	CAHN	
	SOLUTION;TOPICAL							
	LIDEX							
AT	+ ALVOGEN	0.05%	N018849	001	Apr 06, 1984	Jun	CAHN	
	<u>FLUOROURACIL</u>							
	CREAM;TOPICAL							
	FLUOROPLEX							
	+ @ ALMIRALL	1%	N016988	001		Aug	DISC	
	FLUOROURACIL							
AB	ACCORD HLTHCARE	5%	A214845	001	Oct 07, 2021	Oct	NEWA	
	INJECTABLE;INJECTION							
	FLUOROURACIL							
AP	FRESENIUS KABI USA	500MG/10ML (50MG/ML)	A040279	002	Sep 30, 1998	May	CHRS	
AP		1GM/20ML (50MG/ML)	A040279	001	Sep 30, 1998	May	CHRS	
AP		2.5GM/50ML (50MG/ML)	A040278	001	Sep 30, 1998	May	CHRS	
AP		5GM/100ML (50MG/ML)	A040278	002	Sep 30, 1998	May	CHRS	
	@ NOVAST LABS	5GM/100ML (50MG/ML)	A209271	001	Dec 11, 2019	Mar	CPOT	
AP	TEVA PHARMS USA	500MG/10ML (50MG/ML)	A040333	001	Jan 27, 2000	May	CHRS	
	<u>FLUOXETINE HYDROCHLORIDE</u>							
	CAPSULE;ORAL							
	FLUOXETINE HYDROCHLORIDE							
	@ ACCORD HLTHCARE	EQ 10MG BASE	A202729	001	Aug 27, 2020	Feb	DISC	
	@	EQ 20MG BASE	A202729	002	Aug 27, 2020	Feb	DISC	
	@	EQ 40MG BASE	A202729	003	Aug 27, 2020	Feb	DISC	
	@ GRANULES	EQ 10MG BASE	A078143	001	Jan 16, 2008	Jun	CAHN	
	@	EQ 20MG BASE	A078143	002	Jan 16, 2008	Jun	CAHN	
	@	EQ 40MG BASE	A078143	003	Jan 16, 2008	Jun	CAHN	
AB1	HERITAGE PHARMS INC	EQ 10MG BASE	A201336	001	Oct 01, 2012	Aug	CMFD	
AB1		EQ 20MG BASE	A201336	002	Oct 01, 2012	Aug	CMFD	
AB		EQ 40MG BASE	A201336	003	Oct 01, 2012	Aug	CMFD	
	TABLET;ORAL							
	FLUOXETINE HYDROCHLORIDE							
AB	+! ALMATICA	EQ 60MG BASE	N202133	001	Oct 06, 2011	Sep	CAHN	
AB	! DR REDDYS LABS LTD	EQ 20MG BASE	A076006	002	Apr 23, 2018	Jul	CHRS	
	@ MYLAN	EQ 10MG BASE	A075755	001	Aug 02, 2001	Jul	DISC	
	@	EQ 20MG BASE	A075755	002	Aug 02, 2001	Jul	DISC	
	TORRENT	EQ 10MG BASE	A206937	001	Oct 21, 2016	Mar	CHRS	
	!	EQ 20MG BASE	A206937	002	Oct 21, 2016	Mar	CHRS	
AB	UPSHER SMITH LABS	EQ 10MG BASE	A211696	001	Jan 30, 2019	May	CAHN	
AB		EQ 20MG BASE	A211696	002	Jan 30, 2019	May	CAHN	
	SARAFEM							
	+ @ APIL	EQ 10MG BASE	N021860	001	May 19, 2006	Mar	DISC	
	+ @	EQ 20MG BASE	N021860	003	May 19, 2006	Mar	DISC	

FLUOXYMESTERONE

TABLET;ORAL

FLUOXYMESTERONE

@ UPSHER SMITH LABS 10MG A088342 001 Oct 21, 1983 Jan DISC

FLUPHENAZINE HYDROCHLORIDE

TABLET;ORAL

FLUPHENAZINE HYDROCHLORIDE

AB	CEROVENE INC	1MG	A214534	001	Jan 07, 2021	Jan	NEWA
AB		2.5MG	A214534	002	Jan 07, 2021	Jan	NEWA
AB		5MG	A214534	003	Jan 07, 2021	Jan	NEWA
AB		10MG	A214534	004	Jan 07, 2021	Jan	NEWA
AB	ENALTEC	1MG	A215141	001	Oct 20, 2021	Oct	NEWA
AB		2.5MG	A215141	002	Oct 20, 2021	Oct	NEWA
AB		5MG	A215141	003	Oct 20, 2021	Oct	NEWA
AB		10MG	A215141	004	Oct 20, 2021	Oct	NEWA
AB	NOVITIUM PHARMA	1MG	A214674	001	Mar 01, 2021	Feb	NEWA
AB		2.5MG	A214674	002	Mar 01, 2021	Feb	NEWA
AB		5MG	A214674	003	Mar 01, 2021	Feb	NEWA
AB		10MG	A214674	004	Mar 01, 2021	Feb	NEWA
AB	ZYDUS	1MG	A214552	001	May 27, 2021	May	NEWA
AB		2.5MG	A214552	002	May 27, 2021	May	NEWA
AB		5MG	A214552	003	May 27, 2021	May	NEWA
AB		10MG	A214552	004	May 27, 2021	May	NEWA

FLURBIPROFEN SODIUM

SOLUTION/DROPS;OPHTHALMIC

FLURBIPROFEN SODIUM

! BAUSCH AND LOMB 0.03% A074447 001 Jan 04, 1995 Jan CHRS  
 0.03% A074447 001 Jan 04, 1995 Jan CTEC

FLUTAMIDE

CAPSULE;ORAL

FLUTAMIDE

@ CIPLA 125MG A075780 001 Sep 19, 2001 Mar DISC  
 ! PAR PHARM 125MG A075298 001 Sep 18, 2001 Mar CHRS  
 125MG A075298 001 Sep 18, 2001 Mar CTEC  
 ! WAYLIS THERAP 125MG A075298 001 Sep 18, 2001 Jun CAHN

FLUTICASONE PROPIONATE

POWDER;INHALATION

ARMONAIR RESPICLICK

+ @ TEVA PHARM 0.03MG/INH N208798 007 Jul 09, 2021 Sep DISC  
 + 0.03MG/INH N208798 007 Jul 09, 2021 Jul NEWA

FLUVASTATIN SODIUM

TABLET, EXTENDED RELEASE;ORAL

FLUVASTATIN SODIUM

AB BEIJING EQ 80MG BASE A209397 001 Apr 26, 2021 Apr NEWA

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL

FLUVOXAMINE MALEATE

@ BIONPHARMA INC 100MG A212182 002 Sep 16, 2020 Feb DISC

FOLIC ACID

TABLET;ORAL

FOLIC ACID

AA +! WATSON LABS 1MG A080680 001 Aug CRLD

FORMOTEROL FUMARATE

SOLUTION;INHALATION

FORMOTEROL FUMARATE

>A> AN ALEMBIC PHARMS LTD 0.02MG/2ML A215078 001 Nov 22, 2021 Nov NEWA  
 AN TEVA PHARMS USA INC 0.02MG/2ML A091141 001 Jun 22, 2021 Jun NFTG  
 PERFOROMIST  
 AN +! MYLAN SPECLT 0.02MG/2ML N022007 001 May 11, 2007 Jun CFTG

FORMOTEROL FUMARATE; MOMETASONE FUROATE

AEROSOL, METERED; INHALATION  
DULERA

	+	ORGANON	0.005MG/INH;0.05MG/INH	N022518	003	Aug 12, 2019	Jun CAHN
	+	!	0.005MG/INH;0.1MG/INH	N022518	001	Jun 22, 2010	Jun CAHN
	+	!	0.005MG/INH;0.2MG/INH	N022518	002	Jun 22, 2010	Jun CAHN

FOSAPREPITANT DIMEGLUMINE

POWDER; INTRAVENOUS  
FOSAPREPITANT DIMEGLUMINE

AP		ASPIRO	EQ 150MG BASE/VIAL	A214616	001	Jul 29, 2021	Jul NEWA
		@ MYLAN LABS LTD	EQ 115MG BASE/VIAL	A204015	001	Sep 05, 2019	Mar DISC
AP		PRAXGEN	EQ 150MG BASE/VIAL	A211624	001	Sep 05, 2019	Jun CAHN
AP			EQ 150MG BASE/VIAL	A213199	001	Oct 04, 2021	Sep NEWA
>D>	AP	QILU	EQ 150MG BASE/VIAL	A213106	001	Sep 08, 2020	Nov CAHN
>A>	AP	QILU PHARM HAINAN	EQ 150MG BASE/VIAL	A213106	001	Sep 08, 2020	Nov CAHN

FOSCARNET SODIUM

INJECTABLE; INJECTION  
FOSCARNET SODIUM

AP		FRESENIUS KABI USA	2.4GM/100ML	A212483	001	Jan 29, 2021	Jan NEWA
AP		GLAND PHARMA LTD	2.4GM/100ML	A213001	001	Apr 21, 2021	Apr NEWA
		FOSCAVIR					
AP	+	CLINIGEN HLTHCARE	2.4GM/100ML	N020068	001	Sep 27, 1991	Jan CTEC

FOSDENOPTERIN HYDROBROMIDE

POWDER; INTRAVENOUS  
NULIBRY

	+	!	ORIGIN	EQ 9.5MG BASE/VIAL	N214018	001	Feb 26, 2021	Feb NEWA
--	---	---	--------	--------------------	---------	-----	--------------	----------

FOSFOMYCIN TROMETHAMINE

FOR SOLUTION; ORAL  
FOSFOMYCIN TROMETHAMINE

AA		ALKEM LABS LTD	EQ 3GM BASE/PACKET	A214554	001	Oct 21, 2021	Oct NEWA
----	--	----------------	--------------------	---------	-----	--------------	----------

FOSINOPRIL SODIUM

TABLET; ORAL  
FOSINOPRIL SODIUM

AB		CHARTWELL RX	10MG	A076483	001	Apr 23, 2004	Aug CAHN
AB			20MG	A076483	002	Apr 23, 2004	Aug CAHN
AB			40MG	A076483	003	Apr 23, 2004	Aug CAHN

FOSPHENYTOIN SODIUM

SOLUTION; INTRAVENOUS  
SESQUIENT

	+	@	SEDOR PHARMS LLC	EQ 100MG PHENYTOIN NA/2ML (EQ 50MG PHENYTOIN NA/ML)	N210864	001	Nov 05, 2020	Jul DISC
	+	@		EQ 500MG PHENYTOIN NA/10ML (EQ 50MG PHENYTOIN NA/ML)	N210864	002	Nov 05, 2020	Jul DISC

FULVESTRANT

INJECTABLE; INTRAMUSCULAR  
FULVESTRANT

AO		APOTEX	50MG/ML	A211730	001	Jun 11, 2021	Jun NEWA
AO		AUROMEDICS PHARMA	50MG/ML	A208811	001	Jul 23, 2019	Jan CAHN
AO		CHEMO RESEARCH SL	50MG/ML	A213553	001	Aug 13, 2021	Aug NEWA
AO		EUGIA PHARMA	50MG/ML	A208811	001	Jul 23, 2019	Aug CAHN
AO		XIROMED	50MG/ML	A213553	001	Aug 13, 2021	Aug CAHN
AO		ZYDUS PHARMS	50MG/ML	A215234	001	Jul 29, 2021	Jul NEWA

FUROSEMIDE

INJECTABLE; INJECTION  
FUROSEMIDE

AP		ACCORD HLTHCARE	10MG/ML	A070017	001	Dec 15, 1986	Apr CMFD
AP		ATHENEX INC	10MG/ML	A214766	001	Jan 27, 2021	Jan NEWA
		@ HIKMA	10MG/ML	N018267	001		Jul CAHN
		@	10MG/ML	N018267	001		Jun CAHN

TABLET; ORAL  
FUROSEMIDE

>D>		@	DAVA PHARMS INC	20MG	N018415	001	Jul 27, 1982	Nov CAHN
>D>		@		40MG	N018415	002	Jul 27, 1982	Nov CAHN



## TABLET;ORAL

## FUROSEMIDE

>D>	@	80MG	N018415	003	Nov 26, 1984	Nov	CAHN
>A>	@ STRIDES PHARMA	20MG	N018415	001	Jul 27, 1982	Nov	CAHN
>A>	@	40MG	N018415	002	Jul 27, 1982	Nov	CAHN
>A>	@	80MG	N018415	003	Nov 26, 1984	Nov	CAHN

## LASIX

AB	+	VALIDUS PHARMS	20MG	N016273	002		Feb	CAHN
AB	+		40MG	N016273	001		Feb	CAHN
AB	+	!	80MG	N016273	003		Feb	CAHN

GABAPENTIN

## CAPSULE;ORAL

## GABAPENTIN

AB		ASCENT PHARMS INC	100MG	A214956	001	May 10, 2021	Apr	NEWA
AB			300MG	A214956	002	May 10, 2021	Apr	NEWA
AB			400MG	A214956	003	May 10, 2021	Apr	NEWA
AB		GRAVITI PHARMS	100MG	A207099	001	Mar 24, 2017	Jun	CAHN
AB			300MG	A207099	002	Mar 24, 2017	Jun	CAHN
AB			400MG	A207099	003	Mar 24, 2017	Jun	CAHN
AB		ZHEJIANG YONGTAI	100MG	A213603	001	Aug 17, 2020	Apr	CMFD
	@		100MG	A213603	001	Aug 17, 2020	Feb	DISC
AB			300MG	A213603	002	Aug 17, 2020	Apr	CMFD
	@		300MG	A213603	002	Aug 17, 2020	Feb	DISC
AB			400MG	A213603	003	Aug 17, 2020	Apr	CMFD
	@		400MG	A213603	003	Aug 17, 2020	Feb	DISC

## SOLUTION;ORAL

## GABAPENTIN

@	NOVITIUM PHARMA	250MG/5ML	A211330	001	Dec 03, 2019	Sep	CAHN
---	-----------------	-----------	---------	-----	--------------	-----	------

## TABLET;ORAL

## GABAPENTIN

AB		ASCENT PHARMS INC	600MG	A214957	001	Oct 01, 2021	Sep	NEWA
AB			800MG	A214957	002	Oct 01, 2021	Sep	NEWA

GALANTAMINE HYDROBROMIDE

## TABLET;ORAL

## GALANTAMINE HYDROBROMIDE

AB	!	YABAO PHARM	EQ 4MG BASE	A077604	001	Feb 06, 2009	May	CHRS
		RAZADYNE						
	+	@ JANSSEN PHARMS	EQ 4MG BASE	N021169	001	Feb 28, 2001	May	DISC
	+	@	EQ 8MG BASE	N021169	002	Feb 28, 2001	May	DISC
	+	@	EQ 12MG BASE	N021169	003	Feb 28, 2001	May	DISC

GANCICLOVIR SODIUM

## INJECTABLE;INJECTION

## CYTOVENE

	+	@ CHEPLAPHARM	EQ 500MG BASE/VIAL	N019661	001	Jun 23, 1989	Jul	DISC
		GANCICLOVIR SODIUM						
AP	!	PHARMASCIENCE INC	EQ 500MG BASE/VIAL	A207645	001	Dec 08, 2017	Jul	CHRS

GATIFLOXACIN

## SOLUTION/DROPS;OPHTHALMIC

## GATIFLOXACIN

AT		AKORN	0.5%	A203189	001	Sep 03, 2014	Feb	CAHN
	@	MYLAN	0.5%	A206446	001	Jun 08, 2018	Jun	DISC
AT		TORRENT	0.5%	A213542	001	Nov 03, 2021	Oct	NEWA

GEMCITABINE HYDROCHLORIDE

## INJECTABLE;INJECTION

## GEMCITABINE HYDROCHLORIDE

AP		HIKMA INTL PHARMS	EQ 200MG BASE/VIAL	A206617	001	Jun 25, 2021	Jun	NEWA
AP			EQ 1GM BASE/VIAL	A206617	002	Jun 25, 2021	Jun	NEWA
AP	!	JIANGSU HANSON PHARM	EQ 200MG BASE/VIAL	A202485	001	May 07, 2013	Feb	CHRS
AP	!		EQ 1GM BASE/VIAL	A202485	002	May 07, 2013	Feb	CHRS
AP		MEITHEAL	200MG/5.26ML (38MG/ML)	A212129	001	Dec 11, 2020	Jan	CAHN
AP			1GM/26.3ML (38MG/ML)	A212129	002	Dec 11, 2020	Jan	CAHN
AP			2GM/52.6ML (38MG/ML)	A212129	003	Dec 11, 2020	Jan	CAHN

GEMFIBROZIL

TABLET;ORAL  
GEMFIBROZIL  
AB ASCENT PHARMS INC 600MG A214603 001 Jan 13, 2021 Jan NEWA

GLECAPREVIR; PIBRENTASVIR

PELLETS;ORAL  
MAVYRET  
+! ABBVIE INC 50MG;20MG/PACKET N215110 001 Jun 10, 2021 Jun NEWA

GLIPIZIDE

TABLET;ORAL  
GLUCOTROL  
+ @ PFIZER 2.5MG N017783 003 May 11, 1993 Aug CRLD

GLYBURIDE

TABLET;ORAL  
GLYBURIDE  
AB1 SUNNY 1.25MG A203581 001 Apr 14, 2016 Sep CAHN  
AB1 2.5MG A203581 002 Apr 14, 2016 Sep CAHN  
AB1 5MG A203581 003 Apr 14, 2016 Sep CAHN  
GLYBURIDE (MICRONIZED)  
>D> @ DAVA PHARMS INC 1.5MG A074591 001 Dec 22, 1997 Nov CAHN  
>D> @ 3MG A074591 002 Dec 22, 1997 Nov CAHN  
>D> @ 4.5MG A074591 003 Dec 22, 1997 Nov CAHN  
>D> @ 6MG A074591 004 Dec 22, 1997 Nov CAHN  
>A> @ STRIDES PHARMA 1.5MG A074591 001 Dec 22, 1997 Nov CAHN  
>A> @ 3MG A074591 002 Dec 22, 1997 Nov CAHN  
>A> @ 4.5MG A074591 003 Dec 22, 1997 Nov CAHN  
>A> @ 6MG A074591 004 Dec 22, 1997 Nov CAHN  
GLYNASE  
AB + PFIZER 1.5MG N020051 001 Mar 04, 1992 Feb CAHN  
AB + 3MG N020051 002 Mar 04, 1992 Feb CAHN  
+ @ 4.5MG N020051 003 Sep 24, 1993 Feb CAHN  
AB +! 6MG N020051 004 Sep 24, 1993 Feb CAHN  
MICRONASE  
+ @ PFIZER 1.25MG N017498 001 May 01, 1984 Feb CAHN  
@ 2.5MG N017498 002 May 01, 1984 Feb CAHN  
+ @ 5MG N017498 003 May 01, 1984 Feb CAHN

GLYCEROL PHENYLBUTYRATE

LIQUID;ORAL  
>A> GLYCEROL PHENYLBUTYRATE  
>A> AA PAR PHARM INC 1.1GM/ML A205742 001 Dec 02, 2021 Nov NFTG  
RAVICTI  
>D> +! HORIZON THERAP 1.1GM/ML N203284 001 Feb 01, 2013 Nov CFTG  
>A> AA +! 1.1GM/ML N203284 001 Feb 01, 2013 Nov CFTG

GLYCOPYRROLATE

INJECTABLE;INJECTION  
GLYCOPYRROLATE  
AP ATHENEX INC 0.2MG/ML A210083 001 Feb 21, 2020 Jan CAHN  
AP HONG KONG 0.2MG/ML A212802 001 Jul 06, 2021 Jun NEWA  
AP MEITHEAL 0.2MG/ML A212802 001 Jul 06, 2021 Sep CAHN  
AP NIVAGEN PHARMS INC 0.2MG/ML A212591 001 Oct 13, 2021 Oct NEWA  
AP XIROMED 0.2MG/ML A212227 001 Mar 04, 2021 Feb NEWA  
AP ZYDUS PHARMS 0.2MG/ML A214213 001 Nov 09, 2021 Oct NEWA  
ROBINUL  
+ @ HIKMA 0.2MG/ML N017558 001 Jul CAHN  
SOLUTION;INTRAMUSCULAR, INTRAVENOUS  
GLYRX-PF  
+! EXELA PHARMA 0.2MG/ML (0.2MG/ML) N210997 001 Jul 11, 2018 Oct CHRS  
+ 0.2MG/ML (0.2MG/ML) N210997 001 Jul 11, 2018 Oct CRLD  
+! 0.4MG/2ML (0.2MG/ML) N210997 002 Jul 11, 2018 Oct CHRS  
+ 0.4MG/2ML (0.2MG/ML) N210997 002 Jul 11, 2018 Oct CRLD  
+! 0.6MG/3ML (0.2MG/ML) N210997 004 Dec 14, 2020 Oct CHRS  
+ 0.6MG/3ML (0.2MG/ML) N210997 004 Dec 14, 2020 Oct CRLD  
+! 1MG/5ML (0.2MG/ML) N210997 003 Apr 09, 2020 Oct CHRS  
+ 1MG/5ML (0.2MG/ML) N210997 003 Apr 09, 2020 Oct CRLD

SOLUTION;ORAL							
CUVPOSA							
AA	+	MERZ PHARMS	1MG/5ML	N022571	001	Jul 28, 2010	Jul CFTG
GLYCOPYRROLATE							
AA		PAR PHARM INC	1MG/5ML	A204438	001	Aug 09, 2021	Jul NFTG
TABLET;ORAL							
ROBINUL							
AA	+	CASPER PHARMA LLC	1MG	N012827	001		Jun CMFD
ROBINUL FORTE							
AA	+	CASPER PHARMA LLC	2MG	N012827	002		Jun CMFD
<u>GLYCOPYRRONIUM TOSYLATE</u>							
CLOTH;TOPICAL							
QBREXZA							
	+	JOURNEY	EQ 2.4% BASE	N210361	001	Jun 28, 2018	May CAHN
<u>GONADORELIN HYDROCHLORIDE</u>							
INJECTABLE;INJECTION							
FACTREL							
	@	HIKMA	EQ 0.1MG BASE/VIAL	N018123	001	Sep 30, 1982	Jul CAHN
	@		EQ 0.2MG BASE/VIAL	N018123	002	Sep 30, 1982	Jul CAHN
	@		EQ 0.5MG BASE/VIAL	N018123	003	Sep 30, 1982	Jul CAHN
<u>GRANISETRON HYDROCHLORIDE</u>							
SOLUTION;ORAL							
GRANISOL							
	@	INTRA SANA LABS	EQ 2MG BASE/10ML	A078334	001	Feb 28, 2008	Jan CAHN
<u>GRISEOFULVIN, MICROCRYSTALLINE</u>							
TABLET;ORAL							
FULVICIN-U/F							
>D>	@	CHARTWELL RX	250MG	A060569	002		Nov CMFD
>A>	AB		250MG	A060569	002		Nov CMFD
>D>	@		500MG	A060569	001		Nov CMFD
>A>	AB		500MG	A060569	001		Nov CMFD
<u>GRISEOFULVIN, ULTRAMICROCRYSTALLINE</u>							
TABLET;ORAL							
FULVICIN P/G							
>D>	@	CHARTWELL RX	125MG	A061996	001		Nov CMFD
>A>	AB		125MG	A061996	001		Nov CMFD
>D>	@		250MG	A061996	002		Nov CMFD
>A>	AB		250MG	A061996	002		Nov CMFD
FULVICIN P/G 165							
>D>	@	CHARTWELL RX	165MG	A061996	003	Apr 06, 1982	Nov CMFD
>A>	AB		165MG	A061996	003	Apr 06, 1982	Nov CMFD
FULVICIN P/G 330							
>D>	@	CHARTWELL RX	330MG	A061996	004	Apr 06, 1982	Nov CMFD
>A>	AB		330MG	A061996	004	Apr 06, 1982	Nov CMFD
<u>GUANABENZ ACETATE</u>							
TABLET;ORAL							
GUANABENZ ACETATE							
	@	CHARTWELL RX	EQ 4MG BASE	A074517	001	Sep 30, 1998	Aug CAHN
	@		EQ 8MG BASE	A074517	002	Sep 30, 1998	Aug CAHN
<u>GUANFACINE HYDROCHLORIDE</u>							
TABLET;ORAL							
GUANFACINE HYDROCHLORIDE							
AB	!	AMNEAL PHARM	EQ 2MG BASE	A075109	002	Nov 25, 1998	Jan CHRS
	@	MYLAN	EQ 1MG BASE	A074796	001	Jan 27, 1997	Jan DISC
	@		EQ 2MG BASE	A074796	002	Jan 27, 1997	Jan DISC
AB		UNICHEM	EQ 1MG BASE	A214689	001	Mar 03, 2021	Feb NEWA
AB			EQ 2MG BASE	A214689	002	Mar 03, 2021	Feb NEWA
TABLET, EXTENDED RELEASE;ORAL							
GUANFACINE HYDROCHLORIDE							
	@	YICHANG HUMANWELL	EQ 1MG BASE	A213428	001	Nov 25, 2020	May DISC
	@		EQ 2MG BASE	A213428	002	Nov 25, 2020	May DISC
	@		EQ 3MG BASE	A213428	003	Nov 25, 2020	May DISC
	@		EQ 4MG BASE	A213428	004	Nov 25, 2020	May DISC

HALCINONIDE

	CREAM; TOPICAL						
	HALCINONIDE						
AB	GLASSHOUSE PHARMS	0.1%	A214723	001	Sep 08, 2021	Aug	NEWA
	SOLUTION; TOPICAL						
	HALOG						
	+! SUN PHARM INDS INC	0.1%	N017823	001		Apr	CRLD

HALOBETASOL PROPIONATE

	OINTMENT; TOPICAL						
	HALOBETASOL PROPIONATE						
	@ COSETTE	0.05%	A077721	001	Sep 07, 2006	Mar	DISC
	ULTRAVATE						
	+ @ SUN PHARM INDS INC	0.05%	N019968	001	Dec 17, 1990	Mar	DISC

HALOPERIDOL

	TABLET; ORAL						
	HALOPERIDOL						
AB	CYCLE PHARMS LTD	2MG	A071130	001	Feb 17, 1987	Apr	CMFD
AB		5MG	A071131	001	Feb 17, 1987	Apr	CMFD
AB		10MG	A071132	001	May 12, 1987	Apr	CMFD
>A>	@ STRIDES PHARMA	0.5MG	A071235	002	Nov 03, 1986	Nov	CAHN
>A>	@	1MG	A071235	003	Nov 03, 1986	Nov	CAHN
>A>	@	2MG	A071235	001	Nov 03, 1986	Nov	CAHN
>A>	@	5MG	A071235	004	Nov 03, 1986	Nov	CAHN
>A>	@	10MG	A071235	005	Jul 20, 1987	Nov	CAHN
>D>	@ VINTAGE	0.5MG	A071235	002	Nov 03, 1986	Nov	CAHN
>D>	@	1MG	A071235	003	Nov 03, 1986	Nov	CAHN
>D>	@	2MG	A071235	001	Nov 03, 1986	Nov	CAHN
>D>	@	5MG	A071235	004	Nov 03, 1986	Nov	CAHN
>D>	@	10MG	A071235	005	Jul 20, 1987	Nov	CAHN

HALOPERIDOL DECANOATE

	INJECTABLE; INJECTION						
	HALOPERIDOL DECANOATE						
AO	HONG KONG	EQ 50MG BASE/ML	A214507	001	Jul 26, 2021	Jul	NEWA
AO		EQ 100MG BASE/ML	A214507	002	Jul 26, 2021	Jul	NEWA
AO	MEITHEAL	EQ 50MG BASE/ML	A214507	001	Jul 26, 2021	Sep	CAHN
AO		EQ 100MG BASE/ML	A214507	002	Jul 26, 2021	Sep	CAHN

HALOPERIDOL LACTATE

	CONCENTRATE; ORAL						
	HALDOL						
	+ @ ORTHO MCNEIL	EQ 2MG BASE/ML	N015922	001		Mar	CRLD

HEPARIN SODIUM

	INJECTABLE; INJECTION						
	HEPARIN SODIUM						
>D>	@ BE PHARMS	1,000 UNITS/ML	A214804	001	Dec 29, 2020	Nov	CMFD
>A>	AP	1,000 UNITS/ML	A214804	001	Dec 29, 2020	Nov	CMFD
	@	1,000 UNITS/ML	A214804	001	Dec 29, 2020	Jun	DISC
>D>	@	10,000 UNITS/ML	A214839	001	Dec 29, 2020	Nov	CMFD
>A>	AP	10,000 UNITS/ML	A214839	001	Dec 29, 2020	Nov	CMFD
	@	10,000 UNITS/ML	A214839	001	Dec 29, 2020	Jun	DISC
AP	+! HIKMA	1,000 UNITS/ML	N017037	001		Jul	CAHN
AP	+!	5,000 UNITS/ML	N017037	002		Jul	CAHN
	@	5,000 UNITS/0.5ML	N017037	013	Apr 07, 1986	Jul	CAHN
AP	+!	10,000 UNITS/ML	N017037	003		Jul	CAHN
	@ NANJING KING-FRIEND	5,000 UNITS/ML	A212061	001	Jul 15, 2020	Aug	DISC
	HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP	FRESENIUS KABI USA	200 UNITS/100ML	A212441	001	Jul 24, 2020	Apr	CMFD
	@	200 UNITS/100ML	A212441	001	Jul 24, 2020	Jan	DISC
	HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP	FRESENIUS KABI USA	200 UNITS/100ML	A212441	002	Jul 24, 2020	Apr	CMFD
	@	200 UNITS/100ML	A212441	002	Jul 24, 2020	Jan	DISC
	HEPARIN SODIUM PRESERVATIVE FREE						
	@ NANJING KING-FRIEND	10,000 UNITS/ML	A212060	001	Apr 02, 2020	Aug	DISC
	@ SHENZHEN TECHDOW	1,000 UNITS/ML	A202732	001	Jun 12, 2014	Apr	DISC

HISTRELIN ACETATE

IMPLANT;SUBCUTANEOUS  
VANTAS

+ @ ENDO PHARM 50MG N021732 001 Oct 12, 2004 Sep DISC

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

TABLET;ORAL  
HYCODAN

AA + GENUS 1.5MG;5MG N005213 001 Jul 26, 1988 Sep CMFD

HYDRALAZINE HYDROCHLORIDE

TABLET;ORAL  
HYDRALAZINE HYDROCHLORIDE

AA +! PLIVA 25MG A088467 001 May 01, 1984 Aug CRLD  
 AA +! 50MG A088468 001 May 01, 1984 Aug CRLD  
 @ UPSHER SMITH LABS 10MG A209251 001 Jul 09, 2018 Aug DISC  
 AA 10MG A209251 001 Jul 09, 2018 May CAHN  
 @ 25MG A209251 002 Jul 09, 2018 Aug DISC  
 AA 25MG A209251 002 Jul 09, 2018 May CAHN  
 @ 50MG A209251 003 Jul 09, 2018 Aug DISC  
 AA 50MG A209251 003 Jul 09, 2018 May CAHN  
 @ 100MG A209251 004 Jul 09, 2018 Aug DISC  
 AA 100MG A209251 004 Jul 09, 2018 May CAHN

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE;ORAL  
APRESAZIDE

+ @ NOVARTIS 25MG;25MG A084735 001 Aug CRLD  
 + @ 50MG;50MG A084810 001 Aug CRLD

HYDROCHLOROTHIAZIDE

CAPSULE;ORAL  
MICROZIDE

AB +! TEVA BRANDED PHARM 12.5MG N020504 001 Dec 27, 1996 Mar CAHN  
 SOLUTION;ORAL  
 HYDROCHLOROTHIAZIDE  
 + @ ROXANE 50MG/5ML A088587 001 Jul 02, 1984 Aug CRLD  
 TABLET;ORAL  
 HYDROCHLOROTHIAZIDE  
 AB + IVAX SUB TEVA PHARMS 25MG A083177 001 Aug CRLD  
 AB +! 50MG A083177 002 Aug CRLD  
 + @ 100MG A085022 001 Aug CRLD

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET;ORAL  
IRBESARTAN AND HYDROCHLOROTHIAZIDE

>D> @ UNICHEM 12.5MG;150MG A207018 001 Sep 19, 2017 Nov CMFD  
 >A> AB 12.5MG;150MG A207018 001 Sep 19, 2017 Nov CMFD  
 >D> @ 12.5MG;300MG A207018 002 Sep 19, 2017 Nov CMFD  
 >A> AB 12.5MG;300MG A207018 002 Sep 19, 2017 Nov CMFD

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET;ORAL  
ZESTORETIC

AB + ALMATICA 12.5MG;10MG N019888 003 Nov 18, 1993 Jan CAHN  
 AB +! 12.5MG;20MG N019888 001 Sep 20, 1990 Jan CAHN  
 AB +! 25MG;20MG N019888 002 Jul 20, 1989 Jan CAHN

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET;ORAL  
HYZAAR

AB + ORGANON 12.5MG;50MG N020387 001 Apr 28, 1995 Aug CMFD  
 AB + 25MG;100MG N020387 002 Nov 10, 1998 Aug CMFD  
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE  
 AB JUBILANT CADISTA 12.5MG;50MG A201845 001 Sep 18, 2012 Jun CAHN  
 AB 12.5MG;100MG A201845 002 Sep 18, 2012 Jun CAHN  
 AB 25MG;100MG A201845 003 Sep 18, 2012 Jun CAHN  
 >D> @ UNICHEM 12.5MG;50MG A204832 001 Jul 21, 2017 Nov CMFD  
 >A> AB 12.5MG;50MG A204832 001 Jul 21, 2017 Nov CMFD  
 >D> @ 12.5MG;100MG A204832 002 Jul 21, 2017 Nov CMFD  
 >A> AB 12.5MG;100MG A204832 002 Jul 21, 2017 Nov CMFD

TABLET;ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

>D>	@	25MG;100MG	A204832	003	Jul 21, 2017	Nov	CMFD
>A>	AB	25MG;100MG	A204832	003	Jul 21, 2017	Nov	CMFD

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET;ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

	@	CHARTWELL RX	15MG;250MG	A070182	001	Jan 15, 1986	Sep	CAHN
	@		25MG;250MG	A070183	001	Jan 15, 1986	Sep	CAHN
	@		30MG;500MG	A070543	001	Jan 15, 1986	Sep	CAHN
	@		50MG;500MG	A070544	001	Jan 15, 1986	Sep	CAHN
>D>	@	MYLAN	15MG;250MG	A070265	002	Jan 23, 1986	Nov	CAHN
	@		15MG;250MG	A070265	002	Jan 23, 1986	Sep	DISC
>D>	@		25MG;250MG	A070265	001	Jan 23, 1986	Nov	CAHN
	@		25MG;250MG	A070265	001	Jan 23, 1986	Sep	DISC
>A>	@	RISING	15MG;250MG	A070265	002	Jan 23, 1986	Nov	CAHN
>A>	@		25MG;250MG	A070265	001	Jan 23, 1986	Nov	CAHN

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

DUTOPROL

+	@	CONCORDIA	12.5MG;EQ 25MG TARTRATE	N021956	001	Aug 28, 2006	Jun	DISC
+	@		12.5MG;EQ 50MG TARTRATE	N021956	002	Aug 28, 2006	Jun	DISC
+	@		12.5MG;EQ 100MG TARTRATE	N021956	003	Aug 28, 2006	Jun	DISC

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET;ORAL

LOPRESSOR HCT

AB	+	VALIDUS PHARMS	25MG;50MG	N018303	001	Dec 31, 1984	Feb	CAHN
	+	@	25MG;100MG	N018303	002	Dec 31, 1984	Feb	CAHN
	+	@	50MG;100MG	N018303	003	Dec 31, 1984	Feb	CAHN

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

	@	ANI PHARMS	25MG;40MG	A070705	002	Oct 01, 1986	Jul	CMS1
	@	MYLAN	25MG;40MG	A070947	002	Mar 04, 1987	Aug	CAHN
	@		25MG;40MG	A070947	002	Mar 04, 1987	Aug	DISC
	@		25MG;80MG	A070947	001	Apr 01, 1987	Aug	CAHN
	@		25MG;80MG	A070947	001	Apr 01, 1987	Aug	DISC

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET;ORAL

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

	@	CHARTWELL RX	25MG;25MG	A086881	001		Sep	CAHN
--	---	--------------	-----------	---------	-----	--	-----	------

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

	@	CADILA	12.5MG;80MG	A203000	001	Mar 15, 2019	Aug	CAHN
	@		12.5MG;160MG	A203000	002	Mar 15, 2019	Aug	CAHN
	@		12.5MG;320MG	A203000	003	Mar 15, 2019	Aug	CAHN
	@		25MG;160MG	A203000	004	Mar 15, 2019	Aug	CAHN
	@		25MG;320MG	A203000	005	Mar 15, 2019	Aug	CAHN

HYDROCODONE BITARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

HYDROCODONE BITARTRATE

	!	ALVOGEN	10MG	A206986	001	Jan 21, 2020	Oct	CTEC	
AB	!		10MG	A206986	001	Jan 21, 2020	Oct	CHRS	
			15MG	A206986	002	Jan 21, 2020	Oct	CTEC	
			20MG	A206986	003	Jan 21, 2020	Oct	CTEC	
			30MG	A206986	004	Jan 21, 2020	Oct	CTEC	
			40MG	A206986	005	Jan 21, 2020	Oct	CTEC	
			50MG	A206986	006	Jan 21, 2020	Oct	CTEC	
		ZOHYDRO ER							
	+	@	RECRO GAINESVILLE	10MG	N202880	001	Oct 25, 2013	Oct	DISC
AB	+	!		10MG	N202880	001	Oct 25, 2013	May	CAHN
	+	@		15MG	N202880	002	Oct 25, 2013	Oct	DISC
AB	+		15MG	N202880	002	Oct 25, 2013	May	CAHN	
	+	@		20MG	N202880	003	Oct 25, 2013	Oct	DISC

CAPSULE, EXTENDED RELEASE;ORAL  
ZOHYDRO ER

AB	+	20MG	N202880	003	Oct 25, 2013	May CAHN
	+ @	30MG	N202880	004	Oct 25, 2013	Oct DISC
AB	+	30MG	N202880	004	Oct 25, 2013	May CAHN
	+ @	40MG	N202880	005	Oct 25, 2013	Oct DISC
AB	+	40MG	N202880	005	Oct 25, 2013	May CAHN
	+ @	50MG	N202880	006	Oct 25, 2013	Oct DISC
AB	+	50MG	N202880	006	Oct 25, 2013	May CAHN

TABLET, EXTENDED RELEASE;ORAL  
HYDROCODONE BITARTRATE

AB		ALVOGEN PINE BROOK	20MG	A208269	001	Mar 01, 2021	Feb NFTG
AB			30MG	A208269	002	Mar 01, 2021	Feb NFTG
AB			40MG	A208269	003	Mar 01, 2021	Feb NFTG
AB			60MG	A208269	004	Mar 01, 2021	Feb NFTG
AB			80MG	A208269	005	Mar 01, 2021	Feb NFTG
AB			100MG	A208269	006	Mar 01, 2021	Feb NFTG
AB			120MG	A208269	007	Mar 01, 2021	Feb NFTG

HYSINGLA ER

AB	+	PURDUE PHARMA LP	20MG	N206627	001	Nov 20, 2014	Feb CFTG
AB	+		30MG	N206627	002	Nov 20, 2014	Feb CFTG
AB	+		40MG	N206627	003	Nov 20, 2014	Feb CFTG
AB	+		60MG	N206627	004	Nov 20, 2014	Feb CFTG
AB	+		80MG	N206627	005	Nov 20, 2014	Feb CFTG
AB	+		100MG	N206627	006	Nov 20, 2014	Feb CFTG
AB	+		120MG	N206627	007	Nov 20, 2014	Feb CFTG

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET;ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

AB		NOSTRUM LABS INC	5MG;200MG	A077727	001	Nov 06, 2006	Jan CAHN
AB			7.5MG;200MG	A077723	001	Nov 06, 2006	Jan CAHN
			10MG;200MG	A077723	002	Nov 06, 2006	Mar CTEC
AB			10MG;200MG	A077723	002	Nov 06, 2006	Jan CAHN
		REPRESXAIN					
	@	AMNEAL PHARMS NY	2.5MG;200MG	A076642	003	Oct 19, 2007	Mar DISC
	@		10MG;200MG	A076642	004	Oct 19, 2007	Mar DISC

HYDROCORTISONE

CREAM;TOPICAL

HYTONE

	+ @	VALEANT INTL	1%	A080472	003		Aug CRLD
	+ @		2.5%	A080472	004		Aug CRLD
		SYNACORT					
	@	BAUSCH	0.5%	A087459	001		May CAHN
	+ @		1%	A087458	001		Aug CRLD
	@		1%	A087458	001		May CAHN
	+ @		2.5%	A087457	001		Aug CRLD
	@		2.5%	A087457	001		May CAHN

ENEMA;RECTAL

COLOCORT

AB		CHARTWELL	100MG/60ML	A075172	001	Dec 03, 1999	Apr CAHN
----	--	-----------	------------	---------	-----	--------------	----------

LOTION;TOPICAL

HYTONE

	+ @	VALEANT INTL	1%	A080473	003		Aug CRLD
	+ @		2.5%	A080473	004	Nov 30, 1982	Aug CRLD

OINTMENT;TOPICAL

HYDROCORTISONE

AT	+	FOUGERA PHARMS	1%	A080692	001		Aug CRLD
	+ @	DERMIK LABS	1%	A080474	003		Aug CRLD
	+ @		2.5%	A080474	004		Aug CRLD

SOLUTION;TOPICAL

PENECORT

	+ @	ALLERGAN HERBERT	1%	A088214	001	Jun 06, 1984	Aug CRLD
--	-----	------------------	----	---------	-----	--------------	----------

TABLET;ORAL

HYDROCORTISONE

>A>	@	STRIDES PHARMA	5MG	A040761	001	Jul 16, 2007	Nov CAHN
>A>	@		10MG	A040761	002	Jul 16, 2007	Nov CAHN
>A>	@		20MG	A040761	003	Jul 16, 2007	Nov CAHN
>D>	@	VINTAGE	5MG	A040761	001	Jul 16, 2007	Nov CAHN
>D>	@		10MG	A040761	002	Jul 16, 2007	Nov CAHN

	TABLET;ORAL								
	HYDROCORTISONE								
>D>	@	20MG		A 040761	003	Jul 16, 2007		Nov	CAHN
	<u>HYDROCORTISONE ACETATE</u>								
	CREAM;TOPICAL								
	CARMOL HC								
	+ @ FOUGERA PHARMS	1%		A 080505	001			Aug	CRLD
	HYDROCORTISONE ACETATE								
	+ @ PUREPAC PHARM	1%		A 086052	001			Aug	CRLD
	<u>HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE</u>								
	CREAM;TOPICAL								
	CORTISPORIN								
	+ @ MONARCH PHARMS	0.5%;EQ 3.5MG BASE/GM;10,000 UNITS/GM		N 050218	001	Aug 09, 1985		Jul	DISC
	<u>HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE</u>								
	AEROSOL, METERED;TOPICAL								
	PROCTOFOAM HC								
BX	+! MYLAN SPECIALITY LP	1%;1%		A 086195	001			Aug	CHRS
BX	+	1%;1%		A 086195	001			Aug	CRLD
	<u>HYDROCORTISONE PROBUTATE</u>								
	CREAM;TOPICAL								
	PANDEL								
	+! ANI PHARMS	0.1%		N 020453	001	Feb 28, 1997		Apr	CAHN
	<u>HYDROCORTISONE SODIUM PHOSPHATE</u>								
	INJECTABLE;INJECTION								
	HYDROCORTONE								
	+ @ MERCK	EQ 50MG BASE/ML		N 012052	001			Feb	CRLD
	<u>HYDROCORTISONE VALERATE</u>								
	CREAM;TOPICAL								
	HYDROCORTISONE VALERATE								
AB	COSETTE	0.2%		A 213724	001	Feb 11, 2021		Feb	NEWA
AB	ENCUBE ETHICALS	0.2%		A 211047	001	Nov 04, 2021		Oct	NEWA
	<u>HYDROMORPHONE HYDROCHLORIDE</u>								
	SOLUTION;ORAL								
	HYDROMORPHONE HYDROCHLORIDE								
>A>	@ GENUS	5MG/5ML		A 207108	001	Apr 22, 2020		Nov	CAHN
>D>	@ LANNETT CO INC	5MG/5ML		A 207108	001	Apr 22, 2020		Nov	CAHN
	TABLET;ORAL								
	HYDROMORPHONE HYDROCHLORIDE								
>A>	@ GENUS	2MG		A 077471	002	Dec 09, 2009		Nov	CAHN
>A>	@	4MG		A 077471	003	Dec 09, 2009		Nov	CAHN
>A>	@	8MG		A 077471	001	Dec 09, 2009		Nov	CAHN
>D>	@ LANNETT CO INC	2MG		A 077471	002	Dec 09, 2009		Nov	CAHN
	@	2MG		A 077471	002	Dec 09, 2009		Mar	DISC
>D>	@	4MG		A 077471	003	Dec 09, 2009		Nov	CAHN
	@	4MG		A 077471	003	Dec 09, 2009		Mar	DISC
>D>	@	8MG		A 077471	001	Dec 09, 2009		Nov	CAHN
	@	8MG		A 077471	001	Dec 09, 2009		Mar	DISC
	TABLET, EXTENDED RELEASE;ORAL								
	HYDROMORPHONE HYDROCHLORIDE								
AB	OSMOTICA PHARM US	8MG		A 205629	001	Jul 07, 2016		Oct	CAHN
AB		12MG		A 205629	002	Jul 07, 2016		Oct	CAHN
AB		16MG		A 205629	003	Jul 07, 2016		Oct	CAHN
AB	!	32MG		A 205629	004	Jul 07, 2016		Oct	CAHN
	<u>HYDROXYCHLOROQUINE SULFATE</u>								
	TABLET;ORAL								
	HYDROXYCHLOROQUINE SULFATE								
	ACCORD HLTHCARE	100MG		A 213342	002	Aug 18, 2021		Aug	NEWA
		300MG		A 213342	003	Aug 18, 2021		Aug	NEWA
		400MG		A 213342	004	Aug 18, 2021		Aug	NEWA
>A>	AB APPCO	200MG		A 210441	001	May 01, 2018		Nov	CAHN
>D>	AB DR REDDYS	200MG		A 210441	001	May 01, 2018		Nov	CAHN
>A>	AB LAURUS	200MG		A 210959	001	Jan 15, 2019		Nov	CAHN
>D>	AB RISING	200MG		A 210959	001	Jan 15, 2019		Nov	CAHN



TABLET;ORAL

HYDROXYCHLOROQUINE SULFATE							
AB		200MG	A210959	001	Jan 15, 2019	Sep	CAHN
AB	SENORES PHARMS	200MG	A212902	001	May 14, 2020	Jul	CAHN

HYDROXYPROGESTERONE CAPROATE

SOLUTION;INTRAMUSCULAR							
MAKENA							
AP1	+! COVIS	1250MG/5ML (250MG/ML)	N021945	001	Feb 03, 2011	Mar	CAHN
MAKENA PRESERVATIVE FREE							
AP	+! COVIS	250MG/ML (250MG/ML)	N021945	002	Feb 19, 2016	Mar	CAHN
SOLUTION;SUBCUTANEOUS							
MAKENA (AUTOINJECTOR)							
	+! COVIS	275MG/1.1ML (250MG/ML)	N021945	004	Feb 14, 2018	Mar	CAHN

HYDROXYUREA

TABLET;ORAL							
SIKLOS							
	+! ADDMEDICA SAS	1GM	N208843	002	Dec 21, 2017	Mar	CHRS

HYDROXYZINE HYDROCHLORIDE

SYRUP;ORAL							
HYDROXYZINE HYDROCHLORIDE							
AA	+! WOCKHARDT BIO AG	10MG/5ML	A087294	001	Apr 12, 1982	Aug	CRLD
TABLET;ORAL							
HYDROXYZINE HYDROCHLORIDE							
AB	BIOPHARM	10MG	A040804	001	Jun 30, 2008	Sep	CAHN
AB		25MG	A040804	002	Jun 30, 2008	Sep	CAHN
AB		50MG	A040804	003	Jun 30, 2008	Sep	CAHN
AB	+! PLIVA	10MG	A088617	001	Jan 10, 1986	Aug	CRLD
AB	+!	25MG	A088618	001	Jan 10, 1986	Aug	CRLD
AB	+!	50MG	A088619	001	Jan 10, 1986	Aug	CRLD
AB	PRINSTON INC	10MG	A040580	003	May 27, 2005	Feb	CMS1
AB		25MG	A040580	002	May 27, 2005	Feb	CMS1
>A>	@ STRIDES PHARMA	10MG	A087602	001	Jan 22, 1982	Nov	CAHN
>A>	@	25MG	A087603	001	Jan 22, 1982	Nov	CAHN
>A>	@	50MG	A087604	001	Jan 22, 1982	Nov	CAHN
>D>	@ VINTAGE	10MG	A087602	001	Jan 22, 1982	Nov	CAHN
>D>	@	25MG	A087603	001	Jan 22, 1982	Nov	CAHN
>D>	@	50MG	A087604	001	Jan 22, 1982	Nov	CAHN

HYDROXYZINE PAMOATE

CAPSULE;ORAL							
HYDROXYZINE PAMOATE							
BX	HERITAGE PHARMA	EQ 25MG HYDROCHLORIDE	A201507	001	Jun 03, 2013	Sep	CTEC
BX		EQ 50MG HYDROCHLORIDE	A201507	002	Jun 03, 2013	Sep	CTEC

IBANDRONATE SODIUM

INJECTABLE;INTRAVENOUS							
IBANDRONATE SODIUM							
AP	NANG KUANG PHARM CO	EQ 3MG BASE/3ML	A204329	001	Jun 16, 2021	Jun	NEWA
TABLET;ORAL							
BONIVA							
>D>	AB	+! HOFFMANN LA ROCHE	N021455	002	Mar 24, 2005	Nov	DISC
>A>		+ @	N021455	002	Mar 24, 2005	Nov	DISC
IBANDRONATE SODIUM							
>D>	AB	DR REDDYS LABS LTD	A078997	001	Apr 30, 2012	Nov	CHRS
>A>	AB	!	A078997	001	Apr 30, 2012	Nov	CHRS

IBREXAFUNGERP CITRATE

TABLET;ORAL							
BREXAFEMME							
	+! SCYNEXIS	EQ 150MG BASE	N214900	001	Jun 01, 2021	Jun	NEWA

IBRUTINIB

CAPSULE;ORAL							
IBRUTINIB							
	@ ZYDUS	70MG	A211344	001	Mar 31, 2021	Jul	DISC
AB		70MG	A211344	001	Mar 31, 2021	Mar	NFTG
	@	140MG	A211344	002	Mar 31, 2021	Jul	DISC
AB		140MG	A211344	002	Mar 31, 2021	Mar	NFTG

## CAPSULE;ORAL

## IMBRUVICA

	+	PHARMACYCLICS INC	70MG	N205552	002	Dec 20, 2017	Jul CTEC
AB	+		70MG	N205552	002	Dec 20, 2017	Mar CFTG
	+	!	140MG	N205552	001	Nov 13, 2013	Jul CTEC
AB	+	!	140MG	N205552	001	Nov 13, 2013	Mar CFTG

IBUPROFEN

## SUSPENSION;ORAL

## IBUPROFEN

AB		PADAGIS US	100MG/5ML	A076925	001	Sep 23, 2004	Jul CAHN
----	--	------------	-----------	---------	-----	--------------	----------

## TABLET;ORAL

## &gt;D&gt; IBU-TAB

>D>	AB	ALRA	400MG	A071058	001	Aug 11, 1988	Nov DISC
-----	----	------	-------	---------	-----	--------------	----------

>A>		@	400MG	A071058	001	Aug 11, 1988	Nov DISC
-----	--	---	-------	---------	-----	--------------	----------

>D>	AB		600MG	A071059	001	Aug 11, 1988	Nov DISC
-----	----	--	-------	---------	-----	--------------	----------

>A>		@	600MG	A071059	001	Aug 11, 1988	Nov DISC
-----	--	---	-------	---------	-----	--------------	----------

## IBUPROFEN

AB		ALKEM LABS LTD	400MG	A214699	001	Sep 13, 2021	Sep NEWA
----	--	----------------	-------	---------	-----	--------------	----------

AB			600MG	A214699	002	Sep 13, 2021	Sep NEWA
----	--	--	-------	---------	-----	--------------	----------

AB			800MG	A214699	003	Sep 13, 2021	Sep NEWA
----	--	--	-------	---------	-----	--------------	----------

AB		L PERRIGO CO	400MG	A077114	001	Jul 18, 2005	Jul CAHN
----	--	--------------	-------	---------	-----	--------------	----------

AB			600MG	A077114	002	Jul 18, 2005	Jul CAHN
----	--	--	-------	---------	-----	--------------	----------

AB			800MG	A077114	003	Jul 18, 2005	Jul CAHN
----	--	--	-------	---------	-----	--------------	----------

		@ VINTAGE PHARMS	400MG	A071644	001	Feb 01, 1988	Feb DISC
--	--	------------------	-------	---------	-----	--------------	----------

IBUTILIDE FUMARATE

## INJECTABLE; INJECTION

## CORVERT

AP	+	!	PFIZER	0.1MG/ML	N020491	001	Dec 28, 1995	Feb CAHN
----	---	---	--------	----------	---------	-----	--------------	----------

ICATIBANT ACETATE

## INJECTABLE; SUBCUTANEOUS

## ICATIBANT ACETATE

		@ DR REDDYS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A213054	001	Oct 05, 2020	May DISC
--	--	-------------	------------------------------------	---------	-----	--------------	----------

AP		GLENMARK PHARMS LTD	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A213222	001	May 21, 2021	May NEWA
----	--	---------------------	------------------------------------	---------	-----	--------------	----------

ICOSAPENT ETHYL

## CAPSULE;ORAL

## ICOSAPENT ETHYL

AB		APOTEX	1GM	A209437	001	Jun 30, 2021	Jun NEWA
----	--	--------	-----	---------	-----	--------------	----------

		@ TEVA PHARMS USA	500MG	A209525	001	Sep 11, 2020	Mar DISC
--	--	-------------------	-------	---------	-----	--------------	----------

		@	1GM	A209525	002	Sep 11, 2020	Mar DISC
--	--	---	-----	---------	-----	--------------	----------

		VASCEPA					
--	--	---------	--	--	--	--	--

	+	AMARIN PHARMS	500MG	N202057	002	Feb 16, 2017	Mar CTEC
--	---	---------------	-------	---------	-----	--------------	----------

ILOPROST

## SOLUTION; INHALATION

## VENTAVIS

	+	!	ACTELION	10MCG/ML (10MCG/ML)	N021779	002	Dec 08, 2005	Feb CAHN
--	---	---	----------	---------------------	---------	-----	--------------	----------

		@		20MCG/2ML (10MCG/ML)	N021779	001	Dec 29, 2004	Feb CAHN
--	--	---	--	----------------------	---------	-----	--------------	----------

	+	!		20MCG/ML (20MCG/ML)	N021779	003	Aug 07, 2009	Feb CAHN
--	---	---	--	---------------------	---------	-----	--------------	----------

IMIPRAMINE HYDROCHLORIDE

## TABLET;ORAL

## IMIPRAMINE HYDROCHLORIDE

AB	+	SPECGX LLC	10MG	A087846	002	May 22, 1984	Aug CRLD
----	---	------------	------	---------	-----	--------------	----------

AB	+		25MG	A087846	003	May 22, 1984	Aug CRLD
----	---	--	------	---------	-----	--------------	----------

## TOFRANIL

AB	+	!	SPECGX LLC	50MG	A087846	001	May 22, 1984	Aug CRLD
----	---	---	------------	------	---------	-----	--------------	----------

IMIQUIMOD

## CREAM; TOPICAL

## IMIQUIMOD

AB		TARO	3.75%	A205971	001	Jan 26, 2021	Jan NFTG
----	--	------	-------	---------	-----	--------------	----------

		ZYCLARA					
--	--	---------	--	--	--	--	--

AB	+	!	BAUSCH	3.75%	N022483	001	Mar 25, 2010	Jan CFTG
----	---	---	--------	-------	---------	-----	--------------	----------

INDAPAMIDE

	TABLET; ORAL							
	INDAPAMIDE							
AB	!	ANI PHARMS	2.5MG	A074299	001	Jul 27, 1995	Jul	CHRS
	@	MYLAN	1.25MG	A074461	002	Mar 26, 1997	Jul	DISC
	@		2.5MG	A074461	001	Mar 27, 1996	Jul	DISC

INDOCYANINE GREEN

	INJECTABLE; INJECTION							
	INDOCYANINE GREEN							
AP		RENEW PHARMS	25MG/VIAL	A040811	001	Nov 21, 2007	Jun	CAHN

INDOMETHACIN

	CAPSULE; ORAL							
	INDOMETHACIN							
	@	JUBILANT GENERICS	25MG	A205215	001	Aug 25, 2017	Jan	DISC
	@		50MG	A205215	002	Aug 25, 2017	Jan	DISC
	TIVORBEX							
	+	@ GENUS	20MG	N204768	001	Feb 24, 2014	Apr	DISC
	+	@	40MG	N204768	002	Feb 24, 2014	Apr	DISC
	CAPSULE, EXTENDED RELEASE; ORAL							
	INDOMETHACIN							
	@	AUROBINDO PHARMA LTD	75MG	A204243	001	Dec 27, 2016	Jan	DISC
	@	JUBILANT GENERICS	75MG	A202706	001	Oct 05, 2015	Jun	DISC

INFIGRATINIB PHOSPHATE

	CAPSULE; ORAL							
	TRUESELTIQ							
	+	HELSINN HLTHCARE	25MG	N214622	001	May 28, 2021	Sep	CAHN
	+	!	100MG	N214622	002	May 28, 2021	Sep	CAHN
	+	QED THERAP	25MG	N214622	001	May 28, 2021	May	NEWA
	+	!	100MG	N214622	002	May 28, 2021	May	NEWA

IOPAMIDOL

	INJECTABLE; INJECTION							
	ISOVUE-300							
	+	!	BRACCO	N018735	002	Dec 31, 1985	Jan	CTEC
			ISOVUE-370					
	+	!	BRACCO	N018735	003	Dec 31, 1985	Jan	CTEC
			SCANLUX-300					
	@	SANOCHEMIA CORP USA	61%	A090394	001	Jun 18, 2010	Jan	DISC
			SCANLUX-370					
	@	SANOCHEMIA CORP USA	76%	A090394	002	Jun 18, 2010	Jan	DISC

IOVERSOL

	INJECTABLE; INJECTION							
	OPTIRAY 240							
	+	@	LIEBEL-FLARSHEIM	N019710	002	Dec 30, 1988	Sep	DISC

IPRATROPIUM BROMIDE

	SOLUTION; INHALATION							
	IPRATROPIUM BROMIDE							
>D>	AN	LANDELA PHARM	0.02%	A077072	001	Jul 19, 2005	Nov	DISC
>A>		@	0.02%	A077072	001	Jul 19, 2005	Nov	DISC
	AN	LUOXIN AUROVITAS	0.02%	A206543	001	Oct 27, 2016	Aug	CAHN
		@	0.02%	A075507	001	Jan 19, 2001	Oct	CAHN

IRBESARTAN

	TABLET; ORAL							
	IRBESARTAN							
	@	PICKET PHARMS	75MG	A203161	001	Sep 27, 2012	Oct	CAHN
	@		150MG	A203161	002	Sep 27, 2012	Oct	CAHN
	@		300MG	A203161	003	Sep 27, 2012	Oct	CAHN
>D>	@	UNICHEM	75MG	A203020	001	Dec 07, 2015	Nov	CMFD
>A>	AB		75MG	A203020	001	Dec 07, 2015	Nov	CMFD
>D>		@	150MG	A203020	002	Dec 07, 2015	Nov	CMFD
>A>	AB		150MG	A203020	002	Dec 07, 2015	Nov	CMFD
>D>		@	300MG	A203020	003	Dec 07, 2015	Nov	CMFD
>A>	AB		300MG	A203020	003	Dec 07, 2015	Nov	CMFD
	@	US ANTIBIOTICS	75MG	A203161	001	Sep 27, 2012	May	CAHN
	@		150MG	A203161	002	Sep 27, 2012	May	CAHN

TABLET;ORAL  
IRBESARTAN

@ 300MG A203161 003 Sep 27, 2012 May CAHN

IRINOTECAN HYDROCHLORIDE

## INJECTABLE; INJECTION

## IRINOTECAN HYDROCHLORIDE

@ PICKET PHARMS 40MG/2ML (20MG/ML) A078953 001 Apr 15, 2010 Oct CAHN

@ 100MG/5ML (20MG/ML) A078953 002 Apr 15, 2010 Oct CAHN

>D> AP QILU 40MG/2ML (20MG/ML) A203380 001 May 03, 2016 Nov CAHN

>D> AP 100MG/5ML (20MG/ML) A203380 002 May 03, 2016 Nov CAHN

>D> AP 300MG/15ML (20MG/ML) A203380 003 May 03, 2016 Nov CAHN

>A> AP QILU PHARM HAINAN 40MG/2ML (20MG/ML) A203380 001 May 03, 2016 Nov CAHN

>A> AP 100MG/5ML (20MG/ML) A203380 002 May 03, 2016 Nov CAHN

>A> AP 300MG/15ML (20MG/ML) A203380 003 May 03, 2016 Nov CAHN

@ US ANTIBIOTICS 40MG/2ML (20MG/ML) A078953 001 Apr 15, 2010 May CAHN

@ 100MG/5ML (20MG/ML) A078953 002 Apr 15, 2010 May CAHN

ISOETHARINE HYDROCHLORIDE

## SOLUTION; INHALATION

## ISOETHARINE HYDROCHLORIDE

+ @ ASTRAZENECA 0.062% A087937 001 Nov 15, 1982 Aug CRLD

+ @ 0.125% A087938 001 Nov 15, 1982 Aug CRLD

+ @ 0.167% A088470 001 Mar 14, 1984 Aug CRLD

+ @ 0.2% A088471 001 Mar 14, 1984 Aug CRLD

+ @ 0.25% A088472 001 Mar 14, 1984 Aug CRLD

+ @ DEY 1% A086763 001 Aug CRLD

ISOFLURANE

## LIQUID; INHALATION

## ISOFLURANE

AN PIRAMAL PHARMA 99.9% A074502 001 Jun 27, 1995 Aug CAHN

ISONIAZID

## SYRUP; ORAL

## ISONIAZID

+! CMP PHARMA INC 50MG/5ML A088235 001 Nov 10, 1983 Aug CRLD

ISOPROTERENOL HYDROCHLORIDE

## INJECTABLE; INJECTION

## ISOPROTERENOL HYDROCHLORIDE

AP AMRING PHARMS 0.2MG/ML A211237 001 May 19, 2021 May NEWA

@ AUROBINDO PHARMA LTD 0.2MG/ML A211864 001 Feb 09, 2021 Aug DISC

AP 0.2MG/ML A211864 001 Feb 09, 2021 Jan NEWA

>A> AP AVET LIFESCIENCES 0.2MG/ML A212189 001 Nov 19, 2021 Nov NEWA

@ CIPLA 0.2MG/ML A211738 001 Jun 28, 2019 Aug DISC

>D> @ EUGIA PHARMA 0.2MG/ML A211864 001 Feb 09, 2021 Nov CMFD

>A> AP 0.2MG/ML A211864 001 Feb 09, 2021 Nov CMFD

AP MICRO LABS 0.2MG/ML A210845 001 Feb 16, 2021 Feb NEWA

ISOSORBIDE DINITRATE

## TABLET; ORAL

## ISOSORBIDE DINITRATE

>A> AB PAR PHARM INC 40MG A211290 001 Nov 23, 2021 Nov NEWA

ISOSORBIDE MONONITRATE

## TABLET, EXTENDED RELEASE; ORAL

## ISOSORBIDE MONONITRATE

>A> @ STRIDES PHARMA 30MG A090598 001 Aug 11, 2010 Nov CAHN

>A> @ 60MG A090598 002 Aug 11, 2010 Nov CAHN

>A> @ 120MG A090598 003 Aug 11, 2010 Nov CAHN

>D> @ VINTAGE PHARMS 30MG A090598 001 Aug 11, 2010 Nov CAHN

>D> @ 60MG A090598 002 Aug 11, 2010 Nov CAHN

>D> @ 120MG A090598 003 Aug 11, 2010 Nov CAHN

ISOSULFAN BLUE

## INJECTABLE; INJECTION

## ISOSULFAN BLUE

AP HONG KONG 1% A213130 001 Nov 03, 2021 Oct NEWA

ISOTRETINOIN

CAPSULE;ORAL

ABSORICA

AB2	+	SUN PHARM INDS INC	10MG	N021951	001	May 25, 2012	Mar	CFTG
AB2	+		20MG	N021951	002	May 25, 2012	Mar	CFTG
AB2	+		25MG	N021951	005	Aug 15, 2014	Mar	CFTG
AB2	+		30MG	N021951	003	May 25, 2012	Mar	CFTG
AB2	+		35MG	N021951	006	Aug 15, 2014	Mar	CFTG
AB2	+		40MG	N021951	004	May 25, 2012	Mar	CFTG

AMNESTEEM

AB1		MYLAN PHARMS INC	10MG	A075945	001	Nov 08, 2002	Mar	CTEC
AB1			20MG	A075945	002	Nov 08, 2002	Mar	CTEC
AB1			40MG	A075945	003	Nov 08, 2002	Mar	CTEC

CLARAVIS

AB1		TEVA PHARMS USA	10MG	A076356	001	Apr 11, 2003	Mar	CTEC
AB1			20MG	A076135	002	Apr 11, 2003	Mar	CTEC
AB1			30MG	A076135	003	May 11, 2006	Mar	CTEC
AB1	!		40MG	A076135	001	Apr 11, 2003	Mar	CTEC

ISOTRETINOIN

AB2		ACTAVIS LABS FL	10MG	A205063	001	Mar 31, 2021	Mar	NFTG
AB2			20MG	A205063	002	Mar 31, 2021	Mar	NFTG
AB2			25MG	A205063	003	Mar 31, 2021	Mar	NFTG
AB2			30MG	A205063	004	Mar 31, 2021	Mar	NFTG
AB2			35MG	A205063	005	Mar 31, 2021	Mar	NFTG
AB2			40MG	A205063	006	Mar 31, 2021	Mar	NFTG
AB1		AMNEAL PHARMS NY	10MG	A207792	001	Sep 29, 2017	Mar	CTEC
AB1			20MG	A207792	002	Sep 29, 2017	Mar	CTEC
AB1			30MG	A207792	003	Sep 29, 2017	Mar	CTEC
AB1			40MG	A207792	004	Sep 29, 2017	Mar	CTEC
AB2		UPSHER SMITH LABS	10MG	A212333	001	Sep 21, 2021	Sep	NEWA
AB2			20MG	A212333	002	Sep 21, 2021	Sep	NEWA
AB2			30MG	A212333	003	Sep 21, 2021	Sep	NEWA
AB2			40MG	A213571	001	Apr 12, 2021	Apr	NEWA

MYORISAN

AB1		DOUGLAS PHARMS	10MG	A076485	001	Jan 19, 2012	Mar	CTEC
AB1			20MG	A076485	002	Jan 19, 2012	Mar	CTEC
AB1			30MG	A076485	004	Aug 25, 2015	Mar	CTEC
AB1			40MG	A076485	003	Jan 19, 2012	Mar	CTEC

ZENATANE

AB1		DR REDDYS LABS LTD	10MG	A202099	001	Mar 25, 2013	Mar	CTEC
AB1			20MG	A202099	002	Mar 25, 2013	Mar	CTEC
AB1			30MG	A202099	004	Feb 23, 2015	Mar	CTEC
AB1			40MG	A202099	003	Mar 25, 2013	Mar	CTEC

ITRACONAZOLE

CAPSULE;ORAL

ITRACONAZOLE

>D>	BX	MYLAN PHARMS INC	100MG	A200463	001	Jul 20, 2012	Nov	DISC
>A>		@	100MG	A200463	001	Jul 20, 2012	Nov	DISC
	BX		100MG	A200463	001	Jul 20, 2012	Sep	CTEC
	BX	STRIDES PHARMA	100MG	A206410	001	Jul 02, 2019	Sep	CTEC

TABLET;ORAL

ONMEL

	+	@ SEBELA IRELAND LTD	200MG	N022484	001	Apr 29, 2010	Apr	DISC
--	---	----------------------	-------	---------	-----	--------------	-----	------

IVACAFTOR; IVACAFTOR, TEZACAFTOR

TABLET;ORAL

SYMDEKO (COPACKAGED)

	+	VERTEX PHARMS INC	75MG;75MG, 50MG	N210491	002	Jun 21, 2019	Jul	CPOT
	+		75MG,N/A;75MG, 50MG	N210491	002	Jun 21, 2019	Jul	CDFR
	+		150MG;150MG, 100MG	N210491	001	Feb 12, 2018	Jul	CPOT
	+		150MG,N/A;150MG, 100MG	N210491	001	Feb 12, 2018	Jul	CDFR

IVOSIDENIB

TABLET;ORAL

TIBSOVO

	+	SERVIER	250MG	N211192	001	Jul 20, 2018	Apr	CAHN
--	---	---------	-------	---------	-----	--------------	-----	------

IXAZOMIB CITRATE

CAPSULE;ORAL  
NINLARO

+	TAKEDA PHARMS USA	EQ 2.3MG BASE	N208462	001	Nov 20, 2015	May	CAHN
+		EQ 3MG BASE	N208462	002	Nov 20, 2015	May	CAHN
+	!	EQ 4MG BASE	N208462	003	Nov 20, 2015	May	CAHN

KETAMINE HYDROCHLORIDE

INJECTABLE;INJECTION  
KETAMINE HYDROCHLORIDE

AP	AUROMEDICS PHARMA	EQ 10MG BASE/ML	A076092	001	Sep 30, 2008	Jan	CAHN
AP		EQ 50MG BASE/ML	A076092	002	Dec 28, 2001	Jan	CAHN
AP		EQ 100MG BASE/ML	A076092	003	Oct 25, 2002	Jan	CAHN
AP	EUGIA PHARMA	EQ 10MG BASE/ML	A076092	001	Sep 30, 2008	Aug	CAHN
AP		EQ 50MG BASE/ML	A076092	002	Dec 28, 2001	Aug	CAHN
AP		EQ 100MG BASE/ML	A076092	003	Oct 25, 2002	Aug	CAHN

KETOCONAZOLE

AEROSOL, FOAM;TOPICAL  
EXTINA

AB	+	MYLAN	2%	N021738	001	Jun 12, 2007	Sep	CTEC
AB		PADAGIS ISRAEL	2%	A091550	001	Aug 25, 2011	Sep	CTEC
AB		XIROMED	2%	A213601	001	May 21, 2021	Sep	CTEC
AT			2%	A213601	001	May 21, 2021	May	NEWA

CREAM;TOPICAL  
KETOCONAZOLE

AB		ENCUBE	2%	A212443	001	May 20, 2021	May	NEWA
>A>	AB	TASMAN PHARMA	2%	A215185	001	Nov 17, 2021	Nov	NEWA

TABLET;ORAL  
KETOCONAZOLE

AB	@	MYLAN	200MG	A075597	001	Dec 23, 1999	Mar	DISC
AB		SENORES PHARMS	200MG	A075912	001	Jan 10, 2002	Aug	CAHN

KETOPROFEN

CAPSULE;ORAL  
KETOPROFEN

>D>		HERITAGE PHARMS INC	25MG	A074014	001	Jan 29, 1993	Nov	CAHN
>D>	AB		50MG	A074014	002	Jan 29, 1993	Nov	CAHN
>D>		!	75MG	A074014	003	Jan 29, 1993	Nov	CAHN
		!	75MG	A074014	003	Jan 29, 1993	Jul	CTEC
AB		!	75MG	A074014	003	Jan 29, 1993	Jul	CHRS
>A>		MISEMER	25MG	A074014	001	Jan 29, 1993	Nov	CAHN
>A>	AB		50MG	A074014	002	Jan 29, 1993	Nov	CAHN
>A>		!	75MG	A074014	003	Jan 29, 1993	Nov	CAHN
		@ RISING	50MG	A074024	001	Dec 29, 1995	Jan	CAHN
		@	75MG	A074024	002	Dec 29, 1995	Jan	CAHN
		@ TEVA	75MG	A073517	001	Dec 22, 1992	Jul	DISC

KETOROLAC TROMETHAMINE

INJECTABLE;INJECTION  
KETOROLAC TROMETHAMINE  
@ HOSPIRA

15MG/ML	A074993	001	Jan 27, 1999	Mar	DISC
---------	---------	-----	--------------	-----	------

LABETALOL HYDROCHLORIDE

INJECTABLE;INJECTION  
LABETALOL HYDROCHLORIDE

AP		BAXTER HLTHCARE CORP	5MG/ML	A076051	001	Jul 05, 2002	Mar	CMFD
AP		CAPLIN	5MG/ML	A214533	001	Sep 07, 2021	Aug	NEWA

SOLUTION;INTRAVENOUS  
LABETALOL HYDROCHLORIDE IN DEXTROSE

+	!	HIKMA	200MG/200ML (1MG/ML)	N213330	001	Nov 09, 2020	Sep	CAHN
			LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE					
+	!	HIKMA	100MG/100ML (1MG/ML)	N213330	002	Nov 09, 2020	Sep	CAHN
+	!		200MG/200ML (1MG/ML)	N213330	003	Nov 09, 2020	Sep	CAHN
+	!		300MG/300ML (1MG/ML)	N213330	004	Nov 09, 2020	Sep	CAHN

TABLET;ORAL  
LABETALOL HYDROCHLORIDE

AB	!	PAR FORM	200MG	A200908	002	Jul 10, 2012	Jul	CHRS
AB		RUBICON	100MG	A211953	001	Aug 18, 2021	Aug	NEWA
AB			200MG	A211953	002	Aug 18, 2021	Aug	NEWA

TABLET;ORAL  
LABETALOL HYDROCHLORIDE

AB		300MG	A211953	003	Aug 18, 2021	Aug	NEWA
	TRANDATE						
	+ @ ALVOGEN	100MG	N018716	001	May 24, 1985	Jul	DISC
AB	+	100MG	N018716	001	May 24, 1985	Jul	CAHN
AB	+	200MG	N018716	002	Aug 01, 1984	Oct	CMFD
	+ @	200MG	N018716	002	Aug 01, 1984	Jul	DISC
AB	+!	200MG	N018716	002	Aug 01, 1984	Jul	CAHN
AB	+	300MG	N018716	003	Aug 01, 1984	Oct	CMFD
	+ @	300MG	N018716	003	Aug 01, 1984	Jul	DISC
AB	+	300MG	N018716	003	Aug 01, 1984	Jul	CAHN
	+ @	400MG	N018716	004	Aug 01, 1984	Jul	CAHN
AB	+! CNTY LINE PHARMS	200MG	N018716	002	Aug 01, 1984	Apr	CHRS

LACTULOSE

SOLUTION;ORAL

>D>	CONSTILAC						
>D> AA	ALRA	10GM/15ML	A071054	001	Jul 26, 1988	Nov	DISC
>A>	@	10GM/15ML	A071054	001	Jul 26, 1988	Nov	DISC
	LACTULOSE						
AA	TORRENT	10GM/15ML	A207786	001	Jun 11, 2018	Jun	CMFD
	SOLUTION;ORAL, RECTAL						
>D>	CHOLAC						
>D> AA	ALRA	10GM/15ML	A071331	001	Jul 26, 1988	Nov	DISC
>A>	@	10GM/15ML	A071331	001	Jul 26, 1988	Nov	DISC
	LACTULOSE						
AA	TORRENT	10GM/15ML	A203762	001	Mar 27, 2015	Jun	CMFD

LAMIVUDINE

TABLET;ORAL  
LAMIVUDINE

AB	APPCO	150MG	A206974	001	Nov 21, 2016	Sep	CAHN
AB		300MG	A206974	002	Nov 21, 2016	Sep	CAHN
AB	BRECKENRIDGE	150MG	A203586	001	Nov 21, 2016	Sep	CAHN
AB	CENTAUR PHARMS PVT	150MG	A203586	001	Nov 21, 2016	Jun	CAHN

LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL  
LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

	+ @ AUROBINDO PHARMA LTD	300MG;300MG	N022344	001	May 15, 2018	Feb	DISC
	TEMIXYS						
	+ @ CELLTRION	300MG;300MG	N211284	001	Nov 16, 2018	Aug	DISC

LAMOTRIGINE

TABLET;ORAL  
LAMOTRIGINE

	@ GRANULES	25MG	A078982	001	Jan 27, 2009	Jun	CAHN
	@	100MG	A078982	002	Jan 27, 2009	Jun	CAHN
	@	150MG	A078982	003	Jan 27, 2009	Jun	CAHN
	@	200MG	A078982	004	Jan 27, 2009	Jun	CAHN
	@ ZENNOVA	25MG	A078310	001	Feb 04, 2009	Sep	CAHN
	@	100MG	A078310	002	Feb 04, 2009	Sep	CAHN
	@	150MG	A078310	003	Feb 04, 2009	Sep	CAHN
	@	200MG	A078310	004	Feb 04, 2009	Sep	CAHN

TABLET, CHEWABLE;ORAL

LAMOTRIGINE

	@ JUBILANT GENERICS	5MG	A200220	001	Feb 28, 2011	Jun	DISC
	@	25MG	A200220	002	Feb 28, 2011	Jun	DISC

TABLET, EXTENDED RELEASE;ORAL

LAMOTRIGINE

AB	ACTAVIS ELIZABETH	250MG	A200672	006	Nov 13, 2013	Jul	CMS1
>A> AB	YILING	25MG	A213949	001	Dec 08, 2021	Nov	NEWA
>A> AB		50MG	A213949	002	Dec 08, 2021	Nov	NEWA
>A> AB		100MG	A213949	003	Dec 08, 2021	Nov	NEWA
>A> AB		200MG	A213949	004	Dec 08, 2021	Nov	NEWA
>A> AB		250MG	A213949	005	Dec 08, 2021	Nov	NEWA
>A> AB		300MG	A213949	006	Dec 08, 2021	Nov	NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

LAMOTRIGINE

AB	AJANTA PHARMA LTD	25MG	A213271	001	Jan 19, 2021	Jan	NEWA
AB		50MG	A213271	002	Jan 19, 2021	Jan	NEWA

TABLET, ORALLY DISINTEGRATING;ORAL  
LAMOTRIGINE

AB		100MG	A213271	003	Jan 19, 2021	Jan NEWA
AB		200MG	A213271	004	Jan 19, 2021	Jan NEWA

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL  
PREVACID

+ @	TAKEDA PHARMS USA	15MG	N020406	001	May 10, 1995	Jun DISC
-----	-------------------	------	---------	-----	--------------	----------

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL  
LANSOPRAZOLE

AB	DR REDDYS LABS LTD	15MG	A210465	001	Feb 01, 2021	Jan NEWA
AB		30MG	A210465	002	Feb 01, 2021	Jan NEWA

LASMIDITAN SUCCINATE

TABLET;ORAL  
REYVOW

+	ELI LILLY AND CO	EQ 50MG BASE	N211280	001	Jan 31, 2020	May CPOT
+	!	EQ 100MG BASE	N211280	002	Jan 31, 2020	Aug CHRS
+		EQ 100MG BASE	N211280	002	Jan 31, 2020	May CHRS
+	!	EQ 100MG BASE	N211280	002	Jan 31, 2020	May CPOT
+	@	EQ 200MG BASE	N211280	003	Dec 18, 2020	Aug DISC
+	!	EQ 200MG BASE	N211280	003	Dec 18, 2020	May CHRS
+		EQ 200MG BASE	N211280	003	Dec 18, 2020	May CPOT

LATANOPROST

EMULSION;OPHTHALMIC  
XELPROS

+	SUN PHARM	0.005%	N206185	001	Sep 12, 2018	Oct CAHN
---	-----------	--------	---------	-----	--------------	----------

LEFLUNOMIDE

TABLET;ORAL  
LEFLUNOMIDE

>D>	AB	AET PHARMA	10MG	A213497	001	May 10, 2021	Nov DISC
>A>		@	10MG	A213497	001	May 10, 2021	Nov DISC
	AB		10MG	A213497	001	May 10, 2021	Jun CAHN
>D>	AB		20MG	A213497	002	May 10, 2021	Nov DISC
>A>		@	20MG	A213497	002	May 10, 2021	Nov DISC
	AB		20MG	A213497	002	May 10, 2021	Jun CAHN
	AB	AUROBINDO PHARMA LTD	10MG	A213652	001	Mar 29, 2021	Mar NEWA
	AB		20MG	A213652	002	Mar 29, 2021	Mar NEWA
	AB	AXUNIO	10MG	A213497	001	May 10, 2021	Apr NEWA
	AB		20MG	A213497	002	May 10, 2021	Apr NEWA

LENALIDOMIDE

CAPSULE;ORAL  
LENALIDOMIDE

AB	ARROW INTL	5MG	A201452	001	May 21, 2021	Jul CAHN
AB		10MG	A201452	002	May 21, 2021	Jul CAHN
AB		15MG	A201452	003	May 21, 2021	Jul CAHN
AB		25MG	A201452	004	May 21, 2021	Jul CAHN
AB	DR REDDYS	2.5MG	A209348	001	Oct 14, 2021	Oct NFTG
AB		20MG	A209348	002	Oct 14, 2021	Oct NFTG
AB	NATCO PHARMA LTD	5MG	A201452	001	May 21, 2021	May NFTG
AB		10MG	A201452	002	May 21, 2021	May NFTG
AB		15MG	A201452	003	May 21, 2021	May NFTG
AB		25MG	A201452	004	May 21, 2021	May NFTG

REVLIMID

AB	+	CELGENE	2.5MG	N021880	005	Dec 21, 2011	Oct CFTG
AB	+		5MG	N021880	001	Dec 27, 2005	May CFTG
AB	+		10MG	N021880	002	Dec 27, 2005	May CFTG
AB	+		15MG	N021880	003	Jun 29, 2006	May CFTG
AB	+		20MG	N021880	006	Jun 05, 2013	Oct CFTG
AB	+		25MG	N021880	004	Jun 29, 2006	May CFTG

LETROZOLE

TABLET;ORAL  
LETROZOLE

>A>		@	APOTEX INC	2.5MG	A091303	001	Apr 19, 2012	Jan DISC
>D>		@	STRIDES PHARMA	2.5MG	A090789	001	Jun 03, 2011	Nov CAHN
		@	VINTAGE PHARMS LLC	2.5MG	A090789	001	Jun 03, 2011	Nov CAHN



LETROZOLE; RIBOCICLIB SUCCINATE

TABLET; ORAL

KISQALI FEMARA CO-PACK (COPACKAGED)

+!	NOVARTIS	2.5MG;EQ 200MG BASE	N209935	001	May 04, 2017	Jul	CPOT
+!		2.5MG,N/A;N/A,EQ 200MG BASE	N209935	001	May 04, 2017	Jul	CDFR

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM

AP	!	HIKMA	EQ 50MG BASE/VIAL	A089384	001	Sep 14, 1987	Jul	CAHN	
AP	!		EQ 100MG BASE/VIAL	A089717	001	Mar 28, 1988	Jul	CAHN	
	@	NOVAST LABS	EQ 10MG BASE/ML	A210917	001	Nov 23, 2018	Sep	CAHN	
LEUCOVORIN CALCIUM PRESERVATIVE FREE									
>A>	AP	!	HIKMA	EQ 10MG BASE/ML	A040347	001	Apr 25, 2000	Nov	CAHN
>A>	AP	!		EQ 200MG BASE/VIAL	A040056	001	May 23, 1995	Nov	CAHN
>A>	AP	!		EQ 350MG BASE/VIAL	A040335	001	Apr 20, 2000	Nov	CAHN
>D>	AP	!	WEST-WARD PHARMS INT	EQ 10MG BASE/ML	A040347	001	Apr 25, 2000	Nov	CAHN
>D>	AP	!		EQ 200MG BASE/VIAL	A040056	001	May 23, 1995	Nov	CAHN
>D>	AP	!		EQ 350MG BASE/VIAL	A040335	001	Apr 20, 2000	Nov	CAHN

TABLET; ORAL

LEUCOVORIN CALCIUM

AB		EPIC PHARMA LLC	EQ 10MG BASE	A074544	003	May 19, 2021	May	NEWA
AB			EQ 15MG BASE	A074544	004	May 19, 2021	May	NEWA

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

LEUPROLIDE ACETATE

AP		VGYAAN	1MG/0.2ML	A213829	001	Aug 13, 2021	Aug	NEWA
----	--	--------	-----------	---------	-----	--------------	-----	------

LEUPROLIDE ACETATE; NORETHINDRONE ACETATE

INJECTABLE, TABLET; INTRAMUSCULAR, ORAL

LUPANETA PACK

+	@	ABBVIE ENDOCRINE	3.75MG/VIAL,N/A;N/A,5MG	N203696	001	Dec 14, 2012	Aug	DISC
+	@		11.25MG/VIAL,N/A;N/A,5MG	N203696	002	Dec 14, 2012	Aug	DISC

LEUPROLIDE MESYLATE

EMULSION; SUBCUTANEOUS

CAMCEVI KIT

+!	FORESEE PHARMS	EQ 42MG BASE	N211488	001	May 25, 2021	May	NEWA
----	----------------	--------------	---------	-----	--------------	-----	------

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

LEVALBUTEROL HYDROCHLORIDE

AN		LUOXIN AUROVITAS	EQ 0.25% BASE	A207628	001	Jan 31, 2017	Aug	CAHN
AN			EQ 0.0103% BASE	A207625	001	Dec 30, 2016	Aug	CAHN
AN			EQ 0.021% BASE	A207625	002	Dec 30, 2016	Aug	CAHN
AN			EQ 0.042% BASE	A207625	003	Dec 30, 2016	Aug	CAHN

LEVETIRACETAM

INJECTABLE; INTRAVENOUS

LEVETIRACETAM

@ JUBILANT GENERICS 500MG/5ML (100MG/ML)

LEVETIRACETAM IN SODIUM CHLORIDE

		GLAND PHARMA LTD	1GM/100ML (10MG/ML)	A206880	002	Oct 25, 2017	Feb	CPOT
AP			1.5GM/100ML (15MG/ML)	A206880	003	Oct 25, 2017	Feb	CDFR
AP	+!	HQ SPECIALITY PHARMA	1GM/100ML (10MG/ML)	N202543	002	Nov 09, 2011	Feb	CPOT
AP	+!		1.5GM/100ML (15MG/ML)	N202543	003	Nov 09, 2011	Feb	CPOT
AP		NEXUS PHARMS	1GM/100ML (10MG/ML)	A213532	002	Jul 06, 2020	Feb	CPOT
AP			1.5GM/100ML (15MG/ML)	A213532	003	Jul 06, 2020	Feb	CPOT

SOLUTION; ORAL

LEVETIRACETAM

AA		AKORN	100MG/ML	A090601	001	Feb 28, 2012	Feb	CAHN
>D>	@	ANDA REPOSITORY	100MG/ML	A079107	001	Jan 15, 2009	Nov	CAHN
>A>	AA	GENUS	100MG/ML	A090079	001	Apr 11, 2012	Nov	CAHN
>D>	AA	LANNETT CO INC	100MG/ML	A090079	001	Apr 11, 2012	Nov	CAHN
>A>	@	TOLMAR	100MG/ML	A079107	001	Jan 15, 2009	Nov	CAHN

TABLET; ORAL

LEVETIRACETAM

@ LOTUS PHARM CO LTD 250MG

@ 750MG

@ 1GM

A090906	002	Oct 31, 2016	Aug	DISC
A090906	003	Oct 31, 2016	Aug	DISC
A090906	004	Oct 31, 2016	Aug	DISC

TABLET;ORAL

LEVETIRACETAM									
	@ NOSTRUM LABS INC	250MG	A090511	001	Aug 18, 2011	Mar	DISC		
AB		250MG	A090511	001	Aug 18, 2011	Jan	CAHN		
	@	500MG	A090511	002	Aug 18, 2011	Mar	DISC		
AB		500MG	A090511	002	Aug 18, 2011	Jan	CAHN		
	@	750MG	A090511	003	Aug 18, 2011	Mar	DISC		
AB		750MG	A090511	003	Aug 18, 2011	Jan	CAHN		
	@	1GM	A090511	004	Aug 18, 2011	Mar	DISC		
AB		1GM	A090511	004	Aug 18, 2011	Jan	CAHN		
AB	SCIEGEN PHARMS INC	750MG	A215069	001	Jun 11, 2021	Jun	NEWA		
AB		1GM	A215069	002	Jun 11, 2021	Jun	NEWA		

TABLET, EXTENDED RELEASE;ORAL

ELEPSIA XR									
	+ TRIPOINT	1GM	N204417	001	Dec 20, 2018	Jan	CAHN		
	+!	1.5GM	N204417	002	Dec 20, 2018	Jan	CAHN		
LEVETIRACETAM									
AB	GENUS LIFESCIENCES	500MG	A204754	001	Aug 26, 2016	Sep	CAHN		
AB		750MG	A204754	002	Aug 26, 2016	Sep	CAHN		
	@ LOTUS PHARM CO LTD	500MG	A202095	002	Jun 06, 2016	Aug	DISC		
	@	750MG	A202095	001	Jun 06, 2016	Aug	DISC		
AB	OVERSEAS	750MG	A212688	001	Jun 11, 2020	May	CMFD		

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

AKBETA									
	@ AKORN	0.25%	A074779	001	Oct 29, 1996	Jul	DISC		
	@	0.5%	A074780	001	Oct 29, 1996	Jul	DISC		
BETAGAN									
	+ @ ALLERGAN	0.25%	N019814	001	Jun 28, 1989	Jun	DISC		

LEVOCARNITINE

SOLUTION;ORAL

LEVOCARNITINE									
>A>	AA	SAPTALIS PHARMS	1GM/10ML	A212533	001	Nov 10, 2021	Nov	NEWA	

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE									
AA	!	PADAGIS US	2.5MG/5ML	A091263	001	Nov 07, 2011	Jul	CAHN	
		XYZAL							
	+ @	SANOFI	2.5MG/5ML	N022157	001	Jan 28, 2008	Apr	DISC	

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE									
AB	!	GLENMARK GENERICS	5MG	A090385	001	Feb 24, 2011	Apr	CHRS	
	@	GRANULES	5MG	A090486	001	Mar 26, 2013	Apr	CAHN	
	@	NEOPHARMA	5MG	A204323	001	Dec 20, 2016	Mar	DISC	
>D>	AB	SUN PHARM INDS LTD	5MG	A201653	001	Jun 26, 2015	Nov	DISC	
>A>		@	5MG	A201653	001	Jun 26, 2015	Nov	DISC	
	@	US ANTIBIOTICS	5MG	A204323	001	Dec 20, 2016	May	CAHN	
		XYZAL							
	+ @	SANOFI	5MG	N022064	001	May 25, 2007	Apr	DISC	

LEVOFLOXACIN

TABLET;ORAL

LEVOFLOXACIN									
AB		CADILA	250MG	A077652	001	Sep 07, 2012	Jun	CAHN	
AB			500MG	A077652	002	Sep 07, 2012	Jun	CAHN	
AB			750MG	A077652	003	Sep 07, 2012	Jun	CAHN	
	@	JUBILANT GENERICS	250MG	A203613	001	Jun 19, 2015	Jun	DISC	
	@		500MG	A203613	002	Jun 19, 2015	Jun	DISC	

LEVOLEUCOVORIN CALCIUM

POWDER;INTRAVENOUS

LEVOLEUCOVORIN CALCIUM									
AP		HIKMA	EQ 50MG BASE/VIAL	A206263	001	Jun 16, 2016	Jul	CAHN	

SOLUTION;INTRAVENOUS

LEVOLEUCOVORIN CALCIUM									
AP		PRAXGEN	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A213797	001	Nov 02, 2021	Oct	NEWA	

LEVOMILNACIPRAN HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL  
FETZIMA

>D>	AB	+	ALLERGAN	EQ 20MG BASE	N204168	001	Jul 25, 2013	Nov	CTEC
>A>		+		EQ 20MG BASE	N204168	001	Jul 25, 2013	Nov	CTEC
>D>	AB	+		EQ 40MG BASE	N204168	002	Jul 25, 2013	Nov	CTEC
>A>		+		EQ 40MG BASE	N204168	002	Jul 25, 2013	Nov	CTEC
>D>	AB	+		EQ 80MG BASE	N204168	003	Jul 25, 2013	Nov	CTEC
>A>		+		EQ 80MG BASE	N204168	003	Jul 25, 2013	Nov	CTEC
>D>	AB	+	!	EQ 120MG BASE	N204168	004	Jul 25, 2013	Nov	CTEC
>A>		+	!	EQ 120MG BASE	N204168	004	Jul 25, 2013	Nov	CTEC

LEVOMILNACIPRAN HYDROCHLORIDE

>A>		@	HIKMA	EQ 20MG BASE	A210732	001	Nov 05, 2020	Nov	DISC
>A>		@		EQ 40MG BASE	A210732	002	Nov 05, 2020	Nov	DISC
>A>		@		EQ 80MG BASE	A210732	003	Nov 05, 2020	Nov	DISC
>A>		@		EQ 120MG BASE	A210732	004	Nov 05, 2020	Nov	DISC
>D>	AB		HIKMA PHARMS	EQ 20MG BASE	A210732	001	Nov 05, 2020	Nov	DISC
>D>	AB			EQ 40MG BASE	A210732	002	Nov 05, 2020	Nov	DISC
>D>	AB			EQ 80MG BASE	A210732	003	Nov 05, 2020	Nov	DISC
>D>	AB			EQ 120MG BASE	A210732	004	Nov 05, 2020	Nov	DISC

LEVONORGESTRELINTRAUTERINE DEVICE;INTRAUTERINE  
LILETTA

+	!	MEDICINES360	52MG	N206229	001	Feb 26, 2015	Oct	CRLD
!			52MG	N206229	001	Feb 26, 2015	Oct	CHRS

LEVORPHANOL TARTRATE

TABLET;ORAL

LEVORPHANOL TARTRATE

			NOVITIUM PHARMA	1MG	A213479	003	Jul 20, 2021	Jul	NEWA
AB				3MG	A213479	002	Jan 12, 2021	Jan	NEWA
AB	!	SENTYNL THERAPS INC		3MG	A074278	003	Jun 18, 2018	Jan	CTEC
AB		SUN PHARM INDS INC		2MG	A213906	001	Jun 17, 2021	Jun	NEWA

LEVOTHYROXINE SODIUM

CAPSULE;ORAL

LEVOTHYROXINE SODIUM

		@	TEVA PHARMS USA INC	0.075MG	A211369	001	Oct 28, 2020	Apr	DISC
		@		0.088MG	A213256	001	Jan 06, 2021	Jul	DISC
		@		0.1MG	A213256	002	Jan 06, 2021	Jul	DISC
AB				0.112MG	A211369	003	Apr 16, 2021	Apr	NFTG
		@		0.125MG	A213256	003	Jan 06, 2021	Jul	DISC
		@		0.15MG	A211369	002	Oct 28, 2020	Apr	DISC

TIROSINT

+		INSTITUT BIOCHIMIQUE	0.075MG	N021924	004	Oct 13, 2006	Apr	CTEC
+			0.088MG	N021924	010	Oct 02, 2009	Oct	CTEC
+			0.1MG	N021924	005	Oct 13, 2006	Oct	CTEC
AB	+		0.112MG	N021924	008	Oct 02, 2009	Apr	CFTG
+			0.125MG	N021924	006	Oct 13, 2006	Oct	CTEC
+			0.15MG	N021924	007	Oct 13, 2006	Apr	CTEC

POWDER;INTRAVENOUS

LEVOTHYROXINE SODIUM

@ DR REDDYS 100MCG/VIAL

A208837 001 Mar 27, 2020 Feb DISC

SOLUTION;INTRAVENOUS

LEVOTHYROXINE SODIUM

+! CUSTOPHARM INC 100MCG/ML N214253 001 May 17, 2021 May NEWA

SOLUTION;ORAL

THYQUIDITY

+! VISTAPHARM 100MCG/5ML N214047 001 Nov 30, 2020 Apr CAHN

TIROSINT-SOL

+		INSTITUT BIOCHIMIQUE	37.5MCG/ML	N206977	013	Jan 13, 2021	Jan	NEWA
+			44MCG/ML	N206977	014	Jan 13, 2021	Jan	NEWA
+			62.5MCG/ML	N206977	015	Jan 13, 2021	Jan	NEWA

LEVOTHYROXINE SODIUM \*\*

\*\*See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

THYRO-TABS

AB2,	+	ALVOGEN	0.025MG	N021116	001	Oct 24, 2002	Sep	CAHN
AB4								

TABLET;ORAL							
THYRO-TABS							
AB2, +		0.05MG	N021116	002	Oct 24, 2002	Sep	CAHN
AB4							
AB2, +		0.075MG	N021116	003	Oct 24, 2002	Sep	CAHN
AB4							
AB2, +		0.088MG	N021116	010	Oct 24, 2002	Sep	CAHN
AB4							
AB2, +		0.1MG	N021116	004	Oct 24, 2002	Sep	CAHN
AB4							
AB2, +		0.112MG	N021116	011	Oct 24, 2002	Sep	CAHN
AB4							
AB2, +		0.125MG	N021116	005	Oct 24, 2002	Sep	CAHN
AB4							
AB2, +		0.137MG	N021116	012	Dec 07, 2004	Sep	CAHN
AB4							
AB2, +		0.15MG	N021116	006	Oct 24, 2002	Sep	CAHN
AB4							
AB2, +		0.175MG	N021116	007	Oct 24, 2002	Sep	CAHN
AB4							
AB2, +		0.2MG	N021116	008	Oct 24, 2002	Sep	CAHN
AB4							
AB2, +		0.3MG	N021116	009	Oct 24, 2002	Sep	CAHN
AB4							
<u>LIDOCAINE</u>							
OINTMENT;TOPICAL							
LIDOCAINE							
AT	+!	FOUGERA PHARMS INC	5%	A080198	001		Aug CRLD
AT		QUAGEN	5%	A212695	001	Apr 20, 2021	Apr NEWA
	@	RISING	5%	A208604	001	Sep 20, 2017	May CAHN
PATCH;TOPICAL							
LIDOCAINE							
AB		NAL PHARM	5%	A205882	001	Apr 29, 2021	Apr NEWA
<u>LIDOCAINE HYDROCHLORIDE</u>							
INJECTABLE;INJECTION							
LIDOCAINE HYDROCHLORIDE							
AP		ASPIRO	1%	A214336	001	Nov 08, 2021	Oct NEWA
AP			1%	A214339	001	Nov 08, 2021	Oct NEWA
AP			2%	A214339	002	Nov 08, 2021	Oct NEWA
JELLY;TOPICAL							
XYLOCAINE							
	+ @	AKORN	2%	N008816	001		Jan DISC
SOLUTION;ORAL							
LIDOCAINE HYDROCHLORIDE VISCOUS							
AT		LANNETT CO INC	2%	A040708	001	Feb 27, 2007	Jan CMFD
<u>LIDOCAINE; PRILOCAINE</u>							
CREAM;TOPICAL							
LIDOCAINE AND PRILOCAINE							
AB		ACRUX DDS PTY	2.5%;2.5%	A212482	001	Jul 27, 2021	Jul NEWA
<u>LINACLOTIDE</u>							
CAPSULE;ORAL							
LINACLOTIDE							
	@	MYLAN	145MCG	A209564	001	Feb 09, 2021	Feb DISC
AB			145MCG	A209564	001	Feb 09, 2021	Jan NFTG
	@		290MCG	A209564	002	Feb 09, 2021	Feb DISC
AB			290MCG	A209564	002	Feb 09, 2021	Jan NFTG
LINZESS							
	+!	ALLERGAN	145MCG	N202811	001	Aug 30, 2012	Feb CTEC
AB	+!		145MCG	N202811	001	Aug 30, 2012	Jan CFTG
	+		290MCG	N202811	002	Aug 30, 2012	Feb CTEC
AB	+		290MCG	N202811	002	Aug 30, 2012	Jan CFTG
<u>LINAGLIPTIN</u>							
TABLET;ORAL							
LINAGLIPTIN							
AB		SUNSHINE	5MG	A208335	001	Aug 31, 2021	Aug NFTG
AB	+!	BOEHRINGER INGELHEIM	5MG	N201280	001	May 02, 2011	Aug CFTG

LINAGLIPTIN; METFORMIN HYDROCHLORIDETABLET; ORAL  
JENTADUETO

AB	+	BOEHRINGER INGELHEIM	2.5MG;500MG	N201281	001	Jan 30, 2012	Aug CFTG
AB	+		2.5MG;850MG	N201281	002	Jan 30, 2012	Aug CFTG
AB	+		2.5MG;1GM	N201281	003	Jan 30, 2012	Aug CFTG
LINAGLIPTIN AND METFORMIN HYDROCHLORIDE							
AB		SUNSHINE	2.5MG;500MG	A208336	001	Aug 30, 2021	Aug NFTG
AB			2.5MG;850MG	A208336	002	Aug 30, 2021	Aug NFTG
AB			2.5MG;1GM	A208336	003	Aug 30, 2021	Aug NFTG

LINCOMYCININJECTABLE; INJECTION  
LINCOMYCIN

AP		MICRO LABS	EQ 300MG BASE/ML	A215082	001	Nov 08, 2021	Oct NEWA
----	--	------------	------------------	---------	-----	--------------	----------

LINCOMYCIN HYDROCHLORIDEINJECTABLE; INJECTION  
LINCOCIN

AP	+	PFIZER	EQ 300MG BASE/ML	N050317	001		Feb CAHN
LINCOMYCIN HYDROCHLORIDE							
	@	PRAXGEN	EQ 300MG BASE/ML	A212770	001	Mar 12, 2021	Sep DISC
AP			EQ 300MG BASE/ML	A212770	001	Mar 12, 2021	Mar NEWA

LIOTHYRONINE SODIUMTABLET; ORAL  
LIOTHYRONINE SODIUM

AB		ZYDUS	EQ 0.005MG BASE	A214803	001	Jan 22, 2021	Jan NEWA
AB			EQ 0.025MG BASE	A214803	002	Jan 22, 2021	Jan NEWA
AB			EQ 0.05MG BASE	A214803	003	Jan 22, 2021	Jan NEWA

LISINAPRILTABLET; ORAL  
LISINAPRIL

AB		ASCENT PHARMS INC	2.5MG	A075903	001	Jul 01, 2002	Oct CMFD
AB			5MG	A075903	002	Jul 01, 2002	Oct CMFD
AB			10MG	A075903	003	Jul 01, 2002	Oct CMFD
AB			20MG	A075903	004	Jul 01, 2002	Oct CMFD
AB			30MG	A075903	005	Jul 01, 2002	Oct CMFD
AB			40MG	A075903	006	Jul 01, 2002	Oct CMFD
AB		YILING	20MG	A208920	001	Mar 04, 2021	Feb NEWA
AB			30MG	A208920	002	Mar 04, 2021	Feb NEWA
AB			40MG	A208920	003	Mar 04, 2021	Feb NEWA

LOPERAMIDE HYDROCHLORIDECAPSULE; ORAL  
LOPERAMIDE HYDROCHLORIDE

AB		BIONPHARMA INC	2MG	A215579	001	Oct 22, 2021	Oct NEWA
AB		EDENBRIDGE PHARMS	2MG	A215001	001	Oct 06, 2021	Sep NEWA

LOPINAVIR; RITONAVIRTABLET; ORAL  
KALETRA

AB	+	ABBVIE	100MG;25MG	N021906	002	Nov 09, 2007	May CFTG
AB	+		200MG;50MG	N021906	001	Oct 28, 2005	May CFTG
LOPINAVIR AND RITONAVIR							
AB		HETERO LABS LTD III	100MG;25MG	A091677	001	Jun 04, 2021	May NFTG
AB			200MG;50MG	A091677	002	Jun 04, 2021	May NFTG

LORAZEPAMCAPSULE, EXTENDED RELEASE; ORAL  
LOREEV XR

	+	ALMATICA	1MG	N214826	001	Aug 27, 2021	Aug NEWA
	+		2MG	N214826	002	Aug 27, 2021	Aug NEWA
	+		3MG	N214826	003	Aug 27, 2021	Aug NEWA

CONCENTRATE; ORAL  
LORAZEPAM

AA		AKORN	2MG/ML	A200169	001	Jan 30, 2012	Feb CAHN
----	--	-------	--------	---------	-----	--------------	----------

INJECTABLE; INJECTION  
ATIVAN

AP	+	HIKMA	2MG/ML	N018140	001		Jul	CAHN
AP	+		4MG/ML	N018140	002		Jul	CAHN

LOSARTAN POTASSIUM

TABLET; ORAL  
COZAAR

AB	+	ORGANON	25MG	N020386	001	Apr 14, 1995	Aug	CMFD
AB	+		50MG	N020386	002	Apr 14, 1995	Aug	CMFD

LOSARTAN POTASSIUM

AB		HIKMA	25MG	A077459	001	Oct 06, 2010	Jul	CMFD
AB			50MG	A077459	002	Oct 06, 2010	Jul	CMFD
AB			100MG	A077459	003	Oct 06, 2010	Jul	CMFD
AB		JUBILANT CADISTA	25MG	A201170	001	Sep 18, 2012	Jun	CAHN
AB			50MG	A201170	002	Sep 18, 2012	Jun	CAHN
AB			100MG	A201170	003	Sep 18, 2012	Jun	CAHN
>D>	@	UNICHEM	25MG	A203030	001	Oct 14, 2015	Nov	CMFD
>A>	AB		25MG	A203030	001	Oct 14, 2015	Nov	CMFD
>D>	@		50MG	A203030	002	Oct 14, 2015	Nov	CMFD
>A>	AB		50MG	A203030	002	Oct 14, 2015	Nov	CMFD
>D>	@		100MG	A203030	003	Oct 14, 2015	Nov	CMFD
>A>	AB		100MG	A203030	003	Oct 14, 2015	Nov	CMFD

LOTEPREDNOL ETABONATE

GEL; OPHTHALMIC  
LOTEMAX

AB	+	BAUSCH AND LOMB INC	0.5%	N202872	001	Sep 28, 2012	Jan	CFTG
----	---	---------------------	------	---------	-----	--------------	-----	------

LOTEPREDNOL ETABONATE

AB		AKORN	0.5%	A212080	001	Feb 10, 2021	Jan	NFTG
----	--	-------	------	---------	-----	--------------	-----	------

SUSPENSION/DROPS; OPHTHALMIC

LOTEPREDNOL ETABONATE

AB		SUN PHARM	0.5%	A212450	001	Feb 26, 2021	Feb	NEWA
----	--	-----------	------	---------	-----	--------------	-----	------

LUBIPROSTONE

CAPSULE; ORAL  
AMITIZA

>D>	+	SUCAMPO PHARMA LLC	8MCG	N021908	002	Apr 29, 2008	Nov	CFTG
>A>	AB		8MCG	N021908	002	Apr 29, 2008	Nov	CFTG
>D>	+		24MCG	N021908	001	Jan 31, 2006	Nov	CFTG
>A>	AB		24MCG	N021908	001	Jan 31, 2006	Nov	CFTG

LUBIPROSTONE

>A>	AB	AMNEAL	8MCG	A209450	001	Nov 30, 2021	Nov	NFTG
>A>	AB		24MCG	A209450	002	Nov 30, 2021	Nov	NFTG

LULICONAZOLE

CREAM; TOPICAL  
LUZU

+	!	BAUSCH	1%	N204153	001	Nov 14, 2013	May	CAHN
---	---	--------	----	---------	-----	--------------	-----	------

LURASIDONE HYDROCHLORIDE

TABLET; ORAL

LURASIDONE HYDROCHLORIDE

AB		ALEMBIC PHARMS LTD	20MG	A213248	001	May 13, 2021	May	NEWA
AB			40MG	A213248	002	May 13, 2021	May	NEWA
AB			60MG	A213248	003	May 13, 2021	May	NEWA
AB			80MG	A213248	004	May 13, 2021	May	NEWA
AB			120MG	A213248	005	May 13, 2021	May	NEWA
AB		DR REDDYS LABS LTD	20MG	A208047	001	Aug 24, 2021	Aug	NEWA
AB			40MG	A208047	002	Aug 24, 2021	Aug	NEWA
AB			60MG	A208047	003	Aug 24, 2021	Aug	NEWA
AB			80MG	A208047	004	Aug 24, 2021	Aug	NEWA
	@	PIRAMAL HLTHCARE UK	20MG	A212091	001	Dec 28, 2020	Aug	DISC
	@		40MG	A212091	002	Dec 28, 2020	Aug	DISC
	@		60MG	A212091	003	Dec 28, 2020	Aug	DISC
	@		80MG	A212091	004	Dec 28, 2020	Aug	DISC
	@		120MG	A212091	005	Dec 28, 2020	Aug	DISC
	@	WATSON LABS TEVA	20MG	A208016	001	Feb 02, 2021	Sep	DISC
AB			20MG	A208016	001	Feb 02, 2021	Jan	NEWA
	@		40MG	A208016	002	Feb 02, 2021	Sep	DISC
AB			40MG	A208016	002	Feb 02, 2021	Jan	NEWA
	@		60MG	A208016	003	Feb 02, 2021	Sep	DISC

## TABLET;ORAL

## LURASIDONE HYDROCHLORIDE

AB		60MG	A208016	003	Feb 02, 2021	Jan NEWA
	@	80MG	A208016	004	Feb 02, 2021	Sep DISC
AB		80MG	A208016	004	Feb 02, 2021	Jan NEWA
	@	120MG	A208016	005	Feb 02, 2021	Sep DISC
AB		120MG	A208016	005	Feb 02, 2021	Jan NEWA

MACITENTAN

## TABLET;ORAL

## MACITENTAN

AB	@ ZYDUS	10MG	A211224	001	Apr 06, 2021	Aug DISC
		10MG	A211224	001	Apr 06, 2021	Mar NFTG
	OPSUMIT					
AB	+! ACTELION	10MG	N204410	001	Oct 18, 2013	Aug CTEC
	+!	10MG	N204410	001	Oct 18, 2013	Mar CFTG
	+!	10MG	N204410	001	Oct 18, 2013	Feb CAHN

MAGNESIUM SULFATE

## INJECTABLE;INJECTION

## MAGNESIUM SULFATE

AP	B BRAUN MEDICAL INC	2GM/50ML (40MG/ML)	A207967	001	Apr 26, 2021	Apr NEWA
AP		4GM/100ML (40MG/ML)	A207967	002	Apr 26, 2021	Apr NEWA
AP		4GM/50ML (80MG/ML)	A207967	003	Apr 26, 2021	Apr NEWA
	MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER					
AP	BAXTER HLTHCARE CORP	1GM/100ML	A211965	001	Aug 11, 2020	Feb CMFD
	MAGNESIUM SULFATE IN PLASTIC CONTAINER					
AP	BAXTER HLTHCARE CORP	2GM/50ML (40MG/ML)	A211966	001	Jun 01, 2020	Feb CMFD
AP		4GM/50ML (80MG/ML)	A211966	002	Jun 01, 2020	Feb CMFD
AP		4GM/100ML (40MG/ML)	A211966	003	Jun 01, 2020	Feb CMFD
AP	PTS CONSULTING	2GM/50ML (40MG/ML)	A209642	001	Nov 08, 2021	Oct NEWA
AP		4GM/100ML (40MG/ML)	A209642	002	Nov 08, 2021	Oct NEWA
AP		4GM/50ML (80MG/ML)	A209642	003	Nov 08, 2021	Oct NEWA

MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE

## TABLET;ORAL

## SUTAB

>A>	+! BRAINTREE LABS	0.225GM;0.188GM;1.479GM	N213135	001	Nov 10, 2020	Nov CTNA
>D>	SUTAB (COPACKAGED)					
>D>	+! BRAINTREE LABS	0.225GM;0.188GM;1.479GM	N213135	001	Nov 10, 2020	Nov CTNA

MAPROTILINE HYDROCHLORIDE

## TABLET;ORAL

## MAPROTILINE HYDROCHLORIDE

## @ HERITAGE PHARMA

50MG

A072163 001 Jun 01, 1988 Jun CAHN

MARALIXIBAT CHLORIDE

## SOLUTION;ORAL

## LIVMARLI

## +! MIRUM

EQ 9.5MG BASE/ML

N214662 001 Sep 29, 2021 Sep NEWA

>A> MARIBAVIR

## TABLET;ORAL

## LIVTENCITY

## +! TAKEDA PHARMS USA

200MG

N215596 001 Nov 23, 2021 Nov NEWA

MECLIZINE HYDROCHLORIDE

## TABLET;ORAL

## MECLIZINE HYDROCHLORIDE

AA ANI PHARMS

12.5MG

A084657 002 Sep CMFD

AA

25MG

A084657 001 Sep CMFD

&gt;D&gt; @ PAR PHARM

50MG

A089674 001 Mar 31, 1988 Nov CAHN

&gt;A&gt; @ STRIDES PHARMA

50MG

A089674 001 Mar 31, 1988 Nov CAHN

MEDROXYPROGESTERONE ACETATE

## INJECTABLE;INJECTION

## DEPO-PROVERA

## + @ PFIZER

100MG/ML

N012541 002 Mar CAHN

AB +!

150MG/ML

N020246 001 Oct 29, 1992 Mar CAHN

## + @

400MG/ML

N012541 003 May DISC

## +!

400MG/ML

N012541 003 Mar CAHN

INJECTABLE;SUBCUTANEOUS  
DEPO-SUBQ PROVERA 104

	+	PFIZER	104MG/0.65ML	N021583	001	Dec 17, 2004	Mar CAHN
		TABLET;ORAL PROVERA					
AB	+	PFIZER	2.5MG	N011839	001		Mar CAHN
AB	+		5MG	N011839	003		Mar CAHN
AB	+		10MG	N011839	004		Mar CAHN

MEFENAMIC ACID

CAPSULE;ORAL  
MEFENAMIC ACID  
@ STRIDES PHARMA

250MG

A209209 001 Sep 18, 2020 Mar DISC

MEFLOQUINE HYDROCHLORIDE

TABLET;ORAL  
MEFLOQUINE HYDROCHLORIDE

AB	!	BARR	250MG	A076392	001	Dec 29, 2003	Aug CTEC
AB		HIKMA	250MG	A076523	001	Oct 01, 2004	Aug CMFD

MELOXICAM

CAPSULE;ORAL  
MELOXICAM

AB		LUPIN LTD	5MG	A209487	001	Jun 01, 2020	Feb CTEC
AB	!		10MG	A209487	002	Jun 01, 2020	Feb CTEC
AB		NOVITIUM PHARMA	5MG	A211398	001	Mar 09, 2021	Feb NEWA
AB			10MG	A211398	002	Mar 09, 2021	Feb NEWA

TABLET;ORAL  
MELOXICAM

@ AIPING PHARM INC 7.5MG  
@ 15MG

A077920 001 Jul 19, 2006 Oct CAHN  
A077920 002 Jul 19, 2006 Oct CAHN

MELPHALAN

TABLET;ORAL  
MELPHALAN

! ALVOGEN 2MG

A207809 001 Mar 22, 2017 Jan CAHN

MELPHALAN FLUFENAMIDE

POWDER;INTRAVENOUS  
PEPAXTO

+
 ONCOPEPTIDES AB | 20MG/VIAL |

N214383 001 Feb 26, 2021 Feb NEWA

MELPHALAN FLUFENAMIDE HYDROCHLORIDE

POWDER;INTRAVENOUS  
PEPAXTO

>D>	+	ONCOPEPTIDES AB	EQ 20MG BASE/VIAL	N214383	001	Feb 26, 2021	Nov DISC
>A>	+	@	EQ 20MG BASE/VIAL	N214383	001	Feb 26, 2021	Nov DISC
	+	!	EQ 20MG BASE/VIAL	N214383	001	Feb 26, 2021	Mar CPOT
	+	!	20MG/VIAL	N214383	001	Feb 26, 2021	Mar CAIN

MELPHALAN HYDROCHLORIDE

INJECTABLE;INJECTION  
ALKERAN

+ @ APOTEX EQ 50MG BASE/VIAL  
MELPHALAN HYDROCHLORIDE

N020207 001 Nov 18, 1992 Jan DISC

AP		ALMAJECT	EQ 50MG BASE/VIAL	A204817	001	May 17, 2019	Jul CAHN
AP		HIKMA	EQ 50MG BASE/VIAL	A090303	001	Oct 28, 2010	Jul CAHN
AP		HONG KONG	EQ 50MG BASE/VIAL	A212960	001	May 28, 2021	May NEWA
AP		MEITHEAL	EQ 50MG BASE/VIAL	A212960	001	May 28, 2021	Aug CAHN
		@ SCINOPHARM TAIWAN	EQ 50MG BASE/VIAL	A211463	001	Sep 13, 2019	Sep CAHN

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL  
MEMANTINE HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	7MG	A214651	001	Aug 09, 2021	Jul NEWA
AB			14MG	A214651	002	Aug 09, 2021	Jul NEWA
AB			21MG	A214651	003	Aug 09, 2021	Jul NEWA
AB			28MG	A214651	004	Aug 09, 2021	Jul NEWA
		@ MYLAN	7MG	A206032	001	Sep 28, 2016	Jul DISC
		@	14MG	A206032	002	Sep 28, 2016	Jul DISC
		@	21MG	A206032	003	Sep 28, 2016	Jul DISC
		@	28MG	A206032	004	Sep 28, 2016	Jul DISC



CAPSULE, EXTENDED RELEASE;ORAL  
MEMANTINE HYDROCHLORIDE

AB		YICHANG HUMANWELL	7MG	A211100	001	Apr 02, 2021	Mar	NEWA	
AB			14MG	A211100	002	Apr 02, 2021	Mar	NEWA	
AB			21MG	A211100	003	Apr 02, 2021	Mar	NEWA	
AB			28MG	A211100	004	Apr 02, 2021	Mar	NEWA	
		NAMENDA XR							
AB	+	ALLERGAN	7MG	N022525	001	Jun 21, 2010	Oct	CAHN	
AB	+		14MG	N022525	002	Jun 21, 2010	Oct	CAHN	
AB	+		21MG	N022525	003	Jun 21, 2010	Oct	CAHN	
AB	+	!	28MG	N022525	004	Jun 21, 2010	Oct	CAHN	

SOLUTION;ORAL

		MEMANTINE HYDROCHLORIDE							
AA		SETON PHARMS	2MG/ML	A210319	001	Aug 31, 2020	May	CAHN	
		TABLET;ORAL							
		MEMANTINE HYDROCHLORIDE							
		@ JUBILANT GENERICS	5MG	A091585	001	Oct 13, 2015	Jun	DISC	
		@	10MG	A091585	002	Oct 13, 2015	Jun	DISC	

MEPERIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

		DEMEROL							
		@ VALIDUS PHARMS	25MG/ML	N005010	007		Feb	CAHN	
		@	50MG/ML	N005010	002		Feb	CAHN	
		@	75MG/ML	N005010	009		Feb	CAHN	
		@	100MG/ML	N005010	003		Feb	CAHN	
		MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE							
	+	@ ICU MEDICAL INC	10MG/ML	A088432	001	Aug 16, 1984	Aug	CRLD	

SYRUP;ORAL

		DEMEROL							
		@ VALIDUS PHARMS	50MG/5ML	N005010	005		Feb	CAHN	

TABLET;ORAL

		DEMEROL							
	+	@ VALIDUS PHARMS	50MG	N005010	001		Feb	CAHN	
	+	@	100MG	N005010	004		Feb	CAHN	

MEPERIDINE HYDROCHLORIDE

>A>		@ STRIDES PHARMA	50MG	A040191	001	Dec 17, 1998	Nov	CAHN
>A>		@	100MG	A040191	002	Dec 17, 1998	Nov	CAHN
>D>		@ VINTAGE PHARMS	50MG	A040191	001	Dec 17, 1998	Nov	CAHN
>D>		@	100MG	A040191	002	Dec 17, 1998	Nov	CAHN

MEPROBAMATE

TABLET;ORAL

		MEPROBAMATE							
AA	!	ALEMBIC PHARMS LTD	200MG	A090122	001	Feb 18, 2009	Mar	CHRS	
AA	!		400MG	A090122	002	Feb 18, 2009	Mar	CHRS	
	+	@ WATSON LABS	200MG	A083304	001		Aug	CRLD	
		@	200MG	A083304	001		Mar	DISC	
	+	@	400MG	A083308	001		Aug	CRLD	
		@	400MG	A083308	001		Mar	DISC	

MEROPENEM

INJECTABLE;INJECTION

		MEROPENEM							
AP		EUGIA PHARMA	500MG/VIAL	A205835	001	Mar 27, 2017	Aug	CAHN	
AP			1GM/VIAL	A205835	002	Mar 27, 2017	Aug	CAHN	

MEROPENEM; VABORBACTAM

POWDER;INTRAVENOUS

		VABOMERE							
	+	!	REMPEX	N209776	001	Aug 29, 2017	Feb	CAHN	

MESALAMINE

CAPSULE, EXTENDED RELEASE;ORAL

		MESALAMINE							
AB		ALKEM LABS LTD	375MG	A214242	001	Jul 15, 2021	Jul	NEWA	
AB		ZYDUS PHARMS	375MG	A208954	001	Aug 12, 2021	Aug	NEWA	
		SUPPOSITORY;RECTAL							
		MESALAMINE							
AB		APTAPHARMA INC	1GM	A207448	001	Apr 19, 2019	Sep	CAHN	
AB		PHARM SOURCING	1GM	A207448	001	Apr 19, 2019	Oct	CAHN	

## TABLET, DELAYED RELEASE;ORAL

## MESALAMINE

>D>	BX	MYLAN	1.2GM	A203574	001	Nov 20, 2018	Nov	DISC
>A>		@	1.2GM	A203574	001	Nov 20, 2018	Nov	DISC
	BX		1.2GM	A203574	001	Nov 20, 2018	Sep	CTEC

METAPROTERENOL SULFATE

## SYRUP;ORAL

## METAPROTERENOL SULFATE

>A>	!	GENUS	10MG/5ML	A073632	001	Jul 22, 1992	Nov	CAHN
>D>	!	LANNETT CO INC	10MG/5ML	A073632	001	Jul 22, 1992	Nov	CAHN

METARAMINOL BITARTRATE

## INJECTABLE;INJECTION

## METARAMINOL BITARTRATE

		SLAYBACK PHARMA LLC	EQ 10MG BASE/ML	A211304	001	Aug 24, 2021	Aug	NEWA
--	--	---------------------	-----------------	---------	-----	--------------	-----	------

METAXALONE

## TABLET;ORAL

## METAXALONE

BX		APPCO	800MG	A208774	001	Sep 24, 2018	Oct	CAHN
BX		RISING	800MG	A208774	001	Sep 24, 2018	Sep	CTEC

METFORMIN HYDROCHLORIDE

## TABLET;ORAL

## METFORMIN HYDROCHLORIDE

AB		CHARTWELL	500MG	A075972	001	Jan 24, 2002	Jun	CAHN
			625MG	A075972	005	Jan 24, 2002	Jun	CAHN
			750MG	A075972	004	Jan 24, 2002	Jun	CAHN
AB			850MG	A075972	002	Jan 24, 2002	Jun	CAHN
AB			1GM	A075972	003	Jan 24, 2002	Jun	CAHN
>A>	AB	HARMAN FINOCHEM	500MG	A213320	001	Dec 03, 2021	Nov	NEWA
>A>	AB		850MG	A213320	002	Dec 03, 2021	Nov	NEWA
>A>	AB		1GM	A213320	003	Dec 03, 2021	Nov	NEWA
		@ INDICUS PHARMA	500MG	A079148	001	Nov 25, 2008	May	DISC
		@	850MG	A079148	002	Nov 25, 2008	May	DISC
		@	1GM	A079148	003	Nov 25, 2008	May	DISC

## TABLET, EXTENDED RELEASE;ORAL

## METFORMIN HYDROCHLORIDE

AB3		AJANTA PHARMA LTD	500MG	A213962	001	Mar 09, 2021	Feb	NEWA
AB3			1GM	A213962	002	Mar 09, 2021	Feb	NEWA
AB	!	ALKEM LABS LTD	750MG	A206145	002	Oct 22, 2018	Sep	CHRS
BX		AMNEAL PHARMS NY	500MG	A078596	001	Jan 03, 2008	Sep	CTEC
BX			750MG	A078596	002	Jan 03, 2008	Sep	CHRS
BX	!		750MG	A078596	002	Jan 03, 2008	Sep	CTEC
AB2		AMTA	500MG	A213394	001	Aug 03, 2021	Jul	NEWA
AB2			1GM	A213394	002	Aug 03, 2021	Jul	NEWA
		@ APOTEX	500MG	A076706	001	Dec 14, 2004	Apr	DISC
AB3		GRANULES	500MG	A213344	001	Jan 12, 2021	Jan	NEWA
AB3			1GM	A213344	002	Jan 12, 2021	Jan	NEWA
AB3		SCIEGEN PHARMS INC	500MG	A213334	001	Apr 16, 2021	Apr	NEWA
AB3			1GM	A213334	002	Apr 16, 2021	Apr	NEWA
AB2		TWI PHARMS	500MG	A213247	001	Sep 29, 2021	Sep	NEWA
AB2			1GM	A213247	002	Sep 29, 2021	Sep	NEWA
AB1		UNICHEM	500MG	A213359	001	Aug 11, 2021	Jul	NEWA
AB			750MG	A213359	002	Aug 11, 2021	Jul	NEWA

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

## TABLET;ORAL

## PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

		@ SANDOZ	500MG;EQ 15MG BASE	A091273	001	Apr 16, 2013	Sep	DISC
		@	850MG;EQ 15MG BASE	A091273	002	Apr 16, 2013	Sep	DISC
		@ TORRENT PHARMS LTD	500MG;EQ 15MG BASE	A202001	001	Feb 13, 2013	Jan	DISC
		@	850MG;EQ 15MG BASE	A202001	002	Feb 13, 2013	Jan	DISC

METHADONE HYDROCHLORIDE

## CONCENTRATE;ORAL

## METHADONE HYDROCHLORIDE

		@ LANNETT CO INC	10MG/ML	A212094	001	Mar 03, 2021	Aug	DISC
AA			10MG/ML	A212094	001	Mar 03, 2021	Feb	NEWA

SOLUTION;ORAL

METHADONE HYDROCHLORIDE

AA	+	!	HIKMA	5MG/5ML	A087393	001			Aug	CRLD
AA	+	!		10MG/5ML	A087997	001	Aug 30, 1982		Aug	CRLD

METHENAMINE HIPPURATE

TABLET;ORAL

HIPREX

	+	@	VALIDUS PHARMS	1GM	N017681	001			Mar	DISC
AB	+	!		1GM	N017681	001			Feb	CAHN

METHENAMINE HIPPURATE

AB	!		AUROBINDO PHARMA LTD	1GM	A205661	001	Jul 05, 2016		Mar	CHRS
AB			NOVAST LABS	1GM	A210068	001	Nov 27, 2020		Sep	CAHN

UREX

AB			ALVOGEN	1GM	N016151	001			Jul	CAHN
----	--	--	---------	-----	---------	-----	--	--	-----	------

METHIMAZOLE

TABLET;ORAL

METHIMAZOLE

AB			BIOPHARM	5MG	A040547	001	Feb 18, 2005		Sep	CAHN
AB				10MG	A040547	002	Feb 18, 2005		Sep	CAHN
		@		20MG	A040547	004	Feb 18, 2005		Sep	CAHN

METHOCARBAMOL

SOLUTION;IM-IV

ROBAXIN

AP	+	!	HIKMA	1GM/10ML (100MG/ML)	N011790	001			Jul	CAHN
----	---	---	-------	---------------------	---------	-----	--	--	-----	------

TABLET;ORAL

METHOCARBAMOL

>A>		@	AUROBINDO PHARMA LTD	750MG	A213967	001	Aug 12, 2020		Feb	DISC
	!		AUSTARPHARMA LLC	1GM	A200958	003	Dec 06, 2021		Nov	NEWA
AA			GRANULATION TECH	500MG	A212623	001	Apr 30, 2021		Apr	NEWA
AA				750MG	A212623	002	Apr 30, 2021		Apr	NEWA
AA			MLV	500MG	A212623	001	Apr 30, 2021		Jun	CAHN
AA				750MG	A212623	002	Apr 30, 2021		Jun	CAHN

METHOTREXATE SODIUM

INJECTABLE;INJECTION

FOLEX

	+	@	PHARMACIA AND UPJOHN	EQ 25MG BASE/VIAL	A087695	001	Apr 08, 1983		Aug	CRLD
	+	@		EQ 100MG BASE/VIAL	A087695	003	Apr 08, 1983		Aug	CRLD

METHOTREXATE SODIUM

AP	!		HIKMA	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A089341	001	Sep 16, 1986		Jul	CAHN
	!			EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A089342	001	Sep 16, 1986		Jul	CAHN

METHOTREXATE SODIUM PRESERVATIVE FREE

AP	!		HIKMA	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A089340	001	Sep 16, 1986		Jul	CAHN
AP	!			EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A089343	001	Sep 16, 1986		Jul	CAHN
		@	MYLAN	EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A201530	001	Mar 29, 2012		Aug	CAHN
		@	MYLAN LABS LTD	EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A201529	004	Mar 29, 2012		May	DISC
		@		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A201530	001	Mar 29, 2012		Aug	DISC
	+	@	BRISTOL	EQ 20MG BASE/VIAL	A086358	001			Aug	CRLD
	+	@		EQ 50MG BASE/VIAL	A086358	002			Aug	CRLD
	+	@		EQ 100MG BASE/VIAL	A086358	003			Aug	CRLD
	+	@		EQ 250MG BASE/VIAL	A086358	004			Aug	CRLD

TABLET;ORAL

METHOTREXATE SODIUM

>D>	+	@	DAVA PHARMS INC	EQ 2.5MG BASE	N008085	002			Nov	CAHN
AB			LOTUS PHARM CO LTD	EQ 2.5MG BASE	A209787	001	Apr 23, 2021		Apr	NEWA
>A>	+	@	STRIDES PHARMA	EQ 2.5MG BASE	N008085	002			Nov	CAHN

METHOXSALLEN

CAPSULE;ORAL

METHOXSALLEN

>D>	AB		ACTAVIS INC	10MG	A202603	001	Jun 09, 2015		Nov	DISC
>A>		@		10MG	A202603	001	Jun 09, 2015		Nov	DISC

METHSCOPOLAMINE BROMIDE

TABLET;ORAL

METHSCOPOLAMINE BROMIDE

>A>	@ STRIDES PHARMA	2.5MG	A 040624	001	Dec 28, 2006	Nov	CAHN
>A>	@	5MG	A 040624	002	Dec 28, 2006	Nov	CAHN
>D>	@ VINTAGE PHARMS	2.5MG	A 040624	001	Dec 28, 2006	Nov	CAHN
>D>	@	5MG	A 040624	002	Dec 28, 2006	Nov	CAHN

METHYCLOTHIAZIDE

TABLET;ORAL

METHYCLOTHIAZIDE

@ CHARTWELL RX	2.5MG	A 089835	001	Aug 18, 1988	Sep	CAHN
@	5MG	A 089837	001	Aug 18, 1988	Sep	CAHN

METHYLDOPA

TABLET;ORAL

METHYLDOPA

ACCORD HLTHCARE	250MG	A 070084	001	Oct 15, 1985	Sep	CTEC
!	500MG	A 070085	001	Oct 15, 1985	Sep	CHRS
	500MG	A 070085	001	Oct 15, 1985	Sep	CTEC
@ CHARTWELL RX	125MG	A 071700	001	Mar 02, 1988	Sep	CAHN
@	250MG	N 018934	001	Jun 29, 1984	Sep	CAHN
@	500MG	N 018934	002	Jun 29, 1984	Sep	CAHN
>D> @ MYLAN	250MG	A 070076	002	Apr 18, 1985	Nov	CAHN
@	250MG	A 070076	002	Apr 18, 1985	Sep	DISC
>D> @	500MG	A 070076	001	Apr 18, 1985	Nov	CAHN
@	500MG	A 070076	001	Apr 18, 1985	Sep	DISC
>A> @ RISING PHARMA	250MG	A 070076	002	Apr 18, 1985	Nov	CAHN
>A> @	500MG	A 070076	001	Apr 18, 1985	Nov	CAHN

METHYLERGONOVINE MALEATE

TABLET;ORAL

METHYLERGONOVINE MALEATE

AB RISING	0.2MG	A 211919	001	Jan 15, 2021	Jan	NEWA
-----------	-------	----------	-----	--------------	-----	------

METHYLPHENIDATE HYDROCHLORIDE

SOLUTION;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AA ASCENT PHARMS INC	5MG/5ML	A 207417	001	Jan 29, 2021	Jan	NEWA
AA	10MG/5ML	A 207417	002	Jan 29, 2021	Jan	NEWA
@ LANNETT CO INC	5MG/5ML	A 207414	001	Dec 16, 2020	Jan	DISC
@	10MG/5ML	A 207414	002	Dec 16, 2020	Jan	DISC

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

@ ALVOGEN	5MG	A 206840	001	Sep 15, 2016	Jun	CAHN
@	10MG	A 206840	002	Sep 15, 2016	Jun	CAHN
@	20MG	A 206840	003	Sep 15, 2016	Jun	CAHN
AB BIONPHARMA INC	5MG	A 209753	001	Mar 02, 2018	Sep	CAHN
AB	10MG	A 209753	002	Mar 02, 2018	Sep	CAHN
AB	20MG	A 209753	003	Mar 02, 2018	Sep	CAHN

TABLET, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB ALVOGEN	10MG	A 204772	001	Feb 29, 2016	Jun	CAHN
AB	18MG	A 210818	001	Nov 30, 2018	Aug	CAHN
AB	20MG	A 204772	002	Feb 29, 2016	Jun	CAHN
AB	27MG	A 210818	002	Nov 30, 2018	Aug	CAHN
AB	36MG	A 210818	003	Nov 30, 2018	Aug	CAHN
AB	54MG	A 210818	004	Nov 30, 2018	Aug	CAHN
BX AMNEAL PHARMS	18MG	A 207515	001	Feb 01, 2018	Sep	CTEC
BX	27MG	A 207515	002	Feb 01, 2018	Sep	CTEC
BX	36MG	A 207515	003	Feb 01, 2018	Sep	CTEC
BX	54MG	A 207515	004	Feb 01, 2018	Sep	CTEC
>D> @ PAR PHARM	36MG	A 204659	001	Jul 15, 2019	Nov	CAHN
>D> @	54MG	A 204659	002	Jul 15, 2019	Nov	CAHN
>A> @ STRIDES PHARMA	36MG	A 204659	001	Jul 15, 2019	Nov	CAHN
>A> @	54MG	A 204659	002	Jul 15, 2019	Nov	CAHN

METHYLPREDNISOLONE

TABLET; ORAL

METHYLPREDNISOLONE

AB	AMNEAL	4MG	A207481	001	Sep 21, 2021	Sep	NEWA
AB		8MG	A207481	002	Sep 21, 2021	Sep	NEWA
AB		16MG	A207481	003	Sep 21, 2021	Sep	NEWA
AB		32MG	A207481	004	Sep 21, 2021	Sep	NEWA
AB	PRAXGEN	4MG	A212262	001	Jun 27, 2019	Feb	CAHN

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

METHYLPREDNISOLONE SODIUM SUCCINATE

AP	GENEYORK PHARMS	EQ 40MG BASE/VIAL	A212396	001	Apr 20, 2021	Apr	NEWA
AP		EQ 125MG BASE/VIAL	A212396	002	Apr 20, 2021	Apr	NEWA
AP		EQ 500MG BASE/VIAL	A212396	003	Apr 20, 2021	Apr	NEWA
AP		EQ 1GM BASE/VIAL	A212396	004	Apr 20, 2021	Apr	NEWA
AP		EQ 2GM BASE/VIAL	A212396	005	Apr 20, 2021	Apr	NEWA
	@ TIANJIN KINGYORK	EQ 40MG BASE/VIAL	A212396	001	Apr 20, 2021	Oct	DISC
AP		EQ 40MG BASE/VIAL	A212396	001	Apr 20, 2021	May	CAHN
	@	EQ 125MG BASE/VIAL	A212396	002	Apr 20, 2021	Oct	DISC
AP		EQ 125MG BASE/VIAL	A212396	002	Apr 20, 2021	May	CAHN
	@	EQ 500MG BASE/VIAL	A212396	003	Apr 20, 2021	Oct	DISC
AP		EQ 500MG BASE/VIAL	A212396	003	Apr 20, 2021	May	CAHN
	@	EQ 1GM BASE/VIAL	A212396	004	Apr 20, 2021	Oct	DISC
AP		EQ 1GM BASE/VIAL	A212396	004	Apr 20, 2021	May	CAHN
	@	EQ 2GM BASE/VIAL	A212396	005	Apr 20, 2021	Oct	DISC
AP		EQ 2GM BASE/VIAL	A212396	005	Apr 20, 2021	May	CAHN

METHYLTESTOSTERONE

CAPSULE; ORAL

TESTRED

+ @	BAUSCH	10MG	A083976	001		Aug	CRLD
-----	--------	------	---------	-----	--	-----	------

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

REGLAN

@	HIKMA	EQ 5MG BASE/ML	N017862	001		Jul	CAHN
@		EQ 10MG BASE/ML	N017862	004	May 28, 1987	Jul	CAHN

TABLET; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

>A>	AB	STRIDES PHARMA	EQ 5MG BASE	A077878	001	Aug 28, 2006	Nov	CAHN
>A>	AB		EQ 10MG BASE	A077878	002	Aug 28, 2006	Nov	CAHN
>D>	AB	VINTAGE PHARMS	EQ 5MG BASE	A077878	001	Aug 28, 2006	Nov	CAHN
>D>	AB		EQ 10MG BASE	A077878	002	Aug 28, 2006	Nov	CAHN

METOLAZONE

TABLET; ORAL

METOLAZONE

AB	BAYSHORE PHARMS LLC	2.5MG	A214799	001	Mar 30, 2021	Mar	NEWA
AB		5MG	A214799	002	Mar 30, 2021	Mar	NEWA
AB		10MG	A214799	003	Mar 30, 2021	Mar	NEWA
AB	INNOGENIX	2.5MG	A213827	001	Mar 30, 2021	Mar	NEWA
AB		5MG	A213827	002	Mar 30, 2021	Mar	NEWA
AB		10MG	A213827	003	Mar 30, 2021	Mar	NEWA
AB	RUBICON	2.5MG	A215184	001	Aug 20, 2021	Aug	NEWA
AB		5MG	A215184	002	Aug 20, 2021	Aug	NEWA
AB		10MG	A215184	003	Aug 20, 2021	Aug	NEWA
AB	! SANDOZ	5MG	A076466	001	Dec 19, 2003	May	CHRS
AB	! ZAROXOLYN	10MG	A076466	002	Dec 19, 2003	May	CHRS
+ @	LANNETT CO INC	2.5MG	N017386	001		May	DISC
+ @		5MG	N017386	002		May	DISC
+ @		10MG	N017386	003		May	DISC

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

METOPROLOL SUCCINATE

AB	ACTAVIS ELIZABETH	EQ 25MG TARTRATE	A204161	001	Nov 25, 2016	May	CMFD
AB		EQ 50MG TARTRATE	A204161	002	Nov 25, 2016	May	CMFD
AB		EQ 100MG TARTRATE	A204161	003	Nov 25, 2016	May	CMFD
AB		EQ 200MG TARTRATE	A204161	004	Nov 25, 2016	May	CMFD
AB	VISUM PHARM	EQ 25MG TARTRATE	A207206	001	Dec 19, 2018	Oct	CAHN

TABLET, EXTENDED RELEASE;ORAL  
METOPROLOL SUCCINATE

AB		EQ 50MG TARTRATE	A207206	002	Dec 19, 2018	Oct	CAHN
AB		EQ 100MG TARTRATE	A207206	003	Dec 19, 2018	Oct	CAHN
AB		EQ 200MG TARTRATE	A207206	004	Dec 19, 2018	Oct	CAHN
AB	YICHANG HUMANWELL	EQ 50MG TARTRATE	A213854	003	Nov 08, 2021	Oct	NEWA
AB		EQ 100MG TARTRATE	A213854	001	Feb 12, 2021	Feb	NEWA
AB		EQ 200MG TARTRATE	A213854	002	Feb 12, 2021	Feb	NEWA

METOPROLOL TARTRATE

TABLET;ORAL  
LOPRESSOR

AB	+ VALIDUS PHARMS	50MG	N017963	001		Feb	CAHN
AB	+	100MG	N017963	002		Feb	CAHN

METRONIDAZOLE

GEL;TOPICAL  
METRONIDAZOLE

AB	ALEOR DERMACEUTICALS	1%	A212646	001	Sep 03, 2021	Aug	NEWA
----	----------------------	----	---------	-----	--------------	-----	------

GEL;VAGINAL  
METRONIDAZOLE

AB	SOLARIS PHARMA CORP	0.75%	A213648	001	Oct 14, 2021	Oct	NEWA
----	---------------------	-------	---------	-----	--------------	-----	------

TABLET;ORAL  
METRONIDAZOLE

AB	AMICI	250MG	A070772	001	Jul 16, 1986	Sep	CAHN
AB		500MG	A070772	002	Jul 16, 1986	Sep	CAHN

METYROSINE

CAPSULE;ORAL  
DEMSEER

	+! BAUSCH	250MG	N017871	001		Sep	CTEC
--	-----------	-------	---------	-----	--	-----	------

METYROSINE  
AMNEAL

BX	AMNEAL	250MG	A213734	001	Jul 24, 2020	Sep	CTEC
----	--------	-------	---------	-----	--------------	-----	------

MEXILETINE HYDROCHLORIDE

CAPSULE;ORAL  
MEXILETINE HYDROCHLORIDE

AB	HAVIX	150MG	A214089	001	Oct 01, 2021	Sep	NEWA
AB		200MG	A214089	002	Oct 01, 2021	Sep	NEWA
AB		250MG	A214089	003	Oct 01, 2021	Sep	NEWA
AB	NOVAST LABS	150MG	A214352	001	Jan 25, 2021	Sep	CAHN
AB		200MG	A214352	002	Jan 25, 2021	Sep	CAHN
AB		250MG	A214352	003	Jan 25, 2021	Sep	CAHN
AB	RICONPHARMA LLC	150MG	A214352	001	Jan 25, 2021	Jan	NEWA
AB		200MG	A214352	002	Jan 25, 2021	Jan	NEWA
AB		250MG	A214352	003	Jan 25, 2021	Jan	NEWA
AB	SENORES PHARMS	150MG	A214089	001	Oct 01, 2021	Oct	CAHN
AB		200MG	A214089	002	Oct 01, 2021	Oct	CAHN
AB		250MG	A214089	003	Oct 01, 2021	Oct	CAHN

MICAFUNGIN SODIUM

INJECTABLE;INTRAVENOUS  
MICAFUNGIN SODIUM

AP	HIKMA	EQ 50MG BASE/VIAL	A213261	001	Jul 09, 2021	Jul	NEWA
AP		EQ 100MG BASE/VIAL	A213261	002	Jul 09, 2021	Jul	NEWA
AP	JIANGSU HANSOH PHARM	EQ 50MG BASE/VIAL	A213363	001	Jul 09, 2021	Jul	NEWA
AP		EQ 100MG BASE/VIAL	A213363	002	Jul 09, 2021	Jul	NEWA
AP	XELLIA PHARMS APS	EQ 50MG BASE/VIAL	A211713	001	Jun 02, 2021	May	NEWA
AP		EQ 100MG BASE/VIAL	A211713	002	Jun 02, 2021	May	NEWA

POWDER;INTRAVENOUS  
MICAFUNGIN

	+! PAR STERILE PRODUCTS	EQ 50MG BASE/VIAL	N212156	001	Jun 16, 2021	Jun	NEWA
	+!	EQ 100MG BASE/VIAL	N212156	002	Jun 16, 2021	Jun	NEWA
	+ @ TEVA PHARMS USA INC	EQ 50MG BASE/VIAL	N212125	001	Jul 30, 2021	Sep	DISC
	+!	EQ 50MG BASE/VIAL	N212125	001	Jul 30, 2021	Jul	NEWA
	+ @	EQ 100MG BASE/VIAL	N212125	002	Jul 30, 2021	Sep	DISC
	+!	EQ 100MG BASE/VIAL	N212125	002	Jul 30, 2021	Jul	NEWA

MIDAZOLAM

SOLUTION;INTRAVENOUS

MIDAZOLAM IN 0.9% SODIUM CHLORIDE

+!	INFORLIFE	50MG/50ML (1MG/ML)	N211844	001	Mar 22, 2021	Mar	NEWA
+		100MG/100ML (1MG/ML)	N211844	002	Mar 22, 2021	Mar	NEWA

MIDAZOLAM HYDROCHLORIDE

INJECTABLE;INJECTION

MIDAZOLAM HYDROCHLORIDE

@	HOSPIRA	EQ 1MG BASE/ML	A075856	001	Jun 13, 2002	Aug	DISC
@		EQ 5MG BASE/ML	A075856	002	Jun 13, 2002	Aug	DISC

MIDODRINE HYDROCHLORIDE

TABLET;ORAL

MIDODRINE HYDROCHLORIDE

AB	ALEMBIC PHARMS LTD	2.5MG	A214734	001	Jan 21, 2021	Jan	NEWA
AB		5MG	A214734	002	Jan 21, 2021	Jan	NEWA
AB		10MG	A214734	003	Jan 21, 2021	Jan	NEWA

MIGALASTAT HYDROCHLORIDE

CAPSULE;ORAL

GALAFOLD

+	AMICUS THERAP US	EQ 123MG BASE	N208623	001	Aug 10, 2018	Sep	CAHN
---	------------------	---------------	---------	-----	--------------	-----	------

MIGLITOL

TABLET;ORAL

GLYSET

AB	+	PFIZER	25MG	N020682	001	Dec 18, 1996	Feb	CAHN
AB	+		50MG	N020682	002	Dec 18, 1996	Feb	CAHN
AB	+		100MG	N020682	003	Dec 18, 1996	Feb	CAHN

MILNACIPRAN HYDROCHLORIDE

TABLET;ORAL

MILNACIPRAN HYDROCHLORIDE

@	LIBERTY PHARMA INC	12.5MG	A205071	001	Jan 27, 2016	Aug	CAHN
@		25MG	A205071	002	Jan 27, 2016	Aug	CAHN
@		50MG	A205071	003	Jan 27, 2016	Aug	CAHN
@		100MG	A205071	004	Jan 27, 2016	Aug	CAHN
@	USPHARMA WINDLAS	12.5MG	A205071	001	Jan 27, 2016	Sep	CAHN
@		25MG	A205071	002	Jan 27, 2016	Sep	CAHN
@		50MG	A205071	003	Jan 27, 2016	Sep	CAHN
@		100MG	A205071	004	Jan 27, 2016	Sep	CAHN

MILRINONE LACTATE

INJECTABLE;INJECTION

MILRINONE LACTATE

AP	CAPLIN	EQ 1MG BASE/ML	A214380	001	Apr 16, 2021	Apr	NEWA
----	--------	----------------	---------	-----	--------------	-----	------

MINOCYCLINE HYDROCHLORIDE

AEROSOL, FOAM;TOPICAL

AMZEEQ

+	VYNE	EQ 4% BASE	N212379	001	Oct 18, 2019	Mar	CAHN
---	------	------------	---------	-----	--------------	-----	------

ZILXI

+	VYNE	EQ 1.5% BASE	N213690	001	May 28, 2020	Mar	CAHN
---	------	--------------	---------	-----	--------------	-----	------

CAPSULE;ORAL

DYNACIN

AB	ALVOGEN	EQ 50MG BASE	A063067	003	Aug 14, 1990	Jun	CAHN
AB		EQ 75MG BASE	A063067	002	Sep 15, 1999	Jun	CAHN
AB		EQ 100MG BASE	A063067	001	Jul 31, 1990	Jun	CAHN

INJECTABLE;INJECTION

MINOCIN

+	REMPEX	EQ 100MG BASE/VIAL	N050444	001		May	CAHN
---	--------	--------------------	---------	-----	--	-----	------

TABLET, EXTENDED RELEASE;ORAL

MINOCYCLINE HYDROCHLORIDE

@	BARR LABS INC	EQ 65MG BASE	A065485	004	May 18, 2012	May	DISC
@		EQ 80MG BASE	A065485	007	Apr 26, 2017	May	DISC
@		EQ 105MG BASE	A065485	008	Apr 26, 2017	May	DISC
@		EQ 115MG BASE	A065485	005	May 18, 2012	May	DISC
@	MYLAN	EQ 55MG BASE	A203443	001	Aug 21, 2019	Oct	CAHN
@		EQ 80MG BASE	A203443	002	Aug 22, 2014	Oct	DISC
AB		EQ 80MG BASE	A203443	002	Aug 22, 2014	Oct	CAHN

TABLET, EXTENDED RELEASE;ORAL  
MINOCYCLINE HYDROCHLORIDE

	@	EQ 105MG BASE	A203443	003	Aug 22, 2014	Oct	DISC
AB		EQ 105MG BASE	A203443	003	Aug 22, 2014	Oct	CAHN
		MINOLIRA					
	!	EPI HLTH	EQ 135MG BASE	N209269	002	May 08, 2017	Sep CHRS
		SOLODYN					
	+ @	BAUSCH	EQ 45MG BASE	N050808	001	May 08, 2006	May CAHN
AB	+		EQ 55MG BASE	N050808	008	Aug 27, 2010	May CAHN
AB	+		EQ 65MG BASE	N050808	004	Jul 23, 2009	May CAHN
AB	+		EQ 80MG BASE	N050808	007	Aug 27, 2010	May CAHN
	+ @		EQ 90MG BASE	N050808	002	May 08, 2006	May CAHN
AB	+		EQ 105MG BASE	N050808	006	Aug 27, 2010	May CAHN
AB	+!		EQ 115MG BASE	N050808	005	Jul 23, 2009	May CAHN
	+ @		EQ 135MG BASE	N050808	003	May 08, 2006	May CAHN

MINOXIDIL

TABLET;ORAL  
LONITEN

	+ @	PFIZER	2.5MG	N018154	001		Feb CAHN
	+ @		10MG	N018154	003		Feb CAHN

MIRABEGRON

FOR SUSPENSION, EXTENDED RELEASE;ORAL  
MYRBETRIQ GRANULES

	+!	APGDI	8MG/ML	N213801	001	Mar 25, 2021	Mar NEWA
--	----	-------	--------	---------	-----	--------------	----------

MISOPROSTOL

TABLET;ORAL  
CYTOTEK

	+	PFIZER	0.1MG	N019268	003	Sep 21, 1990	Sep CTEC
	+!		0.2MG	N019268	001	Dec 27, 1988	Sep CTEC

MISOPROSTOL

BX		NOVEL LABS INC	0.1MG	A091667	001	Jul 25, 2012	Sep CTEC
BX			0.2MG	A091667	002	Jul 25, 2012	Sep CTEC

MITOMYCIN

INJECTABLE;INJECTION  
MITOMYCIN

AP		GLAND PHARMA LTD	5MG/VIAL	A215687	001	Oct 20, 2021	Oct NEWA
AP			20MG/VIAL	A215687	002	Oct 20, 2021	Oct NEWA
	@	HIKMA	5MG/VIAL	A064117	001	Apr 19, 1995	Oct CAHN
AP			5MG/VIAL	A064180	001	Dec 23, 1999	Oct CAHN
AP			20MG/VIAL	A064117	002	Apr 19, 1995	Oct CAHN
AP			20MG/VIAL	A064180	002	Dec 23, 1999	Oct CAHN
AP			40MG/VIAL	A064117	003	Jun 02, 1999	Oct CAHN

MIVACURIUM CHLORIDE

SOLUTION;INTRAVENOUS  
MIVACURIUM CHLORIDE

		WOODWARD	EQ 10MG BASE/5ML (EQ 2MG BASE/ML)	A209708	001	Oct 12, 2021	Oct NFTG
			EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A209708	002	Oct 12, 2021	Oct NFTG

MOBOCERTINIB SUCCINATE

CAPSULE;ORAL  
EXKIVITY

	+!	TAKEDA PHARMS USA	EQ 40MG BASE	N215310	001	Sep 15, 2021	Sep NEWA
--	----	-------------------	--------------	---------	-----	--------------	----------

MODAFINIL

TABLET;ORAL  
MODAFINIL

	@	MYLAN PHARMS INC	100MG	A076594	001	Jul 16, 2012	Jul DISC
	@		200MG	A076594	002	Jul 16, 2012	Jul DISC

MOLINDONE HYDROCHLORIDE

CAPSULE;ORAL  
MOBAN

>D>	+ @	ENDO PHARMS	5MG	N017111	001		Nov CAHN
>D>	+ @		10MG	N017111	002		Nov CAHN
>D>	+ @		25MG	N017111	003		Nov CAHN
>A>	+ @	STRIDES PHARMA	5MG	N017111	001		Nov CAHN
>A>	+ @		10MG	N017111	002		Nov CAHN



	CAPSULE;ORAL					
	MOBAN					
>A>	+ @	25MG	N017111	003		Nov CAHN
	TABLET;ORAL					
	MOBAN					
>D>	+ @ ENDO PHARMS	5MG	N017111	004		Nov CAHN
>D>	+ @	10MG	N017111	005		Nov CAHN
>D>	+ @	25MG	N017111	006		Nov CAHN
>D>	+ @	50MG	N017111	007		Nov CAHN
>D>	+ @	100MG	N017111	008		Nov CAHN
>A>	+ @ STRIDES PHARMA	5MG	N017111	004		Nov CAHN
>A>	+ @	10MG	N017111	005		Nov CAHN
>A>	+ @	25MG	N017111	006		Nov CAHN
>A>	+ @	50MG	N017111	007		Nov CAHN
>A>	+ @	100MG	N017111	008		Nov CAHN

MOMETASONE FUROATE

	AEROSOL, METERED;INHALATION					
	ASMANEX HFA					
	+ ORGANON	0.05MG/INH	N205641	003	Aug 12, 2019	Jun CAHN
	+ !	0.10MG/INH	N205641	001	Apr 25, 2014	Jun CAHN
	+ !	0.20MG/INH	N205641	002	Apr 25, 2014	Jun CAHN
	OINTMENT;TOPICAL					
	MOMETASONE FUROATE					
	@ TORRENT	0.1%	A207899	001	Jul 13, 2018	Jan DISC
	POWDER;INHALATION					
	ASMANEX TWISTHALER					
	+ ORGANON	0.11MG/INH	N021067	002	Feb 01, 2008	Jun CAHN
	+ !	0.22MG/INH	N021067	001	Mar 30, 2005	Jun CAHN
	SPRAY, METERED;NASAL					
	MOMETASONE FUROATE					
AB	! APOTEX INC	0.05MG/SPRAY	A091161	001	Mar 22, 2016	May CHRS
	NASONEX					
	+ @ ORGANON	0.05MG/SPRAY	N020762	001	Oct 01, 1997	May DISC
AB	+ !	0.05MG/SPRAY	N020762	001	Oct 01, 1997	Feb CAHN

MONTELUKAST SODIUM

	TABLET;ORAL					
	MONTELUKAST SODIUM					
	@ AJANTA PHARMA LTD	EQ 10MG BASE	A203432	001	Jul 31, 2015	Jul DISC
	@ BRECKENRIDGE	EQ 10MG BASE	A205319	001	Oct 30, 2020	Sep CAHN
>A>	@ STRIDES PHARMA	EQ 10MG BASE	A091576	001	Aug 03, 2012	Nov CAHN
>D>	@ VINTAGE PHARMS LLC	EQ 10MG BASE	A091576	001	Aug 03, 2012	Nov CAHN
	TABLET, CHEWABLE;ORAL					
	MONTELUKAST SODIUM					
	@ AJANTA PHARMA LTD	EQ 4MG BASE	A203328	001	Jul 31, 2015	Jul DISC
	@	EQ 5MG BASE	A203328	002	Jul 31, 2015	Jul DISC
	@ HIKMA	EQ 4MG BASE	A091128	001	Aug 03, 2012	Jul DISC
	@	EQ 5MG BASE	A091128	002	Aug 03, 2012	Jul DISC
>A>	@ STRIDES PHARMA	EQ 4MG BASE	A091588	001	Aug 03, 2012	Nov CAHN
>A>	@	EQ 5MG BASE	A091588	002	Aug 03, 2012	Nov CAHN
AB	UNICHEM	EQ 4MG BASE	A208621	001	Jul 02, 2018	Aug CMFD
AB		EQ 5MG BASE	A208621	002	Jul 02, 2018	Aug CMFD
>D>	@ VINTAGE PHARMS LLC	EQ 4MG BASE	A091588	001	Aug 03, 2012	Nov CAHN
>D>	@	EQ 5MG BASE	A091588	002	Aug 03, 2012	Nov CAHN

MORPHINE SULFATE

	CAPSULE, EXTENDED RELEASE;ORAL					
	KADIAN					
	+ @ ALLERGAN	10MG	N020616	008	Apr 20, 2007	Sep DISC
	+ @	20MG	N020616	001	Jul 03, 1996	Sep DISC
	+ @	30MG	N020616	004	Mar 09, 2001	Sep DISC
	+ @	40MG	N020616	009	Jul 09, 2012	May DISC
	+ @	50MG	N020616	002	Jul 03, 1996	Sep DISC
	+ @	60MG	N020616	005	Mar 09, 2001	Sep DISC
	+ @	70MG	N020616	010	Jul 09, 2012	May DISC
	+ @	80MG	N020616	006	Oct 27, 2006	Sep DISC
	+ @	100MG	N020616	003	Jul 03, 1996	Sep DISC
	+ @	130MG	N020616	011	Jul 09, 2012	May DISC
	+ @	150MG	N020616	012	Jul 09, 2012	May DISC
	+ @	200MG	N020616	007	Feb 27, 2007	May DISC

CAPSULE, EXTENDED RELEASE;ORAL

MORPHINE SULFATE

		IMPAX LABS INC	40MG	A200411	007	Jul 25, 2018	May CTEC
AB		NORTEC DEV ASSOC	20MG	A203158	001	Aug 04, 2021	Jul NEWA
AB			30MG	A203158	002	Aug 04, 2021	Jul NEWA
AB			50MG	A203158	003	Aug 04, 2021	Jul NEWA
AB			60MG	A203158	004	Aug 04, 2021	Jul NEWA
AB			80MG	A203158	005	Aug 04, 2021	Jul NEWA
AB			100MG	A203158	006	Aug 04, 2021	Jul NEWA
	!	UPSHER SMITH LABS	10MG	A202104	001	Jun 03, 2013	Sep CHRS
			10MG	A202104	001	Jun 03, 2013	Sep CTEC
AB	!		100MG	A202104	007	Jun 03, 2013	Sep CHRS

INJECTABLE;INJECTION

MORPHINE SULFATE

	+!	HOSPIRA INC	50MG/ML	N202515	006	Apr 29, 2021	Apr NEWA
>D>		INTL MEDICATION SYS	1MG/ML	A202861	001	Apr 29, 2021	Nov DISC
>A>	@		1MG/ML	A202861	001	Apr 29, 2021	Nov DISC
			1MG/ML	A202861	001	Apr 29, 2021	Apr NFTG

SOLUTION;ORAL

MORPHINE SULFATE

	@	ANI PHARMS	10MG/5ML	A205509	001	Apr 17, 2018	Jan DISC
	@		20MG/5ML	A205509	002	Apr 17, 2018	Jan DISC
	@		100MG/5ML	A205509	003	Apr 17, 2018	Jan DISC
	@	WINDER LABS LLC	10MG/5ML	A211454	001	Feb 12, 2021	Aug DISC
AA			10MG/5ML	A211454	001	Feb 12, 2021	Feb NEWA
	@		20MG/5ML	A211454	002	Feb 12, 2021	Aug DISC
AA			20MG/5ML	A211454	002	Feb 12, 2021	Feb NEWA
	@		100MG/5ML	A211454	003	Feb 12, 2021	Aug DISC
AA			100MG/5ML	A211454	003	Feb 12, 2021	Feb NEWA

TABLET;ORAL

MORPHINE SULFATE

AB		UPSHER SMITH LABS	15MG	A210610	001	Jul 22, 2019	May CAHN
AB			30MG	A210610	002	Jul 22, 2019	May CAHN

TABLET, EXTENDED RELEASE;ORAL

MORPHINE SULFATE

>A>	AB	STRIDES PHARMA	15MG	A075295	001	Oct 28, 1998	Nov CAHN
>A>	AB		30MG	A075295	002	Oct 28, 1998	Nov CAHN
>A>	AB		60MG	A075295	003	Oct 28, 1998	Nov CAHN
>A>	AB		100MG	A075295	004	Sep 15, 2000	Nov CAHN
>A>	AB		200MG	A075295	005	Sep 15, 2000	Nov CAHN
>D>	AB	VINTAGE PHARMS LLC	15MG	A075295	001	Oct 28, 1998	Nov CAHN
>D>	AB		30MG	A075295	002	Oct 28, 1998	Nov CAHN
>D>	AB		60MG	A075295	003	Oct 28, 1998	Nov CAHN
>D>	AB		100MG	A075295	004	Sep 15, 2000	Nov CAHN
>D>	AB		200MG	A075295	005	Sep 15, 2000	Nov CAHN

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

MOXIFLOXACIN HYDROCHLORIDE

AT1		UPSHER SMITH LABS	EQ 0.5% BASE	A212616	001	Feb 10, 2021	Jan NEWA
-----	--	-------------------	--------------	---------	-----	--------------	----------

MUPIROCIIN CALCIUM

CREAM;TOPICAL

MUPIROCIIN

>A>	AB	ALEOR DERMACEUTICALS	EQ 2% BASE	A213053	001	Nov 16, 2021	Nov NEWA
	AB	ENCUBE	EQ 2% BASE	A213076	001	Aug 31, 2021	Aug NEWA

MYCOPHENOLATE MOFETIL

CAPSULE;ORAL

MYCOPHENOLATE MOFETIL

>A>		@ STRIDES PHARMA	250MG	A090111	001	Dec 22, 2009	Nov CAHN
>D>		@ VINTAGE PHARMS LLC	250MG	A090111	001	Dec 22, 2009	Nov CAHN

FOR SUSPENSION;ORAL

CELLCEPT

AB	+!	ROCHE PALO	200MG/ML	N050759	001	Oct 01, 1998	Oct CDFR
		MYCOPHENOLATE MOFETIL					
AB		ALKEM LABS LTD	200MG/ML	A203005	001	Nov 14, 2014	Oct CDFR
AB		LANNETT CO INC	200MG/ML	A214525	001	Jul 29, 2021	Oct CDFR
AB		VISTAPHARM	200MG/ML	A210370	001	Feb 12, 2019	Oct CDFR

SUSPENSION;ORAL

MYCOPHENOLATE MOFETIL

AB		AMNEAL	200MG/ML	A214871	001	Nov 02, 2021	Oct NEWA
----	--	--------	----------	---------	-----	--------------	----------

SUSPENSION;ORAL

MYCOPHENOLATE MOFETIL

AB LANNETT CO INC 200MG/ML A214525 001 Jul 29, 2021 Jul NEWA

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE;INJECTION

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

@ AMNEAL 500MG/VIAL A211374 001 Mar 05, 2021 Sep DISC  
 AP 500MG/VIAL A211374 001 Mar 05, 2021 Feb NEWA  
 AP MEITHEAL 500MG/VIAL A212130 001 Jan 15, 2021 Jan CAHN  
 AP NANJING KING-FRIEND 500MG/VIAL A212130 001 Jan 15, 2021 Jan NEWA

MYCOPHENOLIC ACID

TABLET, DELAYED RELEASE;ORAL

>D> MYCOPHENOLIC ACID

>D> AB ACCORD HLTHCARE 180MG A202555 001 Aug 23, 2017 Nov CTNA  
 >D> AB 360MG A202555 002 Aug 23, 2017 Nov CTNA  
 >D> AB ALKEM LABS LTD 180MG A208315 001 Sep 23, 2021 Nov CTNA  
 AB 180MG A208315 001 Sep 23, 2021 Sep NEWA  
 >D> AB 360MG A208315 002 Sep 23, 2021 Nov CTNA  
 AB 360MG A208315 002 Sep 23, 2021 Sep NEWA  
 >D> AB AMTA 180MG A214376 001 Feb 10, 2021 Nov CTNA  
 AB 180MG A214376 001 Feb 10, 2021 Jan NEWA  
 >D> AB 360MG A214376 002 Feb 10, 2021 Nov CTNA  
 AB 360MG A214376 002 Feb 10, 2021 Jan NEWA  
 >D> AB APOTEX INC 180MG A091558 001 Aug 21, 2012 Nov CTNA  
 >D> AB 360MG A091558 002 Aug 19, 2014 Nov CTNA  
 >A> AB BIOCON PHARMA EQ 180MG BASE A214630 001 Nov 29, 2021 Nov NEWA  
 >A> AB EQ 360MG BASE A214630 002 Nov 29, 2021 Nov NEWA  
 >D> AB CONCORD BIOTECH LTD 180MG A211173 001 Dec 13, 2019 Nov CTNA  
 >D> AB 360MG A211173 002 Dec 13, 2019 Nov CTNA  
 >D> AB RK PHARMA 180MG A091248 002 Jan 08, 2014 Nov CTNA  
 >D> AB 360MG A091248 001 Jan 08, 2014 Nov CTNA  
 >D> @ TEVA PHARMS USA 180MG A202720 001 Oct 30, 2014 Nov CTNA  
 >D> @ 360MG A202720 002 Oct 30, 2014 Nov CTNA  
 >D> AB TWI PHARMS 180MG A214289 001 Nov 03, 2021 Nov CTNA  
 AB 180MG A214289 001 Nov 03, 2021 Oct NEWA  
 >D> AB 360MG A214289 002 Nov 03, 2021 Nov CTNA  
 AB 360MG A214289 002 Nov 03, 2021 Oct NEWA  
 >D> MYFORTIC  
 >D> AB + NOVARTIS 180MG N050791 001 Feb 27, 2004 Nov CAIN  
 >D> AB +! 360MG N050791 002 Feb 27, 2004 Nov CAIN

MYCOPHENOLIC SODIUM

TABLET, DELAYED RELEASE;ORAL

>A> MYCOPHENOLIC SODIUM

>A> AB ACCORD HLTHCARE EQ 180MG BASE A202555 001 Aug 23, 2017 Nov CTNA  
 >A> AB EQ 360MG BASE A202555 002 Aug 23, 2017 Nov CTNA  
 >A> AB ALKEM LABS LTD EQ 180MG BASE A208315 001 Sep 23, 2021 Nov CTNA  
 >A> AB EQ 360MG BASE A208315 002 Sep 23, 2021 Nov CTNA  
 >A> AB AMTA EQ 180MG BASE A214376 001 Feb 10, 2021 Nov CTNA  
 >A> AB EQ 360MG BASE A214376 002 Feb 10, 2021 Nov CTNA  
 >A> AB APOTEX INC EQ 180MG BASE A091558 001 Aug 21, 2012 Nov CTNA  
 >A> AB EQ 360MG BASE A091558 002 Aug 19, 2014 Nov CTNA  
 >A> AB CONCORD BIOTECH LTD EQ 180MG BASE A211173 001 Dec 13, 2019 Nov CTNA  
 >A> AB EQ 360MG BASE A211173 002 Dec 13, 2019 Nov CTNA  
 >A> AB RK PHARMA EQ 180MG BASE A091248 002 Jan 08, 2014 Nov CTNA  
 >A> AB EQ 360MG BASE A091248 001 Jan 08, 2014 Nov CTNA  
 >A> @ TEVA PHARMS USA EQ 180MG BASE A202720 001 Oct 30, 2014 Nov CTNA  
 >A> @ EQ 360MG BASE A202720 002 Oct 30, 2014 Nov CTNA  
 >A> AB TWI PHARMS EQ 180MG BASE A214289 001 Nov 03, 2021 Nov CTNA  
 >A> AB EQ 360MG BASE A214289 002 Nov 03, 2021 Nov CTNA  
 >A> MYFORTIC  
 >A> AB + NOVARTIS EQ 180MG BASE N050791 001 Feb 27, 2004 Nov CAIN  
 >A> AB +! EQ 360MG BASE N050791 002 Feb 27, 2004 Nov CAIN

NABUMETONE

TABLET;ORAL

NABUMETONE

AB ANNORA PHARMA 500MG A090445 001 Jan 12, 2011 Mar CAHN  
 AB 750MG A090445 002 Jan 12, 2011 Mar CAHN

NADOLOL

TABLET; ORAL		NADOLOL							
	@ NOVAST LABS	20MG	A210786	001	Jun 01, 2018	May	DISC		
	@	40MG	A210786	002	Jun 01, 2018	May	DISC		
	@	80MG	A210786	003	Jun 01, 2018	May	DISC		
AB	VGYAAN	20MG	A212856	001	Sep 13, 2019	May	CMFD		
AB		40MG	A212856	002	Sep 13, 2019	May	CMFD		
AB		80MG	A212856	003	Sep 13, 2019	May	CMFD		

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION		NALOXONE HYDROCHLORIDE							
>D>	@ BAXTER HLTHCARE CORP	0.4MG/ML	A214785	001	Jan 29, 2021	Nov	CMFD		
>A>	AP	0.4MG/ML	A214785	001	Jan 29, 2021	Nov	CMFD		
	@	0.4MG/ML	A214785	001	Jan 29, 2021	Jul	DISC		
AP		0.4MG/ML	A214785	001	Jan 29, 2021	Jan	NEWA		
SOLUTION; INTRAMUSCULAR, SUBCUTANEOUS		ZIMHI							
	+! ADAMIS PHARMS CORP	5MG/0.5ML (5MG/0.5ML)	N212854	001	Oct 15, 2021	Oct	NEWA		
SPRAY; NASAL		KLOXXADO							
	+! HIKMA	8MG/SPRAY	N212045	001	Apr 29, 2021	Apr	NEWA		

NALTREXONE HYDROCHLORIDE

TABLET; ORAL		REVIA							
	+ @ TEVA WOMENS	50MG	N018932	001	Nov 20, 1984	Jul	CRLD		

NANDROLONE DECANOATE

INJECTABLE; INJECTION		NANDROLONE DECANOATE							
	+ @ WATSON LABS	200MG/ML	A088128	001	Dec 05, 1983	Aug	CRLD		

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC		NAPHCN FORTE							
	+ @ ALCON	0.1%	A080229	001		Aug	CRLD		

NAPROXEN

SUSPENSION; ORAL		NAPROXEN							
AB	NOVITIUM PHARMA	25MG/ML	A211910	001	Mar 10, 2021	Feb	NEWA		
TABLET; ORAL		NAPROXEN							
AB	GRANULES	250MG	A074140	001	Dec 21, 1993	Feb	CMFD		
AB		375MG	A074140	002	Dec 21, 1993	Feb	CMFD		
AB		500MG	A074140	003	Dec 21, 1993	Feb	CMFD		
AB	L PERRIGO CO	250MG	A077339	001	Apr 27, 2005	Jul	CAHN		
AB		375MG	A077339	002	Apr 27, 2005	Jul	CAHN		
AB		500MG	A077339	003	Apr 27, 2005	Jul	CAHN		

NEBIVOLOL HYDROCHLORIDE

TABLET; ORAL		NEBIVOLOL HYDROCHLORIDE							
AB	ANI PHARMS	EQ 2.5MG BASE	A203659	001	Apr 16, 2015	Jul	CMFD		
AB		EQ 5MG BASE	A203659	002	Apr 16, 2015	Jul	CMFD		
AB		EQ 10MG BASE	A203659	003	Apr 16, 2015	Jul	CMFD		
AB		EQ 20MG BASE	A203659	004	Apr 16, 2015	Jul	CMFD		
AB	INDCHEMIE HEALTH	EQ 2.5MG BASE	A203828	001	Jul 29, 2015	Jul	CMFD		
AB		EQ 5MG BASE	A203828	002	Jul 29, 2015	Jul	CMFD		
AB		EQ 10MG BASE	A203828	003	Jul 29, 2015	Jul	CMFD		
AB		EQ 20MG BASE	A203828	004	Jul 29, 2015	Jul	CMFD		
AB	TORRENT	EQ 2.5MG BASE	A203966	001	Mar 02, 2018	Aug	CMFD		
AB		EQ 5MG BASE	A203966	002	Mar 02, 2018	Aug	CMFD		
AB		EQ 10MG BASE	A203966	003	Mar 02, 2018	Aug	CMFD		
AB		EQ 20MG BASE	A203966	004	Mar 02, 2018	Aug	CMFD		

NELARABINE

INJECTABLE; INTRAVENOUS  
ARRANON

>D>	+	NOVARTIS	250MG/50ML (5MG/ML)	N021877	001	Oct 28, 2005	Nov	CFTG
>A>	AP	+	250MG/50ML (5MG/ML)	N021877	001	Oct 28, 2005	Nov	CFTG
>A>		NELARABINE						
>A>	AP	ZYDUS PHARMS	250MG/50ML (5MG/ML)	A215037	001	Nov 17, 2021	Nov	NFTG

NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS  
NEOSTIGMINE METHYLSULFATE

AP		CAPLIN	5MG/10ML (0.5MG/ML)	A213074	001	Apr 20, 2021	Apr	NEWA
AP			10MG/10ML (1MG/ML)	A213074	002	Apr 20, 2021	Apr	NEWA
AP		HONG KONG	5MG/10ML (0.5MG/ML)	A212804	001	Apr 05, 2021	Mar	NEWA
AP			10MG/10ML (1MG/ML)	A212804	002	Apr 05, 2021	Mar	NEWA
AP		INDOCO	5MG/10ML (0.5MG/ML)	A210652	001	Oct 01, 2021	Sep	NEWA
AP			10MG/10ML (1MG/ML)	A210652	002	Oct 01, 2021	Sep	NEWA
AP		MEITHEAL	5MG/10ML (0.5MG/ML)	A212804	001	Apr 05, 2021	Apr	CAHN
AP			10MG/10ML (1MG/ML)	A212804	002	Apr 05, 2021	Apr	CAHN

NIACIN

TABLET; ORAL  
NICOLAR

		+ @ SANOFI AVENTIS US	500MG	A083823	001		Aug	CRLD
		TABLET, EXTENDED RELEASE; ORAL						
		NIACIN						
>A>	AB	BEIJING	500MG	A214428	001	Nov 22, 2021	Nov	NEWA
>A>	AB		1GM	A214428	002	Nov 22, 2021	Nov	NEWA
		@ JUBILANT GENERICS	500MG	A209156	001	May 14, 2018	Jun	DISC
		@	750MG	A209156	002	May 14, 2018	Jun	DISC
		@	1GM	A209156	003	May 14, 2018	Jun	DISC
	AB	! SUN PHARM	750MG	A201273	001	Apr 23, 2014	Aug	CHRS
	AB	!	1GM	A200484	002	Apr 23, 2014	Aug	CHRS
		NIASPAN						
		+ @ ABBVIE	500MG	N020381	002	Jul 28, 1997	Aug	DISC
		+ @	750MG	N020381	003	Jul 28, 1997	Aug	DISC
		+ @	1GM	N020381	004	Jul 28, 1997	Aug	DISC

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL  
CARDENE

>D>		@ CHIESI	20MG	N019488	001	Dec 21, 1988	Nov	CRLD
>A>		+ @	20MG	N019488	001	Dec 21, 1988	Nov	CRLD
>D>		@	30MG	N019488	002	Dec 21, 1988	Nov	CRLD
>A>		+ @	30MG	N019488	002	Dec 21, 1988	Nov	CRLD
		NICARDIPINE HYDROCHLORIDE						
	AB	ANI PHARMS	20MG	A074670	001	Oct 28, 1996	May	CMFD
	AB		30MG	A074670	002	Oct 28, 1996	May	CMFD
	AB	EPIC PHARMA	20MG	A074928	001	Mar 19, 1998	May	CTEC
	AB	!	30MG	A074928	002	Mar 19, 1998	May	CTEC

INJECTABLE; INJECTION

NICARDIPINE HYDROCHLORIDE

AP	!	AM REGENT	25MG/10ML (2.5MG/ML)	A090534	001	Nov 17, 2009	Apr	CTEC
	!		25MG/10ML (2.5MG/ML)	A090534	001	Nov 17, 2009	Feb	CHRS
AP		SUN PHARM	25MG/10ML (2.5MG/ML)	N078405	001	Nov 17, 2009	Jun	CMFD
		@	25MG/10ML (2.5MG/ML)	N078405	001	Nov 17, 2009	Jun	CAHN

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL  
NIFEDIPINE

	AB1	AUROBINDO PHARMA LTD	30MG	A213361	001	Jul 19, 2021	Jul	NEWA
	AB1		60MG	A213361	002	Jul 19, 2021	Jul	NEWA
	AB1		90MG	A213361	003	Jul 19, 2021	Jul	NEWA
>A>		@ AUROBINDO PHARMA USA	30MG	A090649	001	Jun 21, 2010	Nov	CAHN
>A>		@	60MG	A090649	002	Jun 21, 2010	Nov	CAHN
>A>		@	90MG	A090649	003	Jun 21, 2010	Nov	CAHN
		@ ELITE	90MG	A212016	001	Nov 18, 2020	Jun	DISC
	AB2	ELITE PHARM SOLUTION	90MG	A212016	001	Nov 18, 2020	Oct	CMFD
		@	90MG	A212016	001	Nov 18, 2020	Sep	CAHN
>D>		@ MYLAN	30MG	A090649	001	Jun 21, 2010	Nov	CAHN
		@	30MG	A201071	001	Dec 03, 2010	Jul	DISC

TABLET, EXTENDED RELEASE;ORAL  
NIFEDIPINE

>D>	@	60MG	A090649	002	Jun 21, 2010	Nov	CAHN
		60MG	A201071	002	Dec 03, 2010	Jul	DISC
>D>	@	90MG	A090649	003	Jun 21, 2010	Nov	CAHN
		90MG	A201071	003	Dec 03, 2010	Jul	DISC
	@ PAR PHARM	30MG	A077899	001	Dec 13, 2006	Apr	DISC
	@	60MG	A077899	002	Dec 13, 2006	Apr	DISC
	@	90MG	A077899	003	May 25, 2012	Apr	DISC

NIMODIPINE

CAPSULE;ORAL  
NIMODIPINE

>D>	BX	SOFGEN PHARMS	30MG	A201832	001	Jul 24, 2015	Nov	DISC
>A>	@		30MG	A201832	001	Jul 24, 2015	Nov	DISC
	BX		30MG	A201832	001	Jul 24, 2015	Sep	CTEC

NISOLDIPINE

TABLET, EXTENDED RELEASE;ORAL  
NISOLDIPINE

!	MYLAN	20MG	A079051	001	Jul 25, 2008	Jan	CHRS
		30MG	A079051	002	Jul 25, 2008	Jan	CHRS

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL  
NITROFURANTOIN

AB	ALEMBIC PHARMS LTD	25MG	A211935	001	Jun 25, 2021	Jun	NEWA
AB		50MG	A211935	002	Jun 25, 2021	Jun	NEWA
AB		100MG	A211935	003	Jun 25, 2021	Jun	NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL  
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

@	MYLAN	75MG;25MG	A076648	001	Mar 22, 2004	Jul	DISC
---	-------	-----------	---------	-----	--------------	-----	------

NITROGLYCERIN

FILM, EXTENDED RELEASE;TRANSDERMAL  
MINITRAN

@	BAUSCH	0.4MG/HR	A089773	001	Aug 30, 1996	May	CAHN	
+	!	USPHARMA	0.1MG/HR	N020145	001	Apr 04, 1995	Aug	CTEC
+	!		0.2MG/HR	N020145	002	Apr 04, 1995	Aug	CTEC
+	!		0.4MG/HR	N020145	004	Apr 04, 1995	Aug	CTEC
+	!		0.6MG/HR	N020145	005	Apr 04, 1995	Aug	CTEC

POWDER;SUBLINGUAL  
GONITRO

+	@	POHL BOSKAMP	0.4MG/PACKET	N208424	001	Jun 08, 2016	Sep	DISC
+	!		0.4MG/PACKET	N208424	001	Jun 08, 2016	Jul	CMFD
+	@		0.4MG/PACKET	N208424	001	Jun 08, 2016	Jun	DISC

TABLET;SUBLINGUAL  
NITROGLYCERIN

AB	RUBICON	0.3MG	A209779	001	May 03, 2021	Apr	NEWA	
AB		0.4MG	A209779	002	May 03, 2021	Apr	NEWA	
AB		0.6MG	A209779	003	May 03, 2021	Apr	NEWA	
>D>	AB	SIGMAPHARM LABS LLC	0.3MG	A207745	001	May 07, 2018	Nov	DISC
>A>	@		0.3MG	A207745	001	May 07, 2018	Nov	DISC
>D>	AB		0.4MG	A207745	002	May 07, 2018	Nov	DISC
>A>	@		0.4MG	A207745	002	May 07, 2018	Nov	DISC
>D>	AB		0.6MG	A207745	003	May 07, 2018	Nov	DISC
>A>	@		0.6MG	A207745	003	May 07, 2018	Nov	DISC

NOREPINEPHRINE BITARTRATE

INJECTABLE;INJECTION  
NOREPINEPHRINE BITARTRATE

AP	ANDERSEN GLOBAL	EQ 1MG BASE/ML	A214455	001	Jan 22, 2021	Jan	NEWA
AP	BRECKENRIDGE	EQ 1MG BASE/ML	A214455	001	Jan 22, 2021	Mar	CAHN
AP	GLAND PHARMA LTD	EQ 1MG BASE/ML	A214323	001	May 06, 2021	Apr	NEWA
AP	SUN PHARM	EQ 1MG BASE/ML	A211980	001	Jan 29, 2021	Jan	NEWA

SOLUTION;INTRAVENOUS

NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE

+	!	BAXTER HLTHCARE CORP	EQ 4MG BASE/250ML (EQ 16MCG BASE/ML)	N214313	001	Jan 15, 2021	Sep	CMFD
---	---	----------------------	--------------------------------------	---------	-----	--------------	-----	------

SOLUTION;INTRAVENOUS

NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE

+ @	EQ 4MG BASE/250ML (EQ 16MCG BASE/ML)	N214313	001	Jan 15, 2021	Jul	DISC
+!	EQ 4MG BASE/250ML (EQ 16MCG BASE/ML)	N214313	001	Jan 15, 2021	Jan	NEWA
+!	EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	N214313	002	Jan 15, 2021	Sep	CMFD
+ @	EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	N214313	002	Jan 15, 2021	Jul	DISC
+!	EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	N214313	002	Jan 15, 2021	Jan	NEWA

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE;ORAL

NORTRIPTYLINE HYDROCHLORIDE

	@ ZYDUS	EQ 10MG BASE	A213441	001	Feb 24, 2021	Aug	DISC
AB		EQ 10MG BASE	A213441	001	Feb 24, 2021	Feb	NEWA
	@	EQ 25MG BASE	A213441	002	Feb 24, 2021	Aug	DISC
AB		EQ 25MG BASE	A213441	002	Feb 24, 2021	Feb	NEWA
	@	EQ 50MG BASE	A213441	003	Feb 24, 2021	Aug	DISC
AB		EQ 50MG BASE	A213441	003	Feb 24, 2021	Feb	NEWA
	@	EQ 75MG BASE	A213441	004	Feb 24, 2021	Aug	DISC
AB		EQ 75MG BASE	A213441	004	Feb 24, 2021	Feb	NEWA

NYSTATIN

CREAM;TOPICAL

NYSTATIN

AT	MACLEODS PHARMS LTD	100,000 UNITS/GM	A213566	001	Aug 10, 2021	Jul	NEWA
>A>	@ STRIDES PHARMA	100,000 UNITS/GM	A065315	001	May 31, 2006	Nov	CAHN
>D>	@ VINTAGE	100,000 UNITS/GM	A065315	001	May 31, 2006	Nov	CAHN

OINTMENT;TOPICAL

NYSTATIN

AT	MACLEODS PHARMS LTD	100,000 UNITS/GM	A213826	001	Jan 14, 2021	Jan	NEWA
----	---------------------	------------------	---------	-----	--------------	-----	------

POWDER;ORAL

NILSTAT

>D>	+ @ DAVA PHARMS INC	100%	N050576	001	Dec 22, 1983	Nov	CAHN
>A>	+ @ STRIDES PHARMA	100%	N050576	001	Dec 22, 1983	Nov	CAHN

POWDER;TOPICAL

NYSTATIN

AT	ZYDUS PHARMS	100,000 UNITS/GM	A208581	001	Jun 08, 2017	Jul	CAHN
----	--------------	------------------	---------	-----	--------------	-----	------

SUSPENSION;ORAL

NYSTATIN

AA	DASTECH GENERICS	100,000 UNITS/ML	A062832	001	Dec 27, 1991	Oct	CAHN
>A>	GENUS	100,000 UNITS/ML	A065148	001	Jun 28, 2005	Nov	CAHN
>D>	LANNETT CO INC	100,000 UNITS/ML	A065148	001	Jun 28, 2005	Nov	CAHN
AA	NIVAGEN PHARMS INC	100,000 UNITS/ML	A062832	001	Dec 27, 1991	Jun	CAHN

TABLET;ORAL

NYSTATIN

	@ CHARTWELL RX	500,000 UNITS	A062524	001	Nov 26, 1985	Oct	CAHN
--	----------------	---------------	---------	-----	--------------	-----	------

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT	ALEOR DERMACEUTICALS	100,000 UNITS/GM;0.1%	A214090	001	Mar 31, 2021	Mar	NEWA
----	----------------------	-----------------------	---------	-----	--------------	-----	------

OINTMENT;TOPICAL

NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT	MACLEODS PHARMS LTD	100,000 UNITS/GM;0.1%	A214751	001	Aug 17, 2021	Aug	NEWA
----	---------------------	-----------------------	---------	-----	--------------	-----	------

ODEVIXIBAT

CAPSULE;ORAL

BYLVAY

+ ALBIREO	0.4MG	N215498	002	Jul 20, 2021	Jul	NEWA
+!	1.2MG	N215498	004	Jul 20, 2021	Jul	NEWA

CAPSULE, PELLETS;ORAL

BYLVAY

+ ALBIREO	0.2MG	N215498	001	Jul 20, 2021	Jul	NEWA
+!	0.6MG	N215498	003	Jul 20, 2021	Jul	NEWA

OFLOXACIN

SOLUTION/DROPS;OPHTHALMIC							
OFLOXACIN							
	@ ALVOGEN	0.3%	A 076830	001	Aug 31, 2004	Jun	CAHN
	@	0.3%	A 076830	001	Aug 31, 2004	Jan	DISC
SOLUTION/DROPS;OTIC							
OFLOXACIN							
	@ ALVOGEN	0.3%	A 090395	001	Aug 11, 2009	Jun	CAHN
TABLET;ORAL							
FLOXIN							
	+ @ JANSSEN PHARMS	200MG	N 019735	001	Dec 28, 1990	Jan	CRLD
	+ @	300MG	N 019735	002	Dec 28, 1990	Jan	CRLD
	+ @	400MG	N 019735	003	Dec 28, 1990	Jan	CRLD
OFLOXACIN							
AB	LARKEN LABS	400MG	A 076093	003	Sep 02, 2003	May	CMFD

OLANZAPINE

TABLET;ORAL							
OLANZAPINE							
	@ HISUN PHARM HANGZHOU	2.5MG	A 206924	001	Dec 31, 2020	Jul	DISC
AB		2.5MG	A 206924	001	Dec 31, 2020	Feb	CAHN
	@	5MG	A 206924	002	Dec 31, 2020	Jul	DISC
AB		5MG	A 206924	002	Dec 31, 2020	Feb	CAHN
	@	7.5MG	A 206924	003	Dec 31, 2020	Jul	DISC
AB		7.5MG	A 206924	003	Dec 31, 2020	Feb	CAHN
	@	10MG	A 206924	004	Dec 31, 2020	Jul	DISC
AB		10MG	A 206924	004	Dec 31, 2020	Feb	CAHN
	@	15MG	A 206924	005	Dec 31, 2020	Jul	DISC
AB		15MG	A 206924	005	Dec 31, 2020	Feb	CAHN
	@	20MG	A 206924	006	Dec 31, 2020	Jul	DISC
AB		20MG	A 206924	006	Dec 31, 2020	Feb	CAHN
TABLET, ORALLY DISINTEGRATING;ORAL							
OLANZAPINE							
	HEC PHARM	5MG	A 208146	001	Jul 02, 2018	Oct	CMFD
AB		10MG	A 208146	002	Jul 02, 2018	Oct	CMFD
AB		15MG	A 208146	003	Jul 02, 2018	Oct	CMFD
AB		20MG	A 208146	004	Jul 02, 2018	Oct	CMFD
	@ HISUN PHARM HANGZHOU	5MG	A 206892	001	Dec 31, 2020	Jul	DISC
AB		5MG	A 206892	001	Dec 31, 2020	Feb	CAHN
	@	10MG	A 206892	002	Dec 31, 2020	Jul	DISC
AB		10MG	A 206892	002	Dec 31, 2020	Feb	CAHN
	@	15MG	A 206892	003	Dec 31, 2020	Jul	DISC
AB		15MG	A 206892	003	Dec 31, 2020	Feb	CAHN
	@	20MG	A 206892	004	Dec 31, 2020	Jul	DISC
AB		20MG	A 206892	004	Dec 31, 2020	Feb	CAHN
AB	TORRENT	5MG	A 091415	001	Oct 25, 2011	Aug	CAHN
AB		10MG	A 091415	002	Oct 25, 2011	Aug	CAHN
AB		15MG	A 091415	003	Oct 25, 2011	Aug	CAHN
AB		20MG	A 091415	004	Oct 25, 2011	Aug	CAHN

OLANZAPINE; SAMIDORPHAN L-MALATE

TABLET;ORAL							
LYBALVI							
	+! ALKERMES INC	5MG;EQ 10MG BASE	N 213378	001	May 28, 2021	May	NEWA
	+	10MG;EQ 10MG BASE	N 213378	002	May 28, 2021	May	NEWA
	+	15MG;EQ 10MG BASE	N 213378	003	May 28, 2021	May	NEWA
	+	20MG;EQ 10MG BASE	N 213378	004	May 28, 2021	May	NEWA

OLMESARTAN MEDOXOMIL

TABLET;ORAL							
OLMESARTAN MEDOXOMIL							
	@ LUPIN LTD	5MG	A 206631	001	Apr 27, 2017	Aug	DISC
	@	20MG	A 206631	002	Apr 27, 2017	Aug	DISC
	@	40MG	A 206631	003	Apr 27, 2017	Aug	DISC
	@ MYLAN	5MG	A 078276	001	Oct 26, 2016	Jul	DISC
	@	20MG	A 078276	002	Oct 26, 2016	Jul	DISC
	@	40MG	A 078276	003	Oct 26, 2016	Jul	DISC



OLOPATADINE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC  
OLOPATADINE HYDROCHLORIDE

	AKORN	EQ 0.2% BASE	A204723	001	Dec 05, 2017	Mar	CTEC
	SOMERSET THERAPS LLC	EQ 0.1% BASE	A206306	001	Dec 07, 2015	Jul	CTEC
	@ WOCHKHARDT LTD	EQ 0.1% BASE	A200810	001	Jun 28, 2017	Jul	DISC
	SPRAY, METERED;NASAL						
	OLOPATADINE HYDROCHLORIDE						
AB	AMNEAL	0.665MG/SPRAY	A210901	001	Jan 28, 2020	Mar	CMFD
	@	0.665MG/SPRAY	A210901	001	Jan 28, 2020	Jan	DISC

OLSALAZINE SODIUMCAPSULE;ORAL  
DIPENTUM

	+!	MYLAN SPCLT VIATRIS	250MG	N019715	001	Jul 31, 1990	Oct	CAHN
--	----	---------------------	-------	---------	-----	--------------	-----	------

OMEGA-3-ACID ETHYL ESTERSCAPSULE;ORAL  
LOVAZA

AB	+!	WOODWARD	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N021654	001	Nov 10, 2004	Feb	CAHN
>A>	AB	MANKIND PHARMA	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A215458	001	Nov 15, 2021	Nov	NEWA

OMEGA-3-ACID ETHYL ESTERS TYPE ACAPSULE;ORAL  
OMTRYG

	+ @	OSMOTICA PHARM US	1.2GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N204977	001	Apr 23, 2014	Oct	CAHN
--	-----	-------------------	--	---------	-----	--------------	-----	------

ONDANSETRONFILM;ORAL  
ZUPLENZ

	+ @	AQUESTIVE	4MG	N022524	001	Jul 02, 2010	Feb	CAHN
	+ @		8MG	N022524	002	Jul 02, 2010	Feb	CAHN
	TABLET, ORALLY DISINTEGRATING;ORAL							
	ONDANSETRON							
AB	!	AUROBINDO PHARMA	8MG	A090469	002	Apr 12, 2010	Oct	CHRS
	ZOFTRAN ODT							
	+ @	NOVARTIS	4MG	N020781	001	Jan 27, 1999	Oct	DISC
	+ @		8MG	N020781	002	Jan 27, 1999	Oct	DISC

ONDANSETRON HYDROCHLORIDEINJECTABLE;INJECTION  
ONDANSETRON HYDROCHLORIDE

>D>	AP	!	QILU	EQ 2MG BASE/ML	A203711	001	Sep 08, 2014	Nov	CAHN
>A>	AP	!	QILU PHARM HAINAN	EQ 2MG BASE/ML	A203711	001	Sep 08, 2014	Nov	CAHN
	ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE								
		@	EMCURE PHARMS LTD	EQ 2MG BASE/ML	A078945	001	Jan 03, 2013	May	DISC

ORITAVANCIN DIPHOSPHATEPOWDER;INTRAVENOUS  
KIMYRSA

	+!	MELINTA THERAP	EQ 1.2GM BASE/VIAL	N214155	001	Mar 12, 2021	Mar	NEWA
	+!	MELINTA THERAP	EQ 400MG BASE/VIAL	N206334	001	Aug 06, 2014	May	CAHN

ORPHENADRINE CITRATETABLET, EXTENDED RELEASE;ORAL  
NORFLEX

	+ @	BAUSCH	100MG	N012157	001		May	CAHN
	ORPHENADRINE CITRATE							
	@	IMPAX PHARMS	100MG	A040368	001	Jun 23, 2000	Jan	DISC

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL

OSELTAMIVIR PHOSPHATE

AB	EPIC PHARMA LLC	EQ 30MG BASE	A215208	001	Oct 01, 2021	Sep	NEWA
AB		EQ 45MG BASE	A215208	002	Oct 01, 2021	Sep	NEWA
AB		EQ 75MG BASE	A215208	003	Oct 01, 2021	Sep	NEWA
	@ MYLAN	EQ 30MG BASE	A210157	001	Jan 21, 2021	Jan	DISC
AB		EQ 30MG BASE	A210157	001	Jan 21, 2021	Jan	NEWA
	@	EQ 45MG BASE	A210157	002	Jan 21, 2021	Jan	DISC
AB		EQ 45MG BASE	A210157	002	Jan 21, 2021	Jan	NEWA
	@	EQ 75MG BASE	A210157	003	Jan 21, 2021	Jan	DISC
AB		EQ 75MG BASE	A210157	003	Jan 21, 2021	Jan	NEWA
AB	ZYDUS PHARMS	EQ 30MG BASE	A208578	001	Feb 24, 2017	Oct	CAHN
AB		EQ 45MG BASE	A208578	002	Feb 24, 2017	Oct	CAHN
AB		EQ 75MG BASE	A208578	003	Feb 24, 2017	Oct	CAHN

FOR SUSPENSION;ORAL

OSELTAMIVIR PHOSPHATE

AB	APTAPHARMA INC	EQ 6MG BASE/ML	A212858	001	Aug 30, 2021	Aug	NEWA
AB	ZYDUS PHARMS	EQ 6MG BASE/ML	A209113	001	Sep 14, 2017	Oct	CAHN

OXALIPLATIN

INJECTABLE;INTRAVENOUS

OXALIPLATIN

	@ CIPLA	50MG/10ML (5MG/ML)	A208523	001	Feb 10, 2017	May	DISC
	@	100MG/20ML (5MG/ML)	A208523	002	Feb 10, 2017	May	DISC
AP	NOVAST LABS	50MG/10ML (5MG/ML)	A207562	001	Oct 16, 2018	Sep	CAHN
AP		100MG/20ML (5MG/ML)	A207562	002	Oct 16, 2018	Sep	CAHN
>D>	QILU	50MG/VIAL	A204616	001	May 11, 2016	Nov	CAHN
>D>		100MG/VIAL	A204616	002	May 11, 2016	Nov	CAHN
AP	QILU PHARM HAINAN	50MG/10ML (5MG/ML)	A204368	001	Jun 07, 2016	Aug	CAHN
>A>		50MG/VIAL	A204616	001	May 11, 2016	Nov	CAHN
AP		100MG/20ML (5MG/ML)	A204368	002	Jun 07, 2016	Aug	CAHN
>A>		100MG/VIAL	A204616	002	May 11, 2016	Nov	CAHN
	!	200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016	Aug	CAHN

OXCARBAZEPINE

SUSPENSION;ORAL

OXCARBAZEPINE

AB	AKORN	300MG/5ML	A211420	001	Jul 09, 2021	Jul	NEWA
AB	GLASSHOUSE PHARMS	300MG/5ML	A212428	001	Jun 21, 2021	Jun	NEWA

OXICONAZOLE NITRATE

LOTION;TOPICAL

OXISTAT

+!	ANI PHARMS	EQ 1% BASE	N020209	001	Sep 30, 1992	Apr	CAHN
----	------------	------------	---------	-----	--------------	-----	------

OXYBUTYNIN CHLORIDE

TABLET;ORAL

OXYBUTYNIN CHLORIDE

AB	APPCO	5MG	A209025	001	Dec 21, 2017	Jan	CAHN
BX	EMCURE PHARMS LTD	5MG	A211682	001	May 10, 2019	Sep	CTEC
BX	EYWA	5MG	A211062	001	Feb 06, 2019	Sep	CTEC
AB	! STRIDES PHARMA	5MG	A075079	001	Oct 31, 1997	Oct	CAHN
	@	5MG	A208165	001	Dec 17, 2020	Jun	DISC

OXYCODONE HYDROCHLORIDE

CAPSULE;ORAL

OXYCODONE HYDROCHLORIDE

@ LANNETT CO INC

5MG

A203823	001	Aug 01, 2014	Apr	DISC
---------	-----	--------------	-----	------

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

AA	QUAGEN	5MG/5ML	A213761	001	Jun 02, 2021	May	NEWA
AA		100MG/5ML	A213761	002	Jun 02, 2021	May	NEWA

TABLET;ORAL

OXAYDO

+	ZYLA	5MG	N202080	001	Jun 17, 2011	Mar	CRLD
+		7.5MG	N202080	002	Jun 17, 2011	Mar	CRLD

OXYCODONE HYDROCHLORIDE

AB	ALVOGEN	5MG	A202116	001	Dec 30, 2011	Apr	CAHN
AB		15MG	A202116	002	Dec 30, 2011	Apr	CAHN
AB		30MG	A202116	003	Dec 30, 2011	Apr	CAHN

TABLET;ORAL

OXYCODONE HYDROCHLORIDE

AB	SPECGX LLC	10MG	A076758	004	Oct 12, 2021	Oct	NEWA
AB		20MG	A076758	005	Oct 12, 2021	Oct	NEWA
>A>	@ STRIDES PHARMA	5MG	A077712	003	Mar 02, 2009	Nov	CAHN
>A>	@	10MG	A077712	004	Apr 13, 2015	Nov	CAHN
>A>	@	15MG	A077712	001	Jan 31, 2007	Nov	CAHN
>A>	@	20MG	A077712	005	Apr 13, 2015	Nov	CAHN
>A>	@	30MG	A077712	002	Jan 31, 2007	Nov	CAHN
>D>	@ VINTAGE PHARMS	5MG	A077712	003	Mar 02, 2009	Nov	CAHN
>D>	@	10MG	A077712	004	Apr 13, 2015	Nov	CAHN
>D>	@	15MG	A077712	001	Jan 31, 2007	Nov	CAHN
>D>	@	20MG	A077712	005	Apr 13, 2015	Nov	CAHN
>D>	@	30MG	A077712	002	Jan 31, 2007	Nov	CAHN

OXYMETAZOLINE HYDROCHLORIDE

CREAM;TOPICAL

OXYMETAZOLINE HYDROCHLORIDE

	@ TARO PHARMS	1%	A213584	001	Oct 04, 2021	Oct	DISC
AB		1%	A213584	001	Oct 04, 2021	Sep	NFTG
	RHOFADE						
	+! EPI HLTH	1%	N208552	001	Jan 18, 2017	Oct	CTEC
AB	+!	1%	N208552	001	Jan 18, 2017	Sep	CTFG

OXYMETHOLONE

TABLET;ORAL

ANADROL-50

	+ @ MYLAN SPECIALITY LP	50MG	N016848	001		Apr	DISC
--	-------------------------	------	---------	-----	--	-----	------

OXYTOCIN

INJECTABLE;INJECTION

OXYTOCIN

AP	+! HIKMA	10USP UNITS/ML (10USP UNITS/ML)	N018243	001		Jul	CAHN
AP	+!	100USP UNITS/10ML (10USP UNITS/ML)	N018243	002	Jan 10, 2007	Jul	CAHN

OZANIMOD HYDROCHLORIDE

CAPSULE;ORAL

ZEPOSIA

	+ CELGENE INTL	EQ 0.23MG BASE	N209899	001	Mar 25, 2020	May	CPOT
	+	EQ 0.46MG BASE	N209899	002	Mar 25, 2020	May	CPOT
	+!	EQ 0.92MG BASE	N209899	003	Mar 25, 2020	May	CPOT

PACLITAXEL

>D>	FOR SUSPENSION;IV (INFUSION)						
>D>	ABRAXANE						
>D>	+! ABRAXIS BIOSCIENCE	100MG/VIAL	N021660	001	Jan 07, 2005	Nov	CDFR
	INJECTABLE;INJECTION						
	PACLITAXEL						
AP	ACCORD HLTHCARE	6MG/ML	A205720	001	Aug 17, 2018	May	CMFD
	@ MYLAN LABS LTD	6MG/ML	A091540	001	Sep 29, 2011	Mar	DISC
>A>	POWDER;INTRAVENOUS						
>A>	ABRAXANE						
>A>	+! ABRAXIS BIOSCIENCE	100MG/VIAL	N021660	001	Jan 07, 2005	Nov	CDFR

PAFOLACIANINE SODIUM

>A>	SOLUTION;INTRAVENOUS						
>A>	CYTALUX						
>A>	+! ON TARGET LABS	EQ 3.2MG BASE/1.6ML (EQ 2MG BASE/ML)	N214907	001	Nov 29, 2021	Nov	NEWA

PALIPERIDONE

TABLET, EXTENDED RELEASE;ORAL

PALIPERIDONE

BX	AMNEAL PHARMS	1.5MG	A204707	001	Sep 23, 2019	Sep	CTEC
BX		3MG	A204707	002	Sep 23, 2019	Sep	CTEC
BX		6MG	A204707	003	Sep 23, 2019	Sep	CTEC
BX		9MG	A204707	004	Sep 23, 2019	Sep	CTEC

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

INVEGA HAFYERA

	+	JANSSEN PHARMS	1.092GM/3.5ML (312MG/ML)	N207946	005	Aug 30, 2021	Sep	NEWA
	+		1.560GM/5ML (312MG/ML)	N207946	006	Aug 30, 2021	Sep	NEWA
		INVEGA SUSTENNA						
AB	+	JANSSEN PHARMS	39MG/0.25ML (39MG/0.25ML)	N022264	001	Jul 31, 2009	Jul	CTEC
AP	+		39MG/0.25ML (39MG/0.25ML)	N022264	001	Jul 31, 2009	Jun	CFTG
AB	+		78MG/0.5ML (78MG/0.5ML)	N022264	002	Jul 31, 2009	Jul	CTEC
AP	+		78MG/0.5ML (78MG/0.5ML)	N022264	002	Jul 31, 2009	Jun	CFTG
AB	+		117MG/0.75ML (117MG/0.75ML)	N022264	003	Jul 31, 2009	Jul	CTEC
AP	+		117MG/0.75ML (117MG/0.75ML)	N022264	003	Jul 31, 2009	Jun	CFTG
AB	+		156MG/ML (156MG/ML)	N022264	004	Jul 31, 2009	Jul	CTEC
AP	+		156MG/ML (156MG/ML)	N022264	004	Jul 31, 2009	Jun	CFTG
AB	+		234MG/1.5ML (156MG/ML)	N022264	005	Jul 31, 2009	Jul	CTEC
AP	+		234MG/1.5ML (156MG/ML)	N022264	005	Jul 31, 2009	Jun	CFTG

PALIPERIDONE PALMITATE

AB		TEVA PHARMS USA	39MG/0.25ML (39MG/0.25ML)	A211149	001	Jul 06, 2021	Jul	CTEC
AP			39MG/0.25ML (39MG/0.25ML)	A211149	001	Jul 06, 2021	Jun	NFTG
AB			78MG/0.5ML (78MG/0.5ML)	A211149	002	Jul 06, 2021	Jul	CTEC
AP			78MG/0.5ML (78MG/0.5ML)	A211149	002	Jul 06, 2021	Jun	NFTG
AB			117MG/0.75ML (117MG/0.75ML)	A211149	003	Jul 06, 2021	Jul	CTEC
AP			117MG/0.75ML (117MG/0.75ML)	A211149	003	Jul 06, 2021	Jun	NFTG
AB			156MG/ML (156MG/ML)	A211149	004	Jul 06, 2021	Jul	CTEC
AP			156MG/ML (156MG/ML)	A211149	004	Jul 06, 2021	Jun	NFTG
AB			234MG/1.5ML (156MG/ML)	A211149	005	Jul 06, 2021	Jul	CTEC
AP			234MG/1.5ML (156MG/ML)	A211149	005	Jul 06, 2021	Jun	NFTG

PALONOSETRON HYDROCHLORIDE

INJECTABLE; INTRAVENOUS

ALOXI

	+	@ HELSINN HLTHCARE	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N021372	002	Feb 29, 2008	Apr	DISC
	+	@	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N021372	001	Jul 25, 2003	Apr	DISC

PALONOSETRON HYDROCHLORIDE

	@	ACCORD HLTHCARE	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A204615	001	Mar 15, 2021	Sep	DISC
AP			EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A204615	001	Mar 15, 2021	Mar	NEWA
>A>	AP	BAXTER HLTHCARE CORP	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A206916	001	Nov 12, 2021	Nov	NEWA
AP	!	DR REDDYS LABS LTD	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A201533	002	Apr 21, 2016	Apr	CHRS
		EMCURE PHARMS LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A202951	001	Jun 29, 2021	Jun	NEWA
AP			EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A202951	002	Jun 29, 2021	Jun	NEWA
	@	HOSPIRA INC	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A207005	002	Sep 19, 2018	Apr	DISC
>D>	@	QILU	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A205648	002	Sep 19, 2018	Nov	CAHN
	@		EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A205648	002	Sep 19, 2018	Apr	DISC
>D>	AP		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A205648	001	Sep 19, 2018	Nov	CAHN
>A>	@	QILU PHARM HAINAN	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A205648	002	Sep 19, 2018	Nov	CAHN
>A>	AP		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A205648	001	Sep 19, 2018	Nov	CAHN
	@	TEVA PHARMS USA	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A090713	002	Mar 23, 2018	Apr	DISC

SOLUTION; INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

	+	@ FRESENIUS KABI USA	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N208109	001	Nov 21, 2017	May	DISC
--	---	----------------------	--	---------	-----	--------------	-----	------

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

PAMIDRONATE DISODIUM

AP	+	HIKMA	30MG/10ML (3MG/ML)	N021113	001	Mar 04, 2002	Jul	CAHN
AP	+		90MG/10ML (9MG/ML)	N021113	002	Mar 04, 2002	Jul	CAHN

PANTOPRAZOLE SODIUM

>A>	INJECTABLE;INTRAVENOUS								
>A>	PANTOPRAZOLE SODIUM								
>A>	AP	ACIC PHARMS	EQ 40MG BASE/VIAL	A209524	001	Aug 30, 2021	Nov	CDFR	
>A>	AP	AKORN	EQ 40MG BASE/VIAL	A079197	001	Nov 08, 2012	Nov	CDFR	
>A>	AP	EUGIA PHARMA	EQ 40MG BASE/VIAL	A205675	001	Mar 30, 2016	Nov	CDFR	
>A>	@	MYLAN LABS LTD	EQ 40MG BASE/VIAL	A208580	001	May 04, 2018	Nov	CDFR	
>A>	AP	SANDOZ INC	EQ 40MG BASE/VIAL	A090296	001	Jul 14, 2015	Nov	CDFR	
>A>	AP	SUN PHARM	EQ 40MG BASE/VIAL	A077674	001	Aug 19, 2019	Nov	CDFR	
>A>		PROTONIX IV							
>A>	AP	+!	WYETH PHARMS	EQ 40MG BASE/VIAL	N020988	001	Mar 22, 2001	Nov	CDFR
>D>	INJECTABLE;IV (INFUSION)								
>D>	PANTOPRAZOLE SODIUM								
>D>	AP	ACIC PHARMS	EQ 40MG BASE/VIAL	A209524	001	Aug 30, 2021	Nov	CDFR	
	AP		EQ 40MG BASE/VIAL	A209524	001	Aug 30, 2021	Aug	NEWA	
>D>	AP	AKORN	EQ 40MG BASE/VIAL	A079197	001	Nov 08, 2012	Nov	CDFR	
>D>	AP	EUGIA PHARMA	EQ 40MG BASE/VIAL	A205675	001	Mar 30, 2016	Nov	CDFR	
>D>	@	MYLAN LABS LTD	EQ 40MG BASE/VIAL	A208580	001	May 04, 2018	Nov	CDFR	
>D>	AP	SANDOZ INC	EQ 40MG BASE/VIAL	A090296	001	Jul 14, 2015	Nov	CDFR	
>D>	AP	SUN PHARM	EQ 40MG BASE/VIAL	A077674	001	Aug 19, 2019	Nov	CDFR	
>D>		PROTONIX IV							
>D>	AP	+!	WYETH PHARMS	EQ 40MG BASE/VIAL	N020988	001	Mar 22, 2001	Nov	CDFR
>A>	POWDER;INTRAVENOUS								
>A>	PANTOPRAZOLE SODIUM								
>A>	+!	HIKMA	EQ 40MG BASE/VIAL	N209463	001	Jun 30, 2017	Nov	CDFR	
>D>	POWDER;IV (INFUSION)								
>D>	PANTOPRAZOLE SODIUM								
>D>	+!	HIKMA	EQ 40MG BASE/VIAL	N209463	001	Jun 30, 2017	Nov	CDFR	
	TABLET, DELAYED RELEASE;ORAL								
	PANTOPRAZOLE SODIUM								
	@	JUBILANT GENERICS	EQ 20MG BASE	A090901	001	Aug 30, 2011	Jun	DISC	
	@		EQ 40MG BASE	A090901	002	Aug 30, 2011	Jun	DISC	

PAROXETINE HYDROCHLORIDE

	SUSPENSION;ORAL								
	PAROXETINE HYDROCHLORIDE								
AB		NOVITIUM PHARMA	EQ 10MG BASE/5ML	A215003	001	Sep 03, 2021	Aug	NEWA	
		PAXIL							
AB	+!	APOTEX TECHNOLOGIES	EQ 10MG BASE/5ML	N020710	001	Jun 25, 1997	Aug	CTEC	
	TABLET;ORAL								
	PAROXETINE HYDROCHLORIDE								
AB		YILING	EQ 10MG BASE	A211248	001	Nov 02, 2021	Oct	NEWA	
AB			EQ 20MG BASE	A211248	002	Nov 02, 2021	Oct	NEWA	
AB			EQ 30MG BASE	A211248	003	Nov 02, 2021	Oct	NEWA	
AB			EQ 40MG BASE	A211248	004	Nov 02, 2021	Oct	NEWA	
	TABLET, EXTENDED RELEASE;ORAL								
	PAROXETINE HYDROCHLORIDE								
AB		CADILA PHARMS LTD	EQ 12.5MG BASE	A212645	001	Aug 27, 2021	Aug	NEWA	
AB			EQ 25MG BASE	A212645	002	Aug 27, 2021	Aug	NEWA	
AB			EQ 37.5MG BASE	A212645	003	Aug 27, 2021	Aug	NEWA	
AB		CSPC OUYI	EQ 12.5MG BASE	A213485	001	Feb 16, 2021	Feb	NEWA	
AB			EQ 25MG BASE	A213485	002	Feb 16, 2021	Feb	NEWA	
AB			EQ 37.5MG BASE	A213485	003	Feb 16, 2021	Feb	NEWA	
AB		SINOTHERAPEUTICS INC	EQ 12.5MG BASE	A213612	001	Aug 11, 2021	Jul	NEWA	
AB			EQ 25MG BASE	A213612	002	Aug 11, 2021	Jul	NEWA	

PATIROMER SORBITE CALCIUM

	POWDER;ORAL								
	VELTASSA								
+	VIFOR PHARMA		EQ 8.4GM BASE/PACKET	N205739	001	Oct 21, 2015	Jun	CAHN	
+			EQ 16.8GM BASE/PACKET	N205739	002	Oct 21, 2015	Jun	CAHN	
+!			EQ 25.2GM BASE/PACKET	N205739	003	Oct 21, 2015	Jun	CAHN	

PEGCETACOPLAN

	SOLUTION;SUBCUTANEOUS								
	EMPAVELI								
+	APELLIS PHARMS		1080MG/20ML (54MG/ML)	N215014	001	May 14, 2021	May	NEWA	

PEMETREXED

SOLUTION; INTRAVENOUS  
PEMETREXED

+ @	ACTAVIS LLC	100MG/4ML (25MG/ML)	N208419	001	Aug 21, 2020	Jan DISC
+ @		500MG/20ML (25MG/ML)	N208419	002	Aug 21, 2020	Jan DISC
+ @		1GM/40ML (25MG/ML)	N208419	003	Aug 21, 2020	Jan DISC

PENICILLAMINE

CAPSULE; ORAL  
PENICILLAMINE

AB	AGGREGA	250MG	A215409	001	Aug 23, 2021	Aug NEWA
AB	BRECKENRIDGE	250MG	A215409	001	Aug 23, 2021	Sep CAHN
AB	INVAGEN PHARMS	250MG	A213293	001	Aug 19, 2021	Aug NEWA
AB	NAVINTA LLC	250MG	A214363	001	Oct 08, 2021	Oct NEWA

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION  
PENICILLIN G POTASSIUM

	HQ SPECPLT PHARMA	1,000,000 UNITS/VIAL	A065149	001	Jul 23, 2009	Mar CAHN
AP		5,000,000 UNITS/VIAL	A065149	002	Jul 23, 2009	Mar CAHN
AP		20,000,000 UNITS/VIAL	A065149	003	Jul 23, 2009	Mar CAHN

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL  
PENICILLIN V POTASSIUM

>D>	@ DAVA PHARMS INC	EQ 125MG BASE/5ML	A062981	001	Feb 10, 1989	Nov CAHN
	@	EQ 125MG BASE/5ML	A062981	001	Feb 10, 1989	Mar DISC
>D>	@	EQ 250MG BASE/5ML	A062981	002	Feb 10, 1989	Nov CAHN
	@	EQ 250MG BASE/5ML	A062981	002	Feb 10, 1989	Mar DISC
>A>	@ STRIDES PHARMA	EQ 125MG BASE/5ML	A062981	001	Feb 10, 1989	Nov CAHN
>A>	@	EQ 250MG BASE/5ML	A062981	002	Feb 10, 1989	Nov CAHN
	PENICILLIN-VK					
	TEVA	EQ 125MG BASE/5ML	A060456	001		Mar CTEC
	!	EQ 250MG BASE/5ML	A060456	002		Mar CTEC
	TABLET; ORAL					
	PENICILLIN V POTASSIUM					
>D> AB	DAVA PHARMS INC	EQ 250MG BASE	A062936	001	Nov 25, 1988	Nov CAHN
>D> AB		EQ 500MG BASE	A062935	001	Nov 23, 1988	Nov CAHN
>A> AB	STRIDES PHARMA	EQ 250MG BASE	A062936	001	Nov 25, 1988	Nov CAHN
>A> AB		EQ 500MG BASE	A062935	001	Nov 23, 1988	Nov CAHN

PENTAMIDINE ISETHIONATE

INJECTABLE; INJECTION  
PENTAMIDINE ISETHIONATE

AP	EMCURE PHARMS LTD	300MG/VIAL	A213806	001	Jan 07, 2021	Jan NEWA
----	-------------------	------------	---------	-----	--------------	----------

PENTOBARBITAL SODIUM

INJECTABLE; INJECTION  
NEMBUTAL SODIUM

AP	+! AKORN	50MG/ML	A083246	001		Aug CRLD
----	----------	---------	---------	-----	--	----------

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL  
PENTOXIL

	@ UPSHER SMITH LABS	400MG	A074962	001	Mar 31, 1999	May DISC
	TRENTAL					
	+ @ VALIDUS PHARMS	400MG	N018631	001	Aug 30, 1984	Feb CAHN

PERAMPANEL

TABLET; ORAL  
FYCOMPA

	+ EISAI INC	2MG	N202834	001	Oct 22, 2012	Jun CTEC
AB	+	2MG	N202834	001	Oct 22, 2012	May CFTG
	+	4MG	N202834	002	Oct 22, 2012	Jun CTEC
AB	+	4MG	N202834	002	Oct 22, 2012	May CFTG
	+	6MG	N202834	003	Oct 22, 2012	Jun CTEC
AB	+	6MG	N202834	003	Oct 22, 2012	May CFTG
	+	8MG	N202834	004	Oct 22, 2012	Jun CTEC
AB	+	8MG	N202834	004	Oct 22, 2012	May CFTG
	+	10MG	N202834	005	Oct 22, 2012	Jun CTEC
AB	+	10MG	N202834	005	Oct 22, 2012	May CFTG

	TABLET; ORAL								
	FYCOMPA								
	+	12MG	N202834	006	Oct 22, 2012	Jun	CTEC		
AB	+	12MG	N202834	006	Oct 22, 2012	May	CFTG		
	<u>PERMETHRIN</u>								
	CREAM; TOPICAL								
	ELIMITE								
	+	@ MYLAN	5%	N019855	001	Aug 25, 1989	Sep	CAHN	
	<u>PHENDIMETRAZINE TARTRATE</u>								
	TABLET; ORAL								
	BONTRIL PDM								
AA	+	VALEANT	35MG	A085272	001		Aug	CRLD	
	<u>PHENTERMINE HYDROCHLORIDE</u>								
	CAPSULE; ORAL								
	ADIPEX-P								
AA	+	TEVA	37.5MG	A088023	001	Aug 02, 1983	Aug	CRLD	
	PHENTERMINE HYDROCHLORIDE								
AA	+	SANDOZ	15MG	A087190	002		Aug	CRLD	
AA	+		30MG	A086945	001	Jul 20, 1983	Aug	CRLD	
	TABLET; ORAL								
	ADIPEX-P								
AA	+	TEVA	37.5MG	A085128	001		Aug	CRLD	
	PHENTERMINE HYDROCHLORIDE								
AA		MERRO PHARM USA	37.5MG	A206342	001	Nov 18, 2016	Sep	CAHN	
	+	@ USL PHARMA	8MG	A083804	001		Aug	CRLD	
	<u>PHENTOLAMINE MESYLATE</u>								
	INJECTABLE; INJECTION								
	PHENTOLAMINE MESYLATE								
>A>	AP	!	HIKMA	5MG/VIAL	A040235	001	Mar 11, 1998	Nov	CAHN
>D>	AP	!	WEST-WARD PHARMS INT	5MG/VIAL	A040235	001	Mar 11, 1998	Nov	CAHN
	<u>PHENYLEPHRINE HYDROCHLORIDE</u>								
	SOLUTION; INTRAVENOUS								
	BIORPHEN								
	+	ETON PHARMS	0.5MG/5ML (0.1MG/ML)	N212909	001	Oct 21, 2019	Feb	CPOT	
	+	@	10MG/ML (10MG/ML)	N212909	002	Mar 11, 2021	Apr	DISC	
	+		10MG/ML (10MG/ML)	N212909	002	Mar 11, 2021	Mar	NEWA	
	PHENYLEPHRINE HYDROCHLORIDE								
AP1		CAPLIN	10MG/ML (10MG/ML)	A213318	001	Jun 11, 2020	Jul	CMFD	
AP1			50MG/5ML (10MG/ML)	A213318	002	Jun 11, 2020	Jul	CMFD	
AP1			100MG/10ML (10MG/ML)	A213318	003	Jun 11, 2020	Jul	CMFD	
AP1		GLAND PHARMA LTD	10MG/ML (10MG/ML)	A211920	003	Apr 08, 2021	Apr	NEWA	
AP2	+	HIKMA	10MG/ML (10MG/ML)	N203826	001	Dec 20, 2012	Jan	CAHN	
AP2	+		50MG/5ML (10MG/ML)	N203826	002	Jun 19, 2019	Jan	CAHN	
AP2	+		100MG/10ML (10MG/ML)	N203826	003	Jun 19, 2019	Jan	CAHN	
AP1		PROVEPHARM SAS	10MG/ML (10MG/ML)	A211081	001	Jul 17, 2020	Jan	CAHN	
AP1			50MG/5ML (10MG/ML)	A211081	002	Jul 17, 2020	Jan	CAHN	
AP1			100MG/10ML (10MG/ML)	A211081	003	Jul 17, 2020	Jan	CAHN	
	<u>PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE</u>								
	SYRUP; ORAL								
	PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE								
AA		AKORN	5MG/5ML; 6.25MG/5ML	A040675	001	Dec 23, 2014	Feb	CAHN	
	PROMETH VC PLAIN								
	+	@ G AND W LABS INC	5MG/5ML; 6.25MG/5ML	A088761	001	Nov 08, 1984	Aug	CRLD	
	<u>PHENYTOIN</u>								
	TABLET, CHEWABLE; ORAL								
	DILANTIN								
AB	+	PHARMACIA	50MG	A084427	001		Aug	CRLD	
	<u>PHENYTOIN SODIUM</u>								
	CAPSULE; ORAL								
	DILANTIN								
	+	UPJOHN	30MG EXTENDED	A084349	001		Aug	CRLD	
AB	+		100MG EXTENDED	A084349	002		Aug	CRLD	

INJECTABLE; INJECTION									
PHENYTOIN SODIUM									
AP	+	WEST-WARD PHARMS INT	50MG/ML	A084307	001				Aug CRLD
<u>PHYTONADIONE</u>									
INJECTABLE; INJECTION									
PHYTONADIONE									
BP	+	INTL MEDICATION	1MG/0.5ML	A083722	001				May CRLD
VITAMIN K1									
BP	+	HOSPIRA	1MG/0.5ML	A087954	001	Jul 25, 1983			Oct CRLD
AB	+		10MG/ML	A087955	001	Jul 25, 1983			Aug CRLD
<u>PIFLUFOLASTAT F-18</u>									
SOLUTION; INTRAVENOUS									
PYLARIFY									
	+	PROGENICS PHARMS INC	50ML (1-80mCi/ML)	N214793	001	May 26, 2021			May NEWA
<u>PILOCARPINE HYDROCHLORIDE</u>									
SOLUTION; OPHTHALMIC									
VUITY									
	+	ABBVIE INC	1.25%	N214028	001	Oct 28, 2021			Oct NEWA
TABLET; ORAL									
PILOCARPINE HYDROCHLORIDE									
AB		AMICI	5MG	A076963	001	Dec 22, 2004		Sep	CAHN
AB			7.5MG	A076963	002	Feb 27, 2007		Sep	CAHN
AB		INNOGENIX	5MG	A076963	001	Dec 22, 2004		Aug	CAHN
AB			7.5MG	A076963	002	Feb 27, 2007		Aug	CAHN
<u>PIOGLITAZONE HYDROCHLORIDE</u>									
TABLET; ORAL									
PIOGLITAZONE HYDROCHLORIDE									
AB		ANNORA PHARMA	EQ 15MG BASE	A204133	001	Apr 07, 2014		Jan	CAHN
AB			EQ 30MG BASE	A204133	002	Apr 07, 2014		Jan	CAHN
AB			EQ 45MG BASE	A204133	003	Apr 07, 2014		Jan	CAHN
	@	PICKET PHARMS	EQ 15MG BASE	A078383	001	Mar 12, 2013		Oct	CAHN
	@		EQ 30MG BASE	A078383	002	Mar 12, 2013		Oct	CAHN
	@		EQ 45MG BASE	A078383	003	Mar 12, 2013		Oct	CAHN
AB		SHUANGCHENG	EQ 15MG BASE	A210165	001	Jan 22, 2021		Jan	NEWA
AB			EQ 30MG BASE	A210165	002	Jan 22, 2021		Jan	NEWA
AB			EQ 45MG BASE	A210165	003	Jan 22, 2021		Jan	NEWA
	@	US ANTIBIOTICS	EQ 15MG BASE	A078383	001	Mar 12, 2013		May	CAHN
	@		EQ 30MG BASE	A078383	002	Mar 12, 2013		May	CAHN
	@		EQ 45MG BASE	A078383	003	Mar 12, 2013		May	CAHN
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM</u>									
INJECTABLE; INJECTION									
PIPERACILLIN AND TAZOBACTAM									
	@	MYLAN LABS LTD	EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL	A065458	001	Aug 15, 2014		Apr	DISC
	@		EQ 3GM BASE/VIAL; EQ 375MG BASE/VIAL	A065458	002	Aug 15, 2014		Mar	DISC
	@		EQ 4GM BASE/VIAL; EQ 500MG BASE/VIAL	A065458	003	Aug 15, 2014		Jul	DISC
AP		PROVEPHARM SAS	EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL	A207847	001	Jan 13, 2017		Jan	CAHN
AP			EQ 3GM BASE/VIAL; EQ 375MG BASE/VIAL	A207847	002	Jan 13, 2017		Jan	CAHN
AP			EQ 36GM BASE/VIAL; EQ 4.5GM BASE/VIAL	A207848	002	Jan 13, 2017		Jan	CAHN
AP			EQ 4GM BASE/VIAL; EQ 500MG BASE/VIAL	A207847	003	Jan 13, 2017		Jan	CAHN
AP			EQ 12GM BASE/VIAL; EQ 1.5GM BASE/VIAL	A207848	001	May 11, 2018		Jan	CAHN
AP		SAGENT PHARMS INC	EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL	A208674	001	Feb 16, 2021		Feb	NEWA
AP			EQ 3GM BASE/VIAL; EQ 375MG BASE/VIAL	A208674	002	Feb 16, 2021		Feb	NEWA
AP			EQ 4GM BASE/VIAL; EQ 500MG BASE/VIAL	A208674	003	Feb 16, 2021		Feb	NEWA
AP			EQ 36GM BASE/VIAL; EQ 4.5GM BASE/VIAL	A208675	001	Feb 16, 2021		Feb	NEWA
AP		SANDOZ INC	EQ 36GM BASE/VIAL; EQ 4.5GM BASE/VIAL	A203557	002	Jul 08, 2021		Jul	NEWA
AP	!	WOCKHARDT BIO AG	EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL	A206996	001	Mar 22, 2017		Jan	CHRS



## INJECTABLE; INJECTION

## PIPERACILLIN AND TAZOBACTAM

AP	!	EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A206996	002	Mar 22, 2017	Jan	CHRS
AP	!	EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A206996	003	Mar 22, 2017	Jan	CHRS
AP	!	EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A207146	001	Mar 17, 2017	Jan	CHRS

## ZOSYN

+	@	WYETH PHARMS	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	N050684	001	Oct 22, 1993	Jan	DISC
+	@		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	N050684	002	Oct 22, 1993	Jan	DISC
+	@		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	N050684	003	Oct 22, 1993	Jan	DISC
+	@		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	N050684	004	Oct 22, 1993	Jan	DISC

PIRBUTEROL ACETATE

## AEROSOL, METERED; INHALATION

## MAXAIR

@	BAUSCH	EQ 0.2MG BASE/INH	N020014	001	Nov 30, 1992	May	CAHN
---	--------	-------------------	---------	-----	--------------	-----	------

PIROXICAM

## CAPSULE; ORAL

## PIROXICAM

AB		NOSTRUM LABS INC	10MG	A074118	002	Jun 15, 1993	Jan	CMS1
BX		UNICHEM	10MG	A208340	001	Apr 13, 2017	Sep	CTEC
BX			20MG	A208340	002	Apr 13, 2017	Sep	CTEC

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

## FOR SOLUTION; ORAL

## LAX-LYTE WITH FLAVOR PACKS

AA		L PERRIGO CO	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 .2GM/BOT	A079232	001	Feb 25, 2010	Aug	CAHN
		TRILYTE						
	@	MYLAN	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 .2GM/BOT	A076491	001	Feb 05, 2004	Oct	DISC
AA			420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 .2GM/BOT	A076491	001	Feb 05, 2004	Oct	CAHN

POLYMYXIN B SULFATE

## INJECTABLE; INJECTION

## POLYMYXIN B SULFATE

	@	GLAND	EQ 500,000 UNITS BASE/VIAL	A207322	001	Apr 14, 2016	May	DISC
AP	!	XELLIA PHARMS APS	EQ 500,000 UNITS BASE/VIAL	A202766	001	Jan 15, 2014	May	CHRS

POMALIDOMIDE

## CAPSULE; ORAL

## POMALIDOMIDE

	@	BRECKENRIDGE	1MG	A210111	001	Oct 30, 2020	Feb	DISC
	@		2MG	A210111	002	Oct 30, 2020	Feb	DISC
	@		3MG	A210111	003	Oct 30, 2020	Feb	DISC
	@		4MG	A210111	004	Oct 30, 2020	Feb	DISC
	@	EUGIA PHARMA	1MG	A210249	001	Oct 30, 2020	Apr	DISC
	@		2MG	A210249	002	Oct 30, 2020	Apr	DISC
	@		3MG	A210249	003	Oct 30, 2020	Apr	DISC
	@		4MG	A210249	004	Oct 30, 2020	Apr	DISC

## POMALYST

+		CELGENE	1MG	N204026	001	Feb 08, 2013	Apr	CTEC
+			2MG	N204026	002	Feb 08, 2013	Apr	CTEC
+			3MG	N204026	003	Feb 08, 2013	Apr	CTEC
+	!		4MG	N204026	004	Feb 08, 2013	Apr	CTEC

PONATINIB HYDROCHLORIDE

## TABLET; ORAL

## ICLUSIG

+		TAKEDA PHARMS USA	EQ 10MG BASE	N203469	004	Dec 18, 2020	May	CAHN
+			EQ 15MG BASE	N203469	001	Dec 14, 2012	May	CAHN
+			EQ 30MG BASE	N203469	003	Apr 23, 2015	May	CAHN
+	!		EQ 45MG BASE	N203469	002	Dec 14, 2012	May	CAHN

PONESIMOD

TABLET;ORAL  
PONVORY

+	JANSSEN PHARMS	2MG	N213498	001	Mar 18, 2021	Mar	NEWA
+		3MG	N213498	002	Mar 18, 2021	Mar	NEWA
+		4MG	N213498	003	Mar 18, 2021	Mar	NEWA
+		5MG	N213498	004	Mar 18, 2021	Mar	NEWA
+		6MG	N213498	005	Mar 18, 2021	Mar	NEWA
+		7MG	N213498	006	Mar 18, 2021	Mar	NEWA
+		8MG	N213498	007	Mar 18, 2021	Mar	NEWA
+		9MG	N213498	008	Mar 18, 2021	Mar	NEWA
+		10MG	N213498	009	Mar 18, 2021	Mar	NEWA
+		20MG	N213498	010	Mar 18, 2021	Mar	NEWA

POSACONAZOLE

FOR SUSPENSION, DELAYED RELEASE;ORAL  
NOXAFIL POWDERMIX KIT

+	MSD MERCK CO	300MG	N214770	001	May 31, 2021	May	NEWA
---	--------------	-------	---------	-----	--------------	-----	------

TABLET, DELAYED RELEASE;ORAL  
POSACONAZOLE

AB	AET PHARMA	100MG	A213454	001	Feb 01, 2021	Jan	NEWA
----	------------	-------	---------	-----	--------------	-----	------

POTASSIUM ACETATE

INJECTABLE;INJECTION  
POTASSIUM ACETATE

AP	EXELA PHARMA	2MEQ/ML	A212692	001	Oct 20, 2021	Oct	NEWA
----	--------------	---------	---------	-----	--------------	-----	------

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL  
POTASSIUM CHLORIDE

AB	GRANULES	8MEQ	A214686	001	Feb 16, 2021	Feb	NEWA
AB		10MEQ	A214686	002	Feb 16, 2021	Feb	NEWA

FOR SOLUTION;ORAL  
POTASSIUM CHLORIDE

AA	@ STRIDES PHARMA	20MEQ	A211667	001	Mar 11, 2021	Aug	DISC
AA		20MEQ	A211667	001	Mar 11, 2021	Mar	NEWA

INJECTABLE;INJECTION  
POTASSIUM CHLORIDE

AP	+ @ ABRAXIS PHARM	2MEQ/ML	A080204	001		Aug	CRLD
AP	+ FRESENIUS KABI USA	2MEQ/ML	A080225	001		Aug	CRLD

POTASSIUM CHLORIDE 10MEQ

AP	@ FRESENIUS KABI USA	14.9MG/ML	A211087	001	Sep 09, 2020	Mar	DISC
AP	@	746MG/100ML	A211087	002	Sep 09, 2020	Mar	DISC
AP	NEXUS PHARMS	14.9MG/ML	A214727	001	Mar 18, 2021	Mar	NFTG
AP		745MG/100ML	A214727	002	Mar 18, 2021	Mar	NFTG

POTASSIUM CHLORIDE 20MEQ

>D>	AP	@ FRESENIUS KABI USA	29.8MG/ML	A211087	003	Sep 09, 2020	Mar	DISC
>A>	AP	@	1.49GM/100ML	A211087	005	May 07, 2021	Nov	DISC
	AP	@	1.49GM/100ML	A211087	005	May 07, 2021	Nov	DISC
	AP		1.49GM/100ML	A211087	005	May 07, 2021	Apr	NEWA
	AP	NEXUS PHARMS	29.8MG/ML	A214727	003	Mar 18, 2021	Mar	NFTG
	AP		1.49GM/100ML	A214727	004	Mar 18, 2021	Mar	NFTG

POTASSIUM CHLORIDE 40MEQ

AP	@ FRESENIUS KABI USA	2.98GM/100ML	A211087	004	Sep 09, 2020	Mar	DISC
AP	NEXUS PHARMS	2.98GM/100ML	A214727	005	Mar 18, 2021	Mar	NFTG

SOLUTION;ORAL

POTASSIUM CHLORIDE

AA	GRANULES	20MEQ/15ML	A213392	001	Jan 29, 2021	Jan	NEWA
AA		40MEQ/15ML	A213392	002	Jan 29, 2021	Jan	NEWA
AA	SAPTALIS PHARMS	20MEQ/15ML	A211648	001	May 21, 2021	May	NEWA
AA		40MEQ/15ML	A211648	002	May 21, 2021	May	NEWA

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE

AB1	@ AMTA	10MEQ	A214395	001	Jan 28, 2021	Jul	DISC
		10MEQ	A214395	001	Jan 28, 2021	Jan	NEWA
	@	20MEQ	A214395	002	Jan 28, 2021	Jul	DISC
AB1		20MEQ	A214395	002	Jan 28, 2021	Jan	NEWA
	@ AUROBINDO PHARMA LTD	10MEQ	A214728	001	Mar 31, 2021	Sep	DISC
AB1		10MEQ	A214728	001	Mar 31, 2021	Mar	NEWA
	@	15MEQ	A214728	002	Mar 31, 2021	Sep	DISC
AB1		15MEQ	A214728	002	Mar 31, 2021	Mar	NEWA

TABLET, EXTENDED RELEASE;ORAL  
 POTASSIUM CHLORIDE

	@	20MEQ	A214728	003	Mar 31, 2021	Sep	DISC
AB1		20MEQ	A214728	003	Mar 31, 2021	Mar	NEWA
	@ BRECKENRIDGE	10MEQ	A213588	001	Aug 21, 2020	Sep	CAHN
	@	20MEQ	A213588	002	Aug 21, 2020	Sep	CAHN
	@ CENTAUR PHARMS PVT	10MEQ	A213588	001	Aug 21, 2020	Mar	DISC
	@	20MEQ	A213588	002	Aug 21, 2020	Mar	DISC
>D> AB2	SIGMAPHARM LABS LLC	8MEQ	A207528	001	Aug 19, 2016	Nov	DISC
>A>	@	8MEQ	A207528	001	Aug 19, 2016	Nov	DISC
>D> AB2		10MEQ	A207528	002	Aug 19, 2016	Nov	DISC
>A>	@	10MEQ	A207528	002	Aug 19, 2016	Nov	DISC

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45%

	+	BAXTER HLTHCARE	150MG/100ML;450MG/100ML	N017648	005	Nov 26, 2002	Mar	CTNA
	+		150MG/100ML;450MG/100ML	N017648	005	Nov 26, 2002	Mar	CTEC
	@	FRESENIUS KABI USA	150MG/100ML;450MG/100ML	A212347	001	Sep 17, 2020	Mar	DISC
			POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9%					
AP	+	BAXTER HLTHCARE	150MG/100ML;900MG/100ML	N017648	001		Mar	CTNA
AP	+		150MG/100ML;900MG/100ML	N017648	001		Mar	CHRS
>D> AP		FRESENIUS KABI USA	150MG/100ML;900MG/100ML	A212347	003	Jun 02, 2021	Nov	DISC
>A>	@		150MG/100ML;900MG/100ML	A212347	003	Jun 02, 2021	Nov	DISC
AP			150MG/100ML;900MG/100ML	A212347	003	Jun 02, 2021	May	NEWA
			POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9%					
	+	BAXTER HLTHCARE	300MG/100ML;900MG/100ML	N017648	002		Mar	CTNA
	+		300MG/100ML;900MG/100ML	N017648	002		Mar	CHRS
	+		300MG/100ML;900MG/100ML	N017648	002		Mar	CTEC
	@	FRESENIUS KABI USA	300MG/100ML;900MG/100ML	A212347	002	Sep 17, 2020	Mar	DISC
			SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075%					
	@	BAXTER HLTHCARE	75MG/100ML;900MG/100ML	N017648	004		Mar	CTNA

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CITRATE

AB	ASCENT PHARMS INC	5MEQ	A214420	001	Feb 05, 2021	Jan	NEWA
AB		10MEQ	A214420	002	Feb 05, 2021	Jan	NEWA
AB		15MEQ	A214420	003	Feb 05, 2021	Jan	NEWA
AB	BIONPHARMA INC	10MEQ	A212799	001	Jun 29, 2020	Apr	CMFD
	@	10MEQ	A212799	001	Jun 29, 2020	Feb	DISC
AB		15MEQ	A212799	002	Jun 29, 2020	Apr	CMFD
	@	15MEQ	A212799	002	Jun 29, 2020	Feb	DISC
AB	EYWA	5MEQ	A214426	001	Feb 19, 2021	Feb	NEWA
AB		10MEQ	A214426	002	Feb 19, 2021	Feb	NEWA
AB		15MEQ	A214426	003	Feb 19, 2021	Feb	NEWA

PRALSETINIB

CAPSULE;ORAL

GAVRETO

	+	GENENTECH INC	100MG	N213721	001	Sep 04, 2020	Mar	CAHN
--	---	---------------	-------	---------	-----	--------------	-----	------

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

	@	NOSTRUM LABS INC	0.125MG	A091450	001	Oct 08, 2010	Jul	DISC
AB			0.125MG	A091450	001	Oct 08, 2010	Apr	CAHN
	@		0.25MG	A091450	002	Oct 08, 2010	Jul	DISC
AB			0.25MG	A091450	002	Oct 08, 2010	Apr	CAHN
	@		0.5MG	A091450	003	Oct 08, 2010	Jul	DISC
AB			0.5MG	A091450	003	Oct 08, 2010	Apr	CAHN
	@		1MG	A091450	004	Oct 08, 2010	Jul	DISC
AB			1MG	A091450	004	Oct 08, 2010	Apr	CAHN
	@		1.5MG	A091450	005	Oct 08, 2010	Jul	DISC
AB			1.5MG	A091450	005	Oct 08, 2010	Apr	CAHN

TABLET, EXTENDED RELEASE;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB	XIAMEN LP PHARM CO	0.375MG	A212797	001	Jun 11, 2021	Jun	NEWA
AB		0.75MG	A212797	002	Jun 11, 2021	Jun	NEWA

PRASUGREL HYDROCHLORIDE

TABLET;ORAL

PRASUGREL

BX	AMNEAL PHARMS	EQ 5MG BASE	A205913	001	Jun 19, 2018	Sep	CTEC
BX		EQ 10MG BASE	A205913	002	Jun 19, 2018	Sep	CTEC
	@ DR REDDYS LABS LTD	EQ 5MG BASE	A205926	001	Jul 07, 2020	Jan	DISC
	@	EQ 10MG BASE	A205926	002	Jul 07, 2020	Jan	DISC
AB	PANACEA	EQ 5MG BASE	A205897	001	Oct 16, 2017	Jul	CAHN
AB		EQ 10MG BASE	A205897	002	Oct 16, 2017	Jul	CAHN
AB	USPHARMA WINDLAS	EQ 5MG BASE	A205790	001	Oct 16, 2017	Sep	CAHN
AB		EQ 10MG BASE	A205790	002	Oct 16, 2017	Sep	CAHN

PRAVASTATIN SODIUM

TABLET;ORAL

PRAVACHOL

	+ @ BRISTOL MYERS SQUIBB	20MG	N019898	003	Oct 31, 1991	Jun	DISC
	+ @	40MG	N019898	004	Mar 22, 1993	Jun	DISC
	+ @	80MG	N019898	008	Dec 18, 2001	Jun	DISC
	PRAVASTATIN SODIUM						
AB	BIOCON PHARMA	10MG	A209869	001	Apr 13, 2018	Jan	CAHN
AB		20MG	A209869	002	Apr 13, 2018	Jan	CAHN
AB		40MG	A209869	003	Apr 13, 2018	Jan	CAHN
AB		80MG	A209869	004	Apr 13, 2018	Jan	CAHN
	@ HISUN PHARM HANGZHOU	20MG	A206061	001	Nov 23, 2018	Jan	DISC
	@	40MG	A206061	002	Nov 23, 2018	Jan	DISC
	@	80MG	A206061	003	Nov 23, 2018	Jan	DISC
AB	! TEVA PHARMS	80MG	A077793	001	Jan 15, 2008	Jun	CHRS

PRAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

PRAZOSIN HYDROCHLORIDE

AB	ANI PHARMS	EQ 1MG BASE	A072577	002	May 16, 1989	Feb	CMFD
AB		EQ 2MG BASE	A072577	001	May 16, 1989	Feb	CMFD
AB		EQ 5MG BASE	A072577	003	May 16, 1989	Feb	CMFD

PREDNISOLONE

SYRUP;ORAL

PREDNISOLONE

AA	CHARTWELL RX	15MG/5ML	A040323	001	May 13, 1999	Mar	CMFD
----	--------------	----------	---------	-----	--------------	-----	------

TABLET;ORAL

PREDNISOLONE

	@ RISING	5MG	A084773	001		Jan	CAHN
--	----------	-----	---------	-----	--	-----	------

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION;ORAL

PREDNISOLONE SODIUM PHOSPHATE

	@ BAUSCH	EQ 15MG BASE/5ML	A075250	001	Jul 12, 2002	May	CAHN
--	----------	------------------	---------	-----	--------------	-----	------

SOLUTION/DROPS;OPHTHALMIC

INFLAMASE FORTE

	+ @ NOVARTIS	EQ 0.9% PHOSPHATE	A080751	002		Aug	CRLD
--	--------------	-------------------	---------	-----	--	-----	------

INFLAMASE MILD

	+ @ NOVARTIS	EQ 0.11% PHOSPHATE	A080751	001		Aug	CRLD
--	--------------	--------------------	---------	-----	--	-----	------

TABLET, ORALLY DISINTEGRATING;ORAL

ORAPRED ODT

	+ CONCORDIA PHARMS INC	EQ 10MG BASE	N021959	001	Jun 01, 2006	Jul	CTEC
		EQ 15MG BASE	N021959	002	Jun 01, 2006	Jul	CTEC
		EQ 30MG BASE	N021959	003	Jun 01, 2006	Jul	CTEC

PREDNISOLONE SODIUM PHOSPHATE

	@ MYLAN PHARMS INC	EQ 10MG BASE	A202179	001	Apr 10, 2013	Jul	DISC
	@	EQ 15MG BASE	A202179	002	Apr 10, 2013	Jul	DISC
	@	EQ 30MG BASE	A202179	003	Apr 10, 2013	Jul	DISC

PREDNISON

TABLET;ORAL

PREDNISON

AB	AMNEAL	1MG	A213385	001	Jun 16, 2020	Oct	CMFD
AB		5MG	A213385	002	Jun 16, 2020	Oct	CMFD
AB		10MG	A213386	001	Jun 24, 2020	Oct	CMFD
AB		20MG	A213386	002	Jun 24, 2020	Oct	CMFD
>A>	AB AUROBINDO PHARMA LTD	1MG	A215671	001	Nov 16, 2021	Nov	NEWA
AB	+! HIKMA	1MG	A087800	001	Apr 22, 1982	Aug	CRLD

TABLET;ORAL  
PREDNISONE

AB	+	!		10MG	A 084122	001			Aug	CRLD
AB	+	!		20MG	A 087342	001			Aug	CRLD
>D>	AB		MYLAN	5MG	A 080292	001			Nov	CAHN
>A>	AB			5MG	A 080292	001			Nov	CAHN
AB			NOVITIUM PHARMA	1MG	A 215246	001	Jul 06, 2021		Jun	NEWA
		@	RISING	10MG	A 089983	001	Jan 12, 1989		Jan	CAHN
		@		20MG	A 085813	001			Jan	CAHN
		@		50MG	A 089984	001	Jan 12, 1989		Jan	CAHN
AB			STRIDES PHARMA	10MG	A 208412	001	Feb 11, 2021		Feb	NEWA
AB				20MG	A 208412	002	Feb 11, 2021		Feb	NEWA

TABLET, DELAYED RELEASE;ORAL  
RAYOS

+			HORIZON	1MG	N 202020	001	Jul 26, 2012		Apr	CAHN
+				2MG	N 202020	002	Jul 26, 2012		Apr	CAHN
+		!		5MG	N 202020	003	Jul 26, 2012		Apr	CAHN

PREGABALIN

CAPSULE;ORAL  
LYRICA

AB	+		UPJOHN	25MG	N 021446	001	Dec 30, 2004		Apr	CAHN
AB	+			50MG	N 021446	002	Dec 30, 2004		Apr	CAHN
AB	+			75MG	N 021446	003	Dec 30, 2004		Apr	CAHN
AB	+			100MG	N 021446	004	Dec 30, 2004		Apr	CAHN
AB	+			150MG	N 021446	005	Dec 30, 2004		Apr	CAHN
AB	+			200MG	N 021446	006	Dec 30, 2004		Apr	CAHN
AB	+			225MG	N 021446	007	Dec 30, 2004		Apr	CAHN
AB	+	!		300MG	N 021446	008	Dec 30, 2004		Apr	CAHN

PREGABALIN

AB			ALKEM LABS LTD	25MG	A 207799	007	Sep 30, 2019		Feb	CMS1
AB				50MG	A 207799	008	Sep 30, 2019		Feb	CMS1
AB			APOTEX	25MG	A 211685	001	Jul 07, 2021		Jun	NEWA
AB				50MG	A 211685	002	Jul 07, 2021		Jun	NEWA
AB				75MG	A 211685	003	Jul 07, 2021		Jun	NEWA
AB				100MG	A 211685	004	Jul 07, 2021		Jun	NEWA
AB				150MG	A 211685	005	Jul 07, 2021		Jun	NEWA
AB				200MG	A 211685	006	Jul 07, 2021		Jun	NEWA
AB				225MG	A 211685	007	Jul 07, 2021		Jun	NEWA
AB				300MG	A 211685	008	Jul 07, 2021		Jun	NEWA
AB			CHANGZHOU PHARM	50MG	A 214322	001	Jul 15, 2021		Jul	NEWA
AB				75MG	A 214322	002	Jul 15, 2021		Jul	NEWA
AB				100MG	A 214322	003	Jul 15, 2021		Jul	NEWA
AB				150MG	A 214322	004	Jul 15, 2021		Jul	NEWA
AB				200MG	A 214322	005	Jul 15, 2021		Jul	NEWA
AB				225MG	A 214322	006	Jul 15, 2021		Jul	NEWA
AB				300MG	A 214322	007	Jul 15, 2021		Jul	NEWA

SOLUTION;ORAL

LYRICA

AA	+	!	UPJOHN	20MG/ML	N 022488	001	Jan 04, 2010		Apr	CAHN
----	---	---	--------	---------	----------	-----	--------------	--	-----	------

TABLET, EXTENDED RELEASE;ORAL

LYRICA CR

AB	+		PFIZER	82.5MG	N 209501	001	Oct 11, 2017		Apr	CFTG
AB	+			165MG	N 209501	002	Oct 11, 2017		Apr	CFTG
AB	+	!		330MG	N 209501	003	Oct 11, 2017		Apr	CFTG
AB	+		UPJOHN	82.5MG	N 209501	001	Oct 11, 2017		Apr	CAHN
AB	+			165MG	N 209501	002	Oct 11, 2017		Apr	CAHN
AB	+	!		330MG	N 209501	003	Oct 11, 2017		Apr	CAHN

PREGABALIN

AB			ALVOGEN	82.5MG	A 211687	001	Jul 06, 2021		Jun	NEWA
AB				165MG	A 211687	002	Jul 06, 2021		Jun	NEWA
AB				330MG	A 211687	003	Jul 06, 2021		Jun	NEWA
AB			ALVOGEN PINE BROOK	82.5MG	A 211593	001	Apr 13, 2021		Apr	NFTG
AB				165MG	A 211593	002	Apr 13, 2021		Apr	NFTG
AB				330MG	A 211593	003	Apr 13, 2021		Apr	NFTG
AB			APOTEX	165MG	A 213313	001	Apr 13, 2021		Apr	NFTG
AB				330MG	A 213313	002	Apr 13, 2021		Apr	NFTG
AB			MSN	82.5MG	A 213226	001	Apr 13, 2021		Apr	NFTG
AB				165MG	A 213226	002	Apr 13, 2021		Apr	NFTG
AB				330MG	A 213226	003	Apr 13, 2021		Apr	NFTG
AB			MYLAN	82.5MG	A 211948	001	Apr 13, 2021		Apr	NFTG
AB				165MG	A 211967	001	Nov 04, 2021		Oct	NEWA
>D>	AB			330MG	A 211431	001	Jul 02, 2021		Nov	DISC

TABLET, EXTENDED RELEASE;ORAL  
PREGABALIN

>A>	@	330MG	A211431	001	Jul 02, 2021	Nov	DISC
AB		330MG	A211431	001	Jul 02, 2021	Jun	NEWA
AB	SUN PHARM	82.5MG	A211889	001	Apr 13, 2021	Apr	NFTG
AB		165MG	A211889	002	Apr 13, 2021	Apr	NFTG
AB		330MG	A211889	003	Apr 13, 2021	Apr	NFTG

PROBENECID

TABLET;ORAL  
PROBENECID

	@	MYLAN	500MG	A084211	002		Aug	CAHN
	@		500MG	A084211	002		Aug	DISC
AB	!	WATSON LABS TEVA	500MG	A084442	004	Mar 29, 1983	Aug	CTEC

PROCAINAMIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL  
PROCAN SR

	+	@	PARKE DAVIS	250MG	A086468	001		Aug	CRLD
	+	@	PARKEDALE	500MG	A086065	001		Aug	CRLD
	+	@		750MG	A087510	001	Apr 01, 1982	Aug	CRLD

PROCHLORPERAZINE EDISYLATE

CONCENTRATE;ORAL  
COMPAZINE

	+	@	GLAXOSMITHKLINE	EQ 10MG BASE/ML	N011276	001		Oct	CRLD
--	---	---	-----------------	-----------------	---------	-----	--	-----	------

INJECTABLE;INJECTION

PROCHLORPERAZINE EDISYLATE

AP		CAPLIN	EQ 5MG BASE/ML	A214379	001	Apr 22, 2021	Apr	NEWA
AP		GLAND PHARMA LTD	EQ 5MG BASE/ML	A214107	001	Sep 22, 2021	Sep	NEWA
	@	HIKMA	EQ 5MG BASE/ML	A089523	001	May 03, 1988	Jul	CAHN
AP			EQ 5MG BASE/ML	A089903	001	Aug 29, 1989	Jul	CAHN
AP		VIWIT PHARM	EQ 5MG BASE/ML	A213626	001	Sep 28, 2021	Sep	NEWA

PROGESTERONE

CAPSULE;ORAL  
PROGESTERONE

BX		SOFGEN PHARMS	100MG	A200456	001	Sep 28, 2012	Sep	CTEC
BX			200MG	A200456	002	Sep 28, 2012	Sep	CTEC

PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE

AA		AMNEAL PHARMS	6.25MG/5ML	A040882	001	Dec 30, 2009	Aug	CMFD	
	@		6.25MG/5ML	A040882	001	Dec 30, 2009	Feb	DISC	
AA		QUAGEN	6.25MG/5ML	A213890	001	Jul 12, 2021	Jul	NEWA	
AA	+	!	WOCKHARDT BIO AG	6.25MG/5ML	A087953	001	Nov 15, 1982	Aug	CRLD

TABLET;ORAL

PROMETHAZINE HYDROCHLORIDE

AB	+	SANDOZ	25MG	A084176	003		Aug	CRLD
AB	+	!	50MG	A084176	001		Aug	CRLD

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL  
PROPAFENONE HYDROCHLORIDE

	@	MYLAN	225MG	A203803	001	Apr 29, 2016	Jul	DISC
	@		325MG	A203803	002	Apr 29, 2016	Jul	DISC
	@		425MG	A203803	003	Apr 29, 2016	Jul	DISC
BX		SINOTHERAPEUTICS INC	225MG	A210339	001	Jan 04, 2019	Sep	CTEC
BX			325MG	A210339	002	Jan 04, 2019	Sep	CTEC
BX			425MG	A210339	003	Jan 04, 2019	Sep	CTEC
AB		ZYDUS	225MG	A214184	001	Apr 21, 2021	Apr	NEWA
AB			325MG	A214184	002	Apr 21, 2021	Apr	NEWA
AB			425MG	A214184	003	Apr 21, 2021	Apr	NEWA

TABLET;ORAL

PROPAFENONE HYDROCHLORIDE

AB		STRIDES PHARMA	150MG	A075938	001	Oct 17, 2002	Oct	CAHN
AB			225MG	A075938	002	Oct 17, 2002	Oct	CAHN
AB	!		300MG	A075938	003	Oct 17, 2002	Oct	CAHN

<u>PROPANTHELINE BROMIDE</u>									
TABLET; ORAL									
PROPANTHELINE BROMIDE									
	@ HIKMA	15MG		A 080927	002				Apr DISC
<u>PROPOFOL</u>									
INJECTABLE; INJECTION									
PROPOFOL									
AB	EMCURE PHARMS LTD	10MG/ML		A 206408	001	Oct 12, 2021			Oct NEWA
<u>PROPRANOLOL HYDROCHLORIDE</u>									
TABLET; ORAL									
PROPRANOLOL HYDROCHLORIDE									
AB	IMPAX LABS INC	10MG		A 071972	001	Apr 06, 1988		Sep	CMFD
AB		20MG		A 071972	002	Apr 06, 1988		Sep	CMFD
AB		40MG		A 071972	003	Apr 06, 1988		Aug	CMFD
	@ WATSON LABS	60MG		A 070178	002	Apr 23, 2018		Apr	DISC
<u>PROPYLTHIOURACIL</u>									
TABLET; ORAL									
PROPYLTHIOURACIL									
BD	QUAGEN	50MG		A 080154	001				Mar CMFD
<u>PROTAMINE SULFATE</u>									
INJECTABLE; INJECTION									
PROTAMINE SULFATE									
	@ HIKMA	10MG/ML		A 089474	001	Nov 05, 1986		Jul	CAHN
	@	10MG/ML		A 089475	001	Nov 05, 1986		Jul	CAHN
<u>PYRAZINAMIDE</u>									
TABLET; ORAL									
PYRAZINAMIDE									
AB	+ NOVITIUM PHARMA	500MG		A 080157	001				Aug CRLD
AB		500MG		A 080157	001				Apr CMFD
<u>PYRIDOXINE HYDROCHLORIDE</u>									
INJECTABLE; INJECTION									
PYRIDOXINE HYDROCHLORIDE									
	+! FRESENIUS KABI USA	100MG/ML		A 080618	001				Aug CRLD
<u>PYRIMETHAMINE</u>									
TABLET; ORAL									
PYRIMETHAMINE									
AB	ALVOGEN	25MG		A 211271	001	Jul 27, 2021		Aug	CAHN
AB	FERA PHARMS LLC	25MG		A 211271	001	Jul 27, 2021		Jul	NEWA
AB	TEVA PHARMS	25MG		A 215506	001	Aug 13, 2021		Aug	NEWA
<u>QUETIAPINE FUMARATE</u>									
TABLET; ORAL									
QUETIAPINE FUMARATE									
	@ JUBILANT GENERICS	EQ 25MG BASE		A 203150	001	Nov 26, 2013			Jun DISC
TABLET, EXTENDED RELEASE; ORAL									
QUETIAPINE FUMARATE									
	@ ANCHEN PHARMS	EQ 150MG BASE		A 090757	001	Dec 01, 2017		Jun	DISC
	@	EQ 200MG BASE		A 090757	002	Dec 01, 2017		Jun	DISC
	@	EQ 300MG BASE		A 090757	003	Dec 01, 2017		Jun	DISC
	@	EQ 400MG BASE		A 090757	004	Dec 01, 2017		Jun	DISC
	@ MYLAN	EQ 50MG BASE		A 202228	001	Feb 02, 2021		Feb	DISC
AB		EQ 50MG BASE		A 202228	001	Feb 02, 2021		Jan	NEWA
	@	EQ 150MG BASE		A 202228	002	Feb 02, 2021		Feb	DISC
AB		EQ 150MG BASE		A 202228	002	Feb 02, 2021		Jan	NEWA
	@	EQ 200MG BASE		A 202228	003	Feb 02, 2021		Feb	DISC
AB		EQ 200MG BASE		A 202228	003	Feb 02, 2021		Jan	NEWA
	@	EQ 300MG BASE		A 202228	004	Feb 02, 2021		Feb	DISC
AB		EQ 300MG BASE		A 202228	004	Feb 02, 2021		Jan	NEWA
	@	EQ 400MG BASE		A 202228	005	Feb 02, 2021		Feb	DISC
AB		EQ 400MG BASE		A 202228	005	Feb 02, 2021		Jan	NEWA
BX	SCIEGEN PHARMS INC	EQ 50MG BASE		A 209635	005	Nov 16, 2018		Sep	CTEC
BX		EQ 150MG BASE		A 209635	001	Nov 29, 2017		Sep	CTEC
BX		EQ 200MG BASE		A 209635	002	Nov 29, 2017		Sep	CTEC
BX		EQ 300MG BASE		A 209635	003	Nov 29, 2017		Sep	CTEC

TABLET, EXTENDED RELEASE;ORAL  
QUETIAPINE FUMARATE

BX EQ 400MG BASE A209635 004 Nov 29, 2017 Sep CTEC

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE;ORAL  
QUINIDINE GLUCONATE

AB EYWA 324MG A212589 001 Sep 17, 2021 Sep NEWA  
 @ RISING 324MG A089894 001 Dec 15, 1988 Jan CAHN  
 AB ! SUN PHARM INDUSTRIES 324MG A089338 001 Feb 11, 1987 Sep CTEC

QUINIDINE SULFATE

TABLET;ORAL  
CIN-QUIN

+ @ SOLVAY 100MG A085299 001 Aug CRLD  
 + @ 200MG A084932 001 Aug CRLD  
 QUINORA  
 + @ SCHERING 300MG A085222 001 Aug CRLD

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE;ORAL  
ACIPHEX

AB + @ WOODWARD 10MG N020973 001 May 29, 2002 Jul CAHN  
 +! 20MG N020973 002 Aug 19, 1999 Jul CAHN

RANITIDINE HYDROCHLORIDE

CAPSULE;ORAL

RANITIDINE HYDROCHLORIDE

@ AUROBINDO PHARMA LTD EQ 150MG BASE A211058 001 Jul 16, 2018 Jun DISC  
 @ EQ 300MG BASE A211058 002 Jul 16, 2018 Jun DISC

SYRUP;ORAL

RANITIDINE HYDROCHLORIDE

>D> @ ANDA REPOSITORY EQ 15MG BASE/ML A090054 001 Nov 15, 2010 Nov CAHN  
 @ AUROBINDO PHARMA LTD EQ 15MG BASE/ML A090623 001 Jul 28, 2010 Jun DISC  
 >A> @ TOLMAR EQ 15MG BASE/ML A090054 001 Nov 15, 2010 Nov CAHN

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

@ WOCKHARDT LTD EQ 150MG BASE A075208 001 Dec 17, 1998 Jan DISC  
 @ EQ 300MG BASE A075208 002 Dec 17, 1998 Jan DISC

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL  
RANOLAZINE

AB @ AMNEAL 500MG A207690 001 Mar 11, 2021 Apr DISC  
 @ 500MG A207690 001 Mar 11, 2021 Mar NEWA  
 @ 1GM A207690 002 Mar 11, 2021 Apr DISC  
 AB 1GM A207690 002 Mar 11, 2021 Mar NEWA  
 AB GRAVITI PHARMS 500MG A212889 001 Jan 28, 2021 Jan NEWA  
 AB 1GM A212889 002 Jan 28, 2021 Jan NEWA  
 AB PRAXGEN 500MG A212781 001 Mar 23, 2020 Feb CAHN  
 AB 1GM A212781 002 Mar 23, 2020 Feb CAHN

RASAGILINE MESYLATE

TABLET;ORAL

RASAGILINE MESYLATE

>A> AB DR REDDYS EQ 0.5MG BASE A201942 001 Nov 18, 2021 Nov NEWA  
 >A> AB EQ 1MG BASE A201942 002 Nov 18, 2021 Nov NEWA

REPAGLINIDE

TABLET;ORAL

REPAGLINIDE

AB PADAGIS US 0.5MG A201189 001 Jul 17, 2013 Jul CAHN  
 AB 0.5MG A201189 001 Jul 17, 2013 Jul CAHN  
 AB 1MG A201189 002 Jan 22, 2014 Jul CAHN  
 AB 1MG A201189 002 Jan 22, 2014 Jul CAHN  
 AB 2MG A201189 003 Jan 22, 2014 Jul CAHN  
 AB 2MG A201189 003 Jan 22, 2014 Jul CAHN



<u>RIFAMPIN</u>									
INJECTABLE; INJECTION									
RIFAMPIN									
AP	HIKMA	600MG/VIAL	A064217	001	Oct 29, 1999	Oct	CAHN		
<u>RIFAXIMIN</u>									
TABLET; ORAL									
XIFAXAN									
+!	SALIX PHARMS	550MG	N021361	002	Mar 24, 2010	Aug	CMS1		
<u>RILUZOLE</u>									
FILM; ORAL									
EXSERVAN									
+!	mitsubishi holdings	50MG	N212640	001	Nov 22, 2019	Feb	CAHN		
<u>RIMEGEPANT SULFATE</u>									
TABLET, ORALLY DISINTEGRATING; ORAL									
NURTEC ODT									
+!	BIOHAVEN IRELAND	EQ 75MG BASE	N212728	001	Feb 27, 2020	Jul	CAHN		
<u>RISPERIDONE</u>									
TABLET, ORALLY DISINTEGRATING; ORAL									
RISPERDAL									
+ @	JANSSEN PHARMS	0.5MG	N021444	001	Apr 02, 2003	Feb	DISC		
+ @		1MG	N021444	002	Apr 02, 2003	Feb	DISC		
+ @		2MG	N021444	003	Apr 02, 2003	Feb	DISC		
+ @		3MG	N021444	004	Dec 23, 2004	Feb	DISC		
+ @		4MG	N021444	005	Dec 23, 2004	Feb	DISC		
RISPERIDONE									
AB	!	JUBILANT GENERICS	1MG	A090839	002	Nov 04, 2011	Feb	CHRS	
<u>RITONAVIR</u>									
CAPSULE; ORAL									
RITONAVIR									
@	HIKMA	100MG	A205801	001	Dec 03, 2020	Mar	DISC		
<u>RIZATRIPTAN BENZOATE</u>									
TABLET, ORALLY DISINTEGRATING; ORAL									
RIZATRIPTAN BENZOATE									
@	JUBILANT GENERICS	EQ 5MG BASE	A203334	001	Oct 16, 2015	Jun	DISC		
@		EQ 10MG BASE	A203334	002	Oct 16, 2015	Jun	DISC		
AB	PANACEA	EQ 5MG BASE	A204722	001	Jan 11, 2017	Jul	CAHN		
AB		EQ 10MG BASE	A204722	002	Jan 11, 2017	Jul	CAHN		
<u>ROFLUMILAST</u>									
TABLET; ORAL									
ROFLUMILAST									
@	BRECKENRIDGE	500MCG	A208236	001	Oct 03, 2018	Oct	DISC		
<u>ROMIDEPSIN</u>									
POWDER; INTRAVENOUS									
ISTODAX									
AP	+!	CELGENE	10MG/VIAL	N022393	001	Nov 05, 2009	Oct	CFTG	
ROMIDEPSIN									
AP		FRESENIUS KABI USA	10MG/VIAL	A206254	001	Oct 12, 2021	Oct	NFTG	
<u>ROPINIROLE HYDROCHLORIDE</u>									
TABLET; ORAL									
REQUIP									
+ @	GLAXOSMITHKLINE LLC	EQ 0.25MG BASE	N020658	001	Sep 19, 1997	Jul	DISC		
+ @		EQ 0.5MG BASE	N020658	002	Sep 19, 1997	Jul	DISC		
+ @		EQ 1MG BASE	N020658	003	Sep 19, 1997	Jul	DISC		
+ @		EQ 2MG BASE	N020658	004	Sep 19, 1997	Jul	DISC		
+ @		EQ 3MG BASE	N020658	006	Jan 27, 1999	Jul	DISC		
+ @		EQ 4MG BASE	N020658	007	Jan 27, 1999	Jul	DISC		
+ @		EQ 5MG BASE	N020658	005	Sep 19, 1997	Jul	DISC		
ROPINIROLE HYDROCHLORIDE									
AB	!	PRINSTON INC	EQ 0.25MG BASE	A078110	001	May 05, 2008	Jul	CHRS	

TABLET, EXTENDED RELEASE;ORAL  
REQUIP XL

	+ @	GLAXOSMITHKLINE LLC	EQ 2MG BASE	N022008	001	Jun 13, 2008	Jun DISC
AB	+		EQ 2MG BASE	N022008	001	Jun 13, 2008	Jun CHRS
	+ @		EQ 6MG BASE	N022008	006	Apr 10, 2009	Jun DISC
	+ @		EQ 12MG BASE	N022008	005	Oct 31, 2008	Jun DISC
ROPINIROLE HYDROCHLORIDE							
AB	!	DR REDDYS LABS LTD	EQ 2MG BASE	A201576	001	Jun 06, 2012	Jun CHRS

ROPIVACAINE HYDROCHLORIDE

SOLUTION;INJECTION  
NAROPIN

	+ @	FRESENIUS KABI USA	50MG/10ML (5MG/ML)	N020533	013	May 01, 1998	Mar CRLD
	+ @		75MG/10ML (7.5MG/ML)	N020533	012	Sep 24, 1996	Mar CRLD
ROPIVACAINE HYDROCHLORIDE							
	@	MYLAN ASI	150MG/30ML (5MG/ML)	A090318	002	Sep 23, 2014	Jan DISC
	@		200MG/20ML (10MG/ML)	A090318	004	Sep 23, 2014	Jan DISC

ROSIGLITAZONE MALEATE

TABLET;ORAL  
AVANDIA

	+	WOODWARD	EQ 2MG BASE	N021071	002	May 25, 1999	Jul CAHN
	+		EQ 4MG BASE	N021071	003	May 25, 1999	Jul CAHN
	+ @		EQ 8MG BASE	N021071	004	May 25, 1999	Jul CAHN

ROSUVASTATIN CALCIUM

TABLET;ORAL  
CRESTOR

AB	+	IPR	EQ 5MG BASE	N021366	002	Aug 12, 2003	Apr CPOT
AB	+		EQ 10MG BASE	N021366	003	Aug 12, 2003	Apr CPOT
AB	+!		EQ 40MG BASE	N021366	005	Aug 12, 2003	Apr CPOT
ROSUVASTATIN CALCIUM							
AB		ACCORD HLTHCARE	EQ 5MG BASE	A206434	001	Oct 31, 2016	Apr CPOT
AB			EQ 10MG BASE	A206434	002	Oct 31, 2016	Apr CPOT
AB			EQ 20MG BASE	A206434	003	Oct 31, 2016	Apr CPOT
AB			EQ 40MG BASE	A206434	004	Oct 31, 2016	Apr CPOT
AB		ALKEM LABS LTD	EQ 5MG BASE	A206465	001	Mar 21, 2017	Apr CPOT
AB			EQ 10MG BASE	A206465	002	Mar 21, 2017	Apr CPOT
AB			EQ 20MG BASE	A206465	003	Mar 21, 2017	Apr CPOT
AB			EQ 40MG BASE	A206465	004	Mar 21, 2017	Apr CPOT
AB		ALLIED	EQ 5MG BASE	A079168	001	Jul 19, 2016	Apr CPOT
AB			EQ 10MG BASE	A079168	002	Jul 19, 2016	Apr CPOT
AB			EQ 20MG BASE	A079168	003	Jul 19, 2016	Apr CPOT
AB			EQ 40MG BASE	A079168	004	Jul 19, 2016	Apr CPOT
	@	AMNEAL PHARMS CO	EQ 5MG BASE	A208850	001	Oct 16, 2018	Apr CPOT
	@		EQ 10MG BASE	A208850	002	Oct 16, 2018	Apr CPOT
	@		EQ 20MG BASE	A208850	003	Oct 16, 2018	Apr CPOT
	@		EQ 40MG BASE	A208850	004	Oct 16, 2018	Apr CPOT
	@	APOTEX INC	EQ 5MG BASE	A079145	001	Jul 19, 2016	Apr CPOT
	@		EQ 10MG BASE	A079145	002	Jul 19, 2016	Apr CPOT
	@		EQ 20MG BASE	A079145	003	Jul 19, 2016	Apr CPOT
	@		EQ 40MG BASE	A079145	004	Jul 19, 2016	Apr CPOT
AB		AUROBINDO PHARMA LTD	EQ 5MG BASE	A079170	001	Jul 19, 2016	Apr CPOT
AB			EQ 10MG BASE	A079170	002	Jul 19, 2016	Apr CPOT
AB			EQ 20MG BASE	A079170	003	Jul 19, 2016	Apr CPOT
AB			EQ 40MG BASE	A079170	004	Jul 19, 2016	Apr CPOT
AB		BIOCON LTD	EQ 5MG BASE	A207752	001	Oct 31, 2016	Apr CPOT
AB			EQ 10MG BASE	A207752	002	Oct 31, 2016	Apr CPOT
AB			EQ 20MG BASE	A207752	003	Oct 31, 2016	Apr CPOT
AB			EQ 40MG BASE	A207752	004	Oct 31, 2016	Apr CPOT
AB		BIOCON PHARMA	EQ 5MG BASE	A207752	001	Oct 31, 2016	Jul CAHN
AB			EQ 10MG BASE	A207752	002	Oct 31, 2016	Jul CAHN
AB			EQ 20MG BASE	A207752	003	Oct 31, 2016	Jul CAHN
AB			EQ 40MG BASE	A207752	004	Oct 31, 2016	Jul CAHN
AB		CADILA PHARMS LTD	EQ 5MG BASE	A207453	001	Nov 23, 2016	Apr CPOT
AB			EQ 10MG BASE	A207453	002	Nov 23, 2016	Apr CPOT
AB			EQ 20MG BASE	A207453	003	Nov 23, 2016	Apr CPOT
AB			EQ 40MG BASE	A207453	004	Nov 23, 2016	Apr CPOT
AB		CHANGZHOU PHARM	EQ 5MG BASE	A207408	001	Oct 31, 2016	Apr CPOT
AB			EQ 10MG BASE	A207408	002	Oct 31, 2016	Apr CPOT
AB			EQ 20MG BASE	A207408	003	Oct 31, 2016	Apr CPOT
AB			EQ 40MG BASE	A207408	004	Oct 31, 2016	Apr CPOT
AB		CHARTWELL RX	EQ 5MG BASE	A079168	001	Jul 19, 2016	Sep CAHN

TABLET;ORAL  
ROSUVASTATIN CALCIUM

AB		EQ 10MG BASE	A079168	002	Jul 19, 2016	Sep	CAHN
AB		EQ 20MG BASE	A079168	003	Jul 19, 2016	Sep	CAHN
AB		EQ 40MG BASE	A079168	004	Jul 19, 2016	Sep	CAHN
AB	GLENMARK PHARMS	EQ 5MG BASE	A079172	001	Jul 19, 2016	Apr	CPOT
AB		EQ 10MG BASE	A079172	002	Jul 19, 2016	Apr	CPOT
AB		EQ 20MG BASE	A079172	003	Jul 19, 2016	Apr	CPOT
AB		EQ 40MG BASE	A079172	004	Jul 19, 2016	Apr	CPOT
AB	HETERO LABS LTD V	EQ 5MG BASE	A207616	001	Oct 31, 2016	Apr	CPOT
AB		EQ 10MG BASE	A207616	002	Oct 31, 2016	Apr	CPOT
AB		EQ 20MG BASE	A207616	003	Oct 31, 2016	Apr	CPOT
AB		EQ 40MG BASE	A207616	004	Oct 31, 2016	Apr	CPOT
AB	@ INVENTIA	EQ 5MG BASE	A207653	001	Feb 05, 2021	May	DISC
AB		EQ 5MG BASE	A207653	001	Feb 05, 2021	Apr	CPOT
AB		5MG	A207653	001	Feb 05, 2021	Jan	NEWA
AB	@	EQ 10MG BASE	A207653	002	Feb 05, 2021	May	DISC
AB		EQ 10MG BASE	A207653	002	Feb 05, 2021	Apr	CPOT
AB		10MG	A207653	002	Feb 05, 2021	Jan	NEWA
AB	@	EQ 20MG BASE	A207653	003	Feb 05, 2021	May	DISC
AB		EQ 20MG BASE	A207653	003	Feb 05, 2021	Apr	CPOT
AB		20MG	A207653	003	Feb 05, 2021	Jan	NEWA
AB	@	EQ 40MG BASE	A207653	004	Feb 05, 2021	May	DISC
AB		EQ 40MG BASE	A207653	004	Feb 05, 2021	Apr	CPOT
AB		40MG	A207653	004	Feb 05, 2021	Jan	NEWA
AB	LUPIN	EQ 5MG BASE	A205587	001	Jul 31, 2017	Apr	CPOT
AB		EQ 10MG BASE	A205587	002	Jul 31, 2017	Apr	CPOT
AB		EQ 20MG BASE	A205587	003	Jul 31, 2017	Apr	CPOT
AB		EQ 40MG BASE	A205587	004	Jul 31, 2017	Apr	CPOT
AB	MSN	EQ 5MG BASE	A208898	001	Nov 22, 2017	Apr	CPOT
AB		EQ 10MG BASE	A208898	002	Nov 22, 2017	Apr	CPOT
AB		EQ 20MG BASE	A208898	003	Nov 22, 2017	Apr	CPOT
AB		EQ 40MG BASE	A208898	004	Nov 22, 2017	Apr	CPOT
AB	@ MYLAN	EQ 5MG BASE	A079161	001	Jul 19, 2016	Apr	CPOT
AB	@	EQ 10MG BASE	A079161	002	Jul 19, 2016	Apr	CPOT
AB	@	EQ 20MG BASE	A079161	003	Jul 19, 2016	Apr	CPOT
AB	@	EQ 40MG BASE	A079161	004	Jul 19, 2016	Apr	CPOT
AB	RENATA	EQ 5MG BASE	A207062	001	Oct 31, 2016	Apr	CPOT
AB		EQ 10MG BASE	A207062	002	Oct 31, 2016	Apr	CPOT
AB		EQ 20MG BASE	A207062	003	Oct 31, 2016	Apr	CPOT
AB		EQ 40MG BASE	A207062	004	Oct 31, 2016	Apr	CPOT
AB	SANDOZ INC	EQ 5MG BASE	A079171	001	Jul 19, 2016	Apr	CPOT
AB		EQ 10MG BASE	A079171	002	Jul 19, 2016	Apr	CPOT
AB		EQ 20MG BASE	A079171	003	Jul 19, 2016	Apr	CPOT
AB		EQ 40MG BASE	A079171	004	Jul 19, 2016	Apr	CPOT
AB	@ SCIEGEN PHARMS INC	EQ 5MG BASE	A206381	001	Apr 24, 2019	Apr	CPOT
AB	@	EQ 10MG BASE	A206381	002	Apr 24, 2019	Apr	CPOT
AB	@	EQ 20MG BASE	A206381	003	Apr 24, 2019	Apr	CPOT
AB	@	EQ 40MG BASE	A206381	004	Apr 24, 2019	Apr	CPOT
AB	SHANDONG	EQ 5MG BASE	A207375	001	May 07, 2019	Apr	CPOT
AB		EQ 10MG BASE	A207375	002	May 07, 2019	Apr	CPOT
AB		EQ 20MG BASE	A207375	003	May 07, 2019	Apr	CPOT
AB		EQ 40MG BASE	A207375	004	May 07, 2019	Apr	CPOT
AB	SUN PHARM	EQ 5MG BASE	A079169	001	Jul 19, 2016	Apr	CPOT
AB		EQ 10MG BASE	A079169	002	Jul 19, 2016	Apr	CPOT
AB		EQ 20MG BASE	A079169	003	Jul 19, 2016	Apr	CPOT
AB		EQ 40MG BASE	A079169	004	Jul 19, 2016	Apr	CPOT
AB	@ SUNSHINE	EQ 5MG BASE	A210667	001	Apr 01, 2020	Apr	CPOT
AB	@	EQ 10MG BASE	A210667	002	Apr 01, 2020	Apr	CPOT
AB	@	EQ 20MG BASE	A210667	003	Apr 01, 2020	Apr	CPOT
AB	@	EQ 40MG BASE	A210667	004	Apr 01, 2020	Apr	CPOT
AB	@ TEVA PHARMS USA	EQ 5MG BASE	A079166	001	Jul 19, 2016	Apr	CPOT
AB	@	EQ 10MG BASE	A079166	002	Jul 19, 2016	Apr	CPOT
AB	@	EQ 20MG BASE	A079166	003	Jul 19, 2016	Apr	CPOT
AB	@	EQ 40MG BASE	A079166	004	Jul 19, 2016	Apr	CPOT
AB	TORRENT	EQ 5MG BASE	A201619	001	Oct 31, 2016	Apr	CPOT
AB		EQ 10MG BASE	A201619	002	Oct 31, 2016	Apr	CPOT
AB		EQ 20MG BASE	A201619	003	Oct 31, 2016	Apr	CPOT
AB		EQ 40MG BASE	A201619	004	Oct 31, 2016	Apr	CPOT
AB	@ UMEDICA LABS PVT LTD	EQ 5MG BASE	A207626	001	Apr 09, 2019	Apr	CPOT
AB	@	EQ 10MG BASE	A207626	002	Apr 09, 2019	Apr	CPOT
AB	@	EQ 20MG BASE	A207626	003	Apr 09, 2019	Apr	CPOT
AB	@	EQ 40MG BASE	A207626	004	Apr 09, 2019	Apr	CPOT
AB	WATSON LABS INC	EQ 5MG BASE	A079167	001	Apr 29, 2016	Apr	CPOT

TABLET;ORAL

## ROSUVASTATIN CALCIUM

AB		EQ 10MG BASE	A079167	002	Apr 29, 2016	Apr	CPOT
AB		EQ 20MG BASE	A079167	003	Apr 29, 2016	Apr	CPOT
AB		EQ 40MG BASE	A079167	004	Apr 29, 2016	Apr	CPOT
AB	ZHEJIANG YONGTAI	EQ 5MG BASE	A212059	001	Nov 04, 2019	Apr	CPOT
AB		5MG	A212059	001	Nov 04, 2019	Feb	CMFD
AB		EQ 10MG BASE	A212059	002	Nov 04, 2019	Apr	CPOT
AB		10MG	A212059	002	Nov 04, 2019	Feb	CMFD
AB		EQ 20MG BASE	A212059	003	Nov 04, 2019	Apr	CPOT
AB		20MG	A212059	003	Nov 04, 2019	Feb	CMFD
AB		EQ 40MG BASE	A212059	004	Nov 04, 2019	Apr	CPOT
AB		40MG	A212059	004	Nov 04, 2019	Feb	CMFD
	@ ZYDUS PHARMS	EQ 5MG BASE	A206513	001	Mar 01, 2019	Apr	CPOT
	@	EQ 10MG BASE	A206513	002	Mar 01, 2019	Apr	CPOT
	@	EQ 20MG BASE	A206513	003	Mar 01, 2019	Apr	CPOT
	@	EQ 40MG BASE	A206513	004	Mar 01, 2019	Apr	CPOT

RUFINAMIDE

## SUSPENSION;ORAL

## RUFINAMIDE

AB	ALKEM LABS LTD	40MG/ML	A213410	001	Feb 23, 2021	Feb	NEWA
AB	HETERO LABS LTD III	200MG	A204993	001	May 11, 2021	Apr	NEWA
AB		400MG	A204993	002	May 11, 2021	Apr	NEWA
AB	MYLAN	200MG	A205095	001	May 16, 2016	May	CMFD
AB		400MG	A205095	002	May 16, 2016	May	CMFD

RUXOLITINIB PHOSPHATE

## CREAM;TOPICAL

## OPZELURA

+	INCYTE CORP	EQ 1.5% BASE	N215309	001	Sep 21, 2021	Sep	NEWA
---	-------------	--------------	---------	-----	--------------	-----	------

SAFINAMIDE MESYLATE

## TABLET;ORAL

## XADAGO

+	MDD US	EQ 50MG BASE	N207145	001	Mar 21, 2017	Jul	CPOT
+		EQ 100MG BASE	N207145	002	Mar 21, 2017	Jul	CPOT

SAPROPTERIN DIHYDROCHLORIDE

## POWDER;ORAL

## SAPROPTERIN DIHYDROCHLORIDE

AB	DR REDDYS	100MG/PACKET	A209452	001	Mar 30, 2021	Mar	NEWA
AB	DR REDDYS	100MG	A207685	001	Jun 15, 2021	Jun	NEWA

SCOPOLAMINE

## SYSTEM;TRANSDERMAL

## SCOPOLAMINE

AB	PADAGIS US	1MG/72HR	A078830	001	Jan 30, 2015	Jul	CAHN
AB	+! BAXTER HLTHCARE CORP	1MG/72HR	N017874	001		Mar	CAHN

SELEGILINE HYDROCHLORIDE

## CAPSULE;ORAL

## SELEGILINE HYDROCHLORIDE

AB	NOVITIUM PHARMA	5MG	A075352	001	Nov 30, 1998	Apr	CMFD
----	-----------------	-----	---------	-----	--------------	-----	------

SELENIOS ACID

## SOLUTION;INTRAVENOUS

## SELENIOS ACID

>D>	+! AM REGENT	EQ 12MCG BASE/2ML (EQ 6MCG BASE/ML)	N209379	003	Aug 30, 2021	Nov	CPOT
>A>	+!	EQ 12MCG SELENIUM/2ML (EQ 6MCG SELENIUM/ML)	N209379	003	Aug 30, 2021	Nov	CPOT
	+!	EQ 12MCG BASE/2ML (EQ 6MCG BASE/ML)	N209379	003	Aug 30, 2021	Aug	NEWA
>D>	+!	EQ 60MCG BASE/ML (EQ 60MCG BASE/ML)	N209379	002	Jan 25, 2021	Nov	CPOT
>A>	+!	EQ 60MCG SELENIUM/ML (EQ 60MCG SELENIUM/ML)	N209379	002	Jan 25, 2021	Nov	CPOT

SOLUTION; INTRAVENOUS  
SELENIOS ACID

	+	EQ 60MCG BASE/ML (EQ 60MCG BASE/ML)	N209379	002	Jan 25, 2021	Jan NEWA
>D>	+	EQ 600MCG BASE/10ML (EQ 60MCG BASE/ML)	N209379	001	Apr 30, 2019	Nov CPOT
>A>	+	EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	N209379	001	Apr 30, 2019	Nov CPOT

SELEXIPAGPOWDER; INTRAVENOUS  
UPTRAVI

	+	ACTELION	1.8MG/VIAL	N214275	001	Jul 29, 2021	Jul NEWA
	+	ACTELION	0.2MG	N207947	001	Dec 21, 2015	Feb CAHN
	+		0.4MG	N207947	002	Dec 21, 2015	Feb CAHN
	+		0.6MG	N207947	003	Dec 21, 2015	Feb CAHN
	+		0.8MG	N207947	004	Dec 21, 2015	Feb CAHN
	+		1MG	N207947	005	Dec 21, 2015	Feb CAHN
	+		1.2MG	N207947	006	Dec 21, 2015	Feb CAHN
	+		1.4MG	N207947	007	Dec 21, 2015	Feb CAHN
	+		1.6MG	N207947	008	Dec 21, 2015	Feb CAHN

SELINEXORTABLET; ORAL  
XPOVIO

	+	KARYOPHARM THERAPS	40MG	N212306	002	Apr 15, 2021	Apr NEWA
	+		50MG	N212306	003	Apr 15, 2021	Apr NEWA
	+		60MG	N212306	004	Apr 15, 2021	Apr NEWA

SEMAGLUTIDESOLUTION; SUBCUTANEOUS  
WEGOVY

	+	NOVO	0.25MG/0.5ML (0.25MG/0.5ML)	N215256	001	Jun 04, 2021	Jun NEWA
	+		0.5MG/0.5ML (0.5MG/0.5ML)	N215256	002	Jun 04, 2021	Jun NEWA
	+		1MG/0.5ML (1MG/0.5ML)	N215256	003	Jun 04, 2021	Jun NEWA
	+		1.7MG/0.75ML (1.7MG/0.75ML)	N215256	004	Jun 04, 2021	Jun NEWA
	+		2.4MG/0.75ML (2.4MG/0.75ML)	N215256	005	Jun 04, 2021	Jun NEWA

SERTRALINE HYDROCHLORIDECAPSULE; ORAL  
SERTRALINE HYDROCHLORIDE

	+	ALMATICA	EQ 150MG BASE	N215133	001	Oct 04, 2021	Oct NEWA
	+		EQ 200MG BASE	N215133	002	Oct 04, 2021	Oct NEWA

## TABLET; ORAL

## SERTRALINE HYDROCHLORIDE

AB		ACI	EQ 25MG BASE	A076881	001	Feb 06, 2007	Jan CMFD
AB			EQ 50MG BASE	A076881	002	Feb 06, 2007	Jan CMFD
AB			EQ 100MG BASE	A076881	003	Feb 06, 2007	Jan CMFD
AB		ASCENT PHARMS INC	EQ 25MG BASE	A214790	001	May 03, 2021	Apr NEWA
AB			EQ 50MG BASE	A214790	002	May 03, 2021	Apr NEWA
AB			EQ 100MG BASE	A214790	003	May 03, 2021	Apr NEWA
AB		GRANULES	EQ 25MG BASE	A078403	001	Jan 08, 2008	May CAHN
AB			EQ 50MG BASE	A078403	002	Jan 08, 2008	May CAHN
AB			EQ 100MG BASE	A078403	003	Jan 08, 2008	May CAHN
AB		SCIEGEN PHARMS INC	EQ 25MG BASE	A076442	001	Apr 30, 2007	Apr CMFD
AB			EQ 50MG BASE	A076442	002	Apr 30, 2007	Apr CMFD
AB			EQ 100MG BASE	A076442	003	Apr 30, 2007	Apr CMFD

SEVELAMER CARBONATEFOR SUSPENSION; ORAL  
SEVELAMER CARBONATE

AB		BIONPHARMA INC	800MG/PACKET	A209374	001	May 17, 2021	May NEWA
AB		IMPAX	800MG/PACKET	A211316	001	Nov 20, 2020	Aug CMFD
		@	800MG/PACKET	A211316	001	Nov 20, 2020	Mar DISC
AB			2.4GM/PACKET	A211316	002	Nov 20, 2020	Aug CMFD
		@	2.4GM/PACKET	A211316	002	Nov 20, 2020	Mar DISC

## TABLET; ORAL

## SEVELAMER CARBONATE

AB		ANXIN	800MG	A212970	001	Apr 09, 2020	Mar CMFD
AB		LUPIN LTD	800MG	A204600	001	Jan 14, 2021	Jan NEWA

SEVELAMER HYDROCHLORIDE

TABLET;ORAL

SEVELAMER HYDROCHLORIDE

AB	LUPIN LTD	400MG	A213145	001	Jun 16, 2021	Jun	NEWA
AB		800MG	A213145	002	Jun 16, 2021	Jun	NEWA

SILDENAFIL CITRATE

FOR SUSPENSION;ORAL

SILDENAFIL CITRATE

AB	APPCO	EQ 10MG BASE/ML	A213814	001	Apr 29, 2021	Apr	NEWA
AB	HETERO LABS LTD V	EQ 10MG BASE/ML	A213014	001	May 11, 2021	Apr	NEWA
>A>	AB	TARO PHARM INDS LTD	A215522	001	Nov 16, 2021	Nov	NEWA
>A>	AB	TRIS PHARMA INC	A212312	001	Nov 17, 2021	Nov	NEWA

TABLET;ORAL

SILDENAFIL CITRATE

AB	CHARTWELL RX	EQ 20MG BASE	A202598	001	Nov 06, 2012	Oct	CAHN
AB	REYOUNG	EQ 25MG BASE	A208494	001	Jun 12, 2020	Mar	CAHN
AB		EQ 50MG BASE	A208494	002	Jun 12, 2020	Mar	CAHN
AB		EQ 100MG BASE	A208494	003	Jun 12, 2020	Mar	CAHN
AB	UMEDICA LABS PVT LTD	EQ 25MG BASE	A209302	003	Jun 15, 2021	Jun	NEWA
	@ WATSON LABS INC	EQ 25MG BASE	A202506	001	Nov 25, 2020	May	DISC
	@	EQ 50MG BASE	A202506	002	Nov 25, 2020	May	DISC
	@	EQ 100MG BASE	A202506	003	Nov 25, 2020	May	DISC

SIMVASTATIN

TABLET;ORAL

SIMVASTATIN

AB	BIOCON PHARMA	5MG	A078034	001	Dec 20, 2006	Mar	CAHN
AB		10MG	A078034	002	Dec 20, 2006	Mar	CAHN
AB		20MG	A078034	003	Dec 20, 2006	Mar	CAHN
AB		40MG	A078034	004	Dec 20, 2006	Mar	CAHN
AB		80MG	A078034	005	Dec 20, 2006	Mar	CAHN
AB	HISUN PHARM HANGZHOU	10MG	A206557	001	Nov 13, 2017	Apr	CMFD
AB		20MG	A206557	002	Nov 13, 2017	Apr	CMFD
AB		40MG	A206557	003	Nov 13, 2017	Apr	CMFD
AB		80MG	A206557	004	Nov 13, 2017	Apr	CMFD
AB	! LUPIN	80MG	A078103	004	May 11, 2007	Jun	CHRS
	ZOCOR						
AB	+ ORGANON	5MG	N019766	001	Dec 23, 1991	Feb	CAHN
AB	+	10MG	N019766	002	Dec 23, 1991	Feb	CAHN
AB	+	20MG	N019766	003	Dec 23, 1991	Feb	CAHN
AB	+	40MG	N019766	004	Dec 23, 1991	Feb	CAHN
	+ @	80MG	N019766	005	Jul 10, 1998	Jun	DISC
AB	+	80MG	N019766	005	Jul 10, 1998	Feb	CAHN

SINECATECHINS

OINTMENT;TOPICAL

VEREGEN

+!	ANI PHARMS	15%	N021902	001	Oct 31, 2006	Apr	CAHN
----	------------	-----	---------	-----	--------------	-----	------

SIPONIMOD FUMARIC ACID

TABLET;ORAL

MAYZENT

+	NOVARTIS	EQ 1MG BASE	N209884	003	Aug 24, 2021	Aug	NEWA
---	----------	-------------	---------	-----	--------------	-----	------

SIROLIMUS

>A> POWDER; INTRAVENOUS

>A> FYARRO

>A>	+!	AADI	100MG/VIAL	N213312	001	Nov 22, 2021	Nov	NEWA
-----	----	------	------------	---------	-----	--------------	-----	------

TABLET;ORAL

SIROLIMUS

AB	ALKEM LABS LTD	0.5MG	A214753	001	Mar 12, 2021	Mar	NEWA
AB		1MG	A214753	002	Mar 12, 2021	Mar	NEWA
AB		2MG	A214753	003	Mar 12, 2021	Mar	NEWA

SODIUM ACETATE

INJECTABLE; INJECTION

SODIUM ACETATE

AP	+!	HOSPIRA	2MEQ/ML	N018893	001	May 04, 1983	Apr	CFTG
AP		MILLA PHARMS	2MEQ/ML	A214805	001	May 04, 2021	Apr	NFTG

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION;INTRAVENOUS

SODIUM PHENYLACETATE AND SODIUM BENZOATE

+! MAIA PHARMS INC 10%;10% (2GM/20ML;2GM/20ML) N215025 001 Jun 10, 2021 Jun NEWA

SODIUM CHLORIDE

INJECTABLE;INJECTION

SODIUM CHLORIDE 0.9%

AP HIKMA 9MG/ML A201833 001 Sep 24, 2013 Jul CAHN  
 AP HIKMA 9MG/ML A201850 001 Jan 20, 2012 Jul CAHN  
 + @ MEDEFIL INC 9MG/ML (9MG/ML) N202832 001 Jan 06, 2012 Aug DISC  
 + @ 18MG/2ML (9MG/ML) N202832 002 Jan 06, 2012 Aug DISC  
 + @ 22.5MG/2.5ML (9MG/ML) N202832 003 Jan 06, 2012 Aug DISC  
 + @ 27MG/3ML (9MG/ML) N202832 004 Jan 06, 2012 Aug DISC  
 + @ 45MG/5ML (9MG/ML) N202832 005 Jan 06, 2012 Aug DISC

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

@ JUBILANT CADISTA 9MG/ML A203352 001 May 18, 2016 Jun DISC

SODIUM CHLORIDE 23.4%

FRESENIUS KABI USA 234MG/ML A212248 001 Apr 28, 2021 Apr NFTG

SOLUTION;INTRAVENOUS

SODIUM CHLORIDE 14.6%

AP FRESENIUS KABI USA 50MEQ/20ML (2.5MEQ/ML) A212070 001 Apr 28, 2021 Apr NFTG

AP FRESENIUS KABI USA 100MEQ/40ML (2.5MEQ/ML) A212070 002 Apr 28, 2021 Apr NFTG

AP +! HOSPIRA 100MEQ/40ML (2.5MEQ/ML) N018897 002 Jul 20, 1984 Apr CFTG

SOLUTION;IRRIGATION

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

>D> AT ICU MEDICAL INC 900MG/100ML N017514 001 Nov CRLD

>A> AT + 900MG/100ML N017514 001 Nov CRLD

SOLUTION FOR SLUSH;IRRIGATION

SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER

+! BAXTER HLTHCARE 900MG/100ML N019319 002 May 17, 1985 Jul CHRS

+ 900MG/100ML N019319 002 May 17, 1985 Jul CRLD

SODIUM FLUORIDE F-18

INJECTABLE;INTRAVENOUS

SODIUM FLUORIDE F-18

AP @ DECATUR 10-200mCi/ML A204464 001 Oct 21, 2014 Aug DISC

AP NUKEMED 10-200mCi/ML A203912 001 Apr 22, 2015 Jan CAHN

SODIUM NITROPRUSSIDE

INJECTABLE;INJECTION

SODIUM NITROPRUSSIDE

AP BE PHARMS 25MG/ML A214971 001 Jul 12, 2021 Jul NEWA

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET;ORAL

MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE

AB NOVEL LABS INC 0.398GM;1.102GM A079247 001 Dec 30, 2011 Jan CMFD

OSMOPREP

AB +! SALIX PHARMS 0.398GM;1.102GM N021892 001 Mar 16, 2006 Jan CTEC

SODIUM POLYSTYRENE SULFONATE

POWDER;ORAL, RECTAL

KIONEX

AA ANI PHARMS 454GM/BOT A040029 001 Feb 06, 1998 Mar CAHN

AA L PERRIGO CO 454GM/BOT A040029 001 Feb 06, 1998 Mar CAHN

SODIUM POLYSTYRENE SULFONATE

AA BIOPHARM 453.6GM/BOT A090313 001 Dec 21, 2011 Sep CAHN

AA CHARTWELL RX 454GM/BOT A206815 001 Feb 18, 2016 Sep CAHN

+ @ WOCHKHARDT 453.6GM/BOT A088786 001 Sep 11, 1984 Aug CRLD

SUSPENSION;ORAL, RECTAL

KIONEX

@ ANI PHARMS 15GM/60ML A040028 001 Sep 17, 2007 Mar CAHN

@ L PERRIGO CO 15GM/60ML A040028 001 Sep 17, 2007 Mar CAHN

SODIUM POLYSTYRENE SULFONATE

@ ANI PHARMS 15GM/60ML A090590 001 May 13, 2011 Mar CAHN

@ L PERRIGO CO 15GM/60ML A090590 001 May 13, 2011 Mar CAHN

SPS

+! CMP PHARMA INC 15GM/60ML A087859 001 Dec 08, 1982 Aug CRLD

SOFOSBUVIR; VELPATASVIR

PELLETS; ORAL  
EPCLUSA

	+	GILEAD SCIENCES INC	150MG; 37.5MG/PACKET	N214187	001	Jun 10, 2021	Jun	NEWA
	+	!	200MG; 50MG/PACKET	N214187	002	Jun 10, 2021	Jun	NEWA

SOLIFENACIN SUCCINATE

TABLET; ORAL  
SOLIFENACIN SUCCINATE

	@	AJANTA PHARMA LTD	5MG	A205483	001	May 20, 2019	Jun	DISC
	@		10MG	A205483	002	May 20, 2019	Jun	DISC
AB		AUSTARPHARMA	5MG	A210281	001	May 20, 2019	Sep	CAHN
AB			10MG	A210281	002	May 20, 2019	Sep	CAHN
	@	BRECKENRIDGE	5MG	A209818	001	May 20, 2019	Aug	DISC
	@		10MG	A209818	002	May 20, 2019	Aug	DISC
	@	ZYDUS PHARMS	5MG	A207721	001	Oct 19, 2020	Mar	DISC
	@		10MG	A207721	002	Oct 19, 2020	Mar	DISC

SORAFENIB TOSYLATE

TABLET; ORAL  
NEXAVAR

	+	BAYER HLTHCARE	EQ 200MG BASE	N021923	001	Dec 20, 2005	May	CTEC
		SORAFENIB TOSYLATE						
	@	TEVA PHARMS USA INC	EQ 200MG BASE	A209567	001	Nov 12, 2020	May	DISC

SOTORASIB

TABLET; ORAL  
LUMAKRAS

	+	!	AMGEN INC	120MG	N214665	001	May 28, 2021	May	NEWA
--	---	---	-----------	-------	---------	-----	--------------	-----	------

SPIRONOLACTONE

TABLET; ORAL  
SPIRONOLACTONE

	@	OXFORD PHARMS	25MG	A040750	001	Aug 29, 2006	Aug	DISC
	@		50MG	A040750	002	Aug 29, 2006	Aug	DISC
	@		100MG	A040750	003	Aug 29, 2006	Aug	DISC

STERILE WATER FOR INJECTION

LIQUID; N/A  
STERILE WATER FOR INJECTION

AP		HIKMA	100% (10ML)	A206369	001	Sep 02, 2015	Jul	CAHN
	@		100% (20ML)	A206369	002	Sep 02, 2015	Jul	CAHN
	@	NEPHRON	100% (5ML)	A211222	001	Feb 10, 2021	Oct	DISC
	!		100% (5ML)	A211222	001	Feb 10, 2021	Jan	NEWA

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION  
SUCCINYLCHOLINE CHLORIDE

AP		ACCORD HLTHCARE	20MG/ML	A213705	001	May 20, 2020	Mar	CMFD	
AP		HIKMA	20MG/ML	A213229	001	Jun 12, 2020	Apr	CMFD	
	@		20MG/ML	A213229	001	Jun 12, 2020	Feb	DISC	
AP		HONG KONG	20MG/ML	A214514	001	Oct 19, 2021	Oct	NEWA	
AP		SAGENT PHARMS INC	20MG/ML	A215022	001	Mar 29, 2021	Mar	NEWA	
		SOLUTION; INTRAMUSCULAR, INTRAVENOUS							
		SUCCINYLCHOLINE CHLORIDE							
	+	!	HIKMA	100MG/5ML (20MG/ML)	N215143	001	Aug 20, 2021	Aug	NEWA

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC  
BLEPH-10

AT	+	!	ALLERGAN	10%	A080028	001		Aug	CRLD
----	---	---	----------	-----	---------	-----	--	-----	------

SULFADIAZINE

TABLET; ORAL  
SULFADIAZINE

	+	@	IMPAX LABS	500MG	A080081	001		Oct	CRLD
--	---	---	------------	-------	---------	-----	--	-----	------



SULFAMETHOXAZOLE

TABLET;ORAL

SULFAMETHOXAZOLE

@ RISING 500MG A 085844 001 Jan CAHN

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION;ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

>D> AB ANI PHARMS 200MG/5ML;40MG/5ML A 077612 001 Nov 13, 2006 Nov CAHN

>A> AB PRASCO 200MG/5ML;40MG/5ML A 077612 001 Nov 13, 2006 Nov CAHN

SULFASALAZINE

TABLET;ORAL

AZULFIDINE

AB +! PFIZER 500MG N 007073 001 Mar CAHN

SULFASALAZINE

AB CHARTWELL 500MG A 080197 001 Jun CMFD

TABLET, DELAYED RELEASE;ORAL

AZULFIDINE EN-TABS

AB +! PFIZER 500MG N 007073 002 Apr 06, 1983 Mar CAHN

SULFISOXAZOLE

TABLET;ORAL

SULFISOXAZOLE

@ RISING 500MG A 085628 001 Jan CAHN

SULINDAC

TABLET;ORAL

SULINDAC

@ MYLAN 150MG A 073039 002 Jun 22, 1993 Aug CAHN

@ 150MG A 073039 002 Jun 22, 1993 Aug DISC

@ 200MG A 073039 001 Jun 22, 1993 Aug CAHN

@ 200MG A 073039 001 Jun 22, 1993 Aug DISC

SUMATRIPTAN

SPRAY;NASAL

SUMATRIPTAN

AB CIPLA 20MG/SPRAY A 214209 001 Feb 22, 2021 Feb NEWA

AB FLORIDA 20MG/SPRAY A 208967 001 Feb 17, 2021 Mar CAHN

AB PHARMASERVE NW 20MG/SPRAY A 208967 001 Feb 17, 2021 Feb NEWA

SUMATRIPTAN SUCCINATE

INJECTABLE;SUBCUTANEOUS

SUMATRIPTAN SUCCINATE

AP CAPLIN EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A 213998 001 Jul 13, 2021 Jul NEWA

@ MYLAN ASI EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A 090314 001 Jun 10, 2010 May DISC

@ EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A 090641 001 Jul 28, 2010 Jan DISC

SUNITINIB MALATE

CAPSULE;ORAL

SUNITINIB MALATE

>A> AB MYLAN EQ 12.5MG BASE A 201275 001 Dec 06, 2021 Nov NEWA

>A> AB EQ 25MG BASE A 201275 002 Dec 06, 2021 Nov NEWA

>A> AB EQ 37.5MG BASE A 201275 003 Dec 06, 2021 Nov NEWA

>A> AB EQ 50MG BASE A 201275 004 Dec 06, 2021 Nov NEWA

AB SUN PHARM EQ 12.5MG BASE A 213914 001 Aug 16, 2021 Aug NFTG

AB EQ 25MG BASE A 213914 002 Aug 16, 2021 Aug NFTG

AB EQ 37.5MG BASE A 213914 003 Aug 16, 2021 Aug NFTG

AB EQ 50MG BASE A 213914 004 Aug 16, 2021 Aug NFTG

>A> AB TEVA PHARMS USA EQ 12.5MG BASE A 213803 001 Nov 30, 2021 Nov NEWA

>A> AB EQ 25MG BASE A 213803 002 Nov 30, 2021 Nov NEWA

>A> AB EQ 37.5MG BASE A 213803 003 Nov 30, 2021 Nov NEWA

>A> AB EQ 50MG BASE A 213803 004 Nov 30, 2021 Nov NEWA

SUTENT

AB + CPPI CV EQ 12.5MG BASE N 021938 001 Jan 26, 2006 Aug CTEC

AB + EQ 25MG BASE N 021938 002 Jan 26, 2006 Aug CTEC

AB + EQ 37.5MG BASE N 021938 004 Mar 31, 2009 Aug CTEC

AB +! EQ 50MG BASE N 021938 003 Jan 26, 2006 Aug CTEC

TACROLIMUS

CAPSULE;ORAL

TACROLIMUS

	@ CONCORD BIOTECH LTD	EQ 0.5MG BASE	A213112	001	Nov 10, 2020	Apr	DISC
AB	PANACEA	EQ 0.5MG BASE	A090802	001	Sep 28, 2012	Jul	CAHN
AB		EQ 1MG BASE	A090802	002	Sep 28, 2012	Jul	CAHN
AB		EQ 5MG BASE	A090802	003	Sep 28, 2012	Jul	CAHN

TADALAFIL

TABLET;ORAL

CIALIS

AB1	+	LILLY	2.5MG	N021368	004	Jan 07, 2008	Feb	CTEC
AB1	+		5MG	N021368	001	Nov 21, 2003	Feb	CTEC
AB1	+		10MG	N021368	002	Nov 21, 2003	Feb	CTEC

TADALAFIL

AB1		ACCORD HLTHCARE	2.5MG	A209167	001	Mar 26, 2019	Feb	CTEC
AB1			5MG	A209167	002	Mar 26, 2019	Feb	CTEC
AB1			10MG	A209167	003	Oct 23, 2019	Feb	CTEC
AB1		AJANTA PHARMA LTD	2.5MG	A209654	001	Mar 26, 2019	Feb	CTEC
AB1			5MG	A209654	002	Mar 26, 2019	Feb	CTEC
AB1			10MG	A209654	003	Mar 26, 2019	Feb	CTEC
AB1		ALEMBIC PHARMS LTD	2.5MG	A204809	001	Mar 26, 2019	Feb	CTEC
AB1			5MG	A204809	002	Mar 26, 2019	Feb	CTEC
AB1			10MG	A204809	003	Mar 26, 2019	Feb	CTEC
AB1		AMNEAL PHARMS CO	2.5MG	A209744	001	Mar 26, 2019	Feb	CTEC
AB1			5MG	A209744	002	Mar 26, 2019	Feb	CTEC
AB1			10MG	A209744	003	Mar 26, 2019	Feb	CTEC
AB1		AUROBINDO PHARMA LTD	2.5MG	A206285	001	Mar 26, 2019	Feb	CTEC
AB1			5MG	A206285	002	Mar 26, 2019	Feb	CTEC
AB1			10MG	A206285	003	Mar 26, 2019	Feb	CTEC
AB1		CIPLA	2.5MG	A209539	001	Mar 26, 2019	Feb	CTEC
AB1			5MG	A209539	002	Mar 26, 2019	Feb	CTEC
AB1			10MG	A209539	003	Mar 26, 2019	Feb	CTEC
AB1		DR REDDYS LABS LTD	2.5MG	A210069	001	Mar 26, 2019	Feb	CTEC
AB1			5MG	A210069	002	Mar 26, 2019	Feb	CTEC
AB1			10MG	A210069	003	Mar 26, 2019	Feb	CTEC
	@	GLENMARK PHARMS LTD	2.5MG	A210716	001	Dec 29, 2020	Feb	DISC
	@		5MG	A210716	002	Dec 29, 2020	Feb	DISC
	@		10MG	A210716	003	Dec 29, 2020	Feb	DISC
	@		20MG	A210716	004	Dec 29, 2020	Feb	DISC
AB1		HETERO LABS LTD III	2.5MG	A209908	001	Mar 26, 2019	Feb	CTEC
AB1			5MG	A209908	002	Mar 26, 2019	Feb	CTEC
AB1			10MG	A209908	003	Mar 26, 2019	Feb	CTEC
AB1		LUPIN LTD	2.5MG	A210567	001	Mar 26, 2019	Feb	CTEC
AB1			5MG	A210567	002	Mar 26, 2019	Feb	CTEC
AB1			10MG	A210567	003	Mar 26, 2019	Feb	CTEC
AB1		MACLEODS PHARMS LTD	2.5MG	A207244	001	Oct 07, 2019	Feb	CTEC
AB1			5MG	A207244	002	Oct 07, 2019	Feb	CTEC
AB1			10MG	A207244	003	Oct 07, 2019	Feb	CTEC
	@	MYLAN	2.5MG	A206956	001	Apr 29, 2019	Aug	CAHN
	@		2.5MG	A206956	001	Apr 29, 2019	Aug	DISC
AB1			2.5MG	A206956	001	Apr 29, 2019	Feb	CTEC
	@		5MG	A206957	001	Apr 29, 2019	Aug	CAHN
	@		5MG	A206957	001	Apr 29, 2019	Aug	DISC
AB1			5MG	A206957	001	Apr 29, 2019	Feb	CTEC
	@		10MG	A206956	002	Apr 29, 2019	Aug	CAHN
	@		10MG	A206956	002	Apr 29, 2019	Aug	DISC
AB1			10MG	A206956	002	Apr 29, 2019	Feb	CTEC
	@		20MG	A200630	001	Aug 03, 2018	Oct	DISC
AB2			20MG	A200630	001	Aug 03, 2018	Oct	CAHN
	@		20MG	A206956	003	Apr 29, 2019	Aug	CAHN
	@		20MG	A206956	003	Apr 29, 2019	Aug	DISC
>D>	AB1	QILU	2.5MG	A210420	001	Mar 26, 2019	Nov	CAHN
	AB1		2.5MG	A210420	001	Mar 26, 2019	Feb	CTEC
>D>	AB1		5MG	A210420	002	Mar 26, 2019	Nov	CAHN
	AB1		5MG	A210420	002	Mar 26, 2019	Feb	CTEC
>D>	AB1		10MG	A210420	003	Mar 26, 2019	Nov	CAHN
	AB1		10MG	A210420	003	Mar 26, 2019	Feb	CTEC
>D>	AB1		20MG	A210420	004	Mar 26, 2019	Nov	CAHN
>A>	AB1	QILU PHARM HAINAN	2.5MG	A210420	001	Mar 26, 2019	Nov	CAHN
>A>	AB1		5MG	A210420	002	Mar 26, 2019	Nov	CAHN
>A>	AB1		10MG	A210420	003	Mar 26, 2019	Nov	CAHN
>A>	AB1		20MG	A210420	004	Mar 26, 2019	Nov	CAHN

<u>TADALAFIL</u>							
AB1	SUN PHARM	2.5MG	A208934	001	Mar 26, 2019	Feb	CTEC
AB1		5MG	A208934	002	Mar 26, 2019	Feb	CTEC
AB1		10MG	A208934	003	Mar 26, 2019	Feb	CTEC
AB1	SUNSHINE	2.5MG	A211335	001	Mar 26, 2019	Feb	CTEC
AB1		5MG	A211335	002	Mar 26, 2019	Feb	CTEC
AB1		10MG	A211335	003	Mar 26, 2019	Feb	CTEC
AB1	TEVA PHARMS USA	2.5MG	A090141	001	May 22, 2018	Feb	CTEC
AB1		5MG	A090141	002	May 22, 2018	Feb	CTEC
AB1		10MG	A090141	003	May 22, 2018	Feb	CTEC
AB1	TORRENT	2.5MG	A211839	001	Mar 26, 2019	Feb	CTEC
AB1		5MG	A211839	002	Mar 26, 2019	Feb	CTEC
AB1		10MG	A211839	003	Mar 26, 2019	Feb	CTEC
AB1	UMEDICA LABS PVT LTD	2.5MG	A211298	001	Oct 23, 2020	Feb	CTEC
AB1		5MG	A211298	002	Oct 23, 2020	Feb	CTEC
AB1		10MG	A211298	003	Oct 23, 2020	Feb	CTEC
BX	UNICHEM	2.5MG	A209250	001	Mar 26, 2019	Sep	CTEC
AB1		2.5MG	A209250	001	Mar 26, 2019	Feb	CTEC
BX		5MG	A209250	002	Mar 26, 2019	Sep	CTEC
AB1		5MG	A209250	002	Mar 26, 2019	Feb	CTEC
BX		10MG	A209250	003	Mar 26, 2019	Sep	CTEC
AB1		10MG	A209250	003	Mar 26, 2019	Feb	CTEC
BX		20MG	A209250	004	Mar 26, 2019	Sep	CTEC
AB1	VKT PHARMA	2.5MG	A215556	001	Nov 04, 2021	Oct	NEWA
AB1		5MG	A215556	002	Nov 04, 2021	Oct	NEWA
AB1		10MG	A215556	003	Nov 04, 2021	Oct	NEWA
AB1		20MG	A215556	004	Nov 04, 2021	Oct	NEWA
AB1	YANGLING BUCHANG	2.5MG	A208824	001	Oct 27, 2020	Feb	CTEC
AB1		5MG	A208824	002	Oct 27, 2020	Feb	CTEC
AB1		10MG	A208824	003	Oct 27, 2020	Feb	CTEC
AB1	ZYDUS PHARMS	2.5MG	A206693	001	Mar 26, 2019	Feb	CTEC
AB1		5MG	A206693	002	Mar 26, 2019	Feb	CTEC
AB1		10MG	A206693	003	Mar 26, 2019	Feb	CTEC

TAFAMIDIS

CAPSULE;ORAL

VYNDAMAX

+	FOLDRX PHARMS	61MG	N212161	001	May 03, 2019	Oct	CAHN
---	---------------	------	---------	-----	--------------	-----	------

TAFAMIDIS MEGLUMINE

CAPSULE;ORAL

VYNDAQEL

+	FOLDRX PHARMS	20MG	N211996	001	May 03, 2019	Oct	CAHN
---	---------------	------	---------	-----	--------------	-----	------

TALAZOPARIB TOSYLATE

CAPSULE;ORAL

TALZENNA

+	PFIZER	EQ 0.5MG BASE	N211651	003	Sep 20, 2021	Oct	NEWA
+		EQ 0.75MG BASE	N211651	004	Sep 20, 2021	Oct	NEWA

TALC

AEROSOL;INTRAPLEURAL

SCLEROSOL

+	SCIARRA LABS	4GM/SPRAY	N020587	001	Dec 24, 1997	Sep	CAHN
---	--------------	-----------	---------	-----	--------------	-----	------

POWDER;INTRAPLEURAL

TALC

+	SCIARRA LABS	5GM/BOT	N021388	001	Dec 15, 2003	Sep	CAHN
---	--------------	---------	---------	-----	--------------	-----	------

TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL

TAMSULOSIN HYDROCHLORIDE

AB	ANBISON LAB	0.4MG	A211885	001	Oct 17, 2019	Aug	CMFD
@	ANCHEN PHARMS	0.4MG	A202010	001	Jan 04, 2013	Jun	DISC

TAVABOROLE

SOLUTION;TOPICAL

TAVABOROLE

AB	CIPLA	5%	A212224	001	Feb 09, 2021	Jan	NEWA
AB	FLATWING	5%	A211963	001	Feb 03, 2021	Feb	CPOT
AB		5.0%	A211963	001	Feb 03, 2021	Jan	NEWA
@	IDENTIRX	5%	A211963	001	Feb 03, 2021	Sep	DISC

SOLUTION;TOPICAL  
TAVABOROLE

AB		5%	A211963	001	Feb 03, 2021	Feb	CAHN
AB	LUPIN LTD	5%	A212168	001	Feb 08, 2021	Jan	NEWA
AB	TARO PHARMS	5%	A212215	001	May 07, 2021	Apr	NEWA

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION  
CIS-MDP

AP	SUN PHARM INDS INC	N/A	N018124	001		Jul	CTEC
	TECHNETIUM TC-99M MEDRONATE KIT						
AP	CARDINAL HEALTH 414	N/A	N018107	001		Jul	CTNA
AP		N/A	N018107	001		Jul	CMFD

TECHNETIUM TC-99M SUCCIMER KIT

INJECTABLE; INJECTION  
MPI DMSA KIDNEY REAGENT

	+ @ GE HEALTHCARE	N/A	N017944	001	May 18, 1982	Sep	CRLD
--	-------------------	-----	---------	-----	--------------	-----	------

TELMISARTAN

TABLET; ORAL  
TELMISARTAN

AB	CELLTRION	20MG	A078710	001	Jan 08, 2014	Feb	CMFD
AB		40MG	A078710	002	Jan 08, 2014	Feb	CMFD
AB		80MG	A078710	003	Jan 08, 2014	Feb	CMFD
AB	MYLAN	20MG	A202397	001	Jul 07, 2014	Aug	CAHN
AB		40MG	A202397	002	Jul 07, 2014	Aug	CAHN
AB		80MG	A202397	003	Jul 07, 2014	Aug	CAHN

TEMAZEPAM

CAPSULE; ORAL  
TEMAZEPAM

@	MYLAN	7.5MG	A070920	002	May 21, 2010	Sep	CAHN
@		7.5MG	A070920	002	May 21, 2010	Sep	DISC
@		15MG	A070920	004	Jul 07, 1986	Sep	CAHN
@		15MG	A070920	004	Jul 07, 1986	Sep	DISC
@		22.5MG	A070920	003	Jun 12, 2009	Sep	CAHN
@		22.5MG	A070920	003	Jun 12, 2009	Sep	DISC
@		30MG	A070920	001	Jul 10, 1986	Sep	CAHN
@		30MG	A070920	001	Jul 10, 1986	Sep	DISC

TEMOZOLOMIDE

CAPSULE; ORAL  
TEMOZOLOMIDE

@	HERITAGE	5MG	A078879	001	Mar 01, 2010	Feb	CAHN	
@		20MG	A078879	002	Mar 01, 2010	Feb	CAHN	
@		100MG	A078879	003	Mar 01, 2010	Feb	CAHN	
@		140MG	A078879	005	Mar 01, 2010	Feb	CAHN	
@		180MG	A078879	006	Mar 01, 2010	Feb	CAHN	
@		250MG	A078879	004	Mar 01, 2010	Feb	CAHN	
>A>	AB	NIVAGEN PHARMS INC	5MG	A213328	001	Nov 23, 2021	Nov	NEWA
>A>	AB		20MG	A213328	002	Nov 23, 2021	Nov	NEWA
>A>	AB		100MG	A213328	003	Nov 23, 2021	Nov	NEWA
>A>	AB		140MG	A213328	004	Nov 23, 2021	Nov	NEWA
>A>	AB		180MG	A213328	005	Nov 23, 2021	Nov	NEWA
>A>	AB		250MG	A213328	006	Nov 23, 2021	Nov	NEWA
@	WATSON LABS TEVA	5MG	A203959	001	Apr 18, 2017	Jan	DISC	
@		20MG	A203959	002	Apr 18, 2017	Jan	DISC	
@		100MG	A203959	003	Apr 18, 2017	Jan	DISC	
@		140MG	A203959	004	Apr 18, 2017	Jan	DISC	
@		250MG	A203959	005	Apr 18, 2017	Jan	DISC	

TEPOTINIB HYDROCHLORIDE

TABLET; ORAL  
TEPMETKO

+	EMD SERONO INC	EQ 225MG BASE	N214096	001	Feb 03, 2021	Feb	NEWA
---	----------------	---------------	---------	-----	--------------	-----	------

TERAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

TERAZOSIN HYDROCHLORIDE

AB	HERITAGE PHARMA	EQ 1MG BASE	A 075614	002	Jan 30, 2001	May	CMFD
AB		EQ 2MG BASE	A 075614	001	Jan 30, 2001	May	CMFD
AB		EQ 5MG BASE	A 075614	003	Jan 30, 2001	May	CMFD
AB		EQ 10MG BASE	A 075614	004	Jan 30, 2001	May	CMFD
	@ MYLAN	EQ 1MG BASE	A 075140	002	Feb 11, 2000	Aug	CAHN
	@	EQ 1MG BASE	A 075140	002	Feb 11, 2000	Aug	DISC
	@	EQ 2MG BASE	A 075140	003	Feb 11, 2000	Aug	CAHN
	@	EQ 2MG BASE	A 075140	003	Feb 11, 2000	Aug	DISC
	@	EQ 5MG BASE	A 075140	001	Feb 11, 2000	Aug	CAHN
	@	EQ 5MG BASE	A 075140	001	Feb 11, 2000	Aug	DISC
	@	EQ 10MG BASE	A 075140	004	Feb 11, 2000	Aug	CAHN
	@	EQ 10MG BASE	A 075140	004	Feb 11, 2000	Aug	DISC

TERBINAFINE HYDROCHLORIDE

TABLET;ORAL

TERBINAFINE HYDROCHLORIDE

AB	! AUROBINDO PHARMA	EQ 250MG BASE	A 078297	001	Jul 02, 2007	Sep	CHRS
>A>	AB EMED MEDCL	EQ 250MG BASE	A 077919	001	Jul 02, 2007	Nov	CAHN
>D>	AB HARRIS PHARM	EQ 250MG BASE	A 077919	001	Jul 02, 2007	Nov	CAHN

TERIFLUNOMIDE

TABLET;ORAL

TERIFLUNOMIDE

>D>	AB BRECKENRIDGE	7MG	A 209583	001	Sep 24, 2021	Nov	DISC
>A>	AB @	7MG	A 209583	001	Sep 24, 2021	Nov	DISC
	AB	7MG	A 209583	001	Sep 24, 2021	Sep	NEWA
>D>	AB	14MG	A 209583	002	Sep 24, 2021	Nov	DISC
>A>	AB @	14MG	A 209583	002	Sep 24, 2021	Nov	DISC
	AB	14MG	A 209583	002	Sep 24, 2021	Sep	NEWA
	AB @ IMPAX	14MG	A 209677	001	Jun 17, 2020	Feb	DISC
	AB @ SOLA PHARMS	14MG	A 209677	001	Jun 17, 2020	Oct	CAHN

TESTOSTERONE

GEL;TRANSDERMAL

TESTOSTERONE

AB2	ACTAVIS LABS UT INC	1.62% (20.25MG/1.25GM PACKET)	A 204570	002	Jul 17, 2020	Feb	NEWA
AB2		1.62% (40.5MG/2.5GM PACKET)	A 204570	003	Jul 17, 2020	Feb	NEWA
AB1	ENCUBE	50MG/5GM PACKET	A 212984	001	Nov 09, 2021	Oct	NEWA

GEL, METERED;TRANSDERMAL

TESTOSTERONE

	@ ALEOR DERMACEUTICALS	1.62% (20.25MG/1.25GM ACTUATION)	A 213922	001	Mar 03, 2021	Sep	DISC
AB		1.62% (20.25MG/1.25GM ACTUATION)	A 213922	001	Mar 03, 2021	Feb	NEWA

SOLUTION, METERED;TRANSDERMAL

TESTOSTERONE

AT	ALEOR DERMACEUTICALS	30MG/1.5ML ACTUATION	A 212882	001	Jun 14, 2021	Jun	NEWA
	@ APOTEX	30MG/1.5ML ACTUATION	A 209181	001	Nov 25, 2020	May	DISC
AT	DASH PHARMS	30MG/1.5ML ACTUATION	A 212301	001	Jan 11, 2021	May	CAHN
AT	FEMPHARM	30MG/1.5ML ACTUATION	A 212301	001	Jan 11, 2021	Jan	NEWA
AT	TWI PHARMS	30MG/1.5ML ACTUATION	A 209836	001	Sep 03, 2021	Aug	NEWA

TESTOSTERONE CYPIONATE

INJECTABLE;INJECTION

DEPO-TESTOSTERONE

	@ PFIZER	50MG/ML	A 085635	001		Mar	CAHN
AO	+	100MG/ML	A 085635	002		Aug	CRLD
AO	!	100MG/ML	A 085635	002		Mar	CAHN
AO	+	200MG/ML	A 085635	003		Aug	CRLD
AO	!	200MG/ML	A 085635	003		Mar	CAHN

TESTOSTERONE CYPIONATE

AO	HIKMA	100MG/ML	A 090387	001	Jul 15, 2010	Jul	CAHN
AO		200MG/ML	A 090387	002	Jul 15, 2010	Jul	CAHN

TETRABENAZINE

TABLET;ORAL

TETRABENAZINE

	@ AJANTA PHARMA LTD	12.5MG	A 213621	001	Dec 04, 2020	May	DISC
	@	25MG	A 213621	002	Dec 04, 2020	May	DISC

TETRACAINE HYDROCHLORIDE

SOLUTION;OPHTHALMIC  
TETRACAINE HYDROCHLORIDE

+! BAUSCH LOMB IRELAND 0.5% N210821 001 Mar 12, 2019 May CAHN

THALLOUS CHLORIDE TL-201

INJECTABLE;INJECTION  
THALLOUS CHLORIDE TL 201

+ @ GE HEALTHCARE 1mCi/ML N018110 002 Feb 27, 1996 Jun DISC

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE;ORAL  
SLO-PHYLLIN

+ @ SANOFI AVENTIS US 125MG A085203 001 May 24, 1982 Aug CRLD

SOMOPHYLLIN-CRT

+ @ GRAHAM DM 250MG A087193 001 Aug CRLD

THEO-24

+ AUXILIUM PHARMS LLC 200MG A087943 001 Aug 22, 1983 Aug CRLD

ELIXIR;ORAL

THEOPHYLLINE

+ @ PRECISION DOSE 80MG/15ML A085863 001 Aug CRLD

SOLUTION;ORAL

THEOPHYLLINE

+ @ ROXANE 80MG/15ML A087449 001 Sep 15, 1983 Aug CRLD

SOLUTION, ELIXIR;ORAL

ELIXOPHYLLIN

AA +! NOSTRUM LABS INC 80MG/15ML A085186 001 Aug CRLD

SYRUP;ORAL

THEOPHYLLINE

+ @ ALPHARMA US PHARMS 150MG/15ML A086545 001 Aug CRLD

TABLET, EXTENDED RELEASE;ORAL

THEO-DUR

+ @ SCHERING 200MG A086998 001 Aug CRLD

+ @ 300MG A085328 002 Sep CRLD

>D> THEOCHRON

>D> AB NOSTRUM PHARMS LLC 100MG A087400 003 Feb 21, 1985 Nov DISC

>A> @ 100MG A087400 003 Feb 21, 1985 Nov DISC

>D> AB 200MG A087400 004 Feb 21, 1985 Nov DISC

>A> @ 200MG A087400 004 Feb 21, 1985 Nov DISC

THEOPHYLLINE

AB ALEMBIC PHARMS LTD 300MG A090430 001 Oct 27, 2010 May CTEC

AB ! 450MG A090430 002 Oct 27, 2010 May CTEC

AB GLENMARK PHARMS LTD 300MG A212184 001 Jun 03, 2021 May NEWA

AB 450MG A212184 002 Jun 03, 2021 May NEWA

@ HERITAGE PHARMA 100MG A089807 001 Apr 30, 1990 Jul DISC

@ 200MG A089808 001 Apr 30, 1990 Jul DISC

AB + RHODES PHARMS 400MG A040086 002 Sep 01, 1982 Aug CRLD

THIAMINE HYDROCHLORIDE

INJECTABLE;INJECTION  
BETALIN S

+ @ LILLY 100MG/ML A080853 001 Aug CRLD

THIAMINE HYDROCHLORIDE

AP +! FRESENIUS KABI USA 100MG/ML A080556 001 Aug CRLD

AP WEST-WARD PHARMS INT 100MG/ML A080575 001 Apr CMFD

THIORIDAZINE HYDROCHLORIDE

TABLET;ORAL

THIORIDAZINE HYDROCHLORIDE

MYLAN 10MG A088004 002 Mar 15, 1983 Jan CTEC

25MG A088004 003 Mar 15, 1983 Jan CTEC

50MG A088004 004 Mar 15, 1983 Jan CTEC

! 100MG A088004 001 Nov 18, 1983 Jan CTEC

@ SUN PHARM INDUSTRIES 10MG A089953 004 Aug 01, 1986 Jan DISC

@ 25MG A089953 003 Aug 01, 1986 Jan DISC

@ 50MG A089953 002 Aug 01, 1986 Jan DISC

@ 100MG A089953 001 Oct 07, 1988 Jan DISC

THIOTEPA

INJECTABLE;INJECTION  
THIOTEPA

>A>	AP	BELOTECA INC	15MG/VIAL	A211831	001	Dec 08, 2021	Nov	NEWA
		POWDER;INTRACAVITARY, INTRAVENOUS, INTRAVESICAL						
	AP	GLAND PHARMA LTD	15MG/VIAL	A214222	001	Mar 08, 2021	Feb	NEWA

THIOTHIXENE HYDROCHLORIDE

CONCENTRATE;ORAL  
NAVANE

		+ @ PFIZER	EQ 5MG BASE/ML	N016758	001		Oct	CRLD
--	--	------------	----------------	---------	-----	--	-----	------

TIAGABINE HYDROCHLORIDE

TABLET;ORAL  
TIAGABINE HYDROCHLORIDE

>A>	AB	MSN	2MG	A214816	001	Nov 16, 2021	Nov	NEWA
>A>	AB		4MG	A214816	002	Nov 16, 2021	Nov	NEWA
>A>	AB		12MG	A214816	003	Nov 16, 2021	Nov	NEWA
>A>	AB		16MG	A214816	004	Nov 16, 2021	Nov	NEWA
		@ WILSHIRE PHARMS INC	2MG	A206857	001	Oct 13, 2017	Jan	DISC
		@	4MG	A206857	002	Oct 13, 2017	Jan	DISC
		@	12MG	A206857	003	Oct 13, 2017	Jan	DISC
		@	16MG	A206857	004	Oct 13, 2017	Jan	DISC

TICAGRELOR

TABLET;ORAL  
BRILINTA

AB	+	ASTRAZENECA	60MG	N022433	002	Sep 03, 2015	Jul	CFTG
		TICAGRELOR						
AB		MYLAN	60MG	A208597	001	Jul 09, 2021	Jul	NFTG
AB			90MG	A208597	002	Jul 09, 2021	Jul	NEWA
>D>	AB	SIGMAPHARM LABS LLC	90MG	A208596	001	Apr 07, 2020	Nov	DISC
>A>		@	90MG	A208596	001	Apr 07, 2020	Nov	DISC

TICLOPIDINE HYDROCHLORIDE

TABLET;ORAL  
TICLOPIDINE HYDROCHLORIDE

		@ CHARTWELL RX	250MG	A075318	001	Aug 20, 1999	Aug	CAHN
		@	250MG	A075326	001	Aug 20, 1999	Aug	CAHN

TIGECYCLINE

POWDER;INTRAVENOUS  
TIGECYCLINE

AP		HONG KONG	50MG/VIAL	A214020	001	May 13, 2021	May	NEWA
AP		MEITHEAL	50MG/VIAL	A214020	001	May 13, 2021	Aug	CAHN

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS;OPHTHALMIC  
TIMOLOL MALEATE

AB	!	ALEMBIC PHARMS LTD	EQ 0.25% BASE	A212942	001	Oct 22, 2020	Apr	CHRS
AB	!		EQ 0.5% BASE	A212942	002	Oct 22, 2020	Apr	CHRS

TIMOPTIC-XE

AB	+	VALEANT PHARMS LLC	EQ 0.25% BASE	N020330	001	Nov 04, 1993	Apr	CHRS
AB	+		EQ 0.5% BASE	N020330	002	Nov 04, 1993	Apr	CHRS

SOLUTION/DROPS;OPHTHALMIC  
TIMOLOL MALEATE

AT		MANKIND PHARMA	EQ 0.25% BASE	A078771	001	Sep 28, 2009	Apr	CAHN
AT1			EQ 0.5% BASE	A078771	002	Sep 28, 2009	Apr	CAHN

TABLET;ORAL

TIMOLOL MALEATE

>A>		@ CHARTWELL RX	5MG	A072550	001	Apr 13, 1989	Nov	CAHN
>A>		@	10MG	A072551	001	Apr 13, 1989	Nov	CAHN
>A>		@	20MG	A072552	001	Apr 13, 1989	Nov	CAHN
>D>		@ YAOPHARMA CO LTD	5MG	A072550	001	Apr 13, 1989	Nov	CAHN
>D>		@	10MG	A072551	001	Apr 13, 1989	Nov	CAHN
>D>		@	20MG	A072552	001	Apr 13, 1989	Nov	CAHN

TIOPRONINTABLET;ORAL  
THIOLA

AB	+!	MISSION PHARMA	100MG	N019569	001	Aug 11, 1988	Apr	CFTG
AB		TEVA PHARMS USA INC	100MG	A214326	001	Apr 26, 2021	Apr	NFTG

TIOTROPIUM BROMIDESPRAY, METERED; INHALATION  
SPIRIVA RESPIMAT

+!	BOEHRINGER INGELHEIM	EQ 0.00125MG BASE/INH	N021936	002	Sep 15, 2015	Mar	CHRS
----	----------------------	-----------------------	---------	-----	--------------	-----	------

TIROFIBAN HYDROCHLORIDESOLUTION; INTRAVENOUS  
AGGRASTAT

+	MEDICURE	EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)	N020913	002	May 17, 2002	Apr	CDFR	
AP	+!	EQ 12.5MG BASE/250ML (EQ 0.05MG BASE/ML)	N020913	003	Apr 20, 2000	Apr	CFTG	
	@	EQ 25MG BASE/500ML (EQ 0.05MG BASE/ML)	N020913	001	May 14, 1998	Apr	CDFR	
AP		TIROFIBAN HYDROCHLORIDE GLAND PHARMA LTD	EQ 12.5MG BASE/250ML (EQ 0.05MG BASE/ML)	A206888	001	Apr 08, 2021	Apr	NFTG

TIVOZANIB HYDROCHLORIDECAPSULE;ORAL  
FOTIVDA

+	AVEO PHARMS	EQ 0.89MG BASE	N212904	001	Mar 10, 2021	Mar	NEWA
+!		EQ 1.34MG BASE	N212904	002	Mar 10, 2021	Mar	NEWA

TIZANIDINE HYDROCHLORIDE

CAPSULE;ORAL

TIZANIDINE HYDROCHLORIDE

@	PAR PHARM INC	EQ 2MG BASE	A207199	001	Mar 14, 2017	Jun	DISC
@		EQ 4MG BASE	A207199	002	Mar 14, 2017	Jun	DISC
@		EQ 6MG BASE	A207199	003	Mar 14, 2017	Jun	DISC

TABLET;ORAL

TIZANIDINE HYDROCHLORIDE

AB		CADILA	EQ 2MG BASE	A208187	001	Mar 09, 2018	Feb	CAHN
AB			EQ 4MG BASE	A208187	002	Mar 09, 2018	Feb	CAHN
	@	MYLAN	EQ 2MG BASE	A076354	001	Mar 28, 2003	Jan	DISC
	@		EQ 4MG BASE	A076354	002	Mar 28, 2003	Feb	DISC

TOBRAMYCINSOLUTION; INHALATION  
TOBRAMYCIN

AN		ALKEM LABS LTD	300MG/5ML	A212848	001	Apr 01, 2021	Mar	NEWA
	@	AUROBINDO PHARMA LTD	300MG/5ML	A210871	001	Jan 22, 2021	Jul	DISC
AN			300MG/5ML	A210871	001	Jan 22, 2021	Jan	NEWA
	@	LUOXIN AUROVITAS	300MG/5ML	A210871	001	Jan 22, 2021	Aug	CAHN

SOLUTION/DROPS;OPHTHALMIC  
TOBRAMYCIN

AT		GLAND PHARMA LTD	0.3%	A212628	001	Mar 09, 2021	Feb	NEWA
----	--	------------------	------	---------	-----	--------------	-----	------

TOBRAMYCIN SULFATEINJECTABLE; INJECTION  
TOBRAMYCIN SULFATE

AP		GLAND PHARMA LTD	EQ 10MG BASE/ML	A209621	001	Feb 11, 2021	Feb	NEWA
AP			EQ 40MG BASE/ML	A209621	002	Feb 11, 2021	Feb	NEWA
AP			EQ 1.2GM BASE/VIAL	A211189	001	May 18, 2021	May	NEWA
		TOBRAMYCIN SULFATE (PHARMACY BULK)						
AP	!	FRESENIUS KABI USA	EQ 40MG BASE/ML	A065120	001	Nov 29, 2002	Jan	CTEC
AP		GLAND PHARMA LTD	EQ 40MG BASE/ML	A209346	001	Feb 09, 2021	Jan	NEWA

TOFACITINIB CITRATESOLUTION;ORAL  
XELJANZ

+!	PFIZER	EQ 1MG/ML BASE	N213082	001	Sep 25, 2020	Feb	CMS1
----	--------	----------------	---------	-----	--------------	-----	------



<u>TABLET;ORAL</u>									
TOFACITINIB CITRATE									
>D>	AB	AJANTA PHARMA LTD	EQ 10MG BASE	A212943	001	Jun 01, 2021	Nov	DISC	
>A>	@		EQ 10MG BASE	A212943	001	Jun 01, 2021	Nov	DISC	
	AB		EQ 10MG BASE	A212943	001	Jun 01, 2021	May	NFTG	
XELJANZ									
>D>	AB	+! PF PRISM CV	EQ 10MG BASE	N203214	002	May 30, 2018	Nov	CTEC	
>A>		+!	EQ 10MG BASE	N203214	002	May 30, 2018	Nov	CTEC	
	AB	+!	EQ 10MG BASE	N203214	002	May 30, 2018	May	CFTG	
TABLET, EXTENDED RELEASE;ORAL									
TOFACITINIB									
	AB	ZYDUS PHARMS	EQ 11MG BASE	A214264	001	Aug 19, 2021	Aug	NFTG	
	AB		EQ 22MG BASE	A214264	002	Aug 19, 2021	Aug	NFTG	
XELJANZ XR									
	AB	+ PFIZER	EQ 11MG BASE	N208246	001	Feb 23, 2016	Aug	CFTG	
	AB	+!	EQ 22MG BASE	N208246	002	Dec 12, 2019	Aug	CFTG	
<u>TOLAZAMIDE</u>									
TABLET;ORAL									
TOLAZAMIDE									
	@	CHARTWELL RX	100MG	A071633	001	Dec 09, 1987	Aug	CAHN	
	@		250MG	A070289	001	Mar 13, 1986	Aug	CAHN	
	@		500MG	A070290	001	Mar 13, 1986	Aug	CAHN	
<u>TOLBUTAMIDE</u>									
TABLET;ORAL									
TOLBUTAMIDE									
	@	CHARTWELL RX	500MG	A086574	001		Aug	CAHN	
	@	MYLAN PHARMS INC	500MG	A086445	001		Oct	DISC	
<u>TOLCAPONE</u>									
TABLET;ORAL									
TOLCAPONE									
	@	ALVOGEN	100MG	A207729	001	Jul 29, 2020	Jan	DISC	
	@	MAYNE PHARMA	100MG	A210095	001	Aug 01, 2019	Sep	DISC	
<u>TOLMETIN SODIUM</u>									
CAPSULE;ORAL									
TOLMETIN SODIUM									
>D>	@	MYLAN	EQ 400MG BASE	A073393	001	May 27, 1993	Nov	CAHN	
	@		EQ 400MG BASE	A073393	001	May 27, 1993	Aug	DISC	
>A>	@	RISING	EQ 400MG BASE	A073393	001	May 27, 1993	Nov	CAHN	
	@	TEVA	EQ 400MG BASE	A073290	001	Nov 27, 1991	Aug	DISC	
TABLET;ORAL									
TOLMETIN SODIUM									
>D>	@	MYLAN	EQ 600MG BASE	A074473	001	Aug 30, 1994	Nov	CAHN	
	@		EQ 600MG BASE	A074473	001	Aug 30, 1994	Aug	DISC	
>A>	@	RISING	EQ 600MG BASE	A074473	001	Aug 30, 1994	Nov	CAHN	
<u>TOLTERODINE TARTRATE</u>									
CAPSULE, EXTENDED RELEASE;ORAL									
TOLTERODINE TARTRATE									
	AB	AJANTA PHARMA LTD	2MG	A213397	001	May 19, 2020	Jan	CMFD	
	AB		4MG	A213397	002	May 19, 2020	Jan	CMFD	
	AB	AMTA	2MG	A213858	001	Feb 02, 2021	Jan	NEWA	
	AB		4MG	A213858	002	Feb 02, 2021	Jan	NEWA	
TABLET;ORAL									
TOLTERODINE TARTRATE									
	AB	HETERO LABS LTD V	1MG	A204397	001	Aug 02, 2021	Jul	NEWA	
	AB		2MG	A204397	002	Aug 02, 2021	Jul	NEWA	
<u>TOLVAPTAN</u>									
TABLET;ORAL									
SAMSCA									
	+	OTSUKA	15MG	N022275	001	May 19, 2009	Feb	CAHN	
	AB	+!	30MG	N022275	002	May 19, 2009	Feb	CAHN	
		+ @	60MG	N022275	003	May 19, 2009	Feb	CAHN	
TOLVAPTAN									
		ALKEM LABS LTD	60MG	A211891	002	May 19, 2020	Jul	CTEC	
	AB	APOTEX	30MG	A207605	001	May 19, 2020	Aug	CMFD	
	AB	HETERO LABS LTD V	30MG	A205646	001	Jul 16, 2021	Jul	NEWA	

TOPIRAMATE

CAPSULE, EXTENDED RELEASE;ORAL  
QUDEXY XR

AB2	+	UPSHER SMITH LABS	25MG	N205122	001	Mar 11, 2014	Jan CFTG
AB2	+		50MG	N205122	002	Mar 11, 2014	Jan CFTG
AB2	+		100MG	N205122	003	Mar 11, 2014	Jan CFTG
AB2	+		150MG	N205122	004	Mar 11, 2014	Jan CFTG
AB2	+		200MG	N205122	005	Mar 11, 2014	Jan CFTG

TOPIRAMATE

AB2		GLENMARK PHARMS LTD	25MG	A210278	001	Feb 01, 2021	Jan NFTG
AB2			50MG	A210278	002	Feb 01, 2021	Jan NFTG
AB2			100MG	A210278	003	Feb 01, 2021	Jan NFTG
AB2			150MG	A210278	004	Feb 01, 2021	Jan NFTG
AB2			200MG	A210278	005	Feb 01, 2021	Jan NFTG
AB1		ZYDUS PHARMS	25MG	A207382	001	Nov 24, 2017	Jan CTEC
AB1			50MG	A207382	002	Nov 24, 2017	Jan CTEC
AB1			100MG	A207382	003	Nov 24, 2017	Jan CTEC

TROKENDI XR

AB1	+	SUPERNUS PHARMS	25MG	N201635	001	Aug 16, 2013	Jan CTEC
AB1	+		50MG	N201635	002	Aug 16, 2013	Jan CTEC
AB1	+		100MG	N201635	003	Aug 16, 2013	Jan CTEC

>A> SOLUTION;ORAL

>A> EPRONTIA

>A>	+	AZURITY	25MG/ML	N214679	001	Nov 05, 2021	Nov NEWA
-----	---	---------	---------	---------	-----	--------------	----------

TABLET;ORAL

TOPIRAMATE

AB		ASCENT PHARMS INC	25MG	A215414	001	Aug 26, 2021	Aug NEWA
AB			50MG	A215414	002	Aug 26, 2021	Aug NEWA
AB			100MG	A215414	003	Aug 26, 2021	Aug NEWA
AB			200MG	A215414	004	Aug 26, 2021	Aug NEWA

TOPOTECAN HYDROCHLORIDE

INJECTABLE;INJECTION  
TOPOTECAN HYDROCHLORIDE  
@ MEITHEAL

EQ 4MG BASE/VIAL	A201166	001	Aug 08, 2012	Aug DISC
------------------	---------	-----	--------------	----------

TORSEMIDE

TABLET;ORAL  
SOANZ

>A>	+	SARFE PHARMS	20MG	N213218	001	Jun 14, 2021	Jul CHRS
	+		20MG	N213218	001	Jun 14, 2021	Jun NEWA
	+		40MG	N213218	003	Nov 17, 2021	Nov NEWA
	+		60MG	N213218	002	Jun 14, 2021	Jul CHRS
	+		60MG	N213218	002	Jun 14, 2021	Jun NEWA

TORSEMIDE

>A>	AB	STRIDES PHARMA	5MG	A090613	001	Mar 22, 2011	Nov CAHN
>A>	AB		10MG	A090613	002	Mar 22, 2011	Nov CAHN
>A>	AB		20MG	A090613	003	Mar 22, 2011	Nov CAHN
>A>	AB		100MG	A090613	004	Mar 22, 2011	Nov CAHN
>D>	AB	VINTAGE PHARMS	5MG	A090613	001	Mar 22, 2011	Nov CAHN
>D>	AB		10MG	A090613	002	Mar 22, 2011	Nov CAHN
>D>	AB		20MG	A090613	003	Mar 22, 2011	Nov CAHN
>D>	AB		100MG	A090613	004	Mar 22, 2011	Nov CAHN

TRAMADOL HYDROCHLORIDE

TABLET;ORAL  
TRAMADOL HYDROCHLORIDE

AB		GRAVITI PHARMS	50MG	A075968	001	Jun 25, 2002	Apr CAHN
AB		MERRO PHARM USA	50MG	A206706	001	Jul 02, 2019	Sep CAHN
AB		POLYGEN PHARMS	50MG	A206706	001	Jul 02, 2019	Feb CMFD
		@ RISING PHARMA	50MG	A075968	001	Jun 25, 2002	Aug CAHN

TABLET, EXTENDED RELEASE;ORAL

TRAMADOL HYDROCHLORIDE

@ ANCHEN PHARMS	A200491	001	Jun 27, 2012	Apr DISC
@	A200491	002	Jun 27, 2012	Apr DISC
@	A200491	003	Jun 27, 2012	Apr DISC

TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE

	TABLET, EXTENDED RELEASE;ORAL						
	TARKA						
	+ @	ABBVIE	2MG;180MG	N020591	001	Oct 22, 1996	Aug DISC
	+ @		2MG;240MG	N020591	004	Oct 22, 1996	Aug DISC
	+ @		4MG;240MG	N020591	002	Oct 22, 1996	Aug DISC
	TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE						
		GLENMARK GENERICS	2MG;180MG	A079135	001	May 26, 2010	Aug CTEC
			2MG;240MG	A079135	002	May 26, 2010	Aug CTEC
	!		4MG;240MG	A079135	003	May 05, 2010	Aug CTEC
AB	!		4MG;240MG	A079135	003	May 05, 2010	Aug CHRS

TRANEXAMIC ACID

	INJECTABLE; INJECTION						
	CYKLOKAPRON						
AP	+!	PFIZER	100MG/ML	N019281	001	Dec 30, 1986	Mar CAHN
		TRANEXAMIC ACID					
AP		CAPLIN	100MG/ML	A212360	001	Jul 17, 2019	Jun CMFD
AP		PROVEPHARM SAS	100MG/ML	A212676	001	Jul 17, 2019	Jan CAHN
	@	ZYDUS PHARMS	100MG/ML	A205228	001	Jul 17, 2017	Apr DISC
	TABLET;ORAL						
	TRANEXAMIC ACID						
AB		ANI PHARMS	650MG	A203256	001	Jul 25, 2016	Jun CMFD
	@	APOTEX INC	650MG	A202286	001	Jan 27, 2014	Mar DISC

TRANLYCYPROMINE SULFATE

	TABLET;ORAL						
	TRANLYCYPROMINE SULFATE						
AB		NOVITIUM PHARMA	EQ 10MG BASE	A206856	001	Apr 17, 2018	Apr CAHN
AB		STRIDES PHARMA	EQ 10MG BASE	A040640	001	Jun 29, 2006	Oct CAHN
AB			EQ 10MG BASE	A040640	001	Jun 29, 2006	Oct CAHN

TRAVOPROST

	SOLUTION/DROPS;OPHTHALMIC						
	TRAVOPROST						
AT		MICRO LABS	0.004%	A203767	001	Mar 19, 2021	Mar NEWA

TRAZODONE HYDROCHLORIDE

	TABLET;ORAL						
	TRAZODONE HYDROCHLORIDE						
	@	ALVOGEN	50MG	A071636	001	Apr 18, 1988	Jun DISC
	@		100MG	A071514	001	Apr 18, 1988	Jun DISC
AB		AUROLIFE PHARMA LLC	50MG	A204852	001	Feb 05, 2020	Feb CMFD
AB			100MG	A204852	002	Feb 05, 2020	Feb CMFD
AB			150MG	A204852	003	Feb 05, 2020	Feb CMFD
AB			300MG	A204852	004	Feb 05, 2020	Feb CMFD
	@	RISING	50MG	A072484	001	Apr 30, 1990	Jan CAHN

TREPROSTINIL

	INJECTABLE;IV (INFUSION), SUBCUTANEOUS						
	REMODULIN						
	+!	UNITED THERAP	20MG/ML	N021272	005	Jul 30, 2021	Aug NEWA
		TREPROSTINIL					
AP		ALEMBIC GLOBAL	1MG/ML	A211574	001	Feb 11, 2021	Feb NEWA
AP			2.5MG/ML	A211574	002	Feb 11, 2021	Feb NEWA
AP			5MG/ML	A211574	003	Feb 11, 2021	Feb NEWA
AP			10MG/ML	A211574	004	Feb 11, 2021	Feb NEWA
	SOLUTION;INTRAVENOUS, SUBCUTANEOUS						
	REMODULIN						
	@	UNITED THERAP	20MG/20ML (1MG/ML)	N208276	001	Jul 30, 2018	Jun DISC
	@		50MG/20ML (2.5MG/ML)	N208276	002	Jul 30, 2018	Jun DISC
	@		100MG/20ML (5MG/ML)	N208276	003	Jul 30, 2018	Jun DISC
	@		200MG/20ML (10MG/ML)	N208276	004	Jul 30, 2018	Jun DISC

TRETINOIN

	CREAM;TOPICAL						
	RENOVA						
>D>							
>D>	+!	VALEANT PHARMS NORTH	0.05%	N019963	001	Dec 29, 1995	Nov DISC
>A>	+ @		0.05%	N019963	001	Dec 29, 1995	Nov DISC
	+!		0.05%	N019963	001	Dec 29, 1995	Sep CTEC

TRIAMCINOLONE ACETONIDE

	CREAM; TOPICAL						
	ARISTOCORT						
	+ @	ASTELLAS	0.5%	A083015	002		Aug CRLD
		KENALOG					
	+ @	DELCOR ASSET CORP	0.5%	A083943	001		Aug CRLD
		TRIAMCINOLONE ACETONIDE					
AT	+!	FOUGERA PHARMS	0.025%	A085692	001		Aug CRLD
AT	+!		0.1%	A085692	003		Aug CRLD
AT	+!		0.5%	A085692	002		Aug CRLD
AT		MICRO LABS	0.025%	A040671	001	Jun 09, 2006	Aug CAHN
AT			0.1%	A040671	002	Jun 09, 2006	Aug CAHN
AT		SAPTALIS PHARMS	0.025%	A040671	001	Jun 09, 2006	Jan CAHN
AT			0.1%	A040671	002	Jun 09, 2006	Jan CAHN
	INJECTABLE; INJECTION						
	TRIAMCINOLONE ACETONIDE						
BX		AMNEAL	40MG/ML	A207550	001	Dec 11, 2017	Sep CTEC
	LOTION; TOPICAL						
	TRIAMCINOLONE ACETONIDE						
AT		MICRO LABS	0.1%	A040672	002	Dec 13, 2006	Aug CAHN
	OINTMENT; TOPICAL						
	ARISTOCORT						
	+ @	ASTELLAS	0.5%	A080745	002		Aug CRLD
		ARISTOCORT A					
	+ @	ASTELLAS	0.5%	A080745	003		Aug CRLD
		KENALOG					
	+ @	DELCOR ASSET CORP	0.5%	A083944	001		Aug CRLD
		TRIAMCINOLONE ACETONIDE					
AT	+!	PADAGIS US	0.025%	A087385	002		Aug CRLD
AT	+!		0.1%	A087385	003		Aug CRLD
AT	+!		0.5%	A087385	001		Aug CRLD
>D>		TRIAMCINOLONE ACETONIDE	IN ABSORBASE				
>D> AT	!	CMP PHARMA INC	0.05%	A089595	001	Mar 23, 1995	Nov CTNA
>A>		TRIANEX					
>A> AT	!	CMP PHARMA INC	0.05%	A089595	001	Mar 23, 1995	Nov CTNA
	SPRAY, METERED; NASAL						
	TRIAMCINOLONE ACETONIDE						
	@	PERRIGO	0.055MG/SPRAY	A078104	001	Jul 30, 2009	Jul CAHN
	SUSPENSION; INJECTION						
	XIPIERE						
	+!	CLEARSIDE	40MG/ML	N211950	001	Oct 22, 2021	Oct NEWA

TRIAZOLAM

	TABLET; ORAL						
	HALCION						
AB	+	PFIZER	0.125MG	N017892	003	Apr 26, 1985	Feb CAHN
AB	+!		0.25MG	N017892	001	Nov 15, 1982	Feb CAHN
	@		0.5MG	N017892	002	Nov 15, 1982	Feb CAHN
	TRIAZOLAM						
AB		NOVAST LABS	0.125MG	A214219	001	Oct 20, 2020	Sep CAHN
AB			0.25MG	A214219	002	Oct 20, 2020	Sep CAHN

TRIENTINE HYDROCHLORIDE

	CAPSULE; ORAL						
	CLOVIQUE						
	@	CHARTWELL RX	250MG	A209731	001	Oct 21, 2019	Jun DISC
AB			250MG	A209731	001	Oct 21, 2019	Mar CAHN
	TRIENTINE HYDROCHLORIDE						
AB		ACCORD HLTHCARE	250MG	A212929	001	Aug 30, 2021	Aug NEWA
	@	AMNEAL	250MG	A210619	001	Feb 08, 2019	Sep DISC
	@	CHARTWELL RX	250MG	A209415	001	Sep 16, 2019	Jun DISC
AB			250MG	A209415	001	Sep 16, 2019	Mar CAHN
AB		ECI PHARMS LLC	250MG	A209945	001	Aug 13, 2021	Aug NEWA
BX		MSN	250MG	A211134	001	May 22, 2019	Sep CTEC
AB		PHARMA LIFE	250MG	A209945	001	Aug 13, 2021	Sep CAHN

TRILACICLIB DIHYDROCHLORIDEPOWDER; INTRAVENOUS  
COSELA

+! G1 THERAP EQ 300MG BASE/VIAL N214200 001 Feb 12, 2021 Feb NEWA

TRIMETHOBENZAMIDE HYDROCHLORIDECAPSULE; ORAL  
TIGAN+ @ KING PHARMS LLC 300MG N017531 006 Dec 13, 2001 Apr DISC  
AB ! SUN PHARM INDUSTRIES 300MG A076570 001 Aug 28, 2003 Apr CHRSTROPICAMIDESOLUTION/DROPS; OPHTHALMIC  
MYDRIACYLAT +! ALCON LABS INC 1% A084306 001 Aug CRLD  
AT +! SANDOZ INC 0.5% A084305 001 Aug CRLDTROSPIMUM CHLORIDECAPSULE, EXTENDED RELEASE; ORAL  
TROSPIMUM CHLORIDE

AB AMTA 60MG A214760 001 Apr 30, 2021 Apr NEWA

UMBRALISIB TOSYLATETABLET; ORAL  
UKONIQ

+! TG THERAPS EQ 200MG BASE N213176 001 Feb 05, 2021 Feb NEWA

URSODIOLCAPSULE; ORAL  
URSODIOLAB CHARTWELL RX 300MG A213555 001 Aug 17, 2020 Oct CAHN  
AB STRIDES PHARMA 300MG A210344 001 Jan 22, 2021 Jan NEWA  
AB VGYAAN 300MG A214329 001 Jul 28, 2021 Jul NEWAVALACYCLOVIR HYDROCHLORIDETABLET; ORAL  
VALACYCLOVIR HYDROCHLORIDEAB CADILA EQ 500MG BASE A079137 001 Dec 29, 2017 Aug CAHN  
AB EQ 1GM BASE A079137 002 Dec 29, 2017 Aug CAHNVALBENAZINE TOSYLATECAPSULE; ORAL  
INGREZZA

+ NEUROCRINE EQ 60MG BASE N209241 003 Apr 23, 2021 May NEWA

VALGANCICLOVIR HYDROCHLORIDEFOR SOLUTION; ORAL  
VALGANCICLOVIR HYDROCHLORIDE>D> @ GRANULES 50MG/ML A213306 001 Jan 31, 2020 Nov CMFD  
>A> AB 50MG/ML A213306 001 Jan 31, 2020 Nov CMFDTABLET; ORAL  
VALGANCICLOVIR HYDROCHLORIDEAB MYLAN EQ 450MG BASE A205151 001 Mar 03, 2021 Feb NEWA  
AB STRIDES PHARMA EQ 450MG BASE A200790 001 Nov 04, 2014 Oct CAHNVALPROIC ACIDCAPSULE; ORAL  
VALPROIC ACID

BX EYWA 250MG A207611 001 Aug 05, 2019 Sep CTEC

SYRUP; ORAL  
VALPROIC ACIDAA BIOPHARM 250MG/5ML A090517 001 May 28, 2010 Sep CAHN  
AA CHARTWELL RX 250MG/5ML A075782 001 Dec 22, 2000 Mar CMFD

VALSARTAN

SOLUTION;ORAL		VALSARTAN		NOVITIUM PHARMA		20MG/5ML	A214102	001	Nov 02, 2021	Oct	NFTG
TABLET;ORAL		VALSARTAN		DR REDDYS		40MG	A201618	001	Oct 05, 2021	Sep	NEWA
AB						80MG	A201618	002	Oct 05, 2021	Sep	NEWA
AB						160MG	A201618	003	Oct 05, 2021	Sep	NEWA
AB						320MG	A201618	004	Oct 05, 2021	Sep	NEWA
AB		SCIEGEN PHARMS INC				40MG	A204038	001	Oct 27, 2021	Oct	NEWA
AB						80MG	A204038	002	Oct 27, 2021	Oct	NEWA
AB						160MG	A204038	003	Oct 27, 2021	Oct	NEWA
AB						320MG	A204038	004	Oct 27, 2021	Oct	NEWA

VANCOMYCIN

SOLUTION;INTRAVENOUS, ORAL		VANCOMYCIN		+! XELLIA PHARMS APS		5GM/100ML (50MG/ML)	N213895	001	Aug 26, 2021	Aug	NEWA
----------------------------	--	------------	--	----------------------	--	---------------------	---------	-----	--------------	-----	------

VANCOMYCIN HYDROCHLORIDE

INJECTABLE;INJECTION		VANCOMYCIN HYDROCHLORIDE		HAINAN POLY		EQ 5GM BASE/VIAL	A215821	001	Nov 18, 2021	Nov	NEWA
>A>	AP					EQ 10GM BASE/VIAL	A215821	002	Nov 18, 2021	Nov	NEWA
>A>	AP	@ HIKMA				EQ 500MG BASE/VIAL	A203300	001	Aug 11, 2020	Feb	DISC
		@				EQ 1GM BASE/VIAL	A203300	002	Aug 11, 2020	Feb	DISC
		! HOSPIRA				EQ 1.5GM BASE/VIAL	A062912	003	Jul 10, 2020	May	CMFD

VARDENAFIL HYDROCHLORIDE

TABLET;ORAL		LEVITRA		+ @ BAYER HLTHCARE		EQ 5MG BASE	N021400	001	Aug 19, 2003	Apr	DISC
				+ @		EQ 10MG BASE	N021400	002	Aug 19, 2003	Apr	DISC

VARENICLINE

TABLET;ORAL		VARENICLINE TARTRATE		PAR PHARM INC		EQ 0.5MG BASE	A201785	001	Aug 11, 2021	Jul	NFTG
AB						EQ 1MG BASE	A201785	002	Aug 11, 2021	Jul	NFTG

VARENICLINE TARTRATE

SOLUTION;NASAL		TYRVAYA		+! OYSTER POINT PHARMA		EQ 0.03MG BASE/SPRAY	N213978	001	Oct 15, 2021	Oct	NEWA
TABLET;ORAL		CHANTIX		+ PF PRISM CV		EQ 0.5MG BASE	N021928	001	May 10, 2006	Jul	CFTG
AB				+!		EQ 1MG BASE	N021928	002	May 10, 2006	Jul	CFTG
		VARENICLINE TARTRATE		PAR PHARM INC		EQ 0.5MG BASE	A201785	001	Aug 11, 2021	Sep	CTNA
AB						EQ 0.5MG BASE	A201785	001	Aug 11, 2021	Sep	CAIN
AB						EQ 1MG BASE	A201785	002	Aug 11, 2021	Sep	CTNA
AB						EQ 1MG BASE	A201785	002	Aug 11, 2021	Sep	CAIN

VASOPRESSIN

SOLUTION;INTRAVENOUS		VASOSTRICT		+! PAR STERILE PRODUCTS		20UNITS/100ML (0.2UNITS/ML)	N204485	005	Apr 21, 2021	Apr	NEWA
----------------------	--	------------	--	-------------------------	--	-----------------------------	---------	-----	--------------	-----	------

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL		VENLAFAXINE HYDROCHLORIDE		TORRENT		EQ 37.5MG BASE	A090899	001	Jun 01, 2011	Aug	CAHN
AB						EQ 75MG BASE	A090899	002	Jun 01, 2011	Aug	CAHN
AB						EQ 150MG BASE	A090899	003	Jun 01, 2011	Aug	CAHN
AB		YICHANG HUMANWELL				EQ 37.5MG BASE	A214654	001	Aug 06, 2021	Jul	NEWA
AB						EQ 75MG BASE	A214654	002	Aug 06, 2021	Jul	NEWA
AB						EQ 150MG BASE	A214654	003	Aug 06, 2021	Jul	NEWA

TABLET;ORAL

VENLAFAXINE HYDROCHLORIDE

@	MYLAN	EQ 25MG BASE	A077166	001	Jun 13, 2008	Jan DISC
@		EQ 37.5MG BASE	A077166	002	Jun 13, 2008	Jan DISC
@		EQ 50MG BASE	A077166	003	Jun 13, 2008	Jan DISC
@		EQ 75MG BASE	A077166	004	Jun 13, 2008	Jan DISC
@		EQ 100MG BASE	A077166	005	Jun 13, 2008	Jan DISC

TABLET, EXTENDED RELEASE;ORAL

VENLAFAXINE HYDROCHLORIDE

AB	ALKEM LABS LTD	EQ 37.5MG BASE	A214127	001	Jun 10, 2021	Jun NEWA
AB		EQ 75MG BASE	A214127	002	Jun 10, 2021	Jun NEWA
AB		EQ 150MG BASE	A214127	003	Jun 10, 2021	Jun NEWA
AB		EQ 225MG BASE	A214127	004	Jun 10, 2021	Jun NEWA
AB	APPCO	EQ 150MG BASE	A214609	001	Jun 30, 2021	Jun NEWA
AB		EQ 225MG BASE	A214609	002	Jun 30, 2021	Jun NEWA
AB	DEXCEL PHARMA	EQ 75MG BASE	A213927	001	Jan 21, 2021	Jan NEWA

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

VERAPAMIL HYDROCHLORIDE

@	MYLAN	120MG	A074587	002	Feb 21, 1997	Sep CAHN
@		120MG	A074587	002	Feb 21, 1997	Sep DISC
@		180MG	A074587	003	Sep 09, 1997	Sep CAHN
@		180MG	A074587	003	Sep 09, 1997	Sep DISC
@		240MG	A074587	001	Mar 23, 1996	Sep CAHN
@		240MG	A074587	001	Mar 23, 1996	Sep DISC

VERICIGUAT

TABLET;ORAL

VERQUVO

+	MERCK SHARP DOHME	2.5MG	N214377	001	Jan 19, 2021	Jan NEWA
+		5MG	N214377	002	Jan 19, 2021	Jan NEWA
+	!	10MG	N214377	003	Jan 19, 2021	Jan NEWA

VIGABATRIN

FOR SOLUTION;ORAL

VIGABATRIN

AA	ANNORA PHARMA	500MG/PACKET	A213519	001	Jan 26, 2021	Jan NEWA
AA	AUROBINDO PHARMA LTD	500MG/PACKET	A213899	001	Sep 29, 2021	Sep NEWA
AA	DEXCEL PHARMA	500MG/PACKET	A214992	001	May 13, 2021	May NEWA
>D>	AA	NAVISCI	A213390	001	Jul 29, 2021	Nov CAHN
AA		500MG/PACKET	A213390	001	Jul 29, 2021	Jul NEWA
>A>	AA	PROPEL PHARMA	A213390	001	Jul 29, 2021	Nov CAHN
>D>	AA	SPECGX LLC	A212626	001	Jul 28, 2021	Nov DISC
>A>	@	500MG/PACKET	A212626	001	Jul 28, 2021	Nov DISC
AA		500MG/PACKET	A212626	001	Jul 28, 2021	Jul NEWA

TABLET;ORAL

VIGABATRIN

AB	DEXCEL PHARMA	500MG	A215109	001	Sep 23, 2021	Sep NEWA
AB	DR REDDYS	500MG	A211539	001	Jan 29, 2021	Jan NEWA

VILAZODONE HYDROCHLORIDE

TABLET;ORAL

VILAZODONE HYDROCHLORIDE

AB	ACCORD HLTHCARE	10MG	A208209	001	Apr 27, 2021	Apr NEWA
AB		20MG	A208209	002	Apr 27, 2021	Apr NEWA
AB		40MG	A208209	003	Apr 27, 2021	Apr NEWA
AB	INVAGEN PHARMS	10MG	A208200	001	Apr 07, 2021	Mar NEWA
AB		40MG	A208200	002	Apr 07, 2021	Mar NEWA

VILOXAZINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

QELBREE

+	SUPERNUS PHARMS	EQ 100MG BASE	N211964	001	Apr 02, 2021	Apr NEWA
+		EQ 150MG BASE	N211964	002	Apr 02, 2021	Apr NEWA
+	!	EQ 200MG BASE	N211964	003	Apr 02, 2021	Apr NEWA

VINBLASTINE SULFATE

INJECTABLE; INJECTION  
VINBLASTINE SULFATE

! HIKMA 10MG/VIAL A089395 001 Apr 09, 1987 Jul CAHN

VINORELBINE TARTRATE

INJECTABLE; INJECTION  
VINORELBINE TARTRATE

@ FRESENIUS KABI USA EQ 10MG BASE/ML A076849 001 Apr 18, 2005 Jan DISC

VOCLOSPORIN

CAPSULE; ORAL  
LUPKYNIS

+! AURINIA 7.9MG N213716 001 Jan 22, 2021 Jan NEWA

VORICONAZOLE

INJECTABLE; INTRAVENOUS  
VORICONAZOLE

AP ALMAJECT 200MG/VIAL A206398 001 Mar 23, 2016 Feb CAHN

VORTIOXETINE HYDROBROMIDE

TABLET; ORAL  
TRINTELLIX

AB + TAKEDA PHARMS USA EQ 5MG BASE N204447 001 Sep 30, 2013 Sep CFTG

AB + EQ 10MG BASE N204447 002 Sep 30, 2013 Sep CFTG

AB +! EQ 20MG BASE N204447 004 Sep 30, 2013 Sep CFTG

VORTIOXETINE HYDROBROMIDE

AB ZYDUS PHARMS EQ 5MG BASE A211146 001 Sep 17, 2021 Sep NFTG

AB EQ 10MG BASE A211146 002 Sep 17, 2021 Sep NFTG

AB EQ 20MG BASE A211146 003 Sep 17, 2021 Sep NFTG

>A> VOSORITIDE

>A> POWDER; SUBCUTANEOUS  
>A> VOXZOGO

>A> +! BIOMARIN PHARM 0.4MG/VIAL N214938 001 Nov 19, 2021 Nov NEWA

>A> +! 0.56MG/VIAL N214938 002 Nov 19, 2021 Nov NEWA

>A> +! 1.2MG/VIAL N214938 003 Nov 19, 2021 Nov NEWA

WARFARIN SODIUM

TABLET; ORAL  
WARFARIN SODIUM

>A> @ CHARTWELL RX 1MG A040196 001 Sep 30, 1997 Nov CAHN

>A> @ 2MG A040196 002 Sep 30, 1997 Nov CAHN

>A> @ 2.5MG A040196 003 Sep 30, 1997 Nov CAHN

>A> @ 3MG A040196 008 Jul 26, 2000 Nov CAHN

>A> @ 4MG A040196 004 Sep 30, 1997 Nov CAHN

>A> @ 5MG A040196 005 Sep 30, 1997 Nov CAHN

>A> @ 6MG A040196 009 Jul 26, 2000 Nov CAHN

>A> @ 7.5MG A040196 006 Sep 30, 1997 Nov CAHN

>A> @ 10MG A040196 007 Sep 30, 1997 Nov CAHN

>D> @ YAOPHARMA CO LTD 1MG A040196 001 Sep 30, 1997 Nov CAHN

>D> @ 2MG A040196 002 Sep 30, 1997 Nov CAHN

>D> @ 2.5MG A040196 003 Sep 30, 1997 Nov CAHN

>D> @ 3MG A040196 008 Jul 26, 2000 Nov CAHN

>D> @ 4MG A040196 004 Sep 30, 1997 Nov CAHN

>D> @ 5MG A040196 005 Sep 30, 1997 Nov CAHN

>D> @ 6MG A040196 009 Jul 26, 2000 Nov CAHN

>D> @ 7.5MG A040196 006 Sep 30, 1997 Nov CAHN

>D> @ 10MG A040196 007 Sep 30, 1997 Nov CAHN

ZIDOVUDINE

INJECTABLE; INJECTION  
RETROVIR

+! VIIV HLTHCARE 10MG/ML N019951 001 Feb 02, 1990 Sep CTEC

ZILEUTON

TABLET, EXTENDED RELEASE; ORAL  
ZILEUTON

AB DASH PHARMS 600MG A211390 001 Oct 23, 2020 Sep CAHN

BX LUPIN LTD 600MG A211972 001 Nov 05, 2019 Sep CTEC



ZINC CHLORIDE

INJECTABLE; INJECTION  
ZINC CHLORIDE

AP	EXELA PHARMA	EQ 1MG ZINC/ML	A212007	001	May 21, 2021	May NFTG
	ZINC CHLORIDE IN PLASTIC CONTAINER					
AP	+! HOSPIRA	EQ 1MG ZINC/ML	N018959	001	Jun 26, 1986	May CFTG

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL  
ZIPRASIDONE HYDROCHLORIDE

AB	CHARTWELL RX	EQ 20MG BASE	A090348	001	Sep 05, 2012	Jul CAHN
AB		EQ 40MG BASE	A090348	002	Sep 05, 2012	Jul CAHN
AB		EQ 60MG BASE	A090348	003	Sep 05, 2012	Jul CAHN
AB		EQ 80MG BASE	A090348	004	Sep 05, 2012	Jul CAHN

ZOLEDRONIC ACID

INJECTABLE; INTRAVENOUS  
ZOLEDRONIC ACID

@	EMCURE PHARMS LTD	EQ 4MG BASE/5ML	A201783	001	Mar 12, 2013	Aug DISC
---	-------------------	-----------------	---------	-----	--------------	----------

ZOLMITRIPTAN

SPRAY; NASAL  
ZOLMITRIPTAN

AB	PADAGIS ISRAEL	2.5MG/SPRAY	A212469	001	Sep 30, 2021	Sep NFTG
AB		5MG/SPRAY	A212469	002	Sep 30, 2021	Sep NFTG
	ZOMIG					
AB	+ ASTRAZENECA	2.5MG/SPRAY	N021450	003	Sep 16, 2013	Sep CFTG
AB	+!	5MG/SPRAY	N021450	004	Sep 30, 2003	Sep CFTG

ZOLPIDEM TARTRATE

TABLET; ORAL  
ZOLPIDEM TARTRATE

>A>	@ STRIDES PHARMA	5MG	A078616	001	Nov 21, 2008	Nov CAHN
>A>	@	10MG	A078616	002	Nov 21, 2008	Nov CAHN
>D>	@ VINTAGE	5MG	A078616	001	Nov 21, 2008	Nov CAHN
>D>	@	10MG	A078616	002	Nov 21, 2008	Nov CAHN

TABLET, EXTENDED RELEASE; ORAL  
ZOLPIDEM TARTRATE

	@ ACTAVIS ELIZABETH	6.25MG	A078179	002	Oct 13, 2010	Oct DISC
AB		6.25MG	A078179	002	Oct 13, 2010	Oct CAHN
	@	12.5MG	A078179	001	Jun 06, 2011	Oct DISC
AB		12.5MG	A078179	001	Jun 06, 2011	Oct CAHN

TABLET, ORALLY DISINTEGRATING; ORAL  
TOVALT ODT

+ @	BIOVAIL LABS INTL	5MG	N021412	001	Apr 25, 2007	Apr CRLD
+ @		10MG	N021412	002	Apr 25, 2007	Apr CRLD

ZONISAMIDE

CAPSULE; ORAL  
ZONEGRAN

AB	+ CONCORDIA	25MG	N020789	003	Aug 22, 2003	Mar CAHN
	+ @	50MG	N020789	002	Aug 22, 2003	Mar CAHN
AB	+!	100MG	N020789	001	Mar 27, 2000	Mar CAHN

ZONISAMIDE

AB	CADILA	25MG	A077625	001	Oct 16, 2006	Jul CAHN
AB		50MG	A077625	002	Oct 16, 2006	Jul CAHN
AB		100MG	A077625	003	Oct 16, 2006	Jul CAHN
AB	GRANULES	25MG	A077636	003	Jul 27, 2006	Jun CAHN
AB		50MG	A077636	002	Jul 27, 2006	Jun CAHN
AB		100MG	A077636	001	Dec 22, 2005	Jun CAHN
AB	UNICHEM	25MG	A214492	001	Jan 26, 2021	Jan NEWA
AB		50MG	A214492	002	Jan 26, 2021	Jan NEWA
AB		100MG	A214492	003	Jan 26, 2021	Jan NEWA

ACETAMINOPHEN

SUPPOSITORY;RECTAL  
NEOPAP

@ POLYMEDICA 120MG N016401 001 Sep DISC

TABLET, EXTENDED RELEASE;ORAL  
ACETAMINOPHEN

MARKSANS PHARMA 650MG A215486 001 Aug 25, 2021 Aug NEWA

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET;ORAL  
ACETAMINOPHEN, ASPIRIN AND CAFFEINE

GRANULES 250MG;250MG;65MG A214039 001 Feb 23, 2021 Feb NEWA

ASPIRIN

CAPSULE;ORAL  
VAZALORE

+ PLX PHARMA 81MG N203697 002 Feb 26, 2021 Jun NEWA

AZELASTINE HYDROCHLORIDE

SPRAY, METERED;NASAL  
ASTEPRO ALLERGY

+! BAYER HLTHCARE 0.2055MG/SPRAY N213872 001 Jun 17, 2021 Jun NEWA

CHILDREN'S ASTEPRO ALLERGY

+! BAYER HLTHCARE 0.2055MG/SPRAY N213872 002 Jun 17, 2021 Jun NEWA

BUDESONIDE

SPRAY, METERED;NASAL  
RHINOCORT ALLERGY

+! J AND J CONSUMER INC 0.032MG/SPRAY N020746 003 Mar 23, 2015 Mar CAHN

CETIRIZINE HYDROCHLORIDE

CAPSULE;ORAL  
CETIRIZINE HYDROCHLORIDE ALLERGY

APOTEX 10MG A207235 001 Aug 12, 2016 Mar CMFD

@ 10MG A207235 001 Aug 12, 2016 Jan DISC

CATALENT 10MG A213105 001 Sep 21, 2020 Oct CMFD

SYRUP;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

MICRO LABS 5MG/5ML A091327 001 Oct 17, 2011 Sep CAHN

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

MICRO LABS 5MG/5ML A091327 002 Oct 17, 2011 Sep CAHN

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

@ CIPLA LTD 5MG A077318 001 Jul 25, 2013 May DISC

@ 10MG A077318 002 Jul 25, 2013 May DISC

TABLET, CHEWABLE;ORAL

CHILDREN'S ZYRTEC ALLERGY

+ @ J AND J CONSUMER INC 2.5MG N021621 007 Nov 30, 2020 Apr DISC

CHLORHEXIDINE GLUCONATE

SOLUTION;TOPICAL

>D> BRIAN CARE

>D> SOAPCO 4% A071419 001 Dec 17, 1987 Nov DISC

>A> @ 4% A071419 001 Dec 17, 1987 Nov DISC

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL  
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE

SUN PHARM 30MG;600MG A214781 001 Jul 01, 2021 Jun NEWA

60MG;1.2GM A214781 002 Jul 01, 2021 Jun NEWA

DICLOFENAC SODIUM

GEL;TOPICAL

DICLOFENAC SODIUM

AUROLIFE PHARMA LLC 1% A204306 001 May 06, 2019 May CAHN

PERRIGO 1% A211253 001 May 16, 2019 Jun CAHN

PERRIGO PHARMA INTL 1% A211253 001 May 16, 2019 Jul CAHN

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

ANNORA PHARMA	10MG	A215766	001	Nov 08, 2021	Oct	NEWA
	20MG	A215766	002	Nov 08, 2021	Oct	NEWA
ASCENT PHARMS INC	10MG	A216030	001	Nov 03, 2021	Oct	NEWA
	20MG	A216030	002	Nov 03, 2021	Oct	NEWA

FEXOFENADINE HYDROCHLORIDE

SUSPENSION; ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

TARO	30MG/5ML	A208123	001	Nov 09, 2017	Jun	CMFD
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES						
TARO	30MG/5ML	A208123	002	Nov 09, 2017	Jun	CMFD

TABLET; ORAL

FEXOFENADINE HYDROCHLORIDE

L PERRIGO CO	60MG	A212971	001	Feb 24, 2020	Jun	CMFD
	180MG	A212971	002	Feb 24, 2020	Jun	CMFD

FLUTICASONE PROPIONATE

SPRAY, METERED; NASAL

FLONASE ALLERGY RELIEF

+ GLAXOSMITHKLINE CONS	0.05MG/SPRAY	N205434	001	Jul 23, 2014	Apr	CHRS
FLUTICASONE PROPIONATE						
! HIKMA	0.05MG/SPRAY	A207957	001	May 26, 2016	Apr	CHRS

GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL

GUAIFENESIN

OHM LABS INC	600MG	A209254	001	Jul 16, 2018	Aug	CMFD
	1.2GM	A209254	002	Jul 16, 2018	Aug	CMFD

IBUPROFEN

SUSPENSION; ORAL

IBUPROFEN

GUARDIAN DRUG	100MG/5ML	A210149	001	Aug 17, 2018	Jan	CMFD
@ STRIDES PHARMA	100MG/5ML	A211666	001	Feb 22, 2021	Aug	DISC
	100MG/5ML	A211666	001	Feb 22, 2021	Feb	NEWA

TABLET; ORAL

>D>	IBU-TAB 200						
>D>	ALRA	200MG	A071057	001	Aug 11, 1988	Nov	DISC
>A>	@	200MG	A071057	001	Aug 11, 1988	Nov	DISC
	IBUPROFEN						
	@ YICHANG HUMANWELL	200MG	A214003	001	Oct 19, 2020	Apr	DISC

ISOPROPYL ALCOHOL

SOLUTION; TOPICAL

ZURAGARD

+ @ ZUREX PHARMA	70%	N210872	001	Apr 26, 2019	Jul	CPOT
------------------	-----	---------	-----	--------------	-----	------

IVERMECTIN

LOTION; TOPICAL

IVERMECTIN

TARO	0.5%	A210720	001	May 06, 2020	May	CMKT
------	------	---------	-----	--------------	-----	------

KETOCONAZOLE

SHAMPOO; TOPICAL

NIZORAL ANTI-DANDRUFF

+! KRAMER	1%	N020310	001	Oct 10, 1997	Feb	CTNA
-----------	----	---------	-----	--------------	-----	------

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

APOTEX	5MG	A211443	001	Apr 21, 2021	Apr	NEWA
--------	-----	---------	-----	--------------	-----	------

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

LOPERAMIDE HYDROCHLORIDE

STRIDES PHARMA

2MG

A213070 001 Aug 11, 2021 Jul NEWA

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET;ORAL

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

BIONPHARMA INC

2MG;125MG

A213484 001 Sep 10, 2021 Sep NEWA

GUARDIAN DRUG

2MG;125MG

A214541 001 May 27, 2021 May NEWA

HETERO LABS LTD V

2MG;125MG

A211438 001 Jun 17, 2021 Jun NEWA

LORATADINE

SYRUP;ORAL

LORATADINE

HETERO LABS LTD III

1MG/ML

A210409 001 May 07, 2021 Apr NEWA

TABLET;ORAL

LORATADINE

APPCO

10MG

A207569 001 Mar 12, 2019 Sep CAHN

UNIQUE PHARM

10MG

A214684 001 Jan 07, 2021 Jan NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

LORATADINE

@ GLAXOSMITHKLINE

10MG

A075822 001 Feb 10, 2003 Jan DISC

TENSHI

5MG

A212795 001 Sep 18, 2020 Jun CMFD

@

5MG

A212795 001 Sep 18, 2020 Mar DISC

10MG

A213294 001 Oct 30, 2020 Jun CMFD

@

10MG

A213294 001 Oct 30, 2020 Mar DISC

MICONAZOLE NITRATE

CREAM, INSERT;TOPICAL, VAGINAL

MICONAZOLE NITRATE

PERRIGO R AND D

2%,1.2GM

A079114 001 Jun 02, 2010 Jul CDFR

MONISTAT 1 COMBINATION PACK

+! MEDTECH PRODUCTS

2%,1.2GM

N021308 001 Jun 29, 2001 Jul CDFR

CREAM, SUPPOSITORY;TOPICAL, VAGINAL

MICONAZOLE NITRATE COMBINATION PACK

L PERRIGO CO

2%,200MG

A075329 001 Apr 20, 1999 Sep CAHN

MINOXIDIL

AEROSOL, FOAM;TOPICAL

MINOXIDIL

PERRIGO

5%

A091344 001 Apr 28, 2011 Jul CAHN

SOLUTION;TOPICAL

MINOXIDIL EXTRA STRENGTH (FOR MEN)

>D>

AVACOR PRODS

5%

A075619 001 Nov 17, 2000 Nov DISC

>D>

@

5%

A075619 001 Nov 17, 2000 Nov DISC

>A>

NICOTINE POLACRILEX

TROCHE/LOZENGE;ORAL

NICORETTE

+ GLAXOSMITHKLINE

EQ 2MG BASE

N022360 001 May 18, 2009 Mar CAHN

+!

NICOTINE POLACRILEX

EQ 4MG BASE

N022360 002 May 18, 2009 Mar CAHN

AUROBINDO PHARMA LTD

EQ 2MG BASE

A213266 001 Aug 03, 2021 Jul NEWA

EQ 4MG BASE

A213266 002 Aug 03, 2021 Jul NEWA

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

AKORN

EQ 0.1% BASE

A204532 001 Jan 10, 2017 Jun CMKT

EQ 0.2% BASE

A204723 001 Dec 05, 2017 Jun CMKT

ALEMBIC PHARMS LTD

EQ 0.1% BASE

A209919 001 Dec 07, 2018 Feb CMKT

EQ 0.2% BASE

A209420 001 Apr 29, 2019 Jan CMKT

APOTEX INC

EQ 0.2% BASE

A090918 001 Dec 05, 2017 Jan CMKT

BARR LABS INC

EQ 0.2% BASE

A090848 001 Jul 13, 2015 Feb CMKT

@ BAUSCH

EQ 0.1% BASE

A206046 001 Jul 26, 2017 Jun CAHN

@ CIPLA

EQ 0.2% BASE

A206087 001 Dec 05, 2017 Mar CMKT

@ FDC LTD

EQ 0.1% BASE

A209282 001 Sep 26, 2019 Oct DISC

EQ 0.1% BASE

A209282 001 Sep 26, 2019 Feb CMKT

MYLAN

EQ 0.2% BASE

A204620 001 Jun 16, 2020 Jun CAHN

USV

EQ 0.1% BASE

A203152 001 Dec 07, 2015 Apr CMKT

SOLUTION/DROPS;OPHTHALMIC  
OLOPATADINE HYDROCHLORIDE

@ WOCHKHARDT LTD EQ 0.1% BASE A200810 001 Jun 28, 2017 Aug CMKT

OMEPRAZOLE

TABLET, DELAYED RELEASE;ORAL  
OMEPRAZOLE

APOTEX 20MG A210070 001 Feb 11, 2019 May CMFD

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL  
POLYETHYLENE GLYCOL 3350

ANNORA PHARMA 17GM/SCOOPFUL A214990 001 Apr 14, 2021 Apr NEWA

POTASSIUM IODIDE

SOLUTION;ORAL  
POTASSIUM IODIDE

>D> MISSION PHARMACAL CO 65MG/ML A206211 001 Mar 24, 2016 Nov CHRS  
>A> ! 65MG/ML A206211 001 Mar 24, 2016 Nov CHRS

>D> THYROSHIELD

>D> ! ARCO PHARMS LLC 65MG/ML A077218 001 Jan 12, 2005 Nov DISC

>A> @ 65MG/ML A077218 001 Jan 12, 2005 Nov DISC

TABLET;ORAL  
THYROSAFE

! BTG INTL 65MG A076350 001 Sep 10, 2002 Sep CAHN

RANITIDINE HYDROCHLORIDE

TABLET;ORAL  
RANITIDINE HYDROCHLORIDE

@ AUROBINDO PHARMA LTD EQ 75MG BASE A207579 001 Nov 13, 2017 Jun DISC

@ EQ 150MG BASE A207578 001 Nov 13, 2017 Jun DISC

@ WOCHKHARDT EQ 75MG BASE A076760 001 Feb 24, 2006 Jan DISC

ZANTAC 150

+ @ SANOFI US EQ 150MG BASE N021698 001 Aug 31, 2004 Apr DISC

+ @ EQ 150MG BASE N021698 002 Mar 13, 2007 Apr DISC

ZANTAC 75

+ @ SANOFI US EQ 75MG BASE N020520 001 Dec 19, 1995 Apr DISC

TRIAMCINOLONE ACETONIDE

SPRAY, METERED;NASAL  
TRIAMCINOLONE ACETONIDE

PERRIGO 0.055MG/SPRAY A078104 002 Nov 14, 2014 Jul CAHN

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT  
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND  
RESEARCH LIST**

**CUMULATIVE SUPPLEMENT NUMBER 11 NOVEMBER 2021**

NO NOVEMBER 2021 APPROVALS

## ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

[https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.](https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products)

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY  
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO NOVEMBER 2021 ADDITIONS



PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABALOPARATIDE - TYMLOS</u>						
N 208743 001	10996208	Apr 30, 2038	DP		M-270	Sep 20, 2024
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 001	7855211	Dec 15, 2029	DS DP U-2132		>A> I-877	Oct 12, 2024
	7855211	Dec 15, 2029	DS DP U-2135		>A> NPP	Oct 12, 2024
	7855211	Dec 15, 2029	DS DP U-2251			
	7855211	Dec 15, 2029	DS DP U-3241			
	7855211	Dec 15, 2029	DS DP U-3242			
	7855211	Dec 15, 2029	DS DP U-3243			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 002	7855211	Dec 15, 2029	DS DP U-2132		>A> I-877	Oct 12, 2024
	7855211	Dec 15, 2029	DS DP U-2135		>A> NPP	Oct 12, 2024
	7855211	Dec 15, 2029	DS DP U-2251			
	7855211	Dec 15, 2029	DS DP U-3241			
	7855211	Dec 15, 2029	DS DP U-3242			
	7855211	Dec 15, 2029	DS DP U-3243			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 003	7855211	Dec 15, 2029	DS DP U-2132		>A> I-877	Oct 12, 2024
	7855211	Dec 15, 2029	DS DP U-2135		>A> NPP	Oct 12, 2024
	7855211	Dec 15, 2029	DS DP U-2251			
	7855211	Dec 15, 2029	DS DP U-3241			
	7855211	Dec 15, 2029	DS DP U-3242			
	7855211	Dec 15, 2029	DS DP U-3243			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 004					>A> I-877	Oct 12, 2024
					>A> NPP	Oct 12, 2024
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450 001	11000517	Mar 13, 2029	DP U-2513			
<u>ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE - DUAKLIR PRESSAIR</u>						
N 210595 001	11000517	Mar 13, 2029	DP U-2513			
<u>ALBUTEROL SULFATE - PROAIR DIGIHALER</u>						
N 205636 002	10918816	Dec 14, 2035	DP			
	11000653	Dec 18, 2038	DP			
	>A> 11173259	Jul 06, 2040	DP			
<u>ALENDRONATE SODIUM - BINOSTO</u>						
N 202344 001	9592195	Dec 05, 2031	DP			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 001	11065213	Aug 23, 2038	DP			
	11077073	Aug 23, 2038	U-2106			
	11077073	Aug 23, 2038	U-2224			
	11077073	Aug 23, 2038	U-3180			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 002	11065213	Aug 23, 2038	DP			
	11077073	Aug 23, 2038	U-2106			
	11077073	Aug 23, 2038	U-2224			
	11077073	Aug 23, 2038	U-3180			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 001	8389578	Jan 22, 2028	U-219			
	8389578	Jan 22, 2028	U-3054			
	8796337	Nov 23, 2025	U-219			
	8796337	Nov 23, 2025	U-2497			
	8796337	Nov 23, 2025	U-3054			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 001	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025		U-219		
	8895615	Nov 23, 2025		U-3054		
	8895616	Nov 23, 2025		U-219		
	8895616	Nov 23, 2025		U-3054		
	8895617	Nov 23, 2025		U-219		
	8895617	Nov 23, 2025		U-3054		
	8895618	Nov 23, 2025	DP			
	8987333	Nov 23, 2025	DP			
	9072697	Nov 23, 2025		U-219		
	9072697	Nov 23, 2025		U-3054		
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 002	8389578	Jan 22, 2028		U-219		
	8389578	Jan 22, 2028		U-3054		
	8796337	Nov 23, 2025		U-219		
	8796337	Nov 23, 2025		U-2497		
	8796337	Nov 23, 2025		U-3054		
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025		U-219		
	8895615	Nov 23, 2025		U-3054		
	8895616	Nov 23, 2025		U-219		
	8895616	Nov 23, 2025		U-3054		
	8895617	Nov 23, 2025		U-219		
	8895617	Nov 23, 2025		U-3054		
	8895618	Nov 23, 2025	DP			
	8987333	Nov 23, 2025	DP			
	9072697	Nov 23, 2025		U-219		
	9072697	Nov 23, 2025		U-3054		
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 003	8389578	Jan 22, 2028		U-219		
	8389578	Jan 22, 2028		U-3054		
	8796337	Nov 23, 2025		U-219		
	8796337	Nov 23, 2025		U-2497		
	8796337	Nov 23, 2025		U-3054		
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025		U-219		
	8895615	Nov 23, 2025		U-3054		
	8895616	Nov 23, 2025		U-219		
	8895616	Nov 23, 2025		U-3054		
	8895617	Nov 23, 2025		U-219		
	8895617	Nov 23, 2025		U-3054		
	8895618	Nov 23, 2025	DP			
	8987333	Nov 23, 2025	DP			
	9072697	Nov 23, 2025		U-219		
	9072697	Nov 23, 2025		U-3054		
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 004	8389578	Jan 22, 2028		U-219		
	8389578	Jan 22, 2028		U-3054		
	8796337	Nov 23, 2025		U-219		
	8796337	Nov 23, 2025		U-2497		
	8796337	Nov 23, 2025		U-3054		
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025		U-219		
	8895615	Nov 23, 2025		U-3054		
	8895616	Nov 23, 2025		U-219		
	8895616	Nov 23, 2025		U-3054		
	8895617	Nov 23, 2025		U-219		
	8895617	Nov 23, 2025		U-3054		
	8895618	Nov 23, 2025	DP			
	8987333	Nov 23, 2025	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 004	9072697	Nov 23, 2025	U-219			
	9072697	Nov 23, 2025	U-3054			
<u>AMIFAMPRIDINE PHOSPHATE - FIRDAPSE</u>						
N 208078 001	11060128	Jun 29, 2032	U-2956			
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN</u>						
N 020965 001	10357567	Jan 12, 2038	U-3163			
	11077192	Jan 12, 2038	U-3163			
	11135293	Jan 12, 2038	U-3163			
<u>AMLODIPINE BENZOATE - KATERZIA</u>						
N 211340 001	10894039	Oct 06, 2037	U-185			
	10894039	Oct 06, 2037	U-3			
	10952998	Oct 06, 2037	DP			
	10959991	Oct 06, 2037	U-158			
	10959991	Oct 06, 2037	U-39			
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045 001	10925835	Jun 14, 2038	U-2410			
	10945960	Jun 14, 2038	DP			
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045 002	10925835	Jun 14, 2038	U-2410			
	10945960	Jun 14, 2038	DP			
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045 003	10925835	Jun 14, 2038	U-2410			
	10945960	Jun 14, 2038	DP			
<u>AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN - TALICIA</u>						
N 213004 001	11135172	Feb 12, 2034	DP U-2660			
<u>AMPHETAMINE - DYANAVEL XR</u>						
N 210526 001	>A> 8337890	Mar 15, 2027	DP			
	>A> 8747902	Mar 15, 2027	DP			
	>A> 9675704	Mar 15, 2027	DP			
<u>AMPHETAMINE - DYANAVEL XR</u>						
N 210526 002	>A> 8337890	Mar 15, 2027	DP			
	>A> 8747902	Mar 15, 2027	DP			
	>A> 9675704	Mar 15, 2027	DP			
<u>AMPHETAMINE - DYANAVEL XR</u>						
N 210526 003	>A> 8337890	Mar 15, 2027	DP			
	>A> 8747902	Mar 15, 2027	DP			
	>A> 9675704	Mar 15, 2027	DP			
<u>AMPHETAMINE - DYANAVEL XR</u>						
N 210526 004	>A> 8337890	Mar 15, 2027	DP			
	>A> 8747902	Mar 15, 2027	DP			
	>A> 9675704	Mar 15, 2027	DP			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 005	10130580	Apr 19, 2024	DP			
	10441554	Mar 10, 2037	DP			
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 001	11096983	Dec 18, 2034	U-3211			
	11096983	Dec 18, 2034	U-3212			
	>A> 9572856	Jul 18, 2031	U-2221			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 002	11096983	Dec 18, 2034	U-3211			
	11096983	Dec 18, 2034	U-3212			
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 001	9481663	Jun 04, 2033	DS			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 001	10888499	Feb 14, 2022	DP			
	10959943	Apr 19, 2036	U-2825			
	11077068	Feb 14, 2022	DP			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 002	10888499	Feb 14, 2022	DP			
	10959943	Apr 19, 2036	U-2825			
	11077068	Feb 14, 2022	DP			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 003	10888499	Feb 14, 2022	DP			
	10959943	Apr 19, 2036	U-2825			
	11077068	Feb 14, 2022	DP			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 004	10888499	Feb 14, 2022	DP			
	10959943	Apr 19, 2036	U-2825			
	11077068	Feb 14, 2022	DP			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 005	10888499	Feb 14, 2022	DP			
	10959943	Apr 19, 2036	U-2825			
	11077068	Feb 14, 2022	DP			
<u>APREPITANT - CINVANTI</u>						
N 209296 001	10953018	Sep 18, 2035	U-2161			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001	10980803	Sep 24, 2033	U-1632			
	10980803	Sep 24, 2033	U-543			
	>A> 11154553	Sep 24, 2033	U-1632			
	>A> 11154553	Sep 24, 2033	U-3245			
	>A> 11154553	Sep 24, 2033	U-814			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002	10980803	Sep 24, 2033	U-1632			
	10980803	Sep 24, 2033	U-543			
	>A> 11154553	Sep 24, 2033	U-1632			
	>A> 11154553	Sep 24, 2033	U-3245			
	>A> 11154553	Sep 24, 2033	U-814			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 003	10980803	Sep 24, 2033	U-1632			
	10980803	Sep 24, 2033	U-543			
	>A> 11154553	Sep 24, 2033	U-1632			
	>A> 11154553	Sep 24, 2033	U-3245			
	>A> 11154553	Sep 24, 2033	U-814			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 004	10980803	Sep 24, 2033	U-1632			
	10980803	Sep 24, 2033	U-543			
	>A> 11154553	Sep 24, 2033	U-1632			
	>A> 11154553	Sep 24, 2033	U-3245			
	>A> 11154553	Sep 24, 2033	U-814			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 001	11097006	Oct 24, 2033	DP U-764			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 002	11097006	Oct 24, 2033	DP U-764			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 003	11097006	Oct 24, 2033	DP U-764			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 004	11097006	Oct 24, 2033	DP U-764			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA INITIO KIT</u>						
N 209830 001	11154552	Aug 17, 2035	DP			
<u>ASCIMINIB HYDROCHLORIDE - SCEMBLIX</u>						
N 215358 001	>A> 8829195	May 13, 2033	DS U-3249		>A> NCE	Oct 29, 2026
<u>ASCIMINIB HYDROCHLORIDE - SCEMBLIX</u>						
N 215358 002	>A> 8829195	May 13, 2033	DS U-3249		>A> NCE	Oct 29, 2026
<u>ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - PLENVU</u>						
N 209381 001	10918723	Sep 10, 2033	U-2310			
<u>ASENAPINE - SECUADO</u>						
N 212268 001	11123305	Jul 25, 2033	DP			
<u>ASENAPINE - SECUADO</u>						
N 212268 002	11123305	Jul 25, 2033	DP			
<u>ASENAPINE - SECUADO</u>						
N 212268 003	11123305	Jul 25, 2033	DP			
<u>ASENAPINE MALEATE - ASENAPINE MALEATE</u>						
A 206098 002					PC	Jun 08, 2021
<u>ATOGEPAANT - QULIPTA</u>						
N 215206 001	10117836	Jan 30, 2035	DP		NCE	Sep 28, 2026
	8754096	Jul 19, 2032	DS DP U-3142			
	9499545	Nov 10, 2031	DS DP U-3142			
	9850246	Mar 13, 2033	DS			
<u>ATOGEPAANT - QULIPTA</u>						
N 215206 002	10117836	Jan 30, 2035	DP		NCE	Sep 28, 2026
	8754096	Jul 19, 2032	DS DP U-3142			
	9499545	Nov 10, 2031	DS DP U-3142			
	9850246	Mar 13, 2033	DS			
<u>ATOGEPAANT - QULIPTA</u>						
N 215206 003	10117836	Jan 30, 2035	DP		NCE	Sep 28, 2026
	8754096	Jul 19, 2032	DS DP U-3142			
	9499545	Nov 10, 2031	DS DP U-3142			
	9850246	Mar 13, 2033	DS			
<u>ATROPINE SULFATE - ATROPINE SULFATE</u>						
A 212868 001					CGT	Jan 26, 2022
<u>ATROPINE SULFATE - ATROPINE SULFATE</u>						
A 212868 002					CGT	Jan 26, 2022

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ATROPINE SULFATE - ATROPINE SULFATE</u>						
A 212868	003				CGT	Jan 26, 2022
<u>ATROPINE SULFATE - ATROPINE SULFATE</u>						
A 213424	001				CGT	Sep 21, 2021
<u>ATROPINE SULFATE - ATROPINE SULFATE</u>						
A 215624	001				>A> CGT	May 25, 2022
<u>AVACOPAN - TAVNEOS</u>						
N 214487	001	8445515	Feb 03, 2031	DS DP	NCE	Oct 07, 2026
		8906938	Dec 21, 2029	DS DP		
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608	001	9200002	Oct 15, 2034	DS DP U-2726	I-863	Jun 16, 2024
		9200002	Oct 15, 2034	DS DP U-3168	I-864	Jun 16, 2024
		9944651	Oct 15, 2034	DS DP U-2726	ODE-356	Jun 16, 2028
		9944651	Oct 15, 2034	DS DP U-3168		
		9994575	Oct 15, 2034	DS DP U-2726		
		9994575	Oct 15, 2034	DS DP U-3168		
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608	002	9200002	Oct 15, 2034	DS DP U-2726	I-863	Jun 16, 2024
		9200002	Oct 15, 2034	DS DP U-3168	I-864	Jun 16, 2024
		9944651	Oct 15, 2034	DS DP U-2726	ODE-356	Jun 16, 2028
		9944651	Oct 15, 2034	DS DP U-3168		
		9994575	Oct 15, 2034	DS DP U-2726		
		9994575	Oct 15, 2034	DS DP U-3168		
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608	003				ODE-356	Jun 16, 2028
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608	004	9200002	Oct 15, 2034	DS DP U-3168	I-863	Jun 16, 2024
		9944651	Oct 15, 2034	DS DP U-3168	I-864	Jun 16, 2024
		9994575	Oct 15, 2034	DS DP U-3168	NCE	Jan 09, 2025
					ODE-356	Jun 16, 2028
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608	005	9200002	Oct 15, 2034	DS DP U-3168	I-863	Jun 16, 2024
		9944651	Oct 15, 2034	DS DP U-3168	I-864	Jun 16, 2024
		9994575	Oct 15, 2034	DS DP U-3168	NCE	Jan 09, 2025
					ODE-356	Jun 16, 2028
<u>AXITINIB - INLYTA</u>						
N 202324	001	10869924	Nov 05, 2036	U-3044		
<u>AXITINIB - INLYTA</u>						
N 202324	002	10869924	Nov 05, 2036	U-3044		
<u>AZACITIDINE - ONUREG</u>						
N 214120	001				ODE-320	Sep 01, 2027
<u>AZACITIDINE - ONUREG</u>						
N 214120	002				ODE-320	Sep 01, 2027
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO ALLERGY</u>						
N 213872	001	8071073	Jun 04, 2028	DP		
		8518919	Nov 22, 2025	U-3166		
		9919050	Nov 22, 2025	DP		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AZELASTINE HYDROCHLORIDE - CHILDREN'S ASTEPRO ALLERGY</u>						
N 213872 002	8071073	Jun 04, 2028	DP			
	8518919	Nov 22, 2025	U-3166			
	9919050	Nov 22, 2025	DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 003	10392406	Apr 27, 2036	DS		I-811	Oct 16, 2022
	10633397	Apr 27, 2036	U-2816		NCE	Oct 24, 2023
	10633397	Apr 27, 2036	U-3000			
	10759814	Aug 09, 2037	DS DP			
	8927710	May 05, 2031	DP			
	8987441	Sep 21, 2031	DS DP			
	9815835	Jun 14, 2030	DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 214410 001					NCE	Oct 24, 2023
<u>BARICITINIB - OLUMIANT</u>						
N 207924 002					>A> NCE	May 31, 2023
<u>BELINOSTAT - BELEODAO</u>						
N 206256 001	6888027	Aug 10, 2026	DS DP U-1544			
<u>BELUMOSUDIL MESYLATE - REZUROCK</u>						
N 214783 001	>A> 10183931	Oct 07, 2033	U-3246		NCE	Jul 16, 2026
	>A> 10696660	Oct 07, 2033	U-3246		ODE-362	Jul 16, 2028
	>A> 8357693	Oct 30, 2029	DS DP U-3247			
	>A> 9815820	Oct 07, 2033	U-3247			
<u>BELZUTIFAN - WELIREG</u>						
N 215383 001	9908845	Sep 05, 2034	DS DP U-3201		NCE	Aug 13, 2026
	9969689	Sep 05, 2034	DS DP U-3201		ODE-364	Aug 13, 2028
<u>BEMPEDOIC ACID - NEXLETOL</u>						
N 211616 001	10941095	Dec 23, 2023	U-2747			
<u>BEMPEDOIC ACID; EZETIMIBE - NEXLIZET</u>						
N 211617 001	10912751	Mar 14, 2036	U-3224			
	10941095	Dec 23, 2023	U-2746			
<u>BENDAMUSTINE HYDROCHLORIDE - BELRAPZO</u>						
N 205580 001	11103483	Jan 28, 2031	DP U-1971			
	11103483	Jan 28, 2031	DP U-1972			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	11103483	Jan 28, 2031	DP U-1971			
	11103483	Jan 28, 2031	DP U-1972			
<u>BENZOYL PEROXIDE; TRETINOIN - TWYNEO</u>						
N 214902 001	>A> 10420743	Jul 12, 2038	U-3194		NC	Jul 26, 2024
	>A> 10653899	Dec 30, 2030	DP U-3194			
	11071878	Dec 30, 2030	DP			
	>A> 8617580	Feb 03, 2028	DP			
	9868103	Aug 08, 2028	DP U-3194			
<u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYO</u>						
N 214094 001	10125102	Apr 07, 2035	DS U-3010		NCE	Dec 03, 2025
	11117867	Nov 01, 2039	DP U-3010		ODE-333	Dec 03, 2027
<u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYO</u>						
N 214094 002	10125102	Apr 07, 2035	DS U-3010		NCE	Dec 03, 2025
	11117867	Nov 01, 2039	DP U-3010		ODE-333	Dec 03, 2027

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 001	7390791	Apr 17, 2025	DS DP		M-82	Feb 24, 2024
	7390791*PED	Oct 17, 2025				
	8754065	Aug 15, 2032	DS DP U-257			
	8754065*PED	Feb 15, 2033				
	9296769	Aug 15, 2032	DS DP U-257			
	9296769*PED	Feb 15, 2033				
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 002	10385067	Jun 19, 2035		U-257		
	7390791	Apr 17, 2025	DS DP			
	7803788	Feb 02, 2022		U-257		
	8754065	Aug 15, 2032	DS DP U-257			
	9216996	Dec 19, 2033	DS DP			
	9296769	Aug 15, 2032	DS DP U-257			
	9708342	Jun 19, 2035	DS DP			
	9732092	Dec 19, 2033	DS DP			
<u>BOSENTAN - TRACLEER</u>						
N 021290 001					ODE*	Sep 05, 2024
<u>BOSENTAN - TRACLEER</u>						
N 021290 002					ODE*	Sep 05, 2024
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 001	11103497	Feb 28, 2034		U-3216		
	11103497	Feb 28, 2034		U-3217		
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 002	11103497	Feb 28, 2034		U-3216		
	11103497	Feb 28, 2034		U-3217		
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 003	11103497	Feb 28, 2034		U-3216		
	11103497	Feb 28, 2034		U-3217		
<u>BREMELANOTIDE ACETATE - VYLEESI (AUTOINJECTOR)</u>						
N 210557 001	6794489	Jun 28, 2025	DS DP			
<u>BREXANOLONE - ZULRESSO</u>						
N 211371 001	10940156	Mar 08, 2037		U-2552		
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 001	RE48059	Dec 23, 2028	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 002	RE48059	Dec 23, 2028	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 003	RE48059	Dec 23, 2028	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 004	RE48059	Dec 23, 2028	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 005	RE48059	Dec 23, 2028	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 006	RE48059	Dec 23, 2028	DS			
<u>BRIMONIDINE TARTRATE - LUMIFY</u>						
N 208144 001	9259425	Jul 14, 2030		U-2222		



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BRINCIDOFOVIR - TEMBEXA</u>						
N 214460 001	9303051	Aug 31, 2031	DS DP U-3165		NP ODE-354	Jun 04, 2024 Jun 04, 2028
<u>BRINCIDOFOVIR - TEMBEXA</u>						
N 214461 001	10112909	Oct 10, 2034	U-3165		NP	Jun 04, 2024
	10487061	Oct 10, 2034	DP U-3165		ODE-354	Jun 04, 2028
	8962829	Oct 10, 2034	DS DP			
	9303051	Aug 31, 2031	DS DP U-3165			
	9371344	Oct 10, 2034	DP			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 001					NPP NPP	May 10, 2021 Aug 27, 2024
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 002					NPP NPP	May 10, 2021 Aug 27, 2024
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 003					NPP NPP	May 10, 2021 Aug 27, 2024
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 004					NPP NPP	May 10, 2021 Aug 27, 2024
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 005					NPP NPP	May 10, 2021 Aug 27, 2024
<u>BRIVARACETAM - BRIVIACT</u>						
N 205837 001					NPP	Aug 27, 2024
<u>BRIVARACETAM - BRIVIACT</u>						
N 205838 001					NPP NPP	May 10, 2021 Aug 27, 2024
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	11000522	Apr 30, 2032	U-3119			
	11000522	Apr 30, 2032	U-3120			
	11000522	Apr 30, 2032	U-3121			
	11000522	Apr 30, 2032	U-3122			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 001	11033495	Jan 22, 2041	DP U-3182		NPP	Mar 22, 2024
	>A> 11179336	Jan 22, 2041	DP U-3250			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 002	11033495	Jan 22, 2041	DP U-3182		NPP	Mar 22, 2024
	>A> 11179336	Jan 22, 2041	DP U-3250			
<u>BUPIVACAINE - POSIMIR</u>						
N 204803 001	8153149	Sep 15, 2025	DP		NP	Feb 01, 2024
	8153661	Sep 15, 2025	U-3074			
	8753665	Sep 15, 2025	DP U-3074			
	8846072	Sep 15, 2025	DP U-3074			
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 001	10098957	Apr 20, 2035	U-3118		NP	May 12, 2024
	10213510	Apr 20, 2035	DP U-3118			
	10398686	Mar 13, 2034	DP			
	10632199	Apr 20, 2035	DP U-3118			
	10898575	Apr 20, 2035	DP U-3118			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 001	10980886	Apr 20, 2035	DP			
	11083730	Apr 20, 2035	DP U-3118			
	11083797	Apr 20, 2035	DP U-3118			
	9592227	Mar 13, 2034	DP U-3118			
	9694079	Apr 20, 2035	DP U-3118			
	9744163	Mar 13, 2034	DP			
	9801945	Apr 20, 2035	DP U-3118			
	9913909	Mar 13, 2034	U-3118			
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 002	10098957	Apr 20, 2035	U-3118		NP	May 12, 2024
	10213510	Apr 20, 2035	DP U-3118			
	10398686	Mar 13, 2034	DP			
	10632199	Apr 20, 2035	DP U-3118			
	10898575	Apr 20, 2035	DP U-3118			
	10980886	Apr 20, 2035	DP			
	11083730	Apr 20, 2035	DP U-3118			
	11083797	Apr 20, 2035	DP U-3118			
	9592227	Mar 13, 2034	DP U-3118			
	9694079	Apr 20, 2035	DP U-3118			
	9744163	Mar 13, 2034	DP			
	9801945	Apr 20, 2035	DP U-3118			
	9913909	Mar 13, 2034	U-3118			
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 003	10098957	Apr 20, 2035	U-3118		NP	May 12, 2024
	10213510	Apr 20, 2035	DP U-3118			
	10398686	Mar 13, 2034	DP			
	10632199	Apr 20, 2035	DP U-3118			
	10898575	Apr 20, 2035	DP U-3118			
	10980886	Apr 20, 2035	DP			
	11083730	Apr 20, 2035	DP U-3118			
	11083797	Apr 20, 2035	DP U-3118			
	9592227	Mar 13, 2034	DP U-3118			
	9694079	Apr 20, 2035	DP U-3118			
	9744163	Mar 13, 2034	DP			
	9801945	Apr 20, 2035	DP U-3118			
	9913909	Mar 13, 2034	U-3118			
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 004	10098957	Apr 20, 2035	U-3118		NP	May 12, 2024
	10213510	Apr 20, 2035	DP U-3118			
	10398686	Mar 13, 2034	DP			
	10632199	Apr 20, 2035	DP U-3118			
	10898575	Apr 20, 2035	DP U-3118			
	10980886	Apr 20, 2035	DP			
	11083730	Apr 20, 2035	DP U-3118			
	11083797	Apr 20, 2035	DP U-3118			
	9592227	Mar 13, 2034	DP U-3118			
	9694079	Apr 20, 2035	DP U-3118			
	9744163	Mar 13, 2034	DP			
	9801945	Apr 20, 2035	DP U-3118			
	9913909	Mar 13, 2034	U-3118			
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 001	11000520	Nov 06, 2035	U-3111			
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 002	11000520	Nov 06, 2035	U-3111			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 001	11135216	Aug 07, 2029	DP U-3111			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 002	11135216	Aug 07, 2029	DP U-3111			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 003	11135216	Aug 07, 2029	DP U-3111			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 004	11135216	Aug 07, 2029	DP U-3111			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001	10946010	Sep 18, 2032	DP			
	11020388	Sep 18, 2032	DP U-3131			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	10874661	Sep 18, 2032	DP			
	10946010	Sep 18, 2032	DP			
	11020387	Sep 18, 2032	DP U-3131			
	11020388	Sep 18, 2032	DP U-3131			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 003	10946010	Sep 18, 2032	DP			
	11020387	Sep 18, 2032	DP U-3131			
	11020388	Sep 18, 2032	DP U-3131			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 004	10946010	Sep 18, 2032	DP			
	11020387	Sep 18, 2032	DP U-3131			
	11020388	Sep 18, 2032	DP U-3131			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 005	10946010	Sep 18, 2032	DP			
	11020387	Sep 18, 2032	DP U-3131			
	11020388	Sep 18, 2032	DP U-3131			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 006	10946010	Sep 18, 2032	DP			
	11020388	Sep 18, 2032	DP U-3131			
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063 001	10403170	Jun 05, 2033	U-1583			
	11033543	Jan 10, 2031	U-1583			
	11139056	Jun 05, 2033	U-1583			
	9633575	Jun 25, 2033	U-1583			
<u>CABAZITAXEL - JEVTANA KIT</u>						
N 201023 001	8927592	Oct 27, 2030	U-3200		M-128	Dec 18, 2023
	8927592*PED	Apr 27, 2031				
<u>CABOTEGRAVIR SODIUM - VOCABRIA</u>						
N 212887 001	10927129	Apr 28, 2026	DS DP		NCE	Jan 21, 2026
	8410103	Apr 28, 2026	DS DP U-3061			
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888 001	10927129	Apr 28, 2026	DS DP		NCE	Jan 21, 2026
	6838464	Feb 26, 2021	DS DP			
	7125879	Apr 21, 2025	DS DP U-3059			
	8080551	Apr 11, 2023	DS DP			
	8410103	Apr 28, 2026	DS DP U-3060			
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888 002	10927129	Apr 28, 2026	DS DP		NCE	Jan 21, 2026
	6838464	Feb 26, 2021	DS DP			
	7125879	Apr 21, 2025	DS DP U-3059			
	8080551	Apr 11, 2023	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888 002	8410103	Apr 28, 2026	DS DP U-3060			
<u>CABOZANTINIB S-MALATE - COMETRIO</u>						
N 203756 001	11091439	Jan 15, 2030	DS			
	11091440	Jan 15, 2030	DP			
	11098015	Jan 15, 2030	U-1617			
<u>CABOZANTINIB S-MALATE - COMETRIO</u>						
N 203756 002	11091439	Jan 15, 2030	DS			
	11091440	Jan 15, 2030	DP			
	11098015	Jan 15, 2030	U-1617			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 001	11091439	Jan 15, 2030	DS		I-854	Jan 22, 2024
	11091440	Jan 15, 2030	DP		I-873	Sep 17, 2024
	11098015	Jan 15, 2030	U-1220			
	11098015	Jan 15, 2030	U-1480			
	11098015	Jan 15, 2030	U-2488			
	11098015	Jan 15, 2030	U-3225			
	11141413	Apr 17, 2037	U-3239			
	8877776	Oct 08, 2030	DS DP U-3225			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 002	11091439	Jan 15, 2030	DS		I-854	Jan 22, 2024
	11091440	Jan 15, 2030	DP		I-873	Sep 17, 2024
	11098015	Jan 15, 2030	U-1220			
	11098015	Jan 15, 2030	U-1480			
	11098015	Jan 15, 2030	U-2488			
	11098015	Jan 15, 2030	U-3225			
	11141413	Apr 17, 2037	U-3239			
	8877776	Oct 08, 2030	DS DP U-3225			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 003	11091439	Jan 15, 2030	DS		I-854	Jan 22, 2024
	11091440	Jan 15, 2030	DP		I-873	Sep 17, 2024
	11098015	Jan 15, 2030	U-1220			
	11098015	Jan 15, 2030	U-1480			
	11098015	Jan 15, 2030	U-2488			
	11098015	Jan 15, 2030	U-3225			
	11141413	Apr 17, 2037	U-3239			
	8877776	Oct 08, 2030	DS DP U-3225			
<u>CALCIFEDIOL - RAYALDEE</u>						
N 208010 001 >A>	11154509	Apr 25, 2028	U-3248			
<u>CALCITONIN SALMON - CALCITONIN-SALMON</u>						
A 212416 001					CGT	Nov 10, 2021
<u>CALCIUM GLUCONATE - CALCIUM GLUCONATE IN SODIUM CHLORIDE</u>						
N 210906 003	10130646	Jul 25, 2037	DP			
	10342813	Jul 25, 2037	DP			
<u>CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE - XYWAV</u>						
N 212690 001	10864181	Mar 15, 2033	U-3017		I-870	Aug 12, 2024
	8772306	Mar 15, 2033	U-1532		ODE-361	Jul 21, 2027
	8772306	Mar 15, 2033	U-3198			
<u>CANGRELOR - KENGREAL</u>						
N 204958 001	8680052	Mar 09, 2033	U-2979			
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365 001	10918608	Oct 14, 2035	U-3071		ODE-326	Jul 31, 2027
	10918608	Oct 14, 2035	U-3072		ODE-332	Jul 31, 2027
	10918608	Oct 14, 2035	U-3073			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365 001	10966939	Jun 17, 2035	DP U-2780			
	10966939	Jun 17, 2035	DP U-2781			
	11065209	Oct 14, 2035	U-3071			
	11096905	Oct 14, 2035	DS DP U-2780			
	11096905	Oct 14, 2035	DS DP U-2781			
	11154516	Jun 17, 2034	U-3235			
	11154516	Jun 17, 2034	U-3236			
	11160795	Mar 01, 2041	U-3233			
<u>CAPSAICIN - QUTENZA</u>						
N 022395 001	10869827	Sep 05, 2023	DP			
<u>CARGLUMIC ACID - CARBAGLU</u>						
N 022562 001					ODE-345	Jan 22, 2028
<u>CASIMERSEN - AMONDYS 45</u>						
N 213026 001	10287586	Nov 12, 2030	DS DP		NCE	Feb 25, 2026
	10533174	May 04, 2021	DP		ODE-347	Feb 25, 2028
	10781450	Nov 12, 2030	U-3089			
	8524880	Apr 02, 2026	DS DP U-3087			
	8524880	Apr 02, 2026	DS DP U-3088			
	9228187	Nov 12, 2030	DS DP			
	9416361	May 04, 2021	DS			
	9447415	Jun 28, 2025	DS DP			
	9758783	Nov 12, 2030	U-3088			
	9758783	Nov 12, 2030	U-3089			
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	10933053	Sep 09, 2034	U-3090			
	10933053	Sep 09, 2034	U-3091			
<u>CELECOXIB; TRAMADOL HYDROCHLORIDE - SEGLENTIS</u>						
N 213426 001	>A> 10238668	Apr 19, 2030	DS DP U-3244			
	>A> 10245276	Apr 19, 2030	DS DP			
	>A> 10548909	Apr 19, 2030	U-3244			
	>A> 8598152	Apr 19, 2030	DS DP			
	>A> 8846744	Jun 03, 2031	DP			
	>A> 9012440	Apr 19, 2030	DS DP			
<u>CERITINIB - ZYKADIA</u>						
N 211225 001					ODE*	Apr 29, 2021
					ODE*	May 26, 2024
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 212144 001					CGT	Sep 20, 2021
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 212144 002					CGT	Sep 20, 2021
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 212144 003					CGT	Sep 20, 2021
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 212144 004					CGT	Sep 20, 2021
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 212144 005					CGT	Sep 20, 2021
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 214542 001					CGT	Jan 29, 2022

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 214542	002				CGT	Jan 29, 2022
<u>CHLORZOAZONE - CHLORZOAZONE</u>						
A 215158	001				CGT	Mar 29, 2022
<u>CILASTATIN SODIUM; IMIPENEM; RELEBACTAM - RECARBRIO</u>						
N 212819	001				NCE GAIN	Jul 16, 2024 Jul 16, 2029
<u>CIPROFLOXACIN - OTIPRIO</u>						
N 207986	001	11040004	Nov 12, 2037	U-2252		
<u>CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE - PHEXXI</u>						
N 208352	001	6706276	Mar 06, 2022	DP		
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - CLENPIO</u>						
N 209589	001				NPP	Aug 15, 2021
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156	001	11103490	Oct 10, 2031	DP		
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156	002	11103490	Oct 10, 2031	DP		
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156	003	11103490	Oct 10, 2031	DP		
<u>COBICISTAT - TYBOST</u>						
N 203094	001	10039718	Oct 06, 2032	DP		
		10039718*PED	Apr 06, 2033			
		8148374	Sep 03, 2029	DS DP	U-1279	
		8148374*PED	Mar 03, 2030			
<u>COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - SYMTUZA</u>						
N 210455	001	10786518	Jul 19, 2038	U-2978		
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561	001	10039718	Oct 06, 2032	DP		
		10039718*PED	Apr 06, 2033			
		7176220	Aug 27, 2026	DS DP	U-257	
		7176220*PED	Feb 27, 2027			
		7390791	Apr 17, 2025	DS DP		
		7390791*PED	Oct 17, 2025			
		7635704	Oct 26, 2026	DS DP	U-257	
		7635704*PED	Apr 26, 2027			
		8148374	Sep 03, 2029	DS DP	U-1279	
		8148374*PED	Mar 03, 2030			
		8633219	Apr 24, 2030	DP	U-257	
		8633219*PED	Oct 24, 2030			
		8754065	Aug 15, 2032	DS DP	U-257	
		8754065*PED	Feb 15, 2033			
		8981103	Oct 26, 2026	DS DP		
		8981103*PED	Apr 26, 2027			
		9296769	Aug 15, 2032	DS DP	U-257	
		9296769*PED	Feb 15, 2033			
		9891239	Sep 03, 2029	DP	U-257	
		9891239*PED	Mar 03, 2030			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100	001	10039718	Oct 06, 2032	DP		
		10039718*PED	Apr 06, 2033			
		7176220	Aug 27, 2026	DS DP	U-257	
		7176220*PED	Feb 27, 2027			
		7635704	Oct 26, 2026	DS DP	U-257	

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	7635704*PED	Apr 26, 2027				
	8633219	Apr 24, 2030	DP U-257			
	8633219*PED	Oct 24, 2030				
	8981103	Oct 26, 2026	DS DP			
	8981103*PED	Apr 26, 2027				
	9891239	Sep 03, 2029	DP U-257			
	9891239*PED	Mar 03, 2030				
<u>COBIMETINIB FUMARATE - COTELLIC</u>						
N 206192 001	11087354	Jun 22, 2034	U-1776			
<u>COCAINE HYDROCHLORIDE - NUMBRINO</u>						
N 209575 001					NCE NP	Dec 14, 2022 Jan 10, 2023
<u>COCAINE HYDROCHLORIDE - GOPRELTO</u>						
N 209963 001	10894012	Feb 07, 2037	U-3014			
	10933060	Feb 07, 2037	U-3014			
	10973811	Feb 07, 2037	U-2226			
	10987347	Feb 07, 2037	U-2225			
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N 022362 001					>A> M-232	Oct 20, 2024
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N 022362 002					>A> M-232	Oct 20, 2024
<u>COPPER DOTATATE CU-64 - DETECTNET</u>						
N 213227 001	>A> 11160888	Aug 23, 2032	U-2951			
<u>CRIZOTINIB - XALKORI</u>						
N 202570 001					I-852 ODE-328	Jan 14, 2024 Jan 14, 2028
<u>CRIZOTINIB - XALKORI</u>						
N 202570 002					I-852 ODE-328	Jan 14, 2024 Jan 14, 2028
<u>CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - TRALEMENT</u>						
N 209376 002					NCE	Apr 30, 2024
<u>CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - MULTRYS</u>						
N 209376 003					NCE	Apr 30, 2024
<u>CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE</u>						
N 210735 001	9662342	Jun 26, 2035	DP			
<u>CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE</u>						
N 210735 002	9662342	Jun 26, 2035	DP			
<u>CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE</u>						
N 212501 001	10993952	Feb 15, 2036	DP			
<u>CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE</u>						
N 212501 002	10993952	Feb 15, 2036	DP			
<u>CYCLOSPORINE - CEQUA</u>						
N 210913 001	10918694	Feb 28, 2037	DP			
<u>CYCLOSPORINE - VERKAZIA</u>						
N 214965 001	7973081	Jan 27, 2026	DP		NP	Jun 23, 2023
	8298568	Nov 03, 2027	DP		ODE-358	Jun 23, 2028

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CYCLOSPORINE - VERKAZIA</u>						
N 214965 001	8524779	Jan 27, 2026	DP			
	9132071	Jun 02, 2029	DP			
	9220694	Jan 27, 2026	DP			
	9956289	Jan 27, 2026	DP			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	10905662	Aug 16, 2036	U-1399			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	10905662	Aug 16, 2036	U-1399			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 213491 001	10905662	Aug 16, 2036	U-1399		ODE*	Aug 14, 2022
	8026284	Sep 22, 2027	U-1399		ODE*	Dec 22, 2024
	8026284*PED	Mar 22, 2028			PED	Feb 14, 2023
	9173851	Jun 17, 2034	DP			
	9173851*PED	Dec 17, 2034				
	9192590	Jan 26, 2027	U-1399			
	9192590*PED	Jul 26, 2027				
	9198882	Jan 26, 2027	U-1399			
	9198882*PED	Jul 26, 2027				
	9233077	Jun 17, 2034	DP			
	9233077*PED	Dec 17, 2034				
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 213491 002	10905662	Aug 16, 2036	U-1399		ODE*	Aug 14, 2022
	8026284	Sep 22, 2027	U-1399		ODE*	Dec 22, 2024
	8026284*PED	Mar 22, 2028			PED	Feb 14, 2023
	9173851	Jun 17, 2034	DP			
	9173851*PED	Dec 17, 2034				
	9192590	Jan 26, 2027	U-1399			
	9192590*PED	Jul 26, 2027				
	9198882	Jan 26, 2027	U-1399			
	9198882*PED	Jul 26, 2027				
	9233077	Jun 17, 2034	DP			
	9233077*PED	Dec 17, 2034				
<u>CYSTEINE HYDROCHLORIDE - ELCYS</u>						
N 210660 001	10905713	Jan 15, 2039	DP			
	10905714	Jan 15, 2039	DP			
	10912795	Jan 15, 2039	DP			
	10918662	Jan 15, 2039	DP			
	10933089	Jan 15, 2039	DP			
<u>CYSTEINE HYDROCHLORIDE - NOURESS</u>						
N 212535 001	10905713	Jan 15, 2039	DP			
	10905714	Jan 15, 2039	DP			
	10912795	Jan 15, 2039	DP			
	10918662	Jan 15, 2039	DP			
	10933089	Jan 15, 2039	DP			
	11045438	Mar 15, 2039	DP			
<u>CYTARABINE; DAUNORUBICIN - VYXEOS</u>						
N 209401 001	10028912	Sep 29, 2034	DP U-3149		NPP	Mar 30, 2024
	10028912	Sep 29, 2034	DP U-3150		ODE-350	Mar 30, 2028
	10166184	Oct 15, 2032	DP U-3149			
	10835492	Oct 15, 2032	U-3150			
	7850990	Jan 23, 2027	DP U-3147			
	8022279	Sep 14, 2027	DP U-3147			
	8092828	Apr 01, 2029	U-3147			
	8431806	Apr 22, 2025	DP U-3147			
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 001	6087380	Dec 28, 2021	DS DP U-1931		I-862	Jun 21, 2024
	6087380*PED	Jun 28, 2022			PED	Dec 21, 2024



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 001	9034822	Jan 20, 2031	U-1759			
	9034822*PED	Jul 20, 2031				
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 002	6087380	Dec 28, 2021	DS DP U-1931		I-862	Jun 21, 2024
	6087380*PED	Jun 28, 2022			PED	Dec 21, 2024
	9034822	Jan 20, 2031	U-1759			
	9034822*PED	Jul 20, 2031				
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 003	6087380	Dec 28, 2021	DS DP U-1931		I-862	Jun 21, 2024
	6087380*PED	Jun 28, 2022			PED	Dec 21, 2024
	7866474	Aug 31, 2027	DP	Y		
	7866474*PED	Mar 02, 2028				
	7932273	Sep 07, 2025	DS DP			
	7932273*PED	Mar 07, 2026				
	9034822	Jan 20, 2031	U-1759			
	9034822*PED	Jul 20, 2031				
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 214358 001	6087380	Dec 28, 2021	DS DP U-3177		NP	Jun 21, 2024
	6087380	Dec 28, 2021	DS DP U-3178		PED	Dec 21, 2024
	6087380*PED	Jun 28, 2022				
	7932273	Sep 07, 2025	DS DP			
	7932273*PED	Mar 07, 2026				
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 214358 002	6087380	Dec 28, 2021	DS DP U-3177		NP	Jun 21, 2024
	6087380	Dec 28, 2021	DS DP U-3178		PED	Dec 21, 2024
	6087380*PED	Jun 28, 2022				
	7932273	Sep 07, 2025	DS DP			
	7932273*PED	Mar 07, 2026				
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 214358 003	6087380	Dec 28, 2021	DS DP U-3177		NP	Jun 21, 2024
	6087380	Dec 28, 2021	DS DP U-3178		PED	Dec 21, 2024
	6087380*PED	Jun 28, 2022				
	7932273	Sep 07, 2025	DS DP			
	7932273*PED	Mar 07, 2026				
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 214358 004	6087380	Dec 28, 2021	DS DP U-3177		NP	Jun 21, 2024
	6087380	Dec 28, 2021	DS DP U-3178		PED	Dec 21, 2024
	6087380*PED	Jun 28, 2022				
	7932273	Sep 07, 2025	DS DP			
	7932273*PED	Mar 07, 2026				
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 214358 005	6087380	Dec 28, 2021	DS DP U-3177		NP	Jun 21, 2024
	6087380	Dec 28, 2021	DS DP U-3178		PED	Dec 21, 2024
	6087380*PED	Jun 28, 2022				
	7932273	Sep 07, 2025	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 214358 005	7932273*PED	Mar 07, 2026				
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 214358 006	6087380	Dec 28, 2021	DS DP U-3177		NP	Jun 21, 2024
	6087380	Dec 28, 2021	DS DP U-3178		PED	Dec 21, 2024
	6087380*PED	Jun 28, 2022				
	7932273	Sep 07, 2025	DS DP			
	7932273*PED	Mar 07, 2026				
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	10869869	Aug 30, 2033		U-3185		
	8703781	Oct 15, 2030	DS DP U-1713			
	8703781	Oct 15, 2030	DS DP U-2032			
	8703781	Oct 15, 2030	DS DP U-2296			
	8703781	Oct 15, 2030	DS DP U-2298			
	9233956	May 04, 2029		U-1811		
	9233956	May 04, 2029		U-2031		
	9233956	May 04, 2029		U-2032		
	9233956	May 04, 2029		U-2296		
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002	10869869	Aug 30, 2033		U-3185		
	8703781	Oct 15, 2030	DS DP U-1713			
	8703781	Oct 15, 2030	DS DP U-2032			
	8703781	Oct 15, 2030	DS DP U-2296			
	8703781	Oct 15, 2030	DS DP U-2298			
	9233956	May 04, 2029		U-1811		
	9233956	May 04, 2029		U-2031		
	9233956	May 04, 2029		U-2032		
	9233956	May 04, 2029		U-2296		
<u>DALBAVANCIN HYDROCHLORIDE - DALVANCE</u>						
N 021883 001					NPP	Jul 22, 2024
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 001					I-857	Apr 30, 2024
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 002	10973836	Mar 09, 2040		U-3127	I-857	Apr 30, 2024
<u>DAPTOMYCIN - DAPTOMYCIN</u>						
N 210282 001	10357535	Sep 11, 2033	DP U-3176			
	9655946	Sep 11, 2033	DP U-3175			
<u>DAPTOMYCIN - DAPTOMYCIN</u>						
N 210282 002	10357535	Sep 11, 2033	DP U-3176			
	9655946	Sep 11, 2033	DP U-3175			
<u>DAROLUTAMIDE - NUBEQA</u>						
N 212099 001	11046713	Oct 27, 2030	DS			
<u>DASIGLUCAGON HYDROCHLORIDE - ZEGALOGUE</u>						
N 214231 001	10442847	Feb 03, 2035	DS DP		NCE	Mar 22, 2026
<u>DASIGLUCAGON HYDROCHLORIDE - ZEGALOGUE (AUTOINJECTOR)</u>						
N 214231 002	10442847	Feb 03, 2035	DS DP		NCE	Mar 22, 2026

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEFERIPRONE - DEFERIPRONE</u>						
A 208800 001					PC	Mar 27, 2021
<u>DEFERIPRONE - FERRIPROX</u>						
N 021825 001	7049328	Jun 28, 2021	U-3083		I-859	Apr 30, 2024
<u>DEFERIPRONE - FERRIPROX</u>						
N 021825 002	7049328	Jun 28, 2021	U-3083		I-859	Apr 30, 2024
<u>DEFERIPRONE - FERRIPROX</u>						
N 208030 001	7049328	Jun 28, 2021	U-3083		I-859	Apr 30, 2024
	8703156	Oct 26, 2029	DP U-3083			
<u>DEFERIPRONE - FERRIPROX</u>						
N 208030 002	7049328	Jun 28, 2021	U-3083		I-859	Apr 30, 2024
	8703156	Oct 26, 2029	DP U-3083			
<u>DEFERIPRONE - FERRIPROX</u>						
N 212269 001	10780055	Oct 25, 2038	DP U-3083		I-859	Apr 30, 2024
	10940115	Oct 25, 2038	DP U-3083			
	10940116	Oct 25, 2038	DP			
	7049328	Jun 28, 2021	U-3083			
<u>DEFIBROTIDE SODIUM - DEFITELIO</u>						
N 208114 001	11085043	Jun 22, 2032	DP			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 001	10973870	Feb 10, 2029	U-1978			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 002	10973870	Feb 10, 2029	U-1978			
<u>DESMOPRESSIN ACETATE - NOCDURNA</u>						
N 022517 001	11020448	May 21, 2029	U-2327			
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 001	10959996	Mar 07, 2036	U-3055		M-54	Jun 24, 2024
	10959996*PED	Sep 07, 2036			NCE	Apr 03, 2022
	8524733	Apr 03, 2031	DS DP		ODE-134	Apr 03, 2024
	8524733*PED	Oct 03, 2031			PED	Oct 03, 2022
	9233959	Sep 18, 2033	DP		PED	Oct 03, 2024
	9233959*PED	Mar 18, 2034			PED	Dec 24, 2024
	9296739	Sep 18, 2033	DP			
	9296739*PED	Mar 18, 2034				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
	9814708	Sep 18, 2033	DP			
	9814708*PED	Mar 18, 2034				
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 002	10959996	Mar 07, 2036	U-3055		M-54	Jun 24, 2024
	10959996*PED	Sep 07, 2036			NCE	Apr 03, 2022
	8524733	Apr 03, 2031	DS DP		ODE-134	Apr 03, 2024
	8524733*PED	Oct 03, 2031			PED	Oct 03, 2022
	9233959	Sep 18, 2033	DP		PED	Oct 03, 2024
	9233959*PED	Mar 18, 2034			PED	Dec 24, 2024
	9296739	Sep 18, 2033	DP			
	9296739*PED	Mar 18, 2034				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
	9814708	Sep 18, 2033	DP			
	9814708*PED	Mar 18, 2034				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 003	10959996	Mar 07, 2036	U-3055		M-54	Jun 24, 2024
	10959996*PED	Sep 07, 2036			NCE	Apr 03, 2022
	8524733	Apr 03, 2031	DS DP		ODE-134	Apr 03, 2024
	8524733*PED	Oct 03, 2031			PED	Oct 03, 2022
	9233959	Sep 18, 2033	DP		PED	Oct 03, 2024
	9233959*PED	Mar 18, 2034			PED	Dec 24, 2024
	9296739	Sep 18, 2033	DP			
	9296739*PED	Mar 18, 2034				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
	9814708	Sep 18, 2033	DP			
	9814708*PED	Mar 18, 2034				
<u>DEXAMETHASONE - DEXAMETHASONE</u>						
A 215106 001					CGT	Apr 20, 2022
<u>DEXAMETHASONE - DEXAMETHASONE</u>						
A 215106 002					CGT	Apr 19, 2022
<u>DEXAMETHASONE - DEXTENZA</u>						
N 208742 001					>A> I-876	Oct 07, 2024
<u>DEXAMETHASONE - DEXYCU KIT</u>						
N 208912 001	10799642	May 11, 2032	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS</u>						
N 212994 001	10584112	Dec 09, 2037	DS DP		NCE	May 07, 2026
	10584113	Dec 09, 2037	DP			
	10759778	Dec 09, 2037	DP			
	10858341	Dec 09, 2037		U-3094		
	10954213	Dec 09, 2037		U-3094		
	9079928	Jul 27, 2032	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS</u>						
N 212994 002	10584112	Dec 09, 2037	DS DP		NCE	May 07, 2026
	10584113	Dec 09, 2037	DP			
	10759778	Dec 09, 2037	DP			
	10858341	Dec 09, 2037		U-3094		
	10954213	Dec 09, 2037		U-3094		
	9079928	Jul 27, 2032	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS</u>						
N 212994 003	10584112	Dec 09, 2037	DS DP		NCE	May 07, 2026
	10584113	Dec 09, 2037	DP			
	10759778	Dec 09, 2037	DP			
	10858341	Dec 09, 2037		U-3094		
	10954213	Dec 09, 2037		U-3094		
	9079928	Jul 27, 2032	DP			
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N 022202 001					NPP	May 25, 2024
<u>DIFELIKEFALIN ACETATE - KORSUVA</u>						
N 214916 001	10017536	Nov 12, 2027	DS U-3204		NCE	Aug 23, 2026
	10138270	Nov 12, 2027	U-3204			
	10793596	Nov 12, 2027	DS DP U-3204			
	7402564	Nov 12, 2027	DS DP U-3204			
	7713937	Nov 12, 2027	DS DP U-3204			
	7727963	Nov 12, 2027	DS DP U-3204			
	8217007	Nov 12, 2027	U-3204			
	8236766	Nov 12, 2027	U-3204			
	8486894	Nov 12, 2027	U-3204			
	8536131	Nov 12, 2027	DS DP U-3204			
	9334305	Nov 12, 2027	U-3204			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DIFELIKEFALIN ACETATE - KORSUVA</u>						
N 214916 001	9359399	Nov 12, 2027	U-3204			
<u>DIHYDROERGOTAMINE MESYLATE - TRUDHESA</u>						
N 213436 001	10507295	Dec 25, 2032	DP		NP	Sep 02, 2024
	10940278	Jan 23, 2033	DP			
	9550036	Sep 05, 2032	DP			
	9919117	Mar 17, 2033	DP U-3218			
<u>DILTIAZEM HYDROCHLORIDE - DILTIAZEM HYDROCHLORIDE</u>						
A 212317 001					CGT	Sep 26, 2021
<u>DILTIAZEM HYDROCHLORIDE - DILTIAZEM HYDROCHLORIDE</u>						
A 212317 002					CGT	Sep 26, 2021
<u>DILTIAZEM HYDROCHLORIDE - DILTIAZEM HYDROCHLORIDE</u>						
A 212317 003					CGT	Sep 26, 2021
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 001	10391160	Mar 13, 2035	U-3148			
	10555993	Mar 13, 2035	U-3148			
	10959972	Nov 16, 2035	U-1384			
	10994003	Mar 13, 2035	U-3148			
	11007166	Nov 16, 2035	U-1384			
	11007167	Nov 16, 2035	U-1384			
	11129806	Nov 16, 2035	U-1384			
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 002	10391160	Mar 13, 2035	U-3148			
	10555993	Mar 13, 2035	U-3148			
	10959972	Nov 16, 2035	U-1384			
	10994003	Mar 13, 2035	U-3148			
	11007166	Nov 16, 2035	U-1384			
	11007167	Nov 16, 2035	U-1384			
	11129806	Nov 16, 2035	U-1384			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 001	10842770	Aug 07, 2031	DP U-2998			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 002	10842770	Aug 07, 2031	DP U-2998			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 003	10842770	Aug 07, 2031	DP U-2998			
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 001	11096920	Apr 11, 2028	U-620			
	11110074	Jul 20, 2027	U-620			
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 002	11096920	Apr 11, 2028	U-620			
	11110074	Jul 20, 2027	U-620			
<u>DROSPIRENONE - SLYND</u>						
N 211367 001	10603281	Jun 28, 2031	U-2553			
	10849857	Jun 28, 2031	DP U-2553			
	10987364	Jun 28, 2031	DP			
	11123299	Jun 28, 2031	DP			
<u>DROSPIRENONE; ESTETROL - NEXTSTELLIS</u>						
N 214154 001	7732430	Mar 02, 2025	DP U-3152		NCE	Apr 15, 2026

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 001	10959982	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 002	10959982	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 003	10959982	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 004	10959982	Apr 13, 2037	DP			
<u>EDARAVONE - RADICAVA</u>						
N 209176 002					ODE*	May 05, 2024
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 001	7365205	Apr 18, 2027	DS			
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 002	7365205	Apr 18, 2027	DS			
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 003	7365205	Apr 18, 2027	DS			
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	10864274	Oct 02, 2034	U-2720			
	7214506	Feb 22, 2026	U-281			
<u>ELAGOLIX SODIUM, ESTRADIOL, NORETHINDRONE ACETATE; ELAGOLIX SODIUM - ORIAHNN (COPACKAGED)</u>						
N 213388 001	10881659	Mar 14, 2034	U-2842			
	11045470	Mar 14, 2034	U-2842			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 001	10022352	Apr 09, 2027	DP U-2651		NPP	Jun 08, 2024
	10022352	Apr 09, 2027	DP U-3156		ODE-323	Dec 21, 2027
	10081621	Mar 25, 2031	DP U-2652		ODE-357	Jun 08, 2028
	10081621	Mar 25, 2031	DP U-3032			
	10081621	Mar 25, 2031	DP U-3157			
	10239867	Apr 09, 2027	DS DP U-2653			
	10239867	Apr 09, 2027	DS DP U-3033			
	10239867	Apr 09, 2027	DS DP U-3158			
	10758534	Oct 06, 2035	DS DP U-2645			
	10758534	Oct 06, 2035	DS DP U-3028			
	10758534	Oct 06, 2035	DS DP U-3144			
	10793547	Dec 08, 2037	DS DP U-2645			
	10793547	Dec 08, 2037	DS DP U-3028			
	10793547	Dec 08, 2037	DS DP U-3144			
	8324242	Aug 05, 2027	U-2645			
	8324242	Aug 05, 2027	U-3028			
	8324242	Aug 05, 2027	U-3144			
	8354427	Jul 06, 2026	U-2646			
	8354427	Jul 06, 2026	U-3029			
	8354427	Jul 06, 2026	U-3145			
	8415387	Nov 12, 2027	U-2645			
	8415387	Nov 12, 2027	U-3028			
	8415387	Nov 12, 2027	U-3144			
	8598181	May 01, 2027	U-2645			
	8598181	May 01, 2027	U-3028			
	8598181	May 01, 2027	U-3144			
	8629162	Jun 24, 2025	U-2648			
	8629162	Jun 24, 2025	U-3030			
	8629162	Jun 24, 2025	U-3146			
	9012496	Jul 15, 2033	U-2649			
	9012496	Jul 15, 2033	U-3154			
	9670163	Dec 28, 2026	DP U-2650			
	9670163	Dec 28, 2026	DP U-3031			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 001	9670163	Dec 28, 2026	DP U-3155			
	9931334	Dec 28, 2026	DP U-2650			
	9931334	Dec 28, 2026	DP U-3031			
	9931334	Dec 28, 2026	DP U-3155			
	9974781	Apr 09, 2027	DP U-2645			
	9974781	Apr 09, 2027	DP U-3028			
	9974781	Apr 09, 2027	DP U-3144			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 002	10022352	Apr 09, 2027	DP U-3156		NCE	Feb 12, 2023
	10081621	Mar 25, 2031	DP U-3157		NCE	Oct 21, 2024
	10239867	Apr 09, 2027	DS DP U-3158		NPP	Jun 08, 2024
	10646481	Aug 13, 2029	DP		ODE-357	Jun 08, 2028
	10758534	Oct 06, 2035	DS DP U-3144			
	10793547	Dec 08, 2037	DS DP U-3144			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-3144			
	8354427	Jul 06, 2026	U-3145			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-3144			
	8598181	May 01, 2027	U-3144			
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025	U-3146			
	8754224	Dec 28, 2026	DS DP			
	9012496	Jul 15, 2033	U-3154			
	9670163	Dec 28, 2026	DP U-3155			
	9931334	Dec 28, 2026	DP U-3155			
	9974781	Apr 09, 2027	DP U-3144			
<u>ELIGLUSTAT TARTRATE - CERDELGA</u>						
N 205494 001	10888544	Dec 13, 2038	U-3040			
	10888544	Dec 13, 2038	U-3041			
	10888547	Jan 31, 2031	U-3042			
	10888547	Jan 31, 2031	U-3043			
<u>ELTROMBOPAG OLAMINE - PROMACTA KIT</u>						
N 207027 001					ODE*	Nov 16, 2025
<u>ELTROMBOPAG OLAMINE - PROMACTA KIT</u>						
N 207027 002					ODE*	Aug 26, 2021
					ODE*	Nov 16, 2025
					PED	Feb 26, 2022
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001	11007179	Mar 14, 2033	DP			
	11090291	Mar 14, 2033	DP			
	>A> 11160792	Mar 14, 2033	DP			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	11007179	Mar 14, 2033	DP			
	11090291	Mar 14, 2033	DP			
	>A> 11160792	Mar 14, 2033	DP			
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 001	7176220	Aug 27, 2026	DS DP U-257			
	7176220*PED	Feb 27, 2027				
	7635704	Oct 26, 2026	DS DP U-257			
	7635704*PED	Apr 26, 2027				
	8981103	Oct 26, 2026	DS DP			
	8981103*PED	Apr 26, 2027				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 002	7176220	Aug 27, 2026	DS DP U-257			
	7176220*PED	Feb 27, 2027				
	7635704	Oct 26, 2026	DS DP U-257			
	7635704*PED	Apr 26, 2027				
	8981103	Oct 26, 2026	DS DP			
	8981103*PED	Apr 26, 2027				
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	11090323	Apr 03, 2034	U-3191		I-869	Aug 18, 2024
	9949997	May 17, 2034	U-2292			
	9949997	May 17, 2034	U-3199			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	11090323	Apr 03, 2034	U-3191			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	11033552	May 04, 2027	DP			
	11090323	Apr 03, 2034	U-3191			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	11033552	May 04, 2027	DP			
	11090323	Apr 03, 2034	U-3191			
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 001	11090323	Apr 03, 2034	U-3192			
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 002	11090323	Apr 03, 2034	U-3192			
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 003	11090323	Apr 03, 2034	U-3192			
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 004	11090323	Apr 03, 2034	U-3192			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 001	11090323	Apr 03, 2034	U-3193			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002	11090323	Apr 03, 2034	U-3193			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 003	11090323	Apr 03, 2034	U-3193			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 004	11090323	Apr 03, 2034	U-3193			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 001	11090323	Apr 03, 2034	U-3193			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 002	11090323	Apr 03, 2034	U-3193			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 003	11090323	Apr 03, 2034	U-3193			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 004	11090323	Apr 03, 2034	U-3193			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - ODEFSEY</u>						
N 208351 001	7390791	Apr 17, 2025	DS DP			
	7390791*PED	Oct 17, 2025				
	8754065	Aug 15, 2032	DS DP U-257			
	8754065*PED	Feb 15, 2033				
	9296769	Aug 15, 2032	DS DP U-257			
	9296769*PED	Feb 15, 2033				
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 001	7390791	Apr 17, 2025	DS DP			
	7390791*PED	Oct 17, 2025				
	8754065	Aug 15, 2032	DS DP U-1259			
	8754065	Aug 15, 2032	DS DP U-1663			
	8754065	Aug 15, 2032	DS DP U-257			
	8754065*PED	Feb 15, 2033				
	9296769	Aug 15, 2032	DS DP U-1259			
	9296769	Aug 15, 2032	DS DP U-1663			
	9296769	Aug 15, 2032	DS DP U-257			
	9296769*PED	Feb 15, 2033				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE</u>						
A 209721 001					PC	Mar 09, 2021
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE</u>						
A 209721 002					PC	Mar 09, 2021
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE</u>						
A 209721 003					PC	Mar 09, 2021
<u>ENALAPRIL MALEATE - ENALAPRIL MALEATE</u>						
A 212408 001					PC	Feb 13, 2022
<u>ENALAPRIL MALEATE - EPANED</u>						
N 208686 001	11040023	Mar 25, 2036	DP			
	11141405	Mar 25, 2036	DP			
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725 001	11091469	May 18, 2037	U-2617			
	11091469	May 18, 2037	U-2618			
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725 002	11091469	May 18, 2037	U-2617			
	11091469	May 18, 2037	U-2618			
<u>EPHEDRINE SULFATE - EMERPHED</u>						
N 213407 001	11090278	May 16, 2040	U-3183			
<u>EPINEPHRINE - AUVI-O</u>						
N 201739 001	10960155	Jun 25, 2026	DP			
<u>EPINEPHRINE - AUVI-O</u>						
N 201739 002	10842938	Dec 21, 2037	DP U-2980			
	10960155	Jun 25, 2026	DP			
<u>EPINEPHRINE - AUVI-O</u>						
N 201739 003	10842938	Dec 21, 2037	DP U-2980			
	10960155	Jun 25, 2026	DP			
<u>ERAVACYCLINE DIHYDROCHLORIDE - XERAVA</u>						
N 211109 002					>A> NCE	Aug 27, 2023
					>A> GAIN	Aug 27, 2028

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 001	10898482	Feb 09, 2036	DP U-2518			
	10898482	Feb 09, 2036	DP U-3065			
	10898482	Feb 09, 2036	DP U-3066			
	10898482	Feb 09, 2036	DP U-3067			
	11077106	Feb 02, 2038	U-3196			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 002	10898482	Feb 09, 2036	DP U-2518			
	10898482	Feb 09, 2036	DP U-3065			
	10898482	Feb 09, 2036	DP U-3066			
	10898482	Feb 09, 2036	DP U-3067			
	11077106	Feb 02, 2038	U-3196			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 003	10898482	Feb 09, 2036	DP U-2518			
	10898482	Feb 09, 2036	DP U-3065			
	10898482	Feb 09, 2036	DP U-3066			
	10898482	Feb 09, 2036	DP U-3067			
	11077106	Feb 02, 2038	U-3196			
<u>ERYTHROMYCIN - ERYTHROMYCIN</u>						
A 211975 001					CGT	Apr 02, 2022
<u>ERYTHROMYCIN - ERYTHROMYCIN</u>						
A 211975 002					CGT	Apr 02, 2022
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243 001	10869844	Sep 10, 2035	U-3034			
	10869844	Sep 10, 2035	U-3035			
	10869844	Sep 10, 2035	U-3036			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 001	10912781	Oct 23, 2028	DP			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002	10912781	Oct 23, 2028	DP			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 003	10912781	Oct 23, 2028	DP			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 004	10912781	Oct 23, 2028	DP			
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 001	10888516	Jun 18, 2033	U-2316			
	10888516	Jun 18, 2033	U-2317			
	11065197	Jun 18, 2033	DP			
	11116717	Jun 18, 2033	DP			
	11123283	Jun 18, 2033	DP			
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 002	10888516	Jun 18, 2033	U-2316			
	10888516	Jun 18, 2033	U-2317			
	11065197	Jun 18, 2033	DP			
	11116717	Jun 18, 2033	DP			
	11123283	Jun 18, 2033	DP			
<u>ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX - MYFEMBREE</u>						
N 214846 001	11033551	Sep 29, 2037	U-3129		NCE	Dec 18, 2025
	7300935	Jan 28, 2024	DS		NP	May 26, 2024
	8058280	Jan 28, 2024	DS DP			
	9346822	Feb 17, 2024	U-3129			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 001	11033626	Nov 21, 2032	DP U-2439			
	11103513	Nov 21, 2032	U-2439			
	11103516	Nov 21, 2032	DP			
	11110099	Nov 21, 2032	DP			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 001 >A>	11162500	Jun 27, 2034	DP			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 002 >A>	11162500	Jun 27, 2034	DP			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 003 >A>	11162500	Jun 27, 2034	DP			
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 001	RE47769	Feb 02, 2029	DP			
	RE48468	Oct 27, 2028	U-2097			
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 002	RE47769	Feb 02, 2029	DP			
	RE48468	Oct 27, 2028	U-2097			
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - BALCOLTRA</u>						
N 208612 001 >A>	7838042	Jun 01, 2027	DS U-3251			
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - TYBLUME</u>						
N 209405 001					NDF	Mar 30, 2023
<u>ETHINYL ESTRADIOL; NORELGESTROMIN - ETHINYL ESTRADIOL AND NORELGESTROMIN</u>						
A 213950 001					CGT	Aug 25, 2021
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - MERZEE</u>						
A 212706 001					CGT	Jul 17, 2021
<u>ETHINYL ESTRADIOL; SEGESTERONE ACETATE - ANNOVERA</u>						
N 209627 001	10918649	Jun 21, 2039	DP			
	10925882	Jun 21, 2039	DP			
	10940157	Jun 21, 2039	DP			
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N 021773 001					>A> M-232	Nov 04, 2024
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N 021773 002					>A> M-232	Nov 04, 2024
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	6515117	Oct 04, 2025	DS DP U-2588		M-240	Feb 15, 2022
	6515117*PED	Apr 04, 2026			NPP	Jul 22, 2024
	7456254	Jun 30, 2025	DP U-2588		PED	Aug 15, 2023
	7456254	Jun 30, 2025	DP U-2589		PED	Jan 22, 2025
	7456254	Jun 30, 2025	DP U-2590			
	7456254	Jun 30, 2025	DP U-3188			
	7456254	Jun 30, 2025	DP U-3189			
	7456254	Jun 30, 2025	DP U-3190			
	7456254*PED	Dec 30, 2025				
	7612176	Apr 13, 2025	DP U-2588			
	7612176	Apr 13, 2025	DP U-2589			
	7612176	Apr 13, 2025	DP U-2590			
	7612176	Apr 13, 2025	DP U-3188			
	7612176	Apr 13, 2025	DP U-3189			
	7612176	Apr 13, 2025	DP U-3190			
	7612176*PED	Oct 13, 2025				
	8329648	Aug 18, 2026	U-2588			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	8329648	Aug 18, 2026	U-2589			
	8329648	Aug 18, 2026	U-2590			
	8329648	Aug 18, 2026	U-2593			
	8329648	Aug 18, 2026	U-2594			
	8329648	Aug 18, 2026	U-2595			
	8329648	Aug 18, 2026	U-2596			
	8329648	Aug 18, 2026	U-3188			
	8329648	Aug 18, 2026	U-3189			
	8329648	Aug 18, 2026	U-3190			
	8329648*PED	Feb 18, 2027				
	8361972	Mar 21, 2028	U-2588			
	8361972*PED	Sep 21, 2028				
	8431685	Apr 13, 2025	DP U-2588			
	8431685	Apr 13, 2025	DP U-2589			
	8431685	Apr 13, 2025	DP U-2590			
	8431685	Apr 13, 2025	DP U-3188			
	8431685	Apr 13, 2025	DP U-3189			
	8431685	Apr 13, 2025	DP U-3190			
	8431685*PED	Oct 13, 2025				
	8461105	Apr 13, 2025	DP U-2588			
	8461105	Apr 13, 2025	DP U-2589			
	8461105	Apr 13, 2025	DP U-2590			
	8461105	Apr 13, 2025	DP U-3188			
	8461105	Apr 13, 2025	DP U-3189			
	8461105	Apr 13, 2025	DP U-3190			
	8461105*PED	Oct 13, 2025				
	8501698	Jun 20, 2027	DP U-2588			
	8501698*PED	Dec 20, 2027				
	8906851	Aug 18, 2026	U-2588			
	8906851	Aug 18, 2026	U-2589			
	8906851	Aug 18, 2026	U-2590			
	8906851	Aug 18, 2026	U-2593			
	8906851	Aug 18, 2026	U-3188			
	8906851	Aug 18, 2026	U-3189			
	8906851	Aug 18, 2026	U-3190			
	8906851*PED	Feb 18, 2027				
	9238076	Apr 15, 2024	DP U-2588			
	9238076	Apr 15, 2024	DP U-2589			
	9238076	Apr 15, 2024	DP U-2590			
	9238076	Apr 15, 2024	DP U-2599			
	9238076	Apr 15, 2024	DP U-3188			
	9238076	Apr 15, 2024	DP U-3189			
	9238076	Apr 15, 2024	DP U-3190			
	9238076*PED	Oct 15, 2024				
	9884092	Aug 18, 2026	U-2588			
	9884092	Aug 18, 2026	U-2589			
	9884092	Aug 18, 2026	U-2590			
	9884092	Aug 18, 2026	U-2593			
	9884092	Aug 18, 2026	U-2594			
	9884092	Aug 18, 2026	U-2595			
	9884092	Aug 18, 2026	U-2596			
	9884092	Aug 18, 2026	U-3188			
	9884092	Aug 18, 2026	U-3189			
	9884092	Aug 18, 2026	U-3190			
	9884092*PED	Feb 18, 2027				
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	6515117	Oct 04, 2025	DS DP U-2588		M-240	Feb 15, 2022
	6515117*PED	Apr 04, 2026			NPP	Jul 22, 2024
	6824822	Oct 09, 2022	DP		PED	Aug 15, 2023
	6824822*PED	Apr 09, 2023			PED	Jan 22, 2025
	7223440	Aug 31, 2021	DP			
	7223440*PED	Mar 03, 2022				
	7456254	Jun 30, 2025	DP U-2588			
	7456254	Jun 30, 2025	DP U-2589			
	7456254	Jun 30, 2025	DP U-2590			
	7456254	Jun 30, 2025	DP U-3188			
	7456254	Jun 30, 2025	DP U-3189			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	7456254	Jun 30, 2025	DP U-3190			
	7456254*PED	Dec 30, 2025				
	7563871	Apr 15, 2024	DP			
	7563871*PED	Oct 15, 2024				
	7612176	Apr 13, 2025	DP U-2588			
	7612176	Apr 13, 2025	DP U-2589			
	7612176	Apr 13, 2025	DP U-2590			
	7612176	Apr 13, 2025	DP U-3188			
	7612176	Apr 13, 2025	DP U-3189			
	7612176	Apr 13, 2025	DP U-3190			
	7612176*PED	Oct 13, 2025				
	8216180	Jan 12, 2028	DP			
	8216180*PED	Jul 12, 2028				
	8329648	Aug 18, 2026	U-2588			
	8329648	Aug 18, 2026	U-2589			
	8329648	Aug 18, 2026	U-2590			
	8329648	Aug 18, 2026	U-2593			
	8329648	Aug 18, 2026	U-2594			
	8329648	Aug 18, 2026	U-2595			
	8329648	Aug 18, 2026	U-2596			
	8329648	Aug 18, 2026	U-3188			
	8329648	Aug 18, 2026	U-3189			
	8329648	Aug 18, 2026	U-3190			
	8329648*PED	Feb 18, 2027				
	8361972	Mar 21, 2028	U-2588			
	8361972*PED	Sep 21, 2028				
	8431685	Apr 13, 2025	DP U-2588			
	8431685	Apr 13, 2025	DP U-2589			
	8431685	Apr 13, 2025	DP U-2590			
	8431685	Apr 13, 2025	DP U-3188			
	8431685	Apr 13, 2025	DP U-3189			
	8431685	Apr 13, 2025	DP U-3190			
	8431685*PED	Oct 13, 2025				
	8439864	Mar 25, 2028	DP			
	8439864*PED	Sep 25, 2028				
	8461105	Apr 13, 2025	DP U-2588			
	8461105	Apr 13, 2025	DP U-2589			
	8461105	Apr 13, 2025	DP U-2590			
	8461105	Apr 13, 2025	DP U-3188			
	8461105	Apr 13, 2025	DP U-3189			
	8461105	Apr 13, 2025	DP U-3190			
	8461105*PED	Oct 13, 2025				
	8501698	Jun 20, 2027	DP U-2588			
	8501698*PED	Dec 20, 2027				
	8690837	May 19, 2029	DP			
	8690837*PED	Nov 19, 2029				
	8721615	Jan 18, 2030	DP			
	8721615*PED	Jul 18, 2030				
	8758292	Nov 12, 2027	DP			
	8758292*PED	May 12, 2028				
	8827963	Feb 04, 2029	DP			
	8827963*PED	Aug 04, 2029				
	8906851	Aug 18, 2026	U-2588			
	8906851	Aug 18, 2026	U-2589			
	8906851	Aug 18, 2026	U-2590			
	8906851	Aug 18, 2026	U-2593			
	8906851	Aug 18, 2026	U-3188			
	8906851	Aug 18, 2026	U-3189			
	8906851	Aug 18, 2026	U-3190			
	8906851*PED	Feb 18, 2027				
	8998876	Jan 07, 2030	DP			
	8998876*PED	Jul 07, 2030				
	9238076	Apr 15, 2024	DP U-2588			
	9238076	Apr 15, 2024	DP U-2589			
	9238076	Apr 15, 2024	DP U-2590			
	9238076	Apr 15, 2024	DP U-2599			
	9238076	Apr 15, 2024	DP U-3188			
	9238076	Apr 15, 2024	DP U-3189			
	9238076	Apr 15, 2024	DP U-3190			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	9238076*PED	Oct 15, 2024				
	9320853	Mar 25, 2028	DP			
	9320853*PED	Sep 25, 2028				
	9884092	Aug 18, 2026			U-2588	
	9884092	Aug 18, 2026			U-2589	
	9884092	Aug 18, 2026			U-2590	
	9884092	Aug 18, 2026			U-2593	
	9884092	Aug 18, 2026			U-2594	
	9884092	Aug 18, 2026			U-2595	
	9884092	Aug 18, 2026			U-2596	
	9884092	Aug 18, 2026			U-3188	
	9884092	Aug 18, 2026			U-3189	
	9884092	Aug 18, 2026			U-3190	
	9884092*PED	Feb 18, 2027				
<u>EXENATIDE SYNTHETIC - BYDUREON BCISE</u>						
N 209210 001	6515117	Oct 04, 2025	DS DP U-2588		M-240	Feb 15, 2022
	6515117*PED	Apr 04, 2026			NPP	Jul 22, 2024
	6824822	Oct 09, 2022	DP		PED	Aug 15, 2023
	6824822*PED	Apr 09, 2023			PED	Jan 22, 2025
	7223440	Aug 31, 2021	DP			
	7223440*PED	Mar 03, 2022				
	7456254	Jun 30, 2025	DP U-2588			
	7456254	Jun 30, 2025	DP U-2589			
	7456254	Jun 30, 2025	DP U-2590			
	7456254	Jun 30, 2025	DP U-3188			
	7456254	Jun 30, 2025	DP U-3189			
	7456254	Jun 30, 2025	DP U-3190			
	7456254*PED	Dec 30, 2025				
	7563871	Apr 15, 2024	DP			
	7563871*PED	Oct 15, 2024				
	7612176	Apr 13, 2025	DP U-2589			
	7612176	Apr 13, 2025	DP U-2590			
	7612176	Apr 13, 2025	DP U-3188			
	7612176	Apr 13, 2025	DP U-3189			
	7612176	Apr 13, 2025	DP U-3190			
	7612176*PED	Oct 13, 2025				
	8329648	Aug 18, 2026			U-2588	
	8329648	Aug 18, 2026			U-2589	
	8329648	Aug 18, 2026			U-2590	
	8329648	Aug 18, 2026			U-2593	
	8329648	Aug 18, 2026			U-2594	
	8329648	Aug 18, 2026			U-2595	
	8329648	Aug 18, 2026			U-2596	
	8329648	Aug 18, 2026			U-3188	
	8329648	Aug 18, 2026			U-3189	
	8329648	Aug 18, 2026			U-3190	
	8329648*PED	Feb 18, 2027				
	8361972	Mar 21, 2028			U-2588	
	8361972*PED	Sep 21, 2028				
	8431685	Apr 13, 2025	DP U-2588			
	8431685	Apr 13, 2025	DP U-2589			
	8431685	Apr 13, 2025	DP U-2590			
	8431685	Apr 13, 2025	DP U-2597			
	8431685	Apr 13, 2025	DP U-3188			
	8431685	Apr 13, 2025	DP U-3189			
	8431685	Apr 13, 2025	DP U-3190			
	8431685*PED	Oct 13, 2025				
	8461105	Apr 13, 2025	DP U-2588			
	8461105	Apr 13, 2025	DP U-2589			
	8461105	Apr 13, 2025	DP U-2590			
	8461105	Apr 13, 2025	DP U-2597			
	8461105	Apr 13, 2025	DP U-3188			
	8461105	Apr 13, 2025	DP U-3189			
	8461105	Apr 13, 2025	DP U-3190			
	8461105*PED	Oct 13, 2025				
	8501698	Jun 20, 2027			U-2588	
	8501698*PED	Dec 20, 2027				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON BCISE</u>						
N 209210 001	8895033	Oct 04, 2030	DP U-2589			
	8895033	Oct 04, 2030	DP U-2590			
	8895033	Oct 04, 2030	DP U-2597			
	8895033	Oct 04, 2030	DP U-2601			
	8895033	Oct 04, 2030	DP U-2602			
	8895033	Oct 04, 2030	DP U-3188			
	8895033	Oct 04, 2030	DP U-3189			
	8895033	Oct 04, 2030	DP U-3190			
	8895033*PED	Apr 04, 2031				
	8906851	Aug 18, 2026	U-2588			
	8906851	Aug 18, 2026	U-2589			
	8906851	Aug 18, 2026	U-2590			
	8906851	Aug 18, 2026	U-2593			
	8906851	Aug 18, 2026	U-2597			
	8906851	Aug 18, 2026	U-3188			
	8906851	Aug 18, 2026	U-3189			
	8906851	Aug 18, 2026	U-3190			
	8906851*PED	Feb 18, 2027				
	9238076	Apr 15, 2024	DP U-2588			
	9238076	Apr 15, 2024	DP U-2589			
	9238076	Apr 15, 2024	DP U-2590			
	9238076	Apr 15, 2024	DP U-2597			
	9238076	Apr 15, 2024	DP U-2599			
	9238076	Apr 15, 2024	DP U-3188			
	9238076	Apr 15, 2024	DP U-3189			
	9238076	Apr 15, 2024	DP U-3190			
	9238076*PED	Oct 15, 2024				
	9884092	Aug 18, 2026	U-2588			
	9884092	Aug 18, 2026	U-2589			
	9884092	Aug 18, 2026	U-2590			
	9884092	Aug 18, 2026	U-2593			
	9884092	Aug 18, 2026	U-2594			
	9884092	Aug 18, 2026	U-2595			
	9884092	Aug 18, 2026	U-2596			
	9884092	Aug 18, 2026	U-2597			
	9884092	Aug 18, 2026	U-3188			
	9884092	Aug 18, 2026	U-3189			
	9884092	Aug 18, 2026	U-3190			
	9884092*PED	Feb 18, 2027				
<u>EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET</u>						
N 213072 001	10376470	May 01, 2033	DP U-3095			
	9763885	May 01, 2033	DP U-3095			
<u>EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET</u>						
N 213072 002	10376470	May 01, 2033	DP U-3095			
	9763885	May 01, 2033	DP U-3095			
<u>EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET</u>						
N 213072 003	10376470	May 01, 2033	DP U-3095			
	9763885	May 01, 2033	DP U-3095			
<u>EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET</u>						
N 213072 004	10376470	May 01, 2033	DP U-3095			
	9763885	May 01, 2033	DP U-3095			
<u>FENFLURAMINE HYDROCHLORIDE - FINTEPLA</u>						
N 212102 001	10452815	Jun 29, 2038	U-2859			
	10947183	Dec 20, 2036	DS DP			
	10950331	Sep 28, 2035	U-3098			
	11040018	Aug 02, 2037	U-2861			
<u>FERRIC CARBOXYMALTOSSE - INJECTAFER</u>						
N 203565 001	11123321	Oct 20, 2023	DS DP U-2555			
	11123321	Oct 20, 2023	DS DP U-2557			
	7754702	Feb 15, 2028	U-1432			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 002	11123321	Oct 20, 2023	DS DP U-2555			
	11123321	Oct 20, 2023	DS DP U-2557			
	7612109	Feb 05, 2024	DS DP			
	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	9376505	Oct 20, 2023	DS DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 003	11123321	Oct 20, 2023	DS DP U-2555		NS	Apr 28, 2024
	11123321	Oct 20, 2023	DS DP U-2557			
	7612109	Feb 05, 2024	DS DP			
	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	9376505	Oct 20, 2023	DS DP			
<u>FERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109 001	10624855	Nov 26, 2034	DP			
	10624855*PED	May 26, 2035				
	10682376	Nov 13, 2028	DP			
	10682376*PED	May 13, 2029				
	10695367	Nov 13, 2028	DP			
	10695367*PED	May 13, 2029				
	10925896	Nov 13, 2028	DP			
	10925896*PED	May 13, 2029				
	10925897	Nov 13, 2028	DP			
	10925897*PED	May 13, 2029				
	10933090	Nov 13, 2028	DP			
	10933090*PED	May 13, 2029				
	11013761	Nov 13, 2028	DP			
	11013761*PED	May 13, 2029				
	11013762	Nov 13, 2028	DP			
	11013762*PED	May 13, 2029				
	9561251	Jan 23, 2030	DP U-1468			
	9561251*PED	Jul 23, 2030				
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N 022030 001	8501723	Jun 07, 2027	DP		I-861	Jun 17, 2024
	8501723*PED	Dec 07, 2027			PED	Dec 17, 2024
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N 022030 002	8501723	Jun 07, 2027	DP		I-861	Jun 17, 2024
	8501723*PED	Dec 07, 2027			PED	Dec 17, 2024



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FEXINIDAZOLE - FEXINIDAZOLE</u>						
N 214429 001					NCE ODE-359	Jul 16, 2026 Jul 16, 2028
<u>FINERENONE - KERENDIA</u>						
N 215341 001	8436180	Apr 12, 2029	DS DP		NCE	Jul 09, 2026
<u>FINERENONE - KERENDIA</u>						
N 215341 002	8436180	Apr 12, 2029	DS DP		NCE	Jul 09, 2026
<u>FLUCICLOVINE F-18 - AXUMIN</u>						
N 208054 001	10933147	Dec 30, 2035	U-2450			
	10953112	Nov 28, 2026	U-1879			
	10967077	Dec 30, 2035	U-2450			
<u>FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - TRELEGY ELLIPTA</u>						
N 209482 001	11090294	Nov 29, 2030	U-3202			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	11116721	Feb 26, 2029	DP U-1401			
	11116721	Feb 26, 2029	DP U-1691			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 002	11116721	Feb 26, 2029	DP U-1691			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 001	10022510	May 18, 2031	DP		>A> NPP	Jul 09, 2024
	10022510*PED	Nov 18, 2031			>A> PED	Jan 09, 2025
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 002	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 002	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 003	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 004	10022510	May 18, 2031	DP		NPP	Jul 09, 2024
	10022510*PED	Nov 18, 2031			PED	Jan 09, 2025
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10569034	Aug 16, 2036	DP			
	10569034*PED	Feb 16, 2037				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				
	11000653	Dec 18, 2038	DP			
	11000653*PED	Jun 18, 2039				
>A>	11173259	Jul 06, 2040	DP			
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 004	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9782550	Aug 28, 2035	DP			
	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035	DP			
	9782551*PED	Feb 28, 2036				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 005	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10569034	Aug 16, 2036	DP			
	10569034*PED	Feb 16, 2037				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				
	11000653	Dec 18, 2038	DP			
	11000653*PED	Jun 18, 2039				
>A>	11173259	Jul 06, 2040	DP			
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9782550	Aug 28, 2035	DP			
	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035	DP			
	9782551*PED	Feb 28, 2036				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 006	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10569034	Aug 16, 2036	DP			
	10569034*PED	Feb 16, 2037				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 006	11000653	Dec 18, 2038	DP			
	11000653*PED	Jun 18, 2039				
	>A> 11173259	Jul 06, 2040	DP			
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9782550	Aug 28, 2035	DP			
	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035	DP			
	9782551*PED	Feb 28, 2036				
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 007	>A> 10022510	May 18, 2031	DP		NS	Jul 09, 2024
	>A> 10022510*PED	Nov 18, 2031			PED	Jan 09, 2025
	>A> 10124131	May 18, 2031	DP			
	>A> 10124131*PED	Nov 18, 2031				
	>A> 10195375	Feb 14, 2031	DP			
	>A> 10195375*PED	Aug 14, 2031				
	>A> 10561808	Jan 01, 2032	DP			
	>A> 10561808*PED	Jul 01, 2032				
	>A> 10765820	May 19, 2025	DP			
	>A> 10765820*PED	Nov 19, 2025				
	>A> 7540282	May 06, 2023	DP			
	>A> 7540282*PED	Nov 06, 2023				
	>A> 8651103	Mar 26, 2028	DP			
	>A> 8651103*PED	Sep 26, 2028				
	>A> 8714149	Feb 25, 2032	DP			
	>A> 8714149*PED	Aug 25, 2032				
	>A> 8978966	Jan 13, 2032	DP			
	>A> 8978966*PED	Jul 13, 2032				
	>A> 9216260	Jun 28, 2031	DP			
	>A> 9216260*PED	Dec 28, 2031				
	>A> 9463288	May 19, 2025	DP			
	>A> 9463288*PED	Nov 19, 2025				
	>A> 9616024	Sep 01, 2024	DP			
	>A> 9616024*PED	Mar 01, 2025				
	>A> 9731087	May 18, 2031	DP			
	>A> 9731087*PED	Nov 18, 2031				
<u>FLUTICASONE PROPIONATE - XHANCE</u>						
N 209022 001	11033696	May 20, 2033	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 001	10022510	May 18, 2031	DP		M-61	Jul 09, 2024
	10022510*PED	Nov 18, 2031			PED	Jan 09, 2025
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	7540282	May 06, 2023	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 001	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9066957	Oct 06, 2034	DP U-645			
	9066957*PED	Apr 06, 2035				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9415008	Oct 06, 2034	DP U-645			
	9415008*PED	Apr 06, 2035				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9987229	Sep 01, 2024	DP			
	9987229*PED	Mar 01, 2025				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 002	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9066957	Oct 06, 2034	DP U-645			
	9066957*PED	Apr 06, 2035				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9987229	Sep 01, 2024	DP			
	9987229*PED	Mar 01, 2025				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 003	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 003	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9066957	Oct 06, 2034	DP U-645			
	9066957*PED	Apr 06, 2035				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9987229	Sep 01, 2024	DP			
	9987229*PED	Mar 01, 2025				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 004	10022510	May 18, 2031	DP		M-61	Jul 09, 2024
	10022510*PED	Nov 18, 2031			PED	Jan 09, 2025
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10569034	Aug 16, 2036	DP			
	10569034*PED	Feb 16, 2037				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				
	11000653	Dec 18, 2038	DP			
	11000653*PED	Jun 18, 2039				
>A>	11173259	Jul 06, 2040	DP			
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9066957	Oct 06, 2034	DP U-645			
	9066957*PED	Apr 06, 2035				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9415008	Oct 06, 2034	DP U-645			
	9415008*PED	Apr 06, 2035				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9782550	Aug 28, 2035	DP			
	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035	DP			
	9782551*PED	Feb 28, 2036				
	9987229	Sep 01, 2024	DP			
	9987229*PED	Mar 01, 2025				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 005	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 005	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10569034	Aug 16, 2036	DP			
	10569034*PED	Feb 16, 2037				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				
	11000653	Dec 18, 2038	DP			
	11000653*PED	Jun 18, 2039				
>A>	11173259	Jul 06, 2040	DP			
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9066957	Oct 06, 2034	DP U-645			
	9066957*PED	Apr 06, 2035				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9782550	Aug 28, 2035	DP			
	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035	DP			
	9782551*PED	Feb 28, 2036				
	9987229	Sep 01, 2024	DP			
	9987229*PED	Mar 01, 2025				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 006	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10569034	Aug 16, 2036	DP			
	10569034*PED	Feb 16, 2037				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				
	11000653	Dec 18, 2038	DP			
	11000653*PED	Jun 18, 2039				
>A>	11173259	Jul 06, 2040	DP			
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9066957	Oct 06, 2034	DP U-645			
	9066957*PED	Apr 06, 2035				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 006	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9782550	Aug 28, 2035	DP			
	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035	DP			
	9782551*PED	Feb 28, 2036				
	9987229	Sep 01, 2024	DP			
	9987229*PED	Mar 01, 2025				
<u>FOSCARNET SODIUM - FOSCARNET SODIUM</u>						
A 213001 001					CGT	Dec 28, 2021
<u>FOSDENOPTERIN HYDROBROMIDE - NULIBRY</u>						
N 214018 001	7504095	Jan 31, 2025	DP U-3092		NCE ODE-342	Feb 26, 2026 Feb 26, 2028
<u>GALLIUM GA-68 PSMA-11 - GALLIUM GA 68 PSMA-11</u>						
N 212642 001					NCE W	Dec 01, 2025 Dec 01, 2025
<u>GALLIUM GA-68 PSMA-11 - GALLIUM GA 68 PSMA-11</u>						
N 212643 001					NCE W	Dec 01, 2025 Dec 01, 2025
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 209394 001	10028937	Jun 10, 2030	U-2141		D-175	Sep 26, 2022
	10028937	Jun 10, 2030	U-2532		M-259	Apr 10, 2023
	10028937*PED	Dec 10, 2030			NCE	Aug 03, 2022
	10039754	Jun 10, 2030	U-2141		NPP	Apr 30, 2022
	10039754	Jun 10, 2030	U-2532		ODE-232	Apr 30, 2026
	10039754*PED	Dec 10, 2030			ODE-233	Apr 30, 2026
	10286029	Mar 14, 2034	U-2532		PED	Oct 30, 2022
	10286029*PED	Sep 14, 2034			PED	Feb 03, 2023
	8648037	Jan 19, 2032	DS DP U-2141		PED	Mar 26, 2023
	8648037	Jan 19, 2032	DS DP U-2532		PED	Oct 10, 2023
	8648037*PED	Jul 19, 2032			PED	Oct 30, 2026
	8937150	May 18, 2032	DS DP		PED	Oct 30, 2026
	8937150*PED	Nov 18, 2032				
	9321807	Jun 05, 2035	DS			
	9321807*PED	Dec 05, 2035				
	9586978	Nov 06, 2030	U-2141			
	9586978	Nov 06, 2030	U-2532			
	9586978	Nov 06, 2030	U-3237			
	9586978*PED	May 06, 2031				
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 215110 001	10028937	Jun 10, 2030	U-3167		>A> D-175	Sep 26, 2022
	10028937*PED	Dec 10, 2030			>A> M-259	Apr 10, 2023
	10039754	Jun 10, 2030	U-3167		>A> NCE	Aug 03, 2022
	10039754*PED	Dec 10, 2030			>A> PED	Feb 03, 2023
	10286029	Mar 14, 2034	U-3167		>A> PED	Mar 26, 2023
	10286029*PED	Sep 14, 2034			>A> PED	Oct 10, 2023
	8648037	Jan 19, 2032	DS DP U-3167			
	8648037*PED	Jul 19, 2032				
	8937150	May 18, 2032	DS DP			
	8937150*PED	Nov 18, 2032				
	9321807	Jun 05, 2035	DS DP			
	9321807*PED	Dec 05, 2035				
	9586978	Nov 06, 2030	U-3167			
	9586978	Nov 06, 2030	U-3238			
	9586978*PED	May 06, 2031				



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GLUCAGON - BAOSIMI</u>						
N 210134 001	10894133	Jan 03, 2038	DP			
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001					NPP	Dec 21, 2021
<u>GLYCOPYRROLATE - LONHALA MAGNAIR KIT</u>						
N 208437 001	10940110	Feb 26, 2029	DP U-1773			
<u>GOLODIRSEN - VYONDYS 53</u>						
N 211970 001	10968450	Jun 28, 2025	DS DP			
	10995337	Jun 28, 2025	DP U-2675			
<u>HALOBETASOL PROPIONATE - LEXETTE</u>						
N 210566 001	10857159	Nov 30, 2036	DP			
	10857159*PED	May 30, 2037				
	11020407	Nov 30, 2036	DP U-3143			
<u>HYDROCORTISONE - ALKINDI SPRINKLE</u>						
N 213876 001	9649280	May 12, 2034	DP U-3075			
	9675559	Jan 10, 2033	U-3075			
	9717740	Nov 19, 2032	U-3075			
<u>HYDROCORTISONE - ALKINDI SPRINKLE</u>						
N 213876 002	9649280	May 12, 2034	DP U-3075			
	9675559	Jan 10, 2033	U-3075			
	9717740	Nov 19, 2032	U-3075			
<u>HYDROCORTISONE - ALKINDI SPRINKLE</u>						
N 213876 003	9649280	May 12, 2034	DP U-3075			
	9675559	Jan 10, 2033	U-3075			
	9717740	Nov 19, 2032	U-3075			
<u>HYDROCORTISONE - ALKINDI SPRINKLE</u>						
N 213876 004	9649280	May 12, 2034	DP U-3075			
	9675559	Jan 10, 2033	U-3075			
	9717740	Nov 19, 2032	U-3075			
<u>HYDROXYPROGESTERONE CAPROATE - MAKENA (AUTOINJECTOR)</u>						
N 021945 004	>A> 11154562	May 02, 2036	U-2236			
<u>IBREXAFUNGERP CITRATE - BREXAFEMME</u>						
N 214900 001	10174074	Jan 19, 2035	DS DP		NCE	Jun 01, 2026
	10370406	Jan 19, 2035	U-3159		GAIN	Jun 01, 2031
	10927142	Jan 19, 2035	DS			
	8188085	Aug 28, 2030	DS DP U-3159			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	10961251	Jun 03, 2033	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	10961251	Jun 03, 2033	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	10961251	Jun 03, 2033	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002	10961251	Jun 03, 2033	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003	10961251	Jun 03, 2033	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 004	10961251	Jun 03, 2033	DP			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001	10881632	Apr 29, 2030	U-3052			
	10894028	Jun 28, 2033	U-3053			
	11000499	Jun 28, 2033	U-3126			
	11103477	Apr 29, 2030	U-3209			
	11116742	Jun 28, 2033	U-3221			
	11154526	Apr 29, 2030	U-3240			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 002	10881632	Apr 29, 2030	U-3052			
	10894028	Jun 28, 2033	U-3053			
	11000499	Jun 28, 2033	U-3126			
	11103477	Apr 29, 2030	U-3209			
	11116742	Jun 28, 2033	U-3221			
	11154526	Apr 29, 2030	U-3240			
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483 001	10918635	Apr 30, 2030	U-1455			
	10918635	Apr 30, 2030	U-172			
<u>INFIGRATINIB PHOSPHATE - TRUSELTIQ</u>						
N 214622 001	10278969	Dec 11, 2034	DP		NCE	May 28, 2026
	>A> 11160804	Dec 11, 2034	DP		ODE-353	May 28, 2028
	8552002	Aug 25, 2029	DS DP			
	9067896	Aug 06, 2028	DS			
<u>INFIGRATINIB PHOSPHATE - TRUSELTIQ</u>						
N 214622 002	10278969	Dec 11, 2034	DP		NCE	May 28, 2026
	>A> 11160804	Dec 11, 2034	DP		ODE-353	May 28, 2028
	8552002	Aug 25, 2029	DS DP			
	9067896	Aug 06, 2028	DS			
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793 001	10980795	Jun 12, 2033	U-1848			
	10993914	Oct 15, 2036	DP			
	8329213	Jan 06, 2027	DS DP			
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207500 001	>A> 10206879	Sep 14, 2027	DP			
	>A> 10603280	Sep 14, 2027	DP			
<u>ISOPROPYL ALCOHOL - ZURAGARD</u>						
N 210872 001	10688291	Dec 20, 2034	DP U-1397		M-268	Jun 24, 2024
	8226971	May 06, 2025	DP			
	8389583	Aug 09, 2029	U-1397			
	8703828	May 23, 2028	DP			
	9011897	Feb 08, 2025	DP			
	9629368	May 23, 2028	U-1397			
	9844654	Apr 24, 2036	DP U-1397			
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001					ODE-338	Dec 21, 2027
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001					ODE-338	Dec 21, 2027
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002					ODE-338	Dec 21, 2027

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR - KALYDECO</u>						
N 207925	003				ODE-338	Dec 21, 2027
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491	001	10058546	Jul 15, 2033	U-2399	ODE-335	Dec 21, 2027
		10058546	Jul 15, 2033	U-2572		
		10058546	Jul 15, 2033	U-3022		
		10058546	Jul 15, 2033	U-3023		
		10081621	Mar 25, 2031	DP U-2420		
		10081621	Mar 25, 2031	DP U-2571		
		10081621	Mar 25, 2031	DP U-3024		
		10081621	Mar 25, 2031	DP U-3025		
		10206877	Apr 14, 2035	DP U-2498		
		10206877	Apr 14, 2035	DP U-2570		
		10206877	Apr 14, 2035	DP U-3026		
		10206877	Apr 14, 2035	DP U-3027		
		8354427	Jul 06, 2026	U-3021		
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491	002	10058546	Jul 15, 2033	U-2399	ODE-335	Dec 21, 2027
		10058546	Jul 15, 2033	U-2572		
		10058546	Jul 15, 2033	U-3022		
		10058546	Jul 15, 2033	U-3023		
		10081621	Mar 25, 2031	DP U-2420		
		10081621	Mar 25, 2031	DP U-2571		
		10081621	Mar 25, 2031	DP U-3024		
		10081621	Mar 25, 2031	DP U-3025		
		10206877	Apr 14, 2035	DP U-2498		
		10206877	Apr 14, 2035	DP U-2570		
		10206877	Apr 14, 2035	DP U-3026		
		10206877	Apr 14, 2035	DP U-3027		
		8354427	Jul 06, 2026	U-3021		
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038	001	11052075	Dec 04, 2028	DP U-3181		
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038	002	11052075	Dec 04, 2028	DP U-3181		
<u>IVERMECTIN - IVERMECTIN</u>						
A 210720	001				PC	May 29, 2021
<u>IVERMECTIN - SOOLANTRA</u>						
N 206255	001	11033565	Apr 22, 2024	DP		
<u>IVOSIDENIB - TIBSOVO</u>						
N 211192	001	10717764	Jan 18, 2033	U-3215	I-875	Aug 25, 2024
		10980788	Jun 07, 2039	U-3112		
		10980788	Jun 07, 2039	U-3113		
		10980788	Jun 07, 2039	U-3214		
		9474779	Aug 19, 2033	DS DP U-2350		
		9474779	Aug 19, 2033	DS DP U-2533		
		9474779	Aug 19, 2033	DS DP U-2534		
		9474779	Aug 19, 2033	DS DP U-3213		
		9850277	Jan 18, 2033	DS DP U-2350		
		9850277	Jan 18, 2033	DS DP U-2533		
		9850277	Jan 18, 2033	DS DP U-2534		
		9850277	Jan 18, 2033	DS DP U-3213		
<u>LANSOPRAZOLE - LANSOPRAZOLE</u>						
N 208025	001	11077055	Apr 21, 2036	DP		
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 210861	001	10799505	Aug 15, 2036	DS DP		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 210861 002	10799505	Aug 15, 2036	DS DP			
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 211710 001	10799505	Aug 15, 2036	DS			
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 001	11053214	Dec 05, 2037	DS DP U-1719			
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 002	11053214	Dec 05, 2037	DS DP U-1719			
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 003	11053214	Dec 05, 2037	DS DP U-1719		NCE	Jan 31, 2025
	7423050	Apr 06, 2025	DS DP U-1719			
	8748459	Mar 27, 2023	U-1719			
<u>LATANOPROST; NETARSUDIL DIMESYLATE - ROCKLATAN</u>						
N 208259 001	10882840	Jul 11, 2026	U-1524			
	11021456	Jul 11, 2026	U-1524			
	11028081	Jan 27, 2030	U-1524			
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001					ODE*	Aug 28, 2026
					ODE*	Aug 28, 2026
					ODE*	Aug 28, 2026
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 002					ODE*	Apr 07, 2024
					ODE*	Aug 28, 2026
					ODE*	Aug 28, 2026
					ODE*	Aug 28, 2026
					PED	Oct 07, 2024
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 001	7253286	Oct 24, 2025	DS DP		I-868 M-269	Aug 10, 2024 Jul 21, 2024
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002	7253286	Oct 24, 2025	DS DP		I-868 M-269	Aug 10, 2024 Jul 21, 2024
<u>LEUPROLIDE MESYLATE - CAMCEVI KIT</u>						
N 211488 001	10646572	Jan 16, 2027	DP		NP	May 25, 2024
	9572857	Jan 16, 2027	DP			
	9744207	Jan 16, 2027	DP			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 001	>A> 11160786	Mar 14, 2034	DP			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 002	>A> 11160786	Mar 14, 2034	DP			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 003	>A> 11160786	Mar 14, 2034	DP			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 004	>A> 11160786	Mar 14, 2034	DP			
<u>LEVONORGESTREL - MIRENA</u>						
N 021225 001	10987244	Apr 01, 2031	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVONORGESTREL - SKYLA</u>						
N 203159 001	10987244	Apr 01, 2031	DP			
<u>LEVONORGESTREL - LILETTA</u>						
N 206229 001	11090186	Oct 24, 2033	U-2348			
<u>LEVONORGESTREL - KYLEENA</u>						
N 208224 001	10987244	Apr 01, 2031	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 001	11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 002	11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 003	11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 004	11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 005	11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 006	11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 007	11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 008	11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 009	11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 010	11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 011	11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 012	11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 013	11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 014	11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 015	11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 210632 001	11135190	Dec 01, 2036	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 210632 002	11135190	Dec 01, 2036	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 210632 003	11135190	Dec 01, 2036	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 214253 001	11154498	Jul 20, 2036	DP			
<u>LIFITEGRAST - XIIDRA</u>						
N 208073 001	11058677	Dec 18, 2033	DP			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	11033552	May 04, 2027	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	10973827	Apr 02, 2029	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	10973827	Apr 02, 2029	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	10973827	Apr 02, 2029	DP			
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001	11097063	Jul 17, 2026	DP		NPP	Dec 04, 2023
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 001	7105486	Feb 24, 2023	U-727			
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-842			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-842			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-842			
	7678771*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP U-842			
	7687467*PED	Aug 24, 2023				
	7700561	Feb 24, 2023	DP			
	7700561*PED	Aug 24, 2023				
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 002	7105486	Feb 24, 2023	U-727			
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-842			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-842			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-842			
	7678771*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP U-842			
	7687467*PED	Aug 24, 2023				
	7700561	Feb 24, 2023	DP			
	7700561*PED	Aug 24, 2023				
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 003	7105486	Feb 24, 2023	U-727			
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7671031	Feb 24, 2023	U-727			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 003	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-842			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-842			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-842			
	7678771*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP U-842			
	7687467*PED	Aug 24, 2023				
	7700561	Feb 24, 2023	DP			
	7700561*PED	Aug 24, 2023				
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 004	7105486	Feb 24, 2023	U-727			
	7105486	Feb 24, 2023	U-842			
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-842			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-842			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-842			
	7678771*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP U-842			
	7687467*PED	Aug 24, 2023				
	7700561	Feb 24, 2023	DP			
	7700561*PED	Aug 24, 2023				
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 005	7105486	Feb 24, 2023	U-842			
	7105486*PED	Aug 24, 2023				
	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-842			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-842			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-842			
	7678771*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP U-842			
	7687467*PED	Aug 24, 2023				
	7700561	Feb 24, 2023	DP			
	7700561*PED	Aug 24, 2023				
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 006	7105486	Feb 24, 2023	U-727			
	7105486	Feb 24, 2023	U-842			
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-842			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-842			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-842			
	7678771*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP U-842			
	7687467*PED	Aug 24, 2023				
	7700561	Feb 24, 2023	DP			
	7700561*PED	Aug 24, 2023				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 007	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7655630	Feb 24, 2023	DS			
	7655630*PED	Aug 24, 2023				
	7659253	Feb 24, 2023	DS DP		U-727	
	7659253*PED	Aug 24, 2023				
	7659254	Feb 24, 2023			U-1034	
	7659254*PED	Aug 24, 2023				
	7662787	Feb 24, 2023	DS			
	7662787*PED	Aug 24, 2023				
	7662788	Feb 24, 2023			U-727	
	7662788*PED	Aug 24, 2023				
	7671030	Feb 24, 2023	DP		U-727	
	7671030*PED	Aug 24, 2023				
	7671031	Feb 24, 2023			U-727	
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP		U-842	
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023			U-842	
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP			
	7678771*PED	Aug 24, 2023				
	7687466	Feb 24, 2023	DP			
	7687466*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP		U-842	
	7687467*PED	Aug 24, 2023				
	7700561	Feb 24, 2023	DP			
	7700561*PED	Aug 24, 2023				
	7713936	Feb 24, 2023			U-727	
	7713936*PED	Aug 24, 2023				
	7718619	Feb 24, 2023	DP		U-842	
	7718619*PED	Aug 24, 2023				
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 001	7105486	Feb 24, 2023			U-727	
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7655630	Feb 24, 2023	DS DP			
	7655630*PED	Aug 24, 2023				
	7659253	Feb 24, 2023	DS DP		U-727	
	7659253*PED	Aug 24, 2023				
	7659254	Feb 24, 2023			U-727	
	7659254*PED	Aug 24, 2023				
	7662787	Feb 24, 2023	DS			
	7662787*PED	Aug 24, 2023				
	7662788	Feb 24, 2023			U-727	
	7662788*PED	Aug 24, 2023				
	7671030	Feb 24, 2023	DP		U-727	
	7671030*PED	Aug 24, 2023				
	7671031	Feb 24, 2023			U-727	
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP		U-727	
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023			U-727	
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP		U-727	
	7678771*PED	Aug 24, 2023				
	7687466	Feb 24, 2023	DP			
	7687466*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP		U-727	
	7687467*PED	Aug 24, 2023				
	7713936	Feb 24, 2023			U-727	
	7713936*PED	Aug 24, 2023				
	7718619	Feb 24, 2023	DP		U-727	
	7718619*PED	Aug 24, 2023				
	7723305	Feb 24, 2023	DP		U-727	
	7723305*PED	Aug 24, 2023				



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 001	7105486	Feb 24, 2023	U-727			
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7655630	Feb 24, 2023	DS DP			
	7655630*PED	Aug 24, 2023				
	7659253	Feb 24, 2023	DS DP U-727			
	7659253*PED	Aug 24, 2023				
	7659254	Feb 24, 2023	U-727			
	7659254*PED	Aug 24, 2023				
	7662787	Feb 24, 2023	DS			
	7662787*PED	Aug 24, 2023				
	7662788	Feb 24, 2023	U-727			
	7662788*PED	Aug 24, 2023				
	7671030	Feb 24, 2023	DP U-727			
	7671030*PED	Aug 24, 2023				
	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-727			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-727			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-727			
	7678771*PED	Aug 24, 2023				
	7687466	Feb 24, 2023	DP			
	7687466*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP U-727			
	7687467*PED	Aug 24, 2023				
	7713936	Feb 24, 2023	U-727			
	7713936*PED	Aug 24, 2023				
	7718619	Feb 24, 2023	DP U-727			
	7718619*PED	Aug 24, 2023				
	7723305	Feb 24, 2023	DP U-727			
	7723305*PED	Aug 24, 2023				
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 002	7105486	Feb 24, 2023	U-727			
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7655630	Feb 24, 2023	DS DP			
	7655630*PED	Aug 24, 2023				
	7659253	Feb 24, 2023	DS DP U-727			
	7659253*PED	Aug 24, 2023				
	7659254	Feb 24, 2023	U-727			
	7659254*PED	Aug 24, 2023				
	7662787	Feb 24, 2023	DS			
	7662787*PED	Aug 24, 2023				
	7662788	Feb 24, 2023	U-727			
	7662788*PED	Aug 24, 2023				
	7671030	Feb 24, 2023	DP U-727			
	7671030*PED	Aug 24, 2023				
	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-727			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-727			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-727			
	7678771*PED	Aug 24, 2023				
	7687466	Feb 24, 2023	DP			
	7687466*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP U-727			
	7687467*PED	Aug 24, 2023				
	7713936	Feb 24, 2023	U-727			
	7713936*PED	Aug 24, 2023				
	7718619	Feb 24, 2023	DP U-727			
	7718619*PED	Aug 24, 2023				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 002	7723305	Feb 24, 2023	DP U-727			
	7723305*PED	Aug 24, 2023				
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 003	7105486	Feb 24, 2023	U-727			
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7655630	Feb 24, 2023	DS DP			
	7655630*PED	Aug 24, 2023				
	7659253	Feb 24, 2023	DS DP U-727			
	7659253*PED	Aug 24, 2023				
	7659254	Feb 24, 2023	U-727			
	7659254*PED	Aug 24, 2023				
	7662787	Feb 24, 2023	DS			
	7662787*PED	Aug 24, 2023				
	7662788	Feb 24, 2023	U-727			
	7662788*PED	Aug 24, 2023				
	7671030	Feb 24, 2023	DP U-727			
	7671030*PED	Aug 24, 2023				
	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-727			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-727			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-727			
	7678771*PED	Aug 24, 2023				
	7687466	Feb 24, 2023	DP			
	7687466*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP U-727			
	7687467*PED	Aug 24, 2023				
	7713936	Feb 24, 2023	U-727			
	7713936*PED	Aug 24, 2023				
	7718619	Feb 24, 2023	DP U-727			
	7718619*PED	Aug 24, 2023				
	7723305	Feb 24, 2023	DP U-727			
	7723305*PED	Aug 24, 2023				
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 004	7105486	Feb 24, 2023	U-727			
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7655630	Feb 24, 2023	DS DP			
	7655630*PED	Aug 24, 2023				
	7659253	Feb 24, 2023	DS DP U-727			
	7659253*PED	Aug 24, 2023				
	7659254	Feb 24, 2023	U-727			
	7659254*PED	Aug 24, 2023				
	7662787	Feb 24, 2023	DS			
	7662787*PED	Aug 24, 2023				
	7662788	Feb 24, 2023	U-727			
	7662788*PED	Aug 24, 2023				
	7671030	Feb 24, 2023	DP U-727			
	7671030*PED	Aug 24, 2023				
	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-727			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-727			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-727			
	7678771*PED	Aug 24, 2023				
	7687466	Feb 24, 2023	DP			
	7687466*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP U-727			
	7687467*PED	Aug 24, 2023				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 004	7713936	Feb 24, 2023	U-727			
	7713936*PED	Aug 24, 2023				
	7718619	Feb 24, 2023	DP U-727			
	7718619*PED	Aug 24, 2023				
	7723305	Feb 24, 2023	DP U-727			
	7723305*PED	Aug 24, 2023				
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 005	7105486	Feb 24, 2023	U-727			
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7655630	Feb 24, 2023	DS DP			
	7655630*PED	Aug 24, 2023				
	7659253	Feb 24, 2023	DS DP U-727			
	7659253*PED	Aug 24, 2023				
	7659254	Feb 24, 2023	U-727			
	7659254*PED	Aug 24, 2023				
	7662787	Feb 24, 2023	DS			
	7662787*PED	Aug 24, 2023				
	7662788	Feb 24, 2023	U-727			
	7662788*PED	Aug 24, 2023				
	7671030	Feb 24, 2023	DP U-727			
	7671030*PED	Aug 24, 2023				
	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-727			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-727			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-727			
	7678771*PED	Aug 24, 2023				
	7687466	Feb 24, 2023	DP			
	7687466*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP U-727			
	7687467*PED	Aug 24, 2023				
	7713936	Feb 24, 2023	U-727			
	7713936*PED	Aug 24, 2023				
	7718619	Feb 24, 2023	DP U-727			
	7718619*PED	Aug 24, 2023				
	7723305	Feb 24, 2023	DP U-727			
	7723305*PED	Aug 24, 2023				
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 006	7105486	Feb 24, 2023	U-727			
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7655630	Feb 24, 2023	DS DP			
	7655630*PED	Aug 24, 2023				
	7659253	Feb 24, 2023	DS DP U-727			
	7659253*PED	Aug 24, 2023				
	7659254	Feb 24, 2023	U-727			
	7659254*PED	Aug 24, 2023				
	7662787	Feb 24, 2023	DS			
	7662787*PED	Aug 24, 2023				
	7662788	Feb 24, 2023	U-727			
	7662788*PED	Aug 24, 2023				
	7671030	Feb 24, 2023	DP U-727			
	7671030*PED	Aug 24, 2023				
	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-727			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-727			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-727			
	7678771*PED	Aug 24, 2023				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 006	7687466	Feb 24, 2023	DP			
	7687466*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP U-727			
	7687467*PED	Aug 24, 2023				
	7713936	Feb 24, 2023	U-727			
	7713936*PED	Aug 24, 2023				
	7718619	Feb 24, 2023	DP U-727			
	7718619*PED	Aug 24, 2023				
	7723305	Feb 24, 2023	DP U-727			
	7723305*PED	Aug 24, 2023				
<u>LISINAPRIL - OBRELIS</u>						
N 208401 001	10940177	Nov 06, 2035	DP			
	>A> 11179434	Nov 06, 2035	DP			
<u>LONAFARNIB - ZOKINVY</u>						
N 213969 001	7838531	Jul 26, 2024	U-3070		ODE-324	Nov 20, 2027
	8828356	Oct 17, 2023	U-3070			
<u>LONAFARNIB - ZOKINVY</u>						
N 213969 002	7838531	Jul 26, 2024	U-3070		ODE-324	Nov 20, 2027
	8828356	Oct 17, 2023	U-3070			
<u>LOPERAMIDE HYDROCHLORIDE - LOPERAMIDE HYDROCHLORIDE</u>						
A 213070 001					CGT	Apr 20, 2022
<u>LORAZEPAM - LOREEV XR</u>						
N 214826 001	8999393	Jan 08, 2034	DP U-3210			
<u>LORAZEPAM - LOREEV XR</u>						
N 214826 002	8999393	Jan 08, 2034	DP U-3210			
<u>LORAZEPAM - LOREEV XR</u>						
N 214826 003	8999393	Jan 08, 2034	DP U-3210			
<u>LORLATINIB - LOREBENA</u>						
N 210868 001	10420749	Jul 27, 2036	DS DP U-2633		I-847	Mar 03, 2024
	10420749	Jul 27, 2036	DS DP U-3096		ODE-349	Mar 03, 2028
	11020376	Jul 27, 2036	DP			
<u>LORLATINIB - LOREBENA</u>						
N 210868 002	10420749	Jul 27, 2036	DS DP U-2633		I-847	Mar 03, 2024
	10420749	Jul 27, 2036	DS DP U-3096		ODE-349	Mar 03, 2028
	11020376	Jul 27, 2036	DP			
<u>LOTEPREDNOL ETABONATE - LOTEPREDNOL ETABONATE</u>						
A 212450 001					CGT	Nov 02, 2021
<u>LOTEPREDNOL ETABONATE - EYSUVIS</u>						
N 210933 001	10940108	May 03, 2033	U-2985			
	10945948	May 03, 2033	U-2985			
	10993908	May 03, 2033	U-3117			
<u>LUMASIRAN SODIUM - OXLUMO</u>						
N 214103 001	11060093	Dec 26, 2034	DS DP U-2995		ODE-339	Nov 23, 2027
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 001	10960009	Dec 03, 2034	U-814			
<u>MACITENTAN - OPSUMIT</u>						
N 204410 001	10946015	Sep 11, 2026	DP U-1445			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE - SUTAB</u>						
N 213135 001	11033498	Aug 04, 2037	U-3164			
<u>MANNITOL - BRONCHITOL</u>						
N 202049 001					NP ODE-327	Oct 30, 2023 Oct 30, 2027
<u>MARALIXIBAT CHLORIDE - LIVMARLI</u>						
N 214662 001					NCE	Sep 29, 2026
<u>MELOXICAM - ANJESO</u>						
N 210583 001	10881663	Mar 08, 2039	U-3038			
<u>MELPHALAN FLUFENAMIDE HYDROCHLORIDE - PEPAXTO</u>						
N 214383 001	10285946	Apr 25, 2032	DP		NCE	Feb 26, 2026
	10322182	Apr 25, 2032	DP		ODE-348	Feb 26, 2028
	10543274	Apr 25, 2032	U-3093			
	10869928	Apr 25, 2032	DP			
	6992207	Jun 25, 2022	DS DP U-3093			
<u>MELPHALAN HYDROCHLORIDE - EVOMELA</u>						
N 207155 001	10940128	Jun 14, 2030	DP U-3086			
	11020363	May 28, 2030	DP			
<u>MEROPENEM; VABORBACTAM - VABOMERE</u>						
N 209776 001	11007206	Aug 08, 2031	U-3128		NCE	Aug 29, 2022
	8680136	Aug 29, 2031	DS DP		GAIN	Aug 29, 2027
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 001					M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 002					M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 001					M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 002					M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>METHOTREXATE SODIUM - XATMEP</u>						
N 208400 001	>A> 11116724	Jan 02, 2033	U-1349			
	>A> 11116724	Jan 02, 2033	U-1699			
<u>METHYLENE BLUE - PROVAYBLUE</u>						
N 204630 002					ODE*	Apr 08, 2023
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 001	11103494	Aug 14, 2033	DP			
	11103495	Aug 14, 2033	DP U-2993			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 002	11103494	Aug 14, 2033	DP			
	11103495	Aug 14, 2033	DP U-2993			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 003	11103494	Aug 14, 2033	DP			
	11103495	Aug 14, 2033	DP U-2993			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 001	10881618	Mar 23, 2032	U-2357			
	10905652	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 002	10881618	Mar 23, 2032	U-2357			
	10905652	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 003	10881618	Mar 23, 2032	U-2357			
	10905652	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 004	10881618	Mar 23, 2032	U-2357			
	10905652	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 005	10881618	Mar 23, 2032	U-2357			
	10905652	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 001					M-82	Jun 28, 2024
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 002					M-82	Jun 28, 2024
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 003					M-82	Jun 28, 2024
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 004					M-82	Jun 28, 2024
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 005					M-82	Jun 28, 2024
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 006					M-82	Jun 28, 2024
<u>METOCLOPRAMIDE HYDROCHLORIDE - GIMOTI</u>						
N 209388 001	11020361	Dec 22, 2029	U-2843			
<u>MIDAZOLAM - MIDAZOLAM IN 0.9% SODIUM CHLORIDE</u>						
N 211844 001	10966990	Jun 20, 2038	DP			
<u>MIDAZOLAM - MIDAZOLAM IN 0.9% SODIUM CHLORIDE</u>						
N 211844 002	10966990	Jun 20, 2038	DP			
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001	10874655	May 30, 2038	U-2371			
	10874656	May 30, 2038	U-2371			
	10874657	May 30, 2038	U-2371			
	10925866	Apr 28, 2028	U-2371			
	11033538	Apr 28, 2028	U-2371			
	RE48608	Feb 12, 2029	U-2371			
<u>MINOCYCLINE HYDROCHLORIDE - MINOLIRA</u>						
N 209269 001	11103517	Apr 07, 2036	DP			
<u>MINOCYCLINE HYDROCHLORIDE - MINOLIRA</u>						
N 209269 002	11103517	Apr 07, 2036	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MINOCYCLINE HYDROCHLORIDE - ZILXI</u>						
N 213690 001	10946101	Oct 01, 2030	U-1631			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 001	10842780	Sep 28, 2029	DP U-2996		I-777	Apr 27, 2021
	10842780*PED	Mar 28, 2030			I-855	Mar 25, 2024
	6346532	Mar 27, 2022	DS DP		PED	Sep 25, 2024
	6346532*PED	Sep 27, 2022				
	8772315	Oct 30, 2028	U-2300			
	8772315*PED	Apr 30, 2029				
	8835474	Nov 04, 2023	U-1527			
	8835474*PED	May 04, 2024				
	RE44872	Nov 04, 2023	U-1527			
	RE44872*PED	May 04, 2024				
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 002	10842780	Sep 28, 2029	DP U-2996		I-777	Apr 27, 2021
	10842780*PED	Mar 28, 2030			I-855	Mar 25, 2024
	6346532	Mar 27, 2022	DS DP		PED	Sep 25, 2024
	6346532*PED	Sep 27, 2022				
	8772315	Oct 30, 2028	U-2300			
	8772315*PED	Apr 30, 2029				
	8835474	Nov 04, 2023	U-1527			
	8835474*PED	May 04, 2024				
	RE44872	Nov 04, 2023	U-1527			
	RE44872*PED	May 04, 2024				
<u>MIRABEGRON - MYRBETRIO GRANULES</u>						
N 213801 001	10058536	Mar 31, 2036	DP U-3108		NP	Mar 25, 2024
	10058536*PED	Oct 01, 2036			PED	Sep 25, 2024
	6346532	Mar 27, 2022	DS			
	6346532*PED	Sep 27, 2022				
	7342117	Nov 04, 2023	DS			
	7342117*PED	May 04, 2024				
	7982049	Nov 04, 2023	DP			
	7982049*PED	May 04, 2024				
<u>MOBOCERTINIB SUCCINATE - EXKIVITY</u>						
N 215310 001	10227342	May 13, 2035	DS DP U-3220		NCE	Sep 15, 2026
	9796712	May 13, 2035	DS DP			
<u>MONOMETHYL FUMARATE - BAFIERTAM</u>						
N 210296 001	10918615	Aug 12, 2035	DP U-1384			
	10918616	Jun 03, 2035	U-1384			
	10918617	Aug 10, 2035	DP			
	10945985	Aug 14, 2035	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
A 212451 001					CGT	Aug 10, 2021
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
A 212451 002					CGT	Aug 10, 2021
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 022195 001					NPP	Jun 02, 2024
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 022195 002					NPP	Jun 02, 2024
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 022207 001					NPP	Jun 02, 2024
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 022207 002					NPP	Jun 02, 2024

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NALDEMEDINE TOSYLATE - SYMPROIC</u>						
N 208854 001	10952968	May 13, 2033	DS DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	10960155	Jun 25, 2026	DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO (AUTOINJECTOR)</u>						
N 209862 001	10960155	Jun 25, 2026	DP			
<u>NALOXONE HYDROCHLORIDE - KLOXXADO</u>						
N 212045 001	10722510	Aug 26, 2034	DP U-3110			
	10973814	Aug 26, 2034	DP U-3110			
<u>NAPROXEN SODIUM - NAPROXEN SODIUM</u>						
N 021920 001	11090280	Mar 03, 2026	DP U-1731			
	11090280	Mar 03, 2026	DP U-1732			
	11090280	Mar 03, 2026	DP U-3195			
<u>NEBIVOLOL HYDROCHLORIDE - NEBIVOLOL HYDROCHLORIDE</u>						
A 203659 001					PC	Dec 17, 2021
<u>NEBIVOLOL HYDROCHLORIDE - NEBIVOLOL HYDROCHLORIDE</u>						
A 203659 002					PC	Dec 17, 2021
<u>NEBIVOLOL HYDROCHLORIDE - NEBIVOLOL HYDROCHLORIDE</u>						
A 203659 003					PC	Dec 17, 2021
<u>NEBIVOLOL HYDROCHLORIDE - NEBIVOLOL HYDROCHLORIDE</u>						
A 203659 004					PC	Dec 17, 2021
<u>NERATINIB MALEATE - NERLYNX</u>						
N 208051 001	10035788	Oct 15, 2028	U-2043		D-182	Jun 28, 2024
	10035788	Oct 15, 2028	U-3047			
	10035788	Oct 15, 2028	U-3097			
	>A> 7399865	Dec 29, 2030	DS DP			
	7982043	Oct 08, 2025	U-2043			
	7982043	Oct 08, 2025	U-3047			
	7982043	Oct 08, 2025	U-3097			
	8518446	Nov 20, 2030	DP U-2043			
	8518446	Nov 20, 2030	DP U-3047			
	8518446	Nov 20, 2030	DP U-3097			
	8669273	Jul 18, 2031	U-3047			
	8790708	Nov 05, 2030	DP U-2043			
	8790708	Nov 05, 2030	DP U-3047			
	8790708	Nov 05, 2030	DP U-3097			
	9139558	Oct 15, 2028	U-2043			
	9139558	Oct 15, 2028	U-3047			
	9139558	Oct 15, 2028	U-3097			
	9211291	Mar 24, 2030	U-2043			
	9211291	Mar 24, 2030	U-3097			
	9265784	Aug 04, 2029	U-3047			
	9630946	Oct 15, 2028	U-2043			
	9630946	Oct 15, 2028	U-3047			
	9630946	Oct 15, 2028	U-3097			
<u>NETARSUDIL MESYLATE - RHOPRESSA</u>						
N 208254 001	10882840	Jul 11, 2026	U-1524			
	11021456	Jul 11, 2026	U-1524			
	11028081	Jan 27, 2030	U-1524			
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	10961195	Sep 25, 2035	DS DP			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NIFURTIMOX - LAMPIT</u>						
N 213464	001				ODE-319	Aug 06, 2027
<u>NIFURTIMOX - LAMPIT</u>						
N 213464	002				ODE-319	Aug 06, 2027
<u>NILOTINIB HYDROCHLORIDE - TASIGNA</u>						
N 022068	001	8389537				
		8389537*PED				
		8415363	DS DP		U-1374	
		8415363	DS DP		U-1407	
		8415363*PED				
		8501760		DP		
		8501760*PED				
		9061029			U-1374	
		9061029	DS		U-3231	
		9061029*PED				
<u>NILOTINIB HYDROCHLORIDE - TASIGNA</u>						
N 022068	002	8389537				
		8389537*PED				
		8415363	DS DP		U-1374	
		8415363	DS DP		U-1407	
		8415363*PED				
		8501760		DP		
		8501760*PED				
		9061029			U-1374	
		9061029	DS		U-3231	
		9061029*PED				
<u>NILOTINIB HYDROCHLORIDE - TASIGNA</u>						
N 022068	003	8389537				
		8389537*PED				
		8415363	DS DP		U-1374	
		8415363	DS DP		U-1407	
		8415363*PED				
		8501760		DP		
		8501760*PED				
		9061029			U-1374	
		9061029	DS		U-3231	
		9061029*PED				
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 208447	001	11091459				
		8071623		DP		
			DS DP			
<u>NITAZOXANIDE - NITAZOXANIDE</u>						
A 213820	001				CGT	Jun 05, 2021
<u>NITRIC OXIDE - GENOSYL</u>						
N 202860	001	10124142				
		10814092			U-3037	
		10926054		DP		
		11103669		DP		
		7947227			U-3037	
		8057742			U-3037	
		8226916			U-3037	
		8607785		DP		
		8609028			U-3037	
		8821801		DP		
		8944049		DP		
		9522249		DP		
		9701538		DP		
		9956373			U-3037	

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OBETICHOLIC ACID - OCALIVA</u>						
N 207999 001	RE48286	Nov 16, 2027	DS DP			
<u>OBETICHOLIC ACID - OCALIVA</u>						
N 207999 002	RE48286	Nov 16, 2027	DS DP			
<u>OCTREOTIDE ACETATE - MYCAPSSA</u>						
N 208232 001	11052126	Feb 03, 2036		U-2857		
	11141457	Dec 28, 2040		U-3232		
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 001	10011633	Nov 08, 2031		U-3186	NCE	Jul 20, 2026
	10093697	Nov 08, 2031		U-3186	ODE-363	Jul 20, 2028
	10487111	Nov 08, 2031		U-3186		
	10487111	Nov 08, 2031		U-3187		
	10975046	Jun 20, 2039	DS			
	10981952	Nov 08, 2031		U-3186		
	10981952	Nov 08, 2031		U-3187		
	7132416	Sep 05, 2022	DS DP			
	9694018	Nov 08, 2031		U-3186		
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 002	10011633	Nov 08, 2031		U-3186	NCE	Jul 20, 2026
	10093697	Nov 08, 2031		U-3186	ODE-363	Jul 20, 2028
	10487111	Nov 08, 2031		U-3186		
	10487111	Nov 08, 2031		U-3187		
	10975046	Jun 20, 2039	DS			
	10981952	Nov 08, 2031		U-3186		
	10981952	Nov 08, 2031		U-3187		
	7132416	Sep 05, 2022	DS DP			
	9694018	Nov 08, 2031		U-3186		
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 003	10011633	Nov 08, 2031		U-3186	NCE	Jul 20, 2026
	10093697	Nov 08, 2031		U-3186	ODE-363	Jul 20, 2028
	10487111	Nov 08, 2031		U-3186		
	10487111	Nov 08, 2031		U-3187		
	10975046	Jun 20, 2039	DS			
	10981952	Nov 08, 2031		U-3186		
	10981952	Nov 08, 2031		U-3187		
	7132416	Sep 05, 2022	DS DP			
	9694018	Nov 08, 2031		U-3186		
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 004	10011633	Nov 08, 2031		U-3186	NCE	Jul 20, 2026
	10093697	Nov 08, 2031		U-3186	ODE-363	Jul 20, 2028
	10487111	Nov 08, 2031		U-3186		
	10487111	Nov 08, 2031		U-3187		
	10975046	Jun 20, 2039	DS			
	10981952	Nov 08, 2031		U-3186		
	10981952	Nov 08, 2031		U-3187		
	7132416	Sep 05, 2022	DS DP			
	9694018	Nov 08, 2031		U-3186		
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 001	10300054	Aug 23, 2031	DP U-3140		NCE	May 28, 2026
	10300054	Aug 23, 2031	DP U-3141			
	10716785	Aug 23, 2031		U-3136		
	10716785	Aug 23, 2031		U-3137		
	7262298	Nov 23, 2025	DS			
	7956187	Oct 31, 2021	DS			
	8252929	Oct 31, 2021	DS			
	8778960	Feb 13, 2032		U-3136		
	8778960	Feb 13, 2032		U-3137		
	9119848	Aug 30, 2031	DS			
	9126977	Aug 23, 2031	DP U-3136			
	9126977	Aug 23, 2031	DP U-3137			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 001	9517235	Aug 23, 2031	U-3138			
	9517235	Aug 23, 2031	U-3139			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 002	10300054	Aug 23, 2031	DP U-3140		NCE	May 28, 2026
	10300054	Aug 23, 2031	DP U-3141			
	10716785	Aug 23, 2031	U-3136			
	10716785	Aug 23, 2031	U-3137			
	7262298	Nov 23, 2025	DS			
	7956187	Oct 31, 2021	DS			
	8252929	Oct 31, 2021	DS			
	8778960	Feb 13, 2032	U-3136			
	8778960	Feb 13, 2032	U-3137			
	9119848	Aug 30, 2031	DS			
	9126977	Aug 23, 2031	DP U-3136			
	9126977	Aug 23, 2031	DP U-3137			
	9517235	Aug 23, 2031	U-3138			
	9517235	Aug 23, 2031	U-3139			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 003	10300054	Aug 23, 2031	DP U-3140		NCE	May 28, 2026
	10300054	Aug 23, 2031	DP U-3141			
	10716785	Aug 23, 2031	U-3136			
	10716785	Aug 23, 2031	U-3137			
	7262298	Nov 23, 2025	DS			
	7956187	Oct 31, 2021	DS			
	8252929	Oct 31, 2021	DS			
	8778960	Feb 13, 2032	U-3136			
	8778960	Feb 13, 2032	U-3137			
	9119848	Aug 30, 2031	DS			
	9126977	Aug 23, 2031	DP U-3136			
	9126977	Aug 23, 2031	DP U-3137			
	9517235	Aug 23, 2031	U-3138			
	9517235	Aug 23, 2031	U-3139			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 004	10300054	Aug 23, 2031	DP U-3140		NCE	May 28, 2026
	10300054	Aug 23, 2031	DP U-3141			
	10716785	Aug 23, 2031	U-3136			
	10716785	Aug 23, 2031	U-3137			
	7262298	Nov 23, 2025	DS			
	7956187	Oct 31, 2021	DS			
	8252929	Oct 31, 2021	DS			
	8778960	Feb 13, 2032	U-3136			
	8778960	Feb 13, 2032	U-3137			
	9119848	Aug 30, 2031	DS			
	9126977	Aug 23, 2031	DP U-3136			
	9126977	Aug 23, 2031	DP U-3137			
	9517235	Aug 23, 2031	U-3138			
	9517235	Aug 23, 2031	U-3139			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	8071579	Aug 12, 2027	U-2101			
	8071579	Aug 12, 2027	U-2103			
	8071579	Aug 12, 2027	U-2480			
	8071579	Aug 12, 2027	U-2481			
	8071579	Aug 12, 2027	U-2482			
	8071579	Aug 12, 2027	U-2483			
	8071579	Aug 12, 2027	U-2716			
	8071579	Aug 12, 2027	U-2819			
	8071579	Aug 12, 2027	U-2820			
	8071579	Aug 12, 2027	U-2821			
	8071579	Aug 12, 2027	U-2822			
	8071579	Aug 12, 2027	U-2823			
	8071579	Aug 12, 2027	U-2824			
	8071579	Aug 12, 2027	U-2832			
	8071579	Aug 12, 2027	U-2833			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2103			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2481			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8859562	Aug 04, 2031	U-2716			
	8859562	Aug 04, 2031	U-2819			
	8859562	Aug 04, 2031	U-2820			
	8859562	Aug 04, 2031	U-2821			
	8859562	Aug 04, 2031	U-2822			
	8859562	Aug 04, 2031	U-2823			
	8859562	Aug 04, 2031	U-2824			
	8859562	Aug 04, 2031	U-2832			
	8859562	Aug 04, 2031	U-2833			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	8071579	Aug 12, 2027	U-2101			
	8071579	Aug 12, 2027	U-2103			
	8071579	Aug 12, 2027	U-2480			
	8071579	Aug 12, 2027	U-2481			
	8071579	Aug 12, 2027	U-2482			
	8071579	Aug 12, 2027	U-2483			
	8071579	Aug 12, 2027	U-2716			
	8071579	Aug 12, 2027	U-2819			
	8071579	Aug 12, 2027	U-2820			
	8071579	Aug 12, 2027	U-2821			
	8071579	Aug 12, 2027	U-2822			
	8071579	Aug 12, 2027	U-2823			
	8071579	Aug 12, 2027	U-2824			
	8071579	Aug 12, 2027	U-2832			
	8071579	Aug 12, 2027	U-2833			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2103			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2481			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8859562	Aug 04, 2031	U-2716			
	8859562	Aug 04, 2031	U-2819			
	8859562	Aug 04, 2031	U-2820			
	8859562	Aug 04, 2031	U-2821			
	8859562	Aug 04, 2031	U-2822			
	8859562	Aug 04, 2031	U-2823			
	8859562	Aug 04, 2031	U-2824			
	8859562	Aug 04, 2031	U-2832			
	8859562	Aug 04, 2031	U-2833			
<u>OLICERIDINE - OLINVYK</u>						
N 210730 001	11077098	Mar 23, 2032	DS DP U-2986		NCE	Oct 30, 2025
<u>OLICERIDINE - OLINVYK</u>						
N 210730 002	11077098	Mar 23, 2032	DS DP U-2986		NCE	Oct 30, 2025
<u>OLICERIDINE - OLINVYK</u>						
N 210730 003	11077098	Mar 23, 2032	DS DP U-2986		NCE	Oct 30, 2025
<u>ORITAVANCIN DIPHOSPHATE - KIMYRSA</u>						
N 214155 001	8420592	Aug 29, 2029	U-3101		NCE	Aug 06, 2019
	9649352	Jul 16, 2035	DS DP		NP	Mar 12, 2024
	9682061	Apr 26, 2030	U-3101		GAIN	Aug 06, 2024
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001	10183020	Jan 02, 2035	DP U-1777		I-853	Dec 18, 2023
	10183020	Jan 02, 2035	DP U-2289		ODE-337	Dec 18, 2027
	10183020	Jan 02, 2035	DP U-3016			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001	8946235	Aug 08, 2032	DS DP U-1777			
	8946235	Aug 08, 2032	DS DP U-2289			
	8946235	Aug 08, 2032	DS DP U-3016			
	9732058	Jul 25, 2032	DS DP U-1777			
	9732058	Jul 25, 2032	DS DP U-2289			
	9732058	Jul 25, 2032	DS DP U-3016			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002	10183020	Jan 02, 2035	DP U-1777		I-853	Dec 18, 2023
	10183020	Jan 02, 2035	DP U-2289		ODE-337	Dec 18, 2027
	10183020	Jan 02, 2035	DP U-3016			
	8946235	Aug 08, 2032	DS DP U-1777			
	8946235	Aug 08, 2032	DS DP U-2289			
	8946235	Aug 08, 2032	DS DP U-3016			
	9732058	Jul 25, 2032	DS DP U-1777			
	9732058	Jul 25, 2032	DS DP U-2289			
	9732058	Jul 25, 2032	DS DP U-3016			
<u>OSPEMIFENE - OSPHENA</u>						
N 203505 001	9566252	Nov 02, 2022	U-1370			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 001 >A>	11166960	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 002 >A>	11166960	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 003 >A>	11166960	Apr 13, 2027	DP			
<u>OXYMETAZOLINE HYDROCHLORIDE - UPNEEQ</u>						
N 212520 001	10898573	Dec 16, 2039	DP			
	10912765	Aug 26, 2031	U-2849			
	10940138	Dec 16, 2039	U-2849			
	11103482	Dec 16, 2039	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 001	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-3085			
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 002	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-3085			
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 003	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-3085			
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 004	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-3085			
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 005	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-3085			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 005	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 006	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027		U-3085		
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 007	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027		U-3085		
	8871779	Nov 22, 2029	DS			
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 001	10239846	Nov 15, 2030	U-3132		I-860	May 27, 2024
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 002	10239846	Nov 15, 2030	U-3132		I-860	May 27, 2024
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 003	10239846	Nov 15, 2030	U-3132		I-860	May 27, 2024
<u>OZENOXACIN - XEPI</u>						
N 208945 001	6335447	Nov 09, 2023	DS			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	RE47739	Mar 05, 2027	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	RE47739	Mar 05, 2027	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	RE47739	Mar 05, 2027	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 001	11065250	May 24, 2036	DP			
	RE47739	Mar 05, 2027	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 002	11065250	May 24, 2036	DP			
	RE47739	Mar 05, 2027	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 003	11065250	May 24, 2036	DP			
	RE47739	Mar 05, 2027	DS DP			
<u>PALIPERIDONE PALMITATE - INVEGA HAFYERA</u>						
N 207946 005					NS	Aug 30, 2024
<u>PALIPERIDONE PALMITATE - INVEGA HAFYERA</u>						
N 207946 006					NS	Aug 30, 2024
<u>PARICALCITOL - ZEMPLAR</u>						
N 020819 001					ODE*	Oct 18, 2023
<u>PARICALCITOL - ZEMPLAR</u>						
N 020819 002					ODE*	Oct 18, 2023

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PARICALCITOL - ZEMPLAR</u>						
N 020819 003					ODE*	Oct 18, 2023
<u>PAROXETINE HYDROCHLORIDE - PAROXETINE HYDROCHLORIDE</u>						
A 215003 001					CGT	Mar 12, 2022
<u>PATIROMER SORBITEX CALCIUM - VELTASSA</u>						
N 205739 001	11123363	Oct 08, 2033	U-1766			
<u>PATIROMER SORBITEX CALCIUM - VELTASSA</u>						
N 205739 002	11123363	Oct 08, 2033	U-1766			
<u>PATIROMER SORBITEX CALCIUM - VELTASSA</u>						
N 205739 003	11123363	Oct 08, 2033	U-1766			
<u>PATISIRAN SODIUM - ONPATRO</u>						
N 210922 001	10240152	Oct 20, 2029	DS DP U-2378			
	11079379	Aug 27, 2035	DS DP U-2378			
	11141378	Apr 15, 2029	DP			
<u>PEGCETACOPLAN - EMPAVELI</u>						
N 215014 001	10035822	Nov 15, 2033	DS		NCE	May 14, 2026
	10125171	Aug 02, 2033	DS		ODE-351	May 14, 2028
	10875893	Nov 15, 2033	DS	U-3124		
	11040107	Apr 09, 2038	DP	U-3172		
	11040107	Apr 09, 2038	DP	U-3173		
	11040107	Apr 09, 2038	DP	U-3174		
	7888323	Dec 04, 2027	DS			
	7989589	Dec 04, 2027	DS			
	9169307	Nov 18, 2027	DS	U-3123		
<u>PERAMIVIR - RAPIVAB</u>						
N 206426 001	10391075	Feb 12, 2027	U-2622			
	10391075	Feb 12, 2027	U-3069			
	8778997	May 07, 2027	U-1627			
	8778997	May 07, 2027	U-2622			
	8778997	May 07, 2027	U-3069			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 001	6949571	Jun 08, 2022	DS DP U-106			
	6949571	Jun 08, 2022	DS DP U-2088			
	6949571	Jun 08, 2022	DS DP U-2089			
	6949571	Jun 08, 2022	DS DP U-2428			
	6949571	Jun 08, 2022	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 002	6949571	Jun 08, 2022	DS DP U-106			
	6949571	Jun 08, 2022	DS DP U-2088			
	6949571	Jun 08, 2022	DS DP U-2089			
	6949571	Jun 08, 2022	DS DP U-2428			
	6949571	Jun 08, 2022	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 003	6949571	Jun 08, 2022	DS DP U-106			
	6949571	Jun 08, 2022	DS DP U-2088			
	6949571	Jun 08, 2022	DS DP U-2089			
	6949571	Jun 08, 2022	DS DP U-2428			
	6949571	Jun 08, 2022	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 004	6949571	Jun 08, 2022	DS DP U-106			
	6949571	Jun 08, 2022	DS DP U-2088			
	6949571	Jun 08, 2022	DS DP U-2089			
	6949571	Jun 08, 2022	DS DP U-2428			
	6949571	Jun 08, 2022	DS DP U-2429			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 004	6949571	Jun 08, 2022	DS DP U-106			
	6949571	Jun 08, 2022	DS DP U-2088			
	6949571	Jun 08, 2022	DS DP U-2089			
	6949571	Jun 08, 2022	DS DP U-2428			
	6949571	Jun 08, 2022	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 005	6949571	Jun 08, 2022	DS DP U-106			
	6949571	Jun 08, 2022	DS DP U-2088			
	6949571	Jun 08, 2022	DS DP U-2089			
	6949571	Jun 08, 2022	DS DP U-2428			
	6949571	Jun 08, 2022	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 006	6949571	Jun 08, 2022	DS DP U-106			
	6949571	Jun 08, 2022	DS DP U-2088			
	6949571	Jun 08, 2022	DS DP U-2089			
	6949571	Jun 08, 2022	DS DP U-2428			
	6949571	Jun 08, 2022	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 208277 001	6949571	Jun 08, 2022	DS DP U-106			
	6949571	Jun 08, 2022	DS DP U-2088			
	6949571	Jun 08, 2022	DS DP U-2089			
	6949571	Jun 08, 2022	DS DP U-2428			
	6949571	Jun 08, 2022	DS DP U-2429			
<u>PEXIDARTINIB HYDROCHLORIDE - TURALIO</u>						
N 211810 001	10941142	Jul 24, 2038	DP			
	10961240	Jul 24, 2038			U-2606	
<u>PIFLUFOLASTAT F-18 - PYLARIFY</u>						
N 214793 001	10947197	Jun 09, 2037	DS DP U-3130		NCE	May 26, 2026
	8487129	Nov 07, 2027	DS DP			
	8778305	Sep 21, 2030	DS DP U-3130			
	9861713	Jul 31, 2029	DS DP U-3130			
<u>PILOCARPINE HYDROCHLORIDE - VUITY</u>						
N 214028 001	>A> 10610518	Apr 24, 2039	U-3252		>A> NP	Oct 28, 2024
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 002	10953000	Mar 23, 2037	U-1974			
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 001					ODE-331	Oct 13, 2027
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 002					ODE-331	Oct 13, 2027
<u>PLECANATIDE - TRULANCE</u>						
N 208745 001	11142549	Jun 05, 2034	DP			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001					M-14 PED	Nov 20, 2023 May 20, 2024
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002					M-14 PED	Nov 20, 2023 May 20, 2024
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003					M-14 PED	Nov 20, 2023 May 20, 2024



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>POMALIDOMIDE - POMALYST</u>						
N 204026	003				M-14 PED	Nov 20, 2023 May 20, 2024
<u>POMALIDOMIDE - POMALYST</u>						
N 204026	004				M-14 PED	Nov 20, 2023 May 20, 2024
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469	001				I-849	Dec 18, 2023
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469	002				I-849	Dec 18, 2023
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469	003	8114874	Jan 24, 2027	DS DP	I-849	Dec 18, 2023
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469	004	8114874	Jan 24, 2027	DS DP	I-849	Dec 18, 2023
	9029533	Dec 22, 2026		U-1283		
	9029533	Dec 22, 2026		U-1699		
	9029533	Dec 22, 2026		U-1700		
	9029533	Dec 22, 2026		U-1701		
	9029533	Dec 22, 2026		U-836		
	9493470	Dec 12, 2033	DS DP	U-1700		
	9493470	Dec 12, 2033	DS DP	U-1948		
<u>PONESIMOD - PONVORY</u>						
N 213498	001	10220023	Dec 10, 2035		U-3103	NCE
	8273779	Dec 17, 2025		U-2774		Mar 18, 2026
	9000018	Nov 16, 2024		U-3102		
	9062014	May 06, 2032	DS DP	U-2774		
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498	002	10220023	Dec 10, 2035		U-3103	NCE
	8273779	Dec 17, 2025		U-2774		Mar 18, 2026
	9000018	Nov 16, 2024		U-3102		
	9062014	May 06, 2032	DS DP	U-2774		
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498	003	10220023	Dec 10, 2035		U-3103	NCE
	8273779	Dec 17, 2025		U-2774		Mar 18, 2026
	9000018	Nov 16, 2024		U-3102		
	9062014	May 06, 2032	DS DP	U-2774		
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498	004	10220023	Dec 10, 2035		U-3103	NCE
	8273779	Dec 17, 2025		U-2774		Mar 18, 2026
	9000018	Nov 16, 2024		U-3102		
	9062014	May 06, 2032	DS DP	U-2774		
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498	005	10220023	Dec 10, 2035		U-3103	NCE
	8273779	Dec 17, 2025		U-2774		Mar 18, 2026
	9000018	Nov 16, 2024		U-3102		
	9062014	May 06, 2032	DS DP	U-2774		
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498	006	10220023	Dec 10, 2035		U-3103	NCE
	8273779	Dec 17, 2025		U-2774		Mar 18, 2026

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PONESIMOD - PONVORY</u>						
N 213498 006	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 007	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 008	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 009	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 010	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
<u>POSACONAZOLE - NOXAFIL</u>						
N 205053 001					NPP ODE-355	May 31, 2024 Jun 17, 2028
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596 001	9023790	Jul 04, 2031	DP U-1698		NPP ODE-355	May 31, 2024 Jun 17, 2028
	9023790	Jul 04, 2031	DP U-3160			
	9023790	Jul 04, 2031	DP U-3171			
	9358297	Jun 24, 2031	DP U-3160			
	9358297	Jun 24, 2031	DP U-3171			
<u>POSACONAZOLE - NOXAFIL POWDERMIX KIT</u>						
N 214770 001					NP	May 31, 2024
<u>PRALSETINIB - GAVRETO</u>						
N 213721 001					ODE-340 ODE-341	Dec 01, 2027 Dec 01, 2027
<u>PYRIMETHAMINE - PYRIMETHAMINE</u>						
A 211271 001					CGT	Apr 02, 2022
<u>RELUGOLIX - ORGOVYX</u>						
N 214621 001	10350170	Feb 25, 2036	DP		NCE	Dec 18, 2025
	10449191	Sep 29, 2037	U-3020			
	10786501	Sep 29, 2037	U-3020			
	7300935	Jan 28, 2024	DS			
	8058280	Jan 28, 2024	DS DP			
	8735401	Feb 04, 2024	U-3019			
<u>REMEDSIVIR - VEKLURY</u>						
N 214787 001	11007208	Sep 16, 2036	U-2984			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>REMDESIVIR - VEKLURY</u>						
N 214787 002	11007208	Sep 16, 2036	U-2984			
<u>REMIMAZOLAM BESYLATE - BYFAVO</u>						
N 212295 001					NCE	Oct 06, 2025
<u>REVEFENACIN - YUPELRI</u>						
N 210598 001	11008289	Jul 14, 2030	U-2440			
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361 002	10314828	Jul 24, 2029	U-1481			
	10335397	Jul 24, 2029	U-2579			
	10456384	Feb 26, 2029	U-2643			
	10456384	Feb 26, 2029	U-2644			
	10703763	Feb 27, 2026	U-1708			
	10703763	Feb 27, 2026	U-2847			
	10703763	Feb 27, 2026	U-2848			
	10709694	Jul 24, 2029	U-2579			
	10765667	Feb 26, 2029	U-2643			
	10765667	Feb 26, 2029	U-2644			
	7045620	Jun 19, 2024	DS			
	7612199	Jun 19, 2024	DS DP			
	7902206	Jun 19, 2024	DS DP			
	7906542	Jun 01, 2025	DS DP			
	7915275	Feb 23, 2025		U-1707		
	7915275	Feb 23, 2025		U-1708		
	8158644	Jun 19, 2024	DP			
	8158781	Jun 19, 2024	DS			
	8193196	Sep 02, 2027	DS DP	U-1707		
	8193196	Sep 02, 2027	DS DP	U-1708		
	8309569	Jul 18, 2029		U-1707		
	8309569	Jul 18, 2029		U-1708		
	8518949	Feb 27, 2026	DP			
	8642573	Oct 02, 2029		U-1481		
	8741904	Feb 27, 2026	DS	U-1526		
	8741904	Feb 27, 2026	DS	U-1707		
	8741904	Feb 27, 2026	DS	U-1708		
	8829017	Jul 24, 2029		U-1562		
	8835452	Jun 19, 2024	DS DP			
	8853231	Jun 19, 2024	DP			
	8946252	Jul 24, 2029		U-1481		
	8969398	Oct 02, 2029		U-1481		
	9271968	Feb 27, 2026	DP			
	9421195	Jul 24, 2029		U-1481		
	9629828	Jul 24, 2029		U-1994		
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N 202022 001	7125879	Apr 21, 2025	DS DP	U-1153		
	7125879	Apr 21, 2025	DS DP	U-1307		
	7125879	Apr 21, 2025	DS DP	U-1740		
	7125879	Apr 21, 2025	DS DP	U-3068		
<u>RIMEGEPANT SULFATE - NURTEC ODT</u>						
N 212728 001	11083724	Mar 25, 2039	DP	U-2718	I-865	May 27, 2024
	11083724	Mar 25, 2039		U-3142		
	8314117	Feb 22, 2031	DS DP	U-2718		
	8314117	Feb 22, 2031	DS DP	U-3142		
<u>RIPRETINIB - QINLOCK</u>						
N 213973 001	10966966	Aug 12, 2040		U-3153		
	RE48731	Jun 07, 2032		U-3219		
<u>RISDIPLAM - EVRYSDI</u>						
N 213535 001					ODE-334	Aug 07, 2027

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RISPERIDONE - PERSERIS KIT</u>						
N 210655 001	11013809	Feb 13, 2028	DP U-3135			
	11110093	Nov 05, 2026	DP U-3135			
<u>RISPERIDONE - PERSERIS KIT</u>						
N 210655 002	11013809	Feb 13, 2028	DP U-3135			
	11110093	Nov 05, 2026	DP U-3135			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001	>A> 7157456	Aug 28, 2024	DS DP U-1301		>A> I-810	Oct 11, 2022
	>A> 7157456	Aug 28, 2024	DS DP U-1302		>A> I-867	Aug 23, 2024
	>A> 7157456*PED	Feb 28, 2025			>A> PED	Apr 11, 2023
	>A> 9415053	Nov 13, 2024	DP U-1167		>A> PED	Feb 23, 2025
	>A> 9415053	Nov 13, 2024	DP U-2142			
	>A> 9415053	Nov 13, 2024	DP U-2640			
	>A> 9415053*PED	May 13, 2025				
	>A> 9539218	Feb 17, 2034	U-1957			
	>A> 9539218	Feb 17, 2034	U-2143			
	>A> 9539218	Feb 17, 2034	U-2641			
	>A> 9539218*PED	Aug 17, 2034				
<u>RIVAROXABAN - XARELTO</u>						
N 022406 002	>A> 7157456	Aug 28, 2024	DS DP U-1301		>A> I-810	Oct 11, 2022
	>A> 7157456	Aug 28, 2024	DS DP U-1302		>A> I-867	Aug 23, 2024
	>A> 7157456*PED	Feb 28, 2025			>A> PED	Apr 11, 2023
	>A> 9415053	Nov 13, 2024	DP U-1200		>A> PED	Feb 23, 2025
	>A> 9415053	Nov 13, 2024	DP U-1301			
	>A> 9415053	Nov 13, 2024	DP U-1302			
	>A> 9415053*PED	May 13, 2025				
	>A> 9539218	Feb 17, 2034	U-1953			
	>A> 9539218*PED	Aug 17, 2034				
<u>RIVAROXABAN - XARELTO</u>						
N 022406 003	>A> 7157456	Aug 28, 2024	DS DP U-1301		>A> I-810	Oct 11, 2022
	>A> 7157456	Aug 28, 2024	DS DP U-1302		>A> I-867	Aug 23, 2024
	>A> 7157456*PED	Feb 28, 2025			>A> PED	Apr 11, 2023
	>A> 9415053	Nov 13, 2024	DP U-1200		>A> PED	Feb 23, 2025
	>A> 9415053	Nov 13, 2024	DP U-1301			
	>A> 9415053	Nov 13, 2024	DP U-1302			
	>A> 9415053*PED	May 13, 2025				
	>A> 9539218	Feb 17, 2034	U-1953			
	>A> 9539218	Feb 17, 2034	U-1954			
	>A> 9539218	Feb 17, 2034	U-1955			
	>A> 9539218*PED	Aug 17, 2034				
<u>RIVAROXABAN - XARELTO</u>						
N 022406 004	>A> 10828310	Jan 31, 2039	U-3207		>A> I-810	Oct 11, 2022
	>A> 10828310	Jan 31, 2039	U-3208		>A> I-867	Aug 23, 2024
	>A> 10828310*PED	Jul 31, 2039			>A> PED	Apr 11, 2023
	>A> 7157456	Aug 28, 2024	DS DP		>A> PED	Feb 23, 2025
	>A> 7157456*PED	Feb 28, 2025				
	>A> 9415053	Nov 13, 2024	DP U-2435			
	>A> 9415053	Nov 13, 2024	DP U-3205			
	>A> 9415053	Nov 13, 2024	DP U-3206			
	>A> 9415053*PED	May 13, 2025				
<u>ROLAPITANT HYDROCHLORIDE - VARUBI</u>						
N 206500 001	7049320	Aug 19, 2028	DS DP U-1741			
<u>ROLAPITANT HYDROCHLORIDE - VARUBI</u>						
N 208399 001	7049320	Aug 19, 2028	DS DP U-1741			
<u>RUFINAMIDE - RUFINAMIDE</u>						
A 204988 001					PC	Nov 28, 2021

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RUFINAMIDE - RUFINAMIDE</u>						
A 204988	002				PC	Nov 28, 2021
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192	001	10016429	Jun 12, 2028	U-3226	I-872	Sep 22, 2024
		10016429	Jun 12, 2028	U-3230		
		7598257	Dec 24, 2027	DS DP U-3227		
		7598257	Dec 24, 2027	DS DP U-3228		
		8822481	Jun 12, 2028	U-1573		
		8822481	Jun 12, 2028	U-3226		
		8822481	Jun 12, 2028	U-3227		
		8822481	Jun 12, 2028	U-3228		
		8822481	Jun 12, 2028	U-3230		
		8829013	Jun 12, 2028	U-1201		
		8829013	Jun 12, 2028	U-1622		
		8829013	Jun 12, 2028	U-3227		
		8829013	Jun 12, 2028	U-3228		
	>A>	9079912	Dec 12, 2026	U-3226		
	>A>	9079912	Dec 12, 2026	U-3227		
	>A>	9079912	Dec 12, 2026	U-3228		
	>A>	9079912	Dec 12, 2026	U-3230		
		9814722	Dec 12, 2026	U-3226		
		9814722	Dec 12, 2026	U-3230		
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192	002	10016429	Jun 12, 2028	U-3226	I-872	Sep 22, 2024
		10016429	Jun 12, 2028	U-3230		
		7598257	Dec 24, 2027	DS DP U-3227		
		7598257	Dec 24, 2027	DS DP U-3228		
		8822481	Jun 12, 2028	U-1573		
		8822481	Jun 12, 2028	U-3226		
		8822481	Jun 12, 2028	U-3227		
		8822481	Jun 12, 2028	U-3228		
		8822481	Jun 12, 2028	U-3230		
		8829013	Jun 12, 2028	U-1201		
		8829013	Jun 12, 2028	U-1622		
		8829013	Jun 12, 2028	U-3227		
		8829013	Jun 12, 2028	U-3228		
	>A>	9079912	Dec 12, 2026	U-3226		
	>A>	9079912	Dec 12, 2026	U-3227		
	>A>	9079912	Dec 12, 2026	U-3228		
	>A>	9079912	Dec 12, 2026	U-3230		
		9814722	Dec 12, 2026	U-3226		
		9814722	Dec 12, 2026	U-3230		
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192	003	10016429	Jun 12, 2028	U-3226		
		10016429	Jun 12, 2028	U-3230		
		7598257	Dec 24, 2027	DS DP U-3227		
		7598257	Dec 24, 2027	DS DP U-3228		
		8822481	Jun 12, 2028	U-1573		
		8822481	Jun 12, 2028	U-3226		
		8822481	Jun 12, 2028	U-3227		
		8822481	Jun 12, 2028	U-3228		
		8822481	Jun 12, 2028	U-3230		
		8829013	Jun 12, 2028	U-1201		
		8829013	Jun 12, 2028	U-1622		
		8829013	Jun 12, 2028	U-3227		
		8829013	Jun 12, 2028	U-3228		
	>A>	9079912	Dec 12, 2026	U-3226		
	>A>	9079912	Dec 12, 2026	U-3227		
	>A>	9079912	Dec 12, 2026	U-3228		
	>A>	9079912	Dec 12, 2026	U-3230		
		9814722	Dec 12, 2026	U-3226		
		9814722	Dec 12, 2026	U-3230		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 004	10016429	Jun 12, 2028	U-3226			
	10016429	Jun 12, 2028	U-3230			
	7598257	Dec 24, 2027	DS DP U-3227			
	7598257	Dec 24, 2027	DS DP U-3228			
	8822481	Jun 12, 2028	U-1573			
	8822481	Jun 12, 2028	U-3226			
	8822481	Jun 12, 2028	U-3227			
	8822481	Jun 12, 2028	U-3228			
	8822481	Jun 12, 2028	U-3230			
	8829013	Jun 12, 2028	U-1201			
	8829013	Jun 12, 2028	U-1622			
	8829013	Jun 12, 2028	U-3227			
	8829013	Jun 12, 2028	U-3228			
	>A> 9079912	Dec 12, 2026	U-3226			
	>A> 9079912	Dec 12, 2026	U-3227			
	>A> 9079912	Dec 12, 2026	U-3228			
	>A> 9079912	Dec 12, 2026	U-3230			
	9814722	Dec 12, 2026	U-3226			
	9814722	Dec 12, 2026	U-3230			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 005	10016429	Jun 12, 2028	U-3226			
	10016429	Jun 12, 2028	U-3230			
	7598257	Dec 24, 2027	DS DP U-3227			
	7598257	Dec 24, 2027	DS DP U-3228			
	8822481	Jun 12, 2028	U-1573			
	8822481	Jun 12, 2028	U-3226			
	8822481	Jun 12, 2028	U-3227			
	8822481	Jun 12, 2028	U-3228			
	8822481	Jun 12, 2028	U-3230			
	8829013	Jun 12, 2028	U-1201			
	8829013	Jun 12, 2028	U-1622			
	8829013	Jun 12, 2028	U-3227			
	8829013	Jun 12, 2028	U-3228			
	>A> 9079912	Dec 12, 2026	U-3226			
	>A> 9079912	Dec 12, 2026	U-3227			
	>A> 9079912	Dec 12, 2026	U-3228			
	>A> 9079912	Dec 12, 2026	U-3230			
	9814722	Dec 12, 2026	U-3226			
	9814722	Dec 12, 2026	U-3230			
<u>RUXOLITINIB PHOSPHATE - OPZELURA</u>						
N 215309 001	10610530	Jun 12, 2028	U-3229		>A> NP	Sep 21, 2024
	10639310	Dec 12, 2026	U-3229			
	10758543	May 20, 2031	DP			
	10869870	May 20, 2031	U-3229			
	7598257	Dec 24, 2027	DS DP			
	8415362	Dec 24, 2027	DS DP			
	8722693	Jun 12, 2028	DS DP			
	8822481	Jun 12, 2028	U-3229			
	9079912	Dec 12, 2026	U-3229			
	9974790	Dec 12, 2026	U-3229			
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 001	11058667	May 09, 2036	U-3170		M-82	Feb 16, 2024
	11135192	Aug 22, 2033	U-3084			
	8101659	Jan 15, 2025	DP			
	8101659*PED	Jul 15, 2025				
	9517226	Aug 22, 2033	U-3084			
	9937143	Aug 22, 2033	U-3084			
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 002	11058667	May 09, 2036	U-3170		M-82	Feb 16, 2024
	11135192	Aug 22, 2033	U-3084			
	8101659	Jan 15, 2025	DP			
	8101659*PED	Jul 15, 2025				
	9517226	Aug 22, 2033	U-3084			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 002	9937143	Aug 22, 2033	U-3084			
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 003	11058667	May 09, 2036	U-3170		M-82	Feb 16, 2024
	11135192	Aug 22, 2033	U-3084			
	8101659	Jan 15, 2025	DP			
	8101659*PED	Jul 15, 2025				
	9517226	Aug 22, 2033	U-3084			
	9937143	Aug 22, 2033	U-3084			
<u>SAFINAMIDE MESYLATE - XADAGO</u>						
N 207145 001	8283380	Mar 21, 2031	U-1993			
<u>SAFINAMIDE MESYLATE - XADAGO</u>						
N 207145 002	8283380	Mar 21, 2031	U-1993			
<u>SECNIDAZOLE - SOLOSEC</u>						
N 209363 001	10849884	Sep 04, 2035	DP U-2583		I-866	Jun 30, 2024
	10849884	Sep 04, 2035	DP U-3169			
	11000507	Sep 04, 2035	DP U-2583			
	11000507	Sep 04, 2035	DP U-3169			
	11000508	Sep 04, 2035	DP U-2583			
	11000508	Sep 04, 2035	DP U-3169			
	11020377	Sep 04, 2035	DP U-2583			
	11020377	Sep 04, 2035	DP U-3169			
<u>SELENIOS ACID - SELENIOS ACID</u>						
N 209379 002					NCE	Apr 30, 2024
<u>SELENIOS ACID - SELENIOS ACID</u>						
N 209379 003					NCE	Apr 30, 2024
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 001 >A>	7205302	Oct 31, 2026	DS DP U-1797			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 002 >A>	7205302	Oct 31, 2026	DS DP U-1797			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 003 >A>	7205302	Oct 31, 2026	DS DP U-1797			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 004 >A>	7205302	Oct 31, 2026	DS DP U-1797			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 005 >A>	7205302	Oct 31, 2026	DS DP U-1797			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 006 >A>	7205302	Oct 31, 2026	DS DP U-1797			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 007 >A>	7205302	Oct 31, 2026	DS DP U-1797			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 008 >A>	7205302	Oct 31, 2026	DS DP U-1797			
<u>SELEXIPAG - UPTRAVI</u>						
N 214275 001 >A>	7205302	Oct 31, 2026	DS DP U-1797			
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELINEXOR - XPOVIO</u>						
N 212306 001	10519139	Aug 14, 2035	DS DP U-2584		ODE-346	Dec 18, 2027
	10519139	Aug 14, 2035	DS DP U-2855			
	10519139	Aug 14, 2035	DS DP U-3018			
	10544108	Jul 26, 2032	U-2584			
	10544108	Jul 26, 2032	U-3018			
	11034660	Jul 26, 2032	U-2584			
	11034660	Jul 26, 2032	U-3018			
	9079865	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-2855			
	9079865	Jul 26, 2032	U-3018			
<u>SELINEXOR - XPOVIO</u>						
N 212306 002	10519139	Aug 14, 2035	DS DP U-2584		ODE*	Jul 03, 2026
	10519139	Aug 14, 2035	DS DP U-2855		ODE*	Jun 22, 2027
	10519139	Aug 14, 2035	DS DP U-3018		ODE*	Dec 18, 2027
	10544108	Jul 26, 2032	U-2584			
	10544108	Jul 26, 2032	U-3018			
	11034660	Jul 26, 2032	U-2584			
	11034660	Jul 26, 2032	U-3018			
	8999996	Sep 15, 2032	DS DP			
	9079865	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-2855			
	9079865	Jul 26, 2032	U-3018			
	9714226	Jul 26, 2032	DS DP			
<u>SELINEXOR - XPOVIO</u>						
N 212306 003	10519139	Aug 14, 2035	DS DP U-2584		ODE*	Jul 03, 2026
	10519139	Aug 14, 2035	DS DP U-2855		ODE*	Jun 22, 2027
	10519139	Aug 14, 2035	DS DP U-3018		ODE*	Dec 18, 2027
	10544108	Jul 26, 2032	U-2584			
	10544108	Jul 26, 2032	U-3018			
	11034660	Jul 26, 2032	U-2584			
	11034660	Jul 26, 2032	U-3018			
	8999996	Sep 15, 2032	DS DP			
	9079865	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-2855			
	9079865	Jul 26, 2032	U-3018			
	9714226	Jul 26, 2032	DS DP			
<u>SELINEXOR - XPOVIO</u>						
N 212306 004	10519139	Aug 14, 2035	DS DP U-2584		ODE*	Jul 03, 2026
	10519139	Aug 14, 2035	DS DP U-2855		ODE*	Jun 22, 2027
	10519139	Aug 14, 2035	DS DP U-3018		ODE*	Dec 18, 2027
	10544108	Jul 26, 2032	U-2584			
	10544108	Jul 26, 2032	U-3018			
	11034660	Jul 26, 2032	U-2584			
	11034660	Jul 26, 2032	U-3018			
	8999996	Sep 15, 2032	DS DP			
	9079865	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-2855			
	9079865	Jul 26, 2032	U-3018			
	9714226	Jul 26, 2032	DS DP			
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 001	11097063	Jul 17, 2026	DP			
	>A> 8129343	Dec 05, 2031	DS DP U-2202			
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 002	11097063	Jul 17, 2026	DP			
	>A> 8129343	Dec 05, 2031	DS DP U-2202			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 001	10933120	Mar 15, 2033	DP			
	10960052	Dec 16, 2031	DP			
	>A> 8129343	Dec 05, 2031	DS DP U-2628			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 002	10933120	Mar 15, 2033	DP			
	10960052	Dec 16, 2031	DP			
>A>	8129343	Dec 05, 2031	DS DP	U-2628		
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 003	10933120	Mar 15, 2033	DP			
	10960052	Dec 16, 2031	DP			
>A>	8129343	Dec 05, 2031	DS DP	U-2628		
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 001	10888605	Aug 24, 2038	DP	U-3162	NCE	Dec 05, 2022
>A>	8129343	Dec 05, 2031	DS DP		NP	Jun 04, 2024
	8536122	Mar 20, 2026	DS DP			
	9764003	Jun 21, 2033		U-3161		
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 002	10888605	Aug 24, 2038	DP	U-3162	NCE	Dec 05, 2022
>A>	8129343	Dec 05, 2031	DS DP		NP	Jun 04, 2024
	8536122	Mar 20, 2026	DS DP			
	9764003	Jun 21, 2033		U-3161		
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 003	10888605	Aug 24, 2038	DP	U-3162	NCE	Dec 05, 2022
>A>	8129343	Dec 05, 2031	DS DP		NP	Jun 04, 2024
	8536122	Mar 20, 2026	DS DP			
	9764003	Jun 21, 2033		U-3161		
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 004	10888605	Aug 24, 2038	DP	U-3162	NCE	Dec 05, 2022
>A>	8129343	Dec 05, 2031	DS DP		NP	Jun 04, 2024
	8536122	Mar 20, 2026	DS DP			
	9764003	Jun 21, 2033		U-3161		
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 005	10888605	Aug 24, 2038	DP	U-3162	NCE	Dec 05, 2022
>A>	8129343	Dec 05, 2031	DS DP		NP	Jun 04, 2024
	8536122	Mar 20, 2026	DS DP			
	9764003	Jun 21, 2033		U-3161		
<u>SETMELANOTIDE ACETATE - IMCIVREE</u>						
N 213793 001	11129869	Jul 04, 2034	DP		ODE-336	Nov 25, 2027
<u>SIPONIMOD FUMARIC ACID - MAYZENT</u>						
N 209884 003	7939519	May 19, 2024	DS DP		NCE	Mar 26, 2024
	8492441	Nov 30, 2030		U-2511		
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 001					M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 002					M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 003					M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>SODIUM ACETATE - SODIUM ACETATE</u>						
A 214805 001					CGT	Jan 03, 2022

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	10864181	Mar 15, 2033	U-1532			
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 001					ODE*	Aug 28, 2026
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 002					ODE* ODE* PED	Apr 07, 2024 Aug 28, 2026 Oct 07, 2024
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341 001	10086011	Jan 30, 2034	U-1470		D-177	Nov 15, 2022
	10086011*PED	Jul 30, 2034			M-264	Jul 14, 2023
	11116783	Jan 30, 2034	DP U-1470		NPP	Mar 19, 2023
	11116783*PED	Jul 30, 2034			PED	May 15, 2023
	8575135	Nov 16, 2032	DS DP U-1470		PED	Sep 19, 2023
	8575135*PED	May 16, 2033			PED	Jan 14, 2024
	8735372	Mar 21, 2028	U-1470			
	8735372*PED	Sep 21, 2028				
	8921341	Nov 16, 2032	DS DP U-1470			
	8921341*PED	May 16, 2033				
	8940718	Nov 16, 2032	DS DP U-1470			
	8940718*PED	May 16, 2033				
	9757406	Jan 30, 2034	DP			
	9757406*PED	Jul 30, 2034				
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341 002	10086011	Jan 30, 2034	U-1470		M-264	Jul 14, 2023
	10086011*PED	Jul 30, 2034			NS	Mar 19, 2023
	11116783	Jan 30, 2034	DP U-1470		PED	Sep 19, 2023
	11116783*PED	Jul 30, 2034			PED	Jan 14, 2024
	7964580	Mar 26, 2029	DS DP U-1470			
	7964580*PED	Sep 26, 2029				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8575135	Nov 16, 2032	DS DP U-1470			
	8575135*PED	May 16, 2033				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028	U-1470			
	8735372*PED	Sep 21, 2028				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	8921341	Nov 16, 2032	DS DP U-1470			
	8921341*PED	May 16, 2033				
	8940718	Nov 16, 2032	DS DP U-1470			
	8940718*PED	May 16, 2033				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
	9757406	Jan 30, 2034	DP			
	9757406*PED	Jul 30, 2034				
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 214187 001	11116783	Jan 30, 2034	DP U-1470			
	11116783*PED	Jul 30, 2034				
	7964580	Mar 26, 2029	DS DP U-1470			
	7964580*PED	Sep 26, 2029				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8575135	Nov 16, 2032	DS DP U-1470			
	8575135*PED	May 16, 2033				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 214187 001	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028	U-1470			
	8735372*PED	Sep 21, 2028				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	8921341	Nov 16, 2032	DS DP U-1470			
	8921341*PED	May 16, 2033				
	8940718	Nov 16, 2032	DS DP U-1470			
	8940718*PED	May 16, 2033				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 214187 002	11116783	Jan 30, 2034	DP U-1470			
	11116783*PED	Jul 30, 2034				
	7964580	Mar 26, 2029	DS DP U-1470			
	7964580*PED	Sep 26, 2029				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8575135	Nov 16, 2032	DS DP U-1470			
	8575135*PED	May 16, 2033				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028	U-1470			
	8735372*PED	Sep 21, 2028				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	8921341	Nov 16, 2032	DS DP U-1470			
	8921341*PED	May 16, 2033				
	8940718	Nov 16, 2032	DS DP U-1470			
	8940718*PED	May 16, 2033				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
<u>SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI</u>						
N 209195 001	10912814	Jun 01, 2037	DP			
	11116783	Jan 30, 2034	DP U-2039			
	11116783	Jan 30, 2034	DP U-2040			
	11116783*PED	Jul 30, 2034				
	8575135	Nov 16, 2032	DS DP U-2039			
	8575135	Nov 16, 2032	DS DP U-2040			
	8575135*PED	May 16, 2033				
	8735372	Mar 21, 2028	DS DP U-2039			
	8735372	Mar 21, 2028	DS DP U-2040			
	8735372*PED	Sep 21, 2028				
	8921341	Nov 16, 2032	DS DP U-2039			
	8921341	Nov 16, 2032	DS DP U-2040			
	8921341*PED	May 16, 2033				
	8940718	Nov 16, 2032	DS DP U-2039			
	8940718	Nov 16, 2032	DS DP U-2040			
	8940718*PED	May 16, 2033				
	8957046	Mar 21, 2028	U-2039			
	8957046	Mar 21, 2028	U-2040			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOLIFENACIN SUCCINATE - VESICARE LS</u>						
N 209529 001	9918970	May 18, 2031	DP			
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 001	10912754	Jun 01, 2038	U-3082			
	10940133	Mar 19, 2040	U-3099			
	10959976	Jun 01, 2038	U-3151			
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 002	10912754	Jun 01, 2038	U-3082			
	10959976	Jun 01, 2038	U-3151			
<u>SOTALOL HYDROCHLORIDE - SOTALOL HYDROCHLORIDE</u>						
N 022306 001	10799138	Apr 05, 2039	U-3125			
<u>SOTALOL HYDROCHLORIDE - SOTYLIZE</u>						
N 205108 001	11013703	Apr 01, 2034	DP			
<u>SOTORASIB - LUMAKRAS</u>						
N 214665 001					NCE ODE-352	May 28, 2026 May 28, 2028
<u>SPINOSAD - NATROBA</u>						
N 022408 001					I-858	Apr 28, 2024
<u>SPIRONOLACTONE - CAROSPIR</u>						
N 209478 001	10888570	Oct 28, 2036	DP			
<u>SUFENTANIL CITRATE - DSUVIA</u>						
N 209128 001	10896751	Mar 16, 2030	DP			
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 001					NPP	Jun 25, 2024
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 002					NPP	Jun 25, 2024
<u>TACROLIMUS - PROGRAF</u>						
N 050708 001					ODE-360	Jul 16, 2028
<u>TACROLIMUS - PROGRAF</u>						
N 050708 002					ODE-360	Jul 16, 2028
<u>TACROLIMUS - PROGRAF</u>						
N 050708 003					ODE-360	Jul 16, 2028
<u>TACROLIMUS - PROGRAF</u>						
N 050709 001					ODE-360	Jul 16, 2028
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096 001					ODE*	May 24, 2025
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096 002					ODE*	May 24, 2025
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096 003					ODE*	May 24, 2025
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 001	11110081	May 30, 2028	U-2678			
	11123331	May 30, 2028	U-2677			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 002	11110081	May 30, 2028	U-2678			
	11123331	May 30, 2028	U-2677			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 003	11110081	May 30, 2028	U-2678			
	11123331	May 30, 2028	U-2677			
<u>TACROLIMUS - PROGRAF</u>						
N 210115 001					ODE-360	Jul 16, 2028
<u>TACROLIMUS - PROGRAF</u>						
N 210115 002					ODE-360	Jul 16, 2028
<u>TAFENOQUINE SUCCINATE - ARAKODA</u>						
N 210607 001	10888558	Dec 02, 2035	U-2582			
<u>TAFLUPROST - ZIOPTAN</u>						
N 202514 001	10864159	May 28, 2029	DP U-778			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 211651 003	10189837	Oct 20, 2031	DS DP		NCE	Oct 16, 2023
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 211651 004	10189837	Oct 20, 2031	DS DP		NCE	Oct 16, 2023
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 001	11007156	Oct 22, 2022	DP U-1178			
	11007156	Oct 22, 2022	DP U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 002	11007156	Oct 22, 2022	DP U-1178			
	11007156	Oct 22, 2022	DP U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 003	11007156	Oct 22, 2022	DP U-1178			
	11007156	Oct 22, 2022	DP U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 004	11007156	Oct 22, 2022	DP U-1178			
	11007156	Oct 22, 2022	DP U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 005	11007156	Oct 22, 2022	DP U-1178			
	11007156	Oct 22, 2022	DP U-1276			
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	10610511	Oct 10, 2034	U-2615		I-850	Dec 01, 2023
	10610511	Oct 10, 2034	U-3007		ODE-330	Dec 01, 2027
	10945988	Jan 25, 2033	U-2149			
	10980770	Jan 25, 2033	U-3106			
	10980770	Jan 25, 2033	U-3107			
	11141400	Oct 10, 2034	U-2615			
	11141400	Oct 10, 2034	U-3007			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TASIMELTRON - HETLIOZ LO</u>						
N 214517 001	10980770	Jan 25, 2033	U-3106		NP	Dec 01, 2023
	11141400	Oct 10, 2034	U-3007		ODE-329	Dec 01, 2027
<u>TAVABOROLE - TAVABOROLE</u>						
A 211963 001					PC	Apr 17, 2021
<u>TAZEMETOSTAT HYDROBROMIDE - TAZVERIK</u>						
N 211723 001	10786511	Dec 19, 2035	DP			
	11052093	Apr 13, 2032	DS DP U-2736			
	11052093	Apr 13, 2032	DS DP U-3179			
<u>TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT</u>						
N 202207 001					NPP	May 19, 2024
<u>TENOFOVIR ALAFENAMIDE FUMARATE - VEMLIDY</u>						
N 208464 001	7390791	Apr 17, 2025	DS DP			
	7390791*PED	Oct 17, 2025				
	8754065	Aug 15, 2032	DS DP U-999			
	8754065*PED	Feb 15, 2033				
	9296769	Aug 15, 2032	DS DP U-999			
	9296769*PED	Feb 15, 2033				
<u>TEPOTINIB HYDROCHLORIDE - TEPMETKO</u>						
N 214096 001	8329692	Oct 30, 2029	DS DP		NCE	Feb 03, 2026
	8580781	Mar 19, 2030	DS DP		ODE-325	Feb 03, 2028
	8658643	Jul 04, 2028		U-3077		
	8921357	May 30, 2028	DS DP			
	8927540	Jul 21, 2028		U-3078		
	9062029	Jul 04, 2028	DP			
	9284300	Apr 29, 2028	DP			
	9403799	Jul 04, 2028		U-3077		
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N 202992 001	6794410	Sep 12, 2026		U-1285	M-61	Apr 30, 2024
	6794410*PED	Mar 12, 2027			PED	Oct 30, 2024
	8802735	Sep 14, 2030	DP			
	8802735*PED	Mar 14, 2031				
	9186346	Feb 04, 2034		U-1786		
	9186346*PED	Aug 04, 2034				
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N 202992 002	6794410	Sep 12, 2026		U-1285	M-61	Apr 30, 2024
	6794410*PED	Mar 12, 2027			PED	Oct 30, 2024
	8802735	Sep 14, 2030	DP			
	8802735*PED	Mar 14, 2031				
	9186346	Feb 04, 2034		U-1786		
	9186346*PED	Aug 04, 2034				
<u>TESTOSTERONE - NATESTO</u>						
N 205488 001	11090312	Mar 17, 2034		U-1616		
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 001	10881798	Feb 11, 2034	DP			
	10905827	Aug 21, 2031	DP			
	10912782	Feb 19, 2035	DP U-2418			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 002	10881798	Feb 11, 2034	DP			
	10905827	Aug 21, 2031	DP			
	10912782	Feb 19, 2035	DP U-2418			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 003	10881798	Feb 11, 2034	DP			
	10905827	Aug 21, 2031	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 003	10912782	Feb 19, 2035	DP U-2418			
<u>THEOPHYLLINE - THEOPHYLLINE</u>						
A 212184 002					CGT	Dec 08, 2021
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001					I-851	May 28, 2023
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002					I-851	May 28, 2023
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 001	10960004	Feb 03, 2037	U-2642			
	RE46284	Sep 22, 2029	U-1751			
	RE46284	Sep 22, 2029	U-2503			
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 002	10960004	Feb 03, 2037	U-2642			
	RE46284	Sep 22, 2029	U-1751			
	RE46284	Sep 22, 2029	U-2503			
<u>TIRBANIBULIN - KLISYRI</u>						
N 213189 001	10323001	Dec 28, 2027	DP		NCE	Dec 14, 2025
	10617693	Mar 12, 2038	U-3015			
	10669236	Sep 07, 2038	DS DP			
	7300931	Feb 06, 2026	DS DP			
	7851470	Feb 02, 2029	DS DP U-3015			
	8236799	Dec 28, 2025	DS DP			
	8980890	Dec 28, 2025	DS DP			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 001	6821987	Apr 26, 2022	DS DP U-3100		NCE	Mar 10, 2026
	7166722	Nov 16, 2023	DS			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 002	6821987	Apr 26, 2022	DS DP U-3100		NCE	Mar 10, 2026
	7166722	Nov 16, 2023	DS			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 001	10905694	Apr 07, 2030	DP			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 002	10905694	Apr 07, 2030	DP			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 003	10905694	Apr 07, 2030	DP			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 001	10905694	Apr 07, 2030	DP			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 002	10905694	Apr 07, 2030	DP			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 003	10905694	Apr 07, 2030	DP			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 004	10905694	Apr 07, 2030	DP			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 005	10905694	Apr 07, 2030	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TORSEMIDE - SOAANZ</u>						
N 213218 001	10154963	Oct 06, 2033	DP			
<u>TORSEMIDE - SOAANZ</u>						
N 213218 002	10154963	Oct 06, 2033	DP			
<u>TRAMADOL HYDROCHLORIDE - QDOLO</u>						
N 214044 001	11103452	Sep 01, 2040	DP U-3197			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	10869869	Aug 30, 2033	U-3184			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	10869869	Aug 30, 2033	U-3184			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	10869869	Aug 30, 2033	U-3184			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 005	10076505	Dec 16, 2024	DP			
	10695308	Dec 16, 2024	U-2845			
	7999007	Mar 29, 2029	DP U-1437			
	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
	9199908	May 24, 2024	U-1771			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024	U-2036			
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001					I-856	Mar 31, 2024
<u>TRIAMCINOLONE ACETONIDE - XIPERE</u>						
N 211950 001	8636713	May 02, 2027	U-3234		>A> NP	Oct 22, 2024
	9636332	Nov 08, 2033	U-3234			
	9937075	May 02, 2034	DP			
<u>TRIFAROTENE - AKLIEF</u>						
N 211527 001	9498465	May 30, 2033	DP U-1033			
<u>TRILACICLIB DIHYDROCHLORIDE - COSELA</u>						
N 214200 001	10085992	Mar 14, 2034	U-3081		NCE	Feb 12, 2026
	10189849	Oct 25, 2031	DS			
	10189850	Oct 25, 2031	DP			
	10927120	Oct 25, 2031	DP			
	10966984	Mar 14, 2034	U-3079			
	10966984	Mar 14, 2034	U-3080			
	11040042	Mar 14, 2034	DP			
	8598186	Oct 25, 2031	DS DP			
	8598197	Oct 25, 2031	DS DP			
	9487530	Mar 14, 2034	U-3079			
	9487530	Mar 14, 2034	U-3080			
	9957276	Oct 25, 2031	DS			
<u>UMBRALISIB TOSYLATE - UKONIQ</u>						
N 213176 001	10072013	Jul 02, 2033	U-3063		NCE	Feb 05, 2026
	10072013	Jul 02, 2033	U-3064		ODE-343	Feb 05, 2028
	10414773	May 26, 2035	DS DP U-3063		ODE-344	Feb 05, 2028
	10414773	May 26, 2035	DS DP U-3064			
	10570142	Jul 02, 2033	DS DP U-3063			
	10570142	Jul 02, 2033	DS DP U-3064			
	10947244	May 26, 2035	U-3063			
	10947244	May 26, 2035	U-3064			
	9150579	Jul 02, 2033	DS DP			
	9669033	Jul 02, 2033	U-3063			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>UMBRALISIB TOSYLATE - UKONIQ</u>						
N 213176 001	9669033	Jul 02, 2033	U-3064			
	9969740	May 26, 2035	DS DP U-3063			
	9969740	May 26, 2035	DS DP U-3064			
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001	11090294	Nov 29, 2030	U-3203			
<u>UPADACITINIB - RINVOO</u>						
N 211675 001	10981923	Oct 17, 2036	DS			
	10981924	Oct 17, 2036	DP			
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 001	10874648	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-3046			
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037	U-1995			
	10912771	Oct 10, 2037	U-3076			
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040	U-1995			
	10952997	Oct 10, 2037	U-1995			
	10993941	Oct 10, 2037	U-1995			
	11026931	Aug 14, 2039	U-1995			
	11026939	Sep 18, 2038	DP U-1995			
	11040029	Oct 10, 2037	U-1995			
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 002	10874648	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-3046			
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037	U-1995			
	10912771	Oct 10, 2037	U-3076			
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040	U-1995			
	10952997	Oct 10, 2037	U-1995			
	10993941	Oct 10, 2037	U-1995			
	11026931	Aug 14, 2039	U-1995			
	11026939	Sep 18, 2038	DP U-1995			
	11040029	Oct 10, 2037	U-1995			
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 003	10065952	Oct 28, 2036	DS DP U-1995		NCE	Apr 11, 2022
	10844058	Oct 28, 2036	DS DP U-1995			
	10851103	Oct 28, 2036	DS DP U-1995			
	10851104	Oct 28, 2036	DS U-1995			
	10857137	Oct 10, 2037	U-1995			
	10857148	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-3046			
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037	U-1995			
	10912771	Oct 10, 2037	U-3076			
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040	U-1995			
	10952997	Oct 10, 2037	U-1995			
	10993941	Oct 10, 2037	U-1995			
	11026931	Aug 14, 2039	U-1995			
	11026939	Sep 18, 2038	DP U-1995			
	11040029	Oct 10, 2037	U-1995			
	8039627	Oct 06, 2029	DS DP			
	8357697	Nov 08, 2027	U-1995			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VALSARTAN - DIOVAN</u>						
N 021283 001					NPP	Apr 19, 2024
<u>VALSARTAN - DIOVAN</u>						
N 021283 002					NPP	Apr 19, 2024
<u>VALSARTAN - DIOVAN</u>						
N 021283 004					NPP	Apr 19, 2024
<u>VANCOMYCIN - VANCOMYCIN</u>						
N 213895 001	10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			
	10849956	Nov 06, 2035	DP			
	11000567	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - FIRVANO KIT</u>						
N 208910 001	10959946	Mar 13, 2035	DP			
	10959947	Mar 13, 2035	DP U-3104			
	10959947	Mar 13, 2035	DP U-3105			
	10959948	Mar 13, 2035	DP U-3104			
	10959948	Mar 13, 2035	DP U-3105			
	10959949	Mar 13, 2035	DP U-3104			
	10959949	Mar 13, 2035	DP U-3105			
<u>VANCOMYCIN HYDROCHLORIDE - FIRVANO KIT</u>						
N 208910 002	10959946	Mar 13, 2035	DP			
	10959947	Mar 13, 2035	DP U-3104			
	10959947	Mar 13, 2035	DP U-3105			
	10959948	Mar 13, 2035	DP U-3104			
	10959948	Mar 13, 2035	DP U-3105			
	10959949	Mar 13, 2035	DP U-3104			
	10959949	Mar 13, 2035	DP U-3105			
<u>VARENICLINE TARTRATE - TYRVAYA</u>						
N 213978 001	10456396	Oct 19, 2035	DP U-1900		>A> NP	Oct 15, 2024
	9504644	Oct 19, 2035	U-1900			
	9504645	Oct 19, 2035	DP			
	9532944	Oct 19, 2035	U-1900			
	9597284	Oct 19, 2035	U-1900			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 001	10993942	Sep 06, 2033	U-3114			
	11110087	Sep 06, 2033	U-3222			
	11110087	Sep 06, 2033	U-3223			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 002	10993942	Sep 06, 2033	U-3114			
	11110087	Sep 06, 2033	U-3222			
	11110087	Sep 06, 2033	U-3223			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 003	10993942	Sep 06, 2033	U-3114			
	11110087	Sep 06, 2033	U-3222			
	11110087	Sep 06, 2033	U-3223			
<u>VERICIGUAT - VEROUVO</u>						
N 214377 001	10736896	May 19, 2031	DS DP		NCE	Jan 19, 2026
	8420656	May 19, 2031	DS DP			
	8921377	May 19, 2031	U-3062			
	9604948	Nov 26, 2032	DS DP U-3062			
	9993476	May 19, 2031	U-3062			
<u>VERICIGUAT - VEROUVO</u>						
N 214377 002	10736896	May 19, 2031	DS DP		NCE	Jan 19, 2026
	8420656	May 19, 2031	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VERICIGUAT - VEROUVO</u>						
N 214377 002	8921377	May 19, 2031	U-3062			
	9604948	Nov 26, 2032	DS DP U-3062			
	9993476	May 19, 2031	U-3062			
<u>VERICIGUAT - VEROUVO</u>						
N 214377 003	10736896	May 19, 2031	DS DP		NCE	Jan 19, 2026
	8420656	May 19, 2031	DS DP			
	8921377	May 19, 2031	U-3062			
	9604948	Nov 26, 2032	DS DP U-3062			
	9993476	May 19, 2031	U-3062			
<u>VIBEGRON - GEMTESA</u>						
N 213006 001	8247415	Dec 01, 2030	DS DP U-3045		NCE	Dec 23, 2025
	8653260	Apr 02, 2029	DS			
<u>VIGABATRIN - VIGABATRIN</u>						
A 211539 001					CGT	Jul 31, 2021
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 001	9358204	Feb 07, 2033	DP		NCE	Apr 02, 2026
	9603853	Feb 07, 2033	U-727			
	9662338	Feb 07, 2033	DP			
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 002	9358204	Feb 07, 2033	DP		NCE	Apr 02, 2026
	9603853	Feb 07, 2033	U-727			
	9662338	Feb 07, 2033	DP			
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 003	9358204	Feb 07, 2033	DP		NCE	Apr 02, 2026
	9603853	Feb 07, 2033	U-727			
	9662338	Feb 07, 2033	DP			
<u>VILTOLARSEN - VILTEPSO</u>						
N 212154 001	10870676	Aug 31, 2031	DS DP U-3039		ODE-280	Aug 12, 2027
<u>VISMODEGIB - ERIVEDGE</u>						
N 203388 001	9790183	Sep 02, 2025	U-3109			
<u>VOCLOSPORIN - LUPKYNIS</u>						
N 213716 001	10286036	Dec 07, 2037	U-3056		NCE	Jan 22, 2026
	7332472	Oct 17, 2022	DS DP U-3056			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 001					M-187	Jan 22, 2024
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 002					M-187	Jan 22, 2024
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 003					M-187	Jan 22, 2024
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 004					M-187	Jan 22, 2024
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 001	11020382	Dec 02, 2036	U-3133			
	11020382	Dec 02, 2036	U-3134			
<u>ZANUBRUTINIB - BRUKINSA</u>						
N 213217 001	>A> 10570139	Apr 22, 2034	DS DP U-1745		I-871	Aug 31, 2024
	>A> 10570139	Apr 22, 2034	DS DP U-2145		I-874	Sep 14, 2024
	>A> 10570139	Apr 22, 2034	DS DP U-3063			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ZANUBRUTINIB - BRUKINSA</u>						
N 213217 001	10927117	Aug 15, 2037	DS DP			
	>A> 11142528	Apr 22, 2034	DS DP U-1745			
	>A> 11142528	Apr 22, 2034	DS DP U-2145			
	>A> 11142528	Apr 22, 2034	DS DP U-3063			
	>A> 9447106	Apr 22, 2034	DS DP U-1745			
	>A> 9447106	Apr 22, 2034	DS DP U-2145			
	>A> 9447106	Apr 22, 2034	DS DP U-3063			

## PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 41<sup>ST</sup> Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at [http://www.accessdata.fda.gov/scripts/cder/ob/results\\_patent.cfm](http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm)

The current complete list of exclusivity terms is available at [http://www.accessdata.fda.gov/scripts/cder/ob/results\\_exclusivity.cfm](http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm)